{"meta":{"query_hash":"85695e640686","filters":{"venue":"Leukemia & lymphoma/Leukemia and lymphoma"},"cohort_total":430,"direct_labels_cover":0,"predictions_cover":430,"exported":430,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/85695e640686","api":"https://metacan.xera.ac/api/v1/cohort?venue=Leukemia+%26+lymphoma%2FLeukemia+and+lymphoma"},"results":[{"id":"W1724875595","doi":"10.3109/10428194.2015.1086919","title":"Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"ABVD; Medicine; Internal medicine; Chemotherapy; Lymphoma; Multivariate analysis; Univariate analysis; Oncology; Gastroenterology; Disease; Vincristine; Cyclophosphamide","score_opus":0.02645099087539054,"score_gpt":0.3144176601644274,"score_spread":0.28796666928903686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1724875595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965194,0.00016291701,0.000017861048,0.0003434,0.00017842068,0.0014239763,0.00031105094,0.000074959644,0.0009680095],"genre_scores_gemma":[0.9971789,0.00020352476,0.0007596481,0.0009791057,0.000120434685,0.00024171927,0.00030735534,0.00010435153,0.00010494079],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99505705,0.00029687714,0.0016776983,0.0010913808,0.0011688706,0.0007081362],"domain_scores_gemma":[0.9958222,0.0010619039,0.0007064103,0.0009388317,0.0005281166,0.0009425697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041647087,0.0008467068,0.0022289741,0.000520636,0.00006968332,0.000049123475,0.00030009233,0.00051177293,0.00009021547],"category_scores_gemma":[0.0004910512,0.0005904935,0.0005822395,0.00069377077,0.00035645918,0.000279609,0.00014340683,0.000100015655,0.00008653981],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008503872,0.005137275,0.85145634,0.000027482747,0.00087772997,0.00008989792,0.0008809833,0.000058679663,0.00004938592,0.00007417091,0.0013741647,0.13147001],"study_design_scores_gemma":[0.07209689,0.009435912,0.9137143,0.0006095557,0.0002945279,0.00001630778,0.00011705488,0.00042746705,0.0021196336,0.00009374601,0.0005402273,0.00053438527],"about_ca_topic_score_codex":0.0040136417,"about_ca_topic_score_gemma":0.000104946186,"teacher_disagreement_score":0.13093562,"about_ca_system_score_codex":0.008713103,"about_ca_system_score_gemma":0.0032864937,"threshold_uncertainty_score":0.99965465},"labels":[],"label_agreement":null},{"id":"W1821529798","doi":"10.3109/10428194.2015.1071486","title":"Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Myeloid leukemia; Toxicity; Internal medicine; Incidence (geometry); Oncology","score_opus":0.012498052574899658,"score_gpt":0.2532419150282752,"score_spread":0.24074386245337553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1821529798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98936814,0.0061699385,0.000039059032,0.00008134634,0.0000778198,0.0023928618,0.0000664734,0.00019280743,0.0016115437],"genre_scores_gemma":[0.99386865,0.003028407,0.0012757068,0.00013098148,0.0001098879,0.00025726232,0.00031577877,0.0001857178,0.00082761724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942728,0.00018990583,0.0011848982,0.0017885168,0.0012508209,0.0013130162],"domain_scores_gemma":[0.9965975,0.00014133735,0.00063634047,0.0011500521,0.00039128787,0.0010834754],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00045022852,0.0012801634,0.001740018,0.0006407043,0.00025010455,0.00012832505,0.0003469751,0.0005380009,0.00004346057],"category_scores_gemma":[0.000040978277,0.00096139713,0.000097007374,0.0011536534,0.00081074337,0.0007846593,0.00047011333,0.00028964938,0.000013422872],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024475222,0.001465325,0.5199269,0.0045400094,0.0020054039,0.00404126,0.0019448994,0.0005506984,0.0029880027,0.00039113584,0.00081378245,0.4368573],"study_design_scores_gemma":[0.20603713,0.0078027146,0.75647265,0.0044493447,0.0010803118,0.0010510667,0.0003655062,0.008177505,0.011432176,0.00004315947,0.0018081153,0.001280306],"about_ca_topic_score_codex":0.0027709315,"about_ca_topic_score_gemma":0.0005149972,"teacher_disagreement_score":0.43557703,"about_ca_system_score_codex":0.02823736,"about_ca_system_score_gemma":0.006026295,"threshold_uncertainty_score":0.999995},"labels":[],"label_agreement":null},{"id":"W1902656250","doi":"10.3109/10428194.2015.1088651","title":"A link between hypercholesterolemia and chronic lymphocytic leukemia","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Medicine; Incidence (geometry); Internal medicine; Cholesterol; Leukemia; Gastroenterology","score_opus":0.032955813149021185,"score_gpt":0.28930771969680397,"score_spread":0.2563519065477828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1902656250","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9734193,0.013020965,0.00020032995,0.0005886414,0.0005645694,0.001806001,0.00008973016,0.00095804187,0.009352408],"genre_scores_gemma":[0.9834843,0.0029093605,0.0015033946,0.0018132053,0.003930006,0.0003067458,0.00031454276,0.0004665917,0.0052718017],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9889746,0.00045437555,0.0020450193,0.0029110995,0.002493849,0.0031210722],"domain_scores_gemma":[0.9912184,0.00091704226,0.0005525627,0.0025198995,0.0006584194,0.0041337046],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0017609384,0.0018873529,0.0027198403,0.00087207137,0.00069462607,0.0006029942,0.0010188668,0.0017506278,0.0000954212],"category_scores_gemma":[0.00081236596,0.001765454,0.00051394926,0.0015442205,0.0019227695,0.0010067185,0.0014151265,0.0007057969,0.0006640499],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004045251,0.00013009901,0.016711744,0.0030864137,0.0018475802,0.005367948,0.0045883064,0.00067252206,0.0064858687,0.0017754679,0.01660901,0.9386798],"study_design_scores_gemma":[0.33583513,0.005758813,0.089813605,0.0035102877,0.0031702311,0.036749557,0.0023697682,0.16980702,0.019373914,0.0032315522,0.3240582,0.0063219164],"about_ca_topic_score_codex":0.007145869,"about_ca_topic_score_gemma":0.00017934646,"teacher_disagreement_score":0.93235785,"about_ca_system_score_codex":0.3832112,"about_ca_system_score_gemma":0.15789355,"threshold_uncertainty_score":0.99954534},"labels":[],"label_agreement":null},{"id":"W1916555325","doi":"10.3109/10428194.2015.1085534","title":"Bortezomib and melphalan conditioning increases the rate of complete response and MRD negativity for patients with multiple myeloma undergoing single autologous stem cell transplant","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; Calgary Laboratory Services; Baker Hughes (Canada)","funders":"","keywords":"Bortezomib; Medicine; Melphalan; Multiple myeloma; Oncology; Stem cell; Autologous stem-cell transplantation; Internal medicine; Chemotherapy; Surgery; Biology","score_opus":0.02112626161931841,"score_gpt":0.2377327960704628,"score_spread":0.2166065344511444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1916555325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895853,0.0016097401,0.00010527712,0.0034473531,0.00009122088,0.002555049,0.0023567826,0.00011191241,0.0001374108],"genre_scores_gemma":[0.98649865,0.00028093575,0.0006882819,0.009233042,0.00025184487,0.00029776798,0.002086696,0.00017334624,0.000489461],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953401,0.00080724654,0.00083208526,0.0011882614,0.00075855234,0.0010737672],"domain_scores_gemma":[0.9920337,0.0055739083,0.0006746369,0.00074182067,0.00043764073,0.00053825596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007034906,0.0009969207,0.001610245,0.00036843776,0.00064882846,0.0001884746,0.00026027163,0.0007686204,0.000007704731],"category_scores_gemma":[0.0002738353,0.0006892079,0.00019130138,0.00026089046,0.0010857127,0.0002585962,0.000170041,0.0003792038,0.0000033733384],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14031489,0.002574016,0.5491839,0.01613862,0.007285703,0.008864384,0.008715168,0.00006238085,0.008573071,0.00009465533,0.12243049,0.1357627],"study_design_scores_gemma":[0.1117885,0.007474603,0.83026814,0.00273494,0.002279145,0.0018511906,0.0007755721,0.005904392,0.003751086,0.0001957591,0.031318862,0.0016578047],"about_ca_topic_score_codex":0.0019878733,"about_ca_topic_score_gemma":0.00027679326,"teacher_disagreement_score":0.2810842,"about_ca_system_score_codex":0.0024952763,"about_ca_system_score_gemma":0.0032700927,"threshold_uncertainty_score":0.9995559},"labels":[],"label_agreement":null},{"id":"W1933195564","doi":"10.3109/10428194.2015.1055480","title":"Impact of time from diagnosis to initiation of curative chemotherapy on survival of patients with diffuse large B-cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Internal medicine; Chemotherapy; Lymphoma; Gastroenterology; Multivariate analysis; CHOP; Oncology; Surgery","score_opus":0.011959820987386145,"score_gpt":0.2533390327014776,"score_spread":0.24137921171409146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1933195564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99457437,0.0004112164,0.000033489032,0.00006506647,0.00013351881,0.0012520974,0.0013546394,0.00006682272,0.002108796],"genre_scores_gemma":[0.9977141,0.0002919763,0.00048956583,0.0003220787,0.000103523256,0.00016885855,0.0006772147,0.000119671175,0.00011300106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958722,0.00019485883,0.0011427696,0.00087638554,0.0012320001,0.0006817822],"domain_scores_gemma":[0.99591196,0.0006394146,0.0009062752,0.00096026616,0.00081289565,0.0007691792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026652013,0.00081916654,0.0017982599,0.00045287868,0.000092709575,0.000033449556,0.00029300697,0.00038373683,0.00010430819],"category_scores_gemma":[0.00017849971,0.0006062622,0.00043638304,0.00076312956,0.00024952734,0.00028783982,0.00013714333,0.000056813526,0.000048331265],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011640224,0.017319655,0.913803,0.00015567969,0.0012341196,0.00007166056,0.0041758916,0.000062637664,0.0011696244,0.00014725492,0.0016675777,0.048552673],"study_design_scores_gemma":[0.11643529,0.005742162,0.83280325,0.000533544,0.00044726834,0.000009999255,0.00026632496,0.0003509747,0.042187564,0.00007120832,0.00063565397,0.00051678595],"about_ca_topic_score_codex":0.0035404474,"about_ca_topic_score_gemma":0.0000565617,"teacher_disagreement_score":0.10479507,"about_ca_system_score_codex":0.005627714,"about_ca_system_score_gemma":0.003086279,"threshold_uncertainty_score":0.99963886},"labels":[],"label_agreement":null},{"id":"W1946080547","doi":"10.3109/10428194.2015.1080927","title":"Enhancing monoclonal antibody activity in chronic lymphocytic leukemia","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Monoclonal antibody; Medicine; Leukemia; Antibody; Monoclonal; Cancer research; Immunology","score_opus":0.023307284470340316,"score_gpt":0.30278116081969697,"score_spread":0.27947387634935666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1946080547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9529018,0.014335957,0.00018122567,0.010788556,0.0022050433,0.004705143,0.0003757475,0.0013702326,0.013136302],"genre_scores_gemma":[0.74262875,0.009003273,0.0015026778,0.17701758,0.022950687,0.0016736784,0.005102612,0.0025757756,0.037544962],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97845554,0.0010911595,0.0034203841,0.005510982,0.0052630403,0.0062589115],"domain_scores_gemma":[0.9890256,0.0017660029,0.0014936557,0.004567543,0.00096001825,0.0021872027],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0025756445,0.0040950803,0.0059922263,0.0030507524,0.0007139352,0.0007417511,0.002219812,0.007551838,0.00040700674],"category_scores_gemma":[0.0009683778,0.00408529,0.0014176538,0.003032305,0.002022088,0.0012295558,0.0019639984,0.003808687,0.0012331975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005594069,0.00028571772,0.00066161493,0.013326406,0.0024335315,0.079613455,0.0019665628,0.0014827731,0.025564315,0.0001593465,0.77934486,0.08956734],"study_design_scores_gemma":[0.13408393,0.0019683654,0.004165501,0.006637753,0.0015669314,0.021897713,0.0002894442,0.13176577,0.015691413,0.0006091841,0.67534333,0.0059807],"about_ca_topic_score_codex":0.042888686,"about_ca_topic_score_gemma":0.0013705922,"teacher_disagreement_score":0.3182443,"about_ca_system_score_codex":0.7876294,"about_ca_system_score_gemma":0.46938512,"threshold_uncertainty_score":0.99954444},"labels":[],"label_agreement":null},{"id":"W1962960638","doi":"10.3109/10428194.2015.1091927","title":"A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre; University of Alberta; Juravinski Cancer Centre; Saint John Regional Hospital; Dalhousie University; University of New Brunswick; Queen's University","funders":"","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Internal medicine; Oncology; Clinical trial; Kinase; Malignancy; Aurora A kinase; Aurora kinase; Cancer; Biology; Cell cycle","score_opus":0.03363137153877019,"score_gpt":0.31310350323689096,"score_spread":0.2794721316981208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1962960638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99435663,0.0007897493,0.00003060673,0.00023987271,0.00085912854,0.0029720026,0.0005912554,0.00007197396,0.00008878932],"genre_scores_gemma":[0.97234523,0.00040551779,0.00041050816,0.01642477,0.0026575923,0.0003587656,0.0062242467,0.00037987417,0.0007934895],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98904,0.0025877263,0.0034560915,0.0025814176,0.0010939653,0.0012407884],"domain_scores_gemma":[0.9939478,0.00044672145,0.0021747625,0.0022912351,0.0005477411,0.0005917447],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0027862275,0.001582107,0.003114028,0.00056756585,0.00028986245,0.00012283158,0.0010767153,0.003644617,0.000020027499],"category_scores_gemma":[0.0011738992,0.0012701245,0.00048454592,0.00056162215,0.0005347579,0.00007756252,0.0007781238,0.00092745136,0.000008247511],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08062745,0.041492496,0.06162798,0.0012948341,0.0032786673,0.003343557,0.0042486866,0.000050485807,0.017460579,0.000007906585,0.4092667,0.37730065],"study_design_scores_gemma":[0.3617333,0.10267627,0.025657065,0.0009641019,0.0016441756,0.00016293243,0.0015203939,0.0005813569,0.0026009812,0.00003459407,0.49807563,0.004349212],"about_ca_topic_score_codex":0.0015193883,"about_ca_topic_score_gemma":0.0015360041,"teacher_disagreement_score":0.37295142,"about_ca_system_score_codex":0.002153442,"about_ca_system_score_gemma":0.005490752,"threshold_uncertainty_score":0.9996927},"labels":[],"label_agreement":null},{"id":"W1963756566","doi":"10.1080/10428190500467917","title":"Sequential response-adapted induction and consolidation regimens idarubicin/cytarabine and mitoxantrone/etoposide in adult acute myelogenous leukemia: 10 year follow-up of a study by the Canadian Leukemia Studies Group","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Royal University Hospital; Toronto General Hospital; Royal Victoria Hospital; McGill University; University of Saskatchewan; University of Alberta; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Idarubicin; Mitoxantrone; Etoposide; Cytarabine; Medicine; Internal medicine; Induction chemotherapy; Leukemia; Gastroenterology; Myeloid leukemia; Chemotherapy; Surgery","score_opus":0.015760184884850897,"score_gpt":0.2675952253422972,"score_spread":0.2518350404574463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963756566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906798,0.0038598957,0.000017951495,0.0011560513,0.00034275308,0.0029146038,0.00019943391,0.00015297024,0.00067656266],"genre_scores_gemma":[0.99271345,0.0017983625,0.00034099544,0.0006604319,0.00035951432,0.00032124828,0.0003207279,0.00018685301,0.0032984256],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9924234,0.0010479037,0.0017556392,0.0017685734,0.0013135999,0.001690889],"domain_scores_gemma":[0.9957846,0.0008488344,0.0006455752,0.0012185687,0.0007597557,0.0007426571],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020596194,0.0011584972,0.0018992637,0.0012235757,0.0010673545,0.00024347307,0.00049594167,0.000968224,0.00003614915],"category_scores_gemma":[0.0006421892,0.0009712088,0.0002147453,0.0014265821,0.0017740482,0.0005648331,0.00044816796,0.00069566886,0.000021748285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07952483,0.0014246755,0.11452924,0.0017599119,0.008050842,0.0067211613,0.03309136,0.0003148946,0.5749548,0.0039006812,0.09045508,0.085272536],"study_design_scores_gemma":[0.20938927,0.009169016,0.6411736,0.0016729569,0.0048459047,0.010847372,0.037435275,0.009284722,0.05405326,0.0012485228,0.016675504,0.004204628],"about_ca_topic_score_codex":0.3022431,"about_ca_topic_score_gemma":0.15292107,"teacher_disagreement_score":0.52664435,"about_ca_system_score_codex":0.03239385,"about_ca_system_score_gemma":0.011358444,"threshold_uncertainty_score":0.99927384},"labels":[],"label_agreement":null},{"id":"W1965448482","doi":"10.1080/10428190802668873","title":"HLA risk markers for chronic myelogenous leukemia in Eastern Canada","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University","funders":"","keywords":"Human leukocyte antigen; Chronic myelogenous leukemia; Immunology; Odds ratio; Antigen; Medicine; Leukemia; Population; Oncology; Internal medicine","score_opus":0.008109764680904099,"score_gpt":0.22981611971363863,"score_spread":0.22170635503273453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965448482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98316157,0.006434698,0.00013006992,0.0004120589,0.000699336,0.0027297072,0.00024926802,0.0003192335,0.0058640735],"genre_scores_gemma":[0.9875944,0.0020268734,0.0012540474,0.002725844,0.0009052132,0.00037296693,0.00044386403,0.00023008398,0.0044466928],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99219227,0.00022873835,0.0017021224,0.0021248776,0.0011646841,0.0025872819],"domain_scores_gemma":[0.9955858,0.0006109683,0.00067323016,0.0016734026,0.00024231762,0.0012142675],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006884848,0.0015175366,0.001997686,0.0005852881,0.00059216964,0.0001579268,0.0006825768,0.00091056316,0.00012615285],"category_scores_gemma":[0.00034885344,0.0014764235,0.00050900056,0.0009692981,0.00033337064,0.0003901962,0.00019215161,0.0004306889,0.000066907654],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005399802,0.0003746852,0.044370115,0.00086572324,0.000940342,0.0032026442,0.0011270902,0.001582036,0.002826897,0.0004161194,0.019059012,0.9198355],"study_design_scores_gemma":[0.11402038,0.0038405391,0.65769356,0.0015559075,0.0014914069,0.004143486,0.00095733424,0.084617995,0.0057382854,0.0008780991,0.12180335,0.0032596313],"about_ca_topic_score_codex":0.41914842,"about_ca_topic_score_gemma":0.21720411,"teacher_disagreement_score":0.9165759,"about_ca_system_score_codex":0.16297175,"about_ca_system_score_gemma":0.059374757,"threshold_uncertainty_score":0.99975735},"labels":[],"label_agreement":null},{"id":"W1967060888","doi":"10.3109/10428194.2011.559670","title":"Does pretreatment fluorescence<i>in situ</i>hybridization for<i>BCR–ABL</i>predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Fluorescence in situ hybridization; Imatinib; Myeloid leukemia; Medicine; Chronic myelogenous leukemia; Philadelphia chromosome; Internal medicine; Gastroenterology; breakpoint cluster region; Leukemia; Hematology; Haematopoiesis; Myeloid; Immunology; Cancer research; Stem cell; Biology; Chromosomal translocation; Chromosome; Receptor","score_opus":0.015208323174291393,"score_gpt":0.24080128363944112,"score_spread":0.22559296046514973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1967060888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879866,0.0019748525,0.0001868572,0.00011661304,0.00061159796,0.003922049,0.00017901084,0.0005797327,0.00444268],"genre_scores_gemma":[0.99032074,0.002266841,0.0029495952,0.0005807716,0.00030207747,0.0013550202,0.0008122415,0.00024956572,0.0011631424],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914571,0.0003665078,0.0022975202,0.0024006236,0.0010501057,0.0024281484],"domain_scores_gemma":[0.9959474,0.00062140106,0.00087224244,0.0014861383,0.0002753083,0.0007975104],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00096327596,0.0016187727,0.0024312711,0.0008983957,0.0004204144,0.00013028932,0.00066655333,0.0012567195,0.00018146109],"category_scores_gemma":[0.00060992903,0.0012489383,0.00056223664,0.001497757,0.0005786255,0.00074655836,0.00036224237,0.0004065085,0.00008271152],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012633619,0.0063639153,0.60066205,0.0055638263,0.0030030925,0.008394918,0.015999805,0.00087050523,0.110166594,0.0034633812,0.0057123806,0.2271659],"study_design_scores_gemma":[0.117856026,0.0034471462,0.6260915,0.0039092144,0.0011904403,0.0014967748,0.0012733436,0.036257423,0.2010589,0.0024287316,0.00200386,0.0029866586],"about_ca_topic_score_codex":0.006099627,"about_ca_topic_score_gemma":0.0036619524,"teacher_disagreement_score":0.22417924,"about_ca_system_score_codex":0.10008414,"about_ca_system_score_gemma":0.012427078,"threshold_uncertainty_score":0.99965596},"labels":[],"label_agreement":null},{"id":"W1968585362","doi":"10.1080/10428190210181","title":"Malignant Evolution of Schnitzler's Syndrome--Chronic Urticaria and IgM Monoclonal Gammopathy: Report of a New Case and Review of the Literature","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Gammopathy; Dermatology; Waldenstrom macroglobulinemia; Bone marrow; Lymphoproliferative disorders; Macroglobulinemia; Bone pain; Chronic lymphocytic leukemia; Pathology; Monoclonal; Lymphoma; Multiple myeloma; Immunology; Leukemia; Monoclonal antibody; Antibody","score_opus":0.00895995537372538,"score_gpt":0.2407459136849422,"score_spread":0.23178595831121682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968585362","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.092495695,0.90601414,0.000014320165,0.000017404069,0.00015311492,0.0009000479,0.0001428396,0.000010071624,0.0002523926],"genre_scores_gemma":[0.024876807,0.97380775,0.00014142679,0.000049903334,0.00010780434,0.000059494087,0.00022114498,0.0000775826,0.0006580578],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963262,0.0002647124,0.001697796,0.0008870839,0.00034870888,0.00047546698],"domain_scores_gemma":[0.99679244,0.000060523715,0.0015156553,0.0012089037,0.00023168791,0.0001907806],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046821067,0.00076469977,0.0020328362,0.00018429532,0.00014012904,0.000035473877,0.00038106297,0.00089021685,0.00001506272],"category_scores_gemma":[0.00022343248,0.00056653784,0.0006351725,0.00053633074,0.0005461907,0.000027391627,0.0005041974,0.00016682227,0.0000010958223],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009399874,0.00009926041,0.00022044664,0.10505541,0.0012589783,0.0016490741,0.00025437807,0.0000020579328,0.0013446005,0.00044531393,0.0020935955,0.8874829],"study_design_scores_gemma":[0.0047492664,0.0008582935,0.0010657532,0.1369153,0.0048925667,0.17101161,0.00013230031,0.00006718351,0.001728117,0.00013729364,0.6769905,0.0014517751],"about_ca_topic_score_codex":0.0004937633,"about_ca_topic_score_gemma":0.00002755379,"teacher_disagreement_score":0.8860311,"about_ca_system_score_codex":0.00074696745,"about_ca_system_score_gemma":0.0052854205,"threshold_uncertainty_score":0.9996786},"labels":[],"label_agreement":null},{"id":"W1968622004","doi":"10.3109/10428194.2010.496506","title":"Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Biochemical and Molecular Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Ribavirin; IMP dehydrogenase; Cancer; Medicine; Leukemia; Myeloid leukemia; EIF4E; Cancer research; Immunology; Biology; Virus; Hepatitis C virus; Internal medicine; Translation (biology); Transplantation; Mycophenolic acid; Gene; Genetics","score_opus":0.0170753322536928,"score_gpt":0.3112245452087337,"score_spread":0.29414921295504093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968622004","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24205779,0.7536455,0.000018075712,0.000041560743,0.00038708074,0.0011659644,0.00034354065,0.00011248926,0.0022280007],"genre_scores_gemma":[0.005427323,0.9837599,0.00035721442,0.0013088793,0.0013244711,0.00064721465,0.002148651,0.0004468619,0.004579523],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99252146,0.00046647576,0.0012745535,0.0030890151,0.00086024037,0.0017882653],"domain_scores_gemma":[0.99560016,0.00009895362,0.000618552,0.0020671831,0.0002598898,0.0013552834],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006018875,0.0020322998,0.0026761817,0.0003757628,0.00062086975,0.00051404175,0.001545091,0.003696938,0.000100591395],"category_scores_gemma":[0.00010487837,0.0017228998,0.00090834073,0.00056312385,0.0012101621,0.00006020182,0.0012910848,0.00081047876,0.00009166455],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023172038,0.00012521782,0.000030027179,0.0014202687,0.0008164533,0.000196056,0.0000635748,5.1222406e-7,0.056315906,0.00022004482,0.0018424625,0.93873775],"study_design_scores_gemma":[0.0047435146,0.00063606154,0.00011617193,0.00084545516,0.0006892461,0.0021003408,0.000038808586,0.00004335436,0.036192536,0.00015546686,0.9523066,0.0021324183],"about_ca_topic_score_codex":0.0008700863,"about_ca_topic_score_gemma":0.00006912162,"teacher_disagreement_score":0.9504642,"about_ca_system_score_codex":0.0017037323,"about_ca_system_score_gemma":0.008324704,"threshold_uncertainty_score":0.99924195},"labels":[],"label_agreement":null},{"id":"W1969392166","doi":"10.1080/10428190290017114","title":"ALK-positive Anaplastic Large T-cell Lymphoma Preceded by Epstein-Barr Virus Infection Complicated by Development of an Aorto-esophageal Fistula","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lymphoma; Epstein–Barr virus; Fistula; Anaplastic large-cell lymphoma; Anaplastic lymphoma kinase; Virus; Chemotherapy; Pathology; Immunology; Internal medicine; Radiology; Lung cancer","score_opus":0.009485274140353299,"score_gpt":0.23115687166377036,"score_spread":0.22167159752341706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969392166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865221,0.0044344636,0.0002851201,0.000083515704,0.0003151738,0.0015177974,0.00069640717,0.0004206172,0.0057248184],"genre_scores_gemma":[0.99161965,0.0012406464,0.000984781,0.0009526421,0.00016502151,0.00043944083,0.0022630799,0.00020884264,0.0021258795],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99326247,0.00029832608,0.0018017957,0.0018732385,0.001168118,0.0015960677],"domain_scores_gemma":[0.99600327,0.00037678296,0.0008203963,0.0011525949,0.00035835724,0.0012885978],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003813415,0.0014044552,0.0018041799,0.000452189,0.0008636442,0.00018263036,0.0004189616,0.0008552325,0.0003014398],"category_scores_gemma":[0.00007868473,0.0013220763,0.00040476755,0.000928033,0.00042298832,0.00053340883,0.00026797884,0.00014818709,0.0002417474],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004625608,0.03209772,0.05447117,0.0015628263,0.0032087578,0.0015286849,0.0077012377,0.00006178819,0.109650984,0.00040138635,0.07654181,0.708148],"study_design_scores_gemma":[0.10749603,0.003935106,0.2858205,0.00074765,0.0014574152,0.0016339879,0.00039754107,0.016844913,0.5147538,0.000056716162,0.06437477,0.0024815444],"about_ca_topic_score_codex":0.0031482677,"about_ca_topic_score_gemma":0.00033129656,"teacher_disagreement_score":0.7056665,"about_ca_system_score_codex":0.009708332,"about_ca_system_score_gemma":0.0015875272,"threshold_uncertainty_score":0.9998706},"labels":[],"label_agreement":null},{"id":"W1969461242","doi":"10.1080/10428190801993470","title":"Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"National Cancer Institute","keywords":"Medicine; Rituximab; DHAP; Chemotherapy; Oncology; Internal medicine; Lymphoma; Hodgkin lymphoma; Salvage therapy; Biology","score_opus":0.018076305265650464,"score_gpt":0.27221272113167416,"score_spread":0.2541364158660237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969461242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98802954,0.0028033382,0.000091094895,0.0010157712,0.00048047327,0.006156188,0.00028094312,0.00021407702,0.0009285604],"genre_scores_gemma":[0.9824636,0.005307114,0.0009967682,0.0032291287,0.0011406189,0.005187008,0.00056456064,0.00021783862,0.00089336146],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9938071,0.00019820635,0.001279304,0.0017582187,0.0010154599,0.00194176],"domain_scores_gemma":[0.99673796,0.0005440846,0.00051337807,0.0013328838,0.00016462538,0.0007070955],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00033923754,0.0014651911,0.0020478514,0.000406407,0.0012136252,0.00014552091,0.00051333633,0.0005542202,0.00006977784],"category_scores_gemma":[0.0000488971,0.0009421615,0.0007192966,0.00097444194,0.0006104306,0.00039245494,0.00009719128,0.00012232164,0.000020561492],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.23045643,0.03700059,0.068539836,0.00038261144,0.0024863158,0.0057637333,0.018512065,0.00006598773,0.00055824383,0.0005930377,0.011355517,0.62428564],"study_design_scores_gemma":[0.6982388,0.018499756,0.22545874,0.00032342892,0.0009673715,0.0020415538,0.0006115387,0.0019950853,0.0016774593,0.00004847835,0.049051743,0.0010860811],"about_ca_topic_score_codex":0.007955142,"about_ca_topic_score_gemma":0.0020492924,"teacher_disagreement_score":0.6231996,"about_ca_system_score_codex":0.014891688,"about_ca_system_score_gemma":0.005758763,"threshold_uncertainty_score":0.9998777},"labels":[],"label_agreement":null},{"id":"W1969894871","doi":"10.1080/10428190310001615666","title":"Subdural Hematomas during CML Therapy with Imatinib Mesylate","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib mesylate; Mesylate; Medicine; Imatinib; Subdural Hematomas; Oncology; Internal medicine; Myeloid leukemia; Surgery; Hematoma; Chemistry","score_opus":0.009542626261534072,"score_gpt":0.23355689386411407,"score_spread":0.22401426760258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969894871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98623633,0.003774794,0.00006425163,0.0004417179,0.0002479439,0.0014239666,0.00003412672,0.0008222551,0.0069545885],"genre_scores_gemma":[0.9906052,0.0017076471,0.0030691759,0.0011634711,0.00045722668,0.00027525076,0.00015202959,0.00030577587,0.0022642296],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9942943,0.00009716848,0.0010803613,0.0016222025,0.001184088,0.0017219082],"domain_scores_gemma":[0.99664533,0.00014637996,0.0004597623,0.0015052356,0.00022387915,0.0010194011],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00026959725,0.0013405186,0.0015602253,0.00044462414,0.00067798723,0.00020964259,0.00043389606,0.0005982373,0.00024244648],"category_scores_gemma":[0.00006387871,0.0010485386,0.0003968842,0.0008802352,0.000614744,0.0006093073,0.00021514048,0.00027870413,0.00028793962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04830943,0.006034901,0.17225511,0.0058578085,0.011673008,0.04859112,0.02523507,0.0021385716,0.16962545,0.014311476,0.004167665,0.4918004],"study_design_scores_gemma":[0.24495387,0.0029438455,0.4843164,0.0023323952,0.00089484133,0.03903173,0.0014477142,0.001113894,0.20930457,0.001309939,0.00921106,0.0031397382],"about_ca_topic_score_codex":0.0022324806,"about_ca_topic_score_gemma":0.00011981516,"teacher_disagreement_score":0.48866066,"about_ca_system_score_codex":0.018151678,"about_ca_system_score_gemma":0.007275259,"threshold_uncertainty_score":0.9999346},"labels":[],"label_agreement":null},{"id":"W1970810546","doi":"10.3109/10428194.2011.594925","title":"Durable event-free survival following autologous stem cell transplant for relapsed or refractory follicular lymphoma: positive impact of recent rituximab exposure and low-risk Follicular Lymphoma International Prognostic Index score","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Follicular lymphoma; International Prognostic Index; Oncology; Autologous stem-cell transplantation; Refractory (planetary science); Confidence interval; Lymphoma; Chemotherapy; Surgery","score_opus":0.015737094584909357,"score_gpt":0.24472084131699387,"score_spread":0.22898374673208452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1970810546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863373,0.005869914,0.00040162285,0.00009026931,0.0012030428,0.0032464284,0.0011036292,0.00029698497,0.0014507931],"genre_scores_gemma":[0.9911023,0.0052385577,0.001047925,0.00022344984,0.0002734012,0.0007969389,0.0006273584,0.00027862028,0.0004114742],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9922752,0.0004282946,0.0020525001,0.0021220136,0.0014187853,0.0017032068],"domain_scores_gemma":[0.9944022,0.0010360683,0.0012356375,0.001606725,0.0006077335,0.0011116179],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000899258,0.001694648,0.0026388746,0.0006652511,0.00069981185,0.0001845989,0.0008369531,0.00116148,0.000109733526],"category_scores_gemma":[0.00029181025,0.0013317752,0.0015203973,0.00075686077,0.00048399597,0.00071347115,0.00035649326,0.00017205597,0.000019060846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.031006549,0.011192337,0.5591725,0.0016271438,0.010004132,0.008956383,0.008401171,0.00009194352,0.0050551267,0.00064880087,0.0012037811,0.3626401],"study_design_scores_gemma":[0.14297296,0.006163849,0.81620514,0.0017719034,0.003780231,0.0022804167,0.0012561405,0.004141693,0.018155662,0.00042514462,0.0011193032,0.0017275313],"about_ca_topic_score_codex":0.0044523333,"about_ca_topic_score_gemma":0.00022697994,"teacher_disagreement_score":0.3609126,"about_ca_system_score_codex":0.009398334,"about_ca_system_score_gemma":0.0061504156,"threshold_uncertainty_score":0.99958},"labels":[],"label_agreement":null},{"id":"W1971210973","doi":"10.1080/1042819021000040161","title":"It is ALL in the Heart: A Patient with Acute Lymphoblastic Leukemia and Cardiac Infiltration at Time of Diagnosis","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cardiac tumors and thrombi","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Infiltration (HVAC); Lesion; Chemotherapy; Radiology; Cardiology; Leukemia; Internal medicine; Surgery","score_opus":0.010487275243052164,"score_gpt":0.22333701183906607,"score_spread":0.21284973659601392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971210973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98861647,0.0032020602,0.000006005213,0.0011947971,0.00014539072,0.0011617374,0.00014544118,0.00007866705,0.005449449],"genre_scores_gemma":[0.98970336,0.0028803933,0.00019340978,0.0058702747,0.00016761108,0.00031243925,0.0000801597,0.00009743292,0.000694913],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960371,0.00022378567,0.0009351525,0.0009786475,0.0009695208,0.000855764],"domain_scores_gemma":[0.9975885,0.000566844,0.0003437159,0.0009422365,0.00014882079,0.0004098537],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036884338,0.00073305273,0.0013842089,0.00032158804,0.00026707578,0.00011639769,0.00021867633,0.00038942628,0.00020523898],"category_scores_gemma":[0.00007572346,0.0005361927,0.00034403725,0.0007252337,0.000537329,0.00031292447,0.00019978244,0.00016362839,0.00009645365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055788727,0.0018128122,0.35300496,0.0018467216,0.0041643046,0.005490643,0.08738711,0.00033274209,0.028457955,0.0009084051,0.34197617,0.16903931],"study_design_scores_gemma":[0.03317863,0.0044412883,0.79308474,0.0016038825,0.0031338397,0.011815217,0.0023920818,0.012398874,0.020281874,0.00018949504,0.11531831,0.00216177],"about_ca_topic_score_codex":0.0014854649,"about_ca_topic_score_gemma":0.000078499426,"teacher_disagreement_score":0.44007978,"about_ca_system_score_codex":0.0048652794,"about_ca_system_score_gemma":0.0009530276,"threshold_uncertainty_score":0.99970895},"labels":[],"label_agreement":null},{"id":"W1971583640","doi":"10.1080/1042819021000046994","title":"Evaluation for the Development of 11q23 Rearrangements in Lymphoma Patients Treated with a High Dose VP-16 and Cyclophosphamide Salvage Regimen","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McGill University Health Centre","funders":"McGill University","keywords":"Cyclophosphamide; Medicine; Regimen; Internal medicine; Salvage therapy; Lymphoma; Chemotherapy; Oncology; Cytogenetics; Chromosomal translocation; Transplantation; Gastroenterology; Surgery; Biology; Chromosome","score_opus":0.017610928255528475,"score_gpt":0.26809840145091446,"score_spread":0.250487473195386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1971583640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906579,0.0019360319,0.00016238143,0.000119817574,0.00012290596,0.0042199627,0.00004416423,0.00008710374,0.002649678],"genre_scores_gemma":[0.99249446,0.00054334564,0.0039008996,0.00039532653,0.00007241299,0.0011938589,0.00025085834,0.00015968713,0.0009891427],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941416,0.0003957065,0.001290177,0.0012445811,0.0017458347,0.0011821269],"domain_scores_gemma":[0.9964708,0.0007244487,0.0005206017,0.0009923961,0.0008278924,0.0004638227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024752207,0.000814748,0.0011172805,0.0005433063,0.0004952006,0.00010235749,0.0003690699,0.00046208774,0.00005840291],"category_scores_gemma":[0.00067231385,0.0005845168,0.00014152225,0.0010996647,0.00052775705,0.00033804867,0.00018564373,0.000145978,0.000013242524],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008843048,0.0010225589,0.20442078,0.00084241136,0.0014804263,0.00011567879,0.004648604,0.00006836563,0.0031317112,0.00073606486,0.0021145502,0.7725758],"study_design_scores_gemma":[0.09445614,0.0010623013,0.8681654,0.0007063847,0.00085146184,0.00019204937,0.0012993662,0.0029166157,0.019073332,0.0003165833,0.010118202,0.00084219873],"about_ca_topic_score_codex":0.0019780225,"about_ca_topic_score_gemma":0.0004898841,"teacher_disagreement_score":0.77173364,"about_ca_system_score_codex":0.0155094825,"about_ca_system_score_gemma":0.008036297,"threshold_uncertainty_score":0.9996606},"labels":[],"label_agreement":null},{"id":"W1975979823","doi":"10.3109/10428194.2013.783211","title":"High dose salvage therapy with dose intensive cyclophosphamide, etoposide and cisplatin may increase transplant rates for relapsed/refractory aggressive non-Hodgkin lymphoma","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Rituximab; Etoposide; Internal medicine; Salvage therapy; International Prognostic Index; Regimen; Gastroenterology; Cyclophosphamide; Refractory (planetary science); Surgery; Chemotherapy; Induction chemotherapy; Progression-free survival; Oncology; Lymphoma","score_opus":0.008772769486172028,"score_gpt":0.24535839739229398,"score_spread":0.23658562790612195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975979823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98351616,0.009112012,0.000061431965,0.000910942,0.0004264278,0.0044635744,0.00031628672,0.00033643423,0.000856756],"genre_scores_gemma":[0.9765485,0.010505484,0.0029032696,0.0049954606,0.00045869057,0.0025109756,0.0007088961,0.00033316785,0.0010355334],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934649,0.00022415572,0.0014463977,0.0021888118,0.0009117488,0.0017639967],"domain_scores_gemma":[0.99375033,0.0015245219,0.0010311074,0.0013258453,0.0008696964,0.0014985189],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003981635,0.0018520883,0.0022911725,0.0005322822,0.00081838475,0.00043641898,0.0004291384,0.000934337,0.00018880512],"category_scores_gemma":[0.00020628946,0.0013620647,0.00048386373,0.0006219411,0.0009576859,0.0008708505,0.00018825647,0.00020710652,0.00010836772],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028913772,0.0027869628,0.13484257,0.0011316703,0.0038990828,0.0076649715,0.006277368,0.000048244354,0.016179735,0.0017609858,0.015613759,0.78088087],"study_design_scores_gemma":[0.13206461,0.004854204,0.8041553,0.002104947,0.00127529,0.0051664296,0.001513879,0.0016411074,0.03748245,0.0007864671,0.0068552312,0.0021001163],"about_ca_topic_score_codex":0.014002888,"about_ca_topic_score_gemma":0.00020526144,"teacher_disagreement_score":0.77878076,"about_ca_system_score_codex":0.0046612625,"about_ca_system_score_gemma":0.0033440734,"threshold_uncertainty_score":0.9994224},"labels":[],"label_agreement":null},{"id":"W1977454299","doi":"10.3109/10428190009059264","title":"Genetic Susceptibility to Childhood Acute Lymphoblastic Leukemia","year":2000,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Glutathione Transferases and Polymorphisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"Fondation Charles-Bruneau","keywords":"Carcinogen; Gene; Biology; Genotype; Xenobiotic; Genetics; Allele; Disease; Genetic predisposition; Population; Cancer; Leukemia; CYP2D6; Immunology; Enzyme; Cancer research; Medicine; Internal medicine; Environmental health; Biochemistry","score_opus":0.009501121922564146,"score_gpt":0.2501183339075237,"score_spread":0.24061721198495956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977454299","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12581842,0.8680637,0.00023668,0.000022599912,0.0008455212,0.0023053277,0.0010530202,0.00023700988,0.0014177569],"genre_scores_gemma":[0.01491943,0.9757501,0.0008986168,0.0012825719,0.0017407319,0.0006659568,0.0015656413,0.0006032542,0.002573704],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900755,0.0005696091,0.00236326,0.003758471,0.0008931215,0.0023399831],"domain_scores_gemma":[0.9944507,0.00020323096,0.0005542573,0.0029359802,0.00016906788,0.0016867502],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0004300779,0.0028551223,0.0037794288,0.0006088205,0.00071895064,0.0004005416,0.0018053876,0.002565362,0.0002820517],"category_scores_gemma":[0.000103905324,0.0026548672,0.0018960182,0.0010471094,0.0005541086,0.000038013048,0.0006926844,0.00038576446,0.00084733893],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00032001443,0.00018317888,0.000039933562,0.0023062478,0.0011300026,0.0003604199,0.00020576418,0.00009249989,0.000342761,0.00004942019,0.0059684208,0.98900133],"study_design_scores_gemma":[0.0051587555,0.0010932927,0.0014123893,0.0029400566,0.0028643701,0.0038694611,0.000039127663,0.00006982547,0.00031033516,0.00007450849,0.97897106,0.003196805],"about_ca_topic_score_codex":0.0008876534,"about_ca_topic_score_gemma":0.00020995554,"teacher_disagreement_score":0.98580456,"about_ca_system_score_codex":0.0055055143,"about_ca_system_score_gemma":0.012069659,"threshold_uncertainty_score":0.9999306},"labels":[],"label_agreement":null},{"id":"W1977911898","doi":"10.1080/10428190290026259","title":"The Role of Interleukin 13 in Classical Hodgkin Lymphoma","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Autocrine signalling; Lymphoma; Cancer research; Cytokine; STAT protein; Biology; Interleukin 9; Immune system; Immunology; Interleukin; Reed–Sternberg cell; Cell culture; Signal transduction; STAT3; Cell biology; Hodgkin lymphoma","score_opus":0.01843052369170105,"score_gpt":0.2748539430926376,"score_spread":0.25642341940093655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1977911898","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02980521,0.9547249,0.000002110973,0.00011362194,0.00062849105,0.0025038773,0.00016101179,0.0002085035,0.011852287],"genre_scores_gemma":[0.03728555,0.9575989,0.00017456237,0.0002279725,0.0006253357,0.0012088229,0.00028258516,0.00036128866,0.0022349635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899603,0.00070056925,0.00358964,0.002251096,0.0014355791,0.0020628255],"domain_scores_gemma":[0.9925738,0.0021544609,0.0015822479,0.0024916541,0.00023325726,0.0009645755],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00082269224,0.0023800074,0.006252119,0.0010337698,0.00050163275,0.00030670088,0.0012368663,0.0020823993,0.00012158037],"category_scores_gemma":[0.00034075344,0.0016152603,0.0021588383,0.0016930577,0.0012055074,0.00028780525,0.00076118606,0.00039595022,0.00033720437],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033291298,0.0009827394,0.0010205562,0.003935674,0.0010730979,0.0010585262,0.00037367584,0.0000011987989,0.0000067625106,0.0019810654,0.0023542258,0.9868796],"study_design_scores_gemma":[0.015281121,0.00064888445,0.005526684,0.01588034,0.002719829,0.0038570985,0.0003556739,0.00063431775,0.00015474197,0.00036418444,0.9531462,0.0014308926],"about_ca_topic_score_codex":0.002176804,"about_ca_topic_score_gemma":0.00038144094,"teacher_disagreement_score":0.98544866,"about_ca_system_score_codex":0.020534938,"about_ca_system_score_gemma":0.0074296747,"threshold_uncertainty_score":0.9992131},"labels":[],"label_agreement":null},{"id":"W1978479182","doi":"10.3109/10428194.2015.1014360","title":"Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"Celgene","keywords":"Romidepsin; Medicine; Erythroderma; Lymphoma; Cutaneous T-cell lymphoma; Disease; Mycosis fungoides; Compartment (ship); Dermatology; Clinical trial; Oncology; Immunology; Internal medicine; Histone deacetylase; Biology","score_opus":0.02046494650976327,"score_gpt":0.2879299070320824,"score_spread":0.2674649605223191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978479182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935854,0.0005528757,0.000055676326,0.00030283225,0.00015856947,0.0029232765,0.0003066391,0.0003086239,0.0018061234],"genre_scores_gemma":[0.9933792,0.00016956525,0.0011008916,0.00158341,0.00014322215,0.00033182887,0.0005480249,0.00031088557,0.002432969],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99054384,0.0006940622,0.001659015,0.0022357723,0.0025672298,0.002300102],"domain_scores_gemma":[0.99316394,0.0007731422,0.00057396916,0.001715659,0.00094359845,0.0028297007],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000887579,0.0014139925,0.0019438562,0.00052360445,0.0004937293,0.00037608427,0.0007070834,0.00053011125,0.000047344103],"category_scores_gemma":[0.00065954693,0.0010991273,0.0002590229,0.0012854278,0.0014099382,0.0004749575,0.00044725195,0.00029984795,0.00016855594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.116164126,0.003628384,0.84899783,0.00028261507,0.00031347602,0.0066723186,0.001831279,0.00020394956,0.0002398922,0.0000324866,0.00090941583,0.020724205],"study_design_scores_gemma":[0.1264058,0.005598379,0.85524565,0.0006790696,0.00033991973,0.0014755658,0.0018151352,0.0033509282,0.00083063205,0.000109366774,0.0024826592,0.0016668815],"about_ca_topic_score_codex":0.0015587369,"about_ca_topic_score_gemma":0.00031107198,"teacher_disagreement_score":0.019057324,"about_ca_system_score_codex":0.010892394,"about_ca_system_score_gemma":0.013462716,"threshold_uncertainty_score":0.999861},"labels":[],"label_agreement":null},{"id":"W1978835230","doi":"10.1080/10428190310001617295","title":"Clinico-Biological Features and Prognostic Significance of PML/RARα Isoforms in Adult Patients with Acute Promyelocytic Leukemia Treated with All Trans Retinoic Acid (ATRA) and Chemotherapy","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Acute promyelocytic leukemia; Gene isoform; Clinical significance; Interquartile range; Internal medicine; Exon; Retinoic acid; Medicine; Gastroenterology; Chemotherapy; Oncology; Immunology; Biology; Pathology; Gene; Genetics","score_opus":0.0051514193786167525,"score_gpt":0.21096986542169105,"score_spread":0.2058184460430743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1978835230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541515,0.002184743,0.00017861662,0.000040815114,0.00005172367,0.001289466,0.000061017963,0.00005918836,0.00071925676],"genre_scores_gemma":[0.99282235,0.003964456,0.001754391,0.00050183217,0.000071293616,0.00022643953,0.00026997112,0.000114685885,0.0002745557],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960726,0.00022297238,0.00082087045,0.0015098795,0.00043381637,0.0009398946],"domain_scores_gemma":[0.9981942,0.00012084954,0.00043797545,0.00061263476,0.00026787512,0.00036646985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032285677,0.0009195373,0.00097417214,0.00016501184,0.00020120734,0.000104946026,0.00035541985,0.00083881605,0.000010177245],"category_scores_gemma":[0.00013702134,0.00065623503,0.000117974356,0.0004385271,0.0011370415,0.0000608799,0.000081634025,0.00022839576,0.000001185528],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010129893,0.00062031415,0.8177032,0.0010547948,0.0010451903,0.00029446292,0.0015241186,0.00006622977,0.12328121,0.000462352,0.00034978287,0.043468453],"study_design_scores_gemma":[0.041900624,0.0067828004,0.55837184,0.0005897356,0.0004843218,0.0012020846,0.000650953,0.00024169737,0.3847583,0.0002729722,0.0026797676,0.0020648725],"about_ca_topic_score_codex":0.00020585833,"about_ca_topic_score_gemma":0.00009543908,"teacher_disagreement_score":0.26147708,"about_ca_system_score_codex":0.00072087965,"about_ca_system_score_gemma":0.0018320465,"threshold_uncertainty_score":0.9995889},"labels":[],"label_agreement":null},{"id":"W1981484881","doi":"10.1080/10428190601078605","title":"HLA-DR protein status predicts survival in patients with diffuse large B-cell lymphoma treated on the MACOP-B chemotherapy regimen","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"American Cancer Society","keywords":"Regimen; Medicine; Internal medicine; International Prognostic Index; Diffuse large B-cell lymphoma; Proportional hazards model; Lymphoma; Human leukocyte antigen; Chemotherapy; Chemotherapy regimen; Oncology; Rituximab; Gastroenterology; Antigen; Immunology","score_opus":0.006734132314767544,"score_gpt":0.2154206246546265,"score_spread":0.20868649233985895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981484881","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98327345,0.00066031836,0.000017010425,0.0004286612,0.00020000382,0.0036580993,0.00017215032,0.00034305532,0.01124727],"genre_scores_gemma":[0.9926893,0.00041511323,0.00018845587,0.0024761888,0.00026513846,0.0004843996,0.00040958365,0.0002699185,0.0028019147],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926325,0.0002794854,0.0012471235,0.0017204471,0.001656468,0.0024639587],"domain_scores_gemma":[0.99584526,0.0006063216,0.00056464935,0.0016532098,0.00027842255,0.0010521389],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000869651,0.0014412128,0.0014806603,0.0005837405,0.00056141167,0.0002083499,0.00048174255,0.00070112385,0.00010669108],"category_scores_gemma":[0.00010825183,0.0009437771,0.00033335562,0.0012491622,0.0004310472,0.0003225305,0.00019080921,0.00021051714,0.0001258097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02035698,0.02096747,0.83483154,0.00032401778,0.00090315397,0.0021568267,0.0021656347,0.000010396738,0.0007239652,0.0013996642,0.0032406803,0.11291969],"study_design_scores_gemma":[0.17936824,0.0025333718,0.78519386,0.00064989855,0.0002657841,0.00008134247,0.0004958244,0.000357142,0.015447498,0.000052039668,0.014631568,0.000923404],"about_ca_topic_score_codex":0.00265528,"about_ca_topic_score_gemma":0.000378236,"teacher_disagreement_score":0.15901126,"about_ca_system_score_codex":0.013021815,"about_ca_system_score_gemma":0.0023791823,"threshold_uncertainty_score":0.99983376},"labels":[],"label_agreement":null},{"id":"W1982692072","doi":"10.3109/10428194.2011.570394","title":"Mechanism of Action of Pentostatin and Cladribine in Hairy Cell Leukemia","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Deoxyadenosine; Cladribine; Deoxycoformycin; Deoxycytidine kinase; Biochemistry; Chemistry; Pentostatin; Adenosine deaminase; Molecular biology; Adenosine; Biology; Deoxycytidine","score_opus":0.052419454122607866,"score_gpt":0.32326350376375945,"score_spread":0.2708440496411516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982692072","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.112478815,0.87748873,0.00006426707,0.000009561069,0.0004369401,0.0029985092,0.0002028958,0.00014608316,0.006174187],"genre_scores_gemma":[0.05070886,0.9444087,0.001129033,0.000094235365,0.00027846347,0.0003176382,0.0003839846,0.00040252725,0.0022765584],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99019253,0.00063224055,0.0037586603,0.0022440485,0.0014288666,0.0017436565],"domain_scores_gemma":[0.99334073,0.0010728929,0.0021620106,0.0020446456,0.00040948816,0.00097025087],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014109844,0.001946782,0.0067084744,0.0021286209,0.00017935205,0.000075291755,0.0008750094,0.002418572,0.0002114596],"category_scores_gemma":[0.00035916528,0.0017428509,0.001040104,0.0017985678,0.0011565216,0.00043071076,0.00097245345,0.00076868734,0.000063410276],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0010152846,0.0004083875,0.0000702693,0.077159084,0.0005785489,0.0007568247,0.0011862195,0.0000038866274,0.0005238146,0.0023884699,0.00071796146,0.91519123],"study_design_scores_gemma":[0.14940517,0.0043531293,0.0014113337,0.0845852,0.008982746,0.015133445,0.002174318,0.00907568,0.015627429,0.0018920795,0.7015476,0.0058118673],"about_ca_topic_score_codex":0.012270612,"about_ca_topic_score_gemma":0.00035560955,"teacher_disagreement_score":0.90937936,"about_ca_system_score_codex":0.07219717,"about_ca_system_score_gemma":0.06230974,"threshold_uncertainty_score":0.99932754},"labels":[],"label_agreement":null},{"id":"W1984455044","doi":"10.1080/10428190701760029","title":"Alemtuzumab in clinical practice: A British Columbia experience","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Lions Gate Hospital; University of British Columbia; Royal Columbian Hospital; Interior Health; Vancouver General Hospital; Eagle Ridge Hospital","funders":"","keywords":"Alemtuzumab; Medicine; Neutropenia; Internal medicine; Adverse effect; Chronic lymphocytic leukemia; Clinical trial; Surgery; Oncology; Leukemia; Chemotherapy; Transplantation","score_opus":0.02706911312920365,"score_gpt":0.32807800209074184,"score_spread":0.3010088889615382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984455044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97547394,0.004084864,0.00004706602,0.00020045493,0.00060192216,0.001390417,0.000031442218,0.00038201042,0.01778791],"genre_scores_gemma":[0.9730977,0.008041929,0.0030802856,0.0036009678,0.00080071564,0.0003592347,0.00008325952,0.0002045793,0.010731342],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99069744,0.0005182808,0.0024554217,0.0022525927,0.0019691503,0.0021071073],"domain_scores_gemma":[0.9943052,0.0014917041,0.00050571625,0.0017027915,0.00050978275,0.0014848033],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015162799,0.0007243482,0.0018375282,0.0003292675,0.00073668046,0.0004896687,0.00075300405,0.0011287866,0.0004968598],"category_scores_gemma":[0.0030985489,0.0009838623,0.0005178905,0.0015378053,0.0020993184,0.0010378794,0.00066394336,0.0005982074,0.00029360378],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004445058,0.0027253625,0.20511824,0.0008614318,0.00068692176,0.10028234,0.007153762,0.000046473997,0.0006401075,0.00026886418,0.092795394,0.5849761],"study_design_scores_gemma":[0.11306202,0.0011675155,0.56640726,0.0009677024,0.00022633815,0.11535287,0.0021836592,0.014087226,0.00029527835,0.00018284612,0.18448494,0.0015823608],"about_ca_topic_score_codex":0.147828,"about_ca_topic_score_gemma":0.01002501,"teacher_disagreement_score":0.5833937,"about_ca_system_score_codex":0.0654554,"about_ca_system_score_gemma":0.048925653,"threshold_uncertainty_score":0.9992612},"labels":[],"label_agreement":null},{"id":"W1984666457","doi":"10.3109/10428190109058004","title":"Prolonged Molecular and Clinical Remission after Treatment of a Patient with Follicular Lymphoma with Rituximab","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"IC Design Education Center","keywords":"Rituximab; Medicine; Follicular lymphoma; Complete remission; Lymphoma; Refractory (planetary science); Internal medicine; Oncology; CD20; Follicular phase; Monoclonal; Clinical trial; Radiation therapy; Gastroenterology; Monoclonal antibody; Antibody; Chemotherapy; Immunology","score_opus":0.007920645523747646,"score_gpt":0.24652712978806582,"score_spread":0.23860648426431819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984666457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876871,0.008196678,0.000052219963,0.00032020867,0.00009482984,0.0018663551,0.000034282228,0.000168836,0.0015794917],"genre_scores_gemma":[0.9911689,0.0040689916,0.0026893546,0.0007365836,0.00013835785,0.00060583703,0.00009320854,0.00015351354,0.00034522446],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99501896,0.00021404689,0.0012041837,0.0016102431,0.00095113914,0.001001416],"domain_scores_gemma":[0.9966748,0.0002404413,0.0005273394,0.0012175208,0.000289353,0.0010505696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021194543,0.0011248383,0.0019235007,0.00031031301,0.00025339675,0.000104810686,0.00014859748,0.00056703197,0.000050230014],"category_scores_gemma":[0.00004534788,0.0007232154,0.00040571974,0.00059441733,0.0007206587,0.00025180585,0.0001313148,0.000070868584,0.000020129792],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017443402,0.005269557,0.40643457,0.00023651683,0.0017801813,0.016329158,0.0010213354,0.000011795634,0.00053686346,0.00016348677,0.00012480654,0.55064833],"study_design_scores_gemma":[0.15266763,0.023889853,0.74151,0.0017398205,0.0037014533,0.020148875,0.0007202821,0.0011587631,0.021015346,0.000107986896,0.031801645,0.0015383711],"about_ca_topic_score_codex":0.0013475439,"about_ca_topic_score_gemma":0.00011925689,"teacher_disagreement_score":0.54910994,"about_ca_system_score_codex":0.004287149,"about_ca_system_score_gemma":0.0025480406,"threshold_uncertainty_score":0.9995352},"labels":[],"label_agreement":null},{"id":"W1985382327","doi":"10.1080/1042819031000067909","title":"CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Randomized controlled trial; Lymphoma; Chemotherapy; Disease","score_opus":0.009184027187279559,"score_gpt":0.25623875353245246,"score_spread":0.2470547263451729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1985382327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97918874,0.0150773125,0.000013220583,0.0016136146,0.00022723041,0.001620667,0.000101051635,0.00007409359,0.0020840485],"genre_scores_gemma":[0.983726,0.012153747,0.0013523039,0.001445767,0.00020337275,0.000577802,0.00012833856,0.00009895408,0.0003136805],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957665,0.00046357603,0.0008704599,0.0014723223,0.00052541884,0.0009017123],"domain_scores_gemma":[0.99671155,0.0014824235,0.00032099537,0.00088766764,0.00013620648,0.00046117936],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059567485,0.0009123694,0.0011080792,0.00038739285,0.00037432363,0.00038903893,0.0001670331,0.0006634244,0.00002082324],"category_scores_gemma":[0.0004877688,0.0006534055,0.00016537086,0.0009918046,0.0003057254,0.0005762675,0.00013582915,0.00015657282,0.000016769618],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017667665,0.0023027344,0.17183153,0.00015812487,0.0006452192,0.0031395296,0.019248074,0.00002278346,0.0015444815,0.0038579018,0.00040072002,0.79508215],"study_design_scores_gemma":[0.036966026,0.001016023,0.9328106,0.0007524005,0.00052369904,0.0019031982,0.0019872594,0.0009231721,0.00120113,0.0006598906,0.020585395,0.0006712203],"about_ca_topic_score_codex":0.015905319,"about_ca_topic_score_gemma":0.0018541166,"teacher_disagreement_score":0.79441094,"about_ca_system_score_codex":0.0077999188,"about_ca_system_score_gemma":0.0021344835,"threshold_uncertainty_score":0.9995917},"labels":[],"label_agreement":null},{"id":"W1987493240","doi":"10.3109/10428194.2010.483750","title":"Revisiting late relapses in acute myeloid leukemia","year":2010,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Myeloid leukemia; Medicine; Myeloid; Leukemia; Internal medicine; Cancer research; Oncology","score_opus":0.013045270587988864,"score_gpt":0.26275512068170864,"score_spread":0.24970985009371977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987493240","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8310063,0.006247867,0.000047885827,0.13019484,0.0021740186,0.0039278883,0.000501402,0.0014241738,0.024475634],"genre_scores_gemma":[0.09799275,0.021791367,0.0069639157,0.739263,0.025637755,0.001637737,0.0069727995,0.0029955409,0.09674513],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9819746,0.0008321339,0.0037245236,0.004909172,0.0032790683,0.0052805017],"domain_scores_gemma":[0.98997587,0.0017682656,0.0015680336,0.004349088,0.00076896406,0.0015697873],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0021134554,0.003687055,0.005358992,0.0030927307,0.0009474115,0.0008308532,0.0023227392,0.012980459,0.0006464061],"category_scores_gemma":[0.0010889428,0.0035611833,0.0014357712,0.002733734,0.0018011063,0.0010495216,0.001805425,0.011003456,0.0012288981],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0018353872,0.0001203563,0.003978112,0.0034747506,0.0016668683,0.055577725,0.0010764918,0.000028147639,0.009609408,0.00021260398,0.72218263,0.2002375],"study_design_scores_gemma":[0.027794328,0.00058623776,0.023505,0.003997422,0.001768375,0.013810245,0.0002220073,0.0044664247,0.0035206366,0.00069321645,0.9155424,0.0040936726],"about_ca_topic_score_codex":0.00631255,"about_ca_topic_score_gemma":0.00020183716,"teacher_disagreement_score":0.7330135,"about_ca_system_score_codex":0.05084578,"about_ca_system_score_gemma":0.027720906,"threshold_uncertainty_score":0.99954873},"labels":[],"label_agreement":null},{"id":"W1988147245","doi":"10.1080/1042819021000040170","title":"Successful Treatment of Posttransplant Lymphoproliferative Disorder in a Renal Transplant Patient by Autologous Peripheral Blood Stem Cell Transplantation","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Immunosuppression; Transplantation; Lymphoproliferative disorders; Chemotherapy; Lymphoma; Melphalan; Surgery; Stem cell; Post-transplant lymphoproliferative disorder; Rituximab; Gastroenterology; Oncology; Internal medicine","score_opus":0.006831870652802778,"score_gpt":0.20752843376571734,"score_spread":0.20069656311291456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988147245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9830652,0.01226119,0.00008380398,0.00018543818,0.00014119953,0.0010622058,0.00064042903,0.0001256271,0.0024348937],"genre_scores_gemma":[0.97963154,0.018445611,0.000108292916,0.00040892346,0.000050478466,0.00023356361,0.00039629292,0.00009014683,0.000635152],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961388,0.00019272909,0.0011309228,0.00096102915,0.0006261463,0.00095033465],"domain_scores_gemma":[0.9986227,0.0001230927,0.00035711177,0.0004059183,0.00009748048,0.00039369735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00010421282,0.0008079105,0.0012641489,0.00031042888,0.00022442402,0.000054989363,0.00017490573,0.00055378745,0.0001502106],"category_scores_gemma":[0.000003924353,0.0006963833,0.00034597036,0.0005354987,0.0002709395,0.00025797795,0.000014260441,0.00010931026,0.000009916528],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013516587,0.009235521,0.27286962,0.001910307,0.0016512566,0.005894002,0.09204313,0.0013093664,0.06172041,0.00021925074,0.0013607023,0.5382699],"study_design_scores_gemma":[0.39010832,0.0280223,0.1950269,0.0028428272,0.0062900996,0.008827641,0.011690144,0.04509372,0.29512766,0.00017935246,0.011348679,0.0054423767],"about_ca_topic_score_codex":0.005450033,"about_ca_topic_score_gemma":0.00056166167,"teacher_disagreement_score":0.5328275,"about_ca_system_score_codex":0.0038324364,"about_ca_system_score_gemma":0.0009461771,"threshold_uncertainty_score":0.99999166},"labels":[],"label_agreement":null},{"id":"W1988166471","doi":"10.3109/10428190109097680","title":"Liposomal Daunorubicin (Daunoxome) in Combination with Cyclophosphamide, Vincristine and Prednisolone (COP-X) as Salvage Therapy in Poor-Prognosis Non-Hodgkins Lymphoma","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Mucositis; Regimen; Gastroenterology; Vincristine; Cyclophosphamide; Surgery; Salvage therapy; Prednisolone; Lymphoma; Febrile neutropenia; CHOP; Chemotherapy","score_opus":0.008608960792715007,"score_gpt":0.2378536185548517,"score_spread":0.2292446577621367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988166471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860797,0.0049728397,0.000023654884,0.00077666016,0.00023801829,0.0024437662,0.00003981845,0.0002843737,0.0051411837],"genre_scores_gemma":[0.9831968,0.011706379,0.0006861578,0.0020683855,0.00021542003,0.00085957895,0.00025690946,0.0002369602,0.0007734411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933854,0.0003458073,0.0015606299,0.0019258644,0.0010673905,0.0017149438],"domain_scores_gemma":[0.99682444,0.0006058718,0.0005180185,0.0009825544,0.00023502168,0.00083409826],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007336577,0.0014684486,0.0019942643,0.0011030982,0.0005042968,0.0002754333,0.00041559283,0.0008328965,0.00008172191],"category_scores_gemma":[0.00015520885,0.0012523168,0.0002516809,0.0019054706,0.0006303669,0.0007214876,0.00028570555,0.00027366553,0.00007213968],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006189623,0.0032196085,0.67534816,0.00025358825,0.0003593912,0.0049817725,0.0019486762,0.00003641999,0.0030594063,0.0006825161,0.0003480148,0.3035728],"study_design_scores_gemma":[0.09027924,0.0038022734,0.88221276,0.0011866383,0.00024839336,0.004043229,0.0008133627,0.0021440303,0.010390467,0.00037932547,0.003301967,0.0011983473],"about_ca_topic_score_codex":0.02740654,"about_ca_topic_score_gemma":0.0018198319,"teacher_disagreement_score":0.30237445,"about_ca_system_score_codex":0.008996447,"about_ca_system_score_gemma":0.0026451445,"threshold_uncertainty_score":0.9998065},"labels":[],"label_agreement":null},{"id":"W1989577949","doi":"10.1080/10428190290033332","title":"Treatment of Elderly Hodgkin's Lymphoma Patients with a Novel 5-drug Regimen (ODBEP): A Phase II Study","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Medicine; Internal medicine; Vincristine; Chemotherapy; Regimen; Lymphoma; Etoposide; Procarbazine; Prednisone; Combination chemotherapy; Gastroenterology; Neutropenia; Surgery; Oncology; Cyclophosphamide","score_opus":0.01424569885269534,"score_gpt":0.24476227634504188,"score_spread":0.23051657749234655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989577949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98844993,0.0026879814,0.000019011743,0.00025932153,0.000275488,0.0037010447,0.00031331056,0.00033013648,0.003963768],"genre_scores_gemma":[0.9927006,0.0008560134,0.00085702125,0.0003698764,0.00027766256,0.00088542176,0.00024901793,0.00022948641,0.0035749173],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9932507,0.00016919822,0.0015637263,0.0019944294,0.0015372512,0.0014846824],"domain_scores_gemma":[0.99531144,0.0003279448,0.00084916496,0.0019441795,0.00047011976,0.0010971532],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00019853102,0.0016373331,0.0024145832,0.0006532971,0.00076892524,0.00014782233,0.0004254625,0.00043267536,0.00022315375],"category_scores_gemma":[0.00006098451,0.0012127772,0.00056713197,0.0010541036,0.00053346733,0.0004914221,0.00023931052,0.00007692198,0.0000699018],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005979247,0.07067837,0.16578862,0.00023604576,0.003146777,0.0015566413,0.0099901585,0.00001605068,0.00044512836,0.0002801982,0.0028686821,0.7390141],"study_design_scores_gemma":[0.41797823,0.069713615,0.45822087,0.00061589584,0.0037799764,0.0013745389,0.0021730599,0.0021859044,0.005238346,0.000036096557,0.036726095,0.0019573553],"about_ca_topic_score_codex":0.003614209,"about_ca_topic_score_gemma":0.00015506301,"teacher_disagreement_score":0.73705673,"about_ca_system_score_codex":0.010600097,"about_ca_system_score_gemma":0.0016663596,"threshold_uncertainty_score":0.9996374},"labels":[],"label_agreement":null},{"id":"W1989963052","doi":"10.3109/10428194.2011.555892","title":"Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; University Health Network; Sunnybrook Health Science Centre","funders":"","keywords":"Sunitinib; Medicine; Neutropenia; Internal medicine; Refractory (planetary science); Pharmacodynamics; Diffuse large B-cell lymphoma; Oncology; Phases of clinical research; Toxicity; Clinical trial; Febrile neutropenia; Lymphoma; Gastroenterology; Pharmacokinetics; Cancer; Biology","score_opus":0.09485852275559409,"score_gpt":0.3912644948390851,"score_spread":0.296405972083491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989963052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915329,0.0018940237,0.0000065301087,0.00007490869,0.0011998998,0.0038462302,0.00016262867,0.00015106535,0.0011318022],"genre_scores_gemma":[0.99314976,0.003264458,0.00028395248,0.0014503337,0.00039925016,0.0004353594,0.000062831496,0.0001660415,0.0007880313],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9874762,0.003350563,0.005046345,0.0018953276,0.0009576459,0.0012738936],"domain_scores_gemma":[0.9922655,0.003015169,0.001757605,0.0017254506,0.00022151825,0.0010147204],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00577353,0.0011795971,0.0035545868,0.0004688139,0.0005386136,0.000071528724,0.0006559158,0.0009540461,0.00015663456],"category_scores_gemma":[0.0015726639,0.000757657,0.0009769175,0.00080606784,0.0009357801,0.00032025395,0.0008966893,0.00038137176,0.000026536205],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02896218,0.16162759,0.5090455,0.00039421546,0.0013710842,0.0023507662,0.007037765,4.6841654e-7,0.00061668066,0.00014362525,0.0011689906,0.28728113],"study_design_scores_gemma":[0.4162365,0.008183586,0.5623866,0.00047008958,0.0019976334,0.0002656871,0.0028760573,0.0022463952,0.0007258358,0.00003540907,0.0039107143,0.0006655552],"about_ca_topic_score_codex":0.0024923976,"about_ca_topic_score_gemma":0.0008747874,"teacher_disagreement_score":0.3872743,"about_ca_system_score_codex":0.0025111835,"about_ca_system_score_gemma":0.002778672,"threshold_uncertainty_score":0.99948746},"labels":[],"label_agreement":null},{"id":"W1990370347","doi":"10.3109/10428194.2014.963075","title":"Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Prednisone; Vincristine; Internal medicine; CHOP; Cyclophosphamide; Lymphoma; Chemoimmunotherapy; Gastroenterology; Ofatumumab; Oncology; Chemotherapy; Surgery","score_opus":0.0035991984274510364,"score_gpt":0.2022721831625936,"score_spread":0.19867298473514255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1990370347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939457,0.00069003046,0.00010821119,0.00013832045,0.00013604865,0.001236453,0.000032323736,0.0001471682,0.0035657496],"genre_scores_gemma":[0.9951173,0.0005391879,0.0024779132,0.0008882918,0.0001223354,0.0002836715,0.00012631438,0.00018804103,0.00025691383],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99491894,0.00016717597,0.0011712163,0.0013713695,0.0011921976,0.0011791135],"domain_scores_gemma":[0.99670565,0.0004299814,0.0006622084,0.0013101915,0.0003936929,0.0004982666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045374833,0.0010663498,0.0018961519,0.00057262176,0.00027150614,0.0001230355,0.0004258466,0.0004722575,0.000057853023],"category_scores_gemma":[0.00009565069,0.0008093962,0.00022489205,0.0010706154,0.00060110056,0.0005254436,0.00016763314,0.00012382652,0.000040155774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036819833,0.0017283999,0.681426,0.00029296434,0.00033319762,0.0002318784,0.0009219383,0.000034402317,0.0005039761,0.000192405,0.00013018891,0.31052268],"study_design_scores_gemma":[0.094211176,0.0032209854,0.8879123,0.0019941467,0.0003025312,0.00044738594,0.00019125296,0.0011424688,0.007985738,0.00007262798,0.0016404011,0.0008790181],"about_ca_topic_score_codex":0.004308831,"about_ca_topic_score_gemma":0.00033716066,"teacher_disagreement_score":0.30964366,"about_ca_system_score_codex":0.0061990763,"about_ca_system_score_gemma":0.0024643564,"threshold_uncertainty_score":0.99943566},"labels":[],"label_agreement":null},{"id":"W1991589385","doi":"10.3109/10428194.2013.853298","title":"The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study)","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Lymphoplasmacytic Lymphoma; Follicular lymphoma; Lymphoma; Internal medicine; Stage (stratigraphy); Retrospective cohort study; Gastroenterology; Pathology; Oncology; Waldenstrom macroglobulinemia","score_opus":0.011555288649860556,"score_gpt":0.2503653937384022,"score_spread":0.23881010508854167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1991589385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843016,0.0035393285,0.0000012986329,0.00030241394,0.0007795068,0.008551109,0.00006529099,0.000057515696,0.0024018928],"genre_scores_gemma":[0.99611974,0.0012821303,0.00010081798,0.00039854078,0.00016583067,0.0011385743,0.000013784749,0.00009394355,0.0006866342],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99267864,0.0008148551,0.0023068597,0.0014700595,0.0019983272,0.00073127536],"domain_scores_gemma":[0.9952821,0.0007125272,0.0013823078,0.0017840969,0.000491125,0.00034784726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014407446,0.0009380931,0.0018170864,0.000272396,0.00072455686,0.00020134303,0.0010337933,0.0003485189,0.000023318127],"category_scores_gemma":[0.00018341928,0.00052274944,0.00051423034,0.00075955334,0.0012762047,0.00031325885,0.0019079244,0.00020307205,0.0000027840854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014583786,0.011472411,0.76383436,0.00022148057,0.0029341828,0.00010348703,0.005295561,0.0000013822431,0.00014703473,0.00030749655,0.0014297295,0.21279448],"study_design_scores_gemma":[0.059289623,0.0041863867,0.9144285,0.00040507535,0.0017079742,0.0004157499,0.01755203,0.00010667082,0.00051506865,0.00015748163,0.000802969,0.0004324851],"about_ca_topic_score_codex":0.004624951,"about_ca_topic_score_gemma":0.0009133109,"teacher_disagreement_score":0.212362,"about_ca_system_score_codex":0.0031871465,"about_ca_system_score_gemma":0.0013849848,"threshold_uncertainty_score":0.9997224},"labels":[],"label_agreement":null},{"id":"W1992085012","doi":"10.3109/10428194.2013.802313","title":"2-[18F]fluoro-2-deoxy-<scp>d</scp>-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta","keywords":"Medicine; Positron emission tomography; Nuclear medicine; Chronic lymphocytic leukemia; Positron Emission Tomography-Computed Tomography; Standardized uptake value; Positron emission; Radiology; PET-CT; Leukemia; Internal medicine","score_opus":0.005696234891551276,"score_gpt":0.2163362870837772,"score_spread":0.21064005219222592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1992085012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859486,0.0030375782,0.0002930763,0.00008672396,0.0004200964,0.0048418934,0.00006027158,0.0007278075,0.004583949],"genre_scores_gemma":[0.9927925,0.0005833928,0.0013233438,0.0008200955,0.0004687246,0.00082034554,0.0011436407,0.00037227766,0.0016756929],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9885583,0.00065594463,0.0023514738,0.0024740591,0.0028929857,0.0030672236],"domain_scores_gemma":[0.99375355,0.000935641,0.0007927407,0.0018933564,0.0009539548,0.001670752],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011495885,0.0019235163,0.002076219,0.0026728408,0.00070271245,0.0005731488,0.0009775043,0.001331301,0.0001324463],"category_scores_gemma":[0.0002653324,0.0016663813,0.00063085515,0.0038942967,0.00088143797,0.0022941653,0.00039325145,0.00067800534,0.00027030913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005519064,0.0023074818,0.15771404,0.007241181,0.0026050704,0.0017464039,0.011710964,0.0025541482,0.025221743,0.0008530903,0.021730065,0.7607967],"study_design_scores_gemma":[0.118728444,0.0027372781,0.7769493,0.0020328043,0.0005446881,0.0010061046,0.0005415304,0.07106377,0.020451969,0.00020578774,0.004464586,0.0012737666],"about_ca_topic_score_codex":0.008067688,"about_ca_topic_score_gemma":0.00019033716,"teacher_disagreement_score":0.759523,"about_ca_system_score_codex":0.20972563,"about_ca_system_score_gemma":0.03221211,"threshold_uncertainty_score":0.9999652},"labels":[],"label_agreement":null},{"id":"W1995357901","doi":"10.3109/10428194.2010.490312","title":"Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Daunorubicin; Cytarabine; Pharmacology; Medicine; Bone marrow; Leukemia; Drug; Therapeutic index; Myeloid leukemia; Internal medicine","score_opus":0.015134411913510911,"score_gpt":0.28125515738351764,"score_spread":0.26612074547000675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995357901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99229354,0.000843519,0.00019523942,0.00026250293,0.00032603866,0.0020230552,0.00007818527,0.00024623875,0.0037317092],"genre_scores_gemma":[0.9936993,0.0009311185,0.0020593475,0.00040042482,0.0005980843,0.00033162886,0.0006319683,0.00019332158,0.0011547757],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9937081,0.00027575507,0.0019482343,0.0015946946,0.001060028,0.0014132264],"domain_scores_gemma":[0.99588597,0.00062299974,0.00067687366,0.0014247586,0.00050242036,0.0008869785],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092311425,0.0011403774,0.0017760261,0.0013112938,0.0005647057,0.00019371998,0.00045731728,0.0010775871,0.00012884807],"category_scores_gemma":[0.0005592886,0.0010433021,0.00030964497,0.001199858,0.0008687483,0.00072334165,0.00030770578,0.0005380019,0.000044133412],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0025046398,0.0007585145,0.08980388,0.0008814923,0.00058991543,0.00092606567,0.0030960154,0.00031577024,0.78220034,0.008743032,0.00092024135,0.10926009],"study_design_scores_gemma":[0.08931558,0.0026136797,0.61336637,0.001077828,0.0007067203,0.001611812,0.0013526799,0.06199304,0.21882385,0.0014342559,0.0053754784,0.0023287],"about_ca_topic_score_codex":0.005503441,"about_ca_topic_score_gemma":0.0015463968,"teacher_disagreement_score":0.5633765,"about_ca_system_score_codex":0.011762964,"about_ca_system_score_gemma":0.007905026,"threshold_uncertainty_score":0.9992017},"labels":[],"label_agreement":null},{"id":"W1995513757","doi":"10.1080/10428190500051844","title":"Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; BC Cancer Agency; University of California, San Francisco; University of Nebraska Medical Center","keywords":"Concordance; Immunohistochemistry; Medicine; Pathology; Tissue microarray; Stain; Lymphoma; Staining; Internal medicine","score_opus":0.0056392378217780745,"score_gpt":0.246330318001575,"score_spread":0.24069108017979693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995513757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884759,0.0063724695,0.00010912293,0.00017816375,0.00013293809,0.0007394161,0.000061295854,0.00011724251,0.0038134616],"genre_scores_gemma":[0.9951012,0.0013060665,0.0016429564,0.0004684449,0.00017117962,0.00016398705,0.0002691039,0.000094811374,0.00078222575],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99635834,0.0001212446,0.0011866317,0.0010016505,0.0005199758,0.00081218703],"domain_scores_gemma":[0.99795085,0.00028184112,0.00049486523,0.00071237737,0.00016961606,0.00039044957],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042897405,0.00070121035,0.0010827128,0.00042858964,0.00020865207,0.000102549304,0.00021419777,0.00050380954,0.000047881917],"category_scores_gemma":[0.000115316274,0.00067728467,0.00018870298,0.00045462593,0.00027242515,0.00044243678,0.00020344126,0.00009390403,0.000030385689],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025969832,0.007288861,0.0520468,0.0013763062,0.00037337377,0.00046282215,0.0101335645,0.00004982547,0.26757717,0.0005337386,0.0008338974,0.65672666],"study_design_scores_gemma":[0.12919144,0.0006707621,0.15555854,0.0011422206,0.00056463864,0.0011469225,0.0021425418,0.0070585944,0.6920059,0.00013800233,0.009230686,0.0011497996],"about_ca_topic_score_codex":0.0009261516,"about_ca_topic_score_gemma":0.000037025962,"teacher_disagreement_score":0.6555768,"about_ca_system_score_codex":0.0069250325,"about_ca_system_score_gemma":0.0015098777,"threshold_uncertainty_score":0.9995678},"labels":[],"label_agreement":null},{"id":"W1996193488","doi":"10.3109/10428190009113384","title":"18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Lymphoma; Radiology; Stage (stratigraphy); Positron emission tomography; Interim; Internal medicine; Nuclear medicine; Aggressive lymphoma; PET-CT; Rituximab","score_opus":0.010701937970799547,"score_gpt":0.2634812659616695,"score_spread":0.25277932799086994,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996193488","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97998714,0.004958959,0.0000040905716,0.00032967518,0.0001334219,0.0027012879,0.00007777196,0.00014703287,0.011660634],"genre_scores_gemma":[0.990751,0.004757013,0.00046779812,0.0010473864,0.00026800076,0.0013924227,0.00023017656,0.00014613055,0.00094003807],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941466,0.0002892473,0.0014097755,0.0015073409,0.0012657694,0.0013812556],"domain_scores_gemma":[0.99596745,0.00073209545,0.0010062004,0.0015193501,0.00013191385,0.00064302015],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003231318,0.0013030232,0.0020549784,0.0005352303,0.00040433015,0.0001784195,0.00055678585,0.0002912176,0.00048730124],"category_scores_gemma":[0.0000837936,0.00081810344,0.00048466396,0.001159489,0.00076301413,0.00029291314,0.00006485619,0.00010900747,0.00026981867],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039580134,0.0071428916,0.35398516,0.00027063722,0.0010289567,0.012725811,0.006587241,0.00007771091,0.0001513504,0.00025949514,0.0018221495,0.6119906],"study_design_scores_gemma":[0.064671926,0.0088398075,0.86342263,0.0012912722,0.0015625106,0.0127845835,0.0018950725,0.0012574223,0.009524881,0.00014985776,0.033518977,0.0010810707],"about_ca_topic_score_codex":0.006452158,"about_ca_topic_score_gemma":0.00024958432,"teacher_disagreement_score":0.6109095,"about_ca_system_score_codex":0.007501016,"about_ca_system_score_gemma":0.0045373887,"threshold_uncertainty_score":0.9999721},"labels":[],"label_agreement":null},{"id":"W1996846809","doi":"10.1080/1042819021000002901","title":"Phase II Study of Sequential Topotecan and Etoposide in Patients with Intermediate Grade Non-Hodgkin's Lymphoma: A National Cancer Institute of Canada Clinical Trials Group Study","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ontario Institute for Cancer Research; Queen Elizabeth II Health Sciences Centre; Saskatoon Medical Imaging; Humber River Regional Hospital; Hamilton Health Sciences; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Topotecan; Medicine; Etoposide; Neutropenia; Internal medicine; Gastroenterology; Lymphoma; Regimen; Febrile neutropenia; Phases of clinical research; Chemotherapy; Surgery","score_opus":0.05278015313966829,"score_gpt":0.37454118198458514,"score_spread":0.32176102884491686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1996846809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994687,0.0007418654,0.000005260985,0.00012160865,0.00058623846,0.0033504963,0.00018575921,0.00003523538,0.00028652177],"genre_scores_gemma":[0.99819815,0.0004335859,0.00006768126,0.00026565508,0.00030484697,0.0004069483,0.000040088744,0.00006792046,0.00021509531],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930708,0.00066916144,0.0023478793,0.0011064385,0.0020088176,0.00079691905],"domain_scores_gemma":[0.9968378,0.00057802384,0.0009246776,0.00057974923,0.00054647063,0.0005333072],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020154596,0.0006535876,0.0024129213,0.0005216268,0.00030932334,0.000042581498,0.00035422205,0.00023567575,0.000043735523],"category_scores_gemma":[0.00085816486,0.00052210863,0.00016401506,0.0007998241,0.00073994184,0.00035873827,0.000492354,0.0002128091,6.844211e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011795773,0.020395622,0.79055417,0.0005923296,0.0029432354,0.0006940863,0.0094098495,0.000066495544,0.00025913434,0.000035592293,0.0037538907,0.15949984],"study_design_scores_gemma":[0.19994652,0.015636552,0.7781211,0.00049501436,0.00062743074,0.00003569196,0.002170387,0.0014114858,0.00026497256,0.000020877369,0.00076171674,0.0005082396],"about_ca_topic_score_codex":0.27825043,"about_ca_topic_score_gemma":0.25662085,"teacher_disagreement_score":0.18815075,"about_ca_system_score_codex":0.0076643,"about_ca_system_score_gemma":0.00653291,"threshold_uncertainty_score":0.9997231},"labels":[],"label_agreement":null},{"id":"W1997303669","doi":"10.1080/10428190601043252","title":"Characteristics and outcomes of acute myelogenous leukemia patients with very late relapse (&gt;5 years)","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cohort; Internal medicine; Complete remission; Leukemia; Chemotherapy; Oncology; Surgery","score_opus":0.0068160636290141114,"score_gpt":0.23682244162637736,"score_spread":0.23000637799736326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997303669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99525017,0.0005520848,0.00011512492,0.00010107024,0.00031351528,0.0012499191,0.00025857225,0.00025829766,0.0019012264],"genre_scores_gemma":[0.9915895,0.0014372227,0.0022416534,0.0012133978,0.0002482189,0.000049743972,0.00042134203,0.00026662898,0.0025323199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9936204,0.00013593235,0.0015251521,0.0014192021,0.0015079008,0.001791442],"domain_scores_gemma":[0.99548614,0.00060767116,0.0007082563,0.0013926585,0.0005894034,0.0012158443],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009780229,0.0011011146,0.0020343214,0.0008424122,0.0003746173,0.00013160573,0.00053595705,0.0009164251,0.00006273605],"category_scores_gemma":[0.00024694245,0.0009285349,0.0003020154,0.0009657268,0.0011997742,0.0004924379,0.0005707272,0.0004701095,0.00007248054],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006904699,0.00042244498,0.82152677,0.0005894045,0.002078257,0.0027412758,0.0019678306,0.0000057253264,0.006169555,0.0005456915,0.00096450874,0.15608385],"study_design_scores_gemma":[0.026151698,0.0013130793,0.95971054,0.0003236796,0.0010390005,0.0008175643,0.00016857668,0.0004728973,0.002838731,0.00009022554,0.0061020916,0.0009719418],"about_ca_topic_score_codex":0.0009545682,"about_ca_topic_score_gemma":0.000056777506,"teacher_disagreement_score":0.15511191,"about_ca_system_score_codex":0.010138077,"about_ca_system_score_gemma":0.0047692973,"threshold_uncertainty_score":0.9993165},"labels":[],"label_agreement":null},{"id":"W1997316354","doi":"10.3109/10428194.2014.999326","title":"A classification tree approach for improving the utilization of flow cytometry testing of blood specimens for B-cell non-Hodgkin lymphoproliferative disorders","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Health Research Board; University of Calgary","keywords":"Flow cytometry; Logistic regression; Medicine; Receiver operating characteristic; Cytometry; Lymphoproliferative disorders; Immunology; Pathology; Internal medicine; Lymphoma","score_opus":0.055364893703796506,"score_gpt":0.2964314999325053,"score_spread":0.2410666062287088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997316354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9285345,0.0018880062,0.058536984,0.00009354432,0.00022471011,0.005147305,0.0001924205,0.00013035903,0.0052521816],"genre_scores_gemma":[0.9516978,0.00013433263,0.04542651,0.00015333155,0.00042965423,0.0009305298,0.00034787893,0.00017145406,0.00070848357],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9950003,0.00016986023,0.001493648,0.0011794929,0.0011038473,0.001052864],"domain_scores_gemma":[0.99444604,0.0016353737,0.0009792248,0.0011752453,0.0012652455,0.0004988823],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017441227,0.00070873694,0.0012588252,0.0005490606,0.00036202502,0.00009070616,0.00059261965,0.00056803215,0.0000055992173],"category_scores_gemma":[0.0019508413,0.00055887626,0.00042298462,0.0014858245,0.0007839132,0.00032141636,0.00025059422,0.00013806646,0.000003065943],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016048552,0.0043211817,0.015487017,0.013896529,0.0018645047,0.000038187274,0.013149253,0.0032809034,0.28291053,0.0028507907,0.0050292118,0.64112335],"study_design_scores_gemma":[0.08688538,0.0021220918,0.006482154,0.00022212451,0.0010505288,0.0002945063,0.0035687229,0.8084284,0.08918306,0.00040516932,0.00078193215,0.0005759027],"about_ca_topic_score_codex":0.001171565,"about_ca_topic_score_gemma":0.000045197783,"teacher_disagreement_score":0.8051475,"about_ca_system_score_codex":0.015254283,"about_ca_system_score_gemma":0.024861652,"threshold_uncertainty_score":0.9996863},"labels":[],"label_agreement":null},{"id":"W1997358378","doi":"10.1080/10428190701713655","title":"The role of TRAIL death receptors in the treatment of hematological malignancies","year":2008,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Apoptosis; Receptor; Tumor necrosis factor alpha; Cancer research; Lymphoma; Leukemia; Monoclonal antibody; Programmed cell death; Immunology; Signal transduction; Medicine; Biology; Antibody; Cell biology; Internal medicine","score_opus":0.016842454943273993,"score_gpt":0.254111233069388,"score_spread":0.237268778126114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997358378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06804163,0.930261,0.0000108117,0.000008318687,0.0001710017,0.00077039364,0.00003860605,0.000011066206,0.000687173],"genre_scores_gemma":[0.017995413,0.9806944,0.000113871916,0.00002142796,0.0001729494,0.00021542521,0.00022977745,0.000053127605,0.00050360686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997141,0.0003452581,0.0010511617,0.00063895807,0.00034026607,0.0004833688],"domain_scores_gemma":[0.99815494,0.00023644642,0.00063886115,0.0008067372,0.000072319024,0.000090677786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025218603,0.0006528179,0.0013834217,0.00011290068,0.00024329814,0.00003414688,0.0005524542,0.00084583455,0.0000054737043],"category_scores_gemma":[0.00004057357,0.00034124978,0.0007343857,0.0002899513,0.00040554928,0.0000069687294,0.000092538954,0.00006286992,0.0000033005192],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077191646,0.00016928892,0.00006301448,0.00050990144,0.00016624978,0.000022555534,0.0003341666,0.000005149646,0.00036063357,0.0015389825,0.00016658504,0.99658626],"study_design_scores_gemma":[0.0015012973,0.00067163544,0.00029580164,0.00067389646,0.00023754584,0.00082396757,0.0003218279,0.000042488537,0.0028079993,0.0002590199,0.9919839,0.00038061346],"about_ca_topic_score_codex":0.0003033554,"about_ca_topic_score_gemma":0.00006726488,"teacher_disagreement_score":0.9962057,"about_ca_system_score_codex":0.00069716864,"about_ca_system_score_gemma":0.001515937,"threshold_uncertainty_score":0.999904},"labels":[],"label_agreement":null},{"id":"W1998981539","doi":"10.1080/1042819031000149304","title":"Enhancement of Antineoplastic Action of 5-Aza-2′-deoxycytidine by Phenylbutyrate on L1210 Leukemic Cells","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Cancer research; Leukemia; Phenylbutyrate; Histone deacetylase; Hypomethylating agent; Azacitidine; Epigenetics; DNA methylation; Deoxycytidine; In vitro; L1210 cells; Chromatin; Biology; Chemistry; Molecular biology; Histone; Pharmacology; DNA; Gene; Immunology; Cancer; Biochemistry; Cytotoxicity; Genetics; Gene expression","score_opus":0.008982724020270715,"score_gpt":0.24542381072931124,"score_spread":0.23644108670904052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998981539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940163,0.001346765,0.00064263435,0.000020914998,0.00041843244,0.000436133,0.00012779608,0.000029622439,0.0029614072],"genre_scores_gemma":[0.994494,0.0012879455,0.000373635,0.00013870654,0.00017999107,0.000061446495,0.00019071087,0.00009618656,0.0031773516],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963168,0.0002701513,0.0009476211,0.0009880918,0.0006919056,0.0007854471],"domain_scores_gemma":[0.997907,0.0001331111,0.0005154483,0.00087173795,0.00025704422,0.0003156653],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00049126934,0.0005953844,0.0007144888,0.0002461212,0.00018722808,0.0000387477,0.00038085316,0.0005169392,0.00007770703],"category_scores_gemma":[0.00022277854,0.000596541,0.00024875646,0.00041693854,0.0004776587,0.000024928408,0.00014546917,0.00013105363,0.0000424819],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068982795,0.00026964632,0.0002016981,0.00023364575,0.00013743807,0.000014129704,0.000111719106,0.00013925454,0.97895503,0.0001656573,0.011284569,0.0077973786],"study_design_scores_gemma":[0.0060012275,0.0011208078,0.00039391327,0.00014806147,0.0000627778,0.00008298566,0.00015496594,0.00042592295,0.9600326,0.000032108546,0.03101236,0.00053230824],"about_ca_topic_score_codex":0.00037803,"about_ca_topic_score_gemma":0.000019269364,"teacher_disagreement_score":0.01972779,"about_ca_system_score_codex":0.0015569895,"about_ca_system_score_gemma":0.0021597112,"threshold_uncertainty_score":0.9996486},"labels":[],"label_agreement":null},{"id":"W1999897515","doi":"10.1080/10428190802108870","title":"Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University Health Network","keywords":"Medicine; Salvage therapy; Autologous stem-cell transplantation; Chemotherapy; Lymphoma; Refractory (planetary science); Internal medicine; Oncology; Transplantation; Diffuse large B-cell lymphoma; Surgery; Biology","score_opus":0.012832555256231951,"score_gpt":0.2258245512521214,"score_spread":0.21299199599588944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999897515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98579633,0.0060898024,0.0005641873,0.00021322064,0.00041272433,0.0031755748,0.00096145255,0.0006971013,0.0020896113],"genre_scores_gemma":[0.9781298,0.009421814,0.0028944085,0.0032521137,0.00045053748,0.0010180817,0.0012252153,0.0004417675,0.0031662637],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99170184,0.00031172056,0.001774737,0.0024759518,0.0013619928,0.002373742],"domain_scores_gemma":[0.994274,0.0011882907,0.0012296704,0.0014243475,0.00042291865,0.0014607745],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00053556496,0.0020404877,0.0028323778,0.0006427223,0.0014405656,0.0002285224,0.00053898623,0.0011679691,0.000062875304],"category_scores_gemma":[0.000039052768,0.0016145657,0.00057587144,0.000788453,0.0006971943,0.0007261739,0.00018856175,0.00019526697,0.000063576634],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.12539966,0.0988891,0.2882883,0.018525045,0.0032494874,0.038597286,0.034605008,0.000037973023,0.02513131,0.00043054653,0.02420163,0.34264466],"study_design_scores_gemma":[0.36929435,0.0034507925,0.56087196,0.00087557046,0.0015439463,0.0074290363,0.0017279878,0.0020821437,0.022958742,0.000019784613,0.027667895,0.002077774],"about_ca_topic_score_codex":0.0005103246,"about_ca_topic_score_gemma":0.0002230625,"teacher_disagreement_score":0.3405669,"about_ca_system_score_codex":0.007700336,"about_ca_system_score_gemma":0.0059701046,"threshold_uncertainty_score":0.99985945},"labels":[],"label_agreement":null},{"id":"W2001321636","doi":"10.3109/10428194.2013.770847","title":"Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antimicrobial Peptides and Activities","field":"Immunology and Microbiology","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"Natural Sciences and Engineering Research Council of Canada; Dalhousie University; Beatrice Hunter Cancer Research Institute","keywords":"Multiple myeloma; Cancer research; Medicine; Cytotoxic T cell; Immune system; Malignancy; Cancer; Melphalan; Immunology; Internal medicine; Biology; In vitro; Biochemistry","score_opus":0.00705556771187292,"score_gpt":0.1908262009334524,"score_spread":0.1837706332215795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001321636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518627,0.0023223062,0.00007751677,0.00016280203,0.00059630047,0.00080540945,0.00031562196,0.00012871271,0.00040504022],"genre_scores_gemma":[0.9957288,0.0018865941,0.0005508936,0.00053744053,0.00014821408,0.00007862456,0.00017441044,0.00009708073,0.0007979625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963053,0.00036787667,0.001236618,0.0008940109,0.00018469966,0.0010115356],"domain_scores_gemma":[0.99666774,0.0011881331,0.00087682507,0.0007499417,0.00037528845,0.00014206937],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004028992,0.0007867335,0.0012428202,0.00033750682,0.00069999264,0.000115887524,0.00070102286,0.00065181375,0.000085999956],"category_scores_gemma":[0.00018957093,0.00061826827,0.00041024332,0.0004991042,0.002135318,0.0005696063,0.00051197794,0.00022649948,0.000107343694],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035866714,0.00017337906,0.015858028,0.00032120218,0.0005314056,0.0000097812,0.002276683,0.00003471912,0.95192724,0.0002230649,0.010553261,0.01773255],"study_design_scores_gemma":[0.008186104,0.00030038337,0.26707554,0.0002378923,0.00030417272,0.00027859473,0.0018450678,0.00056033366,0.7181629,0.00017741506,0.0020946134,0.0007770053],"about_ca_topic_score_codex":0.011572855,"about_ca_topic_score_gemma":0.00032499086,"teacher_disagreement_score":0.25121748,"about_ca_system_score_codex":0.0005531914,"about_ca_system_score_gemma":0.0008911193,"threshold_uncertainty_score":0.9996269},"labels":[],"label_agreement":null},{"id":"W2001606431","doi":"10.1080/10428190600942769","title":"Very high-dose methotrexate (33.6 g/m<sup>2</sup>) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; U.S. Public Health Service; National Institutes of Health","keywords":"Medicine; Methotrexate; Internal medicine; Cancer; Neutropenia; Oncology; Neurocognitive; Leukemia; Chemotherapy","score_opus":0.014400841934127665,"score_gpt":0.28712327881736066,"score_spread":0.272722436883233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2001606431","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97639835,0.006827846,0.0010147651,0.0003957543,0.0013168672,0.006557148,0.0057872967,0.0005570556,0.0011449113],"genre_scores_gemma":[0.97823554,0.006805211,0.0027647035,0.0011277652,0.003438755,0.0023623828,0.002326217,0.00048258397,0.0024568127],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9851382,0.0011474815,0.0041925292,0.0033569525,0.0030963602,0.003068507],"domain_scores_gemma":[0.99036807,0.003009246,0.0023026837,0.0015043648,0.0013452941,0.0014703381],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0030241762,0.0023324017,0.0046617864,0.0013527739,0.0010750827,0.0004211625,0.0011531524,0.0017548561,0.00009697081],"category_scores_gemma":[0.001274726,0.002024702,0.0012547853,0.0016739644,0.0016375761,0.0012377467,0.0006487956,0.0005710475,0.00003696452],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14560185,0.006698002,0.026058301,0.007698813,0.03246545,0.0030876256,0.0112656,0.031663917,0.040886786,0.022273652,0.089904204,0.5823958],"study_design_scores_gemma":[0.3967036,0.00481626,0.45198223,0.006426391,0.0068245293,0.006688289,0.0016075217,0.064908475,0.03366924,0.0024268457,0.018433336,0.005513278],"about_ca_topic_score_codex":0.04731763,"about_ca_topic_score_gemma":0.0005949937,"teacher_disagreement_score":0.57688254,"about_ca_system_score_codex":0.03784461,"about_ca_system_score_gemma":0.028526995,"threshold_uncertainty_score":0.9995411},"labels":[],"label_agreement":null},{"id":"W2002379912","doi":"10.1080/1042819021000035707","title":"Association of Familial Leukemia with HLA Cw3: Is it Real?","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sudbury Regional Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Leukemia; Myeloid leukemia; Anticipation (artificial intelligence); Human leukocyte antigen; Immunology; Medicine; Haplotype; Genetics; Allele; Biology; Antigen; Gene","score_opus":0.014329316963668234,"score_gpt":0.23759822062964506,"score_spread":0.22326890366597682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002379912","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94164413,0.0014073589,0.000039517647,0.000884912,0.0003750502,0.0011421173,0.00015355407,0.00034522222,0.05400813],"genre_scores_gemma":[0.94221747,0.0052544265,0.0014057579,0.0025238,0.0006317686,0.00014081562,0.00017936173,0.00024550423,0.0474011],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9929296,0.00020708887,0.001589002,0.001674381,0.0019517911,0.0016481477],"domain_scores_gemma":[0.99532634,0.0005402121,0.0011045313,0.0016296201,0.00052112475,0.00087819534],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053772057,0.0012588805,0.001970854,0.00053942495,0.0004269687,0.00012311486,0.000507198,0.0011599517,0.0013865274],"category_scores_gemma":[0.00023191489,0.001094694,0.0005122269,0.0011625836,0.00049043784,0.0005478869,0.00024940076,0.00034627866,0.0005497714],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00570425,0.0018270202,0.22976017,0.002489411,0.0066598514,0.0028846685,0.016842304,0.00020973329,0.01779822,0.0011802892,0.40677297,0.3078711],"study_design_scores_gemma":[0.18821345,0.005809147,0.4569766,0.0033219438,0.0065056053,0.0058567734,0.004447745,0.038840443,0.057855934,0.0004270825,0.22675738,0.0049879164],"about_ca_topic_score_codex":0.005870122,"about_ca_topic_score_gemma":0.00032481187,"teacher_disagreement_score":0.30288318,"about_ca_system_score_codex":0.05069135,"about_ca_system_score_gemma":0.005281811,"threshold_uncertainty_score":0.9995263},"labels":[],"label_agreement":null},{"id":"W2004634154","doi":"10.3109/10428194.2011.584004","title":"High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Western University; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Procarbazine; Primary central nervous system lymphoma; Regimen; Vincristine; Methotrexate; Internal medicine; Surgery; Radiation therapy; Chemotherapy; Oncology; Cyclophosphamide","score_opus":0.01676367970394319,"score_gpt":0.22984616716492057,"score_spread":0.21308248746097738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004634154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895119,0.0034381086,0.0010344583,0.00011598579,0.00043452514,0.0035640628,0.00029246847,0.00042968558,0.0011787856],"genre_scores_gemma":[0.9787779,0.0014865787,0.015808808,0.0006582641,0.0003820156,0.0015234144,0.0007851387,0.0002910813,0.00028684107],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9947085,0.00021132719,0.0013599725,0.0015182267,0.0007778367,0.0014241303],"domain_scores_gemma":[0.99590415,0.0006260243,0.00087994366,0.0013414209,0.0003235542,0.0009249328],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00028554964,0.0013369812,0.0023454092,0.0005295261,0.00037656233,0.00009720131,0.00031096995,0.0005964846,0.00006178374],"category_scores_gemma":[0.000046017492,0.0010379645,0.0007505331,0.00067276414,0.00038463785,0.00031050685,0.00005236371,0.00003972279,0.00001797116],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013424268,0.0036701208,0.022567337,0.0009824211,0.0017081206,0.0011728009,0.0022257774,0.00010807868,0.0018505999,0.0010108938,0.00045137195,0.9508282],"study_design_scores_gemma":[0.12778187,0.0050139166,0.78669435,0.00066476234,0.0021586688,0.0009882834,0.0005327818,0.004443589,0.06449584,0.000060177597,0.006115326,0.0010504423],"about_ca_topic_score_codex":0.007966508,"about_ca_topic_score_gemma":0.00012330998,"teacher_disagreement_score":0.9497778,"about_ca_system_score_codex":0.01649829,"about_ca_system_score_gemma":0.00487499,"threshold_uncertainty_score":0.99993813},"labels":[],"label_agreement":null},{"id":"W2005532233","doi":"10.1080/1042819021000040125","title":"Intra-cerebral Relapse Following Prolonged Remission after Autologous Stem Cell Transplantation for Multiple Myeloma","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; BC Cancer Agency","funders":"","keywords":"Multiple myeloma; Medicine; Autologous stem-cell transplantation; Transplantation; Complication; Stem cell; Pathophysiology; Central nervous system; Oncology; Internal medicine; Surgery; Biology","score_opus":0.015530059102037147,"score_gpt":0.2456129782174663,"score_spread":0.23008291911542916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005532233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910608,0.002919721,0.00036054157,0.0002096998,0.00045438996,0.0023033984,0.00012260869,0.00037770884,0.0021911233],"genre_scores_gemma":[0.9894115,0.0006165395,0.0030478307,0.00049082015,0.0003449734,0.0008969991,0.00029579128,0.00015836993,0.004737223],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956046,0.00017766426,0.0008471313,0.0012500548,0.0007634897,0.0013570695],"domain_scores_gemma":[0.9974461,0.00048318034,0.00022820386,0.00072559516,0.00019582374,0.00092107395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003301793,0.0007697358,0.0009566718,0.00036636082,0.00053943536,0.00013872511,0.00024906712,0.0006678937,0.00011432237],"category_scores_gemma":[0.00015683648,0.000661269,0.00053119776,0.00040809973,0.00018292508,0.00043662818,0.00007933936,0.00019635523,0.00012186358],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011744647,0.0008512821,0.1021257,0.0018861723,0.0006746117,0.0043277587,0.0050471,0.000023173718,0.015069888,0.00004617429,0.0034971277,0.85470635],"study_design_scores_gemma":[0.12670738,0.0030278435,0.6813932,0.0013056048,0.0015836265,0.0024362572,0.000787498,0.0760792,0.08385596,0.00016015115,0.020651655,0.0020116286],"about_ca_topic_score_codex":0.000280569,"about_ca_topic_score_gemma":0.00006160272,"teacher_disagreement_score":0.85269475,"about_ca_system_score_codex":0.0036215798,"about_ca_system_score_gemma":0.00079921825,"threshold_uncertainty_score":0.99958384},"labels":[],"label_agreement":null},{"id":"W2008241551","doi":"10.1080/10428190600572673","title":"Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Induction chemotherapy; Myeloid leukemia; Internal medicine; Cohort; Myeloid; Immunology; Acute leukemia; Leukemia; Chemotherapy; Oncology; Gastroenterology","score_opus":0.010336622605659828,"score_gpt":0.25548349084621347,"score_spread":0.24514686824055365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008241551","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98467636,0.0022167808,0.00006389757,0.00023906991,0.0004073362,0.0016184396,0.000072282244,0.00043013287,0.01027572],"genre_scores_gemma":[0.9867916,0.0024471013,0.0012348875,0.00033543384,0.0008878757,0.00024523618,0.00033852734,0.0002805913,0.007438763],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99140024,0.0003068616,0.002249971,0.0020035638,0.0019930408,0.0020463297],"domain_scores_gemma":[0.995855,0.00032260374,0.00077807787,0.0016180581,0.0005066517,0.00091963395],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009892869,0.0012966513,0.0020297056,0.0015450454,0.00048378916,0.0001577974,0.0007271351,0.0014289134,0.00018356906],"category_scores_gemma":[0.00031195238,0.0012244881,0.0004952037,0.0018922664,0.0007125343,0.0008767083,0.00059752533,0.0007255593,0.00012641553],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016343256,0.0009719023,0.1770702,0.0026731498,0.0010861998,0.006847479,0.0022605332,0.00080498646,0.72585416,0.003675378,0.0067277225,0.055685002],"study_design_scores_gemma":[0.03954372,0.0008909326,0.70272416,0.0015706419,0.0005443373,0.007001881,0.0006061495,0.0069806245,0.22924879,0.0010057809,0.0085073225,0.0013756591],"about_ca_topic_score_codex":0.016466748,"about_ca_topic_score_gemma":0.00021633458,"teacher_disagreement_score":0.52565396,"about_ca_system_score_codex":0.04192316,"about_ca_system_score_gemma":0.01318155,"threshold_uncertainty_score":0.99997854},"labels":[],"label_agreement":null},{"id":"W2009245880","doi":"10.3109/10428190903421177","title":"Lymphoma cells contribute to the augmentation of plasma sL-selectins in the serum of lymphoma-bearing mice","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institut National de la Recherche Scientifique","funders":"National Cancer Institute; Armand-Frappier Foundation; Canadian Institutes of Health Research; Terry Fox Foundation; Cancer Research Society","keywords":"Lymphoma; Selectin; In vitro; Glycoprotein; L-selectin; Immunology; Chemistry; In vivo; Cancer research; Cell adhesion molecule; Molecular biology; Medicine; Biology; Biochemistry","score_opus":0.012094395834983914,"score_gpt":0.26611915155099464,"score_spread":0.25402475571601074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009245880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910551,0.0009289114,0.00015335214,0.001583614,0.00023361582,0.0019301424,0.000077713645,0.000085144966,0.003952424],"genre_scores_gemma":[0.9944809,0.00059645966,0.0005836578,0.00290477,0.00022565079,0.00010845318,0.0000656381,0.00008642206,0.00094805274],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937012,0.0005383468,0.0015992842,0.0010573475,0.0017781009,0.0013256776],"domain_scores_gemma":[0.9961183,0.001038515,0.000569832,0.0013575725,0.00044538165,0.0004704026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016323627,0.00074463355,0.0012402463,0.0007190552,0.00038235285,0.00013552707,0.0010992215,0.00047734386,0.000059599235],"category_scores_gemma":[0.000416588,0.0005317196,0.00039613416,0.0022795512,0.00038210605,0.00025736404,0.0002906382,0.00019066711,0.00007591979],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049692974,0.0012172719,0.0065074526,0.0005434767,0.00031661754,0.00057081465,0.008169995,0.00055744493,0.41541383,0.0013227676,0.006375645,0.55403537],"study_design_scores_gemma":[0.030564778,0.0017492616,0.4199461,0.0006288193,0.00031803045,0.0011047565,0.0032240292,0.008278039,0.51705414,0.00025098675,0.016139802,0.0007412723],"about_ca_topic_score_codex":0.0027586399,"about_ca_topic_score_gemma":0.00035753945,"teacher_disagreement_score":0.5532941,"about_ca_system_score_codex":0.0046113743,"about_ca_system_score_gemma":0.0032009282,"threshold_uncertainty_score":0.9997134},"labels":[],"label_agreement":null},{"id":"W2009764353","doi":"10.3109/10428194.2013.835404","title":"Genetic polymorphisms of<i>RAD51</i>and<i>XRCC3</i>and acute myeloid leukemia risk: a meta-analysis","year":2013,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"XRCC3; Odds ratio; Meta-analysis; Myeloid leukemia; Internal medicine; Oncology; Confidence interval; Population; Medicine; RAD51; Genotype; Biology; Bioinformatics; Genetics; Gene; Single-nucleotide polymorphism; DNA repair","score_opus":0.04042416432050826,"score_gpt":0.30393356689123646,"score_spread":0.2635094025707282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2009764353","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.040475007,0.95134693,0.00022583836,0.00012799763,0.0002718425,0.004484941,0.0012255426,0.00039896436,0.0014429153],"genre_scores_gemma":[0.0043741274,0.9771606,0.0064402795,0.00071679126,0.0006788876,0.0016713694,0.0007170089,0.0007659576,0.0074749934],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9831521,0.001609952,0.0048651374,0.004710767,0.00257389,0.0030881343],"domain_scores_gemma":[0.9864728,0.002344098,0.0033157498,0.004295773,0.000705851,0.0028657427],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018638271,0.00422667,0.0190432,0.0037852523,0.00090420386,0.0005871096,0.0016786231,0.0034928732,0.000681651],"category_scores_gemma":[0.00051291886,0.0032653823,0.0069156783,0.004588878,0.0026764146,0.00066228217,0.002198963,0.0016083176,0.00030425252],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003226533,0.00014668127,0.00032157823,0.0104125645,0.20269726,0.0011851005,0.00055361487,0.000011617918,0.00009884417,0.0002586547,0.003077656,0.7809138],"study_design_scores_gemma":[0.008333013,0.0006896792,0.0024039997,0.0014002633,0.5410822,0.007818799,0.0001197902,0.0016586117,0.0001425033,0.00020584092,0.43338606,0.0027592322],"about_ca_topic_score_codex":0.010744257,"about_ca_topic_score_gemma":0.00012206368,"teacher_disagreement_score":0.77815455,"about_ca_system_score_codex":0.01390371,"about_ca_system_score_gemma":0.016879676,"threshold_uncertainty_score":0.9978008},"labels":[],"label_agreement":null},{"id":"W2010726561","doi":"10.1080/1042819031000116698","title":"Acute Myelogenous Leukemia with t(8;21)—Identification of a Specific Immunophenotype","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Hospital and Health Sciences Centre; University of British Columbia; Leukemia & Lymphoma Society of Canada","funders":"","keywords":"CD33; CD34; Immunophenotyping; Leukemia; CD19; Medicine; Immunology; Internal medicine; Gastroenterology; Antigen; Oncology; Biology; Stem cell; Genetics","score_opus":0.010713451643626224,"score_gpt":0.2410863234620763,"score_spread":0.2303728718184501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010726561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791526,0.0045500854,0.0010676859,0.00015927783,0.00038768677,0.0016712379,0.000099261924,0.00035022132,0.012561945],"genre_scores_gemma":[0.9839178,0.0034288315,0.0044001495,0.00055589085,0.0002919371,0.0002259944,0.0002473029,0.00031859888,0.006613552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923681,0.00037687438,0.0019139481,0.0018597594,0.001654702,0.0018266026],"domain_scores_gemma":[0.99448633,0.0004112625,0.0008777719,0.0024375957,0.00085470546,0.0009323183],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011691132,0.0012167309,0.0018545283,0.0009057942,0.0006359459,0.00021549323,0.0007821825,0.00088235823,0.0002718619],"category_scores_gemma":[0.00024942824,0.0010537896,0.0004337311,0.0020200638,0.0013286887,0.0005614879,0.00025689433,0.0004867833,0.0003167001],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013953724,0.0011027965,0.015101069,0.0016914374,0.0042599402,0.0041173426,0.0052613905,0.00033610003,0.68090725,0.02055306,0.01159592,0.24111997],"study_design_scores_gemma":[0.07867722,0.004335499,0.19336808,0.0012064804,0.002710409,0.022921767,0.0034506256,0.0042165,0.5478724,0.0019289101,0.13522682,0.004085298],"about_ca_topic_score_codex":0.00087753567,"about_ca_topic_score_gemma":0.00003499366,"teacher_disagreement_score":0.23703466,"about_ca_system_score_codex":0.016776247,"about_ca_system_score_gemma":0.012717004,"threshold_uncertainty_score":0.9991912},"labels":[],"label_agreement":null},{"id":"W2011629215","doi":"10.3109/10428190009087023","title":"A Comparison of Elderly Patients with Aggressive Histology Lymphoma who Were Entered or Not Entered on to a Randomized Phase II Trial","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences","funders":"","keywords":"Randomized controlled trial; Medicine; Internal medicine; Randomization; Surgery","score_opus":0.01806251221639087,"score_gpt":0.3000154975304829,"score_spread":0.281952985314092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011629215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892115,0.00080130476,0.000022694121,0.00041491934,0.00049328065,0.0055892733,0.00031605875,0.0002229264,0.0029280277],"genre_scores_gemma":[0.9910898,0.00040877733,0.00054225104,0.00230289,0.0003015063,0.0012618093,0.0004570279,0.00017698435,0.0034589157],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99249476,0.0005305723,0.0023431568,0.0018424368,0.0014020769,0.0013870173],"domain_scores_gemma":[0.9946231,0.0010169767,0.0013555442,0.0014567104,0.00038918728,0.0011584745],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000395426,0.0014723501,0.0047312276,0.0006970773,0.0005777506,0.00011654708,0.0005290267,0.0007004594,0.0008796859],"category_scores_gemma":[0.00038187837,0.0010162079,0.0008208101,0.0006909255,0.00079548743,0.00027210743,0.00019982042,0.00014032905,0.00013260257],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.62836754,0.008446223,0.0024419625,0.00014345147,0.0011523734,0.0005989427,0.002370615,0.000017301873,0.000097265576,0.00013238001,0.0039324327,0.35229954],"study_design_scores_gemma":[0.9099479,0.038470875,0.021278081,0.0017049911,0.0017018286,0.00040632614,0.00026926995,0.00085190684,0.005944847,0.000026062526,0.018343808,0.0010541222],"about_ca_topic_score_codex":0.0012941938,"about_ca_topic_score_gemma":0.00013881612,"teacher_disagreement_score":0.3512454,"about_ca_system_score_codex":0.00670095,"about_ca_system_score_gemma":0.0030428665,"threshold_uncertainty_score":0.9998026},"labels":[],"label_agreement":null},{"id":"W2012098025","doi":"10.3109/10428194.2010.546015","title":"A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172)","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; BC Cancer Agency; Princess Margaret Cancer Centre; Alberta Cancer Foundation; University Health Network; Queen Elizabeth II Health Sciences Centre; Juravinski Hospital","funders":"National Cancer Institute","keywords":"Gemcitabine; Bortezomib; Mantle cell lymphoma; Medicine; Internal medicine; Oncology; Adverse effect; Chemotherapy; Refractory (planetary science); Phases of clinical research; Lymphoma; Multiple myeloma","score_opus":0.07482145748558373,"score_gpt":0.33985409406348344,"score_spread":0.2650326365778997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012098025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99074095,0.003886436,0.0000042610973,0.00016198315,0.00070559786,0.0018306371,0.00047530993,0.000036146306,0.0021587],"genre_scores_gemma":[0.9963504,0.00136068,0.00029578173,0.0008445946,0.00034040253,0.00034976043,0.00011332205,0.00006645341,0.0002785814],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99367315,0.000615981,0.0028064908,0.0011135611,0.0011155411,0.000675291],"domain_scores_gemma":[0.99591684,0.0013448305,0.0012113615,0.00073039386,0.0003007128,0.00049583724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021215987,0.0007134531,0.0022890335,0.00025089242,0.00031243605,0.00003345714,0.0003958075,0.00041936256,0.00012806128],"category_scores_gemma":[0.0005944296,0.0005089969,0.00031131518,0.00058345357,0.0005210735,0.0002205011,0.00032980563,0.00013195384,0.0000025850218],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015231115,0.028285516,0.581189,0.00039199716,0.0030329206,0.0013714087,0.0111953635,0.000025102592,0.0021359876,0.0010901979,0.012058553,0.34399286],"study_design_scores_gemma":[0.17922735,0.0039493167,0.80179405,0.00043958382,0.0011404909,0.00011133193,0.0019769662,0.0008691282,0.0041893553,0.00027317883,0.005492006,0.00053722603],"about_ca_topic_score_codex":0.6153727,"about_ca_topic_score_gemma":0.22532701,"teacher_disagreement_score":0.39004567,"about_ca_system_score_codex":0.0044094697,"about_ca_system_score_gemma":0.010826242,"threshold_uncertainty_score":0.9997362},"labels":[],"label_agreement":null},{"id":"W2012684467","doi":"10.1080/10428190600909578","title":"A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Collège de Maisonneuve","funders":"","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Adverse effect; Internal medicine; Lymphoproliferative disorders; Gastroenterology; Phases of clinical research; Toxicity; Surgery; Lymphoma","score_opus":0.025166442700866824,"score_gpt":0.3165357937164136,"score_spread":0.2913693510155468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012684467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943941,0.0005396449,0.00006963743,0.000063373605,0.000268197,0.003449232,0.000100359895,0.00019036236,0.00092508586],"genre_scores_gemma":[0.9935418,0.00025462906,0.0013153107,0.00035817234,0.0002478973,0.0003343141,0.00013937702,0.00016601894,0.0036425064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9930884,0.00031938578,0.0019736763,0.001514597,0.0013664002,0.001737522],"domain_scores_gemma":[0.9954046,0.0012984787,0.00055438967,0.001207899,0.00038990134,0.0011447056],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009887551,0.0010649243,0.0018852479,0.0011717594,0.00047819005,0.00007020154,0.0004239385,0.0005893333,0.00024643607],"category_scores_gemma":[0.0011950772,0.00075965043,0.00028156713,0.0014477394,0.0004453887,0.00041366633,0.00039931783,0.00030260088,0.00004303468],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18212433,0.030553112,0.20503742,0.0006345891,0.0013760567,0.014611303,0.016800178,0.000026062722,0.017925609,0.000032278025,0.0005270307,0.53035206],"study_design_scores_gemma":[0.4540248,0.03398791,0.45434672,0.00080718537,0.00046399538,0.0011628105,0.011821663,0.016695013,0.022400199,0.000016662,0.0031442633,0.0011288022],"about_ca_topic_score_codex":0.0044050673,"about_ca_topic_score_gemma":0.005893018,"teacher_disagreement_score":0.52922326,"about_ca_system_score_codex":0.007770954,"about_ca_system_score_gemma":0.003913635,"threshold_uncertainty_score":0.99948543},"labels":[],"label_agreement":null},{"id":"W2012998597","doi":"10.1080/10428190400025112","title":"Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University of British Columbia","funders":"","keywords":"Myeloid leukemia; Medicine; Karyotype; Oncology; Value (mathematics); Internal medicine; Myeloid; Cancer research; Leukemia; Biology; Chromosome; Genetics; Gene","score_opus":0.015803030289344492,"score_gpt":0.29667028888014974,"score_spread":0.28086725859080525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2012998597","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876011,0.00094936264,0.0003384275,0.00031397026,0.00028056547,0.0021986687,0.00063127937,0.00017213359,0.0075144786],"genre_scores_gemma":[0.98845464,0.0010236781,0.004427199,0.0009766597,0.0004254812,0.00022419699,0.0003011655,0.00021382795,0.003953167],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.993155,0.00022935172,0.0023146484,0.0015078309,0.0012981246,0.0014950468],"domain_scores_gemma":[0.99565095,0.0010359758,0.0007581534,0.0013388171,0.00043835086,0.0007777452],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001180341,0.0010286579,0.002331438,0.0011892105,0.00021740487,0.000040720213,0.00073933,0.0011459347,0.00018136874],"category_scores_gemma":[0.00038476373,0.0009250273,0.0005876952,0.0010601148,0.0006737659,0.0004725503,0.00024957387,0.00049020903,0.000039562423],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.077145085,0.002100017,0.14306436,0.008576999,0.0043003894,0.0015559874,0.00970139,0.0057658665,0.3304352,0.009265427,0.01845422,0.3896351],"study_design_scores_gemma":[0.0778773,0.005147024,0.46610284,0.00292131,0.0013409635,0.0014803499,0.0006734905,0.10204564,0.3194001,0.0008349865,0.020363525,0.0018124938],"about_ca_topic_score_codex":0.0009912796,"about_ca_topic_score_gemma":0.00012073147,"teacher_disagreement_score":0.38782257,"about_ca_system_score_codex":0.019658538,"about_ca_system_score_gemma":0.008273468,"threshold_uncertainty_score":0.99932003},"labels":[],"label_agreement":null},{"id":"W2013180434","doi":"10.3109/10428190009054894","title":"Lovastatin Induces a Pronounced Differentiation Response in Acute Myeloid Leukemias","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Lovastatin; Myeloid leukemia; Myeloid; Cancer research; Acute promyelocytic leukemia; Retinoic acid; Leukemia; Haematopoiesis; Tretinoin; Biology; Apoptosis; Cytarabine; Immunology; Pharmacology; Cell culture; Endocrinology; Cell biology; Biochemistry; Cholesterol; Stem cell","score_opus":0.006092719136176638,"score_gpt":0.22499170836869092,"score_spread":0.21889898923251427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013180434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369603,0.0018621973,0.00025230265,0.00010800636,0.00022961867,0.0006431101,0.00005301185,0.0001194402,0.0030362855],"genre_scores_gemma":[0.98840326,0.002848375,0.00077022135,0.0007234669,0.0003359485,0.00026178066,0.00041561088,0.00013817602,0.006103176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99518204,0.0004815338,0.0010238987,0.0015620706,0.00059450243,0.001155985],"domain_scores_gemma":[0.9980857,0.00013349445,0.0003068114,0.0009620365,0.00013716318,0.0003747871],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075463497,0.0008744836,0.00073373696,0.0003014859,0.00035720857,0.00024395596,0.000702002,0.0008667797,0.00019962677],"category_scores_gemma":[0.00018374814,0.00085931935,0.00024779653,0.00064629986,0.00041870383,0.00008014244,0.00023390798,0.0002164981,0.00011267862],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0102739325,0.000317728,0.0074471296,0.00022923845,0.00037322615,0.00027206395,0.0018183521,0.00063349004,0.69876266,0.00018259988,0.002019924,0.2776697],"study_design_scores_gemma":[0.028618691,0.0021711972,0.2774208,0.00046809824,0.00032074816,0.0015243026,0.0010682041,0.0040000156,0.61529624,0.0009922247,0.06472755,0.0033919043],"about_ca_topic_score_codex":0.00042907282,"about_ca_topic_score_gemma":0.00007716885,"teacher_disagreement_score":0.27427778,"about_ca_system_score_codex":0.002411153,"about_ca_system_score_gemma":0.0033385165,"threshold_uncertainty_score":0.9993858},"labels":[],"label_agreement":null},{"id":"W2013251910","doi":"10.3109/10428194.2011.604752","title":"Regulation of autophagy in hematological malignancies: role of reactive oxygen species","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Autophagy in Disease and Therapy","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Manitoba; CancerCare Manitoba","funders":"","keywords":"Autophagy; Cancer research; Programmed cell death; Reactive oxygen species; Biology; Drug resistance; Bone marrow; Cancer; Myeloid; Immunology; Medicine; Apoptosis; Cell biology; Internal medicine","score_opus":0.026581577183491377,"score_gpt":0.27612582090251764,"score_spread":0.24954424371902625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013251910","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13151477,0.8588799,0.000008733922,0.000004307507,0.0001409033,0.0011823912,0.00010992304,0.000089279136,0.008069754],"genre_scores_gemma":[0.10215764,0.89559054,0.00030675402,0.000069094756,0.00017267447,0.00017694834,0.00030763927,0.00012585772,0.0010928398],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99536806,0.0002774282,0.0020763837,0.0010196586,0.00056532904,0.0006931108],"domain_scores_gemma":[0.99654365,0.0003812469,0.0014621122,0.0010796225,0.0002057656,0.00032762272],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00039194792,0.0009924177,0.0045312936,0.0007386669,0.000088360226,0.00002025825,0.0004540047,0.0013540584,0.00027054173],"category_scores_gemma":[0.00013800777,0.0007984698,0.00096548937,0.0008589875,0.000659417,0.00020069722,0.00021212449,0.00020810882,0.00003026944],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009913913,0.0006291896,0.0003108341,0.017121224,0.00092630903,0.00034102326,0.0014301039,0.0000014205704,0.0011609744,0.014531331,0.0002821499,0.9622741],"study_design_scores_gemma":[0.013862439,0.0012007477,0.064185485,0.036783293,0.0034867227,0.002701127,0.00095468183,0.00022399292,0.01237238,0.0055188714,0.8568448,0.0018654801],"about_ca_topic_score_codex":0.0005396238,"about_ca_topic_score_gemma":0.000011705029,"teacher_disagreement_score":0.96040857,"about_ca_system_score_codex":0.003368383,"about_ca_system_score_gemma":0.00498403,"threshold_uncertainty_score":0.9999424},"labels":[],"label_agreement":null},{"id":"W2013425043","doi":"10.1080/10428190500272549","title":"Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Melphalan; Multiple myeloma; Medicine; Chemotherapy; Bone marrow; Autologous stem-cell transplantation; Oncology; Internal medicine; Fluorescence in situ hybridization; Pathology; Biology","score_opus":0.020627777997041352,"score_gpt":0.26245457438802133,"score_spread":0.24182679639097998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013425043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949647,0.0020727124,0.000051366555,0.00007418721,0.000027414284,0.0024371033,0.000079146106,0.0001681242,0.00012522063],"genre_scores_gemma":[0.996545,0.00043753276,0.002032414,0.0001205876,0.00006698327,0.00037314172,0.0000997017,0.000111581925,0.00021306078],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99618214,0.00024975848,0.00082542276,0.0010872801,0.00073890935,0.00091647875],"domain_scores_gemma":[0.9973396,0.0010782235,0.00030290967,0.0006207116,0.00013811013,0.00052043656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002970117,0.0007378838,0.0012310375,0.00049915264,0.0002679872,0.000055947366,0.00020463516,0.0003080577,0.00001914369],"category_scores_gemma":[0.000071756986,0.00055096636,0.00010702962,0.0005853314,0.00033658295,0.00024144005,0.000073304785,0.00016962244,0.000006689586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013522564,0.0023693421,0.7646216,0.00062515127,0.00022047981,0.004792203,0.0024987916,0.00022988365,0.02434755,0.0000049421396,0.000029115945,0.18673839],"study_design_scores_gemma":[0.08538923,0.0031664537,0.78857833,0.001064827,0.00024890006,0.0008965489,0.0008366129,0.017599083,0.10157774,0.0000050210515,0.00011780951,0.0005194507],"about_ca_topic_score_codex":0.003057455,"about_ca_topic_score_gemma":0.0008845097,"teacher_disagreement_score":0.18621893,"about_ca_system_score_codex":0.0025170313,"about_ca_system_score_gemma":0.0014263374,"threshold_uncertainty_score":0.99969417},"labels":[],"label_agreement":null},{"id":"W2014488544","doi":"10.1080/10428190290016890","title":"Cytogenetic Analysis in Mantle Cell Lymphoma: A Review of 214 Cases","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Mantle cell lymphoma; Lymphoma; Mantle (geology); Cancer research; Ibrutinib; Medicine; Pathology; Internal medicine; Geology; Leukemia; Chronic lymphocytic leukemia; Geochemistry","score_opus":0.030705201939201874,"score_gpt":0.29829572606515825,"score_spread":0.26759052412595635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014488544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011747343,0.97691536,0.000004478912,0.00004812541,0.0002699821,0.0030884857,0.00047395576,0.00016275558,0.007289499],"genre_scores_gemma":[0.009685474,0.9838109,0.0004240999,0.0008450103,0.00028439844,0.001086488,0.001197342,0.0003145172,0.0023517513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98938054,0.0006530516,0.004127579,0.002649933,0.0014660405,0.0017228558],"domain_scores_gemma":[0.9926405,0.0011942978,0.0020666653,0.0027651978,0.00030794536,0.001025386],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00073542463,0.0025300316,0.01104892,0.002472298,0.0002341282,0.000116575575,0.00084152207,0.0015552945,0.0005668185],"category_scores_gemma":[0.00026068537,0.002069914,0.0038800854,0.0051586493,0.00051182293,0.00021870816,0.0005145783,0.00020110796,0.00027080925],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009692195,0.0017695565,0.0013485196,0.13169779,0.00304853,0.0049884915,0.00011939425,0.0000028620614,0.000002050181,0.00006347195,0.0041258424,0.8527366],"study_design_scores_gemma":[0.016568508,0.00069524575,0.0048132883,0.118470855,0.042491544,0.005621288,0.00007006655,0.00020127055,0.00010299015,0.000015382786,0.8089725,0.001977071],"about_ca_topic_score_codex":0.0027629316,"about_ca_topic_score_gemma":0.00019904166,"teacher_disagreement_score":0.8507595,"about_ca_system_score_codex":0.016019426,"about_ca_system_score_gemma":0.007038617,"threshold_uncertainty_score":0.9997409},"labels":[],"label_agreement":null},{"id":"W2016355237","doi":"10.3109/10428194.2012.719614","title":"Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Bortezomib; Multiple myeloma; Neutropenia; Internal medicine; Dexamethasone; Oncology; Adverse effect; Thalidomide; Gastroenterology; Surgery; Toxicity","score_opus":0.03254678982639751,"score_gpt":0.2968636568573042,"score_spread":0.2643168670309067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016355237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985036,0.00931591,0.00024399212,0.0002491876,0.00035851388,0.0027120986,0.00023306887,0.00040825485,0.0014429771],"genre_scores_gemma":[0.9815932,0.0029374843,0.0074301423,0.000934063,0.0007439862,0.00074970705,0.00045467544,0.00025647928,0.004900268],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99415016,0.00027853256,0.0011006512,0.001348435,0.0008815115,0.0022406857],"domain_scores_gemma":[0.99427724,0.001843094,0.0003938143,0.0010679816,0.00030252433,0.0021153174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008687001,0.0010982448,0.0015795821,0.0005247075,0.0006918942,0.0001580203,0.000298811,0.00086085923,0.00015268088],"category_scores_gemma":[0.0015035016,0.0008552386,0.00037756094,0.00062593486,0.000583295,0.00079422694,0.0002708319,0.00027353366,0.0000785409],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034704607,0.001498599,0.24899457,0.001521844,0.0020014008,0.0008127046,0.00205469,0.000004739608,0.028346673,0.00038604403,0.008955358,0.6707188],"study_design_scores_gemma":[0.11147511,0.002762108,0.7686092,0.00080894196,0.0011625604,0.0034708485,0.00082828704,0.0068793753,0.037373748,0.00012550272,0.06494646,0.0015578462],"about_ca_topic_score_codex":0.0015361967,"about_ca_topic_score_gemma":0.00013811461,"teacher_disagreement_score":0.6691609,"about_ca_system_score_codex":0.0053927363,"about_ca_system_score_gemma":0.0025276544,"threshold_uncertainty_score":0.9993898},"labels":[],"label_agreement":null},{"id":"W2016579260","doi":"10.3109/10428194.2011.584003","title":"The pandemic H1N1 influenza vaccine results in low rates of seroconversion for patients with hematological malignancies","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Western University","funders":"American Society of Hematology","keywords":"Medicine; Seroconversion; Vaccination; Immunology; Influenza vaccine; Antibody; Antibody titer; Population; Titer; Pandemic; Flu season; Internal medicine; Disease; Coronavirus disease 2019 (COVID-19); Infectious disease (medical specialty)","score_opus":0.04350369681274826,"score_gpt":0.2998302026206843,"score_spread":0.2563265058079361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016579260","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954433,0.001732278,0.000016939066,0.00006123182,0.000087992565,0.0016155218,0.00006948783,0.00008331893,0.00088995456],"genre_scores_gemma":[0.9970295,0.0010577011,0.00064787973,0.00057721144,0.00005438873,0.00027656322,0.000042302876,0.000054867567,0.00025957316],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650764,0.00012464277,0.0010615671,0.00071197684,0.0006259499,0.000968235],"domain_scores_gemma":[0.99714786,0.00094201433,0.0004130571,0.0006480895,0.0005904276,0.0002585818],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007050185,0.0005170017,0.0009586107,0.00025700984,0.00040201945,0.00003756207,0.00035687152,0.00034207702,0.000012118089],"category_scores_gemma":[0.000882497,0.00030798934,0.0001913741,0.0005282799,0.00055629533,0.00025364268,0.0002689863,0.00014568018,0.000013501165],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03742904,0.00046831477,0.9272614,0.0008856481,0.00039076974,0.00008772028,0.0029231799,0.000012391652,0.00063663354,0.00060870295,0.0014979979,0.027798211],"study_design_scores_gemma":[0.049424272,0.0017904185,0.9323102,0.0008613684,0.00013432541,0.00007192548,0.0010169725,0.0005415059,0.008041105,0.00033609848,0.0050429283,0.00042885248],"about_ca_topic_score_codex":0.00077579584,"about_ca_topic_score_gemma":0.0001852232,"teacher_disagreement_score":0.02736936,"about_ca_system_score_codex":0.001887707,"about_ca_system_score_gemma":0.0013154534,"threshold_uncertainty_score":0.99993724},"labels":[],"label_agreement":null},{"id":"W2017217800","doi":"10.1080/10428190400025120","title":"Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate","year":2005,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Montreal Children's Hospital","funders":"","keywords":"Myeloid leukemia; Imatinib mesylate; Medicine; Imatinib; Central nervous system; Oncology; Internal medicine; Cancer research","score_opus":0.005834918914286738,"score_gpt":0.20399632849166588,"score_spread":0.19816140957737916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2017217800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97019756,0.003131288,0.000029761004,0.008574533,0.001687854,0.0060214703,0.00062882295,0.0015018687,0.008226869],"genre_scores_gemma":[0.8778684,0.0012341203,0.00079843553,0.0904967,0.007321454,0.0010204187,0.008183898,0.0017473559,0.011329198],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9833366,0.00064446876,0.0033302435,0.004479092,0.0032210937,0.0049884985],"domain_scores_gemma":[0.99179626,0.0006446823,0.0019211073,0.0037739933,0.0004857404,0.0013782292],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00052344496,0.00418097,0.0048975297,0.0018668688,0.00067700754,0.00042397075,0.0013205615,0.0052201226,0.00030081114],"category_scores_gemma":[0.00014192736,0.0035846774,0.0009545472,0.0017587444,0.00083249656,0.0007295773,0.00053142884,0.0030495909,0.0008435651],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019446297,0.0015147334,0.037484974,0.011507095,0.0057351543,0.038244646,0.0023206992,0.0018940178,0.00016813139,0.0002748321,0.5117099,0.36969948],"study_design_scores_gemma":[0.17167877,0.007688094,0.3673608,0.016694684,0.0035615168,0.004925722,0.00020299185,0.019506756,0.00050070806,0.000032700475,0.4010327,0.0068145604],"about_ca_topic_score_codex":0.004690653,"about_ca_topic_score_gemma":0.00036316278,"teacher_disagreement_score":0.3628849,"about_ca_system_score_codex":0.2320173,"about_ca_system_score_gemma":0.02525317,"threshold_uncertainty_score":0.9999344},"labels":[],"label_agreement":null},{"id":"W2018665096","doi":"10.1080/10428190500054426","title":"Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the Toll-like receptor-7/8 agonist, imiquimod","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"The Scarborough Hospital; Grace (Canada); Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"National Institute on Aging","keywords":"Imiquimod; Chronic lymphocytic leukemia; Medicine; Agonist; Dermatology; Cancer research; Toll-like receptor; Toll; Leukemia; Receptor; Internal medicine; Oncology; Immunology","score_opus":0.008737558601018448,"score_gpt":0.24396892048485078,"score_spread":0.23523136188383234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2018665096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98223454,0.009562756,0.00007380814,0.0003114297,0.00022680363,0.002722173,0.00006236091,0.0004288014,0.0043773022],"genre_scores_gemma":[0.9907751,0.0026124027,0.0010070922,0.0012416708,0.00061295193,0.0006025294,0.00021690039,0.00038998315,0.0025413898],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9892217,0.0006088019,0.0023996588,0.00240272,0.002576097,0.0027910324],"domain_scores_gemma":[0.9934617,0.0009215884,0.0010929448,0.0027925174,0.00055159134,0.0011796049],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00092662475,0.0019298748,0.002628867,0.0011016706,0.0007410343,0.00025675027,0.0012363254,0.0012342882,0.00016439536],"category_scores_gemma":[0.00018004,0.001297984,0.00064752036,0.002589875,0.0017616446,0.000736495,0.00078201055,0.0005321864,0.0001881644],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.024894593,0.0010802206,0.006173391,0.0035107299,0.0021337296,0.0059478213,0.010228391,0.017468471,0.04794483,0.00095947366,0.024254588,0.8554038],"study_design_scores_gemma":[0.25675622,0.0067689246,0.0372614,0.007965024,0.0016519069,0.028287789,0.004050806,0.3044975,0.2615095,0.00009551928,0.08641641,0.004738995],"about_ca_topic_score_codex":0.013731902,"about_ca_topic_score_gemma":0.0024177672,"teacher_disagreement_score":0.8506648,"about_ca_system_score_codex":0.38660848,"about_ca_system_score_gemma":0.10391675,"threshold_uncertainty_score":0.99934447},"labels":[],"label_agreement":null},{"id":"W2019726944","doi":"10.3109/10428190903297531","title":"Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV","year":2009,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; University of Arizona; American Cancer Society","keywords":"Methylation; CIITA; CpG site; Transactivation; Lymphoma; Promoter; Diffuse large B-cell lymphoma; DNA methylation; Biology; Cancer research; Major histocompatibility complex; CD74; Immunology; MHC class II; Gene; Genetics; Gene expression","score_opus":0.01056275874558213,"score_gpt":0.2278023158749936,"score_spread":0.21723955712941148,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019726944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807972,0.0014573532,0.00015071256,0.010735411,0.00031526395,0.004363445,0.00068278523,0.00030060616,0.0011972253],"genre_scores_gemma":[0.9586177,0.00067971443,0.0014160142,0.03392092,0.0005382735,0.0008558661,0.0019073104,0.00032075887,0.0017434743],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98994124,0.0006427672,0.0025591585,0.003071092,0.0018397329,0.0019460304],"domain_scores_gemma":[0.99416554,0.00078384,0.0017331503,0.002046461,0.00036328755,0.0009077377],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007003268,0.0024312467,0.0040612575,0.0010846154,0.00093427865,0.00015289593,0.00059942226,0.002759452,0.00011927019],"category_scores_gemma":[0.00008298952,0.0017845088,0.00070275785,0.0007903287,0.00087763293,0.00059756526,0.0003492369,0.0006810527,0.000008728057],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0694099,0.0759514,0.052415915,0.018647177,0.0057026288,0.020647312,0.022802766,0.00008911798,0.119507834,0.00050672895,0.18462993,0.4296893],"study_design_scores_gemma":[0.39598507,0.006260111,0.30745035,0.006108445,0.0039275982,0.0014891952,0.0006027998,0.009238502,0.077475384,0.00032901543,0.18674487,0.0043886765],"about_ca_topic_score_codex":0.0038558962,"about_ca_topic_score_gemma":0.0004082906,"teacher_disagreement_score":0.42530063,"about_ca_system_score_codex":0.014115454,"about_ca_system_score_gemma":0.0041633914,"threshold_uncertainty_score":0.9988425},"labels":[],"label_agreement":null},{"id":"W2022022610","doi":"10.3109/10428190009113379","title":"Matrix Metalloproteinases and Their Tissue Inhibitors - Expression, Role and Regulation in Human Malignant Non-Hodgkin's Lymphomas","year":2000,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Protease and Inhibitor Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; Calgary Laboratory Services; University of Alberta; University of Calgary","funders":"Medical Research Council Canada; Ulster University; Canadian Blood Services","keywords":"Matrix metalloproteinase; Cancer research; Lymphoma; Medicine; Biology; Pathology; Internal medicine","score_opus":0.008402614704211088,"score_gpt":0.257436462538045,"score_spread":0.2490338478338339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022022610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16998929,0.8272414,0.00004083638,0.000007678711,0.00016585793,0.0016656063,0.00012986385,0.00006893505,0.0006905145],"genre_scores_gemma":[0.08726422,0.9079065,0.0003955106,0.00010995853,0.00082327623,0.0006755829,0.0009254816,0.00027001533,0.0016294675],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946623,0.000415209,0.0014358815,0.0021000393,0.00038199517,0.0010045621],"domain_scores_gemma":[0.9975815,0.00007366142,0.000670968,0.001090673,0.000076230936,0.0005070128],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005375849,0.0015822359,0.0022440495,0.0005171894,0.0004990549,0.00027534744,0.00047917475,0.0018148636,0.000046447964],"category_scores_gemma":[0.000051020965,0.0013119135,0.0003737109,0.0004042676,0.00038520026,0.00007578911,0.00067287585,0.00019917153,0.000013684166],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014252006,0.000106428066,0.000021164647,0.0030210428,0.00017285322,0.00009342676,0.00019115504,0.000004292531,0.09253459,0.00018001052,0.00066081004,0.9028717],"study_design_scores_gemma":[0.004302346,0.0005692187,0.00012846624,0.0068848412,0.0003559347,0.0012089148,0.0001456588,0.00007478575,0.20957564,0.00083805795,0.774058,0.001858165],"about_ca_topic_score_codex":0.0007726367,"about_ca_topic_score_gemma":0.000064837965,"teacher_disagreement_score":0.90101355,"about_ca_system_score_codex":0.0009549441,"about_ca_system_score_gemma":0.0017392436,"threshold_uncertainty_score":0.99969256},"labels":[],"label_agreement":null},{"id":"W2025152396","doi":"10.1080/10428190802653776","title":"Anti-tumor immunity in a model of acute myeloid leukemia","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Asthma and Lung UK","keywords":"Cytotoxic T cell; Immunology; Immune system; Myeloid leukemia; Myeloid; Biology; Cancer research; T cell; Leukemia; Antigen; Immunotherapy; In vitro","score_opus":0.009572915527247736,"score_gpt":0.22961908880687595,"score_spread":0.22004617327962822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2025152396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98395586,0.011604384,0.00021558859,0.000114906084,0.00043388098,0.0005817616,0.00013249014,0.00021653871,0.0027445883],"genre_scores_gemma":[0.9909009,0.003522203,0.0003673319,0.0013196233,0.000042599444,0.00005609768,0.00016806314,0.00008681611,0.003536407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952703,0.00056512875,0.00154036,0.0009793888,0.00021095162,0.0014338559],"domain_scores_gemma":[0.9974575,0.00035254852,0.0006057782,0.001299858,0.0001680155,0.00011629982],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00078148686,0.0009543582,0.0016773458,0.00075235195,0.00049731036,0.000075769385,0.001039841,0.0009196431,0.00013821994],"category_scores_gemma":[0.00011205847,0.0009100966,0.0004454532,0.000820924,0.00084096973,0.0005977965,0.00025884804,0.00043917733,0.00014358455],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036739015,0.00036528465,0.0011634399,0.00007358568,0.00052815635,0.00011616161,0.0019690897,0.00046115826,0.89132065,0.0019785948,0.0009909385,0.097359024],"study_design_scores_gemma":[0.041305114,0.0016687982,0.22606854,0.0007014951,0.0004861927,0.0024327103,0.0011078297,0.007244361,0.7027714,0.0024571582,0.011300666,0.0024557195],"about_ca_topic_score_codex":0.002087256,"about_ca_topic_score_gemma":0.00003574832,"teacher_disagreement_score":0.2249051,"about_ca_system_score_codex":0.003778097,"about_ca_system_score_gemma":0.0040617967,"threshold_uncertainty_score":0.999335},"labels":[],"label_agreement":null},{"id":"W2027026214","doi":"10.1080/10428190310001617286","title":"Hyperthyroidism Six Years Post-BMT for Acute Myeloblastic Leukemia in a Patient on Long-Term Lithium Therapy for Bipolar Affective Disorder","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Bipolar Disorder and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; The Scarborough Hospital","funders":"","keywords":"Lithium (medication); Bipolar disorder; Medicine; Thyroid function; Pediatrics; Acute myeloblastic leukemia; Affect (linguistics); Thyroid; Complication; Psychiatry; Internal medicine; Leukemia; Psychology","score_opus":0.007616627718722317,"score_gpt":0.24758517585429643,"score_spread":0.2399685481355741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027026214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97223794,0.021009276,0.0004735201,0.00014216905,0.0005131924,0.0045384024,0.00032851237,0.00018922449,0.00056776335],"genre_scores_gemma":[0.9899814,0.0042015193,0.0008205316,0.0014969361,0.00017804565,0.0018643955,0.00045884764,0.0002645973,0.0007337086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954079,0.00019023674,0.0008694689,0.0015310146,0.0005783787,0.0014230402],"domain_scores_gemma":[0.99727,0.0007309177,0.00029449046,0.0008900212,0.00025009527,0.0005644735],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031271882,0.0010754338,0.0013152022,0.00055820256,0.00039748364,0.00012753047,0.00026657974,0.00070410833,0.000034953988],"category_scores_gemma":[0.00021859599,0.0009360802,0.0006330057,0.00056745386,0.0002762289,0.00026484035,0.00007759433,0.00021666827,0.000044606968],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012593454,0.0022718941,0.10298588,0.0005044826,0.0022766064,0.0004859697,0.0047851764,0.00012483193,0.008094495,0.0025016838,0.0009803106,0.8623952],"study_design_scores_gemma":[0.086882785,0.010698064,0.836731,0.0005527129,0.0010598896,0.0011037244,0.00067668513,0.0013091223,0.0129275555,0.000712926,0.045601875,0.0017436533],"about_ca_topic_score_codex":0.00089955423,"about_ca_topic_score_gemma":0.0005962612,"teacher_disagreement_score":0.86065155,"about_ca_system_score_codex":0.009196493,"about_ca_system_score_gemma":0.0037367719,"threshold_uncertainty_score":0.999309},"labels":[],"label_agreement":null},{"id":"W2027091982","doi":"10.3109/10428194.2011.594193","title":"Is there a role for consolidative radiation therapy for aggressive B-cell lymphoma in the rituximab era?","year":2011,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Rituximab; Lymphoma; Medicine; Radiation therapy; Aggressive lymphoma; Oncology; Chemotherapy; Radioimmunotherapy; Internal medicine; Immunology; Monoclonal antibody; Antibody","score_opus":0.01890653494419384,"score_gpt":0.26031343238437393,"score_spread":0.2414068974401801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027091982","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7772925,0.07809823,0.0001666425,0.10245182,0.0017297779,0.022817938,0.004362013,0.0005154759,0.012565622],"genre_scores_gemma":[0.43609592,0.015681908,0.0012756186,0.518288,0.004847301,0.014242976,0.0049094255,0.0006695055,0.003989295],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922803,0.0004432381,0.0016619996,0.002454907,0.0010905822,0.0020689652],"domain_scores_gemma":[0.9930777,0.0023835758,0.001748599,0.0018904883,0.000527891,0.00037177434],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007031662,0.002114908,0.0027191374,0.000719449,0.0007642137,0.00040886883,0.0010289974,0.0027558315,0.00012791506],"category_scores_gemma":[0.00019331614,0.0015239514,0.001418868,0.0006273908,0.00059649657,0.0003911399,0.00016010502,0.00044022594,0.00010978865],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003644777,0.0023559325,0.0027181723,0.0010768485,0.0013676158,0.0015133198,0.007713294,0.0000014903749,0.00008177215,0.0003714313,0.7075318,0.27162355],"study_design_scores_gemma":[0.133078,0.0025190506,0.025455479,0.0010039663,0.0014258241,0.001479845,0.0009448339,0.0009685016,0.007142043,0.002376277,0.8218192,0.0017870156],"about_ca_topic_score_codex":0.002261479,"about_ca_topic_score_gemma":0.00005746241,"teacher_disagreement_score":0.41583622,"about_ca_system_score_codex":0.009130464,"about_ca_system_score_gemma":0.0069472077,"threshold_uncertainty_score":0.9991592},"labels":[],"label_agreement":null},{"id":"W2027093999","doi":"10.1080/1042819021000016087","title":"Allogeneic Bone Marrow Transplantation in the Management of Chronic Neutrophilic Leukemia","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Leukocytosis; Leukemia; Myeloproliferative Disorders; Disease; Chronic myelogenous leukemia; Bone marrow; Stage (stratigraphy); Transplantation; Immunology; Internal medicine; Oncology; Pathology; Biology","score_opus":0.015940342000825072,"score_gpt":0.24849738086645873,"score_spread":0.23255703886563367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027093999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733579,0.008669571,0.000099129255,0.00084691064,0.00021661942,0.0017632167,0.00004697535,0.00015532925,0.014844318],"genre_scores_gemma":[0.97463226,0.019873045,0.0007629528,0.0011920031,0.00036989173,0.0003533058,0.000155102,0.00014332635,0.0025181132],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99401015,0.0003628271,0.001423924,0.0012734744,0.0014295323,0.001500111],"domain_scores_gemma":[0.9972106,0.00032685592,0.00037124008,0.0015054385,0.00015351472,0.00043235868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000977919,0.0008660361,0.001199646,0.00074643124,0.0003241122,0.000107120075,0.00085336016,0.0006012619,0.00030059222],"category_scores_gemma":[0.000031506763,0.0006944081,0.00040267908,0.0016844007,0.0006745945,0.00037277868,0.00020731342,0.00041867152,0.00017179245],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003631751,0.0013607333,0.009557577,0.008849452,0.0015796493,0.01711176,0.008343017,0.001047735,0.05424864,0.008680629,0.012618027,0.87297106],"study_design_scores_gemma":[0.122770004,0.0038511257,0.6611235,0.0040460727,0.0030402504,0.02333733,0.004353946,0.08263628,0.026870817,0.0013642233,0.06298407,0.003622352],"about_ca_topic_score_codex":0.0012006393,"about_ca_topic_score_gemma":0.0001599145,"teacher_disagreement_score":0.8693487,"about_ca_system_score_codex":0.015624779,"about_ca_system_score_gemma":0.0017798274,"threshold_uncertainty_score":0.9995507},"labels":[],"label_agreement":null},{"id":"W2027904581","doi":"10.3109/10428194.2011.635863","title":"Blood, sex and tears: speculations on the gender imbalance in hematologic malignancies","year":2011,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Prenatal Screening and Diagnostics","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; University of Calgary; Calgary Laboratory Services","funders":"","keywords":"Medicine; Hematologic Neoplasms; Tears; Internal medicine; Dermatology; Immunology; Cancer","score_opus":0.026055523896818797,"score_gpt":0.23219880358617595,"score_spread":0.20614327968935714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2027904581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9454928,0.0052009188,0.000028406148,0.02481647,0.00031947595,0.00117419,0.00013829398,0.00029937126,0.022530077],"genre_scores_gemma":[0.7659466,0.0019260814,0.00057174836,0.22573882,0.0012774313,0.00023140425,0.0002951062,0.00016919138,0.0038435778],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9959291,0.00023494018,0.0008122008,0.0012394113,0.0006919676,0.0010923772],"domain_scores_gemma":[0.9967794,0.0013298009,0.00036155232,0.0011565826,0.000096647986,0.00027601447],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003867842,0.00097496755,0.0012520576,0.000373998,0.00032643572,0.0001564442,0.000431793,0.0015931098,0.00009650933],"category_scores_gemma":[0.000508515,0.000698657,0.00023892774,0.00041724558,0.00066792464,0.0001334241,0.00031585197,0.0008341447,0.00009320961],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005710222,0.00041602607,0.09457151,0.001851263,0.00093349244,0.019007303,0.0029647145,0.000024839357,0.000495063,0.008959889,0.8589775,0.011227385],"study_design_scores_gemma":[0.019021774,0.0009224311,0.65186805,0.0040244837,0.0015969664,0.01322229,0.00074576377,0.0016386213,0.0029133505,0.0067015514,0.29447,0.0028746917],"about_ca_topic_score_codex":0.0016023574,"about_ca_topic_score_gemma":0.000043506327,"teacher_disagreement_score":0.5645075,"about_ca_system_score_codex":0.0015867922,"about_ca_system_score_gemma":0.0013752513,"threshold_uncertainty_score":0.99970305},"labels":[],"label_agreement":null},{"id":"W2028310887","doi":"10.1080/1042819031000119208","title":"Improved Therapeutic Outcome Following Combination Immunogene Vaccination Therapy in Murine Myeloma","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"CD80; Immunology; Vaccination; Antigen; Immunotherapy; Multiple myeloma; Medicine; Genetic enhancement; Minimal residual disease; Cytotoxic T cell; Cancer research; Immune system; Biology; CD40; In vitro; Bone marrow; Gene","score_opus":0.012800592667473002,"score_gpt":0.2473516002169836,"score_spread":0.2345510075495106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028310887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95625997,0.039475415,0.00019337358,0.00009916718,0.0014381062,0.00084484473,0.000010373629,0.0002150371,0.0014637366],"genre_scores_gemma":[0.9914087,0.0026599087,0.000109497596,0.00083493267,0.00002979821,0.00020026587,0.00013341257,0.000116039984,0.0045074555],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9956956,0.0009515863,0.0012105856,0.0008839465,0.0001603347,0.0010979282],"domain_scores_gemma":[0.9981437,0.00047618948,0.00039553526,0.0008055675,0.00011374169,0.00006531366],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011038646,0.00078352424,0.0009539508,0.00060111843,0.0006154254,0.00013139898,0.00049739896,0.00080765144,0.00034345844],"category_scores_gemma":[0.00017114083,0.00072785997,0.0003879751,0.0007243368,0.00017783073,0.00056213,0.000092037284,0.0002584159,0.00013326449],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017692047,0.0004232806,0.014477793,0.000040984494,0.00052897417,0.000045178982,0.0011649833,0.000009670623,0.5775466,0.0027794526,0.00008392528,0.40112993],"study_design_scores_gemma":[0.055762332,0.0011278124,0.4804561,0.00011592203,0.00010749616,0.0006595117,0.00092341966,0.00028625355,0.41586363,0.0009930131,0.042252705,0.001451801],"about_ca_topic_score_codex":0.0008663564,"about_ca_topic_score_gemma":0.000048492817,"teacher_disagreement_score":0.46597832,"about_ca_system_score_codex":0.002962293,"about_ca_system_score_gemma":0.0010388514,"threshold_uncertainty_score":0.99951726},"labels":[],"label_agreement":null},{"id":"W2029150962","doi":"10.1080/10428190902943069","title":"Targeting the Bcl-2 family of proteins in Hodgkin lymphoma:<b><i>in vitro</i></b>cytotoxicity, target modulation and drug combination studies of the Bcl-2 homology 3 mimetic ABT-737","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital","funders":"","keywords":"Survivin; Lymphoma; Cancer research; Cytotoxicity; Bcl-2 family; Apoptosis; In vitro; Medicine; Pharmacology; Drug; Growth inhibition; Biology; Oncology; Immunology; Programmed cell death; Biochemistry","score_opus":0.007915829360495305,"score_gpt":0.22810931968809678,"score_spread":0.22019349032760147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029150962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904365,0.0073783905,0.00047970738,0.00025145797,0.00019384678,0.0010448853,0.000018495653,0.00001901194,0.00017771647],"genre_scores_gemma":[0.99640393,0.0020431739,0.00080902537,0.00028268681,0.000091559334,0.00007366019,0.000070217844,0.000037161277,0.00018859845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971559,0.00038225626,0.0009334849,0.0006722689,0.00037207012,0.00048399033],"domain_scores_gemma":[0.99854314,0.00011119538,0.00055732665,0.00054492714,0.00016778788,0.00007561194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009173203,0.00043261878,0.00064165983,0.00021608137,0.00023626786,0.000033621185,0.00036488404,0.0003897599,0.0000014403292],"category_scores_gemma":[0.00014871306,0.00031198154,0.00015650342,0.00049715553,0.00043362635,0.00003718601,0.00026312654,0.000087158485,6.982642e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036560083,0.00020884602,0.0023107196,0.00014178944,0.000061148276,0.000008884478,0.0010933257,0.0012574116,0.95654386,0.00053800544,0.00014398737,0.03732642],"study_design_scores_gemma":[0.010291537,0.00045855474,0.34905052,0.0002524886,0.000078174955,0.00009445832,0.0014569599,0.029998897,0.6021635,0.0050953194,0.00048789644,0.00057165953],"about_ca_topic_score_codex":0.0006755454,"about_ca_topic_score_gemma":0.00009520065,"teacher_disagreement_score":0.35438034,"about_ca_system_score_codex":0.0006372273,"about_ca_system_score_gemma":0.0005343784,"threshold_uncertainty_score":0.99993324},"labels":[],"label_agreement":null},{"id":"W2029440792","doi":"10.1080/10428190500301231","title":"Generation of<i>in vitro</i>B-CLL specific HLA class I restricted CTL responses using autologous dendritic cells pulsed with necrotictumor lysate","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Leukemia Research Foundation","keywords":"CTL*; In vitro; Dendritic cell; Immunology; Cancer research; Lysis; Human leukocyte antigen; Class (philosophy); Chemistry; Biology; Molecular biology; Immune system; Cytotoxic T cell; Antigen; Biochemistry; Computer science","score_opus":0.034461594973760036,"score_gpt":0.2773981374998455,"score_spread":0.24293654252608546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2029440792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937845,0.0022269003,0.0002797102,0.0002121582,0.00030317067,0.0016228892,0.000072985524,0.000260013,0.0012376598],"genre_scores_gemma":[0.9867591,0.0009452993,0.008982487,0.0006320674,0.00075164356,0.000119362776,0.00015653779,0.00024907658,0.0014043875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923781,0.0005549166,0.0018388465,0.0017112113,0.001578602,0.0019383071],"domain_scores_gemma":[0.99575204,0.00074324093,0.0005798418,0.0016184936,0.00047678954,0.00082957634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007893556,0.0010771822,0.0018468376,0.0013011951,0.00038711925,0.00020268855,0.0005719699,0.000797564,0.000092912385],"category_scores_gemma":[0.00027650507,0.00097156037,0.00031908634,0.0019192653,0.0009970671,0.0005658811,0.00028870473,0.00040233182,0.00007843261],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012119074,0.00057647517,0.001059539,0.0006094987,0.00030403252,0.004112482,0.0011301638,0.0030092022,0.91899866,0.0002440282,0.0010286861,0.05680815],"study_design_scores_gemma":[0.07005855,0.000801867,0.01365891,0.0007001023,0.00038506804,0.00787078,0.00042908965,0.32259634,0.57512057,0.00003827658,0.0071612694,0.001179187],"about_ca_topic_score_codex":0.0029479116,"about_ca_topic_score_gemma":0.00022174488,"teacher_disagreement_score":0.34387812,"about_ca_system_score_codex":0.06662993,"about_ca_system_score_gemma":0.02902437,"threshold_uncertainty_score":0.9992735},"labels":[],"label_agreement":null},{"id":"W2030216096","doi":"10.3109/10428194.2010.528095","title":"Study of specific genetic and epigenetic variables in multiple myeloma","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylenetetrahydrofolate reductase; Methylation; Genotype; CpG site; Single-nucleotide polymorphism; DNA methylation; Epigenetics; CDKN2A; Internal medicine; Biology; Cancer research; Medicine; Genetics; Cancer; Gene; Gene expression","score_opus":0.010377033726410058,"score_gpt":0.22723472910517695,"score_spread":0.2168576953787669,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030216096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993912,0.00431096,0.00019690463,0.000012299215,0.00030608222,0.0005968576,0.000019188195,0.000021912025,0.00062379224],"genre_scores_gemma":[0.9953026,0.002013424,0.0020588909,0.000048334154,0.00024625368,0.00007087151,0.000044105847,0.000070715774,0.00014479233],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99730814,0.00015783965,0.0007560261,0.0009484554,0.00030219273,0.00052734965],"domain_scores_gemma":[0.998494,0.00011997033,0.00024848906,0.00078169914,0.00011303434,0.00024279105],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039728222,0.00044999548,0.0005048329,0.00023501844,0.00017191772,0.0000726559,0.0003130585,0.0004659041,0.000016527574],"category_scores_gemma":[0.00012968358,0.00045522163,0.00008283925,0.00030291214,0.00028330603,0.000015054005,0.0002895467,0.00011465536,0.000004502785],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002144905,0.0003205327,0.2606603,0.000057974437,0.00006442228,0.00004310143,0.0007161132,0.00025123003,0.6379894,0.00009450223,0.000049372895,0.09953858],"study_design_scores_gemma":[0.008237602,0.0007268369,0.8426051,0.000031548498,0.0000472595,0.000073077244,0.0006220528,0.0010993152,0.14001684,0.00037549497,0.005616193,0.0005486884],"about_ca_topic_score_codex":0.0008721486,"about_ca_topic_score_gemma":0.0014085409,"teacher_disagreement_score":0.5819448,"about_ca_system_score_codex":0.000179117,"about_ca_system_score_gemma":0.00049754017,"threshold_uncertainty_score":0.99978995},"labels":[],"label_agreement":null},{"id":"W2030504196","doi":"10.3109/10428190109064590","title":"Outpatient Supportive Care Following Chemotherapy for Acute Myeloblastic Leukemia","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Health Sciences Centre; University of Toronto; Women's College Hospital","funders":"","keywords":"Medicine; Febrile neutropenia; Chemotherapy; Induction chemotherapy; Cytarabine; Neutropenia; Sepsis; Outpatient clinic; Internal medicine; Surgery","score_opus":0.0098518977143296,"score_gpt":0.27482453568250925,"score_spread":0.26497263796817966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2030504196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98369354,0.0015593863,0.0012826816,0.0003243726,0.0013126486,0.0019905602,0.00010859306,0.000474352,0.009253856],"genre_scores_gemma":[0.9869091,0.0011841311,0.0010306677,0.0033986806,0.00086923526,0.00080714014,0.00034868237,0.00024026267,0.0052120807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954483,0.00007650922,0.0009940398,0.0013803242,0.0006986906,0.0014021674],"domain_scores_gemma":[0.9972909,0.00025466757,0.00035826705,0.0009214837,0.00036737838,0.00080727023],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021331724,0.00094727793,0.0013311075,0.00038502598,0.0007940963,0.00018337523,0.00034019494,0.00060676236,0.00017900651],"category_scores_gemma":[0.000083787265,0.00087991654,0.00084681757,0.000730703,0.0002732886,0.00043050584,0.00014171854,0.0002134284,0.00009647029],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013005036,0.00078643195,0.09001527,0.001349685,0.0058169756,0.0031179355,0.015215088,0.00031565822,0.03170289,0.0022976713,0.032217473,0.8041599],"study_design_scores_gemma":[0.11759722,0.007046706,0.2639668,0.0015655014,0.0066089686,0.0063402746,0.007905034,0.0041209594,0.04636352,0.0009842523,0.5333854,0.0041153436],"about_ca_topic_score_codex":0.0007971577,"about_ca_topic_score_gemma":0.00011830398,"teacher_disagreement_score":0.80004454,"about_ca_system_score_codex":0.01531941,"about_ca_system_score_gemma":0.0053542946,"threshold_uncertainty_score":0.99936515},"labels":[],"label_agreement":null},{"id":"W2031912770","doi":"10.3109/10428194.2014.900763","title":"Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chronic myelomonocytic leukemia; Sunitinib malate; Myelodysplastic syndromes; Medicine; Internal medicine; Oncology; Cancer research; Gastroenterology; Sunitinib; Cancer; Bone marrow","score_opus":0.01136352221495713,"score_gpt":0.23605733998542885,"score_spread":0.22469381777047173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2031912770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98427886,0.0006300128,0.000107206244,0.0064710304,0.0011820483,0.004824366,0.0006588181,0.00083131174,0.0010163708],"genre_scores_gemma":[0.83666265,0.0028895936,0.0010381419,0.12196517,0.0051099346,0.0014573417,0.006469958,0.001965462,0.02244175],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.98146355,0.0012704023,0.0034939328,0.0047313618,0.003600913,0.0054398295],"domain_scores_gemma":[0.9883028,0.0031529327,0.0020198333,0.003941766,0.00084046845,0.0017421657],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0012668095,0.0041766604,0.0059526907,0.0033425358,0.0007766149,0.0006662555,0.0023429785,0.0055745468,0.0012229348],"category_scores_gemma":[0.0011692157,0.0030336767,0.0007132554,0.0029322624,0.0022485666,0.0009299134,0.0013663743,0.004924454,0.0012213341],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.048561648,0.0008229632,0.060096752,0.015075345,0.0053574704,0.124671645,0.0015213166,0.00051443634,0.000066083514,0.00006938214,0.5947119,0.14853106],"study_design_scores_gemma":[0.16086641,0.016022932,0.53221047,0.011256935,0.0039345105,0.015455935,0.0002417838,0.009494639,0.00024326674,0.00017372258,0.2430053,0.0070940736],"about_ca_topic_score_codex":0.00861518,"about_ca_topic_score_gemma":0.0012586304,"teacher_disagreement_score":0.47211373,"about_ca_system_score_codex":0.09794548,"about_ca_system_score_gemma":0.044143025,"threshold_uncertainty_score":0.99969006},"labels":[],"label_agreement":null},{"id":"W2032055037","doi":"10.1080/10428190802064941","title":"Treatment of relapsed and refractory myeloma","year":2008,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University; Dalhousie University; Saskatchewan Cancer Agency; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Saskatchewan; London Health Sciences Centre; St. Paul's Hospital; Centre hospitalier universitaire de Québec; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Lenalidomide; Thalidomide; Medicine; Multiple myeloma; Bortezomib; Refractory (planetary science); Salvage therapy; Oncology; Internal medicine; Clinical trial; Pomalidomide; Malignancy; Chemotherapy; Intensive care medicine; Biology","score_opus":0.037678915989462464,"score_gpt":0.3176391694733303,"score_spread":0.2799602534838679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2032055037","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038882416,0.95405835,0.0000032232804,0.000021424237,0.00021727078,0.0022784178,0.00025605274,0.00017584069,0.004106979],"genre_scores_gemma":[0.005913731,0.9867751,0.0005886963,0.000054726777,0.00041513628,0.00047310037,0.0007767948,0.0002727112,0.0047299964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940798,0.00034397826,0.0016770962,0.0016886715,0.0009621359,0.0012482726],"domain_scores_gemma":[0.9953789,0.00080061576,0.00083967776,0.00151154,0.0001949046,0.001274334],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00013823654,0.0017079632,0.0052692755,0.00089366984,0.0003820431,0.00007275722,0.00030605993,0.0013842696,0.00007597707],"category_scores_gemma":[0.00017047545,0.0012577162,0.0011482418,0.00067974837,0.00090066984,0.00020824796,0.00023472353,0.00021321341,0.00011719947],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00061404787,0.0006091143,0.00043338555,0.00814992,0.0017996614,0.0032768848,0.0003261995,1.0958056e-7,0.000016793243,0.000083571445,0.0007728689,0.9839174],"study_design_scores_gemma":[0.022588642,0.002883552,0.0052519157,0.006384677,0.002266886,0.013691528,0.000068693764,0.00010181283,0.00008908901,0.000023140485,0.94569856,0.0009514862],"about_ca_topic_score_codex":0.0013338677,"about_ca_topic_score_gemma":0.000024888306,"teacher_disagreement_score":0.98296595,"about_ca_system_score_codex":0.011625549,"about_ca_system_score_gemma":0.009159661,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W2036791873","doi":"10.1080/10428190802140873","title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":170,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Princess Margaret Cancer Centre; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cardiotoxicity; Doxorubicin; Lymphoma; Chemotherapy; Internal medicine; Radiation therapy; Population; Incidence (geometry); Gastroenterology; Disease; Cardiac toxicity; Oncology; Cardiology; Surgery","score_opus":0.02346052667657797,"score_gpt":0.2627539482421572,"score_spread":0.23929342156557923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036791873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882656,0.006650235,0.00062960514,0.00010835026,0.00043969363,0.00226731,0.00037598438,0.00019005363,0.0010731812],"genre_scores_gemma":[0.98321974,0.013391453,0.0008115659,0.00047137582,0.0007081575,0.00039908456,0.00041618556,0.00013458077,0.00044782463],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99629056,0.0002235894,0.0008561449,0.0011382239,0.0006848767,0.0008065976],"domain_scores_gemma":[0.99763334,0.00052139966,0.0003925823,0.00074175553,0.0002273951,0.00048355185],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004405928,0.00082546397,0.0018911168,0.00032632542,0.00058651285,0.00005629558,0.00015969865,0.0006831756,0.000009922199],"category_scores_gemma":[0.00012111699,0.0007628399,0.0010499124,0.00044913476,0.0004246754,0.0004135822,0.00006221918,0.000086290136,0.0000038121914],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021987727,0.00038227258,0.009713471,0.00017559303,0.0019403017,0.00013286376,0.005068274,0.00004412521,0.39171037,0.0001905206,0.00088476005,0.5875587],"study_design_scores_gemma":[0.039723083,0.0016313646,0.13492855,0.0001784895,0.00065150665,0.0006180512,0.0005042153,0.0029785822,0.8060733,0.00036041156,0.011536956,0.0008154838],"about_ca_topic_score_codex":0.0023744407,"about_ca_topic_score_gemma":0.000029189743,"teacher_disagreement_score":0.5867432,"about_ca_system_score_codex":0.005880597,"about_ca_system_score_gemma":0.0025447283,"threshold_uncertainty_score":0.9994823},"labels":[],"label_agreement":null},{"id":"W2039165844","doi":"10.1080/10428190600923157","title":"Unusual fluid retention with imatinib therapy for chronic myeloid leukemia","year":2006,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Imatinib; Myeloid leukemia; Medicine; Oncology; Cancer research; Internal medicine","score_opus":0.014858361213849139,"score_gpt":0.24383367669860398,"score_spread":0.22897531548475483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039165844","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90545136,0.024428044,0.0010688719,0.03367161,0.002619948,0.01458834,0.0019144346,0.0026213392,0.013636071],"genre_scores_gemma":[0.2654422,0.014004405,0.015206022,0.44148916,0.04714214,0.0125089865,0.063912205,0.0060401005,0.1342548],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9862258,0.0003757174,0.002689919,0.0043428955,0.0025620237,0.0038036904],"domain_scores_gemma":[0.9922982,0.00096681877,0.0017615014,0.0033030456,0.00080836134,0.0008620733],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00073491986,0.003766433,0.004204122,0.0012605971,0.0011093727,0.0005680675,0.0011509277,0.0049217795,0.00031380725],"category_scores_gemma":[0.00011867144,0.003186024,0.0015452618,0.0012212481,0.0012810422,0.00071712723,0.00035265906,0.0014938167,0.00029563965],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033932317,0.00027272882,0.0007914859,0.0034473422,0.0025899394,0.0036044403,0.00033756925,0.00010252728,0.002942503,0.00013826939,0.82082224,0.16155773],"study_design_scores_gemma":[0.09427495,0.0053383154,0.011396533,0.002961918,0.002767249,0.0059145116,0.000108734304,0.005481183,0.008306993,0.000452209,0.8591199,0.0038774977],"about_ca_topic_score_codex":0.0037726357,"about_ca_topic_score_gemma":0.00019871171,"teacher_disagreement_score":0.64000916,"about_ca_system_score_codex":0.0981896,"about_ca_system_score_gemma":0.035849683,"threshold_uncertainty_score":0.9975056},"labels":[],"label_agreement":null},{"id":"W2039431106","doi":"10.1080/10428190400015022","title":"Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Mantle cell lymphoma; Medicine; Transplantation; Lymphoma; Stem cell; Population; Autologous stem-cell transplantation; Internal medicine; Surgery; Oncology; Biology","score_opus":0.01109129190567764,"score_gpt":0.23112762485023536,"score_spread":0.2200363329445577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039431106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98584485,0.0030264542,0.00066782045,0.0008824121,0.0005334796,0.0022388925,0.00040492037,0.00030486324,0.006096278],"genre_scores_gemma":[0.9826513,0.0028931375,0.003570756,0.0048598363,0.00055369537,0.0010052845,0.00071400014,0.00025315286,0.0034988376],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99434096,0.00011549139,0.0012901154,0.0018065207,0.000850591,0.0015963003],"domain_scores_gemma":[0.9967434,0.00047442084,0.00047189932,0.0011334526,0.00025782167,0.0009190056],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00036071107,0.0012827317,0.0014285739,0.00043810363,0.0006556951,0.00025527494,0.00045762662,0.0008112957,0.00010425977],"category_scores_gemma":[0.000019562538,0.0010184,0.0007880144,0.00049134,0.00032545783,0.0004945225,0.00013326785,0.00009694647,0.00026184836],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013489458,0.012537492,0.106736094,0.01245919,0.0031634334,0.00932313,0.016372947,0.00078903325,0.07548682,0.0042332676,0.019609233,0.7257999],"study_design_scores_gemma":[0.17333992,0.0027116975,0.1830551,0.0013011607,0.003702885,0.0032979983,0.002394688,0.00096995337,0.5732422,0.0017482938,0.05132019,0.002915934],"about_ca_topic_score_codex":0.0015248469,"about_ca_topic_score_gemma":0.00029337837,"teacher_disagreement_score":0.72288394,"about_ca_system_score_codex":0.00940539,"about_ca_system_score_gemma":0.003565626,"threshold_uncertainty_score":0.99999243},"labels":[],"label_agreement":null},{"id":"W2040039314","doi":"10.3109/10428190109097717","title":"A Multicentric Study of 41 Cases of B-Prolymphocytic Leukemia: Two Evolutive Forms: The Groupe Français d'Hématologie Cellulaire","year":2001,"lang":"fr","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Prolymphocytic leukemia; Medicine; Chronic lymphocytic leukemia; Internal medicine; Immunophenotyping; Univariate analysis; Leukemia; CD5; Gastroenterology; Anemia; Concordance; Multivariate analysis; Immunology; Lymphoma; Antigen","score_opus":0.022949868926353215,"score_gpt":0.28775321473783533,"score_spread":0.2648033458114821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040039314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8833823,0.1025681,0.00012605479,0.00023876362,0.0022676738,0.0057116854,0.00030886335,0.0003012367,0.0050952937],"genre_scores_gemma":[0.97856236,0.013583483,0.00028542962,0.0005092634,0.001276396,0.00061821163,0.00011225664,0.00048590728,0.004566684],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98105055,0.0017610282,0.0049708737,0.0032293424,0.0040790164,0.004909166],"domain_scores_gemma":[0.9832549,0.006580284,0.0023411908,0.004520293,0.0015169394,0.0017863687],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","sts"],"category_scores_codex":[0.0027984574,0.0027812433,0.004883761,0.001509857,0.0013571561,0.00025808797,0.002811812,0.001957132,0.0005367997],"category_scores_gemma":[0.0026067884,0.0022286596,0.0013543074,0.005127423,0.005256437,0.0011711153,0.0021938314,0.0010535598,0.0003728822],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03344172,0.0149579095,0.11712518,0.016077902,0.012697423,0.055894695,0.077019125,0.007766035,0.0071105263,0.009296043,0.010273903,0.6383395],"study_design_scores_gemma":[0.3920789,0.011798575,0.123228855,0.007012493,0.009783762,0.04750798,0.07577898,0.29486755,0.017787175,0.0010681116,0.014281396,0.004806249],"about_ca_topic_score_codex":0.13222578,"about_ca_topic_score_gemma":0.0038732635,"teacher_disagreement_score":0.6335333,"about_ca_system_score_codex":0.16416802,"about_ca_system_score_gemma":0.075046144,"threshold_uncertainty_score":0.99994296},"labels":[],"label_agreement":null},{"id":"W2040343471","doi":"10.3109/10428190009059279","title":"Accumulation of Sestamibi in Lymphoma Cell Lines<i>In Vitro</i>","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Drug Transport and Resistance Mechanisms","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"","keywords":"Depolarization; Membrane potential; Hyperpolarization (physics); Cell culture; In vitro; Mitochondrion; Valinomycin; Intracellular; Biology; Lymphoma; Inner mitochondrial membrane; Chemistry; Biophysics; Biochemistry; Immunology","score_opus":0.013964985479915138,"score_gpt":0.2524795333093819,"score_spread":0.23851454782946674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2040343471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98346454,0.0019431084,0.000056106797,0.00011785408,0.00022589981,0.00078858325,0.000045579374,0.00014421938,0.013214098],"genre_scores_gemma":[0.99133104,0.0016621209,0.001426599,0.0006810633,0.00019765244,0.00007253765,0.0002194781,0.00012232934,0.004287166],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956256,0.00011610352,0.001464455,0.0010386731,0.00073663035,0.001018518],"domain_scores_gemma":[0.9982186,0.00018651423,0.0002816661,0.0008011592,0.0001143621,0.0003976853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004909942,0.000715658,0.0013433082,0.0006529531,0.0001209339,0.000046787958,0.00032224,0.0006750677,0.0002317471],"category_scores_gemma":[0.000033102144,0.0006764448,0.00031050335,0.0012407657,0.00025919493,0.00036517662,0.000051743715,0.00014494815,0.00006631009],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0099620335,0.0018040679,0.029073594,0.0016733381,0.000118249045,0.0022890384,0.0033646256,0.0012306501,0.20288104,0.00044349098,0.0003826163,0.74677724],"study_design_scores_gemma":[0.06427625,0.0004866156,0.5590947,0.0013546554,0.00030851152,0.0005424259,0.0010494881,0.017490204,0.33627155,0.00082473044,0.01677244,0.001528389],"about_ca_topic_score_codex":0.0023684097,"about_ca_topic_score_gemma":0.00027977317,"teacher_disagreement_score":0.74524885,"about_ca_system_score_codex":0.0034388679,"about_ca_system_score_gemma":0.0022982983,"threshold_uncertainty_score":0.9995687},"labels":[],"label_agreement":null},{"id":"W2041968741","doi":"10.1080/10428190290026295","title":"The Development of Marked Elevation in White Blood Cell Count Does Not Predict Inferior Outcome in Chronic Lymphocytic Leukemia","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; White blood cell; Internal medicine; Stage (stratigraphy); Gastroenterology; Clinical significance; Leukemia; Surgery","score_opus":0.02907200730900288,"score_gpt":0.3000358864022648,"score_spread":0.2709638790932619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2041968741","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.23706886,0.75353366,0.000021014617,0.00002718715,0.00070612825,0.0054551894,0.00014870088,0.00025947587,0.0027797574],"genre_scores_gemma":[0.07849146,0.9103741,0.0006371994,0.00016786672,0.0005873134,0.0018490554,0.0004436031,0.0005639271,0.0068854736],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9817835,0.0009769838,0.0077123335,0.002980676,0.0031199264,0.0034265418],"domain_scores_gemma":[0.99026406,0.002669722,0.0024828685,0.0031242757,0.00045360008,0.0010055035],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003740376,0.0028409834,0.0068994625,0.002334196,0.00062518765,0.00036459893,0.0020539279,0.0027444537,0.00018797595],"category_scores_gemma":[0.0008658192,0.0019909146,0.0012257971,0.0032314383,0.0012340384,0.0005302038,0.0012651018,0.0012065902,0.0002047729],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001123895,0.00033842315,0.0024191488,0.059074204,0.0010183334,0.0016424828,0.0018015924,0.00020024602,0.00016180502,0.00014029382,0.00047626666,0.9316033],"study_design_scores_gemma":[0.13639498,0.0010243148,0.011653976,0.04758877,0.003838287,0.0033912866,0.0006571449,0.04143213,0.001361206,0.00006649754,0.7478578,0.004733619],"about_ca_topic_score_codex":0.0032121218,"about_ca_topic_score_gemma":0.0022173342,"teacher_disagreement_score":0.9268697,"about_ca_system_score_codex":0.54332364,"about_ca_system_score_gemma":0.266445,"threshold_uncertainty_score":0.9985502},"labels":[],"label_agreement":null},{"id":"W2045667534","doi":"10.3109/10428194.2014.1003057","title":"Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Autologous stem-cell transplantation; Multivariate analysis; Oncology; Lymphocyte; Surrogate endpoint; Overall survival; Gastroenterology; Stem cell; Surgery; Urology","score_opus":0.016522998800905204,"score_gpt":0.2301193305084677,"score_spread":0.21359633170756248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045667534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99258155,0.0007305808,0.00023167128,0.000032480155,0.00015351403,0.0031385222,0.0008582531,0.00025746168,0.0020159686],"genre_scores_gemma":[0.9949809,0.0001479154,0.0012119013,0.00014161604,0.00012641701,0.00046535887,0.0010368362,0.00019651449,0.0016925974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949966,0.00014840404,0.0008695892,0.0011805026,0.0014568459,0.0013480376],"domain_scores_gemma":[0.9960437,0.00047618788,0.00046821317,0.0008605388,0.00081691967,0.0013344658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027599954,0.0009504799,0.0014776874,0.00033715894,0.00025719142,0.000094128765,0.00032875783,0.00045905483,0.000019751129],"category_scores_gemma":[0.000056908233,0.00067433715,0.00023676967,0.00041966324,0.0004982081,0.00034579367,0.00008774047,0.00011163011,0.00002742691],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11661455,0.0053224047,0.7619575,0.0018982677,0.0027154768,0.0020194955,0.0033750862,0.00027927183,0.003482494,0.00015710118,0.0011165977,0.10106174],"study_design_scores_gemma":[0.23833457,0.0172898,0.69570756,0.0008982329,0.0012105263,0.00079813204,0.0005461039,0.010707299,0.026639864,0.00003894655,0.006574448,0.0012545356],"about_ca_topic_score_codex":0.003113497,"about_ca_topic_score_gemma":0.0002494862,"teacher_disagreement_score":0.12172002,"about_ca_system_score_codex":0.0068656965,"about_ca_system_score_gemma":0.005344775,"threshold_uncertainty_score":0.9995708},"labels":[],"label_agreement":null},{"id":"W2046562935","doi":"10.3109/10428190009148399","title":"Clinical Significance of the t(14;18) And<i>BCL2</i>Overexpression in Follicular Large Cell Lymphoma","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; U.S. Department of Health and Human Services","keywords":"Follicular lymphoma; Lymphoma; Anthracycline; Trisomy; Medicine; Oncology; Internal medicine; Chemotherapy; Diffuse large B-cell lymphoma; Cancer research; Biology; Cancer; Breast cancer","score_opus":0.01216047175015825,"score_gpt":0.263319022229649,"score_spread":0.2511585504794907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2046562935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98035425,0.0052162143,0.000007460381,0.00026179937,0.00026042687,0.0013653112,0.00010193133,0.000114272414,0.012318306],"genre_scores_gemma":[0.9893399,0.00498753,0.00045124447,0.0018567775,0.00026667284,0.00021837778,0.000054062886,0.000111618865,0.002713814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9942793,0.00043855494,0.0017035146,0.0014710096,0.0009409815,0.0011666344],"domain_scores_gemma":[0.9966333,0.0005885426,0.00050191104,0.0014810729,0.00013967317,0.0006554988],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007814211,0.0008888667,0.0015943163,0.00022103777,0.00037496907,0.0000916827,0.0004963285,0.00081528886,0.00032942044],"category_scores_gemma":[0.0001321988,0.0006376975,0.0006278284,0.000794795,0.00063157146,0.0003041737,0.00033658996,0.00017788842,0.000072643015],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028891796,0.005731442,0.45298254,0.0008505502,0.0003882696,0.00088078616,0.0012849305,0.000044653567,0.005309684,0.00092362374,0.008110375,0.52060395],"study_design_scores_gemma":[0.072861955,0.00056358095,0.83865464,0.0016836909,0.00042004907,0.0006089419,0.00033693903,0.0020645123,0.024407128,0.00037055952,0.05718976,0.0008382718],"about_ca_topic_score_codex":0.00179542,"about_ca_topic_score_gemma":0.00007964709,"teacher_disagreement_score":0.5197657,"about_ca_system_score_codex":0.0030328499,"about_ca_system_score_gemma":0.0025044596,"threshold_uncertainty_score":0.99960744},"labels":[],"label_agreement":null},{"id":"W2048529382","doi":"10.3109/10428194.2011.567317","title":"Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Apoptosis; Fludarabine; Cancer research; Lipid raft; Chlorambucil; Leukemia; Programmed cell death; Cell culture; Immunology; Receptor; Biology; Medicine; Internal medicine; Chemotherapy; Biochemistry","score_opus":0.021245522603849393,"score_gpt":0.24108168273102867,"score_spread":0.21983616012717927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048529382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953242,0.00031712468,0.0007315356,0.000042956002,0.0009967085,0.0016554579,0.00009170323,0.00018921685,0.0006511271],"genre_scores_gemma":[0.99326557,0.00044465467,0.0015525217,0.001129545,0.0004466034,0.00033493803,0.0002293457,0.00023145582,0.0023653544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9930088,0.00040262745,0.0016036461,0.0022144173,0.0006082039,0.002162329],"domain_scores_gemma":[0.99668854,0.0001695765,0.00053673453,0.0013216577,0.00031897266,0.0009645285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011372494,0.0011520248,0.0011563677,0.00091452134,0.0006502358,0.00023915993,0.00077624666,0.0010854292,0.00010587561],"category_scores_gemma":[0.0004748416,0.0011748029,0.00034948267,0.001420987,0.00011955208,0.00006662193,0.0008513545,0.00022551918,0.00016609176],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019019068,0.00006606443,0.00052767916,0.00015039518,0.00020567875,0.000029524394,0.0018856247,0.00073886674,0.9715298,0.00018221322,0.0005762581,0.022206008],"study_design_scores_gemma":[0.008699222,0.0013658821,0.011966949,0.0007873737,0.0002160842,0.00007347172,0.00031053458,0.0040614037,0.9676234,0.00009633372,0.003232759,0.0015665537],"about_ca_topic_score_codex":0.0035964916,"about_ca_topic_score_gemma":0.0001803354,"teacher_disagreement_score":0.020639455,"about_ca_system_score_codex":0.01973471,"about_ca_system_score_gemma":0.008063144,"threshold_uncertainty_score":0.99907017},"labels":[],"label_agreement":null},{"id":"W2048790475","doi":"10.3109/10428194.2014.985673","title":"Structural genomic alterations in primary mediastinal large B-cell lymphoma","year":2014,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"BC Cancer Agency; Canadian Institutes of Health Research","keywords":"Lymphoma; CIITA; Cancer research; Somatic cell; Biology; Breakpoint; Chromothripsis; Pathogenesis; Computational biology; Genetics; Gene; Genome instability; Immunology; DNA; Chromosomal translocation; DNA damage","score_opus":0.01713303286461503,"score_gpt":0.2728314617455311,"score_spread":0.25569842888091604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2048790475","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14118701,0.84640145,0.000017556058,0.000057486766,0.0009892745,0.0028251868,0.00045283418,0.00033283612,0.007736339],"genre_scores_gemma":[0.03542165,0.95333326,0.0008731274,0.0012738499,0.0016215353,0.0013176417,0.0036833645,0.0005038983,0.0019716658],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.989466,0.0006254973,0.003253956,0.0029042219,0.0012735262,0.002476787],"domain_scores_gemma":[0.99385756,0.0010559487,0.0013766795,0.0021040486,0.00020991973,0.0013958289],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007821462,0.0028230294,0.006907969,0.0014384359,0.0006764618,0.00041253382,0.0008937966,0.0019831427,0.00019170204],"category_scores_gemma":[0.00015263089,0.0023554873,0.0017616944,0.0012255635,0.00046910107,0.00042830672,0.0007452288,0.00039216265,0.00063047867],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003211683,0.0011041983,0.0011354683,0.015337619,0.00064096943,0.0020501975,0.00043861518,0.000005004283,0.000014065485,0.00062035397,0.0023010757,0.97603124],"study_design_scores_gemma":[0.052935798,0.0006006367,0.03313953,0.012915854,0.0042779148,0.007510304,0.0001130665,0.0010252212,0.00003976175,0.00010301689,0.88467395,0.0026649623],"about_ca_topic_score_codex":0.0011593885,"about_ca_topic_score_gemma":0.00019355727,"teacher_disagreement_score":0.9733663,"about_ca_system_score_codex":0.032946408,"about_ca_system_score_gemma":0.015111659,"threshold_uncertainty_score":0.9993125},"labels":[],"label_agreement":null},{"id":"W2049281518","doi":"10.3109/10428194.2014.961013","title":"A simplified scoring system to document variant patterns in nodular lymphocyte predominant Hodgkin lymphoma","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Lymphoma; Stage (stratigraphy); Medicine; Multivariate analysis; Lymphocyte; Internal medicine; Pathology; Disease; Scoring system; Hodgkin lymphoma; Overall survival; Oncology; Multivariate statistics; Proportional hazards model; Biology; Computer science","score_opus":0.00739729284019881,"score_gpt":0.2310635807097419,"score_spread":0.2236662878695431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049281518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884318,0.0013171767,0.0009834688,0.0004505329,0.0009889634,0.0026882193,0.00008553795,0.00058993575,0.004464337],"genre_scores_gemma":[0.9917764,0.00062575267,0.0019802991,0.0024402943,0.00077496143,0.0013442569,0.00015816225,0.00029057785,0.00060927565],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9905665,0.00046562977,0.0022051143,0.0027861516,0.0015047732,0.0024718319],"domain_scores_gemma":[0.9944272,0.0005749472,0.0005765444,0.0023035414,0.00026089567,0.0018568409],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013331926,0.0017490209,0.00261031,0.0011523238,0.0005636576,0.0004635169,0.0007435936,0.00082015235,0.00009191342],"category_scores_gemma":[0.0002488382,0.0015529189,0.0006174864,0.0012573487,0.00022056841,0.00047170703,0.00072413177,0.00014490474,0.0005165551],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054956186,0.0019954692,0.09729479,0.0026873262,0.0011909588,0.010139633,0.0038616892,0.0009491998,0.0051731556,0.014082921,0.0015829739,0.85554624],"study_design_scores_gemma":[0.10701346,0.0023572503,0.77570695,0.0064458037,0.0012559629,0.0102545805,0.0019674972,0.024481941,0.023869341,0.00029071164,0.043030124,0.0033263708],"about_ca_topic_score_codex":0.010487816,"about_ca_topic_score_gemma":0.0004503296,"teacher_disagreement_score":0.8522199,"about_ca_system_score_codex":0.032984857,"about_ca_system_score_gemma":0.0034323535,"threshold_uncertainty_score":0.99952555},"labels":[],"label_agreement":null},{"id":"W2050123377","doi":"10.3109/10428194.2014.982641","title":"Mixed fields on RhD typing as an indication of loss of heterozygosity on chromosome 1p in acute myeloid leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Blood groups and transfusion","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Myeloid leukemia; Loss of heterozygosity; Leukemia; Myeloid; Typing; Medicine; Oncology; Biology; Internal medicine; Library science; Genetics; Gene; Allele","score_opus":0.014090964404205299,"score_gpt":0.24229266119246923,"score_spread":0.22820169678826394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2050123377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866941,0.00035581502,0.000057996604,0.0075646155,0.0006376814,0.0011850904,0.0001336447,0.00014617742,0.0032249005],"genre_scores_gemma":[0.915089,0.0011561719,0.00019891608,0.08012419,0.0013056982,0.000105184845,0.0012572408,0.00022343502,0.0005401365],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9935323,0.00041330766,0.0018425843,0.0017969209,0.0012876592,0.0011272556],"domain_scores_gemma":[0.9957585,0.00053348584,0.0011399821,0.0019116868,0.00023952175,0.00041683228],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006170997,0.0013173016,0.0026163468,0.0012237222,0.00021883586,0.00006737353,0.00074367697,0.0035050223,0.00009052222],"category_scores_gemma":[0.00010808483,0.0012240299,0.0005866595,0.0007580997,0.00056290935,0.00028451468,0.00017105982,0.0012722131,0.00006604384],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030636774,0.005274409,0.04579498,0.024695868,0.0069585247,0.015436156,0.011645189,0.0006631774,0.05598993,0.006371221,0.22673868,0.5697951],"study_design_scores_gemma":[0.11087914,0.023998102,0.4656671,0.021995816,0.0052832,0.006798137,0.00044815903,0.006183203,0.1954061,0.0032723397,0.15307471,0.006994003],"about_ca_topic_score_codex":0.0034515886,"about_ca_topic_score_gemma":0.00016082206,"teacher_disagreement_score":0.5628011,"about_ca_system_score_codex":0.0061115213,"about_ca_system_score_gemma":0.0033464136,"threshold_uncertainty_score":0.99995786},"labels":[],"label_agreement":null},{"id":"W2052603677","doi":"10.1080/10428190500080595","title":"N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Case Western Reserve University","keywords":"Protein kinase B; Apoptosis; Multiple myeloma; Cancer research; Kinase; Cell biology; Biology; Immunology; Biochemistry","score_opus":0.017821172388109048,"score_gpt":0.25637748407831695,"score_spread":0.2385563116902079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052603677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912665,0.0017840066,0.000035003522,0.00044882263,0.00028857274,0.0014175277,0.00009315192,0.00033287148,0.00433353],"genre_scores_gemma":[0.9909219,0.0009571759,0.0028993308,0.0013030146,0.00068121456,0.00027858597,0.00025428992,0.00019700053,0.002507477],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99362934,0.00019752952,0.0013033439,0.0016733075,0.0011755148,0.0020209628],"domain_scores_gemma":[0.9964064,0.0004527201,0.0003122762,0.001194037,0.00022201419,0.0014125768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005505443,0.001077061,0.0013763994,0.00095951784,0.00045482707,0.00019123452,0.00041313985,0.00068485114,0.00024272721],"category_scores_gemma":[0.00034701973,0.0009965022,0.00035962954,0.0012344517,0.00037595426,0.00066240533,0.0004168817,0.00037740983,0.00045364667],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031259267,0.0013707114,0.10094754,0.0005766892,0.00039067856,0.0017108385,0.0017385992,0.00022530723,0.118736885,0.00022220668,0.0029935534,0.7679611],"study_design_scores_gemma":[0.062683515,0.0008130288,0.35760784,0.0009079665,0.00022439106,0.00079355325,0.0006761549,0.017020691,0.5289597,0.00008155562,0.02877713,0.0014544543],"about_ca_topic_score_codex":0.0044515184,"about_ca_topic_score_gemma":0.00084422634,"teacher_disagreement_score":0.7665066,"about_ca_system_score_codex":0.010355762,"about_ca_system_score_gemma":0.0027187602,"threshold_uncertainty_score":0.99924856},"labels":[],"label_agreement":null},{"id":"W2053328285","doi":"10.1080/10428190600572582","title":"Yttrium 90 ibritumomab tiuxetan in lymphoma","year":2006,"lang":"pl","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Cancer Care Ontario; Health Sciences Centre","funders":"European Commission; Government of Ontario; GlaxoSmithKline","keywords":"Ibritumomab tiuxetan; Medicine; Rituximab; Radioimmunotherapy; Refractory (planetary science); Follicular lymphoma; Lymphoma; Oncology; Non-Hodgkin's lymphoma; Internal medicine; CD20; Nuclear medicine; Monoclonal antibody; Immunology; Antibody","score_opus":0.01923111208947437,"score_gpt":0.27481083829889047,"score_spread":0.2555797262094161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053328285","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1797979,0.78249174,0.000012682571,0.00031056415,0.0032608833,0.0058910544,0.0010939366,0.0007356636,0.026405582],"genre_scores_gemma":[0.17543054,0.7996742,0.00050901674,0.0015249036,0.003678403,0.002331166,0.00409849,0.0012149719,0.011538277],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97312826,0.0016913859,0.007885642,0.0072429357,0.0035738219,0.0064779413],"domain_scores_gemma":[0.9853369,0.0024538287,0.0033515103,0.005078854,0.0006351106,0.0031438253],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018613734,0.00729812,0.013629449,0.0034404653,0.0013331186,0.0012870202,0.0024703487,0.005838771,0.00068142253],"category_scores_gemma":[0.0005317319,0.006714251,0.003981544,0.004750543,0.0018689254,0.0011958461,0.0016909412,0.00084585865,0.0035246392],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001037464,0.004067933,0.011359351,0.016433995,0.00239566,0.017924972,0.0006177783,0.00002878965,0.000038182312,0.0018097939,0.023503609,0.92078245],"study_design_scores_gemma":[0.06498131,0.0012132539,0.10138984,0.028873803,0.007919634,0.010718908,0.00037272766,0.0011570347,0.0003317583,0.0003019162,0.7769426,0.0057971985],"about_ca_topic_score_codex":0.02513539,"about_ca_topic_score_gemma":0.0015133435,"teacher_disagreement_score":0.9149853,"about_ca_system_score_codex":0.08052968,"about_ca_system_score_gemma":0.031375386,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W2055043352","doi":"10.3109/10428190009053554","title":"Development of a Biologically Distinct EBV-Related Lymphoproliferative Disorder Following Autologous Bone Marrow Transplantation for an EBV-Negative Post-Renal Allograft Burkitt's Lymphoma","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Immunosuppression; Lymphoproliferative disorders; Transplantation; Lymphoma; Bone marrow; Pathology; Cyclophosphamide; Immunology; Gastroenterology; Chemotherapy; Internal medicine","score_opus":0.009213515329400344,"score_gpt":0.2465969674826883,"score_spread":0.23738345215328796,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055043352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924003,0.0015569746,0.00060916087,0.0002326758,0.00024966718,0.001996555,0.00029205694,0.0004028489,0.002259783],"genre_scores_gemma":[0.9882623,0.0005259233,0.0068660495,0.0008961259,0.00010831609,0.0005983775,0.0016603001,0.00015847989,0.0009241537],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9940823,0.00027494083,0.0018592451,0.0015632589,0.0008045498,0.0014157172],"domain_scores_gemma":[0.99730206,0.00039487646,0.000651082,0.00058989256,0.00038150925,0.0006805977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006530416,0.0011520117,0.0018322086,0.00040594902,0.00089893735,0.00012123928,0.00039560156,0.001051228,0.00020600496],"category_scores_gemma":[0.00020108988,0.0009976284,0.0007189321,0.0008184415,0.00057279575,0.00052591885,0.00006981975,0.00015027633,0.000024795345],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014223044,0.0013922993,0.009147415,0.0005476909,0.0020725776,0.00046527106,0.015442508,0.0002193081,0.04470989,0.0005252803,0.00034653224,0.91090816],"study_design_scores_gemma":[0.18848018,0.0073938216,0.71995944,0.0017895623,0.0035991308,0.0022439407,0.0077240802,0.019525448,0.02868359,0.0026573434,0.013193066,0.0047503714],"about_ca_topic_score_codex":0.001967534,"about_ca_topic_score_gemma":0.0009151632,"teacher_disagreement_score":0.9061578,"about_ca_system_score_codex":0.004373509,"about_ca_system_score_gemma":0.0051780376,"threshold_uncertainty_score":0.99944854},"labels":[],"label_agreement":null},{"id":"W2055699311","doi":"10.1080/10428190903015628","title":"pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Etoposide; Vincristine; Oncology; Diffuse large B-cell lymphoma; Internal medicine; Autologous stem-cell transplantation; International Prognostic Index; Transplantation; Cyclophosphamide; Lymphoma; Chemotherapy; Melphalan; Cancer research","score_opus":0.008825021794675286,"score_gpt":0.2302343601438441,"score_spread":0.22140933834916882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055699311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905228,0.004003557,0.0001809767,0.0004972329,0.00011184366,0.0030213783,0.00043191397,0.00045784857,0.00077245454],"genre_scores_gemma":[0.98779196,0.004838973,0.0024484873,0.0019845509,0.00014101197,0.0006725367,0.0005176664,0.00013419705,0.0014706512],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952913,0.00012262864,0.0010567586,0.0016764516,0.0006053903,0.0012474855],"domain_scores_gemma":[0.9974715,0.0004261055,0.0004718557,0.0006399324,0.00019801986,0.00079256255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002770992,0.0012387416,0.0015801489,0.00042890108,0.00064809894,0.00023676129,0.00022026185,0.0007290505,0.000009751906],"category_scores_gemma":[0.000015181472,0.00093218166,0.00025833724,0.0004394484,0.0002802793,0.000436477,0.00006468029,0.00009520695,0.0000057610696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018683922,0.013940894,0.25196788,0.0033557878,0.0007646245,0.0018614056,0.0040158937,0.00000870635,0.03325577,0.00060014875,0.0020839728,0.669461],"study_design_scores_gemma":[0.19832546,0.0038987051,0.6714968,0.0007599484,0.0015929725,0.0011235699,0.0005666215,0.0018400712,0.1163115,0.00007507649,0.0029286093,0.0010806347],"about_ca_topic_score_codex":0.000607665,"about_ca_topic_score_gemma":0.000040495775,"teacher_disagreement_score":0.6683804,"about_ca_system_score_codex":0.0025460497,"about_ca_system_score_gemma":0.0011051112,"threshold_uncertainty_score":0.9993129},"labels":[],"label_agreement":null},{"id":"W2057060618","doi":"10.3109/10428194.2012.704998","title":"Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"","keywords":"Graft-versus-host disease; Hematopoietic stem cell transplantation; Stem cell; Medicine; Haematopoiesis; Disease; Hematopoietic stem cell; Outcome (game theory); Hematopoietic cell; Savior sibling; Transplantation; Oncology; Immunology; Internal medicine; Biology; Genetics","score_opus":0.010236432079492598,"score_gpt":0.24487552649720018,"score_spread":0.23463909441770758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057060618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500686,0.0013690762,0.000023784854,0.00006634851,0.00027754868,0.0014678729,0.00025552424,0.000063116706,0.0014698611],"genre_scores_gemma":[0.9986176,0.00037368265,0.00003975609,0.00024797858,0.000091136404,0.00012571509,0.000121941135,0.000094319075,0.00028787644],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962644,0.00038945727,0.0011826381,0.0005890453,0.00074912247,0.00082532305],"domain_scores_gemma":[0.9969764,0.0011469304,0.00039673597,0.00087592367,0.000054980675,0.0005490436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009333612,0.0006689615,0.0012321046,0.0003230974,0.000111924775,0.00002068013,0.00034686615,0.00029907998,0.00012414857],"category_scores_gemma":[0.000020406407,0.00046760868,0.00041036558,0.00047462637,0.0003274305,0.0001710145,0.000054537602,0.0001694457,0.000044696168],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00942519,0.00056672347,0.9494376,0.0038234757,0.0007739011,0.00023627066,0.003939962,0.00001998767,0.026583875,0.0010832145,0.00012985461,0.0039799013],"study_design_scores_gemma":[0.02553413,0.0010422984,0.71936375,0.0008155843,0.0018882506,0.00062297046,0.00021963198,0.00017561314,0.24969652,0.000014382327,0.00009412252,0.0005327192],"about_ca_topic_score_codex":0.00019831082,"about_ca_topic_score_gemma":0.000014413127,"teacher_disagreement_score":0.23007387,"about_ca_system_score_codex":0.0012253214,"about_ca_system_score_gemma":0.00061899505,"threshold_uncertainty_score":0.99977756},"labels":[],"label_agreement":null},{"id":"W2057310034","doi":"10.1080/1042819021000055066","title":"Vascular Events Associated with Alpha Interferon Therapy","year":2003,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Eosinophilic Disorders and Syndromes","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Discontinuation; Alpha interferon; Context (archaeology); Vasculitis; Adverse effect; Concomitant; Thrombotic thrombocytopenic purpura; Melanoma; Internal medicine; Immunology; Surgery; Interferon; Platelet","score_opus":0.02666636327888802,"score_gpt":0.277149466108012,"score_spread":0.250483102829124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057310034","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.029561495,0.96130896,0.000022612163,0.000029439645,0.00046653592,0.0022648396,0.000077222205,0.00032335275,0.0059455247],"genre_scores_gemma":[0.0029230178,0.9872411,0.00014194532,0.0009137249,0.00021771698,0.0004309189,0.0008950662,0.00048603214,0.0067504994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932078,0.0005508328,0.0016059984,0.0019356494,0.0012171187,0.001482562],"domain_scores_gemma":[0.99604857,0.00034656576,0.000935915,0.0016252731,0.00023659006,0.00080711354],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006837679,0.0020834764,0.005430074,0.00065695134,0.00040204756,0.00017093463,0.0006275991,0.0017700699,0.00029140344],"category_scores_gemma":[0.00012686256,0.0014999657,0.0014221931,0.0011674307,0.00043156056,0.00026522318,0.00018144211,0.000454271,0.00015122507],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020247564,0.00048297097,0.0002513147,0.004216461,0.0032191568,0.00058978435,0.00021670767,6.7311765e-7,0.0000019690035,0.00014559925,0.0031232492,0.98754966],"study_design_scores_gemma":[0.01690707,0.0016250827,0.001692298,0.021613028,0.0031290038,0.0027429438,0.0001038636,0.00003967591,0.0000062958943,0.00012015241,0.9502865,0.0017340867],"about_ca_topic_score_codex":0.00038766695,"about_ca_topic_score_gemma":0.00003221039,"teacher_disagreement_score":0.9858155,"about_ca_system_score_codex":0.008466322,"about_ca_system_score_gemma":0.007699477,"threshold_uncertainty_score":0.99952585},"labels":[],"label_agreement":null},{"id":"W2057527782","doi":"10.3109/10428194.2010.524325","title":"Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Lenalidomide; Thalidomide; Dexamethasone; Multiple myeloma; Bortezomib; Refractory (planetary science); Medicine; Internal medicine; Oncology; Chromosome abnormality; Population; Gastroenterology; Chromosome; Biology; Karyotype; Genetics","score_opus":0.025848618773021297,"score_gpt":0.2825363406879408,"score_spread":0.2566877219149195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057527782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976263,0.00013662386,0.000009664422,0.000043887114,0.00004095631,0.0012319643,0.00026633855,0.00006503682,0.00057924504],"genre_scores_gemma":[0.9980793,0.00011275635,0.0007936519,0.000082381484,0.00006637176,0.00012580708,0.00018230791,0.00009479574,0.00046263437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99703276,0.00016703046,0.00077424507,0.0006223329,0.00072991656,0.00067370763],"domain_scores_gemma":[0.99649036,0.0013093532,0.000530855,0.00085613056,0.00035534447,0.0004579395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033496218,0.0006174467,0.0010380918,0.00037030494,0.00038653563,0.000060858827,0.00022875979,0.00028412367,0.00014140399],"category_scores_gemma":[0.0004221568,0.00031716324,0.00017629462,0.0004314253,0.00090220745,0.00029410474,0.0001311054,0.000256998,0.000007425788],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016072938,0.0005627481,0.9487098,0.00020308892,0.0010583334,0.00012906244,0.000895221,0.000021054933,0.017760942,0.00010272604,0.00006611598,0.014418012],"study_design_scores_gemma":[0.036949307,0.0040119207,0.94849813,0.0002671779,0.00031109064,0.00022300289,0.00029914698,0.0009738071,0.007976849,0.0000137453135,0.00012243443,0.00035337673],"about_ca_topic_score_codex":0.004491833,"about_ca_topic_score_gemma":0.0006931248,"teacher_disagreement_score":0.02087637,"about_ca_system_score_codex":0.0018977174,"about_ca_system_score_gemma":0.0018900824,"threshold_uncertainty_score":0.99992806},"labels":[],"label_agreement":null},{"id":"W2057787725","doi":"10.3109/10428194.2012.701738","title":"Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes","year":2012,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Psychosocial; Genetic testing; Cancer; Intensive care medicine; Genetic counseling; Genetic predisposition; Clinical Practice; Acute leukemia; Leukemia; Family medicine; Psychiatry; Immunology; Internal medicine; Disease; Genetics; Bone marrow","score_opus":0.02981002818768919,"score_gpt":0.3052547347914638,"score_spread":0.2754447066037746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057787725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2898159,0.6974599,0.0006781738,0.000048742615,0.00079532317,0.009943426,0.00073311664,0.00021052605,0.00031491675],"genre_scores_gemma":[0.11602087,0.8789617,0.0014653924,0.00012940782,0.00038101908,0.0015870107,0.0006566851,0.00035383736,0.00044408606],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927975,0.00043199662,0.002232179,0.0019403578,0.00108166,0.0015163402],"domain_scores_gemma":[0.99460775,0.0016122706,0.0012396942,0.0012311825,0.00039855062,0.00091057515],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00137324,0.0017918522,0.0040298793,0.0006317124,0.000680153,0.00019500325,0.00060621666,0.0014898046,0.000010401932],"category_scores_gemma":[0.000079968035,0.0011038255,0.0007479184,0.0008651227,0.0017661978,0.0004783279,0.000734426,0.0006531137,0.0000117040245],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024046723,0.00020535223,0.00053056225,0.028696688,0.0050151465,0.00023014138,0.00030411527,0.0000026216733,0.000009553505,0.00016937038,0.00029499986,0.9621368],"study_design_scores_gemma":[0.08547525,0.014096813,0.1778728,0.043617737,0.06916804,0.02579079,0.0024517018,0.008805124,0.00012101643,0.00027325575,0.566571,0.005756472],"about_ca_topic_score_codex":0.0003953019,"about_ca_topic_score_gemma":0.000049769562,"teacher_disagreement_score":0.9563803,"about_ca_system_score_codex":0.008116919,"about_ca_system_score_gemma":0.0058925413,"threshold_uncertainty_score":0.99980646},"labels":[],"label_agreement":null},{"id":"W2058689898","doi":"10.3109/10428190109097663","title":"Lovastatin Induced Control of Blast Cell Growth in an Elderly Patient with Acute Myeloblastic Leukemia","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer, Lipids, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Lovastatin; Medicine; Acute myeloblastic leukemia; Chemotherapy; In vitro; Pharmacology; Cell culture; Leukemia; Cancer research; Internal medicine; Immunology; Oncology; Cholesterol; Biology; Biochemistry","score_opus":0.004732354167851583,"score_gpt":0.204580555519027,"score_spread":0.19984820135117543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058689898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942897,0.0011981552,0.0009807517,0.00003183647,0.0010838198,0.0006531392,0.00011348912,0.000053804077,0.0015953198],"genre_scores_gemma":[0.9953425,0.0010928231,0.0005368852,0.00060897553,0.001631524,0.00013935678,0.00017921183,0.00013211605,0.0003366215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959812,0.00022288885,0.00096241577,0.0012410156,0.0005418834,0.0010505791],"domain_scores_gemma":[0.99779433,0.00008068176,0.0004953231,0.00082212174,0.000297179,0.00051039015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025445447,0.0008003494,0.00095693837,0.0003145443,0.00017367087,0.000102101636,0.0005000189,0.000577883,0.000027693639],"category_scores_gemma":[0.00005405989,0.0007329353,0.0002039304,0.00056077243,0.0003468223,0.000073863535,0.00015640541,0.00017725464,0.000012038153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008341613,0.0006318895,0.01742271,0.00027728267,0.0004998318,0.00014536805,0.0022253355,0.0010637039,0.81516415,0.00031361726,0.0028265533,0.15108792],"study_design_scores_gemma":[0.12422913,0.017721292,0.24203917,0.00077825756,0.0013896727,0.0041932533,0.004066876,0.007915,0.4814434,0.0004549663,0.10989423,0.005874732],"about_ca_topic_score_codex":0.0025434694,"about_ca_topic_score_gemma":0.0011275148,"teacher_disagreement_score":0.33372077,"about_ca_system_score_codex":0.0013991138,"about_ca_system_score_gemma":0.004064609,"threshold_uncertainty_score":0.9995122},"labels":[],"label_agreement":null},{"id":"W2058946091","doi":"10.1080/10428190500519311","title":"Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkin's lymphoma: A phase II study","year":2006,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; BC Cancer Agency","funders":"","keywords":"Medicine; Lymphoma; Doxorubicin; Non-Hodgkin's lymphoma; Internal medicine; Phases of clinical research; Oncology; Chemotherapy","score_opus":0.010097123899735307,"score_gpt":0.26382400403775796,"score_spread":0.25372688013802264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2058946091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99141103,0.0019524825,0.000030350337,0.00020475262,0.00027222798,0.0029407502,0.000056849763,0.00015091778,0.0029806544],"genre_scores_gemma":[0.9965289,0.000684124,0.00017276208,0.00049705274,0.00059834507,0.00038749343,0.00024007248,0.000116279225,0.00077494385],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99506503,0.0003578474,0.0014157628,0.0011702592,0.0010161492,0.00097492867],"domain_scores_gemma":[0.99715227,0.00034368914,0.00078181573,0.001229513,0.00021725982,0.00027543108],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005340892,0.0009498024,0.001592516,0.00055807276,0.0004997648,0.00009618918,0.0003915223,0.0006217805,0.000037482143],"category_scores_gemma":[0.00007093578,0.0007146999,0.00053074374,0.0012944309,0.0004226983,0.00028743004,0.00008428624,0.000135409,0.000016201688],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008615576,0.024441855,0.012643,0.00029971948,0.001208587,0.00496388,0.032456122,0.00020091586,0.39782906,0.00048720895,0.0015226105,0.51533145],"study_design_scores_gemma":[0.25413084,0.023500824,0.27273864,0.00082112727,0.0015366997,0.003128209,0.008046101,0.004640684,0.42201114,0.0005646673,0.0073811924,0.0014998902],"about_ca_topic_score_codex":0.008176236,"about_ca_topic_score_gemma":0.0004563602,"teacher_disagreement_score":0.51383156,"about_ca_system_score_codex":0.0059961877,"about_ca_system_score_gemma":0.0021913494,"threshold_uncertainty_score":0.99953043},"labels":[],"label_agreement":null},{"id":"W2060523101","doi":"10.1080/10428190600733325","title":"First among equals: The cancer cell hierarchy","year":2006,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer Cells and Metastasis","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Hierarchy; Cancer research; Cancer; Medicine; Chemistry; Internal medicine; Oncology; Political science","score_opus":0.02782102938706812,"score_gpt":0.29587710689049834,"score_spread":0.26805607750343025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060523101","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029611033,0.9733524,0.000034189117,0.00010549544,0.0011973927,0.0024223444,0.00044061485,0.00028329325,0.019203182],"genre_scores_gemma":[0.0011622217,0.97628814,0.00023195881,0.00087014626,0.002374671,0.0013454623,0.0004696128,0.000454129,0.016803667],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99255526,0.00034286152,0.0020397059,0.0021364887,0.0011665933,0.0017591026],"domain_scores_gemma":[0.99466455,0.0008008436,0.0012116458,0.0022654086,0.00020378998,0.00085375825],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00076577446,0.002007838,0.0045782523,0.00038306342,0.0008721799,0.00036154542,0.0010751291,0.0014147592,0.00053536426],"category_scores_gemma":[0.00006945219,0.0013373113,0.0019390231,0.0011561206,0.0009230003,0.00029807322,0.0005976504,0.0005402088,0.00016964113],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00009197799,0.00014596543,0.00009879738,0.02027106,0.00060699176,0.0003903108,0.00024476653,0.000011443321,0.0000027331137,0.00015276931,0.03923591,0.9387473],"study_design_scores_gemma":[0.005589825,0.00017132644,0.0008098316,0.011249503,0.0063382452,0.00084075273,0.00012482202,0.0001237946,0.00005119525,0.000047784328,0.97323316,0.0014197372],"about_ca_topic_score_codex":0.033449803,"about_ca_topic_score_gemma":0.0030973072,"teacher_disagreement_score":0.93732756,"about_ca_system_score_codex":0.01868293,"about_ca_system_score_gemma":0.011467519,"threshold_uncertainty_score":0.9998816},"labels":[],"label_agreement":null},{"id":"W2062082839","doi":"10.3109/10428194.2010.516377","title":"Missing mismatch repair: a key to T cell immortality","year":2010,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"DNA mismatch repair; DNA replication; Genome instability; DNA; DNA repair; Cell biology; Biology; Genome; Nucleotide; Genetics; Computational biology; DNA damage; Cancer research; Gene","score_opus":0.012631034353499866,"score_gpt":0.24789057067486145,"score_spread":0.2352595363213616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062082839","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89850724,0.0037783834,0.000053872285,0.05720987,0.0036279554,0.0025618956,0.00026883456,0.0013203576,0.032671597],"genre_scores_gemma":[0.20146517,0.0005268527,0.014529854,0.7388851,0.011445297,0.0006497116,0.0010169153,0.0010294733,0.030451596],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99035627,0.00027783008,0.0018127072,0.0031304725,0.0020147325,0.0024079694],"domain_scores_gemma":[0.993745,0.00053235295,0.0007042147,0.0031080092,0.00049204606,0.0014183308],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00065830816,0.002141508,0.0026893017,0.0007560893,0.0005628417,0.00035285266,0.0009645885,0.0068605607,0.0006392504],"category_scores_gemma":[0.00037724705,0.0020655908,0.001225296,0.00090969104,0.0006509443,0.00019393407,0.00070497184,0.0026857709,0.00051973853],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0006675903,0.00013584422,0.0023671635,0.0021511072,0.00044323804,0.0038025717,0.0014142208,0.0000058787577,0.018499063,0.0000115536295,0.9240432,0.046458565],"study_design_scores_gemma":[0.007428493,0.00069113116,0.015255267,0.00091284537,0.0011495874,0.0030484057,0.00016664978,0.00050648075,0.017700726,0.0002826092,0.9506152,0.0022425707],"about_ca_topic_score_codex":0.004575073,"about_ca_topic_score_gemma":0.00016901323,"teacher_disagreement_score":0.69704205,"about_ca_system_score_codex":0.013107821,"about_ca_system_score_gemma":0.010832328,"threshold_uncertainty_score":0.9996151},"labels":[],"label_agreement":null},{"id":"W2063207072","doi":"10.3109/10428194.2012.742522","title":"Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital; Queen's University","funders":"","keywords":"Follicular lymphoma; Lymphoma; Cancer research; Cytokine; Immunohistochemistry; Interleukin 9; Interleukin; Receptor; Biopsy; Pathology; Biology; Medicine; Immunology; Internal medicine","score_opus":0.008604430355567336,"score_gpt":0.23427686687463076,"score_spread":0.22567243651906344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063207072","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900369,0.006322302,0.000024110017,0.00025492697,0.0004202802,0.0015900681,0.00026886328,0.00017972304,0.0009028442],"genre_scores_gemma":[0.99458545,0.0012285692,0.0005372538,0.0013742254,0.00027424356,0.0005045226,0.00037858696,0.00019393189,0.0009232188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941463,0.00026304717,0.0013453558,0.0012967272,0.0012993668,0.0016492336],"domain_scores_gemma":[0.99528885,0.00045019155,0.0011374723,0.0012724709,0.00029150856,0.0015594924],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044673507,0.0012136891,0.00184061,0.00060046953,0.0002819738,0.00009917483,0.0004073321,0.0006336886,0.0002144439],"category_scores_gemma":[0.00022678162,0.0009319441,0.0005275769,0.0009097323,0.0006070035,0.0006507976,0.00032078245,0.00013575194,0.0000800305],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010089124,0.00946301,0.7653259,0.0012541896,0.0018632489,0.0051255035,0.012722555,0.00007643226,0.034099158,0.0005163867,0.014678772,0.14478573],"study_design_scores_gemma":[0.04772152,0.0008834932,0.7252565,0.00472586,0.0010268529,0.0005472401,0.0013742298,0.0009458505,0.20597728,0.000064120104,0.0101139285,0.001363152],"about_ca_topic_score_codex":0.001198948,"about_ca_topic_score_gemma":0.000040862407,"teacher_disagreement_score":0.17187811,"about_ca_system_score_codex":0.010437863,"about_ca_system_score_gemma":0.0029549147,"threshold_uncertainty_score":0.9993131},"labels":[],"label_agreement":null},{"id":"W2065622259","doi":"10.1080/10428190290006189","title":"Antigenic Open Reading Frames from HHV-8 are Present in Multiple Myeloma Patients and Normal Individuals at Similar Frequency","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; Ontario Institute for Cancer Research","funders":"","keywords":"Bone marrow; Antigen; Virology; Biology; Population; ORFS; Multiple myeloma; Molecular biology; Stromal cell; Antibody; Immunology; Open reading frame; Medicine; Genetics; Cancer research; Gene; Peptide sequence","score_opus":0.01686107229999625,"score_gpt":0.23619449483575153,"score_spread":0.21933342253575527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065622259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98473907,0.007861853,0.000004632246,0.0004164605,0.00025382187,0.001203385,0.00030415785,0.00012793188,0.0050887163],"genre_scores_gemma":[0.99179226,0.0037118476,0.0005235811,0.002203487,0.00018674637,0.00014995928,0.00032357892,0.00011782332,0.0009906868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99572814,0.00017940825,0.00094912114,0.0012761208,0.0007338421,0.0011333828],"domain_scores_gemma":[0.9977848,0.00030080578,0.0005023529,0.00067318144,0.00012413571,0.0006147477],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002718708,0.000738815,0.0012165636,0.0003346998,0.00054072414,0.0002719366,0.00049767585,0.00071497954,0.00035809976],"category_scores_gemma":[0.00029219087,0.000711702,0.00018559083,0.0005679742,0.0003048163,0.0007220004,0.0007308553,0.00022595013,0.000070614624],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038676837,0.00031982927,0.9008886,0.0001110985,0.00025843698,0.00024475812,0.002673911,0.000020095165,0.0007376265,0.00003188457,0.009721923,0.08460504],"study_design_scores_gemma":[0.03875812,0.00037189905,0.9428678,0.0005383224,0.0002286347,0.00005729601,0.0010583655,0.0040897466,0.0016390794,0.00044943686,0.009064046,0.00087725924],"about_ca_topic_score_codex":0.011172275,"about_ca_topic_score_gemma":0.0010773529,"teacher_disagreement_score":0.08372778,"about_ca_system_score_codex":0.0059720078,"about_ca_system_score_gemma":0.00058696844,"threshold_uncertainty_score":0.9995334},"labels":[],"label_agreement":null},{"id":"W2065628269","doi":"10.1080/10428190600822128","title":"Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma","year":2006,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canada Research Chairs","keywords":"Chromosomal translocation; Multiple myeloma; Mechanism (biology); Outcome (game theory); Chromosome; Disease; Oncology; Biology; Medicine; Genetics; Internal medicine; Immunology; Gene","score_opus":0.020844550676225513,"score_gpt":0.29712161442013624,"score_spread":0.2762770637439107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2065628269","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01865467,0.9753114,0.000012685572,0.0000885861,0.0006549406,0.003080912,0.00033898544,0.00043649122,0.0014213496],"genre_scores_gemma":[0.0036968887,0.98454195,0.00078886776,0.00027207722,0.0012196494,0.0006971808,0.0013752837,0.0005433052,0.006864776],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99021274,0.00045665985,0.002136863,0.0028738638,0.0017881385,0.002531732],"domain_scores_gemma":[0.9937387,0.0012070915,0.0010154641,0.0019702783,0.0003547468,0.0017137286],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007304692,0.0024309359,0.005303662,0.001244017,0.00085351215,0.0017198615,0.00077671633,0.0021361343,0.00014470656],"category_scores_gemma":[0.00037803507,0.0020419012,0.001281097,0.001195746,0.001227619,0.0009318715,0.00082325895,0.0006848793,0.0005153337],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033445633,0.0002923177,0.0014375458,0.012524905,0.0012893506,0.0030349637,0.0002644329,0.000001004971,0.000010068014,0.000093444614,0.0049387757,0.97577876],"study_design_scores_gemma":[0.017394546,0.00042133118,0.008798888,0.032645322,0.002499335,0.0044220705,0.00022130812,0.0005461749,0.000025590647,0.00007448358,0.93121684,0.0017341097],"about_ca_topic_score_codex":0.0025973953,"about_ca_topic_score_gemma":0.00019428,"teacher_disagreement_score":0.9740446,"about_ca_system_score_codex":0.009675984,"about_ca_system_score_gemma":0.008177089,"threshold_uncertainty_score":0.99931645},"labels":[],"label_agreement":null},{"id":"W2066022953","doi":"10.3109/10428194.2013.848982","title":"Isolated bone marrow Hodgkin lymphoma in a human immunodeficiency virus-negative patient: a second case","year":2013,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Lymphoma; Medicine; Hodgkin lymphoma; Bone marrow; Human immunodeficiency virus (HIV); Cancer; Immunodeficiency; Pathology; Oncology; Cancer research; Internal medicine; Virology; Immunology; Immune system","score_opus":0.020159616710042506,"score_gpt":0.27953799006091146,"score_spread":0.25937837335086894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066022953","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31077886,0.6786094,0.000004087478,0.000024118528,0.00047267645,0.004590624,0.0005477268,0.00035344515,0.0046191276],"genre_scores_gemma":[0.13045579,0.85993147,0.00042337883,0.0006956793,0.0003663021,0.0036806965,0.0011312013,0.0006497044,0.0026657556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9865345,0.0009328117,0.004513187,0.0037510924,0.0013519115,0.0029164967],"domain_scores_gemma":[0.9920221,0.0010654082,0.002240959,0.0028215954,0.00041081492,0.0014391401],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006731708,0.0037988941,0.008266656,0.0022673102,0.0010418502,0.00061729155,0.0007947277,0.0028490818,0.0011129273],"category_scores_gemma":[0.00023819013,0.0031825583,0.0021428047,0.002629905,0.00092930207,0.0007968931,0.00092897506,0.0005601093,0.000774428],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00032067564,0.0018949363,0.0001583873,0.008483381,0.0013232024,0.042767316,0.0016498825,0.0000015149282,0.00008353022,0.0003108672,0.0026234756,0.94038284],"study_design_scores_gemma":[0.042039637,0.0029769463,0.0017835202,0.025841018,0.005227478,0.12691234,0.0010148707,0.0007164127,0.0004108727,0.00029123176,0.7880134,0.0047722515],"about_ca_topic_score_codex":0.014988345,"about_ca_topic_score_gemma":0.001008455,"teacher_disagreement_score":0.9356106,"about_ca_system_score_codex":0.032223906,"about_ca_system_score_gemma":0.009215559,"threshold_uncertainty_score":0.9998002},"labels":[],"label_agreement":null},{"id":"W2067305498","doi":"10.3109/10428194.2011.654339","title":"High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Medicine and Dentistry, University of Alberta","keywords":"Medicine; International Prognostic Index; Follicular lymphoma; Hazard ratio; Internal medicine; Lymphoma; Beta-2 microglobulin; Oncology; Proportional hazards model; Lactate dehydrogenase; Chronic lymphocytic leukemia; Rituximab; Stage (stratigraphy); Gastroenterology; Immunology; Leukemia; Confidence interval; Biology","score_opus":0.015060401493968709,"score_gpt":0.23096356657214256,"score_spread":0.21590316507817386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2067305498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992188,0.0025876448,0.00007129171,0.0003850066,0.0007038119,0.0019494605,0.00043101926,0.00037709935,0.0013067053],"genre_scores_gemma":[0.9914892,0.00043025703,0.0022329488,0.0022858856,0.0006183676,0.00044977508,0.0009288034,0.00027421542,0.0012905868],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992271,0.00028967555,0.0017027339,0.0016237722,0.0016017156,0.00251107],"domain_scores_gemma":[0.99532,0.0003908788,0.0005646329,0.0016551316,0.00035705688,0.0017122502],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00092860917,0.0015966023,0.0021455886,0.0007481611,0.00047591628,0.00017615593,0.0004469515,0.0007988127,0.0002247343],"category_scores_gemma":[0.00023989526,0.0012428486,0.00041887106,0.0013401929,0.00038300955,0.0010612122,0.00036419794,0.00017889815,0.00023773575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021993641,0.0034340126,0.9012339,0.0003431925,0.0005278339,0.0006490142,0.00041670314,0.00007604356,0.00010079678,0.0009105962,0.0016405779,0.08846794],"study_design_scores_gemma":[0.08022164,0.001018645,0.9021219,0.0006493081,0.0008214202,0.00041338516,0.0001974952,0.00069029845,0.003237039,0.00006588228,0.009286089,0.0012768728],"about_ca_topic_score_codex":0.004475087,"about_ca_topic_score_gemma":0.00020302641,"teacher_disagreement_score":0.08719107,"about_ca_system_score_codex":0.013033524,"about_ca_system_score_gemma":0.00242605,"threshold_uncertainty_score":0.9996782},"labels":[],"label_agreement":null},{"id":"W2068794772","doi":"10.3109/10428194.2010.500046","title":"Prognostic biomarkers in malignant lymphomas","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lymphoma; Tumor microenvironment; Follicular lymphoma; Disease; Translational research; Chemokine; Medicine; Cancer research; Biology; Bioinformatics; Computational biology; Immunology; Pathology; Immune system; Tumor cells","score_opus":0.022238817785007865,"score_gpt":0.2893704191402985,"score_spread":0.2671316013552906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068794772","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030907586,0.95349294,0.0000036360568,0.00009271821,0.0012412518,0.0047623045,0.00019845946,0.00049712125,0.008804011],"genre_scores_gemma":[0.008555663,0.98362815,0.0008514405,0.0005875276,0.0007776581,0.002466193,0.0011682343,0.0005721247,0.0013929893],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889001,0.00046932368,0.0032289226,0.0034202533,0.0013761292,0.0026052247],"domain_scores_gemma":[0.99304414,0.0012462527,0.0012792599,0.0025513014,0.00022473371,0.0016543003],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008851986,0.0031762943,0.007173788,0.001985887,0.0004570466,0.0004143448,0.00093330693,0.003461533,0.00022779056],"category_scores_gemma":[0.0004381817,0.00252548,0.0020328283,0.0021608083,0.00085806334,0.00040084953,0.00066714536,0.0005819461,0.0006848402],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002512107,0.000980831,0.0046663536,0.010613453,0.0015468481,0.0052806307,0.00019219094,6.5005213e-7,0.000009030572,0.00082004076,0.0018084026,0.97383034],"study_design_scores_gemma":[0.0186505,0.00059713627,0.017605841,0.027992873,0.0056450097,0.013151982,0.000104283434,0.0001367136,0.000055546647,0.00015071947,0.9134595,0.0024498939],"about_ca_topic_score_codex":0.0021678256,"about_ca_topic_score_gemma":0.00031646685,"teacher_disagreement_score":0.9713805,"about_ca_system_score_codex":0.02117475,"about_ca_system_score_gemma":0.018057995,"threshold_uncertainty_score":0.99809647},"labels":[],"label_agreement":null},{"id":"W2070487917","doi":"10.3109/10428194.2015.1022770","title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":307,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"Gilead Sciences","keywords":"Idelalisib; Medicine; Adverse effect; Internal medicine; Diarrhea; Intensive care medicine; Ibrutinib","score_opus":0.07781209335968814,"score_gpt":0.3511248248391235,"score_spread":0.27331273147943536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070487917","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010915141,0.9755473,0.000025400705,0.00002047829,0.0005868771,0.0044947467,0.00035272024,0.00037100888,0.0076863393],"genre_scores_gemma":[0.003213077,0.98447937,0.00062171073,0.00011016498,0.0004814593,0.0010396108,0.0024238045,0.0005357206,0.007095058],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98993653,0.00059491995,0.0025088177,0.0023760535,0.0025859184,0.001997744],"domain_scores_gemma":[0.9932269,0.0005730712,0.0016146457,0.0025390713,0.00057084474,0.0014754578],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00096799707,0.0023980194,0.0063878912,0.0009933211,0.00030543233,0.00004630254,0.00095834176,0.0018128752,0.0001089905],"category_scores_gemma":[0.00012581638,0.001759681,0.0013482347,0.0018662151,0.00074607105,0.00037540914,0.0006755177,0.0003302151,0.00018489822],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011324775,0.00080340484,0.000044099834,0.017092478,0.006317613,0.0033683304,0.0006428214,0.000014085328,0.0000016593286,0.0002947546,0.001737145,0.96855116],"study_design_scores_gemma":[0.08059497,0.0020982823,0.00031411866,0.057410207,0.0054393956,0.0045739086,0.00061163347,0.0010268313,0.00003331022,0.00006613946,0.84593254,0.0018986766],"about_ca_topic_score_codex":0.002856337,"about_ca_topic_score_gemma":0.000041053627,"teacher_disagreement_score":0.96665245,"about_ca_system_score_codex":0.20222163,"about_ca_system_score_gemma":0.05651086,"threshold_uncertainty_score":0.999483},"labels":[],"label_agreement":null},{"id":"W2070685379","doi":"10.3109/10428194.2013.862242","title":"Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Foothills Medical Centre; University of Calgary","funders":"","keywords":"Medicine; Vincristine; Rituximab; Diffuse large B-cell lymphoma; Positron emission tomography; Oncology; Internal medicine; Prednisone; Interim analysis; Lymphoma; Interim; Cyclophosphamide; Chemotherapy; Clinical trial; Nuclear medicine","score_opus":0.024409207622668537,"score_gpt":0.31240700740628746,"score_spread":0.28799779978361895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070685379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836819,0.0023185962,0.000045835728,0.00046532595,0.00063074555,0.010840737,0.00051155896,0.0003649332,0.0011403488],"genre_scores_gemma":[0.98724043,0.0008213967,0.003010654,0.0007904862,0.00065664406,0.005329331,0.0007416467,0.00023263863,0.001176748],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922398,0.00032462683,0.002398305,0.002096916,0.0012656986,0.001674657],"domain_scores_gemma":[0.99470854,0.00075304374,0.0013497863,0.0012352483,0.0009739791,0.0009794115],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00097461906,0.0014383525,0.0022160918,0.00068891764,0.00090149004,0.00024971366,0.0005265111,0.00081798155,0.0000832185],"category_scores_gemma":[0.00042976553,0.0011312183,0.0011192177,0.00094512553,0.00038468483,0.00062724884,0.00039182074,0.0001282969,0.000027262675],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23680389,0.0655155,0.005416514,0.00082883815,0.0020084323,0.00018207332,0.004729111,0.0000031319594,0.10427444,0.0004256974,0.015990406,0.563822],"study_design_scores_gemma":[0.7095359,0.02690673,0.032945648,0.0007673409,0.0009368227,0.00022366375,0.00056228694,0.003614837,0.22051436,0.00043172468,0.0025218572,0.0010388475],"about_ca_topic_score_codex":0.0034939402,"about_ca_topic_score_gemma":0.00002366277,"teacher_disagreement_score":0.5627831,"about_ca_system_score_codex":0.0057292134,"about_ca_system_score_gemma":0.0033960713,"threshold_uncertainty_score":0.9998366},"labels":[],"label_agreement":null},{"id":"W2071296119","doi":"10.1080/10428190801895345","title":"Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas","year":2008,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Leukemia and Lymphoma Society","keywords":"BCL6; Cancer research; Psychological repression; Biology; Lymphoma; Diffuse large B-cell lymphoma; Repressor; Histone deacetylase; Gene; Genetics; B cell; Transcription factor; Histone; Immunology; Germinal center; Gene expression; Antibody","score_opus":0.02476285182321983,"score_gpt":0.2853888692776675,"score_spread":0.26062601745444763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071296119","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018047135,0.972186,0.00003893226,0.000063462074,0.0010203096,0.004876827,0.0007620364,0.00022928331,0.0027759993],"genre_scores_gemma":[0.024737703,0.9670379,0.0006367661,0.0008784925,0.00085977884,0.0016006851,0.0007273887,0.0004983865,0.0030228975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914914,0.00044266845,0.002776507,0.0020999634,0.0012429109,0.0019465876],"domain_scores_gemma":[0.99298906,0.0014338519,0.0020856054,0.002342042,0.00038585963,0.0007635941],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00051918783,0.0023361337,0.0058184736,0.00053474907,0.001008763,0.00012797621,0.0011044851,0.0017720985,0.000057144603],"category_scores_gemma":[0.00022259646,0.0015313114,0.003815566,0.0011811274,0.0006607471,0.00020785691,0.0006631422,0.00026400652,0.000075363896],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00033501585,0.0035836792,0.00068669126,0.017528333,0.001958244,0.00023921397,0.0005075648,0.0000017916892,0.00004803843,0.00088370347,0.008460701,0.965767],"study_design_scores_gemma":[0.043413945,0.0005906924,0.0013217693,0.0083884485,0.006104424,0.002749731,0.00014654727,0.00018823407,0.0009775108,0.00010098942,0.93455774,0.0014599499],"about_ca_topic_score_codex":0.00046868972,"about_ca_topic_score_gemma":0.000023177257,"teacher_disagreement_score":0.96430707,"about_ca_system_score_codex":0.012470882,"about_ca_system_score_gemma":0.013531202,"threshold_uncertainty_score":0.9995238},"labels":[],"label_agreement":null},{"id":"W2071845884","doi":"10.1080/10428190601078126","title":"Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Statistical Methods in Clinical Trials","field":"Mathematics","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Juravinski Cancer Centre; McGill University Health Centre; Princess Margaret Cancer Centre; BC Cancer Agency; Jewish General Hospital; Queen's University; McGill University","funders":"","keywords":"Response Evaluation Criteria in Solid Tumors; Medicine; Concordance; Lymphoma; Hodgkin lymphoma; Concordance correlation coefficient; Nuclear medicine; Clinical trial; Internal medicine; Oncology; Statistics; Mathematics; Phases of clinical research","score_opus":0.2976124603191652,"score_gpt":0.4829481651784053,"score_spread":0.18533570485924006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071845884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91638047,0.00013639765,0.079051435,0.00077563606,0.0012179691,0.0010013914,0.00010375581,0.000109747736,0.0012231995],"genre_scores_gemma":[0.6540934,0.00002095352,0.3440485,0.0011298567,0.00025561778,0.000110575806,0.000008629424,0.000080036196,0.0002524352],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99292666,0.001062287,0.002970817,0.001174606,0.00087845925,0.0009871701],"domain_scores_gemma":[0.9668262,0.030614251,0.0005677422,0.0009969576,0.00033565506,0.0006591774],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011428119,0.00073279865,0.001555954,0.00057209836,0.00029443638,0.0002680258,0.0011685725,0.00051769277,0.000125453],"category_scores_gemma":[0.026317513,0.00056456565,0.00015892353,0.0010008404,0.00032644355,0.00017674093,0.0009852496,0.00016937622,0.00002819865],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02055925,0.00061848096,0.0016428118,0.00022181754,0.00030775013,0.0001334313,0.015522346,0.000022619848,0.028576627,0.0076429816,0.008549485,0.9162024],"study_design_scores_gemma":[0.0319342,0.0011349326,0.5502741,0.0033769608,0.00026413068,0.0004977667,0.017139465,0.012510549,0.13957874,0.06011999,0.17959453,0.003574644],"about_ca_topic_score_codex":0.0001779498,"about_ca_topic_score_gemma":0.0005473459,"teacher_disagreement_score":0.91262776,"about_ca_system_score_codex":0.003965255,"about_ca_system_score_gemma":0.0015084381,"threshold_uncertainty_score":0.9998583},"labels":[],"label_agreement":null},{"id":"W2072259702","doi":"10.1080/1042819031000060573","title":"Acute Myelogenous Leukemia Complicated by Acute Necrotizing Ulcerative Gingivitis Due to Aspergillus terreus","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Aspergillus terreus; Itraconazole; Amphotericin B; Medicine; Leukemia; Chronic myelogenous leukemia; Mortality rate; Internal medicine; Immunology; Dermatology; Chemotherapy; Gastroenterology; Antifungal; Microbiology; Biology","score_opus":0.00975397645633386,"score_gpt":0.2500085407479471,"score_spread":0.24025456429161324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072259702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97373456,0.0017995368,0.0017351715,0.00046225934,0.000494452,0.0017764041,0.00043329448,0.0005788323,0.018985473],"genre_scores_gemma":[0.9816285,0.0007484627,0.0025206152,0.0051920526,0.00023974187,0.00024236519,0.000435943,0.00024461822,0.008747706],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9926663,0.00035441303,0.0014190916,0.0023324965,0.0010818229,0.0021458967],"domain_scores_gemma":[0.9954163,0.0003478923,0.0004033817,0.0017246287,0.0004292457,0.0016785414],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00064784073,0.0014134493,0.002169911,0.0004234973,0.0011598935,0.00032594972,0.0005266983,0.00087270647,0.00027338238],"category_scores_gemma":[0.00030213143,0.001332805,0.0005556933,0.00133983,0.00067246,0.0004953158,0.00029608505,0.00042257988,0.00040168033],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008354973,0.0011330671,0.02398522,0.0008123152,0.005449264,0.017621322,0.008721729,0.00012419454,0.60280067,0.0050296374,0.09516034,0.23080726],"study_design_scores_gemma":[0.054549247,0.004385439,0.4132844,0.0016193992,0.00398454,0.03268283,0.0038112707,0.0045885793,0.24201597,0.0017491399,0.23050226,0.0068269353],"about_ca_topic_score_codex":0.0016503765,"about_ca_topic_score_gemma":0.00027604486,"teacher_disagreement_score":0.38929915,"about_ca_system_score_codex":0.015030433,"about_ca_system_score_gemma":0.00507265,"threshold_uncertainty_score":0.99986154},"labels":[],"label_agreement":null},{"id":"W2073210499","doi":"10.3109/10428194.2010.535183","title":"In a patient with biclonal Waldenstrom macroglobulinemia only one clone expands in three-dimensional culture and includes putative cancer stem cells","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"clone (Java method); Waldenstrom macroglobulinemia; Bone marrow; Biology; Stem cell; Macroglobulinemia; Molecular biology; Antibody; Immunology; Cancer research; Gene; Multiple myeloma; Cell biology; Lymphoma; Genetics","score_opus":0.010021286159338694,"score_gpt":0.25830142249239174,"score_spread":0.24828013633305304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073210499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940856,0.002650854,0.000015475973,0.0004860083,0.0003104672,0.0015011794,0.00016418597,0.00012270157,0.0006635156],"genre_scores_gemma":[0.99331784,0.0006411919,0.0026353102,0.0013373513,0.0003648667,0.00035658144,0.00008839916,0.000162051,0.001096427],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993551,0.00016506173,0.00121964,0.0017987401,0.0016039701,0.0016615961],"domain_scores_gemma":[0.9970784,0.00041038526,0.0003676485,0.000815138,0.00035217626,0.0009762404],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052833284,0.0010604704,0.0015546224,0.00069230783,0.00029920068,0.00016872998,0.00038034498,0.00092982734,0.00015155597],"category_scores_gemma":[0.00006499476,0.00086421013,0.0001643404,0.001246625,0.0013302125,0.00052897213,0.0005998057,0.0008552699,0.000031301573],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0306856,0.0037313406,0.116132274,0.0030768116,0.001645455,0.039303184,0.021398153,0.0016314548,0.36103442,0.0030045062,0.0039678263,0.41438898],"study_design_scores_gemma":[0.34204137,0.0055597527,0.2434729,0.0054774806,0.00086898706,0.03910101,0.0037995982,0.13511778,0.20553607,0.0018946344,0.01187262,0.0052577816],"about_ca_topic_score_codex":0.020795455,"about_ca_topic_score_gemma":0.011716035,"teacher_disagreement_score":0.4091312,"about_ca_system_score_codex":0.03161213,"about_ca_system_score_gemma":0.026683515,"threshold_uncertainty_score":0.9993809},"labels":[],"label_agreement":null},{"id":"W2073523783","doi":"10.1080/10428190210173","title":"Diffuse Large B-cell Lymphoma: A Clinicopathologic Analysis of 444 Cases Classified According to the Updated Kiel Classification","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute","keywords":"Lymphoma; Medicine; Anaplastic large-cell lymphoma; Diffuse large B-cell lymphoma; Internal medicine; Retrospective cohort study; Stage (stratigraphy); Overall survival; Subtyping; Large cell; Pathology; Gastroenterology; Cancer; Adenocarcinoma; Biology","score_opus":0.039268709251652406,"score_gpt":0.2788327295271943,"score_spread":0.23956402027554188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2073523783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874051,0.003145645,0.00012071083,0.0009408429,0.00039603445,0.0013259447,0.0003132219,0.00030578795,0.006046679],"genre_scores_gemma":[0.9907342,0.0023064779,0.00047432454,0.0034873176,0.00027702432,0.00042913225,0.0004818558,0.00011834909,0.0016913164],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99371946,0.00038500334,0.0018199661,0.0017021707,0.0010228403,0.0013505386],"domain_scores_gemma":[0.9948106,0.0009951298,0.00088154007,0.0021135348,0.00037255947,0.00082664884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007595996,0.0010442438,0.0020885868,0.0011290396,0.000720317,0.00021557085,0.0006688663,0.00070109504,0.00021680968],"category_scores_gemma":[0.0003462649,0.0007503422,0.0010242878,0.0034828007,0.0003660741,0.00031390684,0.00040536025,0.00013999295,0.0002773214],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030009628,0.029650643,0.47769836,0.0004979946,0.0066386224,0.0037009004,0.006357049,0.0001848464,0.010831891,0.0039409366,0.035156887,0.42234093],"study_design_scores_gemma":[0.051807053,0.001125194,0.863433,0.0002105022,0.008280741,0.0008947371,0.0037398783,0.034292765,0.0049878363,0.00003475999,0.0300942,0.001099305],"about_ca_topic_score_codex":0.0009054961,"about_ca_topic_score_gemma":0.00018883396,"teacher_disagreement_score":0.4212416,"about_ca_system_score_codex":0.005328424,"about_ca_system_score_gemma":0.000971933,"threshold_uncertainty_score":0.99949473},"labels":[],"label_agreement":null},{"id":"W2074583097","doi":"10.1080/10428190802276289","title":"Paraneoplastic lumbosacral axonal polyradiculopathy preceding the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma: a case report","year":2008,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Autoimmune Neurological Disorders and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University of Toronto","funders":"","keywords":"Medicine; Malignancy; Pathology; Polyradiculopathy; Lymphoma; Lumbosacral joint; Lymphocyte; Immunology; Anatomy","score_opus":0.016115479626238684,"score_gpt":0.23556164416107106,"score_spread":0.21944616453483237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074583097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9647647,0.015719237,0.00006193742,0.012560904,0.0013787844,0.0028295126,0.00040159124,0.00039607455,0.0018872241],"genre_scores_gemma":[0.9063948,0.008956398,0.0004252446,0.07511947,0.0020822072,0.0016171823,0.0013450386,0.0005236791,0.0035359873],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.98920304,0.00059121544,0.002935863,0.0028608744,0.0020619223,0.0023470845],"domain_scores_gemma":[0.9925435,0.0017547626,0.0020999638,0.002585804,0.0003909746,0.00062498054],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005397328,0.0024385825,0.0037695589,0.0005649714,0.0018410005,0.00029788213,0.00091013394,0.0029685092,0.00018342338],"category_scores_gemma":[0.00070736266,0.0017493138,0.001636334,0.0010452634,0.0020516093,0.0002980979,0.0007171045,0.0008464184,0.00009624223],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001836579,0.0009042678,0.01227283,0.0012052099,0.0020562813,0.7131827,0.0006646506,0.000050877527,0.0001077028,0.000022616794,0.18748797,0.08020832],"study_design_scores_gemma":[0.03089385,0.0019362381,0.033729605,0.0012057886,0.0035842166,0.6641555,0.00017638301,0.003331829,0.0010459032,0.0001780507,0.25782135,0.0019413044],"about_ca_topic_score_codex":0.008330175,"about_ca_topic_score_gemma":0.0000940496,"teacher_disagreement_score":0.078267016,"about_ca_system_score_codex":0.0064238226,"about_ca_system_score_gemma":0.006601165,"threshold_uncertainty_score":0.9994585},"labels":[],"label_agreement":null},{"id":"W2074923396","doi":"10.3109/10428190009059283","title":"Bone Marrow Necrosis in Adult Acute Leukemia and Non-Hodgkin's Lymphoma","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Bone and Joint Diseases","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Lymphoma; Bone marrow; Leukemia; Acute leukemia; Myeloid leukemia; Pathology; Haematopoiesis; Internal medicine; Oncology; Stem cell","score_opus":0.006072855173703697,"score_gpt":0.22715335457122884,"score_spread":0.22108049939752514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2074923396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97800386,0.0032973993,0.000016356003,0.0007697556,0.00031292083,0.0012426313,0.00016808222,0.00045805628,0.015730968],"genre_scores_gemma":[0.97276914,0.008795108,0.0011392116,0.0064076623,0.00056711474,0.00031788956,0.0002833569,0.0002896705,0.00943086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9925859,0.00020420225,0.001756473,0.0022245804,0.0011140408,0.0021148094],"domain_scores_gemma":[0.99585295,0.0003190241,0.00038332652,0.0015352771,0.0002575086,0.0016519137],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0004878962,0.0015483603,0.0022985635,0.0008029973,0.0005801777,0.0003603353,0.00044871125,0.0011393722,0.00068655424],"category_scores_gemma":[0.00014992259,0.0014843154,0.0005698098,0.0013459984,0.00090678304,0.00091599993,0.00032281416,0.00030303115,0.00038733493],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074474732,0.00082012045,0.050605956,0.0009615641,0.0008034902,0.007073391,0.0022229298,0.000043666507,0.011928666,0.00046321162,0.02517694,0.8924526],"study_design_scores_gemma":[0.07740197,0.0012584663,0.8391691,0.0020882208,0.0018104163,0.008629788,0.00096997974,0.011338479,0.009149609,0.0011386074,0.043832976,0.0032123951],"about_ca_topic_score_codex":0.007506653,"about_ca_topic_score_gemma":0.0004205108,"teacher_disagreement_score":0.8892402,"about_ca_system_score_codex":0.00798595,"about_ca_system_score_gemma":0.0049497876,"threshold_uncertainty_score":0.9997265},"labels":[],"label_agreement":null},{"id":"W2075891452","doi":"10.3109/10428194.2011.608449","title":"Genomic stratification of multiple myeloma treated with novel agents","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Multiple myeloma; Stratification (seeds); Risk stratification; Computational biology; Medicine; Biology; Oncology; Internal medicine; Cancer research; Bioinformatics","score_opus":0.054621532574841286,"score_gpt":0.30317847664759484,"score_spread":0.24855694407275356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2075891452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11237502,0.878248,0.0000775024,0.0000066571206,0.0001232677,0.003846025,0.0007600459,0.00023535403,0.0043281447],"genre_scores_gemma":[0.06391617,0.92846847,0.001541394,0.000052215175,0.00021695935,0.0006446518,0.0023954494,0.00033798238,0.0024267077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99437624,0.0002129952,0.0016961918,0.001673316,0.00083159114,0.0012096376],"domain_scores_gemma":[0.9954223,0.0003772157,0.001179625,0.0017003742,0.0003394876,0.0009809872],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00029905047,0.001552423,0.0038004962,0.00084376615,0.00028632255,0.000097823366,0.0005758442,0.0010994012,0.00015594775],"category_scores_gemma":[0.00012889279,0.0011295634,0.0007680983,0.00091358554,0.0006055031,0.00023731448,0.0002265516,0.00027819656,0.00014362448],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011131119,0.000683957,0.0032653217,0.0116143795,0.002290481,0.00044018315,0.00020691198,0.0000010786649,0.0001975127,0.00019166613,0.00028181454,0.97971356],"study_design_scores_gemma":[0.047067504,0.002545302,0.1089882,0.022489652,0.0082881935,0.005705988,0.00019211095,0.0012759991,0.0010400155,0.000029361257,0.79987466,0.0025030063],"about_ca_topic_score_codex":0.0028628604,"about_ca_topic_score_gemma":0.00011643354,"teacher_disagreement_score":0.9772106,"about_ca_system_score_codex":0.006990098,"about_ca_system_score_gemma":0.007785958,"threshold_uncertainty_score":0.9997224},"labels":[],"label_agreement":null},{"id":"W2077488231","doi":"10.1080/10428190701799035","title":"Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Toxin Mechanisms and Immunotoxins","field":"Immunology and Microbiology","cited_by":153,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Chills; Diphtheria toxin; Refractory (planetary science); Myeloid leukemia; Gastroenterology; Internal medicine; Hypoalbuminemia; Diphtheria; Leukemia; Surgery; Immunology; Vaccination; Toxin","score_opus":0.01033369051243744,"score_gpt":0.24376718167260625,"score_spread":0.23343349116016882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077488231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586856,0.0006884757,0.000040262057,0.000019445573,0.00052114524,0.0022416217,0.00012003108,0.00014551956,0.00035495876],"genre_scores_gemma":[0.99714255,0.00043103544,0.00037706556,0.00020690353,0.000067702145,0.00020660361,0.00016866093,0.0001290512,0.0012704446],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99455285,0.0006736661,0.0018341322,0.0015125914,0.00031460085,0.0011121883],"domain_scores_gemma":[0.9975191,0.00023015702,0.0007799534,0.0010554539,0.00020338311,0.00021197705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063550944,0.0009858997,0.0017070827,0.00045932818,0.0005697016,0.000059276215,0.0006487105,0.00095993985,0.00014020326],"category_scores_gemma":[0.00009760836,0.000816954,0.00018329124,0.00061884546,0.00095269986,0.00048746023,0.000528244,0.00044780257,0.000056446206],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03943492,0.01565643,0.1905403,0.00029983994,0.0030669377,0.0014708412,0.014480262,0.000019380906,0.38369253,0.00071730174,0.0016982175,0.34892303],"study_design_scores_gemma":[0.18299675,0.0195724,0.73861736,0.0005203695,0.00041938332,0.00083303585,0.002242824,0.00016604604,0.047091052,0.000110719484,0.005701103,0.0017289642],"about_ca_topic_score_codex":0.0017795138,"about_ca_topic_score_gemma":0.0002697476,"teacher_disagreement_score":0.54807705,"about_ca_system_score_codex":0.002006901,"about_ca_system_score_gemma":0.0019414943,"threshold_uncertainty_score":0.99942815},"labels":[],"label_agreement":null},{"id":"W2078051582","doi":"10.1080/10428190601175393","title":"Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®)<i>versus</i>interferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Chronic myelogenous leukemia; PEG ratio; Philadelphia chromosome; Interferon; Adverse effect; Immunology; Leukemia; Chromosomal translocation; Biology","score_opus":0.018731130442451106,"score_gpt":0.2977675554976269,"score_spread":0.2790364250551758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078051582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9824953,0.0038638283,0.00020707365,0.000034634606,0.00092461123,0.00978334,0.0002270872,0.00036472408,0.0020993704],"genre_scores_gemma":[0.99471986,0.0007031389,0.00043605585,0.00014843605,0.0005753016,0.0007723634,0.00092753506,0.00035619564,0.0013611243],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9879124,0.000706183,0.003606848,0.002967588,0.0018314668,0.002975507],"domain_scores_gemma":[0.9925212,0.0012900194,0.0017544454,0.0024767092,0.00060993666,0.0013476644],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011357421,0.0027223853,0.0056264075,0.0014706351,0.0007334476,0.00014685412,0.00090697024,0.0009226803,0.00027307437],"category_scores_gemma":[0.00014867372,0.0021985034,0.0008316356,0.0013780008,0.0014755289,0.00082297885,0.00058551546,0.00059209135,0.00008935074],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.76739866,0.03702735,0.012903849,0.00076682254,0.006630778,0.0020597272,0.02148111,0.0005674236,0.0028020432,0.00009258194,0.00060090044,0.14766878],"study_design_scores_gemma":[0.8686016,0.08660647,0.015625596,0.001292652,0.0029559257,0.00024061254,0.0043266774,0.0072481665,0.009777551,0.000008917589,0.0015675557,0.0017482685],"about_ca_topic_score_codex":0.008830597,"about_ca_topic_score_gemma":0.0073653217,"teacher_disagreement_score":0.14592052,"about_ca_system_score_codex":0.11424369,"about_ca_system_score_gemma":0.010720413,"threshold_uncertainty_score":0.99855095},"labels":[],"label_agreement":null},{"id":"W2078147862","doi":"10.1080/10428190701344881","title":"CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Island Health; BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency","keywords":"Rituximab; Diffuse large B-cell lymphoma; CHOP; Medicine; Internal medicine; Lymphoma; Oncology; Chemotherapy; Progression-free survival; Retrospective cohort study","score_opus":0.008076986968633092,"score_gpt":0.24277807292535974,"score_spread":0.23470108595672665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078147862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866968,0.008188946,0.000028787501,0.00016227349,0.00024798597,0.0018238326,0.000055955294,0.00018008989,0.002615328],"genre_scores_gemma":[0.9923734,0.0044769524,0.00037028347,0.0015450304,0.00021002023,0.0002736487,0.000068363195,0.00013072265,0.00055157684],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942679,0.0002189362,0.0015657872,0.0012316899,0.0011573964,0.0015582934],"domain_scores_gemma":[0.9958245,0.0012025279,0.00065235,0.0014511253,0.00024338636,0.0006260923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010569382,0.0010256816,0.0013590263,0.0005621939,0.00041083398,0.00007827247,0.0005889962,0.0006424543,0.00004707049],"category_scores_gemma":[0.00024071198,0.00069950876,0.00048030925,0.0010994653,0.0005310064,0.00048441935,0.00033006136,0.00015902694,0.00006505897],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047480455,0.014933243,0.77258104,0.00061989424,0.00038063264,0.0021718615,0.0051737553,0.00007549023,0.027603047,0.00087691593,0.0013721378,0.16946396],"study_design_scores_gemma":[0.098621815,0.00053641153,0.8370598,0.00079925876,0.0001900295,0.0004807497,0.0010550261,0.00037770878,0.04829753,0.00013586467,0.011788658,0.0006571634],"about_ca_topic_score_codex":0.0016591955,"about_ca_topic_score_gemma":0.00020872951,"teacher_disagreement_score":0.1688068,"about_ca_system_score_codex":0.005151262,"about_ca_system_score_gemma":0.0023889816,"threshold_uncertainty_score":0.99954563},"labels":[],"label_agreement":null},{"id":"W2078254962","doi":"10.1080/10428190290021632","title":"A Literature Review of Single Agent Treatment of Multiply Relapsed Aggressive Non-Hodgkin's Lymphoma","year":2002,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Inimex Pharmaceuticals (Canada)","funders":"","keywords":"Medicine; Vinorelbine; Etoposide; Oncology; Population; Internal medicine; Clinical trial; Lymphoma; Aggressive lymphoma; Vincristine; Inclusion and exclusion criteria; Rituximab; Chemotherapy; Pathology; Alternative medicine; Cyclophosphamide","score_opus":0.028927631738162974,"score_gpt":0.2899046831440661,"score_spread":0.2609770514059031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078254962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006404272,0.98249114,0.000004812579,0.00006891366,0.0007438618,0.005456779,0.001028608,0.00019406708,0.0036075716],"genre_scores_gemma":[0.0026940333,0.98910606,0.0008576564,0.00047127358,0.00050883496,0.0015662627,0.0019893714,0.00044272386,0.0023638012],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9890803,0.00057899073,0.0044331364,0.0026376399,0.0016412477,0.001628683],"domain_scores_gemma":[0.9888741,0.0010398681,0.0051572123,0.0031213358,0.00077478914,0.0010327378],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00040242542,0.0032394547,0.011405225,0.0012035825,0.00030361186,0.00013414094,0.00077797734,0.0021355683,0.00021100558],"category_scores_gemma":[0.000374489,0.0023720448,0.004291019,0.0021943753,0.0007620767,0.0003171785,0.0003672256,0.00018305834,0.00014455181],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00032244777,0.003636439,0.00009555558,0.13897276,0.0031053717,0.004390969,0.00069794006,6.888451e-7,0.000030848183,0.00006212564,0.003592539,0.8450923],"study_design_scores_gemma":[0.021377422,0.0027655978,0.0006283157,0.33195227,0.010430412,0.0065569747,0.00005197216,0.00005865324,0.00054508983,0.000011505476,0.6242668,0.0013550065],"about_ca_topic_score_codex":0.0006088303,"about_ca_topic_score_gemma":0.000013235866,"teacher_disagreement_score":0.8437373,"about_ca_system_score_codex":0.021573387,"about_ca_system_score_gemma":0.006504773,"threshold_uncertainty_score":0.9991599},"labels":[],"label_agreement":null},{"id":"W2079214894","doi":"10.1080/1042819031000060582","title":"Posterior Leukoencephalopathy in Association with the Tumour Lysis Syndrome in Acute Lymphoblastic Leukaemia--A Case with Clinicopathological Correlation","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Medicine; Autopsy; Leukoencephalopathy; Malignancy; Tumor lysis syndrome; Pathology; Cortical blindness; Chemotherapy; Internal medicine; Blindness; Disease","score_opus":0.010407605167652795,"score_gpt":0.23538475436949485,"score_spread":0.22497714920184206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079214894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962888,0.00040511595,0.0002103603,0.0006168271,0.000093633884,0.0010239774,0.000019027906,0.00012996462,0.0012123212],"genre_scores_gemma":[0.99667096,0.00017791262,0.00059655745,0.0014989882,0.000034243683,0.00031993008,0.000034152567,0.000068405774,0.0005988758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99570537,0.00056328875,0.0009591266,0.0011537515,0.0006810714,0.00093737],"domain_scores_gemma":[0.9973622,0.00093940226,0.0004935821,0.000706479,0.00017640648,0.00032191045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009977896,0.0006503042,0.0011061507,0.000419864,0.0003616814,0.00014926736,0.0002520517,0.00051591423,0.000054376986],"category_scores_gemma":[0.000314241,0.0004053069,0.00015833082,0.0015680831,0.0003450653,0.00032754664,0.00009309743,0.00037943784,0.000051104096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018949208,0.0005474902,0.92435354,0.000100430894,0.00014871226,0.059353903,0.0008155887,0.0009040952,0.0010642257,0.0008271508,0.00013401394,0.009855949],"study_design_scores_gemma":[0.01298304,0.001885293,0.84084296,0.00019837702,0.0003961802,0.1376872,0.00060056103,0.004072049,0.00019199734,0.00015120894,0.00045142323,0.0005396936],"about_ca_topic_score_codex":0.00042407124,"about_ca_topic_score_gemma":0.0003501892,"teacher_disagreement_score":0.08351055,"about_ca_system_score_codex":0.0056109414,"about_ca_system_score_gemma":0.001674047,"threshold_uncertainty_score":0.9998399},"labels":[],"label_agreement":null},{"id":"W2079335457","doi":"10.1080/10428190902756578","title":"Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"University Health Network","keywords":"Medicine; Internal medicine; Etoposide; Transplantation; Melphalan; Chemotherapy; Oncology; Lymphoma; Cumulative incidence; Cancer; Total body irradiation; Population; Hematopoietic stem cell transplantation; Surgery; Cyclophosphamide","score_opus":0.006591239452566481,"score_gpt":0.24115905153030998,"score_spread":0.2345678120777435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079335457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890981,0.005344154,0.0007519713,0.00014655867,0.00037811036,0.0027995207,0.00075664575,0.00019720144,0.000527764],"genre_scores_gemma":[0.9897116,0.0040619113,0.0025939995,0.0010954506,0.0002688739,0.0012353647,0.00035686762,0.0001200836,0.00055588235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99566615,0.00008960748,0.0009885277,0.001526915,0.00049674144,0.0012320329],"domain_scores_gemma":[0.996588,0.0009642381,0.00075942563,0.0006757212,0.00024899142,0.0007636494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029298896,0.0010730571,0.0014132964,0.00035376466,0.0006359656,0.00019773885,0.00024630193,0.0006900925,0.000048124686],"category_scores_gemma":[0.00012790672,0.00091768766,0.0004954483,0.00032580405,0.00033843424,0.00042812963,0.000056068322,0.000086478976,0.000012363815],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016454836,0.0014827467,0.22497743,0.004267514,0.001530822,0.002419625,0.018464724,0.00017153416,0.0057228482,0.00069007557,0.006219597,0.71759826],"study_design_scores_gemma":[0.047482856,0.0027308501,0.8782822,0.00084140856,0.0022146264,0.0018657309,0.0009448188,0.0038566994,0.05576242,0.0010859106,0.0035931352,0.0013393539],"about_ca_topic_score_codex":0.0014960513,"about_ca_topic_score_gemma":0.00031946247,"teacher_disagreement_score":0.7162589,"about_ca_system_score_codex":0.0063212863,"about_ca_system_score_gemma":0.0028171623,"threshold_uncertainty_score":0.99932736},"labels":[],"label_agreement":null},{"id":"W2079909815","doi":"10.3109/10428194.2015.1061189","title":"Co-existent B-cell and plasma cell neoplasms: a case series providing novel clinical insight","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Plasma cell; Concomitant; Multiple myeloma; Medicine; Plasma Cell Myeloma; B cell; Amyloidosis; Group B; Plasma cell leukemia; Lymphocytosis; Chronic lymphocytic leukemia; Monoclonal; Bortezomib; Internal medicine; Pathology; Monoclonal antibody; Antibody; Immunology; Leukemia","score_opus":0.025561715507290264,"score_gpt":0.27568026052508066,"score_spread":0.2501185450177904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079909815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988552,0.004152653,0.000098450226,0.00015120146,0.0005049192,0.00072127994,0.0001398464,0.0001234327,0.005556238],"genre_scores_gemma":[0.98896444,0.0026055435,0.0028701548,0.0011644149,0.0004912281,0.00021743187,0.00023138094,0.00015416412,0.003301265],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957379,0.0002301451,0.0010542664,0.0015823675,0.0004321907,0.0009631117],"domain_scores_gemma":[0.99712414,0.00022258684,0.00047535583,0.00093790836,0.00019010007,0.0010499377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005386153,0.0009290492,0.00092020654,0.00016672244,0.00043933297,0.00026465187,0.00037691314,0.0008887038,0.000010377344],"category_scores_gemma":[0.00023113504,0.00085424085,0.00031116934,0.00022847319,0.0006431701,0.00007752014,0.00046394352,0.00015391318,0.000054838332],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008682912,0.005698531,0.49653068,0.0017683294,0.0024372388,0.016237816,0.009109139,0.0004413397,0.22355796,0.0011354423,0.077025324,0.15737528],"study_design_scores_gemma":[0.06918597,0.0042700907,0.01239417,0.00019216049,0.0008792913,0.03247457,0.0056945905,0.0022224295,0.4677911,0.00008733559,0.4015875,0.0032207984],"about_ca_topic_score_codex":0.00071681954,"about_ca_topic_score_gemma":0.00025433605,"teacher_disagreement_score":0.48413652,"about_ca_system_score_codex":0.0016233581,"about_ca_system_score_gemma":0.002917149,"threshold_uncertainty_score":0.99939084},"labels":[],"label_agreement":null},{"id":"W2080392453","doi":"10.3109/10428190009065824","title":"TALE Homeoproteins as HOX11-Interacting Partners in T-cell Leukemia","year":2000,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Canadian Blood Services; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Leukemia; Cancer research; Medicine; Chemistry; Biology; Genetics","score_opus":0.017937619855348606,"score_gpt":0.28701320237827754,"score_spread":0.26907558252292896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080392453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07977419,0.8831244,0.0000138224705,0.000013090538,0.0005835493,0.001987895,0.00021109953,0.00016198262,0.034129977],"genre_scores_gemma":[0.017876722,0.96862966,0.0003770966,0.0005065296,0.0012727443,0.0009779751,0.0016061575,0.0004770988,0.008276015],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915724,0.0006986136,0.0020932376,0.002873417,0.0007147005,0.0020476324],"domain_scores_gemma":[0.9958783,0.00025768141,0.0010572538,0.0018848043,0.00011431043,0.0008076712],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00079393596,0.002216809,0.0031352977,0.0006905251,0.00046106495,0.00039735844,0.0014272585,0.0026177005,0.00028084058],"category_scores_gemma":[0.00023807639,0.0021588677,0.0012467338,0.00089368835,0.00045671844,0.00006350737,0.00076955813,0.0006457605,0.0006501371],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00026883098,0.00014735536,0.00003516795,0.0052762944,0.00024720933,0.0005486915,0.00025296342,0.000029192437,0.0007073642,0.00007430055,0.0027495257,0.9896631],"study_design_scores_gemma":[0.0051675607,0.0005111398,0.000037804224,0.005883745,0.0004279962,0.0018055874,0.00019243745,0.00013570132,0.0043987683,0.000080950624,0.97889006,0.0024682488],"about_ca_topic_score_codex":0.0017403901,"about_ca_topic_score_gemma":0.00022416434,"teacher_disagreement_score":0.98719484,"about_ca_system_score_codex":0.005685594,"about_ca_system_score_gemma":0.010939303,"threshold_uncertainty_score":0.9990572},"labels":[],"label_agreement":null},{"id":"W2080486808","doi":"10.1080/10428190400019867","title":"Bcl-2 and c-Myc co-operate in the Epstein – Barr virus-immortalized human B-cell line GM607 but do not confer tumorigenicity","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Immortalised cell line; Biology; Lymphoblast; Cancer research; Cell culture; Neoplastic transformation; Epstein–Barr virus; Oncogene; Transformation (genetics); Virus; Lymphoma; Malignant transformation; Cell growth; Virology; Carcinogenesis; Cell; Cancer; Immunology; Cell cycle; Genetics; Gene","score_opus":0.012855520724554625,"score_gpt":0.24607210437897276,"score_spread":0.23321658365441814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080486808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98263556,0.0050791437,0.000030476578,0.00032105568,0.0010318516,0.0006205732,0.000046736248,0.00014935686,0.01008525],"genre_scores_gemma":[0.97625315,0.0013029627,0.000034937235,0.0037290165,0.0002934268,0.000113137634,0.0003636511,0.00007192482,0.01783781],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961321,0.00067382376,0.0010972621,0.0009826598,0.00018349662,0.00093071064],"domain_scores_gemma":[0.9983539,0.00030599383,0.00034763064,0.000757403,0.00012015554,0.00011491817],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008394229,0.00073992007,0.000841809,0.00032021146,0.00087637355,0.00025202765,0.000505243,0.0007178943,0.0011902632],"category_scores_gemma":[0.00005494324,0.00058270973,0.00022561244,0.00028149673,0.0005711288,0.00050925947,0.00016660156,0.00043325688,0.0008660266],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017852566,0.00052710786,0.0023290464,0.00009685527,0.00022992762,0.00011164579,0.004087817,0.00004283698,0.9443391,0.0016045735,0.018352915,0.026492897],"study_design_scores_gemma":[0.02619594,0.0005577766,0.039947145,0.00011819316,0.00018111613,0.0014018198,0.0029095951,0.00046537656,0.40493804,0.00005686417,0.52213776,0.0010903637],"about_ca_topic_score_codex":0.00332562,"about_ca_topic_score_gemma":0.0004158521,"teacher_disagreement_score":0.5394011,"about_ca_system_score_codex":0.0016283395,"about_ca_system_score_gemma":0.0006832563,"threshold_uncertainty_score":0.9999119},"labels":[],"label_agreement":null},{"id":"W2080925567","doi":"10.3109/10428190109057962","title":"Fludarabine in Alkylator-Resistant Follicular Non-Hodgkin's Lymphoma","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canadian Blood Services; Sunnybrook Health Science Centre; Western University","funders":"","keywords":"Fludarabine; Medicine; Chemotherapy; Transplantation; Follicular lymphoma; Salvage therapy; Oncology; Internal medicine; Surgery; Lymphoma; Cyclophosphamide","score_opus":0.009063964940791711,"score_gpt":0.24025947942153852,"score_spread":0.23119551448074682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080925567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742824,0.006750056,0.000056321132,0.0008134749,0.00058105687,0.0016417705,0.000060949547,0.00042261838,0.01539139],"genre_scores_gemma":[0.98797697,0.0041122246,0.001036761,0.0026001385,0.0006388371,0.00061136653,0.00026458743,0.00025919062,0.0024999187],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99213856,0.0002039195,0.0018108753,0.0022389984,0.0013913721,0.0022162735],"domain_scores_gemma":[0.9956152,0.00037990802,0.0004814207,0.0018710287,0.00027036865,0.0013820803],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00066317635,0.0016098856,0.0022651504,0.00095885247,0.00053889194,0.0002877117,0.00058389636,0.0009997081,0.00026855746],"category_scores_gemma":[0.00017236901,0.0014269168,0.00075993704,0.0017788057,0.0005087008,0.00059960264,0.00039337945,0.0001746998,0.00042108743],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007345272,0.0040429165,0.30531463,0.00066103437,0.0014555324,0.027816776,0.0017610282,0.00013292799,0.015541235,0.0034069235,0.010030354,0.62249136],"study_design_scores_gemma":[0.06502645,0.0011066082,0.79573524,0.0009762964,0.00067584787,0.0049499837,0.00054597744,0.0039535854,0.010086822,0.0005184654,0.114737555,0.0016871596],"about_ca_topic_score_codex":0.0065644626,"about_ca_topic_score_gemma":0.0005128073,"teacher_disagreement_score":0.6208042,"about_ca_system_score_codex":0.016156746,"about_ca_system_score_gemma":0.004234705,"threshold_uncertainty_score":0.9996649},"labels":[],"label_agreement":null},{"id":"W2085000409","doi":"10.1080/10428190601043138","title":"Overexpression of SOCS-2 and SOCS-3 genes reverses erythroid overgrowth and IGF-I hypersensitivity of primary polycythemia vera (PV) cells","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Polycythemia vera; Haematopoiesis; Progenitor cell; Myeloid; Biology; Immunology; Cancer research; Peripheral blood mononuclear cell; Population; Cytokine; Stem cell; Cell biology; Medicine; Genetics; In vitro","score_opus":0.009433284318129924,"score_gpt":0.22828275624695313,"score_spread":0.2188494719288232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085000409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883422,0.0062643974,0.00004535653,0.00012404445,0.0001530625,0.00065015326,0.00012501466,0.00006531366,0.0042304373],"genre_scores_gemma":[0.98959315,0.007013263,0.0019633188,0.0007303033,0.00020643714,0.000023023935,0.000059571397,0.00007615765,0.0003348005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967571,0.00011289429,0.0008869478,0.00091726787,0.0006544938,0.0006713356],"domain_scores_gemma":[0.99748003,0.000758289,0.00050836435,0.0005495606,0.00020074526,0.0005030147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004714662,0.00067842944,0.0014260103,0.00028475828,0.0002581879,0.000039955186,0.000107220134,0.00047980144,0.00003227407],"category_scores_gemma":[0.000080537975,0.0005731662,0.00022453268,0.00028395126,0.00074774737,0.00028194374,0.0002671235,0.00012818167,0.0000045837396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005363237,0.0007339166,0.08730246,0.0017695364,0.00066434033,0.0004369154,0.002026378,0.0000065972667,0.73077685,0.001005924,0.0015218671,0.16839199],"study_design_scores_gemma":[0.013849957,0.000883259,0.4535928,0.000928005,0.00042302316,0.0008803317,0.0006004392,0.0002087897,0.52531165,0.00013507248,0.002696363,0.000490316],"about_ca_topic_score_codex":0.0013619126,"about_ca_topic_score_gemma":0.000047494672,"teacher_disagreement_score":0.36629036,"about_ca_system_score_codex":0.0019767287,"about_ca_system_score_gemma":0.0014498928,"threshold_uncertainty_score":0.999672},"labels":[],"label_agreement":null},{"id":"W2085950913","doi":"10.1080/10428190500102555","title":"Troglitazone overcomes doxorubicin-resistance in resistant K562 leukemia cells","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Canadian Institutes of Health Research","keywords":"Troglitazone; K562 cells; Doxorubicin; Leukemia; Cancer research; Resistance (ecology); Medicine; Biology; Internal medicine; Chemotherapy; Receptor","score_opus":0.008235208502196396,"score_gpt":0.23514582218768065,"score_spread":0.22691061368548426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2085950913","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561493,0.0038476912,0.000084789506,0.0012947809,0.0001363736,0.0006448516,0.00010442588,0.0004014747,0.037336335],"genre_scores_gemma":[0.9716163,0.0010516215,0.0032941934,0.0049198954,0.00075042254,0.00011692806,0.00015879459,0.00016088007,0.017930957],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935751,0.00023337046,0.001732979,0.0016578294,0.0011884057,0.0016123094],"domain_scores_gemma":[0.99663913,0.0003386908,0.00045939392,0.0013505719,0.00022581888,0.0009863788],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007022366,0.0010906309,0.0017594656,0.0009944589,0.00042197618,0.00021094776,0.00044526925,0.0007281969,0.0004986733],"category_scores_gemma":[0.00015665378,0.0010259285,0.0006455515,0.0015150191,0.0005509179,0.0006411091,0.00022023272,0.00036233698,0.00041314025],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013610944,0.002666619,0.015879149,0.0028644635,0.0017241274,0.00843706,0.0077703595,0.001039702,0.595503,0.031670526,0.09866365,0.22017045],"study_design_scores_gemma":[0.09109346,0.0009539352,0.21192935,0.006449968,0.0012928833,0.00130665,0.0031561614,0.014771943,0.19827741,0.0030043619,0.46278694,0.0049769282],"about_ca_topic_score_codex":0.0016606594,"about_ca_topic_score_gemma":0.0021564327,"teacher_disagreement_score":0.39722553,"about_ca_system_score_codex":0.018588006,"about_ca_system_score_gemma":0.0036699832,"threshold_uncertainty_score":0.9992191},"labels":[],"label_agreement":null},{"id":"W2088824526","doi":"10.1080/10428190802353617","title":"Catalase activity and arsenic sensitivity in acute leukemia","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Catalase; Acute promyelocytic leukemia; Arsenic trioxide; Myeloid leukemia; Reactive oxygen species; Leukemia; Chemistry; Glutathione peroxidase; Cancer research; Glutathione; Apoptosis; Immunology; Biochemistry; Biology; Enzyme","score_opus":0.007209639999661714,"score_gpt":0.21852901100757016,"score_spread":0.21131937100790846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088824526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99350756,0.0030076255,0.00034031578,0.00007218164,0.0002812135,0.00047114753,0.00006628251,0.000112001355,0.0021416908],"genre_scores_gemma":[0.9890609,0.0069820713,0.0005449943,0.00062121183,0.00037753762,0.00009497804,0.00019718501,0.0001317674,0.0019894037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955699,0.00028267663,0.0006899291,0.0017552837,0.0005074764,0.0011947735],"domain_scores_gemma":[0.9978261,0.00013464264,0.00031292427,0.0010386178,0.00014043984,0.0005472963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005559975,0.0009414391,0.0008961495,0.00027070192,0.00056576956,0.00011662457,0.00037805203,0.0009486796,0.000014549631],"category_scores_gemma":[0.0001692898,0.00095902727,0.00024132383,0.00050454657,0.0010195383,0.000089514804,0.0006106333,0.00027093742,0.000032905053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018085863,0.0002806463,0.057140063,0.0003777383,0.0004427804,0.0034655498,0.0011022496,0.00023473566,0.8454903,0.000285348,0.0032706235,0.08610141],"study_design_scores_gemma":[0.015895683,0.0006939968,0.32196927,0.00019716097,0.00024370523,0.01336533,0.000350635,0.0050189155,0.62070584,0.00030825628,0.018691014,0.0025601718],"about_ca_topic_score_codex":0.0018056872,"about_ca_topic_score_gemma":0.00047693274,"teacher_disagreement_score":0.2648292,"about_ca_system_score_codex":0.0023168353,"about_ca_system_score_gemma":0.003802287,"threshold_uncertainty_score":0.999286},"labels":[],"label_agreement":null},{"id":"W2088941610","doi":"10.1080/10428190802023715","title":"Targeting the follicular lymphoma microenvironment – Ready for prime-time?","year":2008,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Follicular lymphoma; Prime time; Lymphoma; Medicine; Prime (order theory); Cancer research; Oncology; Follicular phase; Internal medicine; Computer science","score_opus":0.02287477505465715,"score_gpt":0.27518199615586886,"score_spread":0.25230722110121173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2088941610","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005905099,0.98274785,0.00005527996,0.00019672637,0.000714431,0.007679807,0.0005754544,0.00043867776,0.001686667],"genre_scores_gemma":[0.00064823765,0.9808669,0.0016150316,0.0013274676,0.0016554984,0.0042907894,0.0032488406,0.00068371627,0.0056635137],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98950356,0.00051807624,0.00294407,0.0031071203,0.0014295294,0.0024976553],"domain_scores_gemma":[0.9924082,0.0016817794,0.0017368903,0.0027899027,0.00023138961,0.0011518165],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00072040316,0.0031474405,0.0062905685,0.00056674704,0.0017106908,0.00035186583,0.0011470189,0.0019696082,0.00011621925],"category_scores_gemma":[0.00027655135,0.0021219628,0.0029890744,0.0008311624,0.000962625,0.000302029,0.0007108839,0.00026690867,0.00084725063],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0003105284,0.0008303621,0.00009096099,0.005240575,0.0028516287,0.001114128,0.0003013945,0.000005737033,0.000043641605,0.00023311628,0.03876007,0.95021784],"study_design_scores_gemma":[0.017681409,0.00074340636,0.0006769807,0.007230982,0.0069038314,0.009735879,0.00010407879,0.00047510152,0.00026886162,0.00004721509,0.9540961,0.0020361575],"about_ca_topic_score_codex":0.00072958716,"about_ca_topic_score_gemma":0.000007803848,"teacher_disagreement_score":0.9481817,"about_ca_system_score_codex":0.024048176,"about_ca_system_score_gemma":0.009111144,"threshold_uncertainty_score":0.9999307},"labels":[],"label_agreement":null},{"id":"W2090218255","doi":"10.3109/10428194.2013.878934","title":"Initial transfusion intensity predicts survival in myelodysplastic syndrome","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Aplastic Anemia and Myelodysplasia Association of Canada; Celgene","keywords":"Medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Internal medicine; Blood transfusion; Overall survival; Myeloid leukemia; Myeloid; Leukemia; Gastroenterology; Surgery; Bone marrow","score_opus":0.0135262473141188,"score_gpt":0.2563653017870442,"score_spread":0.2428390544729254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090218255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98500264,0.00035219462,0.0007471733,0.00049637875,0.00088635506,0.0011356138,0.000041596475,0.00043587235,0.010902179],"genre_scores_gemma":[0.9949294,0.0006402493,0.00062715856,0.0014654137,0.0006318063,0.00013736426,0.00019483312,0.00020048936,0.0011733094],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9932367,0.00044648707,0.0013219111,0.0017072051,0.0014300866,0.0018575765],"domain_scores_gemma":[0.99610484,0.0009037435,0.00023596821,0.0012102626,0.00033321904,0.0012119841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001459027,0.0010209652,0.0018693333,0.0010084787,0.00040600327,0.00015947696,0.0005915351,0.0010239355,0.00017937954],"category_scores_gemma":[0.00089594064,0.00095424353,0.00034399217,0.0013272587,0.0008057126,0.0005054229,0.00044449032,0.0006348457,0.00028299706],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024774136,0.0019741978,0.23780346,0.0038058225,0.0012292356,0.020223074,0.0062379274,0.00047194934,0.042620435,0.006059283,0.008569815,0.64623064],"study_design_scores_gemma":[0.050094455,0.0020614213,0.86995876,0.0011784816,0.00037670284,0.012224981,0.00074373273,0.044676263,0.0046739164,0.0008832943,0.01162589,0.0015020941],"about_ca_topic_score_codex":0.0035576692,"about_ca_topic_score_gemma":0.00036479393,"teacher_disagreement_score":0.64472854,"about_ca_system_score_codex":0.010335633,"about_ca_system_score_gemma":0.004550032,"threshold_uncertainty_score":0.9992908},"labels":[],"label_agreement":null},{"id":"W2090784428","doi":"10.1080/10428190500158797","title":"Cyclin D expression in chronic lymphocytic leukemia","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; University of Manitoba","funders":"University of Manitoba; Leukemia and Lymphoma Society","keywords":"Cyclin D2; Cyclin D1; Cyclin D3; Chronic lymphocytic leukemia; Biology; Cyclin B; Cyclin D; Cyclin; Cancer research; Cyclin A2; Cell cycle; Cyclin A; Molecular biology; Immunology; Leukemia; Cell; Genetics","score_opus":0.014543074738468446,"score_gpt":0.2814525180491777,"score_spread":0.26690944331070926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090784428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696547,0.010454503,0.00018653301,0.00030342446,0.00048328866,0.0019414064,0.000040785577,0.00080512505,0.016130272],"genre_scores_gemma":[0.97939306,0.0042848787,0.0027214063,0.0022212507,0.002225887,0.000491922,0.0002085354,0.00041328275,0.008039788],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98854095,0.00040644026,0.0024734195,0.0028795486,0.002265969,0.0034336932],"domain_scores_gemma":[0.99382395,0.00085475226,0.0005666613,0.00261107,0.00032193455,0.0018216069],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013845286,0.0017570269,0.0023663214,0.0015075976,0.0006076231,0.0003355443,0.0011582633,0.0016294792,0.00064862496],"category_scores_gemma":[0.00053009397,0.0016532054,0.0006753823,0.002017603,0.0011085006,0.0011529331,0.0009943078,0.0006904586,0.0013317683],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008172656,0.00063805317,0.0046402197,0.0033615162,0.0007526203,0.008415884,0.0046989755,0.016981041,0.12224559,0.00221889,0.029204791,0.79866976],"study_design_scores_gemma":[0.19596533,0.0013328729,0.035617627,0.0034037263,0.0004710633,0.0109074265,0.00080505473,0.47103012,0.10493974,0.00059462426,0.17151032,0.003422096],"about_ca_topic_score_codex":0.0068882867,"about_ca_topic_score_gemma":0.0009853515,"teacher_disagreement_score":0.7952477,"about_ca_system_score_codex":0.601335,"about_ca_system_score_gemma":0.15290149,"threshold_uncertainty_score":0.9997249},"labels":[],"label_agreement":null},{"id":"W2092467128","doi":"10.1080/10428190601043278","title":"What is the role of rituximab in salvage treatment for patients with diffuse large B-cell lymphoma?","year":2006,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Rituximab; Diffuse large B-cell lymphoma; Salvage therapy; Lymphoma; Medicine; Internal medicine; Ibrutinib; Oncology; Cancer research; Leukemia; Chronic lymphocytic leukemia; Chemotherapy","score_opus":0.005676256751926217,"score_gpt":0.213364026246244,"score_spread":0.2076877694943178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092467128","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9612464,0.016871402,0.000008007144,0.011952396,0.0006219285,0.005673136,0.001688247,0.00017700695,0.0017615105],"genre_scores_gemma":[0.8811459,0.005650148,0.0005428907,0.09568945,0.0015967861,0.0033546058,0.0063400934,0.0006788486,0.0050012534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919515,0.000244505,0.0018331289,0.0022848865,0.0014977774,0.002188156],"domain_scores_gemma":[0.994609,0.0010989736,0.0011866287,0.0022799617,0.00042897373,0.00039643477],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0002927154,0.0022463966,0.0032038444,0.00072380516,0.00048015357,0.00039048327,0.00069167657,0.0020131567,0.000049569873],"category_scores_gemma":[0.00003153573,0.0014627123,0.001109052,0.00072407234,0.00055532926,0.00056011666,0.00026236178,0.00027491583,0.00006535568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006478026,0.0625572,0.15732828,0.0033804434,0.0038012832,0.0031607582,0.0050744307,0.000008417105,0.000102942686,0.00035012368,0.3634177,0.39434037],"study_design_scores_gemma":[0.26916,0.0026763745,0.08177685,0.0017304447,0.002550496,0.00018914265,0.0005861761,0.0005153935,0.0036971034,0.00035799594,0.6351425,0.0016175343],"about_ca_topic_score_codex":0.0046651685,"about_ca_topic_score_gemma":0.00033724392,"teacher_disagreement_score":0.39272285,"about_ca_system_score_codex":0.01657285,"about_ca_system_score_gemma":0.004281976,"threshold_uncertainty_score":0.9992824},"labels":[],"label_agreement":null},{"id":"W2092568922","doi":"10.1080/10428190902912478","title":"Early stage gastric diffuse large B-cell lymphomas: results of a randomised trial comparing chemotherapy alone<i>versus</i>chemotherapy + involved field radiotherapy","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Chemotherapy; Stage (stratigraphy); Internal medicine; Radiation therapy; Induction chemotherapy; Lymphoma; Anthracycline; Clinical trial; Gastroenterology; Incidence (geometry); Oncology; Radiology; Cancer","score_opus":0.014246067083915251,"score_gpt":0.2543617198471192,"score_spread":0.24011565276320396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092568922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848682,0.0036776953,0.00025214357,0.00063004263,0.000614136,0.0034269488,0.00011714176,0.00040185958,0.0060118036],"genre_scores_gemma":[0.9836308,0.006995981,0.0021918924,0.0042854524,0.00071352924,0.00024659288,0.00022932675,0.00018194514,0.0015244941],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927428,0.0003100088,0.0022358163,0.0017448519,0.0012773088,0.0016892232],"domain_scores_gemma":[0.9947169,0.0010962178,0.0011667174,0.0017803678,0.00026866412,0.0009711486],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00083728676,0.0014667496,0.0029356095,0.00067308446,0.00043999992,0.00023161841,0.00063488464,0.00088912813,0.00011842334],"category_scores_gemma":[0.0001865588,0.0012798049,0.0011139654,0.0010597893,0.00028186903,0.00044015338,0.000103855404,0.00022118689,0.000026470228],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8211003,0.01216235,0.010461036,0.00030466504,0.0016256057,0.00062235346,0.004181681,0.000022390495,0.00963794,0.0005378551,0.007815876,0.13152798],"study_design_scores_gemma":[0.88100207,0.0075271106,0.050393306,0.00034566858,0.00054124906,0.00011748023,0.0003849824,0.0025318959,0.040859804,0.00007738432,0.015089606,0.0011294694],"about_ca_topic_score_codex":0.0020305887,"about_ca_topic_score_gemma":0.00007459455,"teacher_disagreement_score":0.13039851,"about_ca_system_score_codex":0.0055098496,"about_ca_system_score_gemma":0.0026288105,"threshold_uncertainty_score":0.9998082},"labels":[],"label_agreement":null},{"id":"W2093350079","doi":"10.1080/10428190601071717","title":"Zidovudine and interferon-α treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"T-cell and Retrovirus Studies","field":"Immunology and Microbiology","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"","keywords":"Zidovudine; Medicine; Immunology; Leukemia; Chemotherapy; Adult T-cell leukemia/lymphoma; Immunosuppression; Human T-lymphotropic virus 1; Virology; Internal medicine; Virus; T-cell leukemia; Viral disease","score_opus":0.008662121771244423,"score_gpt":0.19467052715843247,"score_spread":0.18600840538718805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093350079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930323,0.0049640043,0.000004875974,0.000079807854,0.00037318474,0.00081835064,0.00033547843,0.00011909562,0.00027290775],"genre_scores_gemma":[0.9969347,0.0010246785,0.00016328669,0.0002265252,0.00009521854,0.00007480527,0.00016824258,0.00008643453,0.0012260898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583113,0.00044345035,0.0008888846,0.0014872979,0.00018602314,0.00116321],"domain_scores_gemma":[0.9980588,0.0006746652,0.00040994416,0.00044951297,0.00015928122,0.00024778472],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005015154,0.0010645762,0.001222145,0.00039433222,0.0006469564,0.0001404131,0.00025174854,0.0006929274,0.000016701104],"category_scores_gemma":[0.00010467705,0.0007969868,0.000085037515,0.00034833743,0.0013064144,0.0003971261,0.0003772862,0.00026301757,0.000026756647],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05799694,0.000864642,0.5179162,0.00023932129,0.0012860956,0.00042824316,0.019629138,0.000011476495,0.17909302,0.00006894179,0.00038135037,0.22208461],"study_design_scores_gemma":[0.04440317,0.0032849421,0.9002762,0.00028037775,0.00024329705,0.00012904772,0.0020650413,0.000030080195,0.04690155,0.000037139234,0.0013568796,0.0009923106],"about_ca_topic_score_codex":0.00900428,"about_ca_topic_score_gemma":0.0040461286,"teacher_disagreement_score":0.38235995,"about_ca_system_score_codex":0.003780269,"about_ca_system_score_gemma":0.0011985989,"threshold_uncertainty_score":0.9994481},"labels":[],"label_agreement":null},{"id":"W2093514907","doi":"10.1080/1042819031000067918","title":"Intermediate Dose Thalidomide (200 mg Daily) has Comparable Efficacy and Less Toxicity than Higher Doses in Relapsed Multiple Myeloma","year":2003,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Thalidomide; Discontinuation; Medicine; Multiple myeloma; Toxicity; Internal medicine; Gastroenterology; Retrospective cohort study","score_opus":0.0664127587477917,"score_gpt":0.3197220966819115,"score_spread":0.2533093379341198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093514907","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39041427,0.60392225,0.000004076247,0.000038293787,0.0004953695,0.0027517872,0.00019528755,0.00020538687,0.0019732995],"genre_scores_gemma":[0.18957849,0.80290616,0.0003692954,0.00029155056,0.00040711142,0.0007278703,0.00083542854,0.00036886527,0.0045152465],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901141,0.0010576317,0.002349383,0.0027239549,0.0012417373,0.0025131889],"domain_scores_gemma":[0.9933341,0.001909366,0.0008899004,0.001855102,0.00018981473,0.0018216852],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008795096,0.0024138424,0.006085051,0.0013147447,0.0006410774,0.0005201113,0.000764904,0.0017837248,0.00016257678],"category_scores_gemma":[0.0004951051,0.0019510885,0.00085040316,0.0013622784,0.0012372256,0.00037393798,0.0006398163,0.0008292434,0.00023675672],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0027320925,0.0011066035,0.0100340415,0.012174394,0.0014354126,0.004924709,0.00046552703,0.0000045289203,0.000058674577,0.00012461747,0.0023820393,0.96455735],"study_design_scores_gemma":[0.09875655,0.0010713043,0.118548244,0.022839949,0.0022813994,0.003520748,0.0002576343,0.0007740037,0.00017263915,0.000092135015,0.74891716,0.0027682083],"about_ca_topic_score_codex":0.0035742864,"about_ca_topic_score_gemma":0.0006193763,"teacher_disagreement_score":0.96178913,"about_ca_system_score_codex":0.01076538,"about_ca_system_score_gemma":0.0070498213,"threshold_uncertainty_score":0.9995122},"labels":[],"label_agreement":null},{"id":"W2094252783","doi":"10.3109/10428194.2013.827785","title":"Preservation of lower incidence of chronic lymphocytic leukemia in Chinese residents in British Columbia: a 26-year survey from 1983 to 2008","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Chronic lymphocytic leukemia; Incidence (geometry); Demography; Medicine; Cancer registry; Cancer incidence; Population; Standardized rate; Chinese population; Leukemia; Internal medicine; Biology; Genetics","score_opus":0.010671169226739606,"score_gpt":0.2565736229097232,"score_spread":0.24590245368298358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094252783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928959,0.0027340525,0.000034685818,0.000042246902,0.0003725627,0.0029358505,0.00020100383,0.00015275496,0.0006309323],"genre_scores_gemma":[0.99446154,0.0015106708,0.00067183375,0.0003814943,0.00026853316,0.00048144258,0.0002418268,0.00025077572,0.0017318648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.990475,0.00064077944,0.0029343632,0.0019602475,0.0021406922,0.0018489148],"domain_scores_gemma":[0.99389195,0.0015529982,0.0007580868,0.001979066,0.00086923747,0.0009486722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016661107,0.0008417891,0.002514012,0.000949552,0.00016128259,0.00032076752,0.0012214427,0.0010489476,0.00065356726],"category_scores_gemma":[0.0027125399,0.00109196,0.00033840875,0.0036152252,0.00077488454,0.0012386456,0.0010216346,0.0004017269,0.00020941626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0031004313,0.0005338718,0.9254373,0.0019023283,0.0003723374,0.0019530883,0.0017132901,0.0032716691,0.014251868,0.00002127624,0.010361146,0.037081398],"study_design_scores_gemma":[0.05202496,0.0008655942,0.88259876,0.0029084347,0.000078502286,0.00048372868,0.00027728945,0.057899684,0.0013707726,0.00047335515,0.00017277492,0.00084616954],"about_ca_topic_score_codex":0.91845345,"about_ca_topic_score_gemma":0.4907937,"teacher_disagreement_score":0.42765975,"about_ca_system_score_codex":0.2358126,"about_ca_system_score_gemma":0.08552586,"threshold_uncertainty_score":0.9991531},"labels":[],"label_agreement":null},{"id":"W2094394948","doi":"10.1080/10428190701824544","title":"Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Microtubule and mitosis dynamics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Aurora inhibitor; Aurora A kinase; Aurora kinase; Centrosome; Kinase; Cancer research; Multiple myeloma; Programmed cell death; Apoptosis; Cell biology; Biology; Cell cycle; Immunology; Genetics","score_opus":0.011075464239785416,"score_gpt":0.19913231274955057,"score_spread":0.18805684850976515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2094394948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969055,0.0015993769,0.00033108902,0.000023259186,0.00009151136,0.000547364,0.00006821941,0.00004145656,0.00039221346],"genre_scores_gemma":[0.9957354,0.0015793142,0.0014952979,0.0004150133,0.00011359756,0.000081052494,0.00021225603,0.00009879446,0.00026925685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972366,0.00013835376,0.0006390597,0.0010151432,0.00026686423,0.0007039918],"domain_scores_gemma":[0.99854785,0.00006627385,0.0003061589,0.0006334791,0.00014471957,0.00030153975],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017191356,0.0006185416,0.00062480546,0.0002587382,0.0002316252,0.000050096507,0.00024720316,0.00052701647,0.0000057188445],"category_scores_gemma":[0.00007112103,0.0005947218,0.00013166558,0.00036012867,0.0004564948,0.000035813504,0.00027279826,0.0001243999,0.0000055408386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010071831,0.00031013534,0.0150227975,0.00024723247,0.00010570976,0.00047264702,0.0005703147,0.00016018556,0.9729104,0.00013056313,0.00024417634,0.008818628],"study_design_scores_gemma":[0.0128761055,0.0010132625,0.07016984,0.00030409504,0.00010366067,0.0010021303,0.0003201124,0.002224169,0.9092835,0.00004947369,0.0016793832,0.0009742652],"about_ca_topic_score_codex":0.0011810061,"about_ca_topic_score_gemma":0.0005306918,"teacher_disagreement_score":0.06362692,"about_ca_system_score_codex":0.0005958856,"about_ca_system_score_gemma":0.0012663999,"threshold_uncertainty_score":0.9996504},"labels":[],"label_agreement":null},{"id":"W2095058829","doi":"10.1080/10428190500062932","title":"Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendations","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":125,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Medicine; Hepatitis B; HBsAg; Lamivudine; Hepatitis B virus; Rituximab; Chemotherapy; Vincristine; Immunology; Hepatitis; Internal medicine; Lymphoma; Gastroenterology; Cyclophosphamide; Virus","score_opus":0.011375562699313314,"score_gpt":0.27604664583183325,"score_spread":0.2646710831325199,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095058829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981406,0.0010230991,0.0039956,0.0027294478,0.00046917854,0.004845417,0.00493435,0.00019246674,0.00040447855],"genre_scores_gemma":[0.96005565,0.00951343,0.023594374,0.0014836332,0.0006198959,0.00096783903,0.0033144904,0.0002072516,0.0002434598],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99500513,0.00016498585,0.0017531858,0.0013942827,0.00056128914,0.0011211511],"domain_scores_gemma":[0.9955126,0.0007825772,0.0009770348,0.00084474497,0.0014988941,0.00038415706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003682632,0.0009357801,0.0015253142,0.00059119763,0.0007827989,0.00010519511,0.00033763156,0.0006920401,0.000048311325],"category_scores_gemma":[0.00046784704,0.00096891803,0.0005204483,0.0010304514,0.00047891896,0.0008515971,0.00016309625,0.00015704054,0.000011449262],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024426102,0.0011229945,0.34752193,0.0005575844,0.0007084915,0.000036166224,0.0064153303,0.000076837736,0.04603453,0.0021014295,0.003222735,0.58975935],"study_design_scores_gemma":[0.019125644,0.0025034137,0.92116576,0.00067577005,0.00023340365,0.00030908248,0.00053719163,0.0052410425,0.036226105,0.0007654001,0.012176205,0.0010409687],"about_ca_topic_score_codex":0.032985818,"about_ca_topic_score_gemma":0.012043004,"teacher_disagreement_score":0.5887184,"about_ca_system_score_codex":0.0055720014,"about_ca_system_score_gemma":0.0025574844,"threshold_uncertainty_score":0.9992761},"labels":[],"label_agreement":null},{"id":"W2095225241","doi":"10.3109/10428190309178811","title":"Cost-effectiveness of a Transplantation Strategy Compared to Melphalan and Prednisone in Younger Patients with Multiple Myeloma","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; Hamilton Health Sciences; Hamilton Regional Laboratory Medicine Program; Cancer Care Ontario; McMaster University","funders":"Hamilton Health Sciences","keywords":"Melphalan; Medicine; Prednisone; Multiple myeloma; Autologous stem-cell transplantation; Transplantation; Internal medicine; Cost effectiveness; Surgery; Oncology","score_opus":0.022135308889808858,"score_gpt":0.2778753257788484,"score_spread":0.2557400168890395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095225241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99533916,0.00039666242,0.00018735876,0.000010668389,0.000046603694,0.0027489415,0.00014236353,0.000053052747,0.00107519],"genre_scores_gemma":[0.99800205,0.00016981339,0.00092334737,0.00007186787,0.00001750621,0.00037454214,0.0003058611,0.00006318001,0.000071805945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970608,0.00033058703,0.0005341075,0.0007663617,0.0006064374,0.0007017364],"domain_scores_gemma":[0.9982169,0.00043935355,0.00013883189,0.0003938501,0.00021689617,0.0005941289],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035438503,0.00048768643,0.0008767469,0.00040722432,0.00012983702,0.000052362873,0.000112402966,0.00021959633,0.000020243788],"category_scores_gemma":[0.00012223869,0.00039824014,0.000075370706,0.00056300184,0.00021266205,0.00029700834,0.000036723624,0.000092095244,0.0000090340345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015016923,0.00079186325,0.923858,0.0010665108,0.00029994114,0.00041089716,0.0010361901,0.00017608919,0.0045214947,0.00028908177,0.000016569635,0.052516453],"study_design_scores_gemma":[0.065824136,0.0011514392,0.9157846,0.0006912379,0.00014497386,0.00023110828,0.00028317093,0.0011877384,0.0141291525,0.000051033338,0.0001587649,0.000362627],"about_ca_topic_score_codex":0.0019431207,"about_ca_topic_score_gemma":0.00036658443,"teacher_disagreement_score":0.052153826,"about_ca_system_score_codex":0.002137247,"about_ca_system_score_gemma":0.0011767983,"threshold_uncertainty_score":0.99984694},"labels":[],"label_agreement":null},{"id":"W2095357289","doi":"10.3109/10428190903370387","title":"State-of-the-art in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors: evolutionary trends in diagnosis, monitoring and treatment","year":2009,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Nilotinib; Dasatinib; Imatinib; Medicine; Chronic myelogenous leukemia; Myeloid leukemia; Tyrosine kinase; Tyrosine-kinase inhibitor; Disease; Imatinib mesylate; Intensive care medicine; Oncology; Internal medicine; Leukemia","score_opus":0.019624493807393912,"score_gpt":0.27948932661892767,"score_spread":0.2598648328115338,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2095357289","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3677781,0.62852085,3.9505906e-7,0.00013013722,0.00027243333,0.0026762797,0.00010860307,0.00002014864,0.00049305684],"genre_scores_gemma":[0.2873456,0.7107818,0.00008632883,0.000070505346,0.00021543268,0.0009878393,0.000111698464,0.000095471296,0.0003052932],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9924994,0.0010411238,0.002715759,0.0012577821,0.0013426252,0.0011433209],"domain_scores_gemma":[0.99514735,0.0008279535,0.0014108494,0.002365399,0.000086536755,0.00016194013],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010182668,0.0014496826,0.0031493085,0.00073293137,0.00024410167,0.000054484837,0.0013147976,0.0006805399,0.000015149931],"category_scores_gemma":[0.000055434444,0.0007631644,0.0009617164,0.0031180852,0.0008290152,0.00018587497,0.00048219055,0.00064587855,0.000004684761],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020540338,0.00085187313,0.006842528,0.005700338,0.00051244465,0.0005949644,0.0021346896,0.00014325422,0.000015526166,0.00010363541,0.00041161824,0.98248374],"study_design_scores_gemma":[0.046734482,0.002597073,0.58249456,0.09897529,0.006014809,0.0031004157,0.0015299137,0.00050510035,0.0009693587,0.00028908654,0.25492615,0.0018637404],"about_ca_topic_score_codex":0.0058966903,"about_ca_topic_score_gemma":0.0009696279,"teacher_disagreement_score":0.98061997,"about_ca_system_score_codex":0.054612115,"about_ca_system_score_gemma":0.008247184,"threshold_uncertainty_score":0.9998253},"labels":[],"label_agreement":null},{"id":"W2097324482","doi":"10.3109/10428194.2011.624227","title":"Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; University of Calgary","funders":"","keywords":"Medicine; Melphalan; Etoposide; Internal medicine; Autologous stem-cell transplantation; Cyclophosphamide; Oncology; Progression-free survival; Gastroenterology; Transplantation; Carmustine; Refractory (planetary science); Stem cell; Salvage therapy; Chemotherapy; Urology; Surgery","score_opus":0.014815767357193631,"score_gpt":0.2296442179792584,"score_spread":0.21482845062206476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097324482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98289096,0.009418841,0.00015657672,0.00027679882,0.00077585934,0.00373036,0.0004413231,0.0005499904,0.0017593144],"genre_scores_gemma":[0.980702,0.009592884,0.0026704867,0.0020852478,0.00024088749,0.0013673977,0.0009972265,0.00036475275,0.0019791103],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.993036,0.0002291518,0.0015780884,0.0023826135,0.0010169776,0.0017572201],"domain_scores_gemma":[0.99521834,0.00071323,0.0009642663,0.0013016124,0.000614679,0.0011879036],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00047964332,0.0018312592,0.0022840002,0.0005022527,0.00083521527,0.0002398708,0.0004706533,0.001142072,0.000094436284],"category_scores_gemma":[0.000026720982,0.0014597832,0.00047554888,0.00065801997,0.0006893788,0.00075271004,0.0001269134,0.00020353241,0.000055580986],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.115463994,0.00570311,0.0817881,0.002043683,0.004060471,0.0081368545,0.017991677,0.000031247586,0.028355582,0.0036127581,0.01887602,0.7139365],"study_design_scores_gemma":[0.23224474,0.0074402564,0.6057937,0.00080062496,0.002356655,0.003469155,0.0018401723,0.0004327918,0.1345825,0.00040856667,0.0082978215,0.002332972],"about_ca_topic_score_codex":0.010601348,"about_ca_topic_score_gemma":0.00031218427,"teacher_disagreement_score":0.7116035,"about_ca_system_score_codex":0.0046832142,"about_ca_system_score_gemma":0.0027633812,"threshold_uncertainty_score":0.99944323},"labels":[],"label_agreement":null},{"id":"W2097752354","doi":"10.1080/10428190310001638832","title":"Detection of Chromosome 13q Deletions and IgH Translocations in Patients with Multiple Myeloma by FISH: Comparison with Karyotype Analysis","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Karyotype; Chromosomal translocation; Multiple myeloma; Fish <Actinopterygii>; Biology; Genetics; Chromosome; Chromosome analysis; Cytogenetics; Molecular biology; Gene; Immunology; Fishery","score_opus":0.0070428659838574215,"score_gpt":0.22985836820092523,"score_spread":0.2228155022170678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097752354","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969836,0.0004363805,0.0011041634,0.00010931048,0.000022061868,0.00091684115,0.0001763984,0.00007374521,0.00017748373],"genre_scores_gemma":[0.9977083,0.00016163192,0.001058512,0.00009885649,0.000024671974,0.00014611716,0.0006767274,0.000054286833,0.00007089388],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99735916,0.000079184836,0.000597065,0.00072278123,0.0006478141,0.00059397094],"domain_scores_gemma":[0.99844676,0.00015112452,0.00021579998,0.0004920944,0.00024130878,0.0004529062],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001166656,0.0004530222,0.00090226,0.0006529245,0.0002767724,0.00005216967,0.00012641409,0.0002184283,0.000015761334],"category_scores_gemma":[0.000050841685,0.00035396786,0.000116546835,0.0016345542,0.0004169191,0.00027848978,0.000041477168,0.00013153515,0.0000051666793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036008265,0.0011631127,0.9301936,0.00018479962,0.0013319238,0.000066890156,0.0008104028,0.00060115213,0.0028011585,0.000026545627,0.000029222389,0.059190355],"study_design_scores_gemma":[0.041673157,0.001704473,0.938986,0.00020171517,0.0008965936,0.000064352316,0.00020116291,0.004033297,0.011673676,0.000015702595,0.00019339449,0.00035644465],"about_ca_topic_score_codex":0.0062075155,"about_ca_topic_score_gemma":0.0056717275,"teacher_disagreement_score":0.05883391,"about_ca_system_score_codex":0.0026531897,"about_ca_system_score_gemma":0.0010147914,"threshold_uncertainty_score":0.9998912},"labels":[],"label_agreement":null},{"id":"W2098205907","doi":"10.3109/10428194.2013.824077","title":"Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"National Cancer Institute","keywords":"STAT3; microRNA; STAT protein; Cancer research; Lymphoma; Carcinogenesis; Diffuse large B-cell lymphoma; Biology; Transfection; Medicine; Signal transduction; Immunology; Cell culture; Gene; Cell biology; Genetics","score_opus":0.003196871236730002,"score_gpt":0.178234416654029,"score_spread":0.175037545417299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098205907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996335,0.0017471197,0.000008565517,0.000033326,0.000105588384,0.0013069307,0.0002704938,0.00005908653,0.00013383526],"genre_scores_gemma":[0.99811697,0.0008961678,0.00017675583,0.00012019266,0.0000283562,0.0000921818,0.0003813451,0.00010019904,0.000087802335],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99675846,0.00016908367,0.001030436,0.0008953789,0.0005770781,0.0005695793],"domain_scores_gemma":[0.99769753,0.00024469316,0.00062094786,0.0005615497,0.00030670615,0.000568546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000116516785,0.00070401,0.0012888438,0.00040030974,0.00011143251,0.000038670554,0.0001419056,0.00057472964,0.00008910029],"category_scores_gemma":[0.000027325295,0.0005556034,0.00016418031,0.0005263385,0.00036704028,0.00048332036,0.000082917446,0.00011625845,0.0000043102114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074646906,0.011473349,0.5624079,0.0011261625,0.00031440024,0.00007407638,0.0019978075,0.00001047964,0.39505777,0.000024801038,0.00011172558,0.019936858],"study_design_scores_gemma":[0.09420364,0.00097031216,0.63941056,0.00095233915,0.00041850744,0.00001403333,0.00017371963,0.00023912788,0.26313192,0.0000646892,0.00005589987,0.000365247],"about_ca_topic_score_codex":0.004568544,"about_ca_topic_score_gemma":0.000031508745,"teacher_disagreement_score":0.13192585,"about_ca_system_score_codex":0.0013158872,"about_ca_system_score_gemma":0.0010278376,"threshold_uncertainty_score":0.9996895},"labels":[],"label_agreement":null},{"id":"W2098380899","doi":"10.3109/10428190903388376","title":"Improved survival using an intensive, pediatric-based chemotherapy regimen in adults with T-cell acute lymphoblastic leukemia","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Regimen; Asparaginase; Internal medicine; Chemotherapy; Oncology; Overall survival; Multivariate analysis; Lymphoblastic Leukemia; Leukemia","score_opus":0.01097828439615595,"score_gpt":0.2549455362204758,"score_spread":0.24396725182431983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2098380899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99097705,0.0007973943,0.0022236,0.0003912269,0.00036400338,0.0023895474,0.000084296626,0.00062251027,0.002150377],"genre_scores_gemma":[0.98373777,0.00082953204,0.0071053477,0.0055638375,0.0009784963,0.00014671675,0.00033390822,0.00043676066,0.0008676138],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98936605,0.00042672598,0.0019266641,0.0030890608,0.0020394118,0.0031520962],"domain_scores_gemma":[0.99299926,0.00065601687,0.00082761806,0.0023263386,0.0011704977,0.0020202575],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00091628125,0.0020753462,0.0026033805,0.0016222884,0.0005662524,0.00036281993,0.0011255321,0.0013983793,0.00010147421],"category_scores_gemma":[0.00029160507,0.001820668,0.0004564604,0.0027009407,0.0007660828,0.0010684232,0.00025722937,0.00066094205,0.000057499634],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.22492726,0.010258617,0.11166136,0.0066992613,0.0030354508,0.040290784,0.017523741,0.011613874,0.26621234,0.0010489917,0.00971841,0.29700992],"study_design_scores_gemma":[0.2268295,0.010196831,0.11284053,0.0018792776,0.0016970258,0.005186866,0.0028060765,0.60364604,0.029179696,0.00023242444,0.0011078954,0.0043978556],"about_ca_topic_score_codex":0.0037612007,"about_ca_topic_score_gemma":0.00020564141,"teacher_disagreement_score":0.59203213,"about_ca_system_score_codex":0.03587992,"about_ca_system_score_gemma":0.026252054,"threshold_uncertainty_score":0.999898},"labels":[],"label_agreement":null},{"id":"W2099220112","doi":"10.3109/10428194.2011.639018","title":"Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis","year":2011,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Institute for Clinical Evaluative Sciences; University of Toronto; SickKids Foundation; Public Health Ontario; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Lymphoblastic Leukemia; Meta-analysis; Internal medicine; Complete remission; Pediatrics; Mortality rate; Leukemia; Chemotherapy","score_opus":0.047082088209867874,"score_gpt":0.32497771594731656,"score_spread":0.2778956277374487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099220112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019828165,0.98315877,0.00010496397,0.000054321918,0.00024730488,0.011436078,0.00065045484,0.00041716758,0.0019481364],"genre_scores_gemma":[0.0021259564,0.9832561,0.0004589651,0.001879874,0.00035351957,0.0055169296,0.00086135656,0.00072277494,0.0048245103],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.97919005,0.001705822,0.007619299,0.005282261,0.0026705773,0.0035319808],"domain_scores_gemma":[0.985386,0.0023041696,0.0035521372,0.005379377,0.0006923272,0.0026859965],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0037242386,0.0049118083,0.034518555,0.0046912674,0.0005644228,0.00044875534,0.0021890341,0.003631812,0.00049739913],"category_scores_gemma":[0.001135249,0.0036709195,0.007818481,0.008927711,0.0011496457,0.00080245483,0.001993357,0.0014194654,0.0005852884],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00015345083,0.00032621028,0.00017436546,0.80159163,0.18422006,0.0040420233,0.00031523476,0.0000040035575,7.0411767e-7,0.0001980593,0.0016799731,0.0072942586],"study_design_scores_gemma":[0.008040002,0.00044384657,0.00086973794,0.03923418,0.928966,0.00735364,0.00006175034,0.0008009239,0.0000030393078,0.00007369647,0.011005008,0.0031482186],"about_ca_topic_score_codex":0.0037577432,"about_ca_topic_score_gemma":0.0003159538,"teacher_disagreement_score":0.7623575,"about_ca_system_score_codex":0.038767204,"about_ca_system_score_gemma":0.028774973,"threshold_uncertainty_score":0.9976617},"labels":[],"label_agreement":null},{"id":"W2099980739","doi":"10.3109/10428194.2014.918972","title":"Is there a role for omacetaxine in the management of chronic myelogenous leukemia in the era of the tyrosine kinase inhibitors?","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Chronic myelogenous leukemia; Tyrosine kinase; Medicine; Cancer research; Leukemia; CD135; Immunology; Internal medicine; Receptor","score_opus":0.012325001069235906,"score_gpt":0.2414652612103483,"score_spread":0.2291402601411124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2099980739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90959114,0.025623664,0.00002825404,0.050311796,0.0006892293,0.008752639,0.0004064585,0.00009194564,0.0045048906],"genre_scores_gemma":[0.88765085,0.0033515827,0.0003326795,0.102039315,0.0022371346,0.001796435,0.00056619017,0.0003366606,0.0016891675],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910117,0.00083573756,0.0024479437,0.0017603638,0.0020795031,0.0018647993],"domain_scores_gemma":[0.9930261,0.001184275,0.0015444837,0.0038401082,0.00024361785,0.00016143928],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001781891,0.0017263979,0.0025047685,0.00048829074,0.00039016534,0.00012563901,0.0025078596,0.0018739424,0.000083698265],"category_scores_gemma":[0.000096726,0.0009946784,0.0011854374,0.0016609404,0.0010696314,0.00017537735,0.00054363103,0.0015261141,0.000024731598],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0034539632,0.0018154023,0.009236692,0.026192656,0.0046259584,0.005639873,0.02047516,0.0005154459,0.0031190335,0.0016855488,0.6104436,0.31279668],"study_design_scores_gemma":[0.08235351,0.0026781433,0.09156585,0.012627049,0.0044703716,0.0036270618,0.0031303475,0.0065071657,0.010213827,0.0015945784,0.7787952,0.0024368877],"about_ca_topic_score_codex":0.0068867053,"about_ca_topic_score_gemma":0.0005882701,"teacher_disagreement_score":0.31035978,"about_ca_system_score_codex":0.029976364,"about_ca_system_score_gemma":0.0086953575,"threshold_uncertainty_score":0.99972653},"labels":[],"label_agreement":null},{"id":"W2100198173","doi":"10.3109/10428194.2012.710907","title":"Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Anthracycline; Chemotherapy; Stage (stratigraphy); Lymphoma; Internal medicine; Radiation therapy; Gastroenterology; Surgery; Diffuse large B-cell lymphoma; Induction chemotherapy; Oncology; Cancer; Breast cancer","score_opus":0.004290189130809547,"score_gpt":0.22056401710279658,"score_spread":0.21627382797198702,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100198173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919984,0.005511275,0.000016996992,0.000033509397,0.00011228398,0.0011242386,0.000064643595,0.00006774176,0.0010709107],"genre_scores_gemma":[0.9963552,0.0013316098,0.0012012626,0.00037472325,0.00013213379,0.00017681102,0.00007705662,0.00016423292,0.00018701592],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954139,0.00016672666,0.0013922994,0.0008693281,0.0008288008,0.0013289413],"domain_scores_gemma":[0.997473,0.0002577395,0.00065691036,0.00091586745,0.00014807886,0.00054841436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005159767,0.0008538362,0.0016641305,0.0006979583,0.00010217983,0.00003880309,0.00026593916,0.0005285689,0.00007907796],"category_scores_gemma":[0.00004536067,0.0006901125,0.000278117,0.00077314314,0.00023771884,0.0005836547,0.00013568204,0.00011989121,0.0000065760805],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007846705,0.0088933585,0.90453094,0.00031890385,0.00017848705,0.00010180587,0.004842003,0.000010375071,0.0027211981,0.000085011394,0.000017540515,0.07045367],"study_design_scores_gemma":[0.13967933,0.0010578185,0.82709366,0.0010436521,0.00012104292,0.00003630229,0.0006217573,0.00094412203,0.02734063,0.000015997723,0.001466574,0.00057913724],"about_ca_topic_score_codex":0.0030716558,"about_ca_topic_score_gemma":0.0001295067,"teacher_disagreement_score":0.13183263,"about_ca_system_score_codex":0.005291068,"about_ca_system_score_gemma":0.0010468133,"threshold_uncertainty_score":0.999555},"labels":[],"label_agreement":null},{"id":"W2100242421","doi":"10.3109/10428194.2014.963082","title":"Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Tuberculosis; Pulmonary tuberculosis; Internal medicine; Oncology; Bone marrow; Pathology","score_opus":0.010706398558013006,"score_gpt":0.22411892115910517,"score_spread":0.21341252260109217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100242421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9393715,0.0021222408,0.00001503946,0.035834815,0.000366486,0.003359202,0.00014270528,0.00031153776,0.018476434],"genre_scores_gemma":[0.7561324,0.0024015247,0.0013032686,0.2254212,0.0021384922,0.003971933,0.0056002135,0.00056446745,0.0024664442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99247974,0.00041197843,0.0015229904,0.0024649065,0.0014523591,0.001668028],"domain_scores_gemma":[0.9962185,0.00088770234,0.00072833087,0.0014339822,0.00019607604,0.0005354044],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00025199822,0.0020759096,0.0029635648,0.0009442559,0.00041442038,0.00023045196,0.0002600887,0.0019238323,0.00006540886],"category_scores_gemma":[0.000068614514,0.0015898062,0.0007918614,0.00076042395,0.00025603973,0.0003915913,0.00016120229,0.0005651998,0.000083323444],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047834027,0.0028425925,0.10024719,0.0030399296,0.005521401,0.07385726,0.0035363827,0.0000610647,0.0017255004,0.00014951736,0.1274143,0.6768215],"study_design_scores_gemma":[0.037744597,0.006677351,0.17830387,0.006305673,0.0037063654,0.014769855,0.00040582265,0.0009802575,0.0070343628,0.00018282265,0.74033237,0.0035566292],"about_ca_topic_score_codex":0.0051745917,"about_ca_topic_score_gemma":0.00010212243,"teacher_disagreement_score":0.6732648,"about_ca_system_score_codex":0.029813793,"about_ca_system_score_gemma":0.0045134737,"threshold_uncertainty_score":0.9993719},"labels":[],"label_agreement":null},{"id":"W2100660242","doi":"10.3109/10428194.2012.711828","title":"Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Blastoid; Mantle cell lymphoma; Stage (stratigraphy); Internal medicine; Univariate analysis; Chemoradiotherapy; Radiation therapy; Lymphoma; Surgery; Oncology; Gastroenterology; Multivariate analysis","score_opus":0.013008611068373449,"score_gpt":0.24576594878896707,"score_spread":0.23275733772059362,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100660242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9634958,0.009838583,0.000012587955,0.0012579005,0.0012193386,0.0019349128,0.00022135198,0.00042616564,0.021593345],"genre_scores_gemma":[0.95868665,0.0034202,0.0003752286,0.0022961714,0.00070670596,0.00082486024,0.00039046502,0.000229696,0.033070028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993652,0.00023712227,0.0011815822,0.0014700621,0.0011824124,0.0022768471],"domain_scores_gemma":[0.99509054,0.0007222752,0.00057952775,0.0020431143,0.00016601082,0.0013985133],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00044519364,0.0016070544,0.0016912972,0.000306452,0.0011712549,0.0002587983,0.0005420597,0.0006905728,0.00044689974],"category_scores_gemma":[0.00008374054,0.0010216472,0.00090591284,0.0006007822,0.00066230434,0.00059412536,0.0006286972,0.00010641258,0.00096985034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008451599,0.005640209,0.8124231,0.00030964252,0.001347191,0.0010424528,0.0033360391,0.000014960616,0.00054438406,0.0016231986,0.013564421,0.15930925],"study_design_scores_gemma":[0.033543672,0.0010440705,0.6880203,0.00012971733,0.0011140226,0.0009118131,0.00092988135,0.00026220764,0.016753525,0.00003478019,0.256172,0.0010840576],"about_ca_topic_score_codex":0.0033049134,"about_ca_topic_score_gemma":0.00018647972,"teacher_disagreement_score":0.24260756,"about_ca_system_score_codex":0.02296672,"about_ca_system_score_gemma":0.0021268213,"threshold_uncertainty_score":0.999808},"labels":[],"label_agreement":null},{"id":"W2100969937","doi":"10.3109/10428194.2013.773996","title":"Medical emergency team involvement in patients hospitalized with acute myeloid leukemia","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Sepsis Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canada Research Chairs; Alberta Innovates - Health Solutions","keywords":"Medicine; Myeloid leukemia; Incidence (geometry); Confidence interval; Internal medicine; Intensive care unit; Retrospective cohort study; Emergency medicine; Emergency department; Pediatrics","score_opus":0.012272568152495247,"score_gpt":0.25154227164907006,"score_spread":0.2392697034965748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100969937","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892942,0.0008826375,0.000017438108,0.0005937274,0.00047507897,0.002277176,0.000029663592,0.00025347594,0.006176612],"genre_scores_gemma":[0.9896328,0.0034930904,0.00069612183,0.0027620716,0.00025575527,0.0012858178,0.00039443345,0.0001790684,0.0013008603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99346673,0.00014984491,0.001456913,0.001541033,0.0019032642,0.0014822062],"domain_scores_gemma":[0.9966064,0.0001207057,0.00040570684,0.0011240015,0.0003511351,0.0013920588],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034272682,0.001123612,0.0015154539,0.0005050023,0.00029806903,0.00012896588,0.0004714831,0.00073104067,0.0015676738],"category_scores_gemma":[0.0001300662,0.000848046,0.00033687957,0.0008967538,0.00035400025,0.00055733166,0.0003182069,0.00025640093,0.0004180814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088269776,0.0015545032,0.86996514,0.00020449854,0.0010337519,0.0006688959,0.0010314931,0.000009040595,0.00013377558,0.0002915118,0.022255063,0.10196962],"study_design_scores_gemma":[0.045865525,0.0020258527,0.9405374,0.0006253777,0.00053104665,0.00026781159,0.0003045111,0.0013086211,0.0012435473,0.0002543802,0.0060465876,0.0009893291],"about_ca_topic_score_codex":0.008862446,"about_ca_topic_score_gemma":0.00025265856,"teacher_disagreement_score":0.10098029,"about_ca_system_score_codex":0.012957437,"about_ca_system_score_gemma":0.004326506,"threshold_uncertainty_score":0.99939704},"labels":[],"label_agreement":null},{"id":"W2101109518","doi":"10.3109/10428194.2011.555888","title":"High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Provincia autonoma di Bolzano - Alto Adige","keywords":"Medicine; Lymphoma; Radiation therapy; Internal medicine; Modalities; Chemotherapy; Survival rate; Thyroid; Oncology; Diffuse large B-cell lymphoma; Surgery; Gastroenterology","score_opus":0.008709439332276173,"score_gpt":0.21736576793321233,"score_spread":0.20865632860093616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101109518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940607,0.00042396583,0.000013586219,0.000026485903,0.00028755088,0.0043914793,0.00040463926,0.00015127032,0.00024033718],"genre_scores_gemma":[0.99716276,0.0005572122,0.00027941263,0.00019366185,0.0000860829,0.00076769234,0.00042588497,0.0001950459,0.00033225166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934046,0.00081203756,0.0015512678,0.001964987,0.0011329466,0.0011341402],"domain_scores_gemma":[0.99631023,0.00047012835,0.00083644706,0.0012758621,0.00030896187,0.0007983546],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010489483,0.0015178908,0.0020742142,0.0007451208,0.00038314087,0.00022547193,0.00043151752,0.00034574297,0.00003041834],"category_scores_gemma":[0.000047707978,0.0011089554,0.00018331973,0.00045293235,0.0005491669,0.0009269897,0.00044663835,0.00010092236,0.0000046206037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07855922,0.05932483,0.81429964,0.00016742964,0.0016622826,0.0016978129,0.0098059205,0.0000018398837,0.00025107464,0.000065014916,0.0000065889267,0.034158316],"study_design_scores_gemma":[0.2708822,0.037779298,0.68352145,0.000226625,0.0010822098,0.00011880237,0.004145825,0.000091517446,0.0013349116,0.000015697799,0.000016039601,0.0007854194],"about_ca_topic_score_codex":0.009764229,"about_ca_topic_score_gemma":0.002119545,"teacher_disagreement_score":0.19232297,"about_ca_system_score_codex":0.0066881655,"about_ca_system_score_gemma":0.0015259354,"threshold_uncertainty_score":0.999757},"labels":[],"label_agreement":null},{"id":"W2101740016","doi":"10.3109/10428194.2014.909039","title":"A single institution experience of extranodal natural killer/T cell lymphoma of nasal type","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; CHOP; Vincristine; Prednisone; Internal medicine; Lymphoma; Cyclophosphamide; Gastroenterology; Nasal cavity; Radiation therapy; Stage (stratigraphy); Chemotherapy; International Prognostic Index; B symptoms; Surgery; Oncology","score_opus":0.010408843332424539,"score_gpt":0.2336162705908109,"score_spread":0.22320742725838635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101740016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843151,0.003506922,0.00009397002,0.00007743917,0.0011887561,0.0006230093,0.000021260592,0.00015557473,0.0100179985],"genre_scores_gemma":[0.9958289,0.0005685803,0.0016277054,0.00046147135,0.00027099033,0.00007669592,0.000101297606,0.00008636005,0.0009779526],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957612,0.00015145288,0.0012694591,0.0010267146,0.0009342967,0.0008568702],"domain_scores_gemma":[0.99714625,0.00032370345,0.0006300157,0.0010212512,0.00036784672,0.00051093794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002947816,0.0007854341,0.0014218559,0.00039754598,0.000247345,0.000058918904,0.00037864488,0.0005031727,0.00007082957],"category_scores_gemma":[0.00020314484,0.000674663,0.00042792337,0.00080653676,0.00087166723,0.00038686962,0.00020950339,0.00008080451,0.00004188013],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006397238,0.006395471,0.097188,0.0020465157,0.00078477885,0.00055185903,0.007772066,0.00009915986,0.19990027,0.01063458,0.002727758,0.6655023],"study_design_scores_gemma":[0.059209675,0.0033570128,0.43298465,0.001119771,0.00075985026,0.0016181493,0.0010477023,0.005525375,0.4568088,0.0003060357,0.035932586,0.0013303688],"about_ca_topic_score_codex":0.0019212458,"about_ca_topic_score_gemma":0.000050472274,"teacher_disagreement_score":0.66417193,"about_ca_system_score_codex":0.003773706,"about_ca_system_score_gemma":0.0023950182,"threshold_uncertainty_score":0.9995704},"labels":[],"label_agreement":null},{"id":"W2103254744","doi":"10.3109/10428194.2012.660631","title":"Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Princess Margaret Cancer Centre","funders":"Takeda Oncology","keywords":"Cytarabine; Medicine; Myeloid leukemia; Neutropenia; Refractory (planetary science); Fms-Like Tyrosine Kinase 3; Phases of clinical research; Internal medicine; Pharmacology; Clinical trial; Chemotherapy; Chemistry; Biology","score_opus":0.016781957473714398,"score_gpt":0.2891959538203783,"score_spread":0.2724139963466639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103254744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990001,0.00084615336,0.000055904322,0.00012362938,0.00075374387,0.0035291768,0.0001906216,0.00030359594,0.004196156],"genre_scores_gemma":[0.9894493,0.0011721312,0.0024251041,0.00092654483,0.0010065695,0.0003893354,0.0005829339,0.0003777629,0.0036703],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9904514,0.00049941003,0.0023834195,0.0016602474,0.0022773866,0.002728146],"domain_scores_gemma":[0.99363786,0.0008915998,0.0010248967,0.0021100203,0.0006089053,0.0017267292],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015376325,0.0014844185,0.0026849753,0.0013482313,0.0003576131,0.00011497902,0.0008601104,0.0013907207,0.00033091957],"category_scores_gemma":[0.0007010315,0.0011401188,0.0004619259,0.0021438336,0.0010594758,0.0013675439,0.000524185,0.0008321214,0.00016506342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6312938,0.009109416,0.05880365,0.0011111146,0.001973098,0.0012696981,0.003995566,0.000020953914,0.007034099,0.0005306343,0.009105941,0.27575207],"study_design_scores_gemma":[0.74844664,0.016645093,0.18825419,0.0009965277,0.001174177,0.00065741927,0.00071969046,0.00095045695,0.008514349,0.00005419032,0.03168878,0.0018984694],"about_ca_topic_score_codex":0.0015147945,"about_ca_topic_score_gemma":0.00008945221,"teacher_disagreement_score":0.2738536,"about_ca_system_score_codex":0.022622287,"about_ca_system_score_gemma":0.014276642,"threshold_uncertainty_score":0.9999057},"labels":[],"label_agreement":null},{"id":"W2103379333","doi":"10.3109/10428194.2015.1004170","title":"Methylenetetrahydrofolate reductase<i>C677T</i>and<i>A1298C</i>polymorphism and susceptibility to acute lymphoblastic leukemia in a cohort of Egyptian children","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Methylenetetrahydrofolate reductase; Genotype; Genetics; Haplotype; Allele; Restriction fragment length polymorphism; Cohort; Medicine; Polymorphism (computer science); Internal medicine; Biology; Gene","score_opus":0.012244770635397247,"score_gpt":0.26354154470093216,"score_spread":0.2512967740655349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2103379333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907225,0.0034014184,0.00019672333,0.0004427196,0.000358426,0.0027356856,0.00035464033,0.00029270226,0.0014952251],"genre_scores_gemma":[0.9909533,0.0017052665,0.0038896387,0.0014618132,0.00037932384,0.000271426,0.00026427145,0.0002878979,0.0007870575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897259,0.0005466674,0.0023449683,0.002964813,0.002028002,0.0023896738],"domain_scores_gemma":[0.99266773,0.0008157213,0.0005871519,0.0020142277,0.0005482572,0.0033669313],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0023062842,0.0016457662,0.002951258,0.0016260798,0.0003308569,0.00021520282,0.00080824894,0.0011963233,0.000047557325],"category_scores_gemma":[0.0011167487,0.0015581199,0.00035274122,0.002222532,0.0017801394,0.00068068464,0.0013751374,0.0005262867,0.000059795886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018875012,0.0011385204,0.6567031,0.0019113856,0.0042323996,0.004067194,0.011470097,0.0006764004,0.14357637,0.0019196941,0.014789364,0.14064047],"study_design_scores_gemma":[0.06755574,0.0035393545,0.8536214,0.0014639815,0.002031501,0.012598303,0.0009992174,0.020060834,0.031105021,0.0013795405,0.0027356893,0.0029093707],"about_ca_topic_score_codex":0.015765978,"about_ca_topic_score_gemma":0.00043830156,"teacher_disagreement_score":0.19691834,"about_ca_system_score_codex":0.024171123,"about_ca_system_score_gemma":0.015122379,"threshold_uncertainty_score":0.99962896},"labels":[],"label_agreement":null},{"id":"W2105993077","doi":"10.3109/10428194.2011.619605","title":"Genetic variability in<i>N-acetyltransferase 2</i>gene determines susceptibility to childhood lymphoid or myeloid leukemia in Brazil","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; DNA Genotek","keywords":"Odds ratio; Haplotype; Myeloid leukemia; Single-nucleotide polymorphism; Leukemia; Genotype; SNP; Tag SNP; Confidence interval; Oncology; Internal medicine; Logistic regression; Acute lymphocytic leukemia; Biology; Medicine; Genetics; Immunology; Lymphoblastic Leukemia; Gene","score_opus":0.016166005579840263,"score_gpt":0.25961122452996854,"score_spread":0.24344521895012827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105993077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98919034,0.000592031,0.00082867465,0.0001748945,0.000542191,0.003707358,0.00016021733,0.0004884478,0.004315844],"genre_scores_gemma":[0.98262036,0.0011413905,0.010000504,0.0035291077,0.0005457402,0.0008254376,0.00010748814,0.0003835349,0.00084644766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9864663,0.0010354286,0.0032008013,0.0039155516,0.0018227169,0.003559229],"domain_scores_gemma":[0.9921208,0.0013741457,0.0003752169,0.0031900129,0.00045956383,0.0024802454],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002744704,0.0020525756,0.0029636787,0.0017485708,0.00042411237,0.00021040926,0.0014919363,0.0015454466,0.0007247968],"category_scores_gemma":[0.002057928,0.0018356319,0.0005813537,0.0036988151,0.0011221177,0.0007867123,0.00094698166,0.0006537655,0.00033015877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022836335,0.0031368132,0.55597717,0.0019337662,0.00056246406,0.011654894,0.015914029,0.0003724607,0.05321127,0.0002683689,0.0019564305,0.332176],"study_design_scores_gemma":[0.045683865,0.001857222,0.8966519,0.0008248669,0.00030536915,0.006839015,0.00076656725,0.007051905,0.03488871,0.00072816556,0.002099412,0.0023029775],"about_ca_topic_score_codex":0.01739169,"about_ca_topic_score_gemma":0.0050521726,"teacher_disagreement_score":0.34067476,"about_ca_system_score_codex":0.052771185,"about_ca_system_score_gemma":0.027992776,"threshold_uncertainty_score":0.99975073},"labels":[],"label_agreement":null},{"id":"W2106860974","doi":"10.3109/10428194.2011.601475","title":"Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency; Leukemia & Lymphoma Society of Canada; University of British Columbia","funders":"","keywords":"Incidence (geometry); Confidence interval; Demography; Ethnic group; Medicine; Standardized rate; Etiology; Population; Plasma cell neoplasm; Ethnic chinese; Epidemiology; Multiple myeloma; Internal medicine; Plasmacytoma","score_opus":0.013042410612530931,"score_gpt":0.23766761615937296,"score_spread":0.22462520554684204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106860974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568033,0.00036104734,0.000020874062,0.00002986882,0.00019787412,0.0011575412,0.0006429847,0.00009173462,0.0018177362],"genre_scores_gemma":[0.994495,0.00030989072,0.002025068,0.0004913897,0.00007890232,0.00014493082,0.00020476163,0.00011272785,0.0021373415],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99540967,0.00022346526,0.0010185377,0.0012466279,0.0009113033,0.0011904191],"domain_scores_gemma":[0.99707925,0.000508834,0.00021768833,0.0008865745,0.00027204357,0.0010355832],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005762034,0.0005620717,0.0012949008,0.00033795182,0.00019547385,0.00017271482,0.0004870781,0.00049383263,0.0011042466],"category_scores_gemma":[0.0005402947,0.00065989874,0.00024956596,0.001045442,0.00031084262,0.00026847408,0.00038605093,0.00020032481,0.0002411772],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027692278,0.0007051974,0.9637494,0.00017811984,0.00020562213,0.0031142028,0.0027577286,0.00000230313,0.002645656,0.0000028494903,0.0034956017,0.020374063],"study_design_scores_gemma":[0.027102025,0.0008357419,0.9639221,0.0005770271,0.000087552115,0.0003243515,0.00031881532,0.0012177968,0.0042248806,0.00015592585,0.0006602898,0.0005735077],"about_ca_topic_score_codex":0.5410566,"about_ca_topic_score_gemma":0.114563085,"teacher_disagreement_score":0.42649347,"about_ca_system_score_codex":0.0038241353,"about_ca_system_score_gemma":0.0026141144,"threshold_uncertainty_score":0.9999981},"labels":[],"label_agreement":null},{"id":"W2107376308","doi":"10.3109/10428194.2014.889825","title":"Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma","year":2014,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ottawa Hospital","funders":"","keywords":"ThioTEPA; Medicine; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Lymphoma; Transplantation; Meta-analysis; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.007150088999730191,"score_gpt":0.23561258928012294,"score_spread":0.22846250028039275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2107376308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64894724,0.34458503,0.000021742577,0.000007861819,0.00024159945,0.005000177,0.00050145,0.00013625559,0.00055861083],"genre_scores_gemma":[0.5848019,0.41284445,0.00013471059,0.000060095666,0.00012121077,0.00095750944,0.0007079305,0.00026623724,0.00010593006],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99254286,0.00069825427,0.0021371113,0.0021549463,0.000980883,0.001485929],"domain_scores_gemma":[0.9952636,0.0010806326,0.0010288771,0.0012297492,0.0002025547,0.0011946261],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00045036434,0.0021376389,0.006397959,0.0009045892,0.0003733618,0.00015005338,0.00035024082,0.0010970398,0.000015578597],"category_scores_gemma":[0.000020029458,0.0015626639,0.0007963684,0.0008652292,0.0003058765,0.00020036225,0.00016686482,0.00014415395,0.000047391306],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031890993,0.0011329697,0.010241617,0.031529527,0.0011720632,0.000905781,0.00088040635,0.000023835766,0.0000046138302,0.00028585052,0.000020958567,0.95061326],"study_design_scores_gemma":[0.082346424,0.0064850794,0.7036214,0.09711403,0.009208299,0.0027623323,0.00039148558,0.00013387547,0.00059035124,0.00000674111,0.0947539,0.0025860982],"about_ca_topic_score_codex":0.0029971204,"about_ca_topic_score_gemma":0.000102117796,"teacher_disagreement_score":0.9480272,"about_ca_system_score_codex":0.026780486,"about_ca_system_score_gemma":0.0054694493,"threshold_uncertainty_score":0.99913645},"labels":[],"label_agreement":null},{"id":"W2110932840","doi":"10.3109/10428190109097658","title":"Establishment of a Cytokine-Producing Anaplastic Large-Cell Lymphoma Cell Line Containing the t(2;5) Translocation: Potential Role of Cytokines in Clinical Manifestations","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Hospital for Sick Children","funders":"","keywords":"Anaplastic large-cell lymphoma; Cytokine; Neutrophilia; Biology; CD30; Immunology; Immunophenotyping; Bone marrow; T cell; Cancer research; Lymphoma; Flow cytometry; Immune system","score_opus":0.009658542660796693,"score_gpt":0.238479385698005,"score_spread":0.22882084303720832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2110932840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889154,0.0057415864,0.00081695826,0.00011185437,0.0016419176,0.000511055,0.000037919894,0.00007390137,0.0021494287],"genre_scores_gemma":[0.99496907,0.0022847946,0.00011424572,0.00027555102,0.00015542116,0.00006369481,0.00027111897,0.00005427627,0.0018118408],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99593604,0.0005275736,0.0018967994,0.0007584247,0.00018867283,0.00069252186],"domain_scores_gemma":[0.9974732,0.0006338607,0.00083279004,0.0006788976,0.00030335598,0.00007791154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010275614,0.00048396844,0.00083618483,0.00040490966,0.0003618301,0.000049919,0.00043860488,0.00051459,0.0002282465],"category_scores_gemma":[0.00016674791,0.00041207985,0.0003140491,0.00063938065,0.00040328765,0.00037581226,0.00013852642,0.00022108476,0.000058542268],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01311658,0.005569207,0.03842516,0.0005345594,0.0006941027,0.00023091097,0.01232988,0.0030433552,0.6667819,0.0012292817,0.002897668,0.25514737],"study_design_scores_gemma":[0.09358319,0.0035462927,0.3288818,0.00082709733,0.0007951114,0.0025089583,0.025620434,0.014628895,0.4414815,0.00039399296,0.0860283,0.0017044104],"about_ca_topic_score_codex":0.001948773,"about_ca_topic_score_gemma":0.00032617335,"teacher_disagreement_score":0.29045665,"about_ca_system_score_codex":0.00091095024,"about_ca_system_score_gemma":0.0012387368,"threshold_uncertainty_score":0.9998331},"labels":[],"label_agreement":null},{"id":"W2111128439","doi":"10.3109/10428194.2013.816700","title":"Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Vincristine; Gastroenterology; Bevacizumab; Neutropenia; Regimen; CHOP; Prednisone; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.00647058112068715,"score_gpt":0.23524904892706575,"score_spread":0.2287784678063786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2111128439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920238,0.0015286847,0.000027793512,0.00015272264,0.00028914202,0.0054059234,0.000037238926,0.00010998638,0.0004246867],"genre_scores_gemma":[0.9936095,0.0004089673,0.0017433105,0.0006814257,0.00009531141,0.0014621214,0.00040547855,0.00012274325,0.0014711267],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960437,0.00022245945,0.000893763,0.0014222057,0.0005234122,0.0008944564],"domain_scores_gemma":[0.9976847,0.00044115345,0.00036465627,0.0005193687,0.0003715063,0.0006185851],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022712092,0.00092724065,0.0013477912,0.0002608271,0.00042660622,0.00025658487,0.00017841735,0.0003998841,0.00005322376],"category_scores_gemma":[0.00006397692,0.0006600992,0.00008546508,0.000367801,0.00041052277,0.00078075373,0.00019693315,0.00014850966,0.000010699999],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0116460975,0.01083236,0.7800323,0.00043272617,0.0003629741,0.00038338854,0.0077070594,0.000019096124,0.0004029745,0.00013090784,0.0007720635,0.18727809],"study_design_scores_gemma":[0.16515748,0.02417139,0.79143345,0.00021982394,0.00048144287,0.0002462717,0.004141957,0.0109531265,0.00073038886,0.00006901677,0.0015442792,0.00085138524],"about_ca_topic_score_codex":0.005102743,"about_ca_topic_score_gemma":0.0015681837,"teacher_disagreement_score":0.1864267,"about_ca_system_score_codex":0.005039828,"about_ca_system_score_gemma":0.001359726,"threshold_uncertainty_score":0.99958503},"labels":[],"label_agreement":null},{"id":"W2112068705","doi":"10.3109/10428194.2015.1068306","title":"Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Silymarin and Mushroom Poisoning","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Silibinin; Anaplastic lymphoma kinase; Cancer research; Anaplastic large-cell lymphoma; Survivin; Protein kinase B; Chemistry; Cell growth; Apoptosis; Biology; Lymphoma; Medicine; Immunology; Biochemistry; Pathology","score_opus":0.012672692621934774,"score_gpt":0.24135518206545545,"score_spread":0.22868248944352068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112068705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97887045,0.003651241,0.00006773664,0.00026970255,0.0006250304,0.00081761647,0.000087932356,0.00029163933,0.015318672],"genre_scores_gemma":[0.99486136,0.0009621947,0.0006648026,0.0014650427,0.0004440775,0.00010692395,0.00018431559,0.00016012875,0.0011511747],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99416775,0.00033428246,0.0010824323,0.001748415,0.00097341806,0.0016937051],"domain_scores_gemma":[0.9963833,0.0008134457,0.0004309398,0.000786706,0.00030879953,0.0012768107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008706506,0.0011471369,0.0016778962,0.0006537958,0.00040592687,0.00028185933,0.00034278416,0.0008561484,0.000030404204],"category_scores_gemma":[0.0005494475,0.0010881972,0.00024326699,0.0009870252,0.0005932279,0.00081442046,0.00057302904,0.00026856718,0.00006544629],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013695776,0.005799425,0.09698815,0.0026307083,0.0012876549,0.005330016,0.032430824,0.000105320985,0.31171024,0.00154905,0.01199881,0.516474],"study_design_scores_gemma":[0.077732466,0.0015537534,0.30227786,0.0015217396,0.0007239656,0.0025267296,0.010027284,0.006280955,0.5880429,0.00040449793,0.0065397015,0.002368144],"about_ca_topic_score_codex":0.0037095968,"about_ca_topic_score_gemma":0.0004271348,"teacher_disagreement_score":0.51410586,"about_ca_system_score_codex":0.004501184,"about_ca_system_score_gemma":0.0036035744,"threshold_uncertainty_score":0.9993204},"labels":[],"label_agreement":null},{"id":"W2112529529","doi":"10.3109/10428194.2013.790968","title":"Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B-cell lymphoma: a population based study","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Internal medicine; Diffuse large B-cell lymphoma; Confidence interval; International Prognostic Index; Retrospective cohort study; Lymphoma; Comorbidity; Cohort; Performance status; Population; Overall survival","score_opus":0.007458380733081112,"score_gpt":0.24030235645578002,"score_spread":0.2328439757226989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112529529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958536,0.00047556285,0.000007515943,0.000028390643,0.00015190497,0.002992385,0.00010721823,0.00012947724,0.00025396392],"genre_scores_gemma":[0.99793994,0.0000444675,0.0002839879,0.0005151508,0.00004457303,0.00037717904,0.00046261676,0.00012774658,0.0002043524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954593,0.00020271198,0.0011671204,0.001215815,0.0010842638,0.00087076705],"domain_scores_gemma":[0.99713063,0.00035605382,0.0007038033,0.000829737,0.0002926213,0.00068712374],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020065525,0.0009841516,0.0017318182,0.00041247156,0.00043322777,0.00019791999,0.00017745234,0.00039450979,0.00005555256],"category_scores_gemma":[0.00007852278,0.0007263804,0.00018670649,0.00039587045,0.000240149,0.0007259542,0.00023850048,0.000089555746,0.000012109424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071128993,0.01540805,0.96413976,0.0002715481,0.00038740842,0.000036176054,0.0013099889,0.0000027938147,0.000029228113,0.000022580653,0.00036727378,0.01731393],"study_design_scores_gemma":[0.15225148,0.0018990805,0.8418542,0.00022219389,0.0008387395,0.000007490945,0.0005478524,0.0013729447,0.0002326818,0.00001557989,0.00010870375,0.00064902834],"about_ca_topic_score_codex":0.0087092975,"about_ca_topic_score_gemma":0.0004018551,"teacher_disagreement_score":0.15154019,"about_ca_system_score_codex":0.0026691693,"about_ca_system_score_gemma":0.0004894114,"threshold_uncertainty_score":0.99951875},"labels":[],"label_agreement":null},{"id":"W2112626326","doi":"10.3109/10428194.2013.858154","title":"The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma","year":2013,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Prednisone; Vincristine; Cyclophosphamide; Medicine; Doxorubicin; Peripheral; Lymphoma; Peripheral T-cell lymphoma; Chemotherapy; Oncology; Internal medicine; Immunology; T cell; Immune system","score_opus":0.008534077756637998,"score_gpt":0.21878022310359987,"score_spread":0.21024614534696187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2112626326","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8613048,0.06650622,0.00009799657,0.055645987,0.00074059796,0.0113919815,0.00067344186,0.00034975825,0.0032891978],"genre_scores_gemma":[0.6977758,0.09439697,0.0068421396,0.11202104,0.0080626765,0.020226123,0.002552038,0.001616928,0.056506313],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928784,0.0002974873,0.0017375511,0.0018765235,0.0012478568,0.0019621842],"domain_scores_gemma":[0.9922416,0.003121721,0.0012915778,0.0021890868,0.0006085097,0.0005474636],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00044498127,0.0022360096,0.0026463193,0.0002500195,0.0019448664,0.00052760897,0.00069149426,0.0015167098,0.000043993492],"category_scores_gemma":[0.00005750586,0.0011542997,0.00080550555,0.00050203846,0.001785031,0.00024231315,0.00021851965,0.00030950838,0.000025093199],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049263095,0.002343208,0.006173768,0.002792211,0.0047269696,0.0011239428,0.002760507,0.000026700454,0.00049193425,0.0003358352,0.39228436,0.58201426],"study_design_scores_gemma":[0.06288914,0.0071727494,0.03182644,0.0008724555,0.0045351177,0.0024317785,0.00075201766,0.0011673338,0.0055929166,0.00029779645,0.881019,0.001443254],"about_ca_topic_score_codex":0.009291051,"about_ca_topic_score_gemma":0.00024043389,"teacher_disagreement_score":0.580571,"about_ca_system_score_codex":0.010062141,"about_ca_system_score_gemma":0.0046090507,"threshold_uncertainty_score":0.9997795},"labels":[],"label_agreement":null},{"id":"W2113262521","doi":"10.3109/10428194.2011.576791","title":"Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Tianjin Science and Technology Program; Natural Science Foundation of Tianjin City; National Natural Science Foundation of China; Peking Union Medical College; Academy of Medical Sciences","keywords":"Bortezomib; Stromal cell; Multiple myeloma; Bone marrow; microRNA; Cancer research; Transfection; Apoptosis; Vascular endothelial growth factor; Medicine; Immunology; Chemistry; Biology; Cell culture; VEGF receptors","score_opus":0.020943145627392513,"score_gpt":0.2422504560969769,"score_spread":0.22130731046958438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113262521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917232,0.001413357,0.00017751943,0.00007166376,0.00048937567,0.0019810041,0.0005116905,0.00041466503,0.003217521],"genre_scores_gemma":[0.9884216,0.0004055153,0.0074149272,0.00044719275,0.00041455904,0.0004147124,0.0005554349,0.00026781764,0.0016582233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9930302,0.000384435,0.0012503546,0.0020074495,0.0013011742,0.002026419],"domain_scores_gemma":[0.99568236,0.00028043514,0.0005547761,0.0015528575,0.00022814347,0.0017014579],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003764432,0.0013180824,0.00158683,0.00045590036,0.0007312686,0.0002763375,0.0006081999,0.0010398407,0.00067800394],"category_scores_gemma":[0.000101728125,0.0011487327,0.00049211894,0.00054881384,0.00044576658,0.0006580416,0.0005290031,0.00042352284,0.00030256153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033383658,0.0006491248,0.004409452,0.00019407085,0.00043012534,0.00086378737,0.0011917902,8.959253e-7,0.89912385,0.000008171999,0.008003741,0.081786595],"study_design_scores_gemma":[0.02506758,0.0008809221,0.042856272,0.00071362004,0.00036861334,0.00028415857,0.0004898461,0.0010181363,0.92363155,0.00008706968,0.0035511218,0.0010511075],"about_ca_topic_score_codex":0.0074681016,"about_ca_topic_score_gemma":0.00005039305,"teacher_disagreement_score":0.08073549,"about_ca_system_score_codex":0.0045004166,"about_ca_system_score_gemma":0.002355627,"threshold_uncertainty_score":0.9999571},"labels":[],"label_agreement":null},{"id":"W2113301890","doi":"10.3109/10428191003802340","title":"Human leukocyte antigen class I alleles and the risk of chronic myelogenous leukemia: a meta-analysis","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Odds ratio; Chronic myelogenous leukemia; Human leukocyte antigen; Meta-analysis; Allele; Immunology; Medicine; Context (archaeology); Population; Leukemia; Oncology; Biology; Genetics; Internal medicine; Antigen; Environmental health; Gene","score_opus":0.03427095306676008,"score_gpt":0.2982893996736653,"score_spread":0.2640184466069052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2113301890","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045280952,0.94628745,0.000038759652,0.00007067198,0.00031348987,0.0045710197,0.0006695741,0.00032874514,0.0024393122],"genre_scores_gemma":[0.028872263,0.96282095,0.00054942747,0.00031757576,0.00090050127,0.0012780966,0.0010742286,0.0005506678,0.0036362659],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.985693,0.0018317126,0.0045288317,0.0036100596,0.0019997195,0.0023366779],"domain_scores_gemma":[0.9866504,0.0022242425,0.004442384,0.004987055,0.00047867149,0.0012172377],"candidate_categories":["metaepi_narrow","metaepi_broad","sts","research_integrity"],"consensus_categories":["metaepi_narrow","metaepi_broad","sts"],"category_scores_codex":[0.0027209884,0.0037602796,0.018823951,0.0018318925,0.0014423041,0.00035675915,0.00174684,0.0036617797,0.00044456267],"category_scores_gemma":[0.00042535597,0.0023714988,0.010156206,0.002783267,0.0039304635,0.0003486332,0.0012765424,0.0017849371,0.00011280326],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004709303,0.00031442547,0.00021581704,0.0112045,0.3104948,0.0007891755,0.0007839713,0.00005155898,0.00004734159,0.001355532,0.0009967148,0.67327523],"study_design_scores_gemma":[0.019788861,0.00049057684,0.0009191321,0.0010481155,0.49526763,0.0029021704,0.00010511907,0.00094722724,0.000091049034,0.00017587439,0.47664547,0.0016187782],"about_ca_topic_score_codex":0.012025677,"about_ca_topic_score_gemma":0.0021417725,"teacher_disagreement_score":0.6716564,"about_ca_system_score_codex":0.028701669,"about_ca_system_score_gemma":0.02514529,"threshold_uncertainty_score":0.99985766},"labels":[],"label_agreement":null},{"id":"W2114541062","doi":"10.3109/10428194.2013.770151","title":"Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1–2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre de Santé et de Services Sociaux de Chicoutimi","funders":"National Comprehensive Cancer Network","keywords":"Medicine; Positron emission tomography; Follicular lymphoma; Stage (stratigraphy); Lymphoma; Nuclear medicine; Radiation therapy; Radiology; Internal medicine","score_opus":0.043497121389043866,"score_gpt":0.33806455552479425,"score_spread":0.2945674341357504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114541062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916913,0.0029456394,0.000026829559,0.00015681928,0.00017675577,0.0030961633,0.0017517677,0.000043952336,0.0001107904],"genre_scores_gemma":[0.9944527,0.0023644657,0.0003753274,0.0007311017,0.00025540593,0.0009683778,0.0007037637,0.00010773395,0.000041111845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99472487,0.00033614508,0.00162656,0.0010737189,0.0011506238,0.0010880741],"domain_scores_gemma":[0.99552125,0.0017505783,0.00095572614,0.0007147351,0.0005972556,0.0004604371],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003671517,0.0011266761,0.0019901355,0.00064798293,0.00028385612,0.00012167123,0.0003445034,0.0004509564,0.000053148393],"category_scores_gemma":[0.00008660433,0.0007576303,0.00076003064,0.0006770142,0.0002786687,0.0005928847,0.00018416604,0.00007932712,0.0000023955956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077303783,0.0068617254,0.7319412,0.0017361136,0.004009841,0.0004472186,0.0027734095,0.0018654584,0.023972748,0.0011675723,0.002358994,0.21513532],"study_design_scores_gemma":[0.043325223,0.0032035038,0.8806025,0.0014034456,0.00080532266,0.00022219443,0.0005525225,0.006938633,0.06177036,0.00016886389,0.0003644588,0.0006430205],"about_ca_topic_score_codex":0.017922066,"about_ca_topic_score_gemma":0.00017815708,"teacher_disagreement_score":0.2144923,"about_ca_system_score_codex":0.003884637,"about_ca_system_score_gemma":0.0025994505,"threshold_uncertainty_score":0.99993926},"labels":[],"label_agreement":null},{"id":"W2115374164","doi":"10.1080/10428190701706410","title":"David A. G. Galton: a personal perspective","year":2007,"lang":"sv","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Academic and Historical Perspectives in Psychology","field":"Psychology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Galton's problem; Perspective (graphical); Genealogy; Medicine; Environmental ethics; Biology; Computer science; History; Philosophy; Mathematics; Statistics; Artificial intelligence","score_opus":0.015434343030066466,"score_gpt":0.30857361458260396,"score_spread":0.2931392715525375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115374164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47815502,0.060342602,0.0017527249,0.001658964,0.00938213,0.001271605,0.00023030606,0.00064402644,0.44656262],"genre_scores_gemma":[0.9345986,0.0034041628,0.00073849567,0.007019663,0.0061643734,0.00010915498,0.00006916318,0.00042172166,0.047474667],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98676956,0.0007797714,0.0023481552,0.004476695,0.0014800604,0.0041457703],"domain_scores_gemma":[0.9926303,0.001597051,0.0011812381,0.00183188,0.00067056966,0.0020889523],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","insufficient_payload"],"category_scores_codex":[0.0023619598,0.002277206,0.0024203914,0.0012390014,0.0016666971,0.00023982815,0.001740099,0.004187531,0.003089831],"category_scores_gemma":[0.0003897456,0.00242727,0.0010454782,0.0019027346,0.0038409932,0.00059352344,0.0006920928,0.0015271961,0.0026640636],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010150378,0.002114464,0.008812519,0.00039456267,0.0030794297,0.005847357,0.18697561,0.0000070926576,0.0023572634,0.28337023,0.20834956,0.28854153],"study_design_scores_gemma":[0.0332023,0.0021452107,0.19983982,0.0004527143,0.0012658356,0.008839069,0.085753925,0.000725446,0.00027753724,0.0125634745,0.6503871,0.00454756],"about_ca_topic_score_codex":0.007360527,"about_ca_topic_score_gemma":0.00020585574,"teacher_disagreement_score":0.45644358,"about_ca_system_score_codex":0.0473445,"about_ca_system_score_gemma":0.0041288687,"threshold_uncertainty_score":0.999633},"labels":[],"label_agreement":null},{"id":"W2118057314","doi":"10.3109/10428194.2012.682314","title":"Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors","year":2012,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Blast Crisis; Imatinib; Imatinib mesylate; Myeloid leukemia; Internal medicine; Immunology; Oncology","score_opus":0.010599954824801078,"score_gpt":0.2298835276421774,"score_spread":0.21928357281737632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118057314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94205624,0.022017464,0.00001997032,0.021261819,0.0011607115,0.004675736,0.0005642977,0.0013200336,0.0069237263],"genre_scores_gemma":[0.8069159,0.0064427895,0.00094876613,0.13791366,0.016192783,0.0019403945,0.00827335,0.0022265892,0.019145804],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98388207,0.0006039556,0.003079038,0.004410985,0.0028550972,0.005168844],"domain_scores_gemma":[0.9916305,0.00071538886,0.0015751094,0.0038750526,0.00049986533,0.0017040855],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00075584045,0.0044725663,0.0051741106,0.002479519,0.0006580533,0.00046278702,0.0012330563,0.005788288,0.00081716035],"category_scores_gemma":[0.00015734494,0.0038732036,0.0010782316,0.002744004,0.0013319446,0.0010669333,0.0007695221,0.0027345617,0.0008512378],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0033103775,0.0005666911,0.018601494,0.004391848,0.0026619001,0.029755,0.0013207057,0.00013101497,0.0028577652,0.000053087275,0.8650594,0.07129077],"study_design_scores_gemma":[0.08901251,0.003115962,0.047141545,0.007044984,0.005081193,0.012676706,0.00060862006,0.0016570652,0.014314119,0.00006391201,0.81295085,0.006332512],"about_ca_topic_score_codex":0.02286553,"about_ca_topic_score_gemma":0.0012538851,"teacher_disagreement_score":0.15329991,"about_ca_system_score_codex":0.186537,"about_ca_system_score_gemma":0.033237085,"threshold_uncertainty_score":0.9999267},"labels":[],"label_agreement":null},{"id":"W2118461306","doi":"10.1080/10428190500032273","title":"Prolonged treatment response in aggressive natural killer cell leukemia","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Cytopenia; Medicine; Hepatosplenomegaly; Bone marrow; Spleen; Splenectomy; Pentostatin; Immunology; Immunosuppression; Leukemia; Pathology; Disease; Lymphoma","score_opus":0.006797536973110428,"score_gpt":0.2207631312537711,"score_spread":0.21396559428066067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118461306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97609895,0.013649242,0.000014349731,0.00034724374,0.0039882823,0.0007183328,0.0000108830845,0.0002818014,0.004890892],"genre_scores_gemma":[0.934904,0.0012735402,0.00012855662,0.00116601,0.0002112804,0.0002249621,0.00023865368,0.00009272261,0.061760265],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99574167,0.00073784316,0.0010090224,0.0011535728,0.0001578857,0.0011999963],"domain_scores_gemma":[0.99787825,0.000517162,0.0005751018,0.00077585096,0.00011554189,0.00013809463],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046646083,0.00088017766,0.00088579266,0.0006099281,0.000521501,0.00011307549,0.00039451057,0.0008997774,0.0007136685],"category_scores_gemma":[0.00016327649,0.00076840626,0.00032703052,0.00045236325,0.0003856206,0.00060657563,0.00017546726,0.00035253356,0.001720112],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04097702,0.0011367146,0.003844531,0.00011405884,0.00066736346,0.00059371325,0.009395884,0.0006225828,0.42725903,0.00035142206,0.03707876,0.47795892],"study_design_scores_gemma":[0.03814423,0.0015127562,0.087068394,0.00024088041,0.0001711894,0.0019576421,0.0013235261,0.0019532302,0.1947883,0.000043018048,0.6713903,0.0014065211],"about_ca_topic_score_codex":0.0013489417,"about_ca_topic_score_gemma":0.0002881287,"teacher_disagreement_score":0.63431156,"about_ca_system_score_codex":0.016821261,"about_ca_system_score_gemma":0.0023627165,"threshold_uncertainty_score":0.9994767},"labels":[],"label_agreement":null},{"id":"W2118515712","doi":"10.3109/10428194.2015.1018248","title":"A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Decitabine; Vorinostat; Medicine; Myeloid leukemia; Schedule; Myeloid; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Biology","score_opus":0.027536819723377324,"score_gpt":0.29850660911470805,"score_spread":0.2709697893913307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2118515712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942765,0.001330349,0.00013624088,0.000099786026,0.00030494694,0.0023768588,0.00026500507,0.000112073896,0.0010982152],"genre_scores_gemma":[0.990887,0.0013232251,0.0063134297,0.00018758408,0.000268607,0.00016185553,0.00034501633,0.00017652371,0.0003367678],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9931181,0.0003152363,0.0018652807,0.0014618969,0.0018761669,0.0013632963],"domain_scores_gemma":[0.9952183,0.00045738544,0.00077980885,0.0013772398,0.00094149547,0.0012258168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011165256,0.0010257591,0.0022691833,0.001151565,0.00015258578,0.000089547255,0.0005781239,0.0005886818,0.000034252564],"category_scores_gemma":[0.00033932773,0.0008537057,0.00023605974,0.0016417078,0.0015837754,0.00070581795,0.00048496874,0.00041115517,0.000015574586],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.4278571,0.004161816,0.15621848,0.0011440433,0.0016504906,0.0020343217,0.0046788105,0.00012899541,0.011769232,0.004508953,0.0021246623,0.38372308],"study_design_scores_gemma":[0.8755259,0.014072043,0.08039785,0.0010822156,0.00063744956,0.00069806,0.0010761829,0.0040063434,0.016798753,0.00077933684,0.003572358,0.0013535235],"about_ca_topic_score_codex":0.002041428,"about_ca_topic_score_gemma":0.00009253364,"teacher_disagreement_score":0.44766876,"about_ca_system_score_codex":0.010028788,"about_ca_system_score_gemma":0.01175225,"threshold_uncertainty_score":0.9993914},"labels":[],"label_agreement":null},{"id":"W2119879346","doi":"10.3109/10428194.2013.796046","title":"Granulocyte colony-stimulating factor as secondary prophylaxis of febrile neutropenia in the management of advanced-stage Hodgkin lymphoma treated with adriamycin, bleomycin, vinblastine and dacarbazine chemotherapy: a decision analysis","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; ABVD; Dacarbazine; Febrile neutropenia; Vinblastine; Neutropenia; Internal medicine; Lymphoma; Granulocyte colony-stimulating factor; Bleomycin; Oncology; Chemotherapy; Vincristine; Cyclophosphamide","score_opus":0.006334859424107247,"score_gpt":0.24027529736222186,"score_spread":0.23394043793811461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119879346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339247,0.0010860225,0.0001349649,0.000104405444,0.00006195874,0.0023208214,0.000080482016,0.00008268709,0.0027362045],"genre_scores_gemma":[0.99525476,0.0009993429,0.0018873976,0.00048078765,0.000065553744,0.0003892716,0.0000869019,0.000095344294,0.0007406191],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.996053,0.00017190543,0.0012137895,0.0010646116,0.0007877587,0.0007089546],"domain_scores_gemma":[0.99729216,0.00033794914,0.00064840395,0.001024026,0.00038986965,0.00030758954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003147166,0.0007533926,0.0016066338,0.0007206684,0.00025767743,0.000108974884,0.00036564088,0.0002924326,0.00034238634],"category_scores_gemma":[0.000034736295,0.0005232325,0.00029190123,0.002534508,0.00040729405,0.00042090876,0.0001795819,0.00016695783,0.0000115546745],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008783279,0.0009079695,0.31823722,0.0017390187,0.0035021694,0.0005818045,0.0023059137,0.0018606592,0.044642165,0.0003371174,0.00030969508,0.616793],"study_design_scores_gemma":[0.03157054,0.0026607562,0.94233483,0.00073408935,0.0013531126,0.00039279312,0.0013889197,0.0033582787,0.014098569,0.000059790582,0.0014595903,0.00058870454],"about_ca_topic_score_codex":0.00611775,"about_ca_topic_score_gemma":0.00044269962,"teacher_disagreement_score":0.62409765,"about_ca_system_score_codex":0.0015647857,"about_ca_system_score_gemma":0.000891278,"threshold_uncertainty_score":0.99972194},"labels":[],"label_agreement":null},{"id":"W2119915366","doi":"10.3109/10428190009148856","title":"The Use of Archival Bone Marrow Specimens in Detecting B-Cell Non-Hodgkin's Lymphomas Using Polymerase Chain Reaction Methods","year":2000,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton","funders":"","keywords":"Lymphoma; Bone marrow; Pathology; Polymerase chain reaction; Biopsy; Non-Hodgkin's lymphoma; Monoclonal; Medicine; Biology; Molecular biology; Monoclonal antibody; Antibody; Gene; Immunology","score_opus":0.026970797353493493,"score_gpt":0.2842633691387643,"score_spread":0.2572925717852708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119915366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913132,0.0028014435,0.00013248688,0.00017586631,0.00036848828,0.0011467178,0.000037566817,0.00013808884,0.0038861153],"genre_scores_gemma":[0.98023504,0.0029127882,0.013716966,0.00057039445,0.00036551125,0.00014757106,0.000052856976,0.00017330736,0.0018255812],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941182,0.0005975882,0.0017063232,0.0013072309,0.00081852445,0.0014521204],"domain_scores_gemma":[0.9956144,0.0016364222,0.000632389,0.0013583385,0.0001377468,0.0006207223],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010562907,0.0009994141,0.0014907776,0.0005669976,0.0007170316,0.00021760832,0.00031469588,0.00046341642,0.00008376155],"category_scores_gemma":[0.0002061338,0.0007948668,0.00054739113,0.0010811135,0.0005649564,0.0005101436,0.00019448566,0.0002176114,0.000034295164],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028251202,0.00085821614,0.012271836,0.00021152291,0.0003026524,0.0010006768,0.0011488667,0.00030653208,0.1158933,0.00018612396,0.00028254764,0.8647126],"study_design_scores_gemma":[0.06247854,0.0015518495,0.4704781,0.0015729017,0.0013852057,0.006607569,0.0012029884,0.0858609,0.32423875,0.00042187856,0.042047422,0.0021539323],"about_ca_topic_score_codex":0.011422258,"about_ca_topic_score_gemma":0.00022487433,"teacher_disagreement_score":0.86255866,"about_ca_system_score_codex":0.008169762,"about_ca_system_score_gemma":0.0025905932,"threshold_uncertainty_score":0.9994502},"labels":[],"label_agreement":null},{"id":"W2120309731","doi":"10.3109/10428194.2014.970548","title":"Development and characterization of a Mantle Cell Lymphoma Cell Bank in the American Type Culture Collection","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Mantle cell lymphoma; Lymphoma; Cell culture; Medicine; Malignancy; Disease; Cancer research; Biology; Pathology; Genetics","score_opus":0.007498928054494789,"score_gpt":0.2181362960515551,"score_spread":0.21063736799706032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120309731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926142,0.0006919033,0.00002703067,0.0001460131,0.00015894265,0.00072181894,0.0000137943725,0.000069215,0.005557092],"genre_scores_gemma":[0.99442065,0.0016254024,0.0010827237,0.0011986987,0.00014124592,0.00014615506,0.00019830724,0.000059303864,0.0011274865],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971974,0.00019668254,0.0007468383,0.0007446457,0.00054110383,0.00057332404],"domain_scores_gemma":[0.99841154,0.00017373974,0.0004891011,0.000531754,0.00014750853,0.00024634958],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004000953,0.0005525588,0.0008714584,0.00030388162,0.000294334,0.000097403245,0.00020685043,0.0002462548,0.000015051851],"category_scores_gemma":[0.000039959905,0.00040289888,0.000121867866,0.00096301804,0.00027327,0.00017318907,0.00010976988,0.000069687434,0.000028475892],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032347317,0.00382438,0.18710057,0.0014708892,0.00035070235,0.00041539693,0.02214977,0.0000116176725,0.13330844,0.0010352685,0.0032266036,0.6438716],"study_design_scores_gemma":[0.017808972,0.0009547638,0.83787954,0.00022994325,0.0002448995,0.0004579158,0.0011796838,0.0014441909,0.08161751,0.00004927832,0.05761581,0.0005174771],"about_ca_topic_score_codex":0.0009406087,"about_ca_topic_score_gemma":0.000095317744,"teacher_disagreement_score":0.65077895,"about_ca_system_score_codex":0.0026170257,"about_ca_system_score_gemma":0.0013936332,"threshold_uncertainty_score":0.9998423},"labels":[],"label_agreement":null},{"id":"W2120629149","doi":"10.3109/10428194.2012.737917","title":"A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Cytarabine; Internal medicine; Sorafenib; Myeloid leukemia; Myelodysplastic syndromes; Oncology; Rash; Cancer; Leukemia; Bone marrow","score_opus":0.03020316122113193,"score_gpt":0.3264832382603513,"score_spread":0.2962800770392194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120629149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99206203,0.0002328288,0.00004158457,0.00017307494,0.00070971175,0.0059108404,0.00076246494,0.000050720948,0.000056714],"genre_scores_gemma":[0.99675345,0.00031465385,0.000367627,0.00032101976,0.00045944634,0.0008724123,0.0005864974,0.00013804124,0.00018682705],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9892795,0.0017691777,0.0033873925,0.001275042,0.0029272926,0.0013616097],"domain_scores_gemma":[0.9920039,0.0035324395,0.002082812,0.0009160293,0.00075074437,0.0007140394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004461394,0.0010186442,0.003218067,0.0007349337,0.00037336088,0.0000655,0.00076454546,0.00064981985,0.00008832252],"category_scores_gemma":[0.002162233,0.000639996,0.00021187941,0.0021700673,0.0008111128,0.0009244379,0.00035539482,0.00082477607,0.0000035029072],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.5228918,0.01920349,0.3511044,0.00041148698,0.004264914,0.0011867404,0.004812072,0.00084579596,0.000607884,0.00019542694,0.002011264,0.09246473],"study_design_scores_gemma":[0.43367037,0.016894272,0.5442885,0.0007774996,0.00084613776,0.00011197208,0.0006382918,0.0016469985,0.00020271548,0.00004011871,0.0003148206,0.00056827965],"about_ca_topic_score_codex":0.44782406,"about_ca_topic_score_gemma":0.2799508,"teacher_disagreement_score":0.19318412,"about_ca_system_score_codex":0.01914441,"about_ca_system_score_gemma":0.03366124,"threshold_uncertainty_score":0.9996051},"labels":[],"label_agreement":null},{"id":"W2121142323","doi":"10.3109/10428194.2015.1010079","title":"Barriers to enrollment of patients with recurrent diffuse large B-cell lymphoma onto clinical trials","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Medicine; Internal medicine; Oncology; Refractory (planetary science); Clinical trial; Biology","score_opus":0.03231703514413337,"score_gpt":0.31077920280161025,"score_spread":0.2784621676574769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121142323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96399283,0.0046697087,0.00004070404,0.014460747,0.0025684012,0.0067590047,0.003001204,0.00037233508,0.0041350853],"genre_scores_gemma":[0.66179866,0.00268741,0.001880941,0.31250522,0.0057536643,0.002027378,0.0062953862,0.0009798801,0.0060714968],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98292226,0.0019816016,0.00529041,0.0034791867,0.0036467277,0.0026798362],"domain_scores_gemma":[0.98644084,0.0021511894,0.0029455773,0.0031714132,0.0013589023,0.0039320765],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0038124705,0.0028943373,0.0076427027,0.0010888575,0.00047051665,0.00028056838,0.001068186,0.0034201352,0.00026484902],"category_scores_gemma":[0.0020675906,0.0021565913,0.0019278079,0.0010029431,0.0006331447,0.0003463615,0.0008020251,0.0006495144,0.0002686134],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008970414,0.007025703,0.071405105,0.0012933766,0.0027714353,0.00206731,0.0010076176,0.000002733369,0.000014959095,0.00004929442,0.7922036,0.11318842],"study_design_scores_gemma":[0.18816221,0.005839722,0.08392619,0.0016474071,0.004081746,0.00017189028,0.00026285404,0.00011040823,0.00045910987,0.000050610226,0.71327376,0.002014113],"about_ca_topic_score_codex":0.0012641299,"about_ca_topic_score_gemma":0.00011325055,"teacher_disagreement_score":0.30219418,"about_ca_system_score_codex":0.020851562,"about_ca_system_score_gemma":0.01925212,"threshold_uncertainty_score":0.9983788},"labels":[],"label_agreement":null},{"id":"W2121252697","doi":"10.1080/10428190410001673409","title":"Intracranial Presentation of Systemic Hodgkin's Disease","year":2004,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cape Breton University; Dalhousie University; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Presentation (obstetrics); Medicine; Disease; Pathology; Radiology","score_opus":0.01975733090592726,"score_gpt":0.2954856302587458,"score_spread":0.27572829935281856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2121252697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032533072,0.96195745,0.000040738996,0.000034372395,0.00069432845,0.0032882828,0.00046015895,0.000257911,0.0007336858],"genre_scores_gemma":[0.05540535,0.9403834,0.0003294168,0.00010380842,0.00073319534,0.00090428913,0.0012150343,0.0003204007,0.00060515734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932504,0.00030214596,0.0023946017,0.0017782091,0.0011895878,0.0010850294],"domain_scores_gemma":[0.99486,0.0005405642,0.0014422612,0.0016435463,0.000268489,0.0012451306],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00033595692,0.0017548195,0.004939467,0.0008459926,0.00027569293,0.0001511018,0.00050205924,0.0011420901,0.000104486615],"category_scores_gemma":[0.00019665378,0.0014404979,0.0017878293,0.00094953127,0.00050655275,0.00028080549,0.00031550668,0.00021955131,0.00017267703],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00041887726,0.00060962903,0.0004782541,0.052812323,0.0012182586,0.0018073247,0.00023292798,0.000009154543,0.000008477718,0.0007746362,0.00041496285,0.94121516],"study_design_scores_gemma":[0.041538324,0.001396721,0.026107408,0.19933264,0.030012382,0.018867983,0.00033689482,0.00044148465,0.000110518755,0.0004901083,0.6777665,0.0035990642],"about_ca_topic_score_codex":0.0014381638,"about_ca_topic_score_gemma":0.000020624366,"teacher_disagreement_score":0.9376161,"about_ca_system_score_codex":0.017746309,"about_ca_system_score_gemma":0.017659875,"threshold_uncertainty_score":0.99951977},"labels":[],"label_agreement":null},{"id":"W2122782874","doi":"10.3109/10428190109097657","title":"Seroprevalence of Helicobacter Pylori Infection in Patients with Lymphoma","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Helicobacter pylori-related gastroenterology studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Seroprevalence; Helicobacter pylori infection; Medicine; Helicobacter pylori; Lymphoma; Internal medicine; Helicobacter Infections; Immunology; Gastroenterology; Serology; Antibody","score_opus":0.008118880540723683,"score_gpt":0.221649423264312,"score_spread":0.21353054272358832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122782874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652886,0.00038290993,0.000052691365,0.00019274683,0.00036178133,0.0009072019,0.00003057687,0.00020682115,0.0013363875],"genre_scores_gemma":[0.99624115,0.0015688465,0.00037399726,0.00089247094,0.00018064838,0.0001144792,0.00010258197,0.000119899814,0.00040594503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99559295,0.00018148536,0.0011711861,0.0011225935,0.00076032575,0.001171432],"domain_scores_gemma":[0.9975336,0.0001437798,0.00047968375,0.00089043233,0.0005077611,0.0004447016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003002151,0.00083205244,0.001318608,0.0006936973,0.00020318474,0.000047541784,0.00025768043,0.00058555236,0.000059140406],"category_scores_gemma":[0.000146387,0.0007080631,0.00019285081,0.001221003,0.0006344077,0.0005497296,0.00024392475,0.0001940913,0.000061082814],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039198496,0.00061529677,0.94098234,0.00023680592,0.0004237038,0.00020961168,0.0008284576,0.000039788345,0.00044242214,0.00003535296,0.00020439032,0.05206201],"study_design_scores_gemma":[0.035330128,0.0015242897,0.9570648,0.0007269276,0.0003553327,0.0005603122,0.00011953089,0.0004191468,0.000883824,0.000026898972,0.0024537873,0.0005350286],"about_ca_topic_score_codex":0.0017873545,"about_ca_topic_score_gemma":0.00041915404,"teacher_disagreement_score":0.05152698,"about_ca_system_score_codex":0.004674383,"about_ca_system_score_gemma":0.0010484449,"threshold_uncertainty_score":0.99953705},"labels":[],"label_agreement":null},{"id":"W2123670570","doi":"10.3109/10428191003729741","title":"Mutations in ABL kinase domain are associated with inferior progression-free survival","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Imatinib mesylate; ABL; Point mutation; Fusion gene; Cancer research; Imatinib; Protein kinase domain; Mutation; Myeloid leukemia; Biology; Medicine; Tyrosine kinase; Gene; Genetics; Mutant; Receptor","score_opus":0.009334364910513348,"score_gpt":0.2532084003162289,"score_spread":0.24387403540571553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123670570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913093,0.0004913733,0.000030870444,0.00046673455,0.0005298089,0.0013674728,0.00015961415,0.00046371258,0.005181113],"genre_scores_gemma":[0.99430245,0.00009820798,0.0026165263,0.0005781434,0.00033707792,0.0004542059,0.0005087283,0.0002135992,0.00089106575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99449724,0.00027942815,0.0010699454,0.0014119989,0.0012891125,0.0014522568],"domain_scores_gemma":[0.9954939,0.0010046808,0.0005951748,0.0016834247,0.00031319336,0.0009096145],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088512193,0.0010366692,0.0014305193,0.0006254421,0.00046933585,0.0001901744,0.0005489754,0.00091314764,0.00022071826],"category_scores_gemma":[0.0014773433,0.00086042425,0.0002441511,0.0013697582,0.00079444796,0.00046165907,0.00033530872,0.0005550879,0.000078975216],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0046152654,0.0025026721,0.82974094,0.00050545624,0.0010518238,0.011199031,0.00432017,0.00008600795,0.012788959,0.0025757619,0.00237134,0.12824255],"study_design_scores_gemma":[0.06353758,0.0005144121,0.92178017,0.0012630023,0.000382851,0.0013102693,0.0010900312,0.0014379558,0.0025264404,0.0009773483,0.0041057505,0.0010742104],"about_ca_topic_score_codex":0.0016599554,"about_ca_topic_score_gemma":0.0067720884,"teacher_disagreement_score":0.12716834,"about_ca_system_score_codex":0.012574623,"about_ca_system_score_gemma":0.00786569,"threshold_uncertainty_score":0.99938464},"labels":[],"label_agreement":null},{"id":"W2123817338","doi":"10.1080/10428190410001697395","title":"Improved Outcome of Human Immunodeficiency Virus-Associated Plasmablastic Lymphoma of the Oral Cavity in the Era of Highly Active Antiretroviral Therapy: A Report of Two Cases","year":2004,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Plasmablastic lymphoma; Medicine; Lymphoma; CHOP; Internal medicine; Chemotherapy; Viral load; Human immunodeficiency virus (HIV); Gastroenterology; Immunology","score_opus":0.015793737149852626,"score_gpt":0.27670560593632115,"score_spread":0.26091186878646855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123817338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963334,0.0011772285,0.000007998457,0.000094413655,0.0002251696,0.0009943774,0.00022721858,0.000043183456,0.00089697354],"genre_scores_gemma":[0.9990709,0.0002881766,0.000053171243,0.0002802205,0.000032725202,0.00005199757,0.00006183144,0.00006977938,0.000091220514],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99512374,0.00032835113,0.002079324,0.0006659516,0.0010462695,0.0007563621],"domain_scores_gemma":[0.9957094,0.00037663776,0.0022647593,0.0011250711,0.00040419455,0.00011989943],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093102857,0.000634584,0.0017970391,0.00028198338,0.00026628,0.000025158772,0.0006861091,0.00045061673,0.000014012337],"category_scores_gemma":[0.00055954163,0.0004273117,0.0006765411,0.0015040978,0.0011965226,0.00024568546,0.00019276899,0.00022900489,6.9131727e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071225376,0.00488639,0.4028551,0.00087354373,0.0014703311,0.00079936645,0.014132988,0.0005578818,0.5083747,0.0020337382,0.00013707143,0.056756355],"study_design_scores_gemma":[0.057381768,0.0031343566,0.775188,0.00078940985,0.00058508466,0.0005788973,0.0031571486,0.0005349696,0.15730599,0.00073488033,0.000044059925,0.00056538533],"about_ca_topic_score_codex":0.08333844,"about_ca_topic_score_gemma":0.0030868247,"teacher_disagreement_score":0.37233293,"about_ca_system_score_codex":0.0042943773,"about_ca_system_score_gemma":0.004380269,"threshold_uncertainty_score":0.99981785},"labels":[],"label_agreement":null},{"id":"W2127063344","doi":"10.1080/00268970500096616","title":"Malignant pleural effusions in lymphoproliferative disorders","year":2005,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Pleural and Pulmonary Diseases","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dartmouth General Hospital; Dalhousie University; University of Saskatchewan","funders":"","keywords":"Lymphoproliferative disorders; Medicine; Hematological disorders; Pleural effusion; Pathology; Dermatology; Immunology; Lymphoma; Internal medicine","score_opus":0.009058763380532296,"score_gpt":0.24037587551305445,"score_spread":0.23131711213252215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2127063344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98218685,0.0037785124,0.000018148234,0.0020352625,0.00022356992,0.0008377381,0.00009411186,0.00028316455,0.010542624],"genre_scores_gemma":[0.9881254,0.0020619468,0.0005417482,0.0038782111,0.00057268434,0.00019655228,0.00021112316,0.00010036464,0.004312002],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99594426,0.00015929325,0.00092117296,0.0011185926,0.000647201,0.0012094958],"domain_scores_gemma":[0.99791753,0.00024389665,0.00019705866,0.0006675355,0.00009489801,0.0008790662],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024104821,0.0007991809,0.0009987758,0.0004724761,0.00039380437,0.00009995874,0.0003172908,0.00040623176,0.00027422982],"category_scores_gemma":[0.00012702035,0.00066987413,0.00034934306,0.0007715447,0.00040653892,0.00053640996,0.00024668782,0.00016282931,0.00024020042],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039970917,0.0014427496,0.23371632,0.00044830755,0.00029845457,0.0016546287,0.0029664892,0.00041505386,0.008823436,0.002841464,0.008868108,0.7345279],"study_design_scores_gemma":[0.02347486,0.0005326292,0.86631817,0.0005790961,0.00027564116,0.002180251,0.0009005996,0.021461539,0.0027189392,0.0009294393,0.0793179,0.0013109614],"about_ca_topic_score_codex":0.0017722258,"about_ca_topic_score_gemma":0.000809642,"teacher_disagreement_score":0.73321694,"about_ca_system_score_codex":0.004723373,"about_ca_system_score_gemma":0.0026093726,"threshold_uncertainty_score":0.99957526},"labels":[],"label_agreement":null},{"id":"W2128096360","doi":"10.1080/1042819021000015989-1","title":"Molecular Analysis of a New Variant of the CBFβ - MYH11 Gene Fusion","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Fusion gene; Chromosomal inversion; Molecular biology; Biology; Breakpoint; Gene; Genetics; Chromosome; Karyotype","score_opus":0.01559876478246606,"score_gpt":0.24700998108138367,"score_spread":0.23141121629891762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128096360","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9882554,0.003667652,0.0005346814,0.0005925635,0.0001777034,0.0007791842,0.00007596808,0.00009366045,0.005823224],"genre_scores_gemma":[0.99180144,0.001367924,0.001613012,0.001065781,0.00014481023,0.000034283607,0.00006116412,0.00010617196,0.0038054255],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9948833,0.0002601596,0.0013438244,0.0010250898,0.0015185649,0.00096906355],"domain_scores_gemma":[0.99593043,0.00028700253,0.00064349564,0.0020651198,0.00037228613,0.0007016783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054540555,0.00067151734,0.0017252775,0.000999008,0.00023897916,0.000051212206,0.0008409527,0.00060975784,0.000561331],"category_scores_gemma":[0.0003679414,0.00050007075,0.0010149474,0.004157379,0.0006492371,0.00018665704,0.00063522294,0.00025048942,0.00003668693],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021463821,0.0010632694,0.02716376,0.0009426081,0.010384921,0.0018409699,0.0062197945,0.0019525834,0.5952272,0.004366029,0.019182615,0.3295099],"study_design_scores_gemma":[0.035716675,0.0010796443,0.43583828,0.00068486534,0.0114535885,0.0023586089,0.0007322852,0.19329953,0.2989655,0.00054810167,0.017841896,0.0014809957],"about_ca_topic_score_codex":0.0051300297,"about_ca_topic_score_gemma":0.000073844196,"teacher_disagreement_score":0.4086745,"about_ca_system_score_codex":0.004566905,"about_ca_system_score_gemma":0.0034306648,"threshold_uncertainty_score":0.9997451},"labels":[],"label_agreement":null},{"id":"W2128185159","doi":"10.3109/10428194.2011.553001","title":"Paired box gene 5 may modulate Proviral Integration of Moloney virus2gene and protein expression in mature B-cells","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atlantic Cancer Research Institute","funders":"Canadian Institutes of Health Research","keywords":"Gene isoform; Molecular biology; Biology; HEK 293 cells; Transfection; Transcription factor; Western blot; Gene; Cell culture; Gene expression; Carcinogenesis; Cancer research; Genetics","score_opus":0.015910921200222087,"score_gpt":0.2265344543100825,"score_spread":0.21062353310986043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2128185159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950139,0.001992453,0.0005370785,0.00005259821,0.00018379958,0.0012135466,0.00003732081,0.00009790025,0.0008714289],"genre_scores_gemma":[0.98701304,0.000642928,0.0106466,0.00036096046,0.00013147158,0.00017687876,0.000049384216,0.000084587016,0.00089412555],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997494,0.00011238181,0.00071832375,0.0007597853,0.00038995233,0.00052559166],"domain_scores_gemma":[0.99869794,0.000028233782,0.00031615002,0.0005626377,0.00010452427,0.00029050236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032461627,0.00050426973,0.00079716806,0.00032182204,0.000111100715,0.000036527264,0.00016529279,0.00052629574,0.00006940913],"category_scores_gemma":[0.000024532847,0.00042213657,0.00013858304,0.0003504947,0.00019799387,0.00027774833,0.0001209629,0.00014748986,0.000007065724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027480042,0.00021481149,0.00077278825,0.00024722106,0.00005783179,0.00017413792,0.0024171993,0.00000419527,0.90721196,0.0007505714,0.00012694995,0.08527432],"study_design_scores_gemma":[0.013838112,0.0007792799,0.03606511,0.000758857,0.00007734781,0.00024302478,0.00033457266,0.002127305,0.9426538,0.0019164489,0.0007508449,0.0004553349],"about_ca_topic_score_codex":0.0024463579,"about_ca_topic_score_gemma":0.00011531268,"teacher_disagreement_score":0.08481898,"about_ca_system_score_codex":0.0014358737,"about_ca_system_score_gemma":0.00092815957,"threshold_uncertainty_score":0.99982303},"labels":[],"label_agreement":null},{"id":"W2129504146","doi":"10.3109/10428194.2014.951848","title":"Single nucleotide polymorphisms in non-coding region of the glucocorticoid receptor gene and prednisone response in childhood acute lymphoblastic leukemia","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Education and Early Childhood Development","funders":"First Hospital of Jilin University","keywords":"Prednisone; Single-nucleotide polymorphism; Haplotype; Odds ratio; Allele; Glucocorticoid; Medicine; Glucocorticoid receptor; Internal medicine; Oncology; Gene; Genetics; Biology; Immunology; Genotype","score_opus":0.014379983887584697,"score_gpt":0.24005891617737168,"score_spread":0.225678932289787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2129504146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99357975,0.001470412,0.00018975708,0.0005762268,0.00066575024,0.0022776688,0.00005982413,0.00014388614,0.0010367185],"genre_scores_gemma":[0.9951058,0.0007464745,0.0010779193,0.0009982132,0.00030843972,0.00018799597,0.000051103867,0.00026576343,0.0012582653],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99165463,0.0007255783,0.0021212893,0.0018649639,0.0017046743,0.0019288729],"domain_scores_gemma":[0.99477786,0.0011688056,0.0007808678,0.0018292012,0.00033842228,0.0011048561],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016185585,0.001201118,0.0020526992,0.0012791204,0.00024985633,0.00016357184,0.0009069726,0.0009961934,0.000022860244],"category_scores_gemma":[0.001446502,0.001010873,0.00035508058,0.0025178427,0.0012048556,0.0006484617,0.0011520556,0.00049877976,0.00006054554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06652053,0.00251477,0.19878088,0.0013048127,0.001249322,0.0065567577,0.022245321,0.0013419113,0.6049207,0.0005171565,0.005484029,0.08856381],"study_design_scores_gemma":[0.08453975,0.0026699917,0.7789195,0.0030116027,0.00052715477,0.008751058,0.0020293165,0.03054992,0.08570598,0.00029166427,0.0013516817,0.0016523574],"about_ca_topic_score_codex":0.0032625545,"about_ca_topic_score_gemma":0.00014538804,"teacher_disagreement_score":0.5801386,"about_ca_system_score_codex":0.034989547,"about_ca_system_score_gemma":0.015808005,"threshold_uncertainty_score":0.99923414},"labels":[],"label_agreement":null},{"id":"W2130198817","doi":"10.3109/10428194.2012.697560","title":"Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AIDS Vancouver; St. Michael's Hospital; University of Toronto; Sunnybrook Health Science Centre; St. Paul's Hospital; Health Sciences Centre; University of British Columbia","funders":"","keywords":"Lymphoma; Medicine; Incidence (geometry); Human immunodeficiency virus (HIV); Hodgkin lymphoma; Oncology; Toxicity; Internal medicine; Immunology; Virology","score_opus":0.00703833338773078,"score_gpt":0.22090101145416002,"score_spread":0.21386267806642925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130198817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937666,0.0023442549,0.0000052923874,0.000029958459,0.00017959767,0.0013333343,0.00015740427,0.0001471194,0.0020364395],"genre_scores_gemma":[0.9981267,0.00048309084,0.00023534827,0.00032882876,0.00009169922,0.00020542419,0.00021066642,0.00010875958,0.00020949259],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99510264,0.00022809945,0.001211184,0.0010168654,0.0010854112,0.0013557692],"domain_scores_gemma":[0.99721515,0.00033183588,0.00067727384,0.000846507,0.0002667908,0.00066245644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00058692676,0.0009172634,0.0014890637,0.0004985584,0.00038581507,0.00008061089,0.0003114468,0.0005734247,0.000056382145],"category_scores_gemma":[0.00013842071,0.00075138285,0.0002002203,0.000999974,0.0006854012,0.0007257426,0.00022362248,0.00012199873,0.000014440422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011157906,0.00278926,0.9653797,0.00021716749,0.00032865186,0.00007328265,0.0018701813,0.000012557561,0.0016518509,0.0004436368,0.00020473852,0.025913142],"study_design_scores_gemma":[0.035038903,0.0013065336,0.9545579,0.0007315525,0.0004133389,0.00014517823,0.0003356289,0.00013105814,0.0060224673,0.00006945036,0.0004724577,0.00077554246],"about_ca_topic_score_codex":0.004695102,"about_ca_topic_score_gemma":0.00032466292,"teacher_disagreement_score":0.03392311,"about_ca_system_score_codex":0.007673319,"about_ca_system_score_gemma":0.0015388161,"threshold_uncertainty_score":0.9994937},"labels":[],"label_agreement":null},{"id":"W2130798268","doi":"10.3109/10428194.2012.664843","title":"Association between obesity at diagnosis and weight change during induction and survival in pediatric acute lymphoblastic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Confidence interval; Internal medicine; Univariate analysis; Obesity; Weight change; Weight gain; Gastroenterology; Weight loss; Body weight; Multivariate analysis","score_opus":0.021269748749087162,"score_gpt":0.25982361407088067,"score_spread":0.2385538653217935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130798268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890172,0.00768003,0.0000087062635,0.0006009922,0.000927172,0.0010152707,0.00010229959,0.00025729317,0.00039107495],"genre_scores_gemma":[0.9796337,0.014737537,0.00016128525,0.000617897,0.0036958905,0.00028619898,0.00014405753,0.0001431483,0.0005803202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943826,0.00044390644,0.0012003239,0.0012571794,0.0011439453,0.0015720456],"domain_scores_gemma":[0.9964756,0.000957057,0.0006886179,0.0006185029,0.00013790558,0.0011223262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001436884,0.0009135251,0.0015424179,0.0006988342,0.00060167495,0.0001369865,0.00021383126,0.001018991,0.00004793409],"category_scores_gemma":[0.00040049036,0.0009514112,0.00019631974,0.00092513656,0.00022436866,0.0011931648,0.0005761297,0.00031895115,0.000048571506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003793104,0.00014959846,0.98109406,0.0007773793,0.00036088697,0.00006894369,0.00415472,0.000001271359,0.00027653694,0.00004548987,0.00053246843,0.01215933],"study_design_scores_gemma":[0.0152476635,0.00021780824,0.97717804,0.00034086252,0.0013708395,0.0004646252,0.0003437717,0.00013547915,0.001885136,0.00007670921,0.0017824403,0.00095662475],"about_ca_topic_score_codex":0.005079174,"about_ca_topic_score_gemma":0.0007778854,"teacher_disagreement_score":0.023224553,"about_ca_system_score_codex":0.024302943,"about_ca_system_score_gemma":0.0010783878,"threshold_uncertainty_score":0.9992936},"labels":[],"label_agreement":null},{"id":"W2131163045","doi":"10.3109/10428194.2014.994178","title":"Very late relapse of Philadelphia chromosome positive acute megakaryoblastic leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Acute megakaryoblastic leukemia; Medicine; Philadelphia chromosome; Acute leukemia; Oncology; Internal medicine; Leukemia; Cancer research; Biology; Chromosomal translocation; Genetics; Gene","score_opus":0.010564894281328053,"score_gpt":0.23509868296768516,"score_spread":0.2245337886863571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131163045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91547424,0.008375283,0.00013802461,0.05158896,0.0031567186,0.0047954535,0.0018683309,0.0014265076,0.013176486],"genre_scores_gemma":[0.6380734,0.007063272,0.0015546288,0.30780682,0.010158759,0.00077201595,0.009820809,0.0019018032,0.022848496],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9853113,0.0006522516,0.0035330886,0.0040536155,0.003013971,0.0034357584],"domain_scores_gemma":[0.98971784,0.0016987114,0.0025113537,0.003959636,0.00078993296,0.0013225222],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.00070951047,0.0038308268,0.0060632974,0.0016871258,0.0006664608,0.00026556372,0.0015581531,0.006062911,0.00052160287],"category_scores_gemma":[0.00036253975,0.0036242711,0.0019189051,0.0015137787,0.0019763594,0.0007132849,0.0010096546,0.0023796118,0.0007789498],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0036864062,0.00041929103,0.00087211345,0.005118017,0.01018757,0.027832344,0.0012984468,0.00016694311,0.009462718,0.00023091158,0.9233623,0.01736295],"study_design_scores_gemma":[0.10686447,0.006196601,0.027896022,0.013332116,0.022300692,0.035947617,0.00019110732,0.011179452,0.021010324,0.0011516676,0.7452034,0.008726547],"about_ca_topic_score_codex":0.003035135,"about_ca_topic_score_gemma":0.000037707785,"teacher_disagreement_score":0.27740082,"about_ca_system_score_codex":0.058953278,"about_ca_system_score_gemma":0.022031806,"threshold_uncertainty_score":0.99999905},"labels":[],"label_agreement":null},{"id":"W2131395115","doi":"10.3109/10428194.2011.643404","title":"Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Vincristine; Rituximab; Internal medicine; Etoposide; Salvage therapy; Oncology; CHOP; DHAP; Diffuse large B-cell lymphoma; Autologous stem-cell transplantation; Chemotherapy; Gemcitabine; Surgery; Cyclophosphamide; Lymphoma; Chemistry","score_opus":0.012257883743986255,"score_gpt":0.21361873074930124,"score_spread":0.20136084700531498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131395115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98447573,0.0086785555,0.000016432012,0.00009055485,0.00025988187,0.001527045,0.00015955849,0.00033488547,0.0044573736],"genre_scores_gemma":[0.9894861,0.006763267,0.00043615757,0.0015968366,0.000078294885,0.00024751908,0.00016324663,0.00019950008,0.0010290758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99467134,0.0002132131,0.0012174336,0.0017189885,0.00066081353,0.001518202],"domain_scores_gemma":[0.9969871,0.00061791367,0.00042826965,0.00091596023,0.00008338756,0.0009673655],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003780659,0.0013859294,0.0019852314,0.0005566293,0.00038033837,0.00014000123,0.0003038535,0.0008620459,0.00004319062],"category_scores_gemma":[0.00002418007,0.0011021056,0.0003183273,0.00041403263,0.00048456335,0.00045474243,0.00021273189,0.00018000745,0.00002737594],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012873565,0.0071837,0.8878057,0.000995968,0.0003224494,0.002489261,0.010242562,2.567706e-7,0.0013029962,0.00018897909,0.00028200727,0.087898746],"study_design_scores_gemma":[0.08732257,0.0010138477,0.8978844,0.0003648661,0.00058281346,0.0008344682,0.0010572551,0.0002252555,0.007121382,0.00007215264,0.0024615314,0.0010594331],"about_ca_topic_score_codex":0.0019183047,"about_ca_topic_score_gemma":0.00014014747,"teacher_disagreement_score":0.08683932,"about_ca_system_score_codex":0.004535478,"about_ca_system_score_gemma":0.0017167851,"threshold_uncertainty_score":0.99988914},"labels":[],"label_agreement":null},{"id":"W2131790261","doi":"10.1080/10428190310001593184","title":"Isolated Central Nervous System Relapse in Lymphoid Blast Crisis Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia in Patients on Imatinib Therapy","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Imatinib; Medicine; Myeloid leukemia; Cytarabine; Imatinib mesylate; Methotrexate; Philadelphia chromosome; Bone marrow; Leukemia; Internal medicine; Oncology; Immunology; Chromosomal translocation; Biology","score_opus":0.0067067921439944445,"score_gpt":0.21897548995774901,"score_spread":0.21226869781375457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2131790261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98670745,0.0040626004,0.000057670728,0.00009326208,0.001077841,0.0034076856,0.00017270798,0.00063812523,0.0037826505],"genre_scores_gemma":[0.99063694,0.004700057,0.0004978502,0.0013492827,0.0003563155,0.0005960768,0.00044549795,0.00055265916,0.00086534244],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98647624,0.0008762614,0.0032119213,0.0036299152,0.001853227,0.0039524427],"domain_scores_gemma":[0.9937932,0.00073175196,0.0010644747,0.0023282259,0.00031734127,0.0017650074],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000940047,0.0027918906,0.0034266075,0.0018394055,0.00066402735,0.00037793373,0.00080903294,0.0018907719,0.00015433133],"category_scores_gemma":[0.00032705424,0.0026370548,0.0006181145,0.0024738444,0.00070258416,0.0009226039,0.00037505725,0.0008105039,0.00025441442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.036002558,0.0040004496,0.5033583,0.005111409,0.0049238093,0.015092731,0.012314695,0.006703029,0.009860052,0.0051419586,0.008808275,0.3886827],"study_design_scores_gemma":[0.21866436,0.0061047394,0.6935863,0.0046276017,0.0010459501,0.0061728065,0.002066043,0.049608547,0.0075760405,0.0002174692,0.006048843,0.004281321],"about_ca_topic_score_codex":0.006910103,"about_ca_topic_score_gemma":0.0005759718,"teacher_disagreement_score":0.38440138,"about_ca_system_score_codex":0.19524068,"about_ca_system_score_gemma":0.021522652,"threshold_uncertainty_score":0.999703},"labels":[],"label_agreement":null},{"id":"W2132862303","doi":"10.3109/10428194.2014.939969","title":"Hyperhemolysis associated with marginal zone lymphoma","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Blood groups and transfusion","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Hemolysis; Medicine; Lymphoma; Marginal zone; Autologous blood; Immunology; Blood transfusion; Intensive care medicine; Surgery; Antibody; B cell","score_opus":0.009615132713618295,"score_gpt":0.2060630755283149,"score_spread":0.1964479428146966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132862303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8983509,0.0042209383,0.0005794777,0.074237674,0.0010741777,0.0023201609,0.0003338561,0.0014293581,0.017453466],"genre_scores_gemma":[0.51292694,0.0018307207,0.0011893646,0.449883,0.006709815,0.0004454816,0.0053026816,0.001138055,0.020573923],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98956424,0.0004464212,0.001706237,0.0030612708,0.0025428564,0.0026789897],"domain_scores_gemma":[0.9942112,0.0008512038,0.0010134851,0.0023149163,0.0005964525,0.0010127367],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00070576393,0.0026571415,0.003928477,0.0010311378,0.00087962195,0.00041613547,0.00086204126,0.0046330676,0.00035513513],"category_scores_gemma":[0.00016968082,0.002208453,0.0010479171,0.0013798809,0.0010450651,0.0003890908,0.0002905582,0.0011305363,0.0002926754],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0030537725,0.00086820737,0.0058104373,0.002250795,0.004999068,0.022023315,0.0006633567,0.000014584583,0.0010197714,0.00021329922,0.7122096,0.2468738],"study_design_scores_gemma":[0.053538714,0.0017296389,0.04143248,0.0034368194,0.0065027047,0.013903936,0.00013048328,0.002047623,0.0012701391,0.00014454353,0.8724088,0.0034541108],"about_ca_topic_score_codex":0.002545914,"about_ca_topic_score_gemma":0.00017386714,"teacher_disagreement_score":0.38542393,"about_ca_system_score_codex":0.010750817,"about_ca_system_score_gemma":0.006109731,"threshold_uncertainty_score":0.9995247},"labels":[],"label_agreement":null},{"id":"W2132959953","doi":"10.1080/10428194310001593193","title":"The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression","year":2004,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"RANKL; Osteoclast; Bone resorption; RANK Ligand; Osteoprotegerin; Osteolysis; Multiple myeloma; Cancer research; Stromal cell; Receptor; Chemistry; Internal medicine; Medicine; Bone remodeling; Endocrinology; Activator (genetics)","score_opus":0.02358573838970978,"score_gpt":0.2861738569402019,"score_spread":0.26258811855049213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132959953","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5627789,0.4340749,0.0000071476875,0.0000788885,0.0001680898,0.002386628,0.00037636023,0.00005535687,0.00007375409],"genre_scores_gemma":[0.24790616,0.7503146,0.00053112354,0.000097273594,0.00016294928,0.00025488343,0.00019154644,0.0001970254,0.00034442684],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942007,0.0005069803,0.0019383207,0.0013465214,0.0009108981,0.0010965436],"domain_scores_gemma":[0.9953614,0.0013188064,0.0009969366,0.0012461426,0.00023939417,0.0008373127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006514678,0.0011919084,0.0038360297,0.0008440976,0.0003765347,0.000109343346,0.00043973688,0.0010618743,0.0000682932],"category_scores_gemma":[0.0006660615,0.00081475195,0.00061532826,0.00097308005,0.0005703021,0.00026510257,0.00047673617,0.00035964308,0.00005394445],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040988326,0.00031942723,0.0004736485,0.013752715,0.00056559534,0.00034069817,0.0010218645,0.0000013027516,0.00981249,0.0000688936,0.0006502992,0.96889424],"study_design_scores_gemma":[0.087298505,0.0026143657,0.07526921,0.094323605,0.0016278184,0.0014850743,0.00070174003,0.0002552922,0.060546,0.00020568259,0.673073,0.002599728],"about_ca_topic_score_codex":0.0036296449,"about_ca_topic_score_gemma":0.00008372964,"teacher_disagreement_score":0.9662945,"about_ca_system_score_codex":0.0053612734,"about_ca_system_score_gemma":0.0036091157,"threshold_uncertainty_score":0.99943036},"labels":[],"label_agreement":null},{"id":"W2133838536","doi":"10.3109/10428194.2012.723211","title":"Analysis of microsatellite instability in gastric mucosa-associated lymphoid tissue lymphoma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Genetic factors in colorectal cancer","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Microsatellite instability; Lymphoma; Pathology; Medicine; General surgery; Biology; Microsatellite; Genetics","score_opus":0.013175636823694601,"score_gpt":0.25968089328242355,"score_spread":0.24650525645872895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133838536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98732704,0.007171637,0.00006433654,0.000059222897,0.0006416191,0.0010104903,0.00019593787,0.00019992847,0.003329805],"genre_scores_gemma":[0.99606234,0.0010957674,0.0009503544,0.00058056024,0.00020285003,0.00014648035,0.00034888033,0.0001424921,0.00047025952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931138,0.0004232327,0.0019848975,0.0013498126,0.0011702424,0.0019579765],"domain_scores_gemma":[0.9957626,0.0006564152,0.0007653435,0.0014375858,0.0003824914,0.0009955697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013631169,0.0010568105,0.0025365148,0.0018125868,0.00021302266,0.00007598319,0.00053330744,0.0010062779,0.00034303515],"category_scores_gemma":[0.0006500413,0.0010321735,0.0006595396,0.005543282,0.000733347,0.0004344947,0.00038673735,0.00017538642,0.00005250676],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011776136,0.0011309381,0.78958625,0.0003003256,0.0015020887,0.000091051144,0.0023851017,0.000116249255,0.038489956,0.00008885338,0.00022639311,0.16490518],"study_design_scores_gemma":[0.013923854,0.0004002633,0.9305044,0.00021149318,0.002375848,0.00043156973,0.0004856025,0.0024788273,0.043294713,0.000064831285,0.0049213087,0.00090732344],"about_ca_topic_score_codex":0.005709814,"about_ca_topic_score_gemma":0.00075015705,"teacher_disagreement_score":0.16399784,"about_ca_system_score_codex":0.018261902,"about_ca_system_score_gemma":0.0036559256,"threshold_uncertainty_score":0.99921286},"labels":[],"label_agreement":null},{"id":"W2133983117","doi":"10.1080/10428190290016935","title":"Bcl-3/IgH translocation (14;19)(q32;q13) in Non-Hodgkin's Lymphomas","year":2002,"lang":"zh","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Chromosomal translocation; Lymphoma; Chronic lymphocytic leukemia; Medicine; Pathology; Abnormality; Non-Hodgkin's lymphoma; Leukemia; Internal medicine; Biology; Gene","score_opus":0.02022337419519823,"score_gpt":0.26642772729422054,"score_spread":0.2462043530990223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2133983117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.85753906,0.05406221,0.00036046546,0.0016002055,0.002950189,0.0047947173,0.00026049672,0.0008007099,0.077631935],"genre_scores_gemma":[0.9298369,0.042036794,0.000796717,0.0035441085,0.0026861003,0.0008247938,0.00040243068,0.0008558714,0.019016242],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.97735244,0.0012431799,0.004944363,0.0054358956,0.0045027556,0.0065213568],"domain_scores_gemma":[0.9869985,0.0021994254,0.0013193215,0.004650984,0.00082260557,0.004009158],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","sts","insufficient_payload"],"category_scores_codex":[0.002974998,0.0037866137,0.0047588353,0.002990881,0.0014095167,0.0009793319,0.0026020806,0.0039982633,0.0029678065],"category_scores_gemma":[0.0014226453,0.0039435946,0.0013694523,0.0052988017,0.002736643,0.001793217,0.0010948506,0.0012974638,0.0037575294],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0053910483,0.004008372,0.007457085,0.0059856903,0.002056206,0.013165518,0.022474324,0.0013759988,0.0047898805,0.0065912013,0.056911062,0.8697936],"study_design_scores_gemma":[0.35685706,0.0031435778,0.067116916,0.007791039,0.001865729,0.013612034,0.004747712,0.4209422,0.005634737,0.0026148204,0.107890375,0.007783799],"about_ca_topic_score_codex":0.03076584,"about_ca_topic_score_gemma":0.0016667522,"teacher_disagreement_score":0.8620098,"about_ca_system_score_codex":0.22488835,"about_ca_system_score_gemma":0.04175525,"threshold_uncertainty_score":0.99997735},"labels":[],"label_agreement":null},{"id":"W2134740705","doi":"10.3109/10428194.2014.883072","title":"A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Ejection fraction; Medicine; Myeloid leukemia; Induction chemotherapy; Single Center; Internal medicine; Retrospective cohort study; Chemotherapy; Intensive care medicine; Acute leukemia; Cardiac function curve; Oncology; Leukemia; Cardiology; Heart failure","score_opus":0.012025073621952246,"score_gpt":0.22398278206855174,"score_spread":0.2119577084465995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134740705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464124,0.00007291637,0.002592389,0.00004157954,0.0002710582,0.0010011608,0.000020635362,0.00007110386,0.0012878972],"genre_scores_gemma":[0.9991055,0.00009570002,0.00025117386,0.00018765667,0.00011977591,0.000068425434,0.00009673232,0.000038504033,0.000036528458],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964301,0.00028549717,0.00093595707,0.00071379804,0.0012291524,0.00040550748],"domain_scores_gemma":[0.9976247,0.00010306712,0.0007736207,0.0007845005,0.0005486855,0.00016540912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000760161,0.00043756142,0.0010226332,0.00060686015,0.00020393587,0.000034432993,0.00017019719,0.00045967448,0.000016346052],"category_scores_gemma":[0.00022291849,0.000343313,0.00039566433,0.0019971398,0.00033277104,0.00041866256,0.000056708952,0.00018013605,0.0000013672048],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006813543,0.0011198241,0.40266818,0.0005027145,0.003241793,0.000012460212,0.0019014924,0.0016109761,0.26898798,0.00019879531,0.00014191189,0.31280032],"study_design_scores_gemma":[0.0115698455,0.0005707589,0.75749624,0.00036660334,0.001971511,0.00003212605,0.00019898055,0.010817481,0.21631838,0.00005284046,0.00034404345,0.00026119],"about_ca_topic_score_codex":0.004512044,"about_ca_topic_score_gemma":0.000891646,"teacher_disagreement_score":0.35482806,"about_ca_system_score_codex":0.009367984,"about_ca_system_score_gemma":0.0017042414,"threshold_uncertainty_score":0.9999019},"labels":[],"label_agreement":null},{"id":"W2134806292","doi":"10.3109/10428194.2011.602771","title":"Treatment of Hodgkin lymphoma with adriamycin, bleomycin, vinblastine and dacarbazine without routine granulocyte-colony stimulating factor support does not increase the risk of febrile neutropenia: a prospective cohort study","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"ABVD; Medicine; Dacarbazine; Neutropenia; Febrile neutropenia; Vinblastine; Internal medicine; Granulocyte colony-stimulating factor; Chemotherapy; Surgery; Lymphoma; Gastroenterology; Vincristine; Cyclophosphamide","score_opus":0.012524684018580885,"score_gpt":0.2424399040712438,"score_spread":0.2299152200526629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2134806292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914431,0.0003564577,0.00005156113,0.000045979326,0.0002031771,0.0048587765,0.00032952387,0.00017644338,0.0025349816],"genre_scores_gemma":[0.9964687,0.0006193812,0.00052785524,0.00014054145,0.00027463553,0.00079749554,0.000058235837,0.00016309251,0.00095004076],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99499464,0.0003906372,0.0014183073,0.0014340586,0.000884621,0.0008777478],"domain_scores_gemma":[0.99580336,0.0004443086,0.001145559,0.0013389846,0.0006996331,0.0005681616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047299912,0.0011091568,0.002271333,0.00035161022,0.00060015795,0.0000772026,0.0003219796,0.0003004614,0.00018346823],"category_scores_gemma":[0.00016039559,0.0006421036,0.00031222243,0.0007799407,0.00094225927,0.00035115946,0.0002492743,0.00016516275,0.000008851369],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01037317,0.0016949392,0.9631545,0.00018044384,0.0019341334,0.00027627,0.0050703185,0.00002927663,0.0050034854,0.00009274303,0.000050679384,0.012140023],"study_design_scores_gemma":[0.045041073,0.010914847,0.90581334,0.00020066126,0.0037387903,0.0012653348,0.0013796508,0.0007309842,0.02992613,0.000031372594,0.00029934398,0.0006584691],"about_ca_topic_score_codex":0.03347227,"about_ca_topic_score_gemma":0.0024269503,"teacher_disagreement_score":0.057341177,"about_ca_system_score_codex":0.0029941625,"about_ca_system_score_gemma":0.0025649595,"threshold_uncertainty_score":0.99960303},"labels":[],"label_agreement":null},{"id":"W2135057615","doi":"10.3109/10428190903585286","title":"A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Sorafenib; Internal medicine; Myeloid leukemia; Refractory (planetary science); Regimen; Myelodysplastic syndromes; Oncology; Population; Phases of clinical research; Chemotherapy; Leukemia; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.053731407724228554,"score_gpt":0.3961122256343599,"score_spread":0.3423808179101313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135057615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913209,0.00028881902,0.000042474334,0.00005773695,0.00089387747,0.0069413627,0.00031531136,0.000054020493,0.00008547151],"genre_scores_gemma":[0.9971207,0.0004517677,0.001035335,0.00017897788,0.00024287107,0.0006045177,0.00011347859,0.00010811909,0.00014426585],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98567444,0.0028599792,0.006293651,0.001742949,0.0023661482,0.0010628228],"domain_scores_gemma":[0.98805296,0.0061634113,0.0026084005,0.001085978,0.0012201373,0.00086908386],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.011880421,0.0010356185,0.0069971997,0.00094780896,0.00021895864,0.00004944733,0.00072651106,0.00079209486,0.00008734],"category_scores_gemma":[0.0075578624,0.0006938462,0.00045184838,0.0014279665,0.0029273606,0.0004158564,0.0005460395,0.0009545447,0.0000017331695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32812423,0.0079296585,0.6348251,0.00046051142,0.0045778374,0.00094845815,0.0008066331,0.00007178038,0.0006364883,0.00026918607,0.00017456946,0.021175535],"study_design_scores_gemma":[0.5296668,0.007538257,0.45647934,0.0003557544,0.001684819,0.0001857647,0.0007487512,0.0025658172,0.00014333565,0.00008244911,0.000052818206,0.0004960881],"about_ca_topic_score_codex":0.094405204,"about_ca_topic_score_gemma":0.115182854,"teacher_disagreement_score":0.20154259,"about_ca_system_score_codex":0.0037010775,"about_ca_system_score_gemma":0.0360927,"threshold_uncertainty_score":0.9997861},"labels":[],"label_agreement":null},{"id":"W2136508030","doi":"10.3109/10428194.2014.915544","title":"Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lenalidomide; Medicine; Neutropenia; Dexamethasone; Granulocyte colony-stimulating factor; Multiple myeloma; Internal medicine; Refractory (planetary science); Absolute neutrophil count; Gastroenterology; Febrile neutropenia; Toxicity; Surgery; Chemotherapy","score_opus":0.016324495911819753,"score_gpt":0.25568155543578397,"score_spread":0.23935705952396422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136508030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935185,0.00012089322,0.00060833985,0.000053858203,0.00008477506,0.004490163,0.000115092495,0.0002135287,0.00079485023],"genre_scores_gemma":[0.9883612,0.000083129635,0.007576631,0.00037451624,0.000109472116,0.0008889826,0.00045858184,0.0002151212,0.0019323789],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99492055,0.00025521638,0.0009374326,0.001469687,0.00097536005,0.0014417592],"domain_scores_gemma":[0.99659175,0.00090246944,0.00041837135,0.0009699715,0.00032490928,0.000792528],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003413661,0.0009931814,0.0014786369,0.000601172,0.0003999688,0.00015841443,0.00033898972,0.00035504703,0.000052443236],"category_scores_gemma":[0.00026503752,0.0006592007,0.00019527858,0.00066396466,0.00033342815,0.00039133115,0.00019788767,0.00021364287,0.000026984797],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.089013815,0.00076969416,0.52577096,0.0006705653,0.0010352584,0.000791723,0.00048808052,0.0002285576,0.00047071965,0.000041353607,0.00015422552,0.38056505],"study_design_scores_gemma":[0.174399,0.0055633113,0.79043245,0.0008778311,0.0003788047,0.000108527514,0.00016264903,0.023756262,0.0012170312,0.000008354519,0.00237325,0.00072249613],"about_ca_topic_score_codex":0.0014493106,"about_ca_topic_score_gemma":0.0007184037,"teacher_disagreement_score":0.37984255,"about_ca_system_score_codex":0.008500445,"about_ca_system_score_gemma":0.0010981318,"threshold_uncertainty_score":0.9995859},"labels":[],"label_agreement":null},{"id":"W2136559095","doi":"10.3109/10428194.2013.866662","title":"Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's College Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Imatinib mesylate; Pregnancy; Adverse effect; Imatinib; Fetus; Pediatrics; Obstetrics; Internal medicine","score_opus":0.007434360182514351,"score_gpt":0.22280724291478163,"score_spread":0.2153728827322673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136559095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98988307,0.0020488224,0.00009114887,0.00010655581,0.00020790155,0.0039987867,0.00012656148,0.0006012122,0.0029359336],"genre_scores_gemma":[0.9890267,0.0004502813,0.004225766,0.0005781698,0.00017939943,0.0009306405,0.0021148731,0.0004057276,0.0020883998],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911731,0.00017867559,0.0020785418,0.0025850195,0.0018061313,0.0021785668],"domain_scores_gemma":[0.9951704,0.000405322,0.0007652141,0.0021719176,0.0005538332,0.00093332643],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00025246342,0.0019796444,0.0026963057,0.00064805546,0.00041544033,0.0002808559,0.000592326,0.0009457371,0.000325537],"category_scores_gemma":[0.0001522664,0.0014555764,0.00026315998,0.0013803215,0.00063137227,0.0012111356,0.00033225457,0.00046201254,0.00019093383],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011829394,0.0003957157,0.8909118,0.00038256907,0.0013174863,0.0030017898,0.0005521273,0.00006929304,0.00030358127,0.000053947926,0.00044964268,0.10137906],"study_design_scores_gemma":[0.054468356,0.0011653205,0.9320367,0.0036869524,0.00073466246,0.001000991,0.00022217768,0.0016583235,0.0021304812,0.00007384308,0.0010687937,0.0017534273],"about_ca_topic_score_codex":0.02360348,"about_ca_topic_score_gemma":0.0015771419,"teacher_disagreement_score":0.09962563,"about_ca_system_score_codex":0.06256108,"about_ca_system_score_gemma":0.016315453,"threshold_uncertainty_score":0.99929464},"labels":[],"label_agreement":null},{"id":"W2136631504","doi":"10.1080/10428190701528491","title":"Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; U.S. Department of Health and Human Services","keywords":"Guanosine; Apoptosis; Nucleoside; Cell biology; Programmed cell death; Intracellular; Nucleoside transporter; Viability assay; Cell cycle; Cell cycle checkpoint; Cell growth; Chemistry; Biology; Transporter; Biochemistry; Gene","score_opus":0.0076918730028687115,"score_gpt":0.23056611370479163,"score_spread":0.2228742407019229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136631504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845733,0.0025336682,0.009896839,0.00009311898,0.00029029135,0.00074439036,0.00006442432,0.00006741521,0.0017365387],"genre_scores_gemma":[0.9926976,0.00034021173,0.0031245546,0.0019338263,0.0006895947,0.0001307814,0.0002490465,0.00013221121,0.00070219865],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965352,0.000057458597,0.0008669443,0.0010735799,0.00031483054,0.0011519982],"domain_scores_gemma":[0.99845,0.00011677952,0.00019578089,0.00057886296,0.00014395716,0.0005146379],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006763346,0.00061774463,0.00059061905,0.0003183868,0.00021581815,0.0000789233,0.00045326943,0.00061600766,0.00002241066],"category_scores_gemma":[0.000080955644,0.00064439425,0.0002448286,0.00046687978,0.00012601711,0.00003747098,0.00014267353,0.000101900914,0.000021408718],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022676745,0.00024485646,0.0030367936,0.00015330611,0.00014681577,0.00012660479,0.0010423601,0.0005861569,0.9537861,0.00045616002,0.0042992025,0.033853974],"study_design_scores_gemma":[0.008950183,0.0006810015,0.0118922405,0.00014923877,0.00010949418,0.00012749588,0.00051555905,0.0005003266,0.8723675,0.0003329021,0.10330477,0.0010692866],"about_ca_topic_score_codex":0.0010557834,"about_ca_topic_score_gemma":0.0002559827,"teacher_disagreement_score":0.09900557,"about_ca_system_score_codex":0.0008155511,"about_ca_system_score_gemma":0.0008958273,"threshold_uncertainty_score":0.9996007},"labels":[],"label_agreement":null},{"id":"W2137344646","doi":"10.3109/10428194.2014.982638","title":"Tumor suppressors in follicular lymphoma","year":2014,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Biology; Epigenetics; Somatic cell; Follicular lymphoma; Cancer research; Suppressor; DNA methylation; Lymphoma; Chromosomal translocation; Gene silencing; Gene; Genetics; Immunology; Gene expression","score_opus":0.01861678396511938,"score_gpt":0.2871781545044321,"score_spread":0.2685613705393127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137344646","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046577416,0.9412538,0.000009572558,0.00008550312,0.0009620763,0.003652122,0.00022196637,0.00052169943,0.0067158765],"genre_scores_gemma":[0.014276989,0.97676754,0.0005297552,0.0012342245,0.0011164269,0.002212622,0.0012045598,0.00066706864,0.0019907975],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98761183,0.000768069,0.0035941072,0.0036272574,0.0016304022,0.002768313],"domain_scores_gemma":[0.9923676,0.0011918036,0.0014824449,0.003022762,0.00022997032,0.0017053843],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009806046,0.0034713934,0.009643789,0.0017956618,0.0004905087,0.00042988043,0.0011200835,0.0022787617,0.00021833122],"category_scores_gemma":[0.00037068425,0.00284197,0.0027504317,0.001891225,0.0006753158,0.000420778,0.0007712733,0.00037535053,0.00097017066],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00028273131,0.00097841,0.00087528856,0.016644608,0.0012562107,0.0062855184,0.00022377711,0.0000044858634,0.0000034132897,0.0010350881,0.004506223,0.96790427],"study_design_scores_gemma":[0.026823694,0.00054159854,0.0073151984,0.024813304,0.004857394,0.009760769,0.00009414966,0.00037398352,0.000088233675,0.00014626238,0.9226219,0.0025635213],"about_ca_topic_score_codex":0.002904284,"about_ca_topic_score_gemma":0.0001631848,"teacher_disagreement_score":0.96534073,"about_ca_system_score_codex":0.027352344,"about_ca_system_score_gemma":0.011443577,"threshold_uncertainty_score":0.9998077},"labels":[],"label_agreement":null},{"id":"W2137372268","doi":"10.3109/10428194.2010.500051","title":"The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Peter MacCallum Cancer Centre; National Cancer Research Institute","keywords":"Medicine; Positron emission tomography; Lymphoma; Interim; Hodgkin lymphoma; Medical physics; Grading (engineering); Oncology; Nuclear medicine; Internal medicine","score_opus":0.01110885524102844,"score_gpt":0.30170028290951584,"score_spread":0.2905914276684874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137372268","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43056294,0.565497,0.0000023494304,0.00013776218,0.00030651817,0.0026883385,0.00007190387,0.00006636776,0.00066685217],"genre_scores_gemma":[0.14554,0.8510033,0.0008645597,0.00015413936,0.0001813121,0.0016244955,0.0001635448,0.0002297636,0.00023890691],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99096864,0.0011555498,0.002983224,0.0020855942,0.0012055939,0.001601402],"domain_scores_gemma":[0.9931711,0.0027965517,0.0013330082,0.0017068735,0.00018463,0.00080785766],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0025231827,0.001919715,0.0047511505,0.0016526716,0.000460224,0.00027097762,0.00073233206,0.0020276112,0.000013608033],"category_scores_gemma":[0.000309941,0.0013243022,0.0011013334,0.001987101,0.0008612555,0.0002837392,0.00062805094,0.0005375197,0.000011244837],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0016091804,0.0010745391,0.018465798,0.005070368,0.00046612232,0.0009472571,0.00046682404,9.482213e-7,0.00015864708,0.00043341256,0.0002823157,0.9710246],"study_design_scores_gemma":[0.029498084,0.0014979424,0.47188547,0.03220084,0.0025541699,0.0026006,0.00038695888,0.0006389866,0.00053300353,0.00021776171,0.45618957,0.0017966053],"about_ca_topic_score_codex":0.002962007,"about_ca_topic_score_gemma":0.000291697,"teacher_disagreement_score":0.96922797,"about_ca_system_score_codex":0.011938574,"about_ca_system_score_gemma":0.011332776,"threshold_uncertainty_score":0.99935466},"labels":[],"label_agreement":null},{"id":"W2137508909","doi":"10.3109/10428194.2014.882507","title":"Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Hematopoietic cell; Medicine; Immunology; Haematopoiesis; Myeloid; Hematopoietic stem cell transplantation; Leukemia; Transplantation; Oncology; Cancer research; Stem cell; Internal medicine; Biology; Genetics","score_opus":0.012048295225232536,"score_gpt":0.24854209005624414,"score_spread":0.2364937948310116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2137508909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9588499,0.015878119,0.0010603569,0.015303109,0.000937238,0.0062365513,0.0009733322,0.0004516791,0.00030971123],"genre_scores_gemma":[0.83310187,0.0015230941,0.0012974984,0.14693771,0.0022950557,0.0029949415,0.0030130057,0.0015296382,0.007307182],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98529905,0.0010732124,0.00333609,0.0042138286,0.002387178,0.0036906598],"domain_scores_gemma":[0.99110466,0.0011087285,0.0014444109,0.004211405,0.00058095047,0.0015498701],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012957259,0.003582597,0.005095137,0.0015622656,0.00039442375,0.0002335564,0.0016289487,0.0047364323,0.00022374988],"category_scores_gemma":[0.00020131146,0.0035191227,0.0021610425,0.0010449314,0.0009884764,0.00036439908,0.00057660183,0.0013560605,0.00038438148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0768908,0.0019647419,0.00625229,0.07377707,0.013340417,0.122553006,0.009571512,0.0025879005,0.46287987,0.0003577374,0.20016283,0.029661825],"study_design_scores_gemma":[0.15411815,0.012115624,0.023641668,0.018301986,0.017053971,0.016520634,0.00025627037,0.0024921454,0.4700716,0.00063479156,0.2715344,0.013258738],"about_ca_topic_score_codex":0.0011581238,"about_ca_topic_score_gemma":0.000106567546,"teacher_disagreement_score":0.13163461,"about_ca_system_score_codex":0.04155174,"about_ca_system_score_gemma":0.019044671,"threshold_uncertainty_score":0.99768966},"labels":[],"label_agreement":null},{"id":"W2138573874","doi":"10.3109/10428194.2014.939967","title":"Classification of non-Hodgkin lymphoma in Algeria according to the World Health Organization classification","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Lymphoma; Mantle cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Medicine; Classical Hodgkin lymphoma; Oncology; Internal medicine","score_opus":0.015628852843106826,"score_gpt":0.27578041283930294,"score_spread":0.2601515599961961,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138573874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98790675,0.00048822552,0.0010444833,0.004677608,0.0004380183,0.001625996,0.000025630467,0.00016103308,0.0036322277],"genre_scores_gemma":[0.99325764,0.00044486107,0.001536208,0.0031005389,0.00038455828,0.00030524144,0.0002924322,0.00012776857,0.000550757],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99533945,0.000330083,0.0014970355,0.0011695143,0.0007761641,0.0008877387],"domain_scores_gemma":[0.9964955,0.00054220256,0.0007548508,0.0013096381,0.0003417905,0.0005560607],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010989336,0.0006771368,0.0011756233,0.0008112123,0.0004411356,0.00015469275,0.0004486586,0.0003255443,0.000040090305],"category_scores_gemma":[0.00041303807,0.00053729705,0.00019443044,0.0026761852,0.00021162974,0.00031305174,0.00019758091,0.00009370731,0.00012766162],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052944536,0.00074176124,0.27030984,0.0003254154,0.00016706267,0.000023586053,0.0019316771,0.00010928429,0.011190322,0.008645486,0.005057105,0.70096904],"study_design_scores_gemma":[0.011976594,0.00049630436,0.9470407,0.0006098255,0.00014850458,0.00017495424,0.0011676071,0.013345414,0.0071683945,0.00015129549,0.017229263,0.00049114286],"about_ca_topic_score_codex":0.0027757387,"about_ca_topic_score_gemma":0.0009278324,"teacher_disagreement_score":0.7004779,"about_ca_system_score_codex":0.010058571,"about_ca_system_score_gemma":0.003222384,"threshold_uncertainty_score":0.9997079},"labels":[],"label_agreement":null},{"id":"W2139199450","doi":"10.3109/10428194.2010.548535","title":"Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Saint John Regional Hospital; University of Calgary; University of Alberta","funders":"Alberta Cancer Foundation","keywords":"Multiple myeloma; Medicine; Oncology; Cancer research; Internal medicine","score_opus":0.04494350580488436,"score_gpt":0.28597660667642627,"score_spread":0.2410331008715419,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139199450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933173,0.0036913496,0.00029949428,0.00009746487,0.000043878485,0.0019136771,0.00012606793,0.00006677444,0.00044398004],"genre_scores_gemma":[0.9908982,0.001134799,0.00684625,0.00015964716,0.000048967773,0.0005952567,0.00009580777,0.000059618127,0.00016143975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779016,0.00008452694,0.0005641147,0.00070901436,0.00023119463,0.00062097143],"domain_scores_gemma":[0.99822116,0.00056401524,0.00019555855,0.0004582627,0.00016572424,0.00039526008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000226574,0.0003885419,0.0006320469,0.00026737966,0.00021170564,0.00003285689,0.00013891801,0.00027592378,0.000010974316],"category_scores_gemma":[0.00022543706,0.00032492357,0.00008796096,0.00029374158,0.00043538545,0.00018670532,0.00012221225,0.00008246755,0.0000023379623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023980327,0.00048742522,0.6546285,0.0006308311,0.00019055605,0.000056237393,0.0018972808,0.0000012418099,0.13795047,0.00041710865,0.0001142422,0.20122807],"study_design_scores_gemma":[0.019399889,0.00063647254,0.9177849,0.0002705533,0.0001462627,0.00017235994,0.00034415966,0.0025213654,0.05687658,0.00082667737,0.0007198589,0.00030089717],"about_ca_topic_score_codex":0.0008622562,"about_ca_topic_score_gemma":0.000102232305,"teacher_disagreement_score":0.2631564,"about_ca_system_score_codex":0.0007732772,"about_ca_system_score_gemma":0.0009265763,"threshold_uncertainty_score":0.9999203},"labels":[],"label_agreement":null},{"id":"W2139569200","doi":"10.3109/10428194.2012.666662","title":"Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Research Institute in Oncology and Hematology; University of Manitoba; CancerCare Manitoba; Research Manitoba","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Medicine; Cohort; Immunology; Internal medicine; Beta-2 microglobulin; Interleukin 6; Interleukin; Stromal cell; Population; Tumor necrosis factor alpha; Leukemia; Oncology; Cytokine","score_opus":0.006982895544242365,"score_gpt":0.23207738180895285,"score_spread":0.22509448626471049,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2139569200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245006,0.0025763698,0.000051266743,0.00011207119,0.0002487059,0.0022340894,0.00005605341,0.00023034577,0.0020410619],"genre_scores_gemma":[0.99519414,0.0006638967,0.0009469381,0.0003766442,0.0003902429,0.0004070264,0.00017514666,0.00027722187,0.0015687334],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919349,0.00032404295,0.0016270527,0.0015242272,0.002066698,0.0025230655],"domain_scores_gemma":[0.9954475,0.00079935597,0.0009670886,0.0009817422,0.0006339562,0.00117032],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001135887,0.0012993517,0.002037228,0.0010752272,0.0002720189,0.00018762452,0.00053240935,0.00093563774,0.00010292551],"category_scores_gemma":[0.00035042153,0.0010325217,0.0002439182,0.0016015834,0.0008733309,0.0011940099,0.00047036327,0.00045752816,0.00005271845],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011466669,0.00078068423,0.8438436,0.0033400788,0.0017953017,0.00049467944,0.0042281635,0.00018975101,0.0017322584,0.00045574596,0.0017901647,0.12988292],"study_design_scores_gemma":[0.19540378,0.008155294,0.7460289,0.004407332,0.0014264426,0.0025070168,0.001084881,0.014768412,0.017760906,0.00006819467,0.0060994774,0.002289358],"about_ca_topic_score_codex":0.0075598094,"about_ca_topic_score_gemma":0.0012864976,"teacher_disagreement_score":0.26511288,"about_ca_system_score_codex":0.30678207,"about_ca_system_score_gemma":0.04166919,"threshold_uncertainty_score":0.9999758},"labels":[],"label_agreement":null},{"id":"W2140486815","doi":"10.3109/10428194.2013.873537","title":"Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Multiple myeloma; Internal medicine; Oncology; Multivariate analysis; Overall survival; Progression-free survival; clone (Java method); Stem cell; Monoclonal; Monoclonal antibody; Immunology; Antibody; Biology","score_opus":0.008659674165426144,"score_gpt":0.23120845890660932,"score_spread":0.22254878474118317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140486815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99600977,0.00092386827,0.0000087832295,0.0001014518,0.00012032296,0.0015682426,0.00027001303,0.0001112518,0.00088632444],"genre_scores_gemma":[0.99806315,0.00019720866,0.0005018247,0.00014954279,0.000105643805,0.00030590498,0.000247976,0.00011281225,0.00031592042],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99554795,0.00021551471,0.0006373276,0.0011844337,0.0011243252,0.0012904608],"domain_scores_gemma":[0.99738395,0.0005216316,0.00018217534,0.0006584958,0.00016321226,0.0010905439],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002433999,0.00091077597,0.0011070131,0.00038870756,0.00024538464,0.00021021099,0.00022061165,0.00043818503,0.00007613816],"category_scores_gemma":[0.000036845588,0.00061903597,0.00014974766,0.00027500055,0.00043424574,0.00041948634,0.00020445324,0.00024139104,0.000024296316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012038062,0.0009882846,0.8850537,0.00026317965,0.0002463342,0.0008611924,0.00057631114,0.000010959826,0.00046621705,0.000021627442,0.00013137651,0.09934277],"study_design_scores_gemma":[0.06026497,0.0032008025,0.9303409,0.00046471797,0.00011484824,0.00024941948,0.000110653746,0.0034158938,0.00104603,0.000051189225,0.000110066365,0.0006305489],"about_ca_topic_score_codex":0.0024205132,"about_ca_topic_score_gemma":0.0002523343,"teacher_disagreement_score":0.09871222,"about_ca_system_score_codex":0.002596634,"about_ca_system_score_gemma":0.0010203571,"threshold_uncertainty_score":0.9996261},"labels":[],"label_agreement":null},{"id":"W2140652862","doi":"10.1080/10428190310001593120","title":"The Spectrum of Lymphoma with 8q24 Aberrations: A Clinical, Pathological and Cytogenetic Study of 87 Consecutive Cases","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Croucher Foundation","keywords":"Lymphoma; Mantle cell lymphoma; Follicular lymphoma; Medicine; Chromosomal translocation; Pathology; Burkitt's lymphoma; Internal medicine; Gastroenterology; Oncology; Biology","score_opus":0.027477785139627432,"score_gpt":0.2930685879245135,"score_spread":0.26559080278488606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140652862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98976356,0.0055913352,0.000015150507,0.00013925266,0.00017472029,0.0017628528,0.000050240338,0.00007389074,0.0024290269],"genre_scores_gemma":[0.9948758,0.0035042,0.00049311,0.00033878098,0.000080441416,0.00028415208,0.000019718958,0.000067768015,0.0003360298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99521744,0.0006202214,0.0015832579,0.0011013284,0.0007345673,0.000743201],"domain_scores_gemma":[0.99528104,0.0020856787,0.0007521283,0.0010968781,0.0002897689,0.00049448886],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007867556,0.00073085766,0.0015484481,0.00020279949,0.0005676362,0.00009634126,0.00024085684,0.000377962,0.000026106269],"category_scores_gemma":[0.0005433973,0.00045226046,0.00026466936,0.00048745266,0.0016616018,0.00013383961,0.00015969572,0.00008740146,0.0000075466082],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044133137,0.006908549,0.86853665,0.00025801707,0.0020995224,0.0033041688,0.002982085,0.000021317106,0.0004657394,0.00892959,0.0010086781,0.10107236],"study_design_scores_gemma":[0.0469272,0.011776215,0.91331106,0.0003448889,0.001531372,0.007112158,0.008497972,0.00018756962,0.005333037,0.00047256387,0.0038924143,0.00061351806],"about_ca_topic_score_codex":0.0011542862,"about_ca_topic_score_gemma":0.00047472533,"teacher_disagreement_score":0.100458845,"about_ca_system_score_codex":0.0013591667,"about_ca_system_score_gemma":0.0031316616,"threshold_uncertainty_score":0.99979293},"labels":[],"label_agreement":null},{"id":"W2140880663","doi":"10.1080/10428190701321277","title":"Clinical progression and outcome of patients with monoclonal B-cell lymphocytosis","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Lymphocytosis; Chronic lymphocytic leukemia; Medicine; Stage (stratigraphy); Internal medicine; Organomegaly; Gastroenterology; Immunophenotyping; Fludarabine; Monoclonal; Leukemia; Immunology; Disease; Cyclophosphamide; Chemotherapy; Monoclonal antibody; Antigen; Antibody","score_opus":0.017757468983474342,"score_gpt":0.32059903198838025,"score_spread":0.3028415630049059,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140880663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913506,0.0018511512,0.00024982367,0.00006801282,0.00026214693,0.0014236402,0.00005194886,0.00019315291,0.0045495187],"genre_scores_gemma":[0.99107605,0.0006251861,0.005772258,0.0006490902,0.00032670965,0.000056331446,0.0001374695,0.00018243838,0.0011744412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992617,0.00018876279,0.0022007113,0.0015752851,0.001854478,0.0015637608],"domain_scores_gemma":[0.99491936,0.0010480488,0.00076267426,0.0012219466,0.00059662975,0.0014513332],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018230774,0.0009345234,0.0018023702,0.0005782721,0.00033996496,0.00009581723,0.00044196058,0.00090308645,0.000070044014],"category_scores_gemma":[0.0003232968,0.0007182292,0.00035690612,0.0008706123,0.0015782258,0.00038138014,0.00056734675,0.00030569176,0.000039645878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008090566,0.0009746069,0.7019075,0.0010338359,0.00030023413,0.0005491029,0.00036182435,0.0000053345416,0.0003998662,0.0002155113,0.0006868849,0.28547475],"study_design_scores_gemma":[0.12810098,0.0024042458,0.84779024,0.0005876363,0.00052117504,0.00076486607,0.0002825232,0.0029990366,0.0070525035,0.000069741516,0.008490911,0.0009361332],"about_ca_topic_score_codex":0.0010029136,"about_ca_topic_score_gemma":0.00007075271,"teacher_disagreement_score":0.2845386,"about_ca_system_score_codex":0.0241467,"about_ca_system_score_gemma":0.012349853,"threshold_uncertainty_score":0.99952686},"labels":[],"label_agreement":null},{"id":"W2141079126","doi":"10.3109/10428191003695652","title":"Gastrointestinal complications in children with acute myeloid leukemia","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Medicine; Etiology; Gastrointestinal cancer; Necrotizing enterocolitis; Gastrointestinal bleeding; Enterocolitis; Myeloid leukemia; Internal medicine; Randomized controlled trial; Intensive care medicine; Natural history; Pediatrics; Colorectal cancer; Cancer","score_opus":0.01586547505808435,"score_gpt":0.28214479965224043,"score_spread":0.2662793245941561,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141079126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09569578,0.88413703,0.00016260917,0.00012345477,0.0004120891,0.005089632,0.0005090373,0.0007462324,0.0131241055],"genre_scores_gemma":[0.00429251,0.98574674,0.0025382538,0.0006976472,0.00086907233,0.0016772284,0.0015377006,0.00047747887,0.0021633857],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99346834,0.00021103187,0.0017537193,0.0021780976,0.0008012994,0.001587531],"domain_scores_gemma":[0.99547255,0.00028618518,0.00092018186,0.002025801,0.00025836338,0.0010368958],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00032780794,0.0019048691,0.0039001799,0.0010967208,0.00058317865,0.00027962396,0.00081807113,0.00092926255,0.00013093412],"category_scores_gemma":[0.00006302055,0.0015444087,0.00084337767,0.0017647119,0.0008711636,0.0003671696,0.00035859545,0.0012778465,0.00033294482],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0002420563,0.0002540198,0.009479186,0.0023971386,0.00087977824,0.00081114203,0.0000767494,0.0000066526504,0.00006288626,0.00081019965,0.0015615196,0.98341864],"study_design_scores_gemma":[0.010882936,0.0007408636,0.069496274,0.013941323,0.004829924,0.13555604,0.000039428593,0.0000719675,0.00003209037,0.00007042899,0.76253974,0.0017989498],"about_ca_topic_score_codex":0.0022256488,"about_ca_topic_score_gemma":0.00047353207,"teacher_disagreement_score":0.9816197,"about_ca_system_score_codex":0.015148149,"about_ca_system_score_gemma":0.02094436,"threshold_uncertainty_score":0.9993695},"labels":[],"label_agreement":null},{"id":"W2141117691","doi":"10.3109/10428190903308064","title":"Early detection of patients with poor risk diffuse large B-cell lymphoma","year":2009,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Rituximab; Medicine; Diffuse large B-cell lymphoma; Vincristine; International Prognostic Index; Prednisone; Internal medicine; Lymphoma; Oncology; Context (archaeology); CHOP; Cyclophosphamide; Clinical trial; Chemotherapy; Biology","score_opus":0.008167993805071017,"score_gpt":0.23357155439725139,"score_spread":0.22540356059218036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141117691","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.40263766,0.592062,0.000028273233,0.0000071198324,0.0003132234,0.0026130595,0.0007673736,0.00026982307,0.0013014612],"genre_scores_gemma":[0.22719775,0.76933557,0.0003144057,0.00021543344,0.00037737607,0.000488862,0.0009917803,0.00037788,0.00070095586],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9908232,0.00050633174,0.0025665194,0.0024835414,0.0017104632,0.0019099422],"domain_scores_gemma":[0.9928283,0.0006107003,0.0026664122,0.0021407318,0.0005252473,0.0012285997],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00046519953,0.0026943448,0.006176568,0.0011389708,0.00063066394,0.0002229862,0.0006716889,0.0019549914,0.000047838235],"category_scores_gemma":[0.00013854224,0.0019823946,0.0017786949,0.0014980562,0.00044173145,0.0004507227,0.0003391611,0.00031537592,0.00020647823],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011500565,0.00795536,0.0048928345,0.007429005,0.0014519156,0.00046728924,0.0002465148,5.205908e-7,0.000004669147,0.00006501057,0.00040371966,0.9759331],"study_design_scores_gemma":[0.1267318,0.0035941382,0.15182361,0.012094611,0.014327837,0.0006820957,0.000078830926,0.00008429545,0.0003994897,0.000045043682,0.68763715,0.0025011317],"about_ca_topic_score_codex":0.0017889369,"about_ca_topic_score_gemma":0.000088917055,"teacher_disagreement_score":0.97343194,"about_ca_system_score_codex":0.013796209,"about_ca_system_score_gemma":0.0059028035,"threshold_uncertainty_score":0.9997328},"labels":[],"label_agreement":null},{"id":"W2141817010","doi":"10.3109/10428194.2013.850685","title":"Early deaths in pediatric acute leukemia: a population-based study","year":2013,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Hospital for Sick Children; Pediatric Oncology Group; University of Toronto","funders":"Canadian Institutes of Health Research; McMaster University","keywords":"Medicine; Myeloid leukemia; Incidence (geometry); Pediatrics; Retrospective cohort study; Population; Acute leukemia; Leukemia; Lymphoblastic Leukemia; Cohort; Internal medicine","score_opus":0.009866601174023082,"score_gpt":0.2582252562685282,"score_spread":0.24835865509450514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141817010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902397,0.00068970583,0.00016048441,0.00033521323,0.000423081,0.00438342,0.00004436631,0.0005998148,0.0031242133],"genre_scores_gemma":[0.9914217,0.0002723008,0.0015162864,0.0016986537,0.0008048026,0.0013468717,0.00022018058,0.00034628037,0.0023729322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99003965,0.00048429784,0.002152757,0.0024380719,0.0022869573,0.0025982864],"domain_scores_gemma":[0.9942323,0.0010587026,0.00054710306,0.0020094176,0.0005537453,0.001598763],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000909301,0.001545454,0.0021177407,0.0019522308,0.00057271635,0.00051061745,0.0009672746,0.001169236,0.00041287753],"category_scores_gemma":[0.0004997913,0.0014193419,0.00048991,0.0028360346,0.00028995165,0.0010471725,0.0005827893,0.0006575192,0.000970097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014088659,0.0010712099,0.9485987,0.00042944076,0.00044569626,0.0027775231,0.0014247679,0.00027349772,0.0007504554,0.00020080991,0.0034667836,0.03915224],"study_design_scores_gemma":[0.04440484,0.0015171097,0.9256045,0.00021077029,0.0007713099,0.0006714051,0.00060445926,0.023764564,0.00032918144,0.00033748618,0.00043914095,0.0013452203],"about_ca_topic_score_codex":0.032332018,"about_ca_topic_score_gemma":0.000472971,"teacher_disagreement_score":0.042995974,"about_ca_system_score_codex":0.037222806,"about_ca_system_score_gemma":0.013650133,"threshold_uncertainty_score":0.9998078},"labels":[],"label_agreement":null},{"id":"W2141969313","doi":"10.3109/10428194.2010.499978","title":"Proton therapy for Hodgkin lymphoma: does a case report make the case?","year":2010,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Advanced Radiotherapy Techniques","field":"Physics and Astronomy","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Public Health Ontario","funders":"","keywords":"Hodgkin lymphoma; Proton therapy; Medicine; Lymphoma; Oncology; Internal medicine; Cancer research; Radiation therapy","score_opus":0.009408159501526216,"score_gpt":0.2614440209089707,"score_spread":0.25203586140744444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141969313","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.835626,0.006122189,0.03729793,0.06659242,0.006556363,0.03179229,0.0053660604,0.0032478457,0.0073988955],"genre_scores_gemma":[0.26530638,0.0021475928,0.05572297,0.47553983,0.07802693,0.060491264,0.0077901725,0.0052080513,0.049766812],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9916225,0.00040353078,0.001973968,0.0028886136,0.0008139784,0.0022974147],"domain_scores_gemma":[0.9923698,0.0013038758,0.0018764215,0.0035609463,0.00047738044,0.00041158352],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010231623,0.0025014777,0.0021459344,0.0004630765,0.001987116,0.0008358047,0.0013960698,0.0032931832,0.00029028198],"category_scores_gemma":[0.0000634993,0.0016791754,0.0012681764,0.0005825814,0.0011808594,0.00047700043,0.00037168842,0.0015405142,0.000012444785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004118404,0.00020928179,0.0005295244,0.00040038774,0.0011547861,0.1796174,0.00089580216,0.0000058309197,0.0005206539,0.0007180581,0.23417935,0.58135706],"study_design_scores_gemma":[0.0082998425,0.00027010258,0.000057153728,0.00015881837,0.00029888406,0.18392172,0.00028819515,0.0007514704,0.0068745194,0.0043481705,0.792719,0.0020121324],"about_ca_topic_score_codex":0.01049011,"about_ca_topic_score_gemma":0.00023696614,"teacher_disagreement_score":0.5793449,"about_ca_system_score_codex":0.0038261225,"about_ca_system_score_gemma":0.004236781,"threshold_uncertainty_score":0.99999803},"labels":[],"label_agreement":null},{"id":"W2142330668","doi":"10.3109/10428194.2014.894190","title":"Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine<sup>131</sup>-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; London Health Sciences Centre; University of Calgary; GlaxoSmithKline (Canada); Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Internal medicine; Rituximab; Radioimmunotherapy; Oncology; Adverse effect; Lymphoma; Gastroenterology; Immunology; Antibody; Monoclonal antibody","score_opus":0.021871265829693374,"score_gpt":0.27748041892764,"score_spread":0.25560915309794663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142330668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987295,0.0025691683,0.000010032005,0.0003773905,0.00009456123,0.008340781,0.00018133326,0.00008068833,0.001051099],"genre_scores_gemma":[0.996236,0.00031376633,0.0003883581,0.0002816142,0.00019010917,0.0022880204,0.00011654207,0.00011730494,0.000068279114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928804,0.00088581076,0.002007863,0.0016576922,0.0012716696,0.0012965612],"domain_scores_gemma":[0.99464613,0.0013163668,0.00089540717,0.0016873339,0.0004904793,0.00096430193],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023489797,0.0011157322,0.0026448735,0.00061813963,0.00063298794,0.00020679351,0.0006949277,0.0006072345,0.000008168383],"category_scores_gemma":[0.00084216014,0.00081303803,0.000310635,0.0007777698,0.00071104587,0.0003488146,0.00040152125,0.00016395263,0.0000024753137],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006832574,0.0051469887,0.9311923,0.0014169286,0.00081289525,0.00015872213,0.01095917,0.000024030518,0.00038922636,0.0011007907,0.00030250242,0.041663922],"study_design_scores_gemma":[0.12324824,0.0051141293,0.85995036,0.00070193195,0.00073261204,0.00022213644,0.0039537866,0.0024054858,0.002472057,0.00025783855,0.00023732144,0.0007041055],"about_ca_topic_score_codex":0.13249084,"about_ca_topic_score_gemma":0.083957635,"teacher_disagreement_score":0.11641567,"about_ca_system_score_codex":0.0036915245,"about_ca_system_score_gemma":0.0038701312,"threshold_uncertainty_score":0.999432},"labels":[],"label_agreement":null},{"id":"W2142822429","doi":"10.1080/1042819031000067530","title":"Intravascular Lymphoma Presenting with Bone Marrow Involvement and Leukemic Phase","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Pancytopenia; Bone marrow; Pathology; Medicine; CD5; Lymphoma; Intravascular large B-cell lymphoma; Leukemia; Immunocytochemistry; Immunology","score_opus":0.011142118670850744,"score_gpt":0.2396114841933541,"score_spread":0.22846936552250335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2142822429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97959554,0.011848723,0.00014912491,0.00023903036,0.00027219046,0.0017723986,0.000048497266,0.00039218148,0.0056823306],"genre_scores_gemma":[0.98921806,0.0036331567,0.0026399724,0.0016094502,0.00029485225,0.0005436242,0.00019929618,0.0002731272,0.0015884923],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9932011,0.00027708168,0.0013187911,0.0021335753,0.0012765392,0.0017929247],"domain_scores_gemma":[0.99591964,0.00035173394,0.0005120133,0.0015023057,0.00028469937,0.0014295918],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000718876,0.0014847664,0.0018352482,0.00059975596,0.00080763217,0.00039463394,0.0002810722,0.00061291864,0.00018093466],"category_scores_gemma":[0.00016124154,0.001236726,0.00041547697,0.0008781562,0.0008044382,0.0005558943,0.00026625305,0.00016584639,0.00007106517],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029969327,0.004160775,0.10034228,0.0015051964,0.003222804,0.008100815,0.0033653323,0.000043875607,0.01339807,0.006550632,0.0049906657,0.8513226],"study_design_scores_gemma":[0.2616177,0.0053196778,0.3762302,0.0021284206,0.005136475,0.034392603,0.0051443144,0.008281492,0.099851325,0.0013522587,0.19557557,0.0049699713],"about_ca_topic_score_codex":0.0017070374,"about_ca_topic_score_gemma":0.00011432556,"teacher_disagreement_score":0.84635264,"about_ca_system_score_codex":0.00783284,"about_ca_system_score_gemma":0.0038636737,"threshold_uncertainty_score":0.99979013},"labels":[],"label_agreement":null},{"id":"W2143651540","doi":"10.3109/10428194.2015.1034699","title":"Isolated<i>MYC</i>cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"BCL6; Fluorescence in situ hybridization; Lymphoma; Diffuse large B-cell lymphoma; Internal medicine; Medicine; Oncology; Cancer research; Biology; B cell; Immunology; Gene; Genetics","score_opus":0.03735700249744781,"score_gpt":0.3056437599755823,"score_spread":0.26828675747813446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2143651540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98586416,0.0038404278,0.000050742274,0.00023440534,0.0012084725,0.0015923638,0.00029322668,0.0005687669,0.006347438],"genre_scores_gemma":[0.9882354,0.002187357,0.0008143931,0.004419772,0.00088610925,0.0003955864,0.00043526528,0.00027960126,0.0023464735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897353,0.0007227092,0.0031594057,0.0024078316,0.0015898728,0.002384888],"domain_scores_gemma":[0.9931419,0.00060037384,0.0007436429,0.0022639234,0.00039261547,0.0028575344],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019046128,0.0016630996,0.0026514903,0.0007793865,0.00041287375,0.00028163788,0.00078621507,0.0014190731,0.00009830979],"category_scores_gemma":[0.00035231787,0.0014670162,0.0008311193,0.0009463904,0.0006997913,0.0009547318,0.00062703167,0.00028851134,0.0004724349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005412781,0.015598422,0.8838878,0.00042653,0.00049201516,0.005688156,0.0032852532,0.00003605256,0.00013689614,0.00089586823,0.0036926246,0.08044757],"study_design_scores_gemma":[0.24932165,0.0036815687,0.68494064,0.00049127155,0.0010663973,0.0028338751,0.003166629,0.009256204,0.001354394,0.0002429524,0.041697573,0.0019468437],"about_ca_topic_score_codex":0.0031520268,"about_ca_topic_score_gemma":0.00043975664,"teacher_disagreement_score":0.24390887,"about_ca_system_score_codex":0.01092163,"about_ca_system_score_gemma":0.00620082,"threshold_uncertainty_score":0.9998773},"labels":[],"label_agreement":null},{"id":"W2145001558","doi":"10.3109/10428194.2012.719615","title":"Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Etoposide; Lymphoma; Diffuse large B-cell lymphoma; Cytarabine; Chemotherapy; Autologous stem-cell transplantation; Gastroenterology; Peripheral T-cell lymphoma; Cohort; Oncology; Salvage therapy; Immunology; T cell","score_opus":0.010972065217812627,"score_gpt":0.2393099212090804,"score_spread":0.22833785599126777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145001558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99035156,0.0049259136,0.00002009661,0.00017979847,0.0003396926,0.0021292893,0.0004413992,0.0002262317,0.0013860405],"genre_scores_gemma":[0.9932863,0.0010081247,0.0014218257,0.0011942026,0.00021480831,0.00037284597,0.00030323767,0.00025426847,0.0019443599],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993319,0.00042153677,0.001537538,0.0016516126,0.0011255231,0.0019448265],"domain_scores_gemma":[0.9946027,0.00073315995,0.0007089389,0.0014679426,0.00030536312,0.002181915],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00050166703,0.001658534,0.0023691435,0.0006018742,0.00058514177,0.00018314783,0.00030112857,0.0006747831,0.00005643567],"category_scores_gemma":[0.00011737876,0.0012820207,0.0003746831,0.0005344754,0.00049996655,0.0006786263,0.0004102886,0.00009219875,0.0000491381],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025630932,0.021350741,0.8978194,0.00055342796,0.00065765553,0.00040585207,0.0053951424,0.000004356416,0.002303507,0.0001943715,0.00083450205,0.04485014],"study_design_scores_gemma":[0.19059621,0.0034444246,0.77164894,0.000240725,0.00093874737,0.00037948918,0.00065035647,0.00026959283,0.004770527,0.000012059456,0.025917664,0.0011312827],"about_ca_topic_score_codex":0.0017554231,"about_ca_topic_score_gemma":0.000079478836,"teacher_disagreement_score":0.16496527,"about_ca_system_score_codex":0.010695535,"about_ca_system_score_gemma":0.0016830488,"threshold_uncertainty_score":0.99961615},"labels":[],"label_agreement":null},{"id":"W2145186497","doi":"10.3109/10428194.2015.1026901","title":"Treatment of patients with secondary central nervous system lymphoma with high-dose busulfan/thiotepa-based conditioning and autologous stem cell transplant","year":2015,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"ThioTEPA; Busulfan; Medicine; Regimen; Cyclophosphamide; Surgery; Melphalan; Rituximab; Autologous stem-cell transplantation; Chemotherapy; Lymphoma; Internal medicine; Oncology","score_opus":0.0074405407810333515,"score_gpt":0.19377833841580097,"score_spread":0.18633779763476763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145186497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99311596,0.0025496972,0.000108952125,0.00009567017,0.0002518708,0.0017852716,0.000668779,0.00033786424,0.0010859404],"genre_scores_gemma":[0.9965378,0.00022625456,0.0011397507,0.00023439429,0.00013307299,0.0003161198,0.000995948,0.00018981719,0.00022685758],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99510723,0.00019826493,0.0010437921,0.0013945377,0.0010153631,0.0012408119],"domain_scores_gemma":[0.99638474,0.00029538744,0.0006488531,0.00093132403,0.00038415717,0.0013555489],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014816804,0.0012524823,0.0019264088,0.00041896367,0.00039478586,0.0001456704,0.00020598978,0.00051463814,0.000021207205],"category_scores_gemma":[0.0000070299025,0.00089275226,0.00024481624,0.0004983308,0.00062644965,0.0003187635,0.000058193404,0.00008275966,0.000015214723],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.017403537,0.004054434,0.33729973,0.0018608789,0.0016916028,0.0061007887,0.0044464013,0.00059253327,0.00026011324,0.0006845509,0.0003425577,0.62526286],"study_design_scores_gemma":[0.10508999,0.00868646,0.8640903,0.00090103986,0.0019341046,0.0021580842,0.0013644943,0.0022528328,0.011059458,0.000010513491,0.0014805931,0.00097211637],"about_ca_topic_score_codex":0.003926454,"about_ca_topic_score_gemma":0.000167548,"teacher_disagreement_score":0.62429076,"about_ca_system_score_codex":0.010866304,"about_ca_system_score_gemma":0.0062345327,"threshold_uncertainty_score":0.9993992},"labels":[],"label_agreement":null},{"id":"W2146054188","doi":"10.3109/10428194.2014.944519","title":"Skeletal, neuromuscular and fitness impairments among children with newly diagnosed acute lymphoblastic leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Percentile; Confidence interval; Bone mineral; Rehabilitation; Weakness; Physical therapy; Quality of life (healthcare); Internal medicine; Lymphoblastic Leukemia; Body mass index; Logistic regression; Pediatrics; Surgery; Leukemia; Osteoporosis","score_opus":0.006386891828701512,"score_gpt":0.23106590579247213,"score_spread":0.22467901396377063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146054188","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935146,0.0012392056,0.0007448734,0.000367503,0.00044729174,0.0017237004,0.000085083666,0.00069450994,0.0011832376],"genre_scores_gemma":[0.9905664,0.0009926328,0.0011828379,0.0046217637,0.00092427916,0.00025281223,0.00033536053,0.00037098007,0.00075298926],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920585,0.0004916243,0.0014516714,0.0024397676,0.001687099,0.0018713289],"domain_scores_gemma":[0.9946263,0.0006616684,0.00072053063,0.0018940885,0.00025972188,0.001837706],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008696431,0.0016667546,0.0022177547,0.00054459344,0.0008041217,0.00042348227,0.0006732455,0.0007896348,0.00007715434],"category_scores_gemma":[0.0003470232,0.001469584,0.00044757937,0.0009444914,0.0014083444,0.00081640447,0.0005376584,0.00037859206,0.000078957084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00341524,0.00094574085,0.7736756,0.001735107,0.004695134,0.0025680396,0.0054427614,0.00048803515,0.0026780944,0.00080660376,0.008171563,0.19537807],"study_design_scores_gemma":[0.046477783,0.002006824,0.93063456,0.0009960937,0.0017379854,0.005226413,0.00034944335,0.005524715,0.0010988315,0.00018653042,0.003986563,0.0017742483],"about_ca_topic_score_codex":0.006584548,"about_ca_topic_score_gemma":0.00046898384,"teacher_disagreement_score":0.19360381,"about_ca_system_score_codex":0.005352264,"about_ca_system_score_gemma":0.0037767661,"threshold_uncertainty_score":0.9996079},"labels":[],"label_agreement":null},{"id":"W2146651952","doi":"10.3109/10428194.2012.731599","title":"Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Chronic lymphocytic leukemia; Medicine; ROR1; Cancer research; Follicular lymphoma; Lymphoma; Mantle cell lymphoma; Leukemia; Internal medicine; Receptor; Platelet-derived growth factor receptor","score_opus":0.020076497107328888,"score_gpt":0.27465724116146906,"score_spread":0.25458074405414016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2146651952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97722906,0.01666576,0.00003434029,0.0003976529,0.00041072853,0.0009797061,0.00003705904,0.00030344896,0.003942267],"genre_scores_gemma":[0.9906952,0.003074172,0.0013454692,0.0013691874,0.0006528981,0.00023046831,0.0001165258,0.00015129703,0.0023647787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99387044,0.00026590563,0.0011736078,0.0012806475,0.0010735027,0.0023359286],"domain_scores_gemma":[0.9964403,0.00067350996,0.0002641426,0.0009989934,0.00018179584,0.0014412949],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010169338,0.00097134226,0.0015935407,0.0006118687,0.00036149367,0.00017430776,0.00038941702,0.0008895164,0.00032601002],"category_scores_gemma":[0.0006651438,0.00081779703,0.00024705948,0.0010496926,0.0010535509,0.00072028843,0.0006268835,0.00030272716,0.00025455182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011857806,0.004190064,0.39708242,0.0066099428,0.00118529,0.007004811,0.011474252,0.000052814965,0.10098162,0.034991063,0.043848287,0.38072166],"study_design_scores_gemma":[0.15107447,0.0018593894,0.56567806,0.0029394936,0.0005462959,0.031524263,0.0038806903,0.008953816,0.09527226,0.0009428715,0.13347362,0.0038548035],"about_ca_topic_score_codex":0.002914983,"about_ca_topic_score_gemma":0.00011309259,"teacher_disagreement_score":0.37686685,"about_ca_system_score_codex":0.03390253,"about_ca_system_score_gemma":0.008470983,"threshold_uncertainty_score":0.99942726},"labels":[],"label_agreement":null},{"id":"W2147655719","doi":"10.3109/10428194.2012.723210","title":"Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignancies","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Sick Kids Foundation","keywords":"Klebsiella pneumoniae; Carbapenem-resistant enterobacteriaceae; Pulsed-field gel electrophoresis; Enterobacter cloacae; Microbiology; Population; Medicine; Fungemia; Carbapenem; Biology; Antibiotics; Genotype; Escherichia coli; Gene","score_opus":0.0047940171867644965,"score_gpt":0.21038817693394263,"score_spread":0.20559415974717812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147655719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775755,0.0009311562,0.0000258738,0.000005330113,0.00021669135,0.00033610335,0.00007327589,0.000019742794,0.00063427316],"genre_scores_gemma":[0.99871886,0.00043131234,0.00042631177,0.00005152721,0.000059733135,0.000025593785,0.00011318289,0.00004617562,0.00012731706],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978094,0.00011283386,0.0007124572,0.0004898662,0.00028166143,0.0005937548],"domain_scores_gemma":[0.9985359,0.000045335437,0.00047041566,0.0006000143,0.00017396346,0.00017438116],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017273362,0.00041741028,0.0006014154,0.00014650408,0.00008696071,0.000020671598,0.00027370985,0.00031213832,0.00004936775],"category_scores_gemma":[0.000107324595,0.00035710662,0.0001182515,0.00029916601,0.00043559854,0.00004362065,0.00019122033,0.000045376994,0.000004717635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005549137,0.00040500832,0.87106,0.00018586367,0.000119666176,0.0000054425086,0.00019658041,0.0000101099795,0.12651843,0.00026863304,0.00012334548,0.00055200816],"study_design_scores_gemma":[0.0037987703,0.00068068126,0.8422919,0.00021836165,0.000080393525,0.000053795262,0.00043808392,0.0000051848056,0.15148966,0.000024465911,0.0005452112,0.00037350002],"about_ca_topic_score_codex":0.0008809069,"about_ca_topic_score_gemma":0.00032572926,"teacher_disagreement_score":0.028768105,"about_ca_system_score_codex":0.00026071796,"about_ca_system_score_gemma":0.00066988805,"threshold_uncertainty_score":0.99988806},"labels":[],"label_agreement":null},{"id":"W2148047768","doi":"10.3109/10428194.2012.740558","title":"Clinical characteristics and outcome associated with pandemic (2009) H1N1 influenza infection in patients with hematologic malignancies: a retrospective cohort study","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Influenza Virus Research Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Mount Sinai Hospital; University of Toronto","funders":"","keywords":"Medicine; Hematologic malignancy; Malignancy; Internal medicine; Retrospective cohort study; Hematological malignancy; Cohort; Immunology; Gastroenterology","score_opus":0.0409784437075487,"score_gpt":0.33538123134180386,"score_spread":0.29440278763425515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148047768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960799,0.00046726924,0.000010402106,0.00001077619,0.00016369132,0.0025858865,0.00005757768,0.00022840616,0.00039608355],"genre_scores_gemma":[0.9979601,0.00033064443,0.00009697911,0.00084188144,0.00014308371,0.00032370354,0.00006156994,0.000096473246,0.00014558114],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946994,0.000424091,0.0013632716,0.0010267304,0.0011429744,0.001343494],"domain_scores_gemma":[0.9970536,0.0005086004,0.00062013924,0.00064004667,0.0005881667,0.00058942067],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018845104,0.0007745193,0.0019919309,0.00042409828,0.00038549097,0.000097666314,0.00015492643,0.00053007115,0.000018861958],"category_scores_gemma":[0.0017093001,0.00055282214,0.00013074018,0.00087221776,0.00075495354,0.00055011496,0.0002841947,0.00045019758,0.000021933198],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025533289,0.001349331,0.99078846,0.00013038791,0.0008560713,0.00012311761,0.0011096762,0.0000013889158,0.00000940664,0.000033290882,0.00007749687,0.0029680629],"study_design_scores_gemma":[0.03251074,0.002725875,0.962327,0.00040524302,0.00055986556,0.0001182877,0.00032289608,0.00008436113,0.0000108979875,0.000013616228,0.00027066635,0.00065055833],"about_ca_topic_score_codex":0.0014591559,"about_ca_topic_score_gemma":0.00034674405,"teacher_disagreement_score":0.029957412,"about_ca_system_score_codex":0.008065184,"about_ca_system_score_gemma":0.0010835888,"threshold_uncertainty_score":0.9996923},"labels":[],"label_agreement":null},{"id":"W2148153235","doi":"10.1080/1042819031000139774","title":"Rescue of Interferon Induced Bone Marrow Aplasia in a Patient with Chronic Myeloid Leukemia by Allogeneic Bone Marrow Transplant","year":2003,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Markham Stouffville Hospital; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Bone marrow; Aplasia; Prednisone; Bone Marrow Aplasia; Complication; Hypoplasia; Myeloid leukemia; Immunology; Chronic myelogenous leukemia; Philadelphia chromosome; Leukemia; Gastroenterology; Internal medicine; Chromosomal translocation; Biology","score_opus":0.008472961117209849,"score_gpt":0.2164746803923874,"score_spread":0.20800171927517755,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148153235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864699,0.0066305455,0.000034852044,0.00011419461,0.00048149296,0.0022283792,0.00018903273,0.00023206376,0.0036195081],"genre_scores_gemma":[0.99452376,0.0013734224,0.0007412968,0.00057275733,0.00012632179,0.00040667527,0.0003056291,0.00034494698,0.00160517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99115247,0.000490068,0.0023105282,0.0022950044,0.0015706423,0.0021812983],"domain_scores_gemma":[0.9957089,0.00022167657,0.00081305194,0.0019606194,0.00022926235,0.0010664774],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005423418,0.0017717071,0.0026635677,0.000857316,0.00028254732,0.00008567267,0.000533736,0.0012948017,0.00023147986],"category_scores_gemma":[0.00014523171,0.0015676576,0.0005481426,0.001561598,0.00062968594,0.00046457793,0.00022861383,0.00060068356,0.000052757096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012342863,0.0020007654,0.090153076,0.0029432443,0.0015983128,0.006559725,0.0038549202,0.0005267822,0.7697647,0.00065970904,0.003918357,0.105677515],"study_design_scores_gemma":[0.14253344,0.009138641,0.10022433,0.007965948,0.0016694335,0.025659718,0.00085101865,0.0030009162,0.68834615,0.00017460017,0.016453328,0.003982516],"about_ca_topic_score_codex":0.0053389263,"about_ca_topic_score_gemma":0.0025428953,"teacher_disagreement_score":0.13019057,"about_ca_system_score_codex":0.054524813,"about_ca_system_score_gemma":0.016647888,"threshold_uncertainty_score":0.99950284},"labels":[],"label_agreement":null},{"id":"W2148893624","doi":"10.3109/10428190903275586","title":"Lysophosphatidic acid receptor expression in chronic lymphocytic leukemia leads to cell survival mediated though vascular endothelial growth factor expression","year":2009,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; Research Manitoba","funders":"CancerCare Manitoba Foundation; Manitoba Health Research Council; Friedreich's Ataxia Research Alliance","keywords":"Lysophosphatidic acid; Autocrine signalling; Chronic lymphocytic leukemia; Apoptosis; Receptor; Cancer research; Biology; Vascular endothelial growth factor; Endocrinology; Internal medicine; Leukemia; Immunology; Medicine; VEGF receptors; Biochemistry","score_opus":0.012765486987522282,"score_gpt":0.2597939234841367,"score_spread":0.24702843649661443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2148893624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9820286,0.008490662,0.0004167488,0.00021100945,0.0010800236,0.003155995,0.000197705,0.0009123295,0.0035068982],"genre_scores_gemma":[0.9851924,0.0052860593,0.0023257392,0.0020571153,0.0016406043,0.00034806013,0.00049246673,0.00044763598,0.002209872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98525923,0.0008212053,0.0026895138,0.0036445174,0.0036311725,0.003954332],"domain_scores_gemma":[0.9918873,0.0012228183,0.00070406724,0.0027792987,0.00057375437,0.0028327995],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001383739,0.0023589216,0.0031382865,0.0016547128,0.0007403434,0.0004051693,0.0016731779,0.0019632687,0.0006212349],"category_scores_gemma":[0.0014001732,0.0021410915,0.00089919975,0.002932958,0.00062945735,0.0011150276,0.0008859323,0.0008106798,0.0010739171],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005342474,0.00037474482,0.0015921608,0.0011650723,0.00016058702,0.0018684063,0.0031800654,0.00078787334,0.9497428,0.00016395483,0.006309088,0.029312782],"study_design_scores_gemma":[0.11489149,0.002417629,0.02092683,0.0026964494,0.00025708682,0.0006823251,0.00055444374,0.015355687,0.8238034,0.0002145209,0.015420342,0.0027797485],"about_ca_topic_score_codex":0.0033471752,"about_ca_topic_score_gemma":0.00014502177,"teacher_disagreement_score":0.27472013,"about_ca_system_score_codex":0.36842915,"about_ca_system_score_gemma":0.09370902,"threshold_uncertainty_score":0.9997039},"labels":[],"label_agreement":null},{"id":"W2149077277","doi":"10.3109/10428194.2014.947607","title":"<i>DNMT3A</i>mutations and prognostic significance in childhood acute lymphoblastic leukemia","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"","keywords":"Exon; Mutation; Minimal residual disease; Intron; Coding region; Medicine; Lymphoblastic Leukemia; Biology; Cancer research; Genetics; Internal medicine; Leukemia; Molecular biology; Oncology; Gene","score_opus":0.0073971769516722515,"score_gpt":0.24177743551813394,"score_spread":0.2343802585664617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149077277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98530126,0.0015469613,0.0016462366,0.00059565326,0.00041242022,0.0023009158,0.00010087463,0.0005828167,0.007512842],"genre_scores_gemma":[0.9888315,0.0012618317,0.00347282,0.002650995,0.0006662059,0.0006947526,0.00027003864,0.00034024342,0.0018115708],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.990813,0.00048350467,0.0018657974,0.0026132758,0.0016606601,0.0025637446],"domain_scores_gemma":[0.9935424,0.0022281455,0.000524451,0.0015671307,0.0003938398,0.0017440814],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011462673,0.0015600544,0.0021075117,0.0012204907,0.0007156768,0.0004142372,0.00075798604,0.0010634868,0.00010194904],"category_scores_gemma":[0.0015687941,0.0014835226,0.0003553286,0.002018211,0.0015194644,0.0007869672,0.00068630243,0.00056905183,0.0002720862],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0065701846,0.0025317501,0.21533416,0.0038573926,0.0029442376,0.0069482857,0.0106064,0.001595408,0.044320397,0.013684905,0.012611444,0.67899543],"study_design_scores_gemma":[0.06514357,0.002128655,0.7947051,0.001897082,0.0015485968,0.010314107,0.0009985996,0.09665724,0.0064731976,0.003340166,0.013841687,0.0029520323],"about_ca_topic_score_codex":0.0019420844,"about_ca_topic_score_gemma":0.00020521264,"teacher_disagreement_score":0.6760434,"about_ca_system_score_codex":0.018128702,"about_ca_system_score_gemma":0.01185924,"threshold_uncertainty_score":0.9997148},"labels":[],"label_agreement":null},{"id":"W2151599813","doi":"10.3109/10428194.2012.661854","title":"Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Methylation; CpG site; DNA methylation; Multiple myeloma; Disease; Medicine; Stage (stratigraphy); Gene silencing; Internal medicine; Cancer research; Epigenetics; Oncology; Immunology; Gastroenterology; Biology; Gene; Gene expression; Genetics","score_opus":0.020197574919612844,"score_gpt":0.275966272670074,"score_spread":0.2557686977504612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151599813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99417,0.0025165372,0.0007004849,0.00019232735,0.00021577445,0.0011323891,0.00007349589,0.000120458884,0.00087853207],"genre_scores_gemma":[0.99695385,0.000307324,0.0009286114,0.00017796444,0.00026759697,0.00039960726,0.00027845,0.000100401965,0.00058620627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966918,0.00021303864,0.00075201486,0.000668053,0.0006772185,0.0009978419],"domain_scores_gemma":[0.9972003,0.0005358206,0.00034883834,0.0007608952,0.00021015658,0.0009439684],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003536832,0.0005210624,0.0007122318,0.00049729244,0.000258702,0.000051212788,0.00019924711,0.0002601363,0.000104008635],"category_scores_gemma":[0.00029745945,0.00041381957,0.00020447363,0.00057610264,0.0002918685,0.00068205514,0.00012680396,0.000192205,0.000034042274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006193462,0.0013404314,0.8140175,0.00035905055,0.0005084565,0.00017864263,0.0012456644,0.00008662454,0.014612069,0.00035808585,0.00020330456,0.1608967],"study_design_scores_gemma":[0.023349166,0.00040349047,0.96238095,0.00036734872,0.00033960555,0.00027653782,0.00039013522,0.0071758954,0.0024478803,0.00010111245,0.0023829748,0.0003848779],"about_ca_topic_score_codex":0.0010419345,"about_ca_topic_score_gemma":0.000071621624,"teacher_disagreement_score":0.16051182,"about_ca_system_score_codex":0.003539282,"about_ca_system_score_gemma":0.0018922907,"threshold_uncertainty_score":0.9998314},"labels":[],"label_agreement":null},{"id":"W2153978703","doi":"10.3109/10428194.2010.504872","title":"Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Vincristine; Rituximab; Prednisone; International Prognostic Index; Internal medicine; Cyclophosphamide; CHOP; B symptoms; Diffuse large B-cell lymphoma; Lymphoma; Oncology; Anthracycline; Gastroenterology; Doxorubicin; Chemotherapy; Cancer","score_opus":0.004040064221313318,"score_gpt":0.2000309562857332,"score_spread":0.19599089206441989,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2153978703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946375,0.001520566,0.00002632445,0.00015043152,0.00006399415,0.002309379,0.00026729357,0.00014367863,0.0008808729],"genre_scores_gemma":[0.9958927,0.00067095045,0.0017168394,0.00039865045,0.00006304517,0.00053347467,0.0004023819,0.00013836738,0.00018358951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957769,0.00008631543,0.0010151283,0.0013999295,0.0006729408,0.0010488051],"domain_scores_gemma":[0.99712527,0.00033461416,0.00048117113,0.0009525231,0.00034882472,0.00075758825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024459988,0.0009889497,0.0014020344,0.0004421967,0.00034164506,0.00012474644,0.00021765061,0.0004458889,0.000024666375],"category_scores_gemma":[0.000068143294,0.0007330009,0.00011154707,0.000727125,0.00069352007,0.0003510015,0.0002075112,0.0001466227,0.000006802808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027639605,0.01006669,0.95004994,0.00049703376,0.00027492002,0.00018924047,0.0006546306,0.0000013387829,0.0014157917,0.00058847753,0.00012131872,0.033376634],"study_design_scores_gemma":[0.16054319,0.0020252885,0.8292954,0.00046634497,0.0007180657,0.00032066295,0.00021700257,0.00031456267,0.004578233,0.000066127854,0.0007803516,0.00067476183],"about_ca_topic_score_codex":0.0027760016,"about_ca_topic_score_gemma":0.0010234505,"teacher_disagreement_score":0.15777922,"about_ca_system_score_codex":0.0016975447,"about_ca_system_score_gemma":0.001531737,"threshold_uncertainty_score":0.9995121},"labels":[],"label_agreement":null},{"id":"W2154423235","doi":"10.1080/10428190801910912","title":"Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-<b>kappa</b>B pathways","year":2008,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Bortezomib; Proteasome inhibitor; Mantle cell lymphoma; Apoptosis; Protein kinase B; Cancer research; Proteasome; Downregulation and upregulation; Chemistry; Cell culture; Biology; Lymphoma; Multiple myeloma; Immunology; Biochemistry; Gene","score_opus":0.008174629035748681,"score_gpt":0.2006906936547852,"score_spread":0.19251606461903653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154423235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99492383,0.0019170814,0.000013352318,0.000037127138,0.0001241123,0.00080920453,0.00029711332,0.00002002632,0.0018581531],"genre_scores_gemma":[0.99586797,0.0034301109,0.0001529047,0.00025092295,0.00007612636,0.000051526946,0.000021150847,0.000050431627,0.000098833385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99695647,0.00041694404,0.0006300721,0.0009960649,0.00042769522,0.0005727603],"domain_scores_gemma":[0.9981988,0.0003231652,0.00048114962,0.00057590916,0.00013335704,0.0002876234],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005311261,0.00061478803,0.0008998671,0.00017758876,0.0002985676,0.00003587578,0.00025858186,0.0006619152,0.000006026861],"category_scores_gemma":[0.000137968,0.00049870246,0.00015508122,0.00028589432,0.0012881884,0.000040411986,0.00065525377,0.00014620733,0.0000014691783],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001534874,0.00019761772,0.008426404,0.00035243493,0.00013358163,0.000059070655,0.0020735597,0.000001991781,0.9701221,0.00010326915,0.00020554315,0.016789554],"study_design_scores_gemma":[0.009275386,0.00087711384,0.086934924,0.00019025273,0.00010093594,0.00022617832,0.000319759,0.00018589298,0.90088665,0.0000681793,0.00043808928,0.0004966254],"about_ca_topic_score_codex":0.0018719492,"about_ca_topic_score_gemma":0.0001573215,"teacher_disagreement_score":0.07850852,"about_ca_system_score_codex":0.00042238735,"about_ca_system_score_gemma":0.0014462529,"threshold_uncertainty_score":0.99974644},"labels":[],"label_agreement":null},{"id":"W2155791176","doi":"10.3109/10428194.2013.840889","title":"Genetic risk of chronic lymphocytic leukemia: a tale of two cities","year":2013,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chronic lymphocytic leukemia; Genetics; Family aggregation; Allele; Population; Disease; Biology; Medicine; Leukemia; Gene; Internal medicine","score_opus":0.011787878781792348,"score_gpt":0.2531573642100715,"score_spread":0.24136948542827916,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155791176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547634,0.026898133,0.00018450673,0.0018316708,0.0013635019,0.0041764663,0.0009270996,0.00057486474,0.009280354],"genre_scores_gemma":[0.8818692,0.024330981,0.0036363415,0.046418723,0.011014442,0.001430629,0.0015635301,0.0017734544,0.027962692],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98267514,0.0009421196,0.0047475817,0.0034828344,0.004262884,0.0038894329],"domain_scores_gemma":[0.9864545,0.0023471545,0.0034940692,0.005008623,0.0014769136,0.0012187804],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011217843,0.0031896345,0.0062813303,0.0022854586,0.0005367067,0.0002635856,0.0022705754,0.004791991,0.0010691218],"category_scores_gemma":[0.00080794375,0.002970994,0.002076352,0.0020022865,0.004483584,0.00058856816,0.0015799361,0.0020726153,0.0005098766],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0020838878,0.0003328884,0.0020670525,0.02809667,0.007115551,0.009712807,0.0022150865,0.002159546,0.0056742756,0.00044029905,0.81803656,0.12206537],"study_design_scores_gemma":[0.25348535,0.0063319937,0.012224021,0.012490013,0.011589596,0.028547743,0.0009224397,0.22378764,0.036193904,0.0030678427,0.4032719,0.008087542],"about_ca_topic_score_codex":0.06620459,"about_ca_topic_score_gemma":0.0002769741,"teacher_disagreement_score":0.41476464,"about_ca_system_score_codex":0.35957855,"about_ca_system_score_gemma":0.22967228,"threshold_uncertainty_score":0.999844},"labels":[],"label_agreement":null},{"id":"W2157783814","doi":"10.3109/10428194.2011.633250","title":"Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; ThioTEPA; Busulfan; Primary central nervous system lymphoma; Cyclophosphamide; Internal medicine; Autologous stem-cell transplantation; Oncology; Vincristine; Surgery; Chemotherapy; Regimen; Performance status","score_opus":0.014925888919821618,"score_gpt":0.21909359956061303,"score_spread":0.20416771064079142,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157783814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816262,0.007899575,0.0003619269,0.00015976893,0.00053728715,0.001999057,0.00020554577,0.00043875756,0.0067718686],"genre_scores_gemma":[0.98753166,0.0033854174,0.0045052767,0.0014165544,0.00021233853,0.0005793227,0.00030696884,0.00019686615,0.0018655801],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948266,0.00012338592,0.0011894902,0.0017837798,0.00066394085,0.001412796],"domain_scores_gemma":[0.9969862,0.00040702824,0.00048521414,0.00093401864,0.0002479158,0.0009396091],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002721672,0.0011592779,0.0014495099,0.0003381175,0.0006488248,0.00016749943,0.00033399882,0.00073512434,0.0000699411],"category_scores_gemma":[0.00003275293,0.0010498901,0.0004262696,0.00043502738,0.0005406519,0.0005173429,0.00016521965,0.0000929266,0.00004396868],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003569453,0.0017565085,0.03463092,0.0012247494,0.00038131524,0.0015587045,0.015780216,0.0000053670483,0.006225039,0.0007304388,0.0014492039,0.93268806],"study_design_scores_gemma":[0.030882314,0.001387798,0.8777183,0.0005448377,0.0011970619,0.0028553782,0.002585556,0.0006808943,0.06596318,0.00027491926,0.014563352,0.001346389],"about_ca_topic_score_codex":0.0018835351,"about_ca_topic_score_gemma":0.00015949689,"teacher_disagreement_score":0.9313417,"about_ca_system_score_codex":0.0060016788,"about_ca_system_score_gemma":0.0019118774,"threshold_uncertainty_score":0.99919516},"labels":[],"label_agreement":null},{"id":"W2157797828","doi":"10.3109/10428190109064600","title":"BAD Induces Apoptosis in Cells Over-Expressing Bcl-2 or Bcl-xL without Loss of Mitochondrial Membrane Potential","year":2001,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Transfection; Bcl-xL; Apoptosis; Programmed cell death; Cell biology; Cell culture; Biology; Leukemia; Cancer research; Chemistry; Immunology; Biochemistry; Genetics","score_opus":0.007304111917981187,"score_gpt":0.2289915247457736,"score_spread":0.22168741282779242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157797828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99562776,0.0010547442,0.00084775564,0.00003248457,0.00085160113,0.00044743944,0.000033512853,0.0000414085,0.0010632738],"genre_scores_gemma":[0.99185795,0.0031840813,0.0013605463,0.00018384022,0.0007728824,0.00004614768,0.00016048661,0.00008748058,0.0023466046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99680483,0.00015210417,0.00084869575,0.0009911223,0.00047737657,0.00072585867],"domain_scores_gemma":[0.99852484,0.000044801724,0.00040218243,0.00065864314,0.00011199226,0.00025755697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024198108,0.00058084715,0.0006898966,0.00025315068,0.00021880477,0.000110712994,0.0003965415,0.0008180509,0.00009267717],"category_scores_gemma":[0.00004685715,0.00050627196,0.0002454504,0.00038621706,0.00026568217,0.000051158382,0.00022460338,0.000100689074,0.000006699898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017121885,0.0001577321,0.00077977945,0.00009603382,0.00009130641,0.00006816805,0.00021027256,0.00056398386,0.95573545,0.00004488735,0.00035995917,0.04018023],"study_design_scores_gemma":[0.012480902,0.00038655073,0.0073599857,0.00022711478,0.00011798899,0.00032900524,0.00021980784,0.0023604312,0.96379876,0.00012316387,0.011820831,0.00077543705],"about_ca_topic_score_codex":0.0012154003,"about_ca_topic_score_gemma":0.00018158442,"teacher_disagreement_score":0.03940479,"about_ca_system_score_codex":0.00065251905,"about_ca_system_score_gemma":0.0011162038,"threshold_uncertainty_score":0.9997389},"labels":[],"label_agreement":null},{"id":"W2157912932","doi":"10.3109/10428194.2014.971407","title":"The deregulated promoter methylation of the<i>Polo-like kinases</i>as a potential biomarker in hematological malignancies","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Windsor Regional Hospital; University of Windsor","funders":"Windsor Cancer Centre Foundation","keywords":"Polo-like kinase; Methylation; DNA methylation; Carcinogenesis; PLK1; Biology; Cancer research; Leukemia; Kinase; Biomarker; Myelodysplastic syndromes; Bone marrow; Molecular biology; Cancer; Genetics; Immunology; DNA; Gene; Cell cycle; Gene expression","score_opus":0.011268430685235196,"score_gpt":0.2545168655827003,"score_spread":0.24324843489746512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157912932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99247134,0.0015156376,0.00015551443,0.0016590621,0.00036526768,0.0012991283,0.000013351702,0.00013143854,0.0023892717],"genre_scores_gemma":[0.99584764,0.00037941616,0.00031569894,0.0011098698,0.00012266278,0.00014734572,0.000041077008,0.00009143954,0.0019448383],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9946922,0.000772924,0.0012215097,0.0009589996,0.0011436347,0.001210725],"domain_scores_gemma":[0.9967266,0.00076598424,0.00046255338,0.0013461943,0.0003297141,0.00036899513],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014889365,0.00065833406,0.0010196767,0.00033122473,0.0005852782,0.00013453553,0.0007506427,0.0007410528,0.00006582507],"category_scores_gemma":[0.000860365,0.0003944778,0.00040786687,0.0012882607,0.0014452619,0.00023323661,0.0005878323,0.0003113363,0.000052581843],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009702514,0.0009587331,0.05963998,0.0015042722,0.0011030697,0.0011722357,0.0029393774,0.000230093,0.41378015,0.01526956,0.011714255,0.48198578],"study_design_scores_gemma":[0.025480272,0.000753167,0.80243623,0.0008606782,0.00039854785,0.0052225552,0.00082201743,0.04612943,0.08645119,0.005046267,0.025388995,0.0010106245],"about_ca_topic_score_codex":0.0020947426,"about_ca_topic_score_gemma":0.00017847944,"teacher_disagreement_score":0.74279624,"about_ca_system_score_codex":0.00361264,"about_ca_system_score_gemma":0.0030884328,"threshold_uncertainty_score":0.9998507},"labels":[],"label_agreement":null},{"id":"W2158664264","doi":"10.3109/10428194.2012.722217","title":"Correlation of the microculture-kinetic drug-induced apoptosis assay with patient outcomes in initial treatment of adult acute myelocytic leukemia","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Semtech (Canada)","funders":"Leukemia and Lymphoma Society","keywords":"Idarubicin; Microculture; Apoptosis; Medicine; Daunorubicin; Myeloid leukemia; Chemotherapy; Internal medicine; Leukemia; Oncology; Pharmacology; Immunology; Cytarabine; Biology; Cell culture; Biochemistry","score_opus":0.010439009679549102,"score_gpt":0.2573961836601869,"score_spread":0.2469571739806378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2158664264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428,0.0005797168,0.000035384222,0.00030275123,0.00041057187,0.0020129932,0.00009041668,0.00008510615,0.0022030782],"genre_scores_gemma":[0.9965792,0.00042579378,0.00075844803,0.000524712,0.0001787396,0.0002885372,0.00011259617,0.00014395597,0.0009880584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99439526,0.00044158855,0.0015666712,0.00088053267,0.00133209,0.0013838625],"domain_scores_gemma":[0.996159,0.0005854405,0.000854658,0.0013095825,0.0005114382,0.00057984696],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037173534,0.0009993172,0.0018197299,0.000574641,0.0002444549,0.000046909503,0.00046159205,0.00064155244,0.000041883923],"category_scores_gemma":[0.00020770672,0.0006338193,0.00048897916,0.0013295168,0.0006446081,0.0004265142,0.0002608764,0.00024836362,0.000027334416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00817989,0.002773619,0.6275636,0.0010039785,0.003015678,0.0002458482,0.026602881,0.0003883781,0.111930534,0.0012770315,0.0017699377,0.21524861],"study_design_scores_gemma":[0.04444544,0.0024289773,0.50517535,0.0010103069,0.0015767855,0.0011480126,0.0029071232,0.0039011978,0.4344309,0.000055407956,0.0018052593,0.0011152278],"about_ca_topic_score_codex":0.0063777855,"about_ca_topic_score_gemma":0.0002872909,"teacher_disagreement_score":0.32250038,"about_ca_system_score_codex":0.021454506,"about_ca_system_score_gemma":0.005670812,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W2160932375","doi":"10.3109/10428194.2014.927457","title":"Shelf-life extension of azacitidine: waste and cost reduction in the treatment of myelodysplastic syndromes","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Azacitidine; Myelodysplastic syndromes; Reduction (mathematics); Medicine; Extension (predicate logic); Oncology; Internal medicine; Computer science; Biology; Genetics","score_opus":0.02607203243919772,"score_gpt":0.27239053465651586,"score_spread":0.24631850221731813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2160932375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669129,0.00534318,0.000041500363,0.023063147,0.000444473,0.0026278668,0.0001356036,0.000088459696,0.0013428454],"genre_scores_gemma":[0.94453394,0.01608381,0.00045589305,0.032128576,0.0027262939,0.0005168199,0.0009901394,0.00031893366,0.0022456036],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930134,0.0006630427,0.0018408227,0.0016213689,0.0015641054,0.0012973077],"domain_scores_gemma":[0.9950178,0.001463282,0.0009334166,0.0017890497,0.0003887114,0.00040771434],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008237331,0.001311742,0.002827621,0.0012452326,0.00023867349,0.00009281375,0.0005610388,0.0019241226,0.000052692896],"category_scores_gemma":[0.00036104448,0.0009400149,0.00047626943,0.0009825288,0.0014294747,0.00021987289,0.00018470928,0.0006788926,0.00002414212],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067487685,0.0015053812,0.0046662404,0.012324621,0.0025778753,0.009135444,0.008293243,0.00017892799,0.01820982,0.00046829882,0.66436404,0.27152735],"study_design_scores_gemma":[0.08952759,0.012228041,0.05977097,0.0075187217,0.00478595,0.04152124,0.004793767,0.01577809,0.014973129,0.00055997923,0.74494183,0.003600704],"about_ca_topic_score_codex":0.0028400794,"about_ca_topic_score_gemma":0.000031654003,"teacher_disagreement_score":0.26792666,"about_ca_system_score_codex":0.008098158,"about_ca_system_score_gemma":0.004919562,"threshold_uncertainty_score":0.9999634},"labels":[],"label_agreement":null},{"id":"W2161794113","doi":"10.3109/10428194.2011.652108","title":"Long-term follow-up of patients with chronic myeloid leukemia in chronic phase developing sudden blast phase on imatinib therapy","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Imatinib; Cumulative incidence; Internal medicine; Imatinib mesylate; Myeloid leukemia; Incidence (geometry); Oncology; Dasatinib; Tyrosine-kinase inhibitor; Nilotinib; Pediatrics; Transplantation; Cancer","score_opus":0.023020625815163804,"score_gpt":0.2731842722756763,"score_spread":0.25016364646051253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161794113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99084747,0.002706527,0.00016164672,0.00003069617,0.0004873364,0.0030029411,0.0001694249,0.00031300454,0.0022809315],"genre_scores_gemma":[0.9936508,0.0021265186,0.0009171057,0.00047906136,0.0004061679,0.00046953378,0.00085546443,0.00037336536,0.00072198303],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99179965,0.00026151954,0.0021422992,0.0021335022,0.0015227767,0.0021402508],"domain_scores_gemma":[0.9953154,0.00034236026,0.0011345209,0.0019389188,0.0004163497,0.00085246016],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005041737,0.001821299,0.0024272804,0.0010904795,0.00037618668,0.00009827647,0.00082006044,0.0008637375,0.0005694962],"category_scores_gemma":[0.00011455101,0.0015293488,0.00048459118,0.0014295485,0.0008432934,0.00071935065,0.00029703722,0.000463209,0.0001403173],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.037108786,0.0036692098,0.15947089,0.002115438,0.0023141424,0.002199744,0.0062339576,0.0000847394,0.009326064,0.0006232269,0.0006999016,0.7761539],"study_design_scores_gemma":[0.3696922,0.012126514,0.5399015,0.0035437911,0.0005675406,0.0004308356,0.0001919354,0.001945642,0.06800396,0.00008309959,0.0014903952,0.0020225903],"about_ca_topic_score_codex":0.0024472089,"about_ca_topic_score_gemma":0.00084162736,"teacher_disagreement_score":0.7741313,"about_ca_system_score_codex":0.08581747,"about_ca_system_score_gemma":0.029661715,"threshold_uncertainty_score":0.9994532},"labels":[],"label_agreement":null},{"id":"W2162410017","doi":"10.3109/10428194.2014.971409","title":"Comparative effectiveness analysis of different salvage therapy intensities used for diffuse large B-cell lymphoma in Northern or Southern Alberta: an instrumental variable analysis","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Alberta; University of Calgary","funders":"Alberta Health Services","keywords":"Salvage therapy; Medicine; Internal medicine; Refractory (planetary science); Oncology; Chemotherapy; Lymphoma; Diffuse large B-cell lymphoma; Population; Surgery; Biology","score_opus":0.013599289130931717,"score_gpt":0.2619701770272454,"score_spread":0.24837088789631367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2162410017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582905,0.00048299646,0.00064908597,0.000029636758,0.0001552755,0.0017195408,0.00045994887,0.00011430118,0.0005601864],"genre_scores_gemma":[0.99603564,0.00018752599,0.00037698756,0.00045449665,0.00011338524,0.0007128245,0.0015177625,0.00012260616,0.00047876398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99441135,0.0006667636,0.0014147975,0.0016190008,0.0006826785,0.0012054114],"domain_scores_gemma":[0.9949572,0.002079355,0.00070174737,0.0013082123,0.00034786278,0.0006056262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007254524,0.0012199696,0.0041157715,0.0016962058,0.00035631747,0.00016402491,0.00041465016,0.00055275974,0.00006456174],"category_scores_gemma":[0.000098917466,0.0008959851,0.0011718429,0.00275808,0.000362507,0.00034480004,0.00018350167,0.00009288448,0.000012720347],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0129500255,0.016445057,0.90892094,0.00049272366,0.020072151,0.00010225387,0.013989933,0.0006846256,0.004963392,0.0011291165,0.00003468501,0.020215085],"study_design_scores_gemma":[0.11823201,0.0024822098,0.762077,0.00025705327,0.011879929,0.000049465205,0.0052431575,0.073801465,0.024143144,0.00014936496,0.00056523463,0.0011200093],"about_ca_topic_score_codex":0.019841824,"about_ca_topic_score_gemma":0.03384397,"teacher_disagreement_score":0.146844,"about_ca_system_score_codex":0.005845361,"about_ca_system_score_gemma":0.0012884692,"threshold_uncertainty_score":0.99934906},"labels":[],"label_agreement":null},{"id":"W2163004538","doi":"10.3109/10428194.2014.964699","title":"Risk and prophylaxis strategy of hepatitis B virus reactivation in patients with lymphoma undergoing chemotherapy with or without rituximab","year":2014,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec","funders":"","keywords":"Medicine; Rituximab; HBsAg; Hepatitis B virus; Chemotherapy; Fulminant hepatitis; Lymphoma; Internal medicine; Hepatitis B; Asymptomatic; Gastroenterology; Viremia; Immunology; Hepatitis; Antibody; Virus","score_opus":0.013079890692348512,"score_gpt":0.26004543575576455,"score_spread":0.24696554506341603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163004538","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6950929,0.30059537,0.00007481437,0.0000069456396,0.00009378456,0.0031942972,0.00018973349,0.00015416408,0.0005979746],"genre_scores_gemma":[0.26888812,0.728638,0.0009866975,0.00012236809,0.00015462052,0.00036446992,0.00024217716,0.0003300726,0.0002734728],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9933381,0.00049569586,0.0019590282,0.0018673049,0.001217076,0.0011228088],"domain_scores_gemma":[0.9950482,0.00082875293,0.0020087287,0.0011967596,0.00044423272,0.00047332238],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00053436134,0.0018366901,0.005921104,0.0009464486,0.00035650513,0.0001448251,0.00034547705,0.0011186886,0.00003070893],"category_scores_gemma":[0.00029354304,0.0012337038,0.00029665758,0.0013364666,0.0008806315,0.00047241736,0.00019837229,0.00035551694,0.000016946891],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024655731,0.00053867325,0.17295527,0.013253777,0.00086274726,0.00012152566,0.00043873538,0.000002063368,0.000002586362,0.00003673237,0.000065263914,0.80925703],"study_design_scores_gemma":[0.09787977,0.011337479,0.6913415,0.058165126,0.0040117595,0.0010574417,0.00015822785,0.00040709195,0.00013193888,0.000075497475,0.1319383,0.0034958469],"about_ca_topic_score_codex":0.027361605,"about_ca_topic_score_gemma":0.01405066,"teacher_disagreement_score":0.8057612,"about_ca_system_score_codex":0.0069352314,"about_ca_system_score_gemma":0.008354787,"threshold_uncertainty_score":0.9994378},"labels":[],"label_agreement":null},{"id":"W2164257516","doi":"10.3109/10428194.2014.893304","title":"Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Bortezomib; Plasma cell leukemia; Dexamethasone; Medicine; Multiple myeloma; Pharmacology; Leukemia; Oncology; Internal medicine","score_opus":0.024237332105817144,"score_gpt":0.2679509948797453,"score_spread":0.24371366277392814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164257516","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9216449,0.033307616,0.00030148734,0.029248394,0.0009377358,0.007905803,0.0014797221,0.00034931093,0.004825035],"genre_scores_gemma":[0.590307,0.09813689,0.011121201,0.21261908,0.016014269,0.0069569037,0.008165172,0.0022085842,0.054470923],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99211925,0.0003898838,0.0017409053,0.0022172828,0.0013493182,0.0021833363],"domain_scores_gemma":[0.99117655,0.0044234665,0.0010455978,0.0020786182,0.00040495902,0.0008708319],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006319774,0.0020505493,0.0032844488,0.00069318735,0.0007617257,0.00023366488,0.00068960356,0.0024191525,0.00013976968],"category_scores_gemma":[0.0002341051,0.0014251057,0.0011415316,0.00045244495,0.001317938,0.0002328166,0.00024593883,0.0007234651,0.000058663678],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0060292818,0.00051529845,0.0025592898,0.0050094663,0.0040557054,0.0021453775,0.0011385549,0.000021325213,0.0019508518,0.00005661749,0.40758142,0.5689368],"study_design_scores_gemma":[0.072719395,0.0038931125,0.01186033,0.0006408634,0.0034934191,0.0022535995,0.0002452536,0.0084323,0.016600892,0.00015080691,0.8783102,0.0013997942],"about_ca_topic_score_codex":0.00416234,"about_ca_topic_score_gemma":0.00013572298,"teacher_disagreement_score":0.567537,"about_ca_system_score_codex":0.013349751,"about_ca_system_score_gemma":0.0086532105,"threshold_uncertainty_score":0.99922365},"labels":[],"label_agreement":null},{"id":"W2165807556","doi":"10.3109/10428194.2012.738365","title":"Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures","year":2012,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital","funders":"Karolinska Institutet","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Anaplastic lymphoma kinase; Biology; Gene expression; Cancer research; STAT protein; Pathogenesis; Gene expression profiling; Real-time polymerase chain reaction; Lymph node; STAT3; Gene; Pathology; Immunology; Medicine; Genetics","score_opus":0.0033394312183381014,"score_gpt":0.18860214547219378,"score_spread":0.18526271425385568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165807556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99156153,0.004881435,0.000011034908,0.000057094687,0.00041332797,0.0018458236,0.00021064052,0.000307862,0.0007112594],"genre_scores_gemma":[0.9947819,0.0013059571,0.00009294822,0.001363835,0.00034102684,0.00054003124,0.00075486995,0.00024781984,0.0005715785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99416286,0.0002637792,0.0010175676,0.0014856007,0.0010728446,0.0019973225],"domain_scores_gemma":[0.9956044,0.00039035722,0.00052120915,0.0011499115,0.0002179159,0.0021162126],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00023520929,0.001542793,0.001534957,0.0006692991,0.00048566642,0.00021037467,0.000276271,0.0007226148,0.000047665606],"category_scores_gemma":[0.000071685936,0.0011858372,0.00028881815,0.0004946944,0.00036988934,0.0007314361,0.00040403812,0.00019092439,0.00003978928],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032375294,0.016878368,0.9564663,0.00068286515,0.00034579026,0.0007927242,0.0010789384,0.000014992856,0.0016411708,0.00014031588,0.0006677117,0.01805328],"study_design_scores_gemma":[0.13785282,0.00063976616,0.84119165,0.0004889173,0.00067558023,0.00012372933,0.00018287444,0.00042998302,0.015057006,0.00004640589,0.0021173365,0.0011939539],"about_ca_topic_score_codex":0.0009881336,"about_ca_topic_score_gemma":0.0001778514,"teacher_disagreement_score":0.13461529,"about_ca_system_score_codex":0.008260065,"about_ca_system_score_gemma":0.0016069266,"threshold_uncertainty_score":0.9997321},"labels":[],"label_agreement":null},{"id":"W2168354819","doi":"10.3109/10428194.2014.935368","title":"Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital","funders":"","keywords":"Medicine; Lymphoma; Refractory (planetary science); Chemotherapy; Castleman disease; Viral load; Internal medicine; Human immunodeficiency virus (HIV); Immunotherapy; Antiretroviral therapy; Virus; Immunology; Gastroenterology; Disease; Cancer","score_opus":0.023639807940394206,"score_gpt":0.3122604062879047,"score_spread":0.28862059834751047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168354819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893491,0.006341799,0.000012769452,0.0002932758,0.00046118602,0.0010129182,0.00009930975,0.00029845408,0.0021311662],"genre_scores_gemma":[0.9895628,0.0027430963,0.00008236982,0.0038884147,0.00030748578,0.00009329297,0.00018377705,0.00013801725,0.0030007532],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.995289,0.00038667477,0.0011890597,0.0013273676,0.00061607873,0.0011918092],"domain_scores_gemma":[0.99695426,0.00025019355,0.00046096602,0.00092208816,0.0001551643,0.0012573099],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000685073,0.0008737747,0.0014337272,0.000360146,0.00077141635,0.00019595462,0.00028497487,0.00059527124,0.000054035154],"category_scores_gemma":[0.0004382258,0.0007237251,0.00047992633,0.0005726089,0.0003786114,0.00023530706,0.00017034585,0.00023284441,0.00005304457],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029262023,0.0018874456,0.49157706,0.0001370833,0.0006290782,0.00031962123,0.0014983262,0.000021443873,0.00343477,0.00048372435,0.0036038582,0.49348137],"study_design_scores_gemma":[0.042340923,0.0048218924,0.9265923,0.00017339709,0.00055522064,0.00006141951,0.00038446658,0.0009377654,0.00016362956,0.000107874774,0.022940611,0.00092048495],"about_ca_topic_score_codex":0.007506273,"about_ca_topic_score_gemma":0.00036080327,"teacher_disagreement_score":0.4925609,"about_ca_system_score_codex":0.006971606,"about_ca_system_score_gemma":0.0016382167,"threshold_uncertainty_score":0.9995214},"labels":[],"label_agreement":null},{"id":"W2168366051","doi":"10.3109/10428194.2010.500072","title":"Targeting the microenvironment","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer, Hypoxia, and Metabolism","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Tumor microenvironment; Stromal cell; Bystander effect; Cancer research; Carcinogenesis; Immune system; Cancer; Medicine; Function (biology); Biology; Tumor cells; Immunology; Cell biology; Internal medicine","score_opus":0.009931421058738251,"score_gpt":0.24448532256989608,"score_spread":0.23455390151115782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2168366051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004739384,0.98941404,0.00006028694,0.000031725325,0.0031529632,0.0010867983,0.00019850851,0.00006343832,0.0012528761],"genre_scores_gemma":[0.00024491292,0.9848103,0.00034238558,0.000739521,0.0072154854,0.00042484546,0.00085127284,0.00027330697,0.005097948],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99519897,0.00031699956,0.0011522531,0.0016629712,0.00048278228,0.0011860423],"domain_scores_gemma":[0.9969486,0.00011789439,0.0007457001,0.0016886923,0.00006682828,0.00043231176],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00061447505,0.0013718838,0.0018487676,0.00015265985,0.00065816747,0.00023602626,0.0012102784,0.0017016312,0.000058595026],"category_scores_gemma":[0.00012453327,0.000996747,0.0009903092,0.00026444206,0.00065997394,0.000016452896,0.0008423333,0.00041964752,0.00013262454],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039400937,0.000044379194,0.000005195176,0.0012888038,0.00027501045,0.000013424913,0.000074090574,0.0000041653234,0.0028972737,0.00007718492,0.017547322,0.97773373],"study_design_scores_gemma":[0.0019283067,0.00008837718,0.00005429932,0.00078888086,0.00095408276,0.0008587371,0.00006460719,0.000023288021,0.0005957671,0.000026814098,0.99342924,0.0011875996],"about_ca_topic_score_codex":0.00026896066,"about_ca_topic_score_gemma":0.000053166244,"teacher_disagreement_score":0.97654617,"about_ca_system_score_codex":0.0012666114,"about_ca_system_score_gemma":0.0035990435,"threshold_uncertainty_score":0.9999032},"labels":[],"label_agreement":null},{"id":"W2169038235","doi":"10.3109/10428194.2011.605188","title":"Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials","year":2011,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"BC Cancer Agency; University of British Columbia","keywords":"Fludarabine; Medicine; Chronic lymphocytic leukemia; Rituximab; Internal medicine; Discontinuation; Oncology; Clinical trial; Population; Lymphoma; Gastroenterology; Leukemia; Chemotherapy; Cyclophosphamide","score_opus":0.16902655781496087,"score_gpt":0.4110555117732854,"score_spread":0.24202895395832455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169038235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98224974,0.0065996978,0.0008607837,0.00015002576,0.0014822974,0.0061166277,0.00021683217,0.0010186302,0.0013053897],"genre_scores_gemma":[0.9768345,0.0046451837,0.0064228186,0.0040626638,0.002075733,0.002274258,0.0005984796,0.0006563668,0.002429996],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.983153,0.001778013,0.0051964703,0.0041572424,0.0020702505,0.0036450168],"domain_scores_gemma":[0.985309,0.0062262067,0.0018208304,0.0029640738,0.00089165894,0.00278824],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0062896474,0.0026829324,0.0058737206,0.0012391909,0.0013744883,0.0006260576,0.001509934,0.0024620027,0.0006739728],"category_scores_gemma":[0.0052683675,0.0022041271,0.0016680532,0.0016519644,0.0024450838,0.0009895059,0.00071447936,0.00044372122,0.00026296536],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09926279,0.0021084626,0.00884541,0.0039745793,0.0030125733,0.00480382,0.00553016,0.00027635702,0.0020908562,0.0023844868,0.004052529,0.86365795],"study_design_scores_gemma":[0.6312615,0.009349074,0.056142997,0.0022934193,0.0023340138,0.011225383,0.0019325655,0.22993234,0.023821412,0.0022210223,0.024391815,0.005094463],"about_ca_topic_score_codex":0.028592868,"about_ca_topic_score_gemma":0.00073121785,"teacher_disagreement_score":0.8585635,"about_ca_system_score_codex":0.23871256,"about_ca_system_score_gemma":0.2065082,"threshold_uncertainty_score":0.9999256},"labels":[],"label_agreement":null},{"id":"W2169096446","doi":"10.3109/10428191003661860","title":"Multiple myeloma may include microvessel endothelial cells of malignant origin","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"clone (Java method); Paracrine signalling; Progenitor cell; Biology; Autocrine signalling; Pathology; Population; Bone marrow; Malignancy; Pericyte; Cancer research; Neovascularization; Endothelium; Cancer cell; Cancer; Angiogenesis; Stem cell; Endothelial stem cell; Immunology; Medicine; Cell biology; Cell culture; Genetics; Gene; Receptor","score_opus":0.029841449146530356,"score_gpt":0.3123519019111376,"score_spread":0.28251045276460723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169096446","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.063270554,0.9262341,0.000024997802,0.00003094769,0.001074244,0.0037946068,0.0020855512,0.00028605113,0.0031989003],"genre_scores_gemma":[0.012338797,0.9756647,0.0024573207,0.00016910792,0.0010123758,0.00058014016,0.00124257,0.0004874342,0.0060475743],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99123245,0.00043846833,0.0025182248,0.0022054457,0.001510261,0.0020951263],"domain_scores_gemma":[0.99311286,0.0012707004,0.0013578627,0.002288146,0.00036892193,0.001601483],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006725356,0.0022160532,0.0059253047,0.0011590783,0.0004398831,0.0001821711,0.0010643826,0.0023150176,0.00022464727],"category_scores_gemma":[0.00036305343,0.0017185479,0.0017910517,0.0009856604,0.0009820582,0.00027241855,0.0007992849,0.00075414823,0.0004956798],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007316618,0.00055812375,0.00050766784,0.01805346,0.0012842305,0.0019350237,0.00018623474,4.7972895e-7,0.004536043,0.00016866604,0.0016352806,0.97040313],"study_design_scores_gemma":[0.018838737,0.00058371486,0.0011982011,0.010638703,0.0024475085,0.0034358238,0.0000614675,0.00019309112,0.01091413,0.000035761168,0.9502227,0.00143018],"about_ca_topic_score_codex":0.0027395638,"about_ca_topic_score_gemma":0.00014135036,"teacher_disagreement_score":0.9689729,"about_ca_system_score_codex":0.007017675,"about_ca_system_score_gemma":0.014234438,"threshold_uncertainty_score":0.99905795},"labels":[],"label_agreement":null},{"id":"W2169395626","doi":"10.3109/10428194.2010.531409","title":"Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (&lt;12 months)","year":2010,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Hospital and Health Sciences Centre","funders":"Celgene","keywords":"Lenalidomide; Medicine; Thalidomide; Bortezomib; Multiple myeloma; Internal medicine; Cohort; Oncology; Population; Autologous stem-cell transplantation; Surgery","score_opus":0.010861604291262782,"score_gpt":0.23001383547196608,"score_spread":0.2191522311807033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169395626","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940742,0.0002492433,0.00027510012,0.000051162617,0.0003407709,0.0018679217,0.0025416685,0.00019134497,0.00040854764],"genre_scores_gemma":[0.9941694,0.00025134246,0.0030543874,0.00011556129,0.00015515031,0.0002686004,0.001286073,0.00021746874,0.00048197422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944734,0.00014228703,0.0008972012,0.0014137498,0.0016896124,0.0013837799],"domain_scores_gemma":[0.9954444,0.0005312097,0.00057848793,0.0012466938,0.00040955064,0.0017896446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033940186,0.001049857,0.0012733679,0.00035282524,0.000551189,0.0001189071,0.00043917488,0.00044853255,0.000055139066],"category_scores_gemma":[0.00030011658,0.0007544112,0.0002487292,0.0005169179,0.0006669858,0.0005114906,0.00019748493,0.00039227697,0.000023648934],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020971658,0.0019213554,0.9114928,0.0003678407,0.0010513726,0.0006603463,0.00078090944,0.000016674172,0.022730622,0.000117755386,0.0002374396,0.039651208],"study_design_scores_gemma":[0.0829513,0.002034874,0.9019502,0.00046676898,0.0008640128,0.000077373355,0.00009996515,0.0025471258,0.0075534414,0.000028892931,0.00060818007,0.00081790745],"about_ca_topic_score_codex":0.01063625,"about_ca_topic_score_gemma":0.0014241209,"teacher_disagreement_score":0.061979644,"about_ca_system_score_codex":0.0017356172,"about_ca_system_score_gemma":0.0023676152,"threshold_uncertainty_score":0.9994907},"labels":[],"label_agreement":null},{"id":"W2169400635","doi":"10.1080/10428190601136163","title":"Acute promyelocytic leukemia: A novel<i>PML/RARα</i>fusion that generates a frameshift in the RARα transcript and ATRA resistance","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Capital District Health Authority; Dalhousie University","funders":"","keywords":"Acute promyelocytic leukemia; Promyelocyte; Cancer research; Leukemia; Fusion transcript; Cytarabine; Promyelocytic leukemia protein; Fusion gene; Medicine; Frameshift mutation; Biology; Retinoic acid; Exon; Immunology; Genetics; Gene","score_opus":0.008408581974120337,"score_gpt":0.22523637538504357,"score_spread":0.21682779341092323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2169400635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9752732,0.016371408,0.0027540473,0.0002885452,0.00034395733,0.00095747993,0.00006175045,0.000099345445,0.0038502885],"genre_scores_gemma":[0.9863202,0.0056483503,0.0021672484,0.00259888,0.00061244116,0.00018557155,0.0002413429,0.00015014315,0.0020758442],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9945304,0.00023610961,0.0010578128,0.0017996096,0.00082575233,0.0015503599],"domain_scores_gemma":[0.9975913,0.00023042693,0.00039064177,0.001199152,0.0001608561,0.00042757706],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014615655,0.0010875495,0.00085195864,0.0002770965,0.00068883284,0.00039677208,0.0010628477,0.0011788802,0.000017474653],"category_scores_gemma":[0.00014105787,0.00088037545,0.0002972838,0.0007551508,0.00085630384,0.00009352002,0.0003165542,0.00039766557,0.000011770802],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034368846,0.00035130174,0.009422514,0.0009538085,0.000490239,0.0011639021,0.0060405065,0.000081504135,0.91226965,0.0022880167,0.006487688,0.057014003],"study_design_scores_gemma":[0.029527053,0.00114972,0.05046444,0.0007449885,0.00069191115,0.003929154,0.0048317094,0.0017331146,0.6827614,0.001742404,0.21874797,0.003676189],"about_ca_topic_score_codex":0.00039027736,"about_ca_topic_score_gemma":0.0006337504,"teacher_disagreement_score":0.22950828,"about_ca_system_score_codex":0.0018005021,"about_ca_system_score_gemma":0.0026513485,"threshold_uncertainty_score":0.9993647},"labels":[],"label_agreement":null},{"id":"W2171081863","doi":"10.1080/10428190701694186","title":"Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: Final results of E1497","year":2007,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Mycobacterium research and diagnosis","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Hodgkin lymphoma; Lymphoma; Medicine; Internal medicine; Oncology","score_opus":0.025739308410309865,"score_gpt":0.318033629001405,"score_spread":0.29229432059109517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171081863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99233097,0.00097192865,0.00020101437,0.00006385903,0.00027411105,0.0038898268,0.00041647325,0.00014449697,0.0017073402],"genre_scores_gemma":[0.99588317,0.00051695446,0.0008073769,0.00020703369,0.00047236882,0.00040712315,0.0004136861,0.00014718248,0.0011450999],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927643,0.00019074626,0.0025274577,0.0014252573,0.0013891316,0.0017030875],"domain_scores_gemma":[0.9944029,0.0012305157,0.0010013448,0.0014377504,0.00078898465,0.0011385434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001825924,0.00095890736,0.0021157144,0.0009595583,0.00043098372,0.00006655874,0.0006091826,0.0006382542,0.000046868798],"category_scores_gemma":[0.00095847266,0.0008426256,0.00055814843,0.001200829,0.00047044057,0.0003151789,0.0004135386,0.00015382419,0.000013441239],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10458881,0.029647414,0.04774721,0.002694871,0.0017852572,0.0015929226,0.011490341,0.000024077031,0.07381695,0.0001536481,0.014963992,0.7114945],"study_design_scores_gemma":[0.36719057,0.050011814,0.34409133,0.0014091418,0.0014267953,0.0006786236,0.0031376686,0.001953017,0.21779335,0.00007215124,0.010958588,0.0012769738],"about_ca_topic_score_codex":0.006316554,"about_ca_topic_score_gemma":0.0006358343,"teacher_disagreement_score":0.71021754,"about_ca_system_score_codex":0.003864341,"about_ca_system_score_gemma":0.0036668396,"threshold_uncertainty_score":0.99995965},"labels":[],"label_agreement":null},{"id":"W2171440950","doi":"10.3109/10428194.2014.970550","title":"Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma","year":2014,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chromosomal translocation; Fluorescence in situ hybridization; Immunohistochemistry; Lymphoma; Internal medicine; Cancer research; Gene expression; Oncology; Gene; Risk stratification; Progression-free survival; Biology; Medicine; Overall survival; Genetics","score_opus":0.006580176482716248,"score_gpt":0.2217849288754741,"score_spread":0.21520475239275785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171440950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99264026,0.0032608698,0.00025654255,0.0002110725,0.00014881058,0.0015600147,0.00008079947,0.00019649735,0.0016451154],"genre_scores_gemma":[0.9932552,0.002001953,0.0024465495,0.0004925233,0.00022369662,0.00063004106,0.00027033748,0.00011316769,0.0005665459],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99559176,0.00033878785,0.0010632046,0.0014828705,0.00055373495,0.0009696292],"domain_scores_gemma":[0.99733907,0.00039460798,0.0005045908,0.00091632165,0.00013366365,0.0007117601],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063242705,0.0008600779,0.0010575808,0.0004275995,0.00074228196,0.00036396825,0.00019491542,0.0005494322,0.000014257741],"category_scores_gemma":[0.0001970953,0.0007499877,0.00015497126,0.0004006371,0.0003089765,0.0005503363,0.00026125734,0.00014033011,0.000023420838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018114276,0.009991149,0.14769135,0.0011777923,0.0003482333,0.00042850856,0.006523712,0.000016775139,0.29542232,0.0063379216,0.00093670265,0.5293141],"study_design_scores_gemma":[0.13564491,0.0011647136,0.6781931,0.0009317654,0.0005251741,0.00065365207,0.0009965963,0.025608338,0.14780453,0.0013882992,0.005738878,0.0013500601],"about_ca_topic_score_codex":0.0016198341,"about_ca_topic_score_gemma":0.00021204507,"teacher_disagreement_score":0.5305017,"about_ca_system_score_codex":0.0023504884,"about_ca_system_score_gemma":0.0010057186,"threshold_uncertainty_score":0.9994951},"labels":[],"label_agreement":null},{"id":"W2171830805","doi":"10.3109/10428194.2014.953152","title":"Aggressive congenital juvenile myelomonocytic leukemia associated with somatic<i>KRAS</i>p.G13D mutation and concurrent germline<i>IGF1R</i>duplication","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Juvenile myelomonocytic leukemia; Germline mutation; Germline; KRAS; Cancer research; Gene duplication; Mutation; Biology; Somatic cell; Genetics; Medicine; Gene; Haematopoiesis","score_opus":0.015535477822808326,"score_gpt":0.2567419644317981,"score_spread":0.24120648660898977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2171830805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9567749,0.0056337905,0.0005785914,0.02551845,0.0008265822,0.005014315,0.0006171872,0.0011643809,0.0038718053],"genre_scores_gemma":[0.8116956,0.002504657,0.0009485791,0.15601523,0.0050411928,0.0016667262,0.011785373,0.0011606406,0.00918205],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9872681,0.0008820499,0.0025889508,0.003538866,0.0027930175,0.0029290337],"domain_scores_gemma":[0.98964244,0.0023041568,0.0030624026,0.0022543168,0.0013842519,0.0013524222],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0011425783,0.0028429353,0.003902371,0.0012649669,0.001033693,0.00077253394,0.0010303288,0.004146276,0.00015526787],"category_scores_gemma":[0.0013498766,0.002522336,0.0006314154,0.0013453563,0.002153708,0.0007806547,0.0006386858,0.0023889362,0.00025022242],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001916699,0.0003676901,0.002734363,0.004754322,0.005091965,0.019667776,0.0028566143,0.00010037762,0.0030531636,0.00024543254,0.77200264,0.18720894],"study_design_scores_gemma":[0.13102806,0.006325545,0.060990427,0.0125318905,0.012431112,0.052422743,0.0013325122,0.12734321,0.0070159053,0.001098083,0.57611126,0.011369285],"about_ca_topic_score_codex":0.0015313029,"about_ca_topic_score_gemma":0.00012040502,"teacher_disagreement_score":0.19589141,"about_ca_system_score_codex":0.036291808,"about_ca_system_score_gemma":0.017543769,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W2216590292","doi":"10.3109/10428194.2015.1115032","title":"Allogeneic Hematopoietic Stem Cell Transplantions in Blastic Plasmacytoid Dendritic Cell Neoplasm in first complete remission: an effective therapy for a rare disease","year":2015,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Disease; Neoplasm; Stem cell; Myeloproliferative neoplasm; Haematopoiesis; Complete remission; Hematopoietic stem cell; Cancer research; Oncology; Internal medicine; Immunology; Pathology; Bone marrow; Chemotherapy; Biology; Myelofibrosis; Genetics","score_opus":0.02325502392348319,"score_gpt":0.26783664146040326,"score_spread":0.24458161753692007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216590292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96720964,0.01103698,0.00013743501,0.00943402,0.00045525492,0.008995983,0.0014904067,0.00026912475,0.0009711331],"genre_scores_gemma":[0.948057,0.0029506388,0.00023413787,0.035325207,0.0011123614,0.003951157,0.004104352,0.0006719066,0.003593222],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99050796,0.00086450845,0.0017199108,0.0028387115,0.00162676,0.0024421718],"domain_scores_gemma":[0.993863,0.0021833673,0.00044271644,0.0015904857,0.00049374625,0.001426687],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006671188,0.001966078,0.0028026926,0.0015829958,0.0005284091,0.00028023982,0.000911485,0.002034371,0.000087335124],"category_scores_gemma":[0.00013309468,0.001881222,0.0008065413,0.0011179886,0.00065046316,0.0003289368,0.00019193185,0.0011466566,0.00007923237],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07505959,0.010311255,0.08291683,0.07263961,0.00221081,0.16890869,0.03691235,0.0054977117,0.013296515,0.000119840755,0.43851277,0.09361403],"study_design_scores_gemma":[0.28512305,0.00894949,0.039853096,0.014830481,0.0025449104,0.021645498,0.004330755,0.103327364,0.0064471345,0.001695673,0.50088334,0.010369197],"about_ca_topic_score_codex":0.0011294157,"about_ca_topic_score_gemma":0.0008777255,"teacher_disagreement_score":0.21006346,"about_ca_system_score_codex":0.013716992,"about_ca_system_score_gemma":0.010272669,"threshold_uncertainty_score":0.9993082},"labels":[],"label_agreement":null},{"id":"W2216707999","doi":"10.3109/10428194.2014.974043","title":"The risk of secondary primary malignancies after therapy for multiple myeloma","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Multiple myeloma; Medicine; Context (archaeology); Malignancy; Incidence (geometry); Disease; Oncology; Maintenance therapy; Internal medicine; Hematologic malignancy; Cancer; Intensive care medicine; Chemotherapy","score_opus":0.028808453546756495,"score_gpt":0.30089248121573137,"score_spread":0.2720840276689749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2216707999","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027863212,0.9632012,0.000022294162,0.000027153517,0.00041534647,0.0051584453,0.0016408548,0.00014247057,0.001528995],"genre_scores_gemma":[0.0036128708,0.98638827,0.0009545567,0.00019279617,0.00059964095,0.0032311217,0.0010586757,0.00032164343,0.0036404443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99352264,0.0005426235,0.001802217,0.001401714,0.0011892365,0.0015415818],"domain_scores_gemma":[0.9929837,0.0025027008,0.0011572798,0.0018215291,0.0006156462,0.0009191586],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001316678,0.0015226724,0.004089642,0.00044599496,0.0006212487,0.00018754856,0.00073237193,0.0011164799,0.00004257504],"category_scores_gemma":[0.00055784563,0.0009186662,0.001756989,0.00059494335,0.0009507832,0.00023060541,0.0003962762,0.00037182836,0.00006901572],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0031947533,0.00021558697,0.0011345036,0.0103987,0.0023691773,0.00025844923,0.00020843183,3.1507412e-7,0.000009662242,0.000041799103,0.0042661685,0.9779025],"study_design_scores_gemma":[0.02301249,0.0010690896,0.015804527,0.0049303565,0.001936375,0.000874547,0.000110550085,0.00014366882,0.00009511913,0.00017290146,0.9509984,0.0008519726],"about_ca_topic_score_codex":0.0006144787,"about_ca_topic_score_gemma":0.00007832634,"teacher_disagreement_score":0.9770505,"about_ca_system_score_codex":0.007225386,"about_ca_system_score_gemma":0.017710784,"threshold_uncertainty_score":0.9997522},"labels":[],"label_agreement":null},{"id":"W2220816567","doi":"10.3109/10428194.2015.1091929","title":"Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a meta-analysis","year":2015,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; McMaster University","funders":"","keywords":"Nilotinib; Bosutinib; Dasatinib; Medicine; Ponatinib; Imatinib; Internal medicine; Tyrosine kinase; Myeloid leukemia; Tyrosine-kinase inhibitor; Imatinib mesylate; Incidence (geometry); Oncology; Cancer","score_opus":0.024971778580207896,"score_gpt":0.26893631047231953,"score_spread":0.24396453189211165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2220816567","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18396448,0.8066948,0.000013657011,0.000031869695,0.0002760717,0.00693035,0.00090811274,0.00048125346,0.0006994304],"genre_scores_gemma":[0.09396694,0.87043667,0.0012190081,0.00048307847,0.0018366101,0.005496725,0.018033117,0.0019041881,0.0066236816],"study_design_codex":"design_other","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9846769,0.00096134096,0.0037555634,0.004538249,0.0031026902,0.0029652766],"domain_scores_gemma":[0.99042344,0.00044084725,0.0025441477,0.0037886158,0.0007683996,0.0020345752],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009377371,0.004730899,0.016262958,0.0031765879,0.00044541105,0.0002705017,0.0010979214,0.0024659368,0.00045644687],"category_scores_gemma":[0.000118869815,0.003177645,0.003557829,0.00617502,0.0007984769,0.000806957,0.00059047516,0.0009075677,0.0002896315],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009219454,0.002554103,0.012221639,0.01851291,0.30717462,0.0046886657,0.0005279018,0.00016287749,0.000009263734,0.00005470829,0.0023994371,0.6424744],"study_design_scores_gemma":[0.09894878,0.0041763294,0.014824317,0.0077162446,0.56769645,0.0012681712,0.00005980675,0.0002653416,0.000059209477,0.000017475375,0.3005133,0.004454611],"about_ca_topic_score_codex":0.0070366706,"about_ca_topic_score_gemma":0.0016462435,"teacher_disagreement_score":0.6380198,"about_ca_system_score_codex":0.12374479,"about_ca_system_score_gemma":0.039710417,"threshold_uncertainty_score":0.99957556},"labels":[],"label_agreement":null},{"id":"W2223535813","doi":"10.3109/10428194.2016.1138292","title":"Investigating the synergistic mechanism between ibrutinib and daunorubicin in acute myeloid leukemia cells","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Ibrutinib; Bruton's tyrosine kinase; Daunorubicin; Myeloid leukemia; Tyrosine kinase; Cancer research; Leukemia; Tyrosine-kinase inhibitor; Cytotoxic T cell; Medicine; Pharmacology; Immunology; Chemistry; Internal medicine; Receptor; Chronic lymphocytic leukemia; Biochemistry; Cancer","score_opus":0.018939623820719117,"score_gpt":0.26311155212537624,"score_spread":0.24417192830465712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2223535813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9136488,0.0043673916,0.0002115705,0.06840407,0.0014369369,0.0045048557,0.00075581763,0.0007420183,0.0059285536],"genre_scores_gemma":[0.650047,0.008043885,0.0015682825,0.2943932,0.015745591,0.0012333591,0.0015780773,0.0016208595,0.025769718],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9841071,0.0010844923,0.00311588,0.0040266747,0.003146472,0.0045194095],"domain_scores_gemma":[0.9888003,0.004515615,0.0013447996,0.003510116,0.00040635423,0.0014228091],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.002300312,0.003011582,0.004116242,0.0015019386,0.0010869098,0.00070653926,0.0020212291,0.004790472,0.00017308856],"category_scores_gemma":[0.0007673169,0.0021748692,0.0007423379,0.001644392,0.00308153,0.00060431956,0.0020960083,0.002891617,0.0003873189],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001067001,0.00012309423,0.002488111,0.007057077,0.0042163567,0.025666824,0.004021488,0.0000323264,0.027778186,0.0022958098,0.7322857,0.19296803],"study_design_scores_gemma":[0.13850518,0.0018493179,0.011476974,0.012787465,0.0058606295,0.013350323,0.0009614109,0.015264098,0.04315953,0.011003838,0.7376396,0.008141616],"about_ca_topic_score_codex":0.009742142,"about_ca_topic_score_gemma":0.00017311377,"teacher_disagreement_score":0.26360178,"about_ca_system_score_codex":0.11987108,"about_ca_system_score_gemma":0.05447726,"threshold_uncertainty_score":0.9996315},"labels":[],"label_agreement":null},{"id":"W2226640202","doi":"10.3109/10428194.2015.1128542","title":"Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Royal Victoria Hospital","funders":"","keywords":"Medicine; Multiple myeloma; Skin biopsy; Biopsy; Infiltration (HVAC); Immunohistochemistry; Pathology; Retrospective cohort study; Internal medicine","score_opus":0.02067668219786432,"score_gpt":0.2621880326709159,"score_spread":0.24151135047305158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2226640202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633855,0.00026138223,0.00007413267,0.000048286583,0.00019147866,0.0022584717,0.00014889815,0.000103671824,0.00057513063],"genre_scores_gemma":[0.9979338,0.00022507587,0.0005519721,0.00011732649,0.00009645628,0.00032088108,0.00008537805,0.00006951213,0.0005996111],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99564,0.0001821843,0.001007066,0.0010017469,0.0012116835,0.0009573586],"domain_scores_gemma":[0.9976939,0.00026903817,0.0002969711,0.0007639185,0.00039136212,0.00058481493],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026102422,0.0006583328,0.0010884772,0.00058881956,0.00027516112,0.00003768145,0.00028280652,0.0002952964,0.00007213036],"category_scores_gemma":[0.00056478276,0.0004412387,0.00020343415,0.00059545407,0.00045416033,0.00029807418,0.00030821745,0.000119260476,0.00006678237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025895266,0.004351259,0.8893927,0.00011892402,0.00039091107,0.0010306081,0.0016674437,0.000008912221,0.0032434457,0.00008953584,0.00009679745,0.09701993],"study_design_scores_gemma":[0.094459765,0.0027720488,0.8959623,0.00042209748,0.0001182725,0.00024282897,0.00078443676,0.0013451918,0.0030273665,0.000058531605,0.00038374626,0.00042344772],"about_ca_topic_score_codex":0.006043948,"about_ca_topic_score_gemma":0.002106369,"teacher_disagreement_score":0.09659649,"about_ca_system_score_codex":0.012260817,"about_ca_system_score_gemma":0.0020645335,"threshold_uncertainty_score":0.99980396},"labels":[],"label_agreement":null},{"id":"W2257900942","doi":"10.3109/10428194.2015.1088652","title":"A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children’s Oncology Group","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Chemotherapy; Myeloid leukemia; Induction chemotherapy; Bacteremia; Hypoxia (environmental); Internal medicine; Oncology; Antibiotics","score_opus":0.008103024406947731,"score_gpt":0.26274451110494745,"score_spread":0.25464148669799974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2257900942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958172,0.00077710405,0.00035502567,0.00042513807,0.00026012433,0.0011188835,0.00015111479,0.000106701154,0.0009887525],"genre_scores_gemma":[0.99685425,0.0009129567,0.0002769678,0.0006643972,0.0004436851,0.00035685065,0.0002448981,0.000088265544,0.00015770584],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99651057,0.00017186349,0.001089581,0.0009157712,0.0006394895,0.00067275163],"domain_scores_gemma":[0.9977305,0.00033353802,0.00065343524,0.000834478,0.00019097533,0.0002571055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024397881,0.000590074,0.0011917172,0.0002367597,0.0002065754,0.000069896116,0.00028850956,0.00040573307,0.00013891126],"category_scores_gemma":[0.00003147596,0.00034119718,0.0002098846,0.00058153947,0.00047260858,0.00043298243,0.0001275146,0.00020611037,0.0000231689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035791649,0.00048390782,0.9567033,0.000048745183,0.00031572065,0.00016302656,0.00095398154,0.0000056127737,0.0015571867,0.00020574655,0.0012075882,0.034776043],"study_design_scores_gemma":[0.025850441,0.0010608518,0.96620435,0.00021241786,0.0005571921,0.00041599484,0.00025938847,0.000043076834,0.0009415418,0.0001806943,0.0038198126,0.0004542209],"about_ca_topic_score_codex":0.003583386,"about_ca_topic_score_gemma":0.001315696,"teacher_disagreement_score":0.034321822,"about_ca_system_score_codex":0.0061853887,"about_ca_system_score_gemma":0.003409112,"threshold_uncertainty_score":0.999904},"labels":[],"label_agreement":null},{"id":"W2275216622","doi":"10.3109/10428194.2015.1117609","title":"Granulocyte colony-stimulating factor in secondary prophylaxis for advanced-stage Hodgkin lymphoma treated with ABVD chemotherapy: a cost-effectiveness analysis","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Public Health Ontario; Grand River Hospital; Princess Margaret Cancer Centre; University of Toronto; Health Sciences Centre; Mount Sinai Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"ABVD; Medicine; Neutropenia; Granulocyte colony-stimulating factor; Oncology; Internal medicine; Febrile neutropenia; Lymphoma; Chemotherapy; Quality-adjusted life year; Intensive care medicine; Cost effectiveness; Cyclophosphamide","score_opus":0.014681539980273708,"score_gpt":0.2786988909212562,"score_spread":0.2640173509409825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2275216622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902049,0.0005149296,0.0030352667,0.0001171858,0.00015892342,0.00407184,0.00042216788,0.00034051633,0.0011343135],"genre_scores_gemma":[0.9930606,0.00031129862,0.00072579744,0.0005096164,0.0001780607,0.0023145077,0.00014474985,0.00020582958,0.0025495691],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952424,0.00025282745,0.0009449274,0.001707063,0.0005778165,0.0012749574],"domain_scores_gemma":[0.9968156,0.0008426453,0.0004610445,0.0009765909,0.00036333175,0.0005407949],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042397244,0.0010193754,0.0019136725,0.0009781147,0.0004585047,0.0001642738,0.0002919788,0.0005527436,0.00013139943],"category_scores_gemma":[0.000114301205,0.00072457275,0.0005518594,0.0021847195,0.0003846056,0.00073695206,0.000094249684,0.0001388042,0.00001723309],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011709795,0.00039076977,0.32664642,0.00056557474,0.0015215746,0.00031591486,0.0003942329,0.0002778415,0.050730888,0.00016042124,0.000051979434,0.6072346],"study_design_scores_gemma":[0.07926317,0.0027472451,0.84193283,0.00075793103,0.00097395515,0.00032081368,0.00019308738,0.001419587,0.06315561,0.00005886603,0.008027284,0.0011495939],"about_ca_topic_score_codex":0.0021574476,"about_ca_topic_score_gemma":0.0009930576,"teacher_disagreement_score":0.606085,"about_ca_system_score_codex":0.011516361,"about_ca_system_score_gemma":0.0033200001,"threshold_uncertainty_score":0.99952054},"labels":[],"label_agreement":null},{"id":"W2283880462","doi":"10.3109/10428194.2016.1140161","title":"B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL)","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Bortezomib; Internal medicine; Refractory (planetary science); Chemotherapy; Transplantation; Autologous stem-cell transplantation; Lymphoma; Gastroenterology; Oncology; Clinical endpoint; Randomized controlled trial; Multiple myeloma","score_opus":0.010912618588100553,"score_gpt":0.25292783276751835,"score_spread":0.2420152141794178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283880462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877025,0.0023087254,0.00007133934,0.0014634246,0.0017492984,0.005044584,0.00054283143,0.00026045257,0.0008568346],"genre_scores_gemma":[0.988525,0.0042360947,0.00029801164,0.00080448977,0.00036652107,0.0011392094,0.00029716105,0.000223321,0.0041102148],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920811,0.0007583029,0.0026458316,0.0016953903,0.0013829274,0.0014364264],"domain_scores_gemma":[0.99420506,0.0017545456,0.0014573298,0.0016649985,0.00024247434,0.0006755965],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001153628,0.0014795818,0.0033438012,0.0005543186,0.0005669906,0.00009601063,0.0007158939,0.0012325349,0.00015318455],"category_scores_gemma":[0.00022690916,0.0008774308,0.0012299651,0.0010442536,0.0009896811,0.00046161565,0.00018351406,0.00017948021,0.000038708993],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.6994758,0.003955436,0.00035327015,0.00032732432,0.00094343093,0.00077845587,0.0028481714,0.0000092689415,0.005480781,0.00036401444,0.0036447712,0.28181925],"study_design_scores_gemma":[0.9372476,0.00748597,0.005967781,0.00099396,0.0017360462,0.00040212984,0.00040588644,0.0005765842,0.037201155,0.000120079,0.006864522,0.0009982944],"about_ca_topic_score_codex":0.0040953103,"about_ca_topic_score_gemma":0.0005889703,"teacher_disagreement_score":0.28082097,"about_ca_system_score_codex":0.0133755095,"about_ca_system_score_gemma":0.007427762,"threshold_uncertainty_score":0.9997954},"labels":[],"label_agreement":null},{"id":"W2294536664","doi":"10.3109/10428194.2016.1146950","title":"Impact of ruxolitinib treatment on the hemoglobin dynamics and the negative prognosis of anemia in patients with myelofibrosis","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Hemoglobin; Internal medicine; Oncology; Bone marrow","score_opus":0.007914056492146979,"score_gpt":0.22774553025526542,"score_spread":0.21983147376311846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2294536664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96973526,0.00044217167,0.0000022841925,0.0229647,0.00007816945,0.0037495845,0.0011156752,0.000035939844,0.001876227],"genre_scores_gemma":[0.98161215,0.0012593457,0.00011736666,0.014411692,0.00034852306,0.0010180409,0.00046900343,0.00015528643,0.0006086017],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953312,0.00048617,0.0011686485,0.0011224442,0.0009691366,0.0009223795],"domain_scores_gemma":[0.99448967,0.0027582196,0.0010729968,0.001088822,0.0003728162,0.00021747244],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003059684,0.0013264869,0.002361072,0.00038356337,0.00023032288,0.00007362951,0.00032038853,0.0008664607,0.00007187508],"category_scores_gemma":[0.0001570469,0.000557823,0.0005664933,0.0004995738,0.0016108287,0.00012594966,0.00014912005,0.00032948173,0.000007681557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017929867,0.0013934271,0.79107875,0.00093215966,0.004002605,0.00036687186,0.0029145826,0.000012655221,0.000026679096,0.002026061,0.028710216,0.15060611],"study_design_scores_gemma":[0.07994082,0.008509719,0.90021163,0.0034359586,0.0015242966,0.00014101643,0.0002000086,0.00037537407,0.002397103,0.00030188047,0.0021289696,0.0008332032],"about_ca_topic_score_codex":0.0036881955,"about_ca_topic_score_gemma":0.00013118572,"teacher_disagreement_score":0.1497729,"about_ca_system_score_codex":0.0109605845,"about_ca_system_score_gemma":0.0027419738,"threshold_uncertainty_score":0.9999486},"labels":[],"label_agreement":null},{"id":"W2296118977","doi":"10.3109/10428194.2015.1128540","title":"Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Lenalidomide; Medicine; Tolerability; Neutropenia; Internal medicine; Discontinuation; Refractory (planetary science); Chronic lymphocytic leukemia; Adverse effect; Gastroenterology; Oncology; Surgery; Leukemia; Chemotherapy; Multiple myeloma","score_opus":0.01989551389267892,"score_gpt":0.3024081237141699,"score_spread":0.282512609821491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296118977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99341404,0.0005513245,0.000060439124,0.0000958726,0.00039218535,0.0045709056,0.00019703872,0.00013827963,0.00057990407],"genre_scores_gemma":[0.99543005,0.0021149672,0.00045406504,0.00013381455,0.000323945,0.00021051365,0.00026542856,0.00017645447,0.00089074206],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99056286,0.0007029036,0.003627785,0.0017827159,0.0019670802,0.0013566861],"domain_scores_gemma":[0.9918565,0.0032931096,0.0017748254,0.0015962129,0.0006620474,0.000817285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019986469,0.0011364679,0.0032642893,0.0010712362,0.000270625,0.00008531444,0.00070703484,0.0007326555,0.00011670578],"category_scores_gemma":[0.0020677522,0.0006873038,0.0004157271,0.0007171004,0.0017418177,0.0009605083,0.0006124028,0.0002849013,0.0000067582605],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8949283,0.0017369164,0.00061467604,0.0005029995,0.00086591113,0.0002283656,0.0013229428,0.00007948845,0.0029337541,0.00013291671,0.000044273685,0.096609496],"study_design_scores_gemma":[0.9492813,0.009097452,0.008906893,0.0029436655,0.00062867295,0.00012088403,0.00018854531,0.01267979,0.014733968,0.000040240655,0.0005758569,0.0008027429],"about_ca_topic_score_codex":0.00385048,"about_ca_topic_score_gemma":0.00041186166,"teacher_disagreement_score":0.09580675,"about_ca_system_score_codex":0.12422739,"about_ca_system_score_gemma":0.035901684,"threshold_uncertainty_score":0.9995578},"labels":[],"label_agreement":null},{"id":"W2296287591","doi":"10.3109/10428194.2016.1153089","title":"STAT3 inhibitor has potent antitumor activity in B-lineage acute lymphoblastic leukemia cells overexpressing the high mobility group A1 (HMGA1)–STAT3 pathway","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute","keywords":"Malignancy; Cancer research; Lymphoblastic Leukemia; Medicine; Acute leukemia; Cancer; STAT3; Leukemia; Immunology; Internal medicine; Apoptosis; Biology","score_opus":0.01465642014332335,"score_gpt":0.24176507810135878,"score_spread":0.22710865795803542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2296287591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94496953,0.0017827613,0.0014628222,0.03456685,0.0037873313,0.0065934686,0.0036804406,0.0011168455,0.0020399753],"genre_scores_gemma":[0.8630662,0.0027711482,0.0013332622,0.10557852,0.0130772535,0.0021974768,0.0015128175,0.0016059619,0.008857365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9752724,0.0021437674,0.0040997877,0.006270321,0.0055319807,0.0066817175],"domain_scores_gemma":[0.9832225,0.005862095,0.0023175871,0.0058750026,0.00087560597,0.0018471986],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity"],"consensus_categories":["metaepi_narrow","sts","research_integrity"],"category_scores_codex":[0.0028466636,0.004776858,0.0058496264,0.001977563,0.0019206471,0.0015868538,0.0030865085,0.005709067,0.00041255765],"category_scores_gemma":[0.0009794757,0.003449306,0.0017719792,0.00232471,0.00480646,0.0016391027,0.002978738,0.0038734782,0.00067584484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0107117845,0.0012445253,0.0010384576,0.0059106764,0.0032020358,0.049245045,0.0016561196,0.00020019508,0.11757603,0.00022823592,0.6815856,0.12740126],"study_design_scores_gemma":[0.09593264,0.0028328612,0.024862714,0.011419901,0.0037293525,0.010709464,0.0005758854,0.019563636,0.16130233,0.0008909184,0.6589792,0.009201148],"about_ca_topic_score_codex":0.012010295,"about_ca_topic_score_gemma":0.00032097206,"teacher_disagreement_score":0.118200116,"about_ca_system_score_codex":0.10004538,"about_ca_system_score_gemma":0.04122614,"threshold_uncertainty_score":0.9994496},"labels":[],"label_agreement":null},{"id":"W2299133976","doi":"10.3109/10428194.2016.1157878","title":"Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of British Columbia","funders":"","keywords":"Myelodysplastic syndromes; Azacitidine; Medicine; Myeloid leukemia; Internal medicine; Serum ferritin; Anemia; Oncology; Ferritin; Myeloid; Bone marrow; Gene","score_opus":0.011453141841531444,"score_gpt":0.23782365249906168,"score_spread":0.22637051065753022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299133976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96764034,0.0017044537,0.000017222355,0.02331287,0.0004915456,0.002909177,0.0019560512,0.00037566607,0.0015926702],"genre_scores_gemma":[0.90321934,0.0027823688,0.0008093462,0.058149267,0.0030959288,0.00072797626,0.0016092465,0.00091936585,0.028687168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9895198,0.00065024116,0.0016646878,0.0031698758,0.0019354791,0.0030599253],"domain_scores_gemma":[0.99402934,0.0015998161,0.00086930057,0.0019099237,0.0005926676,0.0009989592],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00057191163,0.0025089902,0.003172453,0.0015542507,0.0005686634,0.00036070845,0.0006682525,0.0028748363,0.0003831517],"category_scores_gemma":[0.00032222504,0.0018031,0.00037703826,0.0008760871,0.0010913936,0.0006673646,0.0006326317,0.0013768703,0.0001622015],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0069104107,0.0005752903,0.49709213,0.0034372786,0.0034500752,0.014198651,0.0014454161,0.000012765261,0.0004685678,0.00007022278,0.088179976,0.38415924],"study_design_scores_gemma":[0.045913596,0.003082742,0.8083161,0.0033620924,0.0009809975,0.00152158,0.000064273176,0.00015406971,0.0002353773,0.00008958304,0.13439685,0.0018827461],"about_ca_topic_score_codex":0.0044743535,"about_ca_topic_score_gemma":0.00023607948,"teacher_disagreement_score":0.38227648,"about_ca_system_score_codex":0.031255536,"about_ca_system_score_gemma":0.0073617976,"threshold_uncertainty_score":0.99876463},"labels":[],"label_agreement":null},{"id":"W2301625000","doi":"10.3109/10428194.2016.1160084","title":"Azacitidine in the treatment of blastic plasmacytoid dendritic cell neoplasm: a report of 3 cases","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Azacitidine; Medicine; Neoplasm; Cancer research; Myeloproliferative neoplasm; Plasmacytoid dendritic cell; Internal medicine; Immunology; Bone marrow; Biology; Pathology; Dendritic cell; Genetics; Antigen; Myelofibrosis; Gene","score_opus":0.020069063602651687,"score_gpt":0.2746700720578132,"score_spread":0.2546010084551615,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301625000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688739,0.0049497867,0.00002930817,0.015291767,0.00035306797,0.0026279623,0.00056549424,0.00008464995,0.0072240443],"genre_scores_gemma":[0.95055765,0.0073583927,0.00022839525,0.026575448,0.002010788,0.00073510106,0.0009962493,0.0003588915,0.011179059],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921227,0.0005371635,0.002220374,0.0016002043,0.0019190549,0.0016004761],"domain_scores_gemma":[0.9926918,0.003490809,0.0010004371,0.0019883206,0.0005255846,0.0003030253],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00047376318,0.0014004613,0.0028315901,0.0011433038,0.0002043877,0.00007834304,0.0006829919,0.0015029793,0.0001713603],"category_scores_gemma":[0.0004890065,0.00092757255,0.00079690083,0.0008936623,0.0013671844,0.00014588634,0.00015326217,0.00036982392,0.000046107594],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00644353,0.003302149,0.023575116,0.010794963,0.0021450196,0.4896261,0.008224173,0.00003678671,0.013762923,0.00015027015,0.347912,0.09402695],"study_design_scores_gemma":[0.04733981,0.0074515473,0.0043337625,0.0032813465,0.0018169308,0.26606473,0.0014149854,0.0008585317,0.037742123,0.00041401046,0.6273144,0.001967835],"about_ca_topic_score_codex":0.0034704641,"about_ca_topic_score_gemma":0.00038215995,"teacher_disagreement_score":0.27940238,"about_ca_system_score_codex":0.009153993,"about_ca_system_score_gemma":0.009321827,"threshold_uncertainty_score":0.9998746},"labels":[],"label_agreement":null},{"id":"W2344741804","doi":"10.1080/10428194.2016.1177772","title":"A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation","year":2016,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Celgene","keywords":"Lenalidomide; Multiple myeloma; Medicine; Thalidomide; Oncology; Internal medicine; Autologous stem-cell transplantation; Bortezomib; Melphalan; Transplantation; Progression-free survival; Meta-analysis; Surgery; Chemotherapy","score_opus":0.033855129194133374,"score_gpt":0.30208937127960067,"score_spread":0.2682342420854673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2344741804","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017852881,0.975114,0.00017567708,0.000015738202,0.00005515863,0.01602083,0.0066990466,0.000078964826,0.000055279343],"genre_scores_gemma":[0.002091062,0.9786516,0.0010570964,0.0001354553,0.00006117536,0.0073315967,0.008359158,0.00021100369,0.002101881],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99409485,0.00044523543,0.0021246665,0.0015641218,0.0007076147,0.0010635328],"domain_scores_gemma":[0.9935698,0.0024190983,0.0016394504,0.0011150003,0.00070192,0.0005547463],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005125261,0.0015856026,0.01127696,0.00083589635,0.00031005777,0.00012275537,0.00029819345,0.0007396879,0.000019335384],"category_scores_gemma":[0.00008873851,0.000865113,0.0030160428,0.0015310862,0.00016583194,0.00024054084,0.00006514062,0.000102733575,0.000008366675],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014873667,0.00034327633,0.00028707308,0.61472714,0.20809777,0.0000831543,0.00013813123,0.0000021263027,0.000001752036,0.000021004418,0.00024665985,0.17456454],"study_design_scores_gemma":[0.026349721,0.0014855282,0.0009806304,0.13653095,0.8191066,0.00018890444,0.00001296598,0.00019223355,0.000044500648,0.000005318683,0.014220624,0.0008820618],"about_ca_topic_score_codex":0.00008677837,"about_ca_topic_score_gemma":0.000029596278,"teacher_disagreement_score":0.61100876,"about_ca_system_score_codex":0.0025635746,"about_ca_system_score_gemma":0.001596363,"threshold_uncertainty_score":0.9996892},"labels":[],"label_agreement":null},{"id":"W2377143140","doi":"10.1080/10428194.2016.1180685","title":"Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS)","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Hotel Dieu Hospital","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Lenalidomide; Randomization; Multiple myeloma; Internal medicine; Refractory (planetary science); Gastroenterology; Phases of clinical research; Randomized controlled trial; Progressive disease; Surgery; Clinical trial; Chemotherapy","score_opus":0.018214258481873274,"score_gpt":0.2731410443367429,"score_spread":0.2549267858548696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2377143140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99249035,0.00050424377,0.000033724307,0.00015949598,0.0000787813,0.0064112083,0.00008462374,0.000057357145,0.00018022611],"genre_scores_gemma":[0.99801534,0.00024443195,0.000380257,0.000077804856,0.00008937397,0.00063061964,0.00011456093,0.00008839565,0.00035922608],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99321204,0.0025345418,0.0013116933,0.001024038,0.0010692733,0.00084842485],"domain_scores_gemma":[0.9889561,0.009001662,0.0005607471,0.00081078924,0.0001903352,0.0004803431],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028603396,0.0007258201,0.0020262187,0.0007380535,0.00023099013,0.0000796133,0.00022108144,0.00044682386,0.000019522322],"category_scores_gemma":[0.0032731118,0.00038333194,0.00016242494,0.0008069505,0.0011849141,0.0004159129,0.00010250199,0.00023418436,0.0000034511113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85542494,0.0012462229,0.119510725,0.00008393068,0.00028662506,0.0005393638,0.0010559086,0.000002640648,0.0004364966,0.000049097383,0.000022269065,0.021341754],"study_design_scores_gemma":[0.62279856,0.004795893,0.37032005,0.00044159,0.00024509418,0.0000771528,0.0002493104,0.00038718848,0.0003055019,0.000029217921,0.00004746093,0.00030300455],"about_ca_topic_score_codex":0.0022780555,"about_ca_topic_score_gemma":0.00050865964,"teacher_disagreement_score":0.2508093,"about_ca_system_score_codex":0.0029102634,"about_ca_system_score_gemma":0.0024548692,"threshold_uncertainty_score":0.99986184},"labels":[],"label_agreement":null},{"id":"W2397442087","doi":"10.1080/10428194.2016.1179295","title":"Validation of the NCCN-IPI in both <i>de novo</i> and transformed diffuse large B cell lymphoma","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Diffuse large B-cell lymphoma; International Prognostic Index; Medicine; Lymphoma; Risk stratification; Internal medicine; Oncology","score_opus":0.0074482426832511335,"score_gpt":0.21808160447531527,"score_spread":0.21063336179206413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397442087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95604146,0.004674649,0.00002537993,0.031040885,0.0006439481,0.002075364,0.00069268246,0.00016412292,0.004641531],"genre_scores_gemma":[0.89412975,0.005804031,0.00018322004,0.09334474,0.0015750235,0.0005169399,0.0004542185,0.00032798608,0.0036640586],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926148,0.00043377344,0.0017705961,0.0018100688,0.0013351167,0.002035617],"domain_scores_gemma":[0.9958394,0.00083894277,0.000887776,0.0017378235,0.00018487989,0.0005111853],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00065676175,0.0016461799,0.002329129,0.000644808,0.0003967639,0.00017162929,0.00069130014,0.0023980206,0.00007566378],"category_scores_gemma":[0.0001079516,0.0011212409,0.0007821775,0.00073502056,0.0007109936,0.00036807384,0.00035759262,0.00040521214,0.000039434548],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0045041805,0.009206516,0.20014223,0.011579902,0.002561416,0.010201567,0.008972303,0.000008484612,0.012603763,0.0010927707,0.43610817,0.3030187],"study_design_scores_gemma":[0.18001156,0.00074219774,0.21395354,0.0042310013,0.002198769,0.0037685467,0.00033326016,0.0002988003,0.05865811,0.0006470494,0.5328032,0.002354011],"about_ca_topic_score_codex":0.001690714,"about_ca_topic_score_gemma":0.00011833942,"teacher_disagreement_score":0.30066466,"about_ca_system_score_codex":0.011785549,"about_ca_system_score_gemma":0.006025765,"threshold_uncertainty_score":0.99962854},"labels":[],"label_agreement":null},{"id":"W2399783955","doi":"10.3109/10428194.2016.1171861","title":"Next-generation sequencing identifies a novel<i>ELAVL1–TYK2</i>fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer Mechanisms and Therapy","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Institute for Health and Care Research","keywords":"Fusion gene; Gene; Biology; Kinase; DNA sequencing; Cancer research; Genetics; Computational biology","score_opus":0.029012575121624855,"score_gpt":0.24390346093335952,"score_spread":0.21489088581173466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2399783955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9322902,0.0016532787,0.0020540708,0.05647431,0.0029602842,0.0031496133,0.00053471426,0.00032178315,0.0005617608],"genre_scores_gemma":[0.5634056,0.0018771882,0.0013439313,0.39617604,0.025469383,0.00068688113,0.0021161544,0.00056772784,0.008357137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9922656,0.00040551234,0.0016243717,0.0024427448,0.0015226564,0.0017391591],"domain_scores_gemma":[0.9958614,0.00030653964,0.000732047,0.0019490888,0.0005086476,0.0006422469],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009785887,0.0016633605,0.0018485088,0.0009789247,0.00066776306,0.0005469505,0.00062071456,0.001987247,0.0000904191],"category_scores_gemma":[0.00009035535,0.0012343331,0.00051010866,0.0009378743,0.0002947683,0.0006820596,0.0004203447,0.00086119986,0.00014338762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012168771,0.00014047876,0.000023712326,0.00044090836,0.00019485984,0.0032496732,0.0029653,0.00012300652,0.80913156,0.00008838766,0.11672938,0.06569588],"study_design_scores_gemma":[0.022625735,0.0016918712,0.00044660337,0.0022447605,0.0006068262,0.0021144066,0.0008675757,0.00620976,0.5562511,0.00023965837,0.40421832,0.0024833798],"about_ca_topic_score_codex":0.008581576,"about_ca_topic_score_gemma":0.0021784513,"teacher_disagreement_score":0.36888462,"about_ca_system_score_codex":0.020902067,"about_ca_system_score_gemma":0.005865278,"threshold_uncertainty_score":0.9997705},"labels":[],"label_agreement":null},{"id":"W2404590269","doi":"10.1080/10428194.2016.1180681","title":"Chemotherapeutic treatment is associated with Notch1 induction in cutaneous T-cell lymphoma","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Gemcitabine; Etoposide; Cancer research; Chemotherapy; Doxorubicin; Notch signaling pathway; Downregulation and upregulation; Gene knockdown; Lymphoma; Medicine; Biology; Cell culture; Immunology; Internal medicine; Receptor; Gene","score_opus":0.01645850853920417,"score_gpt":0.25578618355007976,"score_spread":0.2393276750108756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2404590269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887779,0.0012563461,0.00006693765,0.00096977956,0.00015790529,0.0016144088,0.00009855707,0.00030027848,0.006757914],"genre_scores_gemma":[0.98223865,0.0021479526,0.00018439021,0.0015895554,0.00021233123,0.00031191512,0.00010252404,0.0002592758,0.012953431],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99396926,0.00027206578,0.0010039941,0.0017681525,0.0012354428,0.0017510965],"domain_scores_gemma":[0.99679977,0.00057493796,0.00037167472,0.0011250802,0.00037398995,0.00075452845],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031590456,0.0011935987,0.0015149076,0.0007889984,0.00037883926,0.00015565362,0.00035563335,0.0008385785,0.00045253945],"category_scores_gemma":[0.00017116644,0.0008169504,0.0003192686,0.001242195,0.0007358234,0.00037091973,0.00013469745,0.00012563521,0.0002908713],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009321126,0.0036891333,0.093137205,0.000279115,0.0012139758,0.005458729,0.0045593004,0.000019657242,0.08440338,0.00014149758,0.0016791308,0.79609776],"study_design_scores_gemma":[0.3020459,0.011947298,0.21927513,0.003671893,0.0015195392,0.055733763,0.0034511858,0.0095147155,0.34575188,0.0010387405,0.040497668,0.0055522756],"about_ca_topic_score_codex":0.0025388545,"about_ca_topic_score_gemma":0.0007201731,"teacher_disagreement_score":0.79054546,"about_ca_system_score_codex":0.029586174,"about_ca_system_score_gemma":0.006399241,"threshold_uncertainty_score":0.99942815},"labels":[],"label_agreement":null},{"id":"W2406330856","doi":"10.1080/10428194.2016.1180684","title":"Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; Doris Duke Charitable Foundation; Roche; Canadian Institutes of Health Research; Novartis; American Society of Hematology; Samuel Waxman Cancer Research Foundation","keywords":"Histone deacetylase; Cancer research; Gene signature; Proteasome; Histone; HDAC11; Histone deacetylase inhibitor; Gene; Proteasome inhibitor; Biology; Chemistry; Gene expression; Cell biology; Genetics","score_opus":0.005991476028193569,"score_gpt":0.22485079635543084,"score_spread":0.21885932032723726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2406330856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97313136,0.0032823654,0.00007019279,0.017275024,0.0004114186,0.0043335315,0.000770939,0.00022973883,0.0004954274],"genre_scores_gemma":[0.8757103,0.00029006676,0.0014071767,0.08529575,0.0111989165,0.0039463467,0.0016514031,0.0010849779,0.019415034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9893973,0.0013985042,0.0015844437,0.0032387858,0.0017829004,0.0025980803],"domain_scores_gemma":[0.99583906,0.00019487056,0.000648652,0.0019508157,0.00047264804,0.0008939336],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016444711,0.0018105003,0.0014679407,0.0012291225,0.00048437034,0.00036035472,0.0014126052,0.004533243,0.00003393944],"category_scores_gemma":[0.00077600847,0.0016395563,0.00043888885,0.0010152016,0.00066922035,0.000060245955,0.0009924312,0.0010680963,0.00014570508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004796659,0.000069621834,0.000024186886,0.0005875432,0.00008672984,0.0020038274,0.00020622506,0.000011678945,0.7145403,0.000001157916,0.2669555,0.010716571],"study_design_scores_gemma":[0.0059743277,0.0006926573,0.00027754545,0.0014812849,0.000045082455,0.00020007908,0.00003427366,0.00006333217,0.5152462,0.000019641768,0.47454885,0.0014167017],"about_ca_topic_score_codex":0.0009267397,"about_ca_topic_score_gemma":0.00013204735,"teacher_disagreement_score":0.20759337,"about_ca_system_score_codex":0.008858972,"about_ca_system_score_gemma":0.012522794,"threshold_uncertainty_score":0.99946404},"labels":[],"label_agreement":null},{"id":"W2409070542","doi":"10.1080/10428194.2016.1177181","title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Vancouver General Hospital","funders":"Celgene","keywords":"Pomalidomide; Medicine; Dexamethasone; Multiple myeloma; Internal medicine; Clinical trial; Urology; Renal function; Refractory (planetary science); Creatinine; Dosing; Surgery; Lenalidomide; Gastroenterology","score_opus":0.034032644198169676,"score_gpt":0.3138947330508331,"score_spread":0.2798620888526634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2409070542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960508,0.00094806805,0.0003704603,0.00009872345,0.000092561204,0.0019029712,0.00028670626,0.000091702546,0.00015801255],"genre_scores_gemma":[0.9966307,0.0007181789,0.0015068552,0.00020564716,0.00011476275,0.00018692178,0.00021362418,0.00010338304,0.00031987327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99267,0.0011168064,0.0024081254,0.001478773,0.0011635853,0.0011626992],"domain_scores_gemma":[0.9929114,0.0035100551,0.00097510475,0.0011054381,0.00037307793,0.001124945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002743719,0.000838792,0.003449233,0.0012551843,0.00019754446,0.00008224562,0.0002827621,0.0006249066,0.000112969414],"category_scores_gemma":[0.0020689147,0.0005212768,0.00062334654,0.0011375434,0.00076314504,0.00045155745,0.00026907225,0.00021040108,0.00001993801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.046495635,0.0011097908,0.7118794,0.00013521529,0.0052575185,0.0004367518,0.000262922,0.00004969442,0.0013928043,0.000031564232,0.00007501043,0.23287371],"study_design_scores_gemma":[0.15938456,0.0021869368,0.8173243,0.00062088843,0.0028044411,0.00004311616,0.000060974533,0.015709301,0.0012032324,0.00007482703,0.00008501813,0.0005024382],"about_ca_topic_score_codex":0.0019596312,"about_ca_topic_score_gemma":0.0010025325,"teacher_disagreement_score":0.23237127,"about_ca_system_score_codex":0.0043002767,"about_ca_system_score_gemma":0.002959663,"threshold_uncertainty_score":0.99972385},"labels":[],"label_agreement":null},{"id":"W2411938662","doi":"10.1080/10428194.2016.1185785","title":"Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning","year":2016,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fluidigm (Canada)","funders":"","keywords":"Carmustine; Melphalan; Medicine; Etoposide; Bendamustine; Oncology; Busulfan; Tolerability; Lymphoma; Internal medicine; Regimen; Brentuximab vedotin; Transplantation; Cyclophosphamide; Chemotherapy; Surgery; Hodgkin lymphoma; Rituximab","score_opus":0.015033059829724846,"score_gpt":0.27165723905321304,"score_spread":0.2566241792234882,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411938662","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2381151,0.73714453,0.004623555,0.00028165383,0.0009005914,0.014877343,0.0022019825,0.000347063,0.0015081847],"genre_scores_gemma":[0.07079872,0.91194177,0.007290484,0.0006846047,0.0004403209,0.0056041754,0.00057840627,0.00047609434,0.0021854513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9922382,0.00018623316,0.0021774338,0.002639296,0.0012023974,0.0015564336],"domain_scores_gemma":[0.99347246,0.0018229886,0.0015484912,0.0016896548,0.0004046858,0.0010617175],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000654684,0.0021746098,0.003968132,0.0009019584,0.00079843664,0.00023211307,0.00081412424,0.00093583146,0.000022464115],"category_scores_gemma":[0.000029366738,0.0014003587,0.00085210777,0.00091601233,0.0005278505,0.0003630107,0.0003609057,0.00012690808,0.00006672898],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032515223,0.000858288,0.00010099399,0.019439142,0.0028277389,0.0006823329,0.0023076592,0.0000160604,0.000077762896,0.00044615494,0.0008762134,0.96911615],"study_design_scores_gemma":[0.1107507,0.0076982947,0.04225275,0.105091825,0.017840507,0.006832823,0.0025123989,0.0002058015,0.0036342659,0.00004268521,0.69918096,0.003957008],"about_ca_topic_score_codex":0.0007341239,"about_ca_topic_score_gemma":0.00007378087,"teacher_disagreement_score":0.9651591,"about_ca_system_score_codex":0.008892342,"about_ca_system_score_gemma":0.0035137963,"threshold_uncertainty_score":0.99909943},"labels":[],"label_agreement":null},{"id":"W2419412633","doi":"10.1080/10428194.2016.1187274","title":"Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12<sup>*</sup>","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Manitoba; Princess Margaret Cancer Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; Queen's University; Juravinski Hospital; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre","funders":"Canadian Cancer Society Research Institute","keywords":"Medicine; Rituximab; CHOP; Internal medicine; Cohort; Oncology; Autologous stem-cell transplantation; Transplantation; Chemotherapy; Surgery; Salvage therapy; Lymphoma; Gastroenterology","score_opus":0.022262845710548543,"score_gpt":0.3168151131251936,"score_spread":0.2945522674146451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2419412633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98837066,0.001661586,0.000086933585,0.00061482075,0.00045837628,0.007695651,0.00076405896,0.00011378014,0.0002341562],"genre_scores_gemma":[0.9960227,0.00067850394,0.00016883563,0.0011943778,0.00035360333,0.0012218509,0.00008283639,0.0001303133,0.00014698811],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9887544,0.003650709,0.0035289933,0.0016734456,0.0013689862,0.0010234559],"domain_scores_gemma":[0.98642445,0.009151244,0.0016793921,0.0019260684,0.00018098467,0.0006378662],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004556044,0.0011356743,0.0043476266,0.00032678366,0.00030823002,0.000076259916,0.000935794,0.000699225,0.00008591967],"category_scores_gemma":[0.0006893989,0.00057447853,0.0010657645,0.00083778705,0.00051497074,0.00017872067,0.00029253247,0.00016235845,0.00006517231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012239161,0.0038564727,0.4677309,0.0001729762,0.0009955824,0.00031333065,0.005435679,0.00003128107,0.0017923624,0.00003056404,0.00225722,0.5051445],"study_design_scores_gemma":[0.107684396,0.0063289213,0.8435687,0.0022520607,0.0019189114,0.0001679752,0.00102146,0.0005380407,0.034131438,0.000027133337,0.0017385802,0.0006223698],"about_ca_topic_score_codex":0.0043222304,"about_ca_topic_score_gemma":0.00045606526,"teacher_disagreement_score":0.5045221,"about_ca_system_score_codex":0.0050846096,"about_ca_system_score_gemma":0.0019604785,"threshold_uncertainty_score":0.9996707},"labels":[],"label_agreement":null},{"id":"W2460247604","doi":"10.1080/10428194.2016.1193852","title":"Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Gemcitabine; Salvage therapy; Medicine; Internal medicine; Regimen; Oncology; Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Dexamethasone; Chemotherapy; Surgery; Biology","score_opus":0.009841282103977077,"score_gpt":0.2455668701614619,"score_spread":0.2357255880574848,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2460247604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774195,0.015787961,0.00024392316,0.00052157353,0.00038465933,0.003630317,0.0005628991,0.00042753608,0.00102161],"genre_scores_gemma":[0.97550154,0.01589039,0.0016486425,0.0031040672,0.00047742433,0.0011847869,0.00021196858,0.00038263373,0.0015985757],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99216735,0.00049110444,0.0013974758,0.0030458493,0.00087540835,0.0020228329],"domain_scores_gemma":[0.99332327,0.0022936559,0.0007061185,0.0014778532,0.00039169966,0.0018073788],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009663803,0.001978314,0.0023741997,0.00067822076,0.0010980945,0.00046688793,0.0003703057,0.0013122553,0.000082515435],"category_scores_gemma":[0.00024855006,0.0014578947,0.00040871763,0.0006097662,0.0010031381,0.0011274588,0.0004077568,0.00013029162,0.000046305715],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0076406025,0.0054846895,0.0846614,0.0006389431,0.0010637501,0.00067142013,0.003390013,4.2331305e-7,0.020280614,0.0009912467,0.0035849381,0.8715919],"study_design_scores_gemma":[0.2625751,0.0046503106,0.6514587,0.0008072863,0.0009919327,0.0018702244,0.000779433,0.0021268507,0.033550467,0.0006273926,0.038507495,0.002054852],"about_ca_topic_score_codex":0.0013263511,"about_ca_topic_score_gemma":0.0001601379,"teacher_disagreement_score":0.8695371,"about_ca_system_score_codex":0.004327113,"about_ca_system_score_gemma":0.0015688378,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W2470838233","doi":"10.1080/10428194.2016.1196815","title":"FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Queen's University; BC Cancer Agency; Princess Margaret Cancer Centre; Kingston General Hospital; University of Toronto","funders":"F. Hoffmann-La Roche; Roche","keywords":"Medicine; Follicular lymphoma; Internal medicine; Hazard ratio; Oncology; Positron emission tomography; Lymphoma; Obinutuzumab; Nuclear medicine; Standardized uptake value; Rituximab; Progression-free survival; Prospective cohort study; PET-CT; Overall survival; Confidence interval","score_opus":0.013231878525028678,"score_gpt":0.2600789023359821,"score_spread":0.2468470238109534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2470838233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99173,0.0023737517,0.000065606,0.0005423095,0.00030030974,0.004030188,0.0004984992,0.00011129838,0.00034803737],"genre_scores_gemma":[0.99620426,0.0005293772,0.00027408407,0.0004011481,0.00013417203,0.0019474374,0.000059182898,0.00011241673,0.00033793808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99439824,0.00039373894,0.0013676079,0.0016137365,0.001226296,0.0010003828],"domain_scores_gemma":[0.9952404,0.001376281,0.0006517757,0.0018360605,0.0003782287,0.0005172884],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092499837,0.0009207078,0.001962037,0.0007526348,0.00038553192,0.000084861465,0.0005673647,0.0003775781,0.000029546087],"category_scores_gemma":[0.000728007,0.0005400838,0.0006713071,0.0018385833,0.0006466738,0.0002905565,0.00057276397,0.000072561445,0.0000057908487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022630957,0.002755778,0.91828626,0.00022048935,0.0041381484,0.00043646002,0.0030743585,0.000016673963,0.00075965916,0.00040773352,0.00094508193,0.06669625],"study_design_scores_gemma":[0.06538109,0.0017423644,0.9150428,0.0008823453,0.0061881305,0.00016379757,0.0021392682,0.0024944048,0.0039792918,0.00044386205,0.0009137626,0.00062886503],"about_ca_topic_score_codex":0.0005673115,"about_ca_topic_score_gemma":0.00029327025,"teacher_disagreement_score":0.06606738,"about_ca_system_score_codex":0.0046801823,"about_ca_system_score_gemma":0.0024733215,"threshold_uncertainty_score":0.9997051},"labels":[],"label_agreement":null},{"id":"W2508095929","doi":"10.1080/10428194.2016.1218005","title":"The mitochondria target drug avocatin B synergizes with induction chemotherapeutics to induce leukemia cell death","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Centre for Drug Research and Development; University of Waterloo","funders":"","keywords":"Drug; Leukemia; Programmed cell death; Cancer research; Mitochondrion; Apoptosis; Biology; Medicine; Pharmacology; Immunology; Cell biology; Biochemistry","score_opus":0.013085849444078186,"score_gpt":0.24691204312996085,"score_spread":0.23382619368588267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508095929","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.57872623,0.007456903,0.0010983365,0.36196306,0.0039888853,0.009921342,0.00064061634,0.0019065923,0.03429802],"genre_scores_gemma":[0.053041477,0.0073627965,0.012505116,0.5633934,0.028513424,0.0029095402,0.0016049414,0.0027042655,0.32796502],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.98553956,0.0008069229,0.002175223,0.0037554372,0.0034168754,0.00430596],"domain_scores_gemma":[0.98976976,0.0019901723,0.0012418999,0.004274218,0.0011413991,0.001582573],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0013258344,0.0031011477,0.0029313888,0.0013510368,0.0021900716,0.0011024233,0.0023593819,0.003804548,0.00020336136],"category_scores_gemma":[0.0003549002,0.0020110074,0.00075541687,0.0021682738,0.0014781598,0.0006171155,0.0009847716,0.0029989504,0.0007872984],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024624672,0.000087769,0.00046500188,0.00091879873,0.0010907331,0.002127289,0.0010714737,0.000021437614,0.008399394,0.00011514298,0.9075421,0.07569839],"study_design_scores_gemma":[0.017074127,0.00096143293,0.0018262892,0.0015735888,0.00093274313,0.0031698288,0.000632118,0.00071141485,0.025606018,0.0004117423,0.94441134,0.0026893797],"about_ca_topic_score_codex":0.0027920303,"about_ca_topic_score_gemma":0.00012285869,"teacher_disagreement_score":0.5256848,"about_ca_system_score_codex":0.045659225,"about_ca_system_score_gemma":0.02696631,"threshold_uncertainty_score":0.9999907},"labels":[],"label_agreement":null},{"id":"W2508313410","doi":"10.1080/10428194.2016.1222376","title":"Comparison of a pediatric-inspired treatment protocol versus standard-intensity chemotherapy for young adults with standard-risk BCR-ABL negative acute lymphoblastic leukemia","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Vancouver General Hospital","funders":"BC Cancer Agency","keywords":"Medicine; Lymphoblastic Leukemia; Retrospective cohort study; Cohort; Chemotherapy; Pediatrics; Young adult; Internal medicine; Complete remission; Overall survival; Acute lymphocytic leukemia; Oncology; Leukemia","score_opus":0.017547924228737764,"score_gpt":0.306720113224732,"score_spread":0.2891721889959943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508313410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9428126,0.00020292563,0.0071566235,0.00023551482,0.00046139932,0.045880653,0.0017204257,0.00056230713,0.00096754974],"genre_scores_gemma":[0.9562373,0.0009046199,0.009177415,0.00021031311,0.0010358205,0.030541146,0.00014570117,0.00048791472,0.0012597259],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9897014,0.00031230893,0.0023265167,0.0026363835,0.002501858,0.0025215656],"domain_scores_gemma":[0.990127,0.002446495,0.0017882878,0.0020040565,0.0021252611,0.0015088591],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00078506,0.002047325,0.0038436053,0.00082212425,0.0008559747,0.00019241507,0.0008013086,0.0010843301,0.00013582806],"category_scores_gemma":[0.0008858464,0.0013513047,0.0008410558,0.0013147021,0.0014470792,0.00066754426,0.00034130662,0.00026893758,0.00004871925],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.63263935,0.0012151523,0.06922407,0.0018124623,0.0055763074,0.0007475609,0.0075225774,0.00010632517,0.005004839,0.00032356626,0.009752991,0.26607478],"study_design_scores_gemma":[0.65290844,0.06530248,0.055119902,0.0025868241,0.0059510577,0.0015468705,0.0032474638,0.017796516,0.17270564,0.000360015,0.018862834,0.0036119358],"about_ca_topic_score_codex":0.0024638039,"about_ca_topic_score_gemma":0.00046632672,"teacher_disagreement_score":0.26246285,"about_ca_system_score_codex":0.07166165,"about_ca_system_score_gemma":0.025136711,"threshold_uncertainty_score":0.99922687},"labels":[],"label_agreement":null},{"id":"W2515657367","doi":"10.1080/10428194.2016.1204657","title":"Leukocytoclastic vasculitis following lenalidomide during the treatment of follicular lymphoma","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Lenalidomide; Thalidomide; Medicine; Multiple myeloma; Follicular lymphoma; Lymphoma; Dermatology; Oncology; Internal medicine","score_opus":0.014584976461774424,"score_gpt":0.2546905278786067,"score_spread":0.24010555141683226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2515657367","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613703,0.012169581,0.00005110244,0.018938117,0.00094945775,0.0033226665,0.00047713748,0.00035514837,0.0023664725],"genre_scores_gemma":[0.904293,0.0154839605,0.0005486921,0.035211336,0.00988523,0.002265605,0.001388324,0.0009730756,0.029950794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9899904,0.0005639536,0.0018744658,0.002311909,0.0024377457,0.0028215244],"domain_scores_gemma":[0.9936518,0.0014712847,0.00086362,0.0028200985,0.00032119072,0.00087201607],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00040015535,0.0022169221,0.0033613457,0.00084091193,0.00096176664,0.00025423942,0.0008813568,0.0020188617,0.00021423245],"category_scores_gemma":[0.00023878098,0.0013663383,0.0026913602,0.0007252202,0.0009334922,0.00034842978,0.00033073337,0.00035313482,0.00028328536],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007476324,0.0014169872,0.017334705,0.005088924,0.025353631,0.07929614,0.0024176904,0.000021945787,0.008741436,0.00014756666,0.120957956,0.7317467],"study_design_scores_gemma":[0.10347604,0.0020126256,0.064979136,0.0029175833,0.0040129106,0.0059361863,0.0002029822,0.0004591784,0.017507836,0.00022390462,0.7962252,0.0020464114],"about_ca_topic_score_codex":0.003987126,"about_ca_topic_score_gemma":0.00008275888,"teacher_disagreement_score":0.72970027,"about_ca_system_score_codex":0.025967868,"about_ca_system_score_gemma":0.0064012343,"threshold_uncertainty_score":0.9992767},"labels":[],"label_agreement":null},{"id":"W2521333572","doi":"10.1080/10428194.2016.1213825","title":"Chest CT scans are frequently abnormal in asymptomatic patients with newly diagnosed acute myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; Institute for Clinical Evaluative Sciences; University Health Network; University of Toronto","funders":"University Health Network","keywords":"Asymptomatic; Medicine; Radiology; Myeloid leukemia; Pneumonia; Febrile neutropenia; Neutropenia; Internal medicine","score_opus":0.006568723383776506,"score_gpt":0.21871192484718555,"score_spread":0.21214320146340904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2521333572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99150515,0.00041164053,0.00015167295,0.00039126945,0.0004988759,0.0014188273,0.00018978312,0.0004132683,0.005019509],"genre_scores_gemma":[0.9936163,0.0008511611,0.00045590664,0.0018838808,0.00038821576,0.0005302519,0.00013175941,0.00022184354,0.001920692],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99454963,0.0001715323,0.0011840863,0.0014645829,0.0010326474,0.0015974938],"domain_scores_gemma":[0.996563,0.00036472845,0.0005741211,0.0012388044,0.00030341157,0.00095594634],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002820785,0.0011176257,0.0014720411,0.0006468287,0.00044757643,0.00017840983,0.0004876185,0.0003945511,0.00023359641],"category_scores_gemma":[0.00011552023,0.0007864437,0.00029181544,0.0012207791,0.00061072066,0.0009753583,0.00021543966,0.00025723796,0.00023373606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001614746,0.00046769128,0.8430009,0.0003221115,0.0005823863,0.0020980658,0.00049657817,0.000055024124,0.0024197223,0.00033303472,0.0031576012,0.14545214],"study_design_scores_gemma":[0.05591957,0.0008982577,0.923614,0.0017222983,0.0006033367,0.0012750614,0.00023519764,0.00019075871,0.0039767474,0.00011380436,0.010291033,0.0011599327],"about_ca_topic_score_codex":0.0033469393,"about_ca_topic_score_gemma":0.0013565855,"teacher_disagreement_score":0.1442922,"about_ca_system_score_codex":0.017638661,"about_ca_system_score_gemma":0.005648085,"threshold_uncertainty_score":0.999989},"labels":[],"label_agreement":null},{"id":"W2531543939","doi":"10.1080/10428194.2016.1243680","title":"Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia","year":2016,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Incidence (geometry); Myeloid leukemia; Adverse effect; Internal medicine; Randomization; Clinical trial; Emergency medicine","score_opus":0.007809037247689415,"score_gpt":0.2445108173246626,"score_spread":0.23670178007697318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531543939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960121,0.0005839349,0.00009092858,0.00018336848,0.00008833262,0.002308441,0.00022080986,0.00013091663,0.00038114798],"genre_scores_gemma":[0.99529576,0.0010907655,0.00089284097,0.00010783043,0.000056672598,0.00030965253,0.00070616696,0.0001755537,0.0013647291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99501187,0.00022060025,0.0010704689,0.001492698,0.0011424455,0.0010618937],"domain_scores_gemma":[0.99646133,0.00021094209,0.0008328165,0.0008930894,0.00093482493,0.0006670234],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021039262,0.0010169196,0.0014396199,0.0006683394,0.00028580628,0.000031097723,0.00029268963,0.00044692488,0.000085133695],"category_scores_gemma":[0.00006907477,0.00063134456,0.00014479867,0.001160537,0.0009247801,0.0007126555,0.00017624919,0.00016709194,0.000015931173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011332958,0.00041525543,0.9707021,0.00049043563,0.0013569163,0.00092441734,0.0023667314,0.00014928772,0.0040174443,0.00016012411,0.00022781902,0.007856502],"study_design_scores_gemma":[0.08584023,0.0035992477,0.8919214,0.003243273,0.00071080023,0.00081064866,0.0021622174,0.00071264,0.009891286,0.000031008527,0.00020680824,0.00087046635],"about_ca_topic_score_codex":0.0014371176,"about_ca_topic_score_gemma":0.0003911839,"teacher_disagreement_score":0.07878073,"about_ca_system_score_codex":0.018832577,"about_ca_system_score_gemma":0.006356872,"threshold_uncertainty_score":0.99961376},"labels":[],"label_agreement":null},{"id":"W2559063049","doi":"10.1080/10428194.2016.1207765","title":"A common ancestral DNMT3A-mutated preleukemic clone giving rise to AML and MDS in an adolescent girl","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Gene; clone (Java method); Myeloid leukemia; Mutation; Myeloid; Genetics; Biology; Methyltransferase; Cancer research; Medicine; Methylation","score_opus":0.01909827924751811,"score_gpt":0.2877261521024222,"score_spread":0.2686278728549041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559063049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93754965,0.003602893,0.000071099326,0.051573336,0.0006876181,0.0037618217,0.00048421623,0.00069587346,0.0015735129],"genre_scores_gemma":[0.727114,0.0044966387,0.0014382197,0.24585178,0.007688442,0.0010278566,0.0012748045,0.0011490188,0.009959219],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9854185,0.0010160129,0.0026202765,0.004244935,0.0022663802,0.004433895],"domain_scores_gemma":[0.99250984,0.0008500115,0.0008274769,0.0029763796,0.00050403987,0.002332259],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0013661117,0.0028063038,0.0040045986,0.002487265,0.00059125037,0.0006066303,0.0015648393,0.004201211,0.00017790304],"category_scores_gemma":[0.00036415187,0.0024811935,0.0005338242,0.0017831584,0.0013639942,0.0010143692,0.0013320555,0.002740816,0.00030716226],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005563875,0.00042616506,0.040721796,0.00463408,0.00069879997,0.024950977,0.0023803134,0.000035228273,0.0139447255,0.00006463506,0.56761867,0.3389607],"study_design_scores_gemma":[0.055206705,0.003309896,0.21704935,0.010343264,0.00092465646,0.010547425,0.0005392325,0.0063898456,0.004536382,0.00043048945,0.6851483,0.0055744294],"about_ca_topic_score_codex":0.005696386,"about_ca_topic_score_gemma":0.0006272127,"teacher_disagreement_score":0.33338627,"about_ca_system_score_codex":0.038789593,"about_ca_system_score_gemma":0.0114990305,"threshold_uncertainty_score":0.9995599},"labels":[],"label_agreement":null},{"id":"W2560764121","doi":"10.1080/10428194.2016.1265115","title":"Severe inflammatory myositis in a patient receiving concurrent nivolumab and azacitidine","year":2016,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Nivolumab; Azacitidine; Medicine; Myositis; Nilotinib; Internal medicine; Ipilimumab; Oncology; Dermatology; Immunotherapy; Cancer; Myeloid leukemia","score_opus":0.007861848712363367,"score_gpt":0.2188114789362649,"score_spread":0.21094963022390154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2560764121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93544054,0.018367965,0.00001284789,0.038288828,0.0014959709,0.0016872481,0.00033505302,0.00029962754,0.0040719225],"genre_scores_gemma":[0.6305825,0.020941822,0.0001907171,0.33359748,0.00549016,0.00064890774,0.0008378724,0.0005834134,0.0071271043],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939602,0.00022849748,0.0015393395,0.0017511225,0.0009800514,0.0015407793],"domain_scores_gemma":[0.9972651,0.0004521588,0.0006842234,0.0010012635,0.00017995274,0.00041728106],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00041531314,0.001374845,0.0018207503,0.0007833174,0.00029691384,0.00019650454,0.00034213567,0.0020991436,0.00029388975],"category_scores_gemma":[0.00008950967,0.0011794845,0.00042348204,0.00045319862,0.00077400607,0.00035765438,0.00033713583,0.0007226797,0.00004820343],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001315039,0.00004804799,0.0031337112,0.0014134097,0.00044081002,0.0047905603,0.001007925,4.0699612e-7,0.0015844294,0.000022133805,0.3273003,0.65894324],"study_design_scores_gemma":[0.030639015,0.0006959559,0.040725242,0.0069179744,0.0003130663,0.00667533,0.00022443941,0.00013777212,0.00096168154,0.00011161846,0.91075957,0.0018383281],"about_ca_topic_score_codex":0.0018111898,"about_ca_topic_score_gemma":0.00017621643,"teacher_disagreement_score":0.6571049,"about_ca_system_score_codex":0.0135232005,"about_ca_system_score_gemma":0.004219558,"threshold_uncertainty_score":0.9999002},"labels":[],"label_agreement":null},{"id":"W2614736655","doi":"10.1080/10428194.2017.1307980","title":"Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of British Columbia","funders":"","keywords":"Bleomycin; Medicine; ABVD; Dacarbazine; Vinblastine; Internal medicine; Pulmonary toxicity; Lymphoma; Oncology; Discontinuation; Incidence (geometry); Gastroenterology; Chemotherapy; Toxicity; Hodgkin's lymphoma; Surgery; Cyclophosphamide; Vincristine","score_opus":0.013137404206686028,"score_gpt":0.25038566945046503,"score_spread":0.237248265243779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614736655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99001336,0.000530924,0.00001706863,0.0008075326,0.0005654151,0.0018122866,0.0003082539,0.00018964913,0.0057555176],"genre_scores_gemma":[0.99520785,0.00036690402,0.00045404563,0.0015836495,0.0003380591,0.00029628846,0.00014830037,0.00015775191,0.0014471654],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943092,0.00021760639,0.0012684972,0.0014726921,0.0014570844,0.0012749064],"domain_scores_gemma":[0.9939283,0.00060567295,0.0012761699,0.002989197,0.0004936236,0.0007069943],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0006023361,0.001228918,0.0018188558,0.0002864352,0.0015480377,0.00031564885,0.0010446924,0.00057406846,0.00010370267],"category_scores_gemma":[0.0003741611,0.00068936247,0.00061612314,0.00031399605,0.0013758272,0.00068126875,0.00060914,0.00014215759,0.000074228505],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033046165,0.0013185554,0.82379216,0.000376054,0.00076826726,0.0006478634,0.00036658018,0.000010006423,0.00075945037,0.00063305674,0.000582299,0.1674411],"study_design_scores_gemma":[0.03133758,0.0008761716,0.93722993,0.00047431167,0.0010723693,0.0003718191,0.00026203008,0.00047636937,0.021876223,0.00010378387,0.0050594797,0.00085993606],"about_ca_topic_score_codex":0.004552304,"about_ca_topic_score_gemma":0.00034815373,"teacher_disagreement_score":0.16658115,"about_ca_system_score_codex":0.004954665,"about_ca_system_score_gemma":0.0020175858,"threshold_uncertainty_score":0.9997518},"labels":[],"label_agreement":null},{"id":"W2614912162","doi":"10.1080/10428194.2017.1318439","title":"Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia","year":2017,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Roche (Canada); University of Calgary; McGill University; Jewish General Hospital; Queen Elizabeth II Health Sciences Centre; Fluidigm (Canada); Foothills Medical Centre","funders":"","keywords":"Medicine; Minimal residual disease; Oncology; Clinical trial; Chronic lymphocytic leukemia; Clinical endpoint; Surrogate endpoint; Internal medicine; Complete remission; Leukemia; Intensive care medicine; Chemotherapy","score_opus":0.11134316876918608,"score_gpt":0.38885895669780457,"score_spread":0.2775157879286185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2614912162","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09879533,0.89312845,0.000008431781,0.000044304354,0.0004983382,0.005445675,0.0006433938,0.00012380096,0.0013122594],"genre_scores_gemma":[0.033053327,0.9599508,0.00039297342,0.000113527334,0.0010999573,0.0013216187,0.0009455033,0.00041630544,0.0027059808],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9863018,0.0013044319,0.004342975,0.0026897225,0.0029420045,0.002419092],"domain_scores_gemma":[0.98616886,0.0033677705,0.0028940833,0.005935559,0.00043013573,0.0012036171],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014723269,0.002656914,0.008188273,0.0016695372,0.0005431803,0.00039108624,0.0021791076,0.0017674796,0.000107139684],"category_scores_gemma":[0.00068376085,0.0018518064,0.0024444438,0.0013370715,0.002573791,0.0006162332,0.0006600285,0.00057271286,0.00006575434],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014417379,0.000866835,0.00018919846,0.034627713,0.0016077422,0.004875625,0.00088264316,0.00011119534,0.000017158354,0.00063964765,0.0017122484,0.95302826],"study_design_scores_gemma":[0.04948489,0.0033533173,0.0037484663,0.027468257,0.0070537142,0.0034333707,0.00022860366,0.010906074,0.00008868147,0.00007645426,0.8923485,0.0018096238],"about_ca_topic_score_codex":0.016060172,"about_ca_topic_score_gemma":0.0004794671,"teacher_disagreement_score":0.9512186,"about_ca_system_score_codex":0.44323438,"about_ca_system_score_gemma":0.3764756,"threshold_uncertainty_score":0.9995284},"labels":[],"label_agreement":null},{"id":"W2616989782","doi":"10.3109/10428194.2010.532893","title":"Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop","year":2010,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Penn State Hershey Cancer Institute; National Institutes of Health; University of Rochester; Moffitt Cancer Center; University of Virginia; Lymphoma Research Foundation","keywords":"Mantle cell lymphoma; Cyclin D1; Lymphoma; Medicine; Cancer research; Epigenetics; Bioinformatics; Biology; Cell cycle; Immunology; Internal medicine; Cancer; Gene; Genetics","score_opus":0.020294859893623795,"score_gpt":0.27303801513273673,"score_spread":0.25274315523911295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2616989782","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09156496,0.87159324,0.000012598229,0.00019428605,0.0046211635,0.0047076284,0.00061022677,0.00045488414,0.026240997],"genre_scores_gemma":[0.03299253,0.92293936,0.000861406,0.0008198805,0.0014782371,0.0012697908,0.0011053638,0.00084687734,0.037686534],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9847492,0.00067295966,0.0051485584,0.0039808284,0.0025449435,0.002903523],"domain_scores_gemma":[0.9849392,0.001628568,0.004587222,0.006444991,0.00066570623,0.0017342747],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012477173,0.0039328425,0.008316012,0.0010636536,0.0012178774,0.00041728164,0.0022517713,0.0044435314,0.00036744654],"category_scores_gemma":[0.00039944713,0.0028036288,0.0042936695,0.0021617995,0.0019099906,0.00046536984,0.001715682,0.00067308155,0.00065998046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00037142288,0.0040412648,0.0011975821,0.016208421,0.0012540485,0.0068891556,0.0004185211,0.0000024555789,0.00014205254,0.00029590807,0.030792495,0.9383867],"study_design_scores_gemma":[0.02905933,0.00038630064,0.005822372,0.010504355,0.009138064,0.023069838,0.00029404365,0.00008610777,0.003888467,0.00009496651,0.9150153,0.0026408455],"about_ca_topic_score_codex":0.002535698,"about_ca_topic_score_gemma":0.00018543168,"teacher_disagreement_score":0.93574584,"about_ca_system_score_codex":0.012983079,"about_ca_system_score_gemma":0.022756983,"threshold_uncertainty_score":0.997441},"labels":[],"label_agreement":null},{"id":"W2619012808","doi":"10.1080/10428194.2017.1326034","title":"Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Janssen Research and Development","keywords":"Ibrutinib; Mantle cell lymphoma; Temsirolimus; Medicine; Quality of life (healthcare); Internal medicine; Oncology; Clinical trial; Lymphoma; Phases of clinical research; Randomized controlled trial; Leukemia; Discovery and development of mTOR inhibitors; Chronic lymphocytic leukemia","score_opus":0.07370496193561728,"score_gpt":0.3693687295541824,"score_spread":0.2956637676185651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2619012808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98626006,0.0010053552,0.000015462805,0.00018881146,0.00030812688,0.00840022,0.0009275394,0.0001690429,0.0027253844],"genre_scores_gemma":[0.9939965,0.0005136609,0.0004945311,0.00026678888,0.0001318994,0.00041995267,0.003120015,0.00024846641,0.0008082056],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98915,0.0012598612,0.0031543532,0.00270651,0.0021305776,0.0015987306],"domain_scores_gemma":[0.9886148,0.0014850852,0.0027596292,0.005250993,0.00067171507,0.0012178046],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002453384,0.0013369794,0.004378041,0.00060267857,0.0006866151,0.0006451206,0.0033840614,0.0005585453,0.00016654244],"category_scores_gemma":[0.0013279096,0.000999423,0.00018594557,0.0006492258,0.0014271435,0.0014549504,0.002250296,0.00030026986,0.000059754857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.70674187,0.01671436,0.24057992,0.00046647614,0.0033235564,0.00085753785,0.0021343671,0.000017761888,0.00008584744,0.000026761207,0.00075733854,0.028294215],"study_design_scores_gemma":[0.74710006,0.0035894094,0.22781336,0.00087361684,0.0006802783,0.000035962523,0.00062150974,0.017917085,0.00025288868,0.000007148583,0.0002745621,0.00083410414],"about_ca_topic_score_codex":0.18438335,"about_ca_topic_score_gemma":0.005552835,"teacher_disagreement_score":0.17883052,"about_ca_system_score_codex":0.029141026,"about_ca_system_score_gemma":0.021409294,"threshold_uncertainty_score":0.99993813},"labels":[],"label_agreement":null},{"id":"W2703436965","doi":"10.1080/10428194.2017.1334125","title":"Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"Celgene","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Quality of life (healthcare); Internal medicine; Confidence interval; Pediatrics; Oncology","score_opus":0.027634969815474822,"score_gpt":0.2933253349468921,"score_spread":0.2656903651314173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2703436965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99487275,0.0025232416,0.000054303055,0.00025765784,0.00010717716,0.0015628622,0.00014718986,0.000093174625,0.00038167386],"genre_scores_gemma":[0.99600893,0.0019749613,0.0010019252,0.00024388352,0.00006492492,0.00012337866,0.0002797169,0.000100546815,0.00020170848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99495095,0.00037012025,0.00148823,0.0011061386,0.00090629904,0.0011782746],"domain_scores_gemma":[0.9955639,0.0009140824,0.00095452706,0.0011886391,0.00021997234,0.0011588351],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00088018476,0.0007040323,0.0018680878,0.00042727316,0.00060997845,0.00016286543,0.00038335536,0.00040528935,0.000035989022],"category_scores_gemma":[0.0010543369,0.0005737295,0.00018017355,0.00030684605,0.00068409124,0.00053240464,0.00019244089,0.00022856142,0.000011182749],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00886758,0.0005114862,0.85751396,0.0008880871,0.00036869035,0.00040017036,0.00096934306,0.0000104364135,0.00043748738,0.000028769065,0.00004641306,0.1299576],"study_design_scores_gemma":[0.107834056,0.0006757394,0.88729393,0.0014623785,0.00009854324,0.00010963392,0.00010672692,0.0008392577,0.0010356375,0.000031897922,0.000027924678,0.00048424213],"about_ca_topic_score_codex":0.031679243,"about_ca_topic_score_gemma":0.0055614305,"teacher_disagreement_score":0.12947336,"about_ca_system_score_codex":0.0024853048,"about_ca_system_score_gemma":0.0027756114,"threshold_uncertainty_score":0.9996714},"labels":[],"label_agreement":null},{"id":"W2765329477","doi":"10.1080/10428194.2017.1387904","title":"Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada","year":2017,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; St. John’s Health Sciences Centre; Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"","keywords":"Chemoimmunotherapy; Rituximab; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Chemotherapy; Cohort; Population; Clinical trial; Purine analogue; Leukemia; Immunology; Lymphoma","score_opus":0.01682509996718804,"score_gpt":0.2938357957084521,"score_spread":0.277010695741264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765329477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99238855,0.0007669914,0.00037012086,0.00016302493,0.0001808614,0.0047069043,0.0007971845,0.000041704247,0.0005846374],"genre_scores_gemma":[0.99695075,0.00016255063,0.00017946895,0.0004589675,0.00020150193,0.0012425728,0.0001801873,0.00008856807,0.0005354276],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943394,0.00057506125,0.0011480653,0.001212835,0.0015226747,0.001201975],"domain_scores_gemma":[0.99297863,0.0028789632,0.00094411656,0.0021300684,0.00072214624,0.00034605648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017323117,0.00065072946,0.0025507875,0.00027485864,0.0008215301,0.00039775184,0.0014462397,0.00037234306,0.000033572607],"category_scores_gemma":[0.0004132803,0.0005325139,0.0004982513,0.0010808297,0.0013984813,0.00035051507,0.00031058898,0.0002505098,0.0000019563224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09199942,0.0045228717,0.17821112,0.017005317,0.041550122,0.0093043875,0.016324813,0.017325819,0.016533466,0.0015114079,0.033218797,0.5724925],"study_design_scores_gemma":[0.1515875,0.002984672,0.78446853,0.00096275803,0.0016835401,0.0007428417,0.002147968,0.046768416,0.005135488,0.00007610493,0.0024120866,0.001030127],"about_ca_topic_score_codex":0.9320624,"about_ca_topic_score_gemma":0.9457703,"teacher_disagreement_score":0.6062574,"about_ca_system_score_codex":0.114033654,"about_ca_system_score_gemma":0.1434394,"threshold_uncertainty_score":0.99971265},"labels":[],"label_agreement":null},{"id":"W2781752934","doi":"10.1080/10428194.2017.1416364","title":"Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Johnson and Johnson; Astellas Pharma; Celgene; Gilead Sciences","keywords":"Bendamustine; Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Placebo; Quality of life (healthcare); Rituximab; Clinical endpoint; Oncology; Clinical trial; Lymphoma; Leukemia; Pathology","score_opus":0.0091424588777352,"score_gpt":0.24512924548105156,"score_spread":0.23598678660331635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781752934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914584,0.0005379183,0.00017118755,0.00006202502,0.0001648994,0.0068278755,0.00003811637,0.0001409856,0.00059858424],"genre_scores_gemma":[0.9965786,0.00023614195,0.00050615834,0.0003557901,0.0003363784,0.0010658152,0.00023811993,0.00023591568,0.00044710436],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919239,0.00047103784,0.0017652645,0.0022347106,0.0017443155,0.0018607483],"domain_scores_gemma":[0.9949017,0.0015837866,0.00086852326,0.001379018,0.0006762335,0.000590713],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002096185,0.0013706174,0.001979974,0.0009855222,0.00078564096,0.00023630833,0.00055199687,0.00049480883,0.00002777718],"category_scores_gemma":[0.00038468686,0.001013931,0.00019073539,0.0017100465,0.0015083709,0.0006028214,0.0006112783,0.0002730178,0.000008725726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06491352,0.009052085,0.6217577,0.008832851,0.0022443729,0.0014691302,0.046926685,0.0028150857,0.0025025348,0.00065051304,0.00077788363,0.23805763],"study_design_scores_gemma":[0.35490483,0.016380271,0.4169529,0.002367069,0.00078826776,0.00093021424,0.0036447356,0.19973573,0.0027005852,0.00011132566,0.000231827,0.0012522435],"about_ca_topic_score_codex":0.010769079,"about_ca_topic_score_gemma":0.005020913,"teacher_disagreement_score":0.2899913,"about_ca_system_score_codex":0.16523571,"about_ca_system_score_gemma":0.024653086,"threshold_uncertainty_score":0.99990445},"labels":[],"label_agreement":null},{"id":"W2793121285","doi":"10.1080/10428194.2017.1365855","title":"Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Rituximab; Vincristine; Mantle cell lymphoma; Internal medicine; Bortezomib; Hazard ratio; Prednisone; CHOP; Neutropenia; Gastroenterology; Cyclophosphamide; Autologous stem-cell transplantation; Transplantation; Bendamustine; Surgery; Oncology; Lymphoma; Chemotherapy; Confidence interval; Multiple myeloma","score_opus":0.010090361013395142,"score_gpt":0.27379315675973653,"score_spread":0.26370279574634137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793121285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98774683,0.0037073968,0.00016830619,0.00015433494,0.00018239937,0.007152092,0.00044133727,0.000053746375,0.00039354374],"genre_scores_gemma":[0.98972774,0.0069563678,0.0011764383,0.00047181372,0.00015445052,0.000919354,0.00039977022,0.0000966679,0.000097414944],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99391246,0.0005245587,0.0024767339,0.0012510829,0.00094035827,0.00089482457],"domain_scores_gemma":[0.99468684,0.0029555028,0.000828668,0.00078315724,0.0003199836,0.00042582158],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016951829,0.0009185379,0.002814175,0.00055682403,0.0002549782,0.00007411561,0.0003635136,0.00044841398,0.000036599577],"category_scores_gemma":[0.0006274801,0.0006282173,0.00025589502,0.00077574933,0.0009983039,0.00028362632,0.00013905819,0.0001064807,0.0000041263465],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6227808,0.026607776,0.10804724,0.0023566752,0.0009312609,0.0013955365,0.026586305,0.00002655273,0.0012252769,0.00022142672,0.0010694516,0.20875168],"study_design_scores_gemma":[0.6591945,0.004217758,0.32496765,0.0007634513,0.001209026,0.00018179402,0.0013966418,0.0034984343,0.0035529751,0.00008362954,0.00045592154,0.00047822003],"about_ca_topic_score_codex":0.008871607,"about_ca_topic_score_gemma":0.0018679322,"teacher_disagreement_score":0.2169204,"about_ca_system_score_codex":0.0019140013,"about_ca_system_score_gemma":0.0018586834,"threshold_uncertainty_score":0.9996169},"labels":[],"label_agreement":null},{"id":"W2796416879","doi":"10.1080/10428194.2018.1452208","title":"Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; McGill University; Jewish General Hospital","funders":"","keywords":"Panobinostat; Medicine; Internal medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Oncology; Overall survival; Gastroenterology; Biology","score_opus":0.04424755085223389,"score_gpt":0.31793521721302564,"score_spread":0.2736876663607918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2796416879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251056,0.0015872739,0.00020979036,0.0001582072,0.0008334468,0.0035369368,0.0005312909,0.00013613775,0.00049633847],"genre_scores_gemma":[0.99547476,0.00039022043,0.0007192227,0.0010345009,0.0005268779,0.00023982025,0.00042068437,0.00016378911,0.0010301118],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994194,0.00029883633,0.0019614196,0.0017382482,0.0008187348,0.000988787],"domain_scores_gemma":[0.9944789,0.00089777255,0.0011253806,0.0024536997,0.00037979207,0.00066446257],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008909448,0.00094330125,0.001617982,0.00026258032,0.00077934534,0.00015122103,0.0006214885,0.0005367453,0.000023150616],"category_scores_gemma":[0.00030492336,0.0006390871,0.00033333478,0.00049214065,0.00080897653,0.0004720314,0.00077240367,0.00013508448,0.000030337356],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012991421,0.058210395,0.7177869,0.00063284184,0.0018590621,0.00039355058,0.0047979895,0.0000058349924,0.0017588512,0.0002918248,0.0061118263,0.1951595],"study_design_scores_gemma":[0.35785764,0.014609624,0.5742953,0.00036852338,0.0033022407,0.00059906096,0.0026732313,0.0069915154,0.001555238,0.000038563194,0.036747072,0.0009619908],"about_ca_topic_score_codex":0.00075265946,"about_ca_topic_score_gemma":0.00039222802,"teacher_disagreement_score":0.34486622,"about_ca_system_score_codex":0.003729459,"about_ca_system_score_gemma":0.0024140263,"threshold_uncertainty_score":0.999606},"labels":[],"label_agreement":null},{"id":"W2811117276","doi":"10.1080/10428194.2018.1473576","title":"Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"Alberta Cancer Foundation","keywords":"Chemoimmunotherapy; Medicine; Retrospective cohort study; Transplantation; Single Center; Surgery; Follicular lymphoma; Lymphoma; Internal medicine; Rituximab; Oncology","score_opus":0.011123329664823167,"score_gpt":0.2756643720021961,"score_spread":0.26454104233737297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811117276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965522,0.00018672294,0.000032045533,0.000032028725,0.00019850014,0.001908635,0.00065878034,0.00005527477,0.000375771],"genre_scores_gemma":[0.9970388,0.0005637544,0.0005387335,0.00029566017,0.00005558623,0.00031035324,0.0009831699,0.00007594804,0.00013799504],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960435,0.00029566805,0.0013681534,0.0009442021,0.00069901085,0.0006494424],"domain_scores_gemma":[0.9970523,0.0005248441,0.00090085535,0.0006997525,0.0006534379,0.00016878007],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000501525,0.00064267457,0.0016871532,0.0008717022,0.00019185703,0.00005515128,0.00031800006,0.00031136477,0.000011312285],"category_scores_gemma":[0.0001275957,0.0004981533,0.0006008285,0.0018170972,0.00067741616,0.00021687467,0.00005427267,0.00006642364,0.0000033560275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061649503,0.0033140897,0.9521465,0.00013401525,0.0029114892,0.000069895104,0.0067322855,0.000007823033,0.000767836,0.0003504773,0.000080305115,0.027320342],"study_design_scores_gemma":[0.08256508,0.0018882505,0.89592946,0.00029113906,0.0024513933,0.000017165143,0.0003679367,0.0032386095,0.0126836505,0.00004668953,0.00010967151,0.00041098922],"about_ca_topic_score_codex":0.010059548,"about_ca_topic_score_gemma":0.0033199266,"teacher_disagreement_score":0.07640012,"about_ca_system_score_codex":0.0036476096,"about_ca_system_score_gemma":0.00097429403,"threshold_uncertainty_score":0.99974704},"labels":[],"label_agreement":null},{"id":"W2897571764","doi":"10.1080/10428194.2018.1515937","title":"A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†","year":2018,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University; Sunnybrook Health Science Centre; BC Cancer Agency; Princess Margaret Cancer Centre; Health Sciences Centre; Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"","keywords":"Romidepsin; Gemcitabine; Medicine; Internal medicine; Cisplatin; Lymphoma; Dexamethasone; Peripheral T-cell lymphoma; Cancer; Phases of clinical research; Chemotherapy; Oncology; Gastroenterology; Chemistry; Immunology; T cell","score_opus":0.03095222513590106,"score_gpt":0.31236087569468546,"score_spread":0.2814086505587844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897571764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98475575,0.008838539,0.0000032189241,0.00022337965,0.00020750093,0.0053420095,0.00014922807,0.000034879726,0.00044551262],"genre_scores_gemma":[0.99302197,0.004801148,0.000079448255,0.0004857042,0.00019751444,0.0010982936,0.000058811132,0.000082356935,0.0001747875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946968,0.0011408814,0.001489492,0.0010258694,0.00080433197,0.0008426163],"domain_scores_gemma":[0.99642426,0.0011196706,0.00075590966,0.0010126114,0.0002546483,0.00043289858],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016842285,0.000861798,0.0018978752,0.00045537043,0.00068963994,0.0001810775,0.00032063515,0.00032014365,0.000044094166],"category_scores_gemma":[0.00010369151,0.00050664146,0.00023399976,0.0007687529,0.0005561082,0.00021298155,0.000085956504,0.00007761675,0.0000025387233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058600875,0.100376345,0.42878273,0.00018034353,0.0012703872,0.00046735557,0.07782594,0.0000033206343,0.0025992722,0.00025035543,0.0004161301,0.38196772],"study_design_scores_gemma":[0.35244104,0.024088351,0.59964204,0.000121327896,0.0011575696,0.00013538939,0.014297751,0.0014807606,0.0039440067,0.000067020206,0.0021393436,0.00048536574],"about_ca_topic_score_codex":0.25809044,"about_ca_topic_score_gemma":0.17051761,"teacher_disagreement_score":0.38148236,"about_ca_system_score_codex":0.004838402,"about_ca_system_score_gemma":0.0021990335,"threshold_uncertainty_score":0.9997385},"labels":[],"label_agreement":null},{"id":"W2909446572","doi":"10.1080/10428194.2018.1562180","title":"Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Refractory (planetary science); Chronic lymphocytic leukemia; Adverse effect; Syk; Phases of clinical research; Leukemia; Oncology; Chemotherapy; Tyrosine kinase; Receptor","score_opus":0.008657355297071786,"score_gpt":0.25424940007524544,"score_spread":0.24559204477817365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2909446572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877868,0.0011108064,0.000009176239,0.000027464832,0.00020911725,0.008253513,0.00015654216,0.00036450246,0.0020820466],"genre_scores_gemma":[0.99109405,0.0007533093,0.00047775146,0.0002533025,0.0002924553,0.0005517757,0.0005335336,0.00047652845,0.005567263],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98847145,0.0006396284,0.0027888648,0.0029374443,0.002771113,0.0023915146],"domain_scores_gemma":[0.9927727,0.0009509694,0.0014187895,0.002984812,0.0007511355,0.0011216088],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012640483,0.0018327143,0.003063739,0.0013025502,0.00025609112,0.00017596254,0.0009135167,0.00096116395,0.00030925413],"category_scores_gemma":[0.0002572066,0.0013096979,0.00034253774,0.0027351847,0.0008121526,0.0007763642,0.0003476139,0.0005665284,0.00019664921],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.61723435,0.015181473,0.176992,0.006144222,0.0034489988,0.004165655,0.016626213,0.0021254295,0.018074522,0.00004566779,0.005695185,0.13426627],"study_design_scores_gemma":[0.85797596,0.056661453,0.03641014,0.0038863714,0.0007765232,0.00044926247,0.0019788328,0.01254829,0.017576104,0.000005704543,0.009464492,0.0022668955],"about_ca_topic_score_codex":0.012997337,"about_ca_topic_score_gemma":0.0006450981,"teacher_disagreement_score":0.24074157,"about_ca_system_score_codex":0.25452447,"about_ca_system_score_gemma":0.10060454,"threshold_uncertainty_score":0.99944174},"labels":[],"label_agreement":null},{"id":"W2910383185","doi":"10.1080/10428194.2018.1563691","title":"Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; University of Calgary; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Oncology; Autologous stem-cell transplantation; Lymphoma; Randomized controlled trial; Transplantation; Aggressive lymphoma; Randomization; Subgroup analysis; Gastroenterology; Surgery; Rituximab; Confidence interval","score_opus":0.005829918759344031,"score_gpt":0.24275891050548834,"score_spread":0.23692899174614432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910383185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883006,0.0013724476,0.0011371141,0.00015771635,0.0011743454,0.004441647,0.00048061847,0.00034801447,0.0025874458],"genre_scores_gemma":[0.98803777,0.0032263955,0.0015224459,0.0009613399,0.00052396173,0.0013930134,0.0025063439,0.0001786727,0.0016500893],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99348044,0.00031667828,0.0017034776,0.00213651,0.0009829815,0.0013798797],"domain_scores_gemma":[0.99469423,0.0011880597,0.0016141806,0.0013299292,0.00040853565,0.0007650588],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00064681435,0.0013063999,0.002399559,0.0010796691,0.000578095,0.0003121347,0.00044820204,0.0010375006,0.0002414064],"category_scores_gemma":[0.0001970436,0.0011584125,0.0012341293,0.0013594194,0.0003193808,0.0005508823,0.00013467782,0.00014450704,0.0003843659],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21123803,0.0071643456,0.16803783,0.003215681,0.016358562,0.003690101,0.00778397,0.0008157162,0.0076442957,0.005189372,0.005728289,0.5631338],"study_design_scores_gemma":[0.5569246,0.008766156,0.33770716,0.00078714965,0.01920746,0.001718618,0.0010849627,0.017509762,0.048867084,0.0010989258,0.0040054526,0.002322721],"about_ca_topic_score_codex":0.0077759516,"about_ca_topic_score_gemma":0.00031139315,"teacher_disagreement_score":0.5608111,"about_ca_system_score_codex":0.007706749,"about_ca_system_score_gemma":0.0033533107,"threshold_uncertainty_score":0.99996877},"labels":[],"label_agreement":null},{"id":"W2912598520","doi":"10.1080/10428194.2018.1498490","title":"Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders","year":2019,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Obinutuzumab; Rituximab; Medicine; Chronic lymphocytic leukemia; CD20; Follicular lymphoma; Lymphoma; Immunology; Antibody; Monoclonal antibody; Lymphoproliferative disorders; Oncology; Internal medicine; Leukemia","score_opus":0.03349201169399164,"score_gpt":0.34155322463289023,"score_spread":0.3080612129388986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912598520","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025770241,0.9586641,0.000048926147,0.000046612335,0.0010711878,0.0071274103,0.00018014398,0.0005071108,0.0065842476],"genre_scores_gemma":[0.0077533196,0.98167485,0.00035281896,0.0006566182,0.0010278168,0.0011717998,0.001330052,0.0009141606,0.005118577],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9853822,0.0009418011,0.0034976301,0.004278148,0.0022773524,0.0036228509],"domain_scores_gemma":[0.9918277,0.0016041802,0.0014603894,0.0034248007,0.00032318707,0.0013597113],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014493663,0.0034774258,0.008667381,0.0024361364,0.0005157117,0.00055170036,0.0016401871,0.0033522637,0.00024330463],"category_scores_gemma":[0.00054341834,0.0029241915,0.0021263647,0.0030298077,0.0011248696,0.0007702844,0.0012544506,0.0011516756,0.00089751405],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00093511346,0.00029864008,0.00014583078,0.02574668,0.0009939623,0.0013738162,0.00069355045,0.00001908313,0.000041447653,0.00033721788,0.0008213774,0.9685933],"study_design_scores_gemma":[0.07724666,0.0011052988,0.000382093,0.020678926,0.0016392209,0.006502877,0.0003739727,0.012050982,0.00006777579,0.00014452444,0.8763864,0.0034212468],"about_ca_topic_score_codex":0.012340509,"about_ca_topic_score_gemma":0.00032492442,"teacher_disagreement_score":0.96517205,"about_ca_system_score_codex":0.2583163,"about_ca_system_score_gemma":0.1749903,"threshold_uncertainty_score":0.9998804},"labels":[],"label_agreement":null},{"id":"W2930076345","doi":"10.1080/10428194.2019.1576872","title":"Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Kite Pharma; Celgene; Regeneron Pharmaceuticals; Novartis; Servier; Amgen; Pfizer; Roche","keywords":"Blinatumomab; Salvage therapy; Medicine; Chemotherapy; Hematopoietic stem cell transplantation; Refractory (planetary science); Internal medicine; Lymphoblastic Leukemia; Oncology; Leukemia; Transplantation; Biology","score_opus":0.012450703097188843,"score_gpt":0.2686966968504686,"score_spread":0.2562459937532798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2930076345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836483,0.0012012528,0.00018640562,0.00062741246,0.0012912031,0.005245895,0.00021653419,0.00043064644,0.007152354],"genre_scores_gemma":[0.9766115,0.0017659933,0.0026385952,0.0022085086,0.0006026291,0.0011135506,0.00040613985,0.0006067203,0.014046362],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9891147,0.00027166985,0.002318566,0.0030821736,0.0016817475,0.0035311347],"domain_scores_gemma":[0.9928222,0.0029015804,0.0006176015,0.0021349578,0.0003542734,0.0011694456],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001215362,0.0019507699,0.0028928895,0.0018768653,0.00035038058,0.0003392599,0.0012987644,0.0018072593,0.00052635086],"category_scores_gemma":[0.00054365135,0.0017157727,0.0006862862,0.002469448,0.00064383494,0.0009326355,0.00063952495,0.00065528596,0.00071008765],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.42785195,0.008039434,0.14719139,0.017327556,0.0045999954,0.021857265,0.017473824,0.002579605,0.07185576,0.0024538261,0.07422437,0.20454502],"study_design_scores_gemma":[0.5275181,0.0088061355,0.1931174,0.003300517,0.001064715,0.0030027558,0.0016134921,0.14417644,0.037201658,0.00053592527,0.07469242,0.004970432],"about_ca_topic_score_codex":0.0015251001,"about_ca_topic_score_gemma":0.0011123765,"teacher_disagreement_score":0.19957459,"about_ca_system_score_codex":0.04778494,"about_ca_system_score_gemma":0.015780676,"threshold_uncertainty_score":0.9994886},"labels":[],"label_agreement":null},{"id":"W2945425711","doi":"10.1080/10428194.2019.1613539","title":"Management of cardiovascular health in acute leukemia: a national survey","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Vancouver General Hospital","funders":"","keywords":"Medicine; Cardiotoxicity; Comorbidity; Intensive care medicine; Internal medicine; Disease; Health care; Hematology; Multidisciplinary approach; Anthracycline; Chemotherapy; Cancer","score_opus":0.015152967176642013,"score_gpt":0.2615875773783027,"score_spread":0.24643461020166066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2945425711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9825735,0.0028796373,0.00017773952,0.00017451392,0.0002925645,0.0013658601,0.00009905206,0.0001016133,0.012335532],"genre_scores_gemma":[0.99109924,0.004915894,0.00083387527,0.0012776938,0.00012233444,0.00007872214,0.00038023695,0.000086957225,0.001205061],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958705,0.00026488045,0.0009802884,0.0009744559,0.0011627956,0.00074711017],"domain_scores_gemma":[0.99811924,0.00015475153,0.00030942028,0.00082853093,0.00024981739,0.00033823305],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017031943,0.00052885275,0.0014815634,0.00045530865,0.0001156183,0.00004493708,0.00026238404,0.0004433427,0.00005664741],"category_scores_gemma":[0.000035479094,0.00053553743,0.00055214425,0.0009638097,0.00017338489,0.00026135545,0.00014835654,0.00018627301,0.0000538534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004398452,0.0007895872,0.054697603,0.00456354,0.012612542,0.00092971197,0.002811542,0.002886997,0.018429348,0.007878847,0.0045353277,0.8854665],"study_design_scores_gemma":[0.049708556,0.00070717424,0.88691515,0.0015050467,0.0005484693,0.0012354719,0.00070721307,0.0044533205,0.025865795,0.00071124884,0.026491417,0.0011511444],"about_ca_topic_score_codex":0.0035882369,"about_ca_topic_score_gemma":0.000071222545,"teacher_disagreement_score":0.8843154,"about_ca_system_score_codex":0.013410267,"about_ca_system_score_gemma":0.004517695,"threshold_uncertainty_score":0.9997096},"labels":[],"label_agreement":null},{"id":"W2948560683","doi":"10.1080/10428194.2019.1620940","title":"Anti-leukemia effect of vitamin K3 is mediated through mitochondrial complexes I and II","year":2019,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Guelph","funders":"University of Guelph","keywords":"Leukemia; Cancer research; Mitochondrion; Chemistry; Medicine; Internal medicine; Biochemistry","score_opus":0.00586690514693654,"score_gpt":0.2236275928983494,"score_spread":0.21776068775141286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2948560683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775663,0.010702251,0.0001310081,0.003715427,0.001805378,0.0016262273,0.0008456685,0.00015477004,0.0034529443],"genre_scores_gemma":[0.7534532,0.021362763,0.0017729308,0.17806634,0.012953257,0.00058732234,0.012032051,0.0013407475,0.018431405],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914712,0.0006425003,0.0017831892,0.0030319944,0.0012758232,0.0017952997],"domain_scores_gemma":[0.99510765,0.0006967041,0.001342775,0.0021673678,0.00036712378,0.00031835554],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005033763,0.0023017179,0.002998538,0.00037227734,0.00061928324,0.00024781103,0.0014649658,0.004919772,0.000106596795],"category_scores_gemma":[0.00042104055,0.002089685,0.0008008272,0.00055371685,0.0015659382,0.000079652455,0.0014345716,0.0008746747,0.00007174541],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092455914,0.00006534015,0.0013712163,0.0038589914,0.001098357,0.00036387975,0.0006057434,0.00001947751,0.24315137,0.00003828731,0.74091196,0.0075908345],"study_design_scores_gemma":[0.013267341,0.0021131046,0.00065897626,0.0006704117,0.0007476666,0.00091559347,0.00008366089,0.00031838572,0.32026756,0.00010241602,0.658666,0.0021888693],"about_ca_topic_score_codex":0.00093659695,"about_ca_topic_score_gemma":0.000015955216,"teacher_disagreement_score":0.22411315,"about_ca_system_score_codex":0.002016197,"about_ca_system_score_gemma":0.004412317,"threshold_uncertainty_score":0.9989722},"labels":[],"label_agreement":null},{"id":"W2955661053","doi":"10.1080/10428194.2019.1620941","title":"Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"CancerCare Manitoba Foundation; Manitoba Health Research Council","keywords":"Medicine; Chronic lymphocytic leukemia; Skin cancer; Chemotherapy; Internal medicine; Cancer; Incidence (geometry); Leukemia; Oncology; Dermatology","score_opus":0.007728653774308125,"score_gpt":0.26915934534176517,"score_spread":0.261430691567457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955661053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919606,0.0025628896,0.00001945265,0.000037747115,0.00025875657,0.004194003,0.0004101516,0.00010093144,0.00045547987],"genre_scores_gemma":[0.9948974,0.0033030591,0.000074626274,0.0001496575,0.0002552367,0.00043296427,0.00017587146,0.00024373583,0.00046739817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99316305,0.00044983398,0.0014188437,0.001799455,0.0013307083,0.0018380936],"domain_scores_gemma":[0.9925184,0.004071514,0.0008725334,0.0013960056,0.00039980878,0.0007416871],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001276348,0.001327655,0.0026650936,0.0006287667,0.0003624705,0.00018057917,0.0005624758,0.0006281032,0.00006292514],"category_scores_gemma":[0.0006605098,0.0008511823,0.0004774696,0.00101611,0.0015451387,0.00037978558,0.00037282234,0.00038442918,0.000013460756],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.029250905,0.00031348804,0.88318944,0.0018851287,0.0016154407,0.00016432206,0.004326646,0.0126415845,0.00031142464,0.00049176853,0.00062733924,0.0651825],"study_design_scores_gemma":[0.20294042,0.002252546,0.7022319,0.00086237106,0.00021050475,0.0001205139,0.00042216445,0.08885928,0.00095325743,0.00011201862,0.0002015727,0.0008334516],"about_ca_topic_score_codex":0.10604014,"about_ca_topic_score_gemma":0.003218318,"teacher_disagreement_score":0.18095756,"about_ca_system_score_codex":0.1465837,"about_ca_system_score_gemma":0.049081262,"threshold_uncertainty_score":0.9999475},"labels":[],"label_agreement":null},{"id":"W2975621535","doi":"10.1080/10428194.2019.1660977","title":"Granulocyte transfusions – bridging to allogeneic hematopoietic stem cell transplantation","year":2019,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Neutropenia; Medicine; Hematopoietic stem cell transplantation; Bridging (networking); Haematopoiesis; Granulocyte; Transplantation; Stem cell; Chemotherapy; Disease; Intensive care medicine; Immunology; Internal medicine; Biology","score_opus":0.0119281698805527,"score_gpt":0.23265665868198396,"score_spread":0.22072848880143126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975621535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9525736,0.0031370837,0.0015036399,0.031999994,0.001038074,0.002705108,0.00043956158,0.0004746872,0.006128274],"genre_scores_gemma":[0.6826612,0.0032730084,0.00038719195,0.28773543,0.0019942198,0.00021259279,0.0010885868,0.00039040914,0.022257378],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99259746,0.0002800024,0.0014667996,0.0024015056,0.0014937224,0.001760505],"domain_scores_gemma":[0.9964403,0.0004947844,0.00038127243,0.0017690662,0.000267406,0.00064715487],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00047698486,0.001539583,0.0022694839,0.00067033246,0.00052063446,0.00021067372,0.0006068574,0.0022910817,0.000174968],"category_scores_gemma":[0.0000259513,0.0014517173,0.0009157921,0.0007544968,0.0003126511,0.00026598002,0.000117213945,0.0008926526,0.00063369126],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036591191,0.0003525745,0.011145083,0.018607365,0.0007576871,0.011750842,0.00685271,0.00010311277,0.02968501,0.00008234219,0.7879755,0.12902866],"study_design_scores_gemma":[0.02799621,0.0015148337,0.10960486,0.0052323877,0.0042622834,0.0057026716,0.0010702948,0.00093328446,0.023429027,0.00013973564,0.8151925,0.004921894],"about_ca_topic_score_codex":0.0009896333,"about_ca_topic_score_gemma":0.00013142238,"teacher_disagreement_score":0.2699124,"about_ca_system_score_codex":0.0061874953,"about_ca_system_score_gemma":0.0048259054,"threshold_uncertainty_score":0.9997353},"labels":[],"label_agreement":null},{"id":"W2981763967","doi":"10.1080/10428194.2019.1675879","title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Dasatinib; Discontinuation; Medicine; Myeloid leukemia; Internal medicine; Imatinib; Tyrosine-kinase inhibitor; Adverse effect; Tyrosine kinase; Oncology; Gastroenterology; Cancer; Receptor","score_opus":0.005489341495418336,"score_gpt":0.237756561886154,"score_spread":0.23226722039073566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981763967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886814,0.003611557,0.00007097985,0.00020418363,0.00027230312,0.0059250197,0.000064382875,0.00022044253,0.00094977586],"genre_scores_gemma":[0.9959876,0.0002713385,0.00027251727,0.00046863142,0.00021948872,0.00055528875,0.0003368316,0.00026303937,0.0016252449],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99247026,0.00068780925,0.0014137125,0.0021316565,0.0015894821,0.0017070612],"domain_scores_gemma":[0.9954694,0.0006597249,0.0006488294,0.002334487,0.0002657352,0.000621806],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012396532,0.0013648468,0.0016398,0.00056770426,0.0004887492,0.00031174612,0.0006338631,0.0005489395,0.0002009546],"category_scores_gemma":[0.00023297676,0.0010014595,0.00020979025,0.0011872357,0.00057460583,0.00078975526,0.0005378468,0.00048088736,0.00012287006],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.028162407,0.0030944948,0.65694654,0.0007544224,0.0017065163,0.001338179,0.0069860374,0.0012462144,0.008746474,0.0004095305,0.0005692219,0.29003996],"study_design_scores_gemma":[0.15715867,0.008724243,0.8130581,0.0006995277,0.000684537,0.00027096728,0.0012849207,0.010900307,0.002171424,0.00005100688,0.0038053708,0.0011909519],"about_ca_topic_score_codex":0.0029697795,"about_ca_topic_score_gemma":0.0013027863,"teacher_disagreement_score":0.288849,"about_ca_system_score_codex":0.04769249,"about_ca_system_score_gemma":0.011627966,"threshold_uncertainty_score":0.99991024},"labels":[],"label_agreement":null},{"id":"W2990938107","doi":"10.1080/10428194.2019.1688320","title":"Consolidation outcomes in CPX-351 versus cytarabine/daunorubicin-treated older patients with high-risk/secondary acute myeloid leukemia","year":2019,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Medicine; Cytarabine; Daunorubicin; Internal medicine; Myeloid leukemia; Population; Leukemia; Surgery; Oncology","score_opus":0.006292642361575587,"score_gpt":0.23580892617668242,"score_spread":0.22951628381510683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990938107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98810786,0.00044541864,0.00003669634,0.00027353133,0.000802284,0.0035357117,0.00037996052,0.0005241889,0.0058943755],"genre_scores_gemma":[0.9886045,0.0009454369,0.0010875654,0.001307111,0.00025965777,0.00031630482,0.0018926233,0.00040457782,0.0051822327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99057525,0.00046707687,0.0018417552,0.0026214123,0.0019768388,0.0025176387],"domain_scores_gemma":[0.9939256,0.0010724658,0.00085859327,0.0022721016,0.0006994522,0.0011718109],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007504465,0.0018232865,0.0027387526,0.0014819619,0.0005047147,0.00030493538,0.0008794932,0.0012955033,0.0007782045],"category_scores_gemma":[0.00030810057,0.0015116448,0.0004377246,0.0018967233,0.00076538476,0.001257246,0.0005876448,0.0010400211,0.0009980996],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016433382,0.0006285358,0.89189607,0.00046950864,0.0020729823,0.0010550125,0.0010594035,0.00019889098,0.0025090447,0.00039369517,0.0031522168,0.08013127],"study_design_scores_gemma":[0.13101566,0.002335869,0.8504254,0.00050324085,0.00088263693,0.00028440688,0.0004998541,0.002301486,0.006285353,0.00007311339,0.0037607213,0.0016322559],"about_ca_topic_score_codex":0.011143366,"about_ca_topic_score_gemma":0.00059814507,"teacher_disagreement_score":0.11458227,"about_ca_system_score_codex":0.028980039,"about_ca_system_score_gemma":0.009832718,"threshold_uncertainty_score":0.99977976},"labels":[],"label_agreement":null},{"id":"W2993163009","doi":"10.1080/10428194.2019.1697877","title":"The option of treatment and outcomes for patients with AIDS-related diffuse large B-cell lymphoma from a resource-limited setting in China","year":2019,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Cart; Lymphoma; Antiretroviral therapy; Medicine; Human immunodeficiency virus (HIV); Diffuse large B-cell lymphoma; China; Intensive care medicine; Oncology; Internal medicine; Virology; Viral load; Political science; Geography","score_opus":0.004419475394368583,"score_gpt":0.20793332043203167,"score_spread":0.2035138450376631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993163009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859602,0.002765884,0.000012102488,0.006188632,0.00030099144,0.0028635762,0.0009978062,0.0001242203,0.00078660116],"genre_scores_gemma":[0.95863503,0.0016662001,0.00024307075,0.02984932,0.00034374464,0.0004572992,0.004709554,0.0003549625,0.003740834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486315,0.00027048774,0.0013551221,0.0014324563,0.0007106278,0.0013681543],"domain_scores_gemma":[0.9961044,0.0012173862,0.0012132959,0.0010601993,0.00018243451,0.00022226006],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003487483,0.0012945624,0.0020884317,0.0004620761,0.0004650117,0.00016259153,0.00034731205,0.0017784403,0.000010634243],"category_scores_gemma":[0.00016835643,0.000870615,0.0004883838,0.00049897505,0.00032947035,0.00020241117,0.00016527015,0.0003389045,0.000008160171],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011461923,0.004336579,0.55638546,0.0020280615,0.0044270814,0.00038778153,0.007814462,0.000054674212,0.00017181685,0.0001361388,0.11449948,0.29829654],"study_design_scores_gemma":[0.30546033,0.004141996,0.46749902,0.0014344769,0.0021004092,0.000039366554,0.0011350272,0.0036800965,0.00012874717,0.00028004526,0.2125049,0.0015956091],"about_ca_topic_score_codex":0.004014152,"about_ca_topic_score_gemma":0.00021331164,"teacher_disagreement_score":0.29670092,"about_ca_system_score_codex":0.01030176,"about_ca_system_score_gemma":0.0024849253,"threshold_uncertainty_score":0.9999806},"labels":[],"label_agreement":null},{"id":"W3012118048","doi":"10.1080/10428194.2020.1734594","title":"IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Princess Margaret Cancer Centre; University Health Network; McGill University; University of Alberta; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Chronic lymphocytic leukemia; Toxicity; Gastroenterology; Oncology; Leukemia","score_opus":0.012710099089056265,"score_gpt":0.25567834900218644,"score_spread":0.24296824991313018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3012118048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075186,0.005134879,0.000011119042,0.000106318425,0.00011725166,0.0031283924,0.000113360235,0.00022812378,0.00040867267],"genre_scores_gemma":[0.9967407,0.0014942631,0.00017639951,0.0005750541,0.00017209054,0.00017787666,0.00017790671,0.00024223402,0.00024349938],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920836,0.0004863288,0.0017900984,0.0023536738,0.0016754495,0.0016108112],"domain_scores_gemma":[0.995411,0.00072821026,0.0008007487,0.0010729814,0.00039441904,0.0015926365],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008892646,0.0013431787,0.0024506834,0.0008325037,0.00054358644,0.0001861461,0.00044568893,0.00091342215,0.000058291404],"category_scores_gemma":[0.00077403255,0.0011842827,0.00015126773,0.0016817524,0.001345808,0.0007332564,0.0010128849,0.00048393817,0.0000076045067],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10242456,0.00862267,0.38641867,0.008691515,0.008624648,0.006222683,0.055692293,0.00031701222,0.012270851,0.00034781065,0.006105786,0.4042615],"study_design_scores_gemma":[0.56511617,0.031012742,0.3384935,0.0016647134,0.0012484947,0.00058506767,0.0036161318,0.05344158,0.0012209661,0.000046388148,0.0016298575,0.0019243674],"about_ca_topic_score_codex":0.007405919,"about_ca_topic_score_gemma":0.00052690034,"teacher_disagreement_score":0.46269163,"about_ca_system_score_codex":0.09334176,"about_ca_system_score_gemma":0.033855006,"threshold_uncertainty_score":0.99993193},"labels":[],"label_agreement":null},{"id":"W3020462214","doi":"10.1080/10428194.2020.1749607","title":"Healthcare resource utilization in myeloproliferative neoplasms: a population-based study from Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; Entomological Society of Canada; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Polycythemia vera; Myelofibrosis; Population; Cohort; Health care; Comorbidity; Venous thrombosis; Internal medicine; Essential thrombocythemia; Thrombosis; Emergency medicine; Surgery; Environmental health","score_opus":0.02424562514465522,"score_gpt":0.25278177620426145,"score_spread":0.22853615105960623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3020462214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269664,0.00091484486,0.000028211942,0.0032021066,0.00015332541,0.0021576327,0.00015438756,0.00013957552,0.00055325736],"genre_scores_gemma":[0.9861825,0.000049837057,0.00041677855,0.011190306,0.0002509237,0.0004219938,0.001187267,0.00009497696,0.0002054122],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954166,0.0003402374,0.0010976007,0.0014231933,0.0009674202,0.00075495365],"domain_scores_gemma":[0.99756473,0.00045721227,0.00032171592,0.00056755723,0.0001941359,0.000894666],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00017355567,0.000791407,0.001280559,0.00020522584,0.00038212354,0.000121687524,0.00020768766,0.00032226765,0.00024304629],"category_scores_gemma":[0.00019836103,0.0007273669,0.0001397674,0.0007427171,0.000062178406,0.0001947751,0.00010794133,0.00024290466,0.000017208846],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0017116889,0.00046403447,0.9707844,0.0001112873,0.00022798472,0.0010244849,0.0066646244,0.0005246477,0.000031974545,0.00017073078,0.0016236228,0.016660478],"study_design_scores_gemma":[0.022310447,0.0011212266,0.9545682,0.00029354973,0.00022233583,0.000039246515,0.0025282083,0.0101399645,0.00084321806,0.000057012996,0.0072481823,0.00062837533],"about_ca_topic_score_codex":0.9590221,"about_ca_topic_score_gemma":0.97026104,"teacher_disagreement_score":0.020598758,"about_ca_system_score_codex":0.020615583,"about_ca_system_score_gemma":0.016462846,"threshold_uncertainty_score":0.99951774},"labels":[],"label_agreement":null},{"id":"W3028254761","doi":"10.1080/10428194.2020.1765234","title":"Changes in primary outcome and sample size measures after initiation of accrual among trials supporting approval of drugs for hematological malignancies by the US food and drug administration","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Sample size determination; Medicine; Accrual; Clinical trial; Internal medicine; Food and drug administration; Pharmacology; Accounting","score_opus":0.16665121526340146,"score_gpt":0.3539382664629288,"score_spread":0.18728705119952735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028254761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99036187,0.0025933976,0.00045325293,0.004117289,0.00009333915,0.0013164165,0.0009296652,0.000026565125,0.000108202126],"genre_scores_gemma":[0.99447757,0.00026257613,0.001435133,0.0032380621,0.00012427462,0.00035399877,0.000056787845,0.000030713465,0.000020886138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99436516,0.0004643969,0.003972115,0.00063792954,0.00016653075,0.0003938509],"domain_scores_gemma":[0.9903,0.006284632,0.002918982,0.00024386171,0.00007717753,0.00017536162],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009759679,0.0003055329,0.0017682564,0.00013559592,0.00014423963,0.00009173656,0.00018376579,0.00026305843,0.000019033896],"category_scores_gemma":[0.009965204,0.00028605878,0.00013242246,0.0001807904,0.00030218883,0.00037400777,0.0001019855,0.00007107234,0.0000015050839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011989613,0.00013687657,0.9553877,0.004297551,0.00022122708,0.0000037000464,0.017771354,0.000024520547,0.0004213778,0.008905553,0.0017439879,0.009887164],"study_design_scores_gemma":[0.014878237,0.0008547251,0.95496935,0.00029884875,0.00012124665,0.0000471332,0.008049405,0.005924929,0.0035067874,0.007930104,0.0025131004,0.00090614444],"about_ca_topic_score_codex":0.0007288418,"about_ca_topic_score_gemma":0.0003789545,"teacher_disagreement_score":0.013679275,"about_ca_system_score_codex":0.0007438811,"about_ca_system_score_gemma":0.0005799222,"threshold_uncertainty_score":0.9999592},"labels":[],"label_agreement":null},{"id":"W3032936560","doi":"10.1080/10428194.2020.1772472","title":"Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC; Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont; University of Toronto","funders":"","keywords":"Follicular lymphoma; Rituximab; Medicine; Oncology; Internal medicine; Chemotherapy; Lymphoma; Follicular phase; Stage (stratigraphy)","score_opus":0.007847507902116808,"score_gpt":0.21658497532236864,"score_spread":0.20873746742025184,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032936560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955634,0.0012103185,0.00006604604,0.00056368514,0.00011788776,0.0014623315,0.0001680205,0.00021301702,0.00063531694],"genre_scores_gemma":[0.992723,0.00046527962,0.0023640026,0.0033059518,0.00012917694,0.00018338529,0.00041280413,0.00019681144,0.00021957626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955467,0.00009804296,0.0010836537,0.0013777049,0.0009778761,0.00091605133],"domain_scores_gemma":[0.9970933,0.00028682276,0.0006533865,0.0007910947,0.00025345339,0.0009218963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018746336,0.0011690604,0.0023464002,0.00022242762,0.0003444001,0.0001355701,0.00022821578,0.00040873993,0.00007051881],"category_scores_gemma":[0.00008528223,0.0008189255,0.0003705617,0.0005428468,0.00034137422,0.00037179122,0.0001518319,0.00009959687,0.0000152328],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051832795,0.0013167766,0.8929477,0.00037701926,0.0025383064,0.0010751928,0.0018129132,0.0000033564681,0.0002474008,0.00018626198,0.00014075213,0.09417106],"study_design_scores_gemma":[0.1135379,0.0047080144,0.86978483,0.00051572686,0.0014920905,0.00019342036,0.0003720082,0.0006020805,0.004642379,0.000020814168,0.0032896209,0.0008411313],"about_ca_topic_score_codex":0.00041408595,"about_ca_topic_score_gemma":0.000032672044,"teacher_disagreement_score":0.10835462,"about_ca_system_score_codex":0.003003072,"about_ca_system_score_gemma":0.0016205562,"threshold_uncertainty_score":0.9994262},"labels":[],"label_agreement":null},{"id":"W3041025600","doi":"10.1080/10428194.2020.1789626","title":"Severe infections following treatment for childhood cancer: a report from CYP-C","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; SickKids Foundation; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"Canadian Institutes of Health Research; Public Health Agency of Canada","keywords":"Medicine; Leukemia; Hazard ratio; Internal medicine; Confidence interval; Cancer; Cumulative incidence; Population; Incidence (geometry); Childhood leukemia; Cohort; Multivariate analysis; Univariate analysis; Proportional hazards model; Oncology; Lymphoblastic Leukemia; Environmental health","score_opus":0.024315173166287982,"score_gpt":0.29210512193379096,"score_spread":0.26778994876750295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041025600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98312056,0.004736361,0.0005495247,0.0051535424,0.0010481268,0.001896358,0.00048809106,0.00072101544,0.0022864484],"genre_scores_gemma":[0.9823754,0.0009965632,0.0018676999,0.009248421,0.0027725194,0.00082761305,0.0007538809,0.00021370387,0.00094420946],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951978,0.00012423181,0.0012796121,0.0016895655,0.0007361378,0.0009726805],"domain_scores_gemma":[0.99663997,0.00055236946,0.00049708923,0.00096100697,0.00015657229,0.0011930175],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002728834,0.00092043227,0.0016456814,0.0001733868,0.00061586685,0.00016718607,0.0002721128,0.00051586377,0.0001282458],"category_scores_gemma":[0.00045690069,0.00087695295,0.0009833835,0.00060065195,0.00015662712,0.0003625706,0.00016403814,0.00015218396,0.000051739447],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0047860565,0.0027351924,0.25054762,0.0013790616,0.011096364,0.0049394886,0.045734584,0.00037636238,0.0070397435,0.0006264313,0.06170286,0.6090362],"study_design_scores_gemma":[0.0982596,0.0036293948,0.39866862,0.0016015467,0.0047735944,0.0036991742,0.0035267272,0.004477463,0.011317784,0.000925063,0.46591195,0.0032090833],"about_ca_topic_score_codex":0.019791657,"about_ca_topic_score_gemma":0.0010337207,"teacher_disagreement_score":0.60582715,"about_ca_system_score_codex":0.00790584,"about_ca_system_score_gemma":0.007154929,"threshold_uncertainty_score":0.99936813},"labels":[],"label_agreement":null},{"id":"W3045653281","doi":"10.1080/10428194.2020.1795161","title":"Prolonged progression free survival in a subset of responders to the combination of brentuximab vedotin and bendamustine in heavily treated patients with relapsed or refractory Hodgkin lymphoma: updated results from an international multi-center phase I/II experience","year":2020,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Princess Margaret Cancer Centre; University of Toronto","funders":"H. Lundbeck A/S; Seattle Genetics; AstraZeneca","keywords":"Brentuximab vedotin; Bendamustine; Medicine; Oncology; Internal medicine; Refractory (planetary science); Lymphoma; Malignancy; Hodgkin lymphoma; Biology; Rituximab","score_opus":0.020722327468934282,"score_gpt":0.2885611615219742,"score_spread":0.26783883405303993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045653281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779122,0.0002337628,0.000004665941,0.015188474,0.00032816303,0.002926251,0.0032559652,0.00008865177,0.000061899256],"genre_scores_gemma":[0.9736729,0.00023069252,0.0006482362,0.0112508,0.00021096526,0.00046724995,0.013250886,0.00014935256,0.00011890809],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931316,0.0006521279,0.0020013838,0.0018799866,0.0015417296,0.0007932219],"domain_scores_gemma":[0.99603117,0.0005502213,0.001257562,0.0013325402,0.00045197413,0.0003765239],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004292404,0.0011056878,0.0018418581,0.0008584524,0.00018839378,0.00009225634,0.00076177163,0.00090488046,0.000026140266],"category_scores_gemma":[0.000598285,0.0007528489,0.00016589563,0.0011092324,0.00050983403,0.00047628884,0.00048506953,0.00037263808,0.0000029081164],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22923917,0.03372565,0.455432,0.00074811635,0.0015254399,0.00715109,0.029251982,0.000026245982,0.0014752959,0.000022281387,0.04049668,0.20090607],"study_design_scores_gemma":[0.3027945,0.008636601,0.6639245,0.0024944628,0.00035542648,0.000083807565,0.0006609979,0.0022595155,0.0021972223,0.000009891321,0.015744379,0.00083866075],"about_ca_topic_score_codex":0.006133379,"about_ca_topic_score_gemma":0.0014490223,"teacher_disagreement_score":0.20849255,"about_ca_system_score_codex":0.0048270863,"about_ca_system_score_gemma":0.0020742253,"threshold_uncertainty_score":0.9994922},"labels":[],"label_agreement":null},{"id":"W3048067521","doi":"10.1080/10428194.2020.1795159","title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute","keywords":"Ibrutinib; Bendamustine; Medicine; Chronic lymphocytic leukemia; Internal medicine; Rituximab; Ofatumumab; Placebo; Hazard ratio; Alemtuzumab; Oncology; Lymphoma; Gastroenterology; Leukemia; Confidence interval; Transplantation; Pathology","score_opus":0.02279744231098206,"score_gpt":0.2582515279847478,"score_spread":0.23545408567376575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048067521","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901012,0.0037179077,0.000050713643,0.0001879773,0.00030527133,0.0044818055,0.00032891647,0.0003714549,0.0004547509],"genre_scores_gemma":[0.99500257,0.00090594386,0.0004417398,0.001415913,0.00070313545,0.00036136693,0.0004661717,0.00043212387,0.0002710269],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9877979,0.00067448645,0.0028244029,0.0032978065,0.002795586,0.002609821],"domain_scores_gemma":[0.99238265,0.0018786422,0.0010122068,0.0023690572,0.0006169433,0.0017405194],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009896046,0.0021031697,0.0034246577,0.00076990976,0.00076865795,0.0003549491,0.0015315459,0.0010587204,0.00020296861],"category_scores_gemma":[0.0009600634,0.0016566514,0.00042900245,0.0026021518,0.0016843987,0.00076607004,0.0013739703,0.0006627818,0.00014250746],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.24220943,0.018233722,0.22525895,0.009602859,0.00877781,0.0145823015,0.074361116,0.0063522845,0.0066399626,0.0008586314,0.009038593,0.38408434],"study_design_scores_gemma":[0.71899,0.011061027,0.16291471,0.0018382956,0.0015852232,0.0007053579,0.0050603407,0.0910971,0.0019990907,0.000059712613,0.0025260327,0.0021630672],"about_ca_topic_score_codex":0.021604922,"about_ca_topic_score_gemma":0.0010523804,"teacher_disagreement_score":0.4767806,"about_ca_system_score_codex":0.22048838,"about_ca_system_score_gemma":0.09826215,"threshold_uncertainty_score":0.99917096},"labels":[],"label_agreement":null},{"id":"W3080882593","doi":"10.1080/10428194.2020.1791846","title":"Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Neutropenia; Brentuximab vedotin; Internal medicine; Febrile neutropenia; Dacarbazine; Vinblastine; Adverse effect; Lymphoma; Chemotherapy; Gastroenterology; Surgery; Oncology; Hodgkin lymphoma","score_opus":0.0064694461906447676,"score_gpt":0.20612635667743887,"score_spread":0.1996569104867941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080882593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913423,0.0006125823,0.00006403126,0.00072242535,0.00010956223,0.004416846,0.00026697316,0.00054317235,0.0019221231],"genre_scores_gemma":[0.9887227,0.00033224237,0.0019207429,0.0054014423,0.00020211152,0.00094240217,0.00068295765,0.00042291693,0.0013725306],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99200696,0.00021896482,0.0013940156,0.0026478823,0.0018187265,0.0019134472],"domain_scores_gemma":[0.99548316,0.00039203154,0.0008164948,0.001454109,0.00042605467,0.0014281325],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00022871897,0.0021110177,0.003054555,0.0005134103,0.0004069229,0.00035281747,0.000571245,0.00069028774,0.00011014285],"category_scores_gemma":[0.00006864055,0.0013878671,0.00034879227,0.0015505071,0.0007103642,0.0007639743,0.00023081154,0.00025308144,0.00006209899],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.027007187,0.0028650719,0.81035316,0.00054711447,0.0013552515,0.003076435,0.0018362962,0.00009658105,0.00026113237,0.00006040947,0.00030554668,0.15223582],"study_design_scores_gemma":[0.23410305,0.010419258,0.74591,0.00058730616,0.0005729772,0.00017066125,0.0004698154,0.0007317884,0.003382123,0.0000048654633,0.0021715516,0.0014766239],"about_ca_topic_score_codex":0.0056058,"about_ca_topic_score_gemma":0.0003648184,"teacher_disagreement_score":0.20709586,"about_ca_system_score_codex":0.013866392,"about_ca_system_score_gemma":0.0063550076,"threshold_uncertainty_score":0.999278},"labels":[],"label_agreement":null},{"id":"W3081847310","doi":"10.1080/10428194.2020.1808206","title":"Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Post-transplant lymphoproliferative disorder; Lymphoproliferative disorders; Internal medicine; Medicine; Incidence (geometry); Medical microbiology; Lymphoma; Gastroenterology; Pathology; Immunology; Rituximab","score_opus":0.008089078092508206,"score_gpt":0.22072056191069214,"score_spread":0.21263148381818395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081847310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97280395,0.008003323,0.00031893796,0.008910168,0.0005634272,0.0017797261,0.00096971006,0.00082530745,0.0058254767],"genre_scores_gemma":[0.97170097,0.0053706896,0.00023310764,0.018923713,0.00052641204,0.00035536665,0.001053431,0.00034796668,0.0014883331],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99210817,0.0003443525,0.0015609626,0.0024204801,0.0014387481,0.0021273177],"domain_scores_gemma":[0.99567354,0.00030912017,0.0008629253,0.0010117097,0.00033059902,0.0018121299],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003454473,0.0017530348,0.0022782017,0.00034235325,0.0008805885,0.0003624284,0.00076098583,0.00091208564,0.00030606202],"category_scores_gemma":[0.0003029242,0.001572075,0.0008073158,0.0012852793,0.0008307941,0.0007574368,0.00028997412,0.0003133844,0.00020128145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031499732,0.0029270905,0.17119929,0.0030749775,0.0051139244,0.002611545,0.021483127,0.00026331557,0.068007864,0.0022056813,0.19841595,0.4931975],"study_design_scores_gemma":[0.22830375,0.009974618,0.39493045,0.0032915971,0.005372789,0.0026982082,0.02593014,0.026004221,0.05011252,0.0021125535,0.24031521,0.010953948],"about_ca_topic_score_codex":0.0039737187,"about_ca_topic_score_gemma":0.0008152226,"teacher_disagreement_score":0.48224354,"about_ca_system_score_codex":0.0067737987,"about_ca_system_score_gemma":0.005049826,"threshold_uncertainty_score":0.99952155},"labels":[],"label_agreement":null},{"id":"W3088246524","doi":"10.1080/10428194.2020.1817445","title":"Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review","year":2020,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Pfizer","keywords":"Medicine; Cytarabine; Myeloid leukemia; Concomitant; Oncology; Adverse effect; Internal medicine; Intensive care medicine","score_opus":0.01785343812651554,"score_gpt":0.278385460990264,"score_spread":0.2605320228637485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088246524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0354603,0.9522109,0.0000824535,0.00012857768,0.00013825661,0.009733041,0.00028132912,0.0004946391,0.0014704894],"genre_scores_gemma":[0.0015064256,0.98857677,0.0020624446,0.001079328,0.00034769112,0.0017109965,0.0020481555,0.0007393002,0.0019288601],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9889154,0.0005581259,0.0026852377,0.0034163613,0.0023855881,0.0020393012],"domain_scores_gemma":[0.99344164,0.0003700532,0.0017934785,0.0019368969,0.00079184375,0.0016661076],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005499121,0.0031265847,0.007993116,0.0009481076,0.00049097085,0.00020621126,0.0009770632,0.0014389325,0.000119182725],"category_scores_gemma":[0.000071647766,0.002213787,0.0008336156,0.0033769272,0.00095850555,0.0005935442,0.0008197059,0.0009186146,0.00009523748],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.003158019,0.00028355178,0.00032310584,0.1172422,0.0061920206,0.0029824947,0.00028166038,0.0000033430222,0.000014876948,0.00007331158,0.0056508873,0.8637945],"study_design_scores_gemma":[0.052570254,0.0033898852,0.006614553,0.19257669,0.018688112,0.0074035237,0.0001731271,0.00075278955,0.00013258512,0.0000064437227,0.7141857,0.0035062996],"about_ca_topic_score_codex":0.0010841736,"about_ca_topic_score_gemma":0.000034264925,"teacher_disagreement_score":0.8602882,"about_ca_system_score_codex":0.029476235,"about_ca_system_score_gemma":0.0146861365,"threshold_uncertainty_score":0.9998574},"labels":[],"label_agreement":null},{"id":"W3104232645","doi":"10.1080/10428194.2020.1845334","title":"Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Princess Margaret Cancer Centre","funders":"AOP Orphan; Incyte; Sierra Oncology; European Hematology Association; Celgene; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Jump; Phase (matter); Oncology; Physics; Bone marrow","score_opus":0.016623192033264837,"score_gpt":0.2876019261148819,"score_spread":0.27097873408161705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3104232645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967818,0.00012856707,0.00001234827,0.00032548665,0.000040203056,0.0022545499,0.0001962599,0.000031663094,0.00022910851],"genre_scores_gemma":[0.99823296,0.00004730084,0.00009543065,0.0010046201,0.00004369291,0.00039159931,0.00011838204,0.000044713146,0.000021296655],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959838,0.0005041272,0.0011634137,0.0008617679,0.00096646504,0.00052046386],"domain_scores_gemma":[0.9976572,0.0006698964,0.00037255994,0.0006886199,0.00022475724,0.0003870103],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005803132,0.0005245319,0.0015758448,0.00091011345,0.00008795926,0.000056726858,0.0003977921,0.0001664489,0.000050267605],"category_scores_gemma":[0.0003015074,0.00035072863,0.00021824936,0.0035041568,0.00017525871,0.0002157636,0.00016970541,0.00010221526,0.0000035371154],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022985958,0.003299906,0.9462074,0.00011160181,0.0010988347,0.00016180756,0.015000885,0.00023902072,0.00024015612,0.000021601572,0.00012751286,0.01050534],"study_design_scores_gemma":[0.048444927,0.006975145,0.9363012,0.00023209851,0.0015129461,0.000006594626,0.002812458,0.00076716964,0.0024418975,0.0000035434925,0.00020339664,0.00029863892],"about_ca_topic_score_codex":0.0015461154,"about_ca_topic_score_gemma":0.00037595414,"teacher_disagreement_score":0.025458971,"about_ca_system_score_codex":0.0015729901,"about_ca_system_score_gemma":0.0012339149,"threshold_uncertainty_score":0.9998945},"labels":[],"label_agreement":null},{"id":"W3110487414","doi":"10.1080/10428194.2020.1850718","title":"Investigating the gut microbial community and genes in children with differing levels of change in serum asparaginase activity during pegaspargase treatment for acute lymphoblastic leukemia","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"IWK Health Centre; Nova Scotia Health Research Foundation; Crohn's and Colitis Foundation","keywords":"Asparaginase; Lymphoblastic Leukemia; Medicine; Microbiome; Metagenomics; Gene; Escherichia coli; Bacteroides; Microbial population biology; Microbiology; Immunology; Biology; Leukemia; Bacteria; Bioinformatics; Biochemistry; Genetics","score_opus":0.044493276827956056,"score_gpt":0.2871279467115785,"score_spread":0.24263466988362242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110487414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99455154,0.0008529862,0.000105862884,0.0006853343,0.00005985964,0.0031794617,0.0003779307,0.00013209342,0.000054957745],"genre_scores_gemma":[0.99638635,0.00058256276,0.0009070344,0.0008089773,0.00032280266,0.0006657191,0.00007215558,0.00019119112,0.000063183],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99503803,0.0005175457,0.0010429972,0.0012232107,0.00067640335,0.0015017997],"domain_scores_gemma":[0.99664176,0.00093125127,0.0004890513,0.0009594371,0.00016157076,0.00081695174],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057906256,0.0011092569,0.0017882971,0.00048516435,0.00064417935,0.00014739676,0.0005782935,0.00049618003,0.000012737984],"category_scores_gemma":[0.00029732444,0.0008403056,0.0002206784,0.001139274,0.0010718025,0.0005356002,0.0006557319,0.00044697576,0.000004384711],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073091085,0.0006637953,0.6288377,0.001967915,0.0016520696,0.0006502348,0.019278614,0.0006701629,0.23125279,0.000115278286,0.000050632003,0.10755169],"study_design_scores_gemma":[0.049391247,0.0016117312,0.85298455,0.00081135804,0.0005707437,0.0020295219,0.0007794363,0.03205428,0.05892043,0.000037622336,0.00003866124,0.00077044655],"about_ca_topic_score_codex":0.0130475145,"about_ca_topic_score_gemma":0.001360679,"teacher_disagreement_score":0.2241468,"about_ca_system_score_codex":0.014283823,"about_ca_system_score_gemma":0.0049514077,"threshold_uncertainty_score":0.9994048},"labels":[],"label_agreement":null},{"id":"W3112812645","doi":"10.1080/10428194.2020.1849674","title":"Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma","year":2020,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"F. Hoffmann-La Roche","keywords":"Biomarker; Diffuse large B-cell lymphoma; Lymphoma; Medicine; Oncology; Chemotherapy; Internal medicine; Cancer research; Biology","score_opus":0.021800845148916583,"score_gpt":0.275620091838249,"score_spread":0.2538192466893324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112812645","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9719258,0.003061686,0.0000020767725,0.009551421,0.00090519595,0.0055903406,0.000470093,0.00015851717,0.00833485],"genre_scores_gemma":[0.9816733,0.00018221073,0.0001479799,0.01502355,0.00087416754,0.0012303499,0.00035395598,0.00029384234,0.0002206195],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98799765,0.0018894727,0.001980456,0.0020625638,0.0046905014,0.001379362],"domain_scores_gemma":[0.9919178,0.002676466,0.0017890072,0.0024572704,0.00079984154,0.00035961086],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0022145456,0.0017565751,0.0030423203,0.0006693094,0.00033358263,0.00009596977,0.0010341441,0.0016947731,0.00003444952],"category_scores_gemma":[0.0027339107,0.0011776047,0.0009528716,0.0017895312,0.0006559093,0.0001944612,0.0008459815,0.0005166498,0.00002988874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0062836446,0.008742888,0.41367078,0.0075892373,0.0028960698,0.0036125423,0.0016102598,0.00003116711,0.0025782322,0.000119905795,0.13420852,0.41865674],"study_design_scores_gemma":[0.2781024,0.0042272215,0.6400464,0.0070105004,0.0055193314,0.00049431744,0.00015632292,0.008398656,0.043385956,0.00045397168,0.010525178,0.0016796938],"about_ca_topic_score_codex":0.0011284208,"about_ca_topic_score_gemma":0.000081179525,"teacher_disagreement_score":0.41697705,"about_ca_system_score_codex":0.015501732,"about_ca_system_score_gemma":0.006554647,"threshold_uncertainty_score":0.99960124},"labels":[],"label_agreement":null},{"id":"W3117683236","doi":"10.1080/10428194.2020.1861277","title":"Evolving management strategies for lymphomas during the COVID-19 pandemic","year":2020,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Pandemic; Medicine; Coronavirus disease 2019 (COVID-19); Population; Quality (philosophy); Adaptation (eye); Intensive care medicine; Psychology; Disease; Pathology; Environmental health","score_opus":0.05738243624992581,"score_gpt":0.3307174995746764,"score_spread":0.27333506332475055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117683236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730785,0.0047637005,0.002634925,0.01085283,0.00039626693,0.002894575,0.000101614314,0.0009685759,0.004309011],"genre_scores_gemma":[0.94791675,0.0017132028,0.0007689649,0.046807062,0.0009977322,0.00039349133,0.00007837908,0.00015389976,0.0011705387],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951463,0.00015961543,0.0010297407,0.0013572623,0.00083098584,0.001476119],"domain_scores_gemma":[0.9957133,0.0008076902,0.00036430516,0.00093585305,0.00019215258,0.0019866875],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0006610638,0.00084663567,0.0010496767,0.00027467794,0.001308659,0.00039443967,0.0005750998,0.00047194352,0.00014227848],"category_scores_gemma":[0.0006152703,0.00066119607,0.00043973126,0.0007811865,0.00041895584,0.00049220124,0.00037724836,0.00020536709,0.000059666814],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022935564,0.0007526979,0.22636795,0.04986498,0.0039744205,0.005649359,0.048672773,0.0020752777,0.021631325,0.04403272,0.10047432,0.47356862],"study_design_scores_gemma":[0.0646089,0.0014171122,0.38335097,0.0006600373,0.0013200275,0.0044922405,0.014368147,0.017029224,0.00091749127,0.0040542097,0.5056038,0.0021778685],"about_ca_topic_score_codex":0.0018873685,"about_ca_topic_score_gemma":0.00017870571,"teacher_disagreement_score":0.47139075,"about_ca_system_score_codex":0.012801966,"about_ca_system_score_gemma":0.009967613,"threshold_uncertainty_score":0.9999915},"labels":[],"label_agreement":null},{"id":"W3133799417","doi":"10.1080/10428194.2021.1889536","title":"The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study","year":2021,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Dasatinib; Myeloid leukemia; Medicine; Nivolumab; Nilotinib; Oncology; Internal medicine; Leukemia; Immunotherapy; Cancer; Imatinib","score_opus":0.011044376472123788,"score_gpt":0.24454907450342167,"score_spread":0.2335046980312979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133799417","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98256505,0.00537205,0.000009651316,0.0026313984,0.00039095228,0.0067845667,0.0011632353,0.00025119205,0.0008319186],"genre_scores_gemma":[0.96963185,0.00340488,0.00024684737,0.0067999256,0.0017187371,0.0004908359,0.014233888,0.0005694901,0.00290354],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9874582,0.0010438131,0.0036029052,0.0034748365,0.0023383007,0.0020818892],"domain_scores_gemma":[0.9905841,0.002719428,0.0021967413,0.00329187,0.0005986927,0.00060918875],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008653371,0.002373576,0.003901492,0.0006887115,0.0007593598,0.00033338094,0.00082296197,0.0023472456,0.00006202679],"category_scores_gemma":[0.00064747175,0.0017876673,0.00048231802,0.001492619,0.0010692735,0.00044325,0.00063744345,0.0015591867,0.000024886878],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.119640015,0.008575644,0.09055955,0.002803934,0.010968024,0.012014721,0.015187759,0.0004255697,0.00025825892,0.000022257573,0.07212713,0.6674171],"study_design_scores_gemma":[0.47149014,0.00710686,0.46355885,0.003705134,0.003279295,0.000303531,0.0006178853,0.003069235,0.00026841465,0.00001698104,0.044719927,0.0018637239],"about_ca_topic_score_codex":0.015981292,"about_ca_topic_score_gemma":0.0020291514,"teacher_disagreement_score":0.6655534,"about_ca_system_score_codex":0.0708144,"about_ca_system_score_gemma":0.022177381,"threshold_uncertainty_score":0.9989479},"labels":[],"label_agreement":null},{"id":"W3143688388","doi":"10.1080/10428194.2021.1910688","title":"Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Manitoba; Princess Margaret Cancer Centre; CancerCare Manitoba; BC Children's Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Hematopoietic cell; Transplantation; Single Center; Internal medicine; Hematopoietic stem cell transplantation; Conditioning; Acute leukemia; Lymphoblastic Leukemia; Multivariate analysis; Retrospective cohort study; Oncology; Leukemia; Gastroenterology; Surgery; Haematopoiesis; Stem cell","score_opus":0.0215223810949936,"score_gpt":0.26363405859038924,"score_spread":0.24211167749539564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3143688388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954013,0.00034600307,0.0005002253,0.00038659954,0.00013676516,0.0018728324,0.00064923475,0.00012897758,0.0005780598],"genre_scores_gemma":[0.9932754,0.00014640769,0.0022194257,0.0014079764,0.00004280404,0.00021212043,0.0022136422,0.00013889048,0.0003433199],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99490017,0.00023091437,0.0011485103,0.0017760798,0.00087294105,0.001071408],"domain_scores_gemma":[0.99668556,0.00036446817,0.00034646338,0.0012643436,0.00025489336,0.0010842428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041307753,0.00089391397,0.0016229382,0.00053414144,0.00036923485,0.00031324464,0.00039896043,0.00044406293,0.000037329537],"category_scores_gemma":[0.000078989964,0.00079590565,0.0000957685,0.0009467616,0.00025583798,0.0004473018,0.00014072323,0.0002511588,0.00001805813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021150846,0.00081511127,0.9609234,0.0010656016,0.00086179486,0.009642275,0.010301794,0.00011192702,0.011572953,0.00001356778,0.0010773868,0.0014991222],"study_design_scores_gemma":[0.058990758,0.0017833394,0.88229233,0.0024570075,0.0031587211,0.02003754,0.008394101,0.0009924631,0.019637283,0.000011744871,0.00062188145,0.0016228328],"about_ca_topic_score_codex":0.01891755,"about_ca_topic_score_gemma":0.04432585,"teacher_disagreement_score":0.07863105,"about_ca_system_score_codex":0.005418314,"about_ca_system_score_gemma":0.0071651577,"threshold_uncertainty_score":0.9994492},"labels":[],"label_agreement":null},{"id":"W3162249178","doi":"10.1080/10428194.2021.1919658","title":"A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Canadian Institutes of Health Research","keywords":"Chronic lymphocytic leukemia; Minimal residual disease; Immunophenotyping; Medicine; Flow cytometry; Multilocus sequence typing; clone (Java method); Leukemia; Immunology; Oncology; Biology","score_opus":0.02986774142796106,"score_gpt":0.2905386127932589,"score_spread":0.2606708713652978,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162249178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97126013,0.022797205,0.00009353007,0.00042973383,0.00036616216,0.0025865952,0.00045407683,0.00040332033,0.0016092634],"genre_scores_gemma":[0.97136575,0.006460032,0.002674992,0.001522023,0.0014708695,0.0024114456,0.0007484229,0.00042651634,0.012919949],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9894962,0.00041012545,0.00199747,0.0032768117,0.0017429787,0.003076418],"domain_scores_gemma":[0.9920009,0.0024724002,0.00043495945,0.0020444111,0.0006367852,0.002410589],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011893939,0.0016207123,0.002429768,0.0012016695,0.0006883168,0.0004909919,0.0007042317,0.0012026626,0.00078178284],"category_scores_gemma":[0.0024331058,0.0016317966,0.00064714596,0.002176167,0.0012309938,0.0007141244,0.0010695,0.00040705374,0.00026337706],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.050185017,0.0016737068,0.032915413,0.02368093,0.0035093823,0.051427927,0.004848832,0.0074415607,0.016401105,0.0028307051,0.066017285,0.73906815],"study_design_scores_gemma":[0.2174319,0.002569014,0.100094415,0.0032652216,0.0017215338,0.0064962762,0.0010113257,0.5523805,0.018386504,0.0008020547,0.0923603,0.003480934],"about_ca_topic_score_codex":0.0032459714,"about_ca_topic_score_gemma":0.00057167996,"teacher_disagreement_score":0.7355872,"about_ca_system_score_codex":0.33471158,"about_ca_system_score_gemma":0.19911395,"threshold_uncertainty_score":0.99965405},"labels":[],"label_agreement":null},{"id":"W3164483329","doi":"10.1080/10428194.2021.1933472","title":"Hsa-miR-372-5p regulates the NIMA related kinase 7 and IL-1β release in NK/T-cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Basic and Applied Basic Research Foundation of Guangdong Province; Applied Basic Research Foundation of Yunnan Province; Canadian Network for Research and Innovation in Machining Technology, Natural Sciences and Engineering Research Council of Canada; National Natural Science Foundation of China","keywords":"Mononucleosis; Lymphoma; microRNA; Biology; Cancer research; Epstein–Barr virus; Immunology; Downregulation and upregulation; Virus; Virology; Gene; Genetics","score_opus":0.0063253099479392855,"score_gpt":0.21608363143746917,"score_spread":0.2097583214895299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164483329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9553353,0.026624225,0.0000073537635,0.0019270029,0.00044592167,0.0007763148,0.00007595684,0.0002897292,0.014518178],"genre_scores_gemma":[0.97853863,0.00914435,0.0002197419,0.0039560287,0.00022216188,0.00013883812,0.00024834118,0.00020245362,0.007329428],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9941231,0.0003930467,0.0013344812,0.0017189621,0.0008885058,0.0015419195],"domain_scores_gemma":[0.9966061,0.00045123583,0.00048448637,0.0013556103,0.0002841054,0.0008184469],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006661843,0.0010517106,0.0014043141,0.0003830346,0.0007022597,0.0002914349,0.0004042195,0.0010314003,0.00017991083],"category_scores_gemma":[0.00042287173,0.0008834089,0.00041799733,0.0016374168,0.0007618526,0.00043963786,0.00040391498,0.00034056194,0.000095710864],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066578733,0.0029385549,0.05972045,0.002250107,0.0014050034,0.014775341,0.010673662,0.0002986222,0.06529324,0.0052057356,0.05078006,0.78000134],"study_design_scores_gemma":[0.21370232,0.0015615734,0.47376803,0.0028173965,0.0022286933,0.0076559875,0.015863616,0.022092901,0.07159803,0.008768912,0.17510466,0.0048378715],"about_ca_topic_score_codex":0.0036351325,"about_ca_topic_score_gemma":0.00051384507,"teacher_disagreement_score":0.7751635,"about_ca_system_score_codex":0.0065618115,"about_ca_system_score_gemma":0.0054687145,"threshold_uncertainty_score":0.99936163},"labels":[],"label_agreement":null},{"id":"W3165356648","doi":"10.1080/10428194.2021.1910685","title":"Mitochondrial metabolism: powering new directions in acute myeloid leukemia","year":2021,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"BC Cancer Foundation; University of British Columbia; Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Myeloid leukemia; Leukemia; Mitochondrion; Context (archaeology); Cancer research; Oxidative phosphorylation; Myeloid; Biology; Stem cell; Medicine; Immunology; Cell biology; Biochemistry","score_opus":0.024508357642982058,"score_gpt":0.3126004999898599,"score_spread":0.28809214234687786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165356648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005533977,0.9781935,0.00012059336,0.00019215721,0.0031087946,0.0038454845,0.00030706142,0.0007982131,0.007900202],"genre_scores_gemma":[0.00012756052,0.9609458,0.004075451,0.0007617764,0.0042732675,0.000980154,0.0017192141,0.000980589,0.026136177],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98401034,0.0010522581,0.0041492768,0.0046167714,0.0023172349,0.0038540948],"domain_scores_gemma":[0.9903274,0.0013241224,0.0013031013,0.0036324537,0.00049262773,0.0029202604],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0009791336,0.003700494,0.010796222,0.0032654663,0.00077503774,0.0008118577,0.0017756418,0.004102748,0.00064373494],"category_scores_gemma":[0.00096892676,0.0034603695,0.003066363,0.0056129666,0.0008176782,0.00092914037,0.0018694219,0.0023024909,0.00069960265],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00048138367,0.0001999283,0.000035529112,0.006110091,0.0026879227,0.0065799137,0.0005540997,0.0000097362845,0.00019803167,0.00060351676,0.025200376,0.95733947],"study_design_scores_gemma":[0.018056799,0.00025911097,0.0005823201,0.017242104,0.0062426557,0.014948224,0.00026288832,0.0003475804,0.00021569499,0.000094586605,0.93887115,0.0028768629],"about_ca_topic_score_codex":0.008080269,"about_ca_topic_score_gemma":0.0004694278,"teacher_disagreement_score":0.9544626,"about_ca_system_score_codex":0.064075865,"about_ca_system_score_gemma":0.08234224,"threshold_uncertainty_score":0.9999992},"labels":[],"label_agreement":null},{"id":"W3172578726","doi":"10.1080/10428194.2021.1938029","title":"Prognostic value of disease risk score versus gait speed in older adults with lymphoma","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Nutrition and Health in Aging","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Dana-Farber Cancer Institute","keywords":"Medicine; Gait; Internal medicine; Lymphoma; Cohort; Disease; Preferred walking speed; Oncology; Physical medicine and rehabilitation","score_opus":0.013297063889686184,"score_gpt":0.25933042327733996,"score_spread":0.24603335938765378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172578726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899909,0.0049978974,0.000054900156,0.0004235085,0.00041238256,0.001237949,0.00011037305,0.00018619366,0.002585934],"genre_scores_gemma":[0.99410766,0.0021406838,0.001306928,0.0010743272,0.00033726715,0.00011315082,0.00027853565,0.00013952288,0.00050189503],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951259,0.00026909867,0.0011751172,0.0013275588,0.0009697975,0.0011325089],"domain_scores_gemma":[0.9963364,0.0005300782,0.0004879565,0.0010208931,0.0004389318,0.0011857213],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039599166,0.0007289982,0.0012517562,0.0004957925,0.0002805088,0.00008142789,0.00025281787,0.0003909742,0.000151958],"category_scores_gemma":[0.0004900335,0.000667125,0.00026363353,0.0010981468,0.00044999525,0.00028033048,0.00017958418,0.00020739176,0.000038292554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03414351,0.0022786732,0.7996058,0.0060168817,0.00042030658,0.0065495027,0.0031686446,0.00016154235,0.0006056984,0.0022701137,0.0013147121,0.14346465],"study_design_scores_gemma":[0.09328866,0.0005801931,0.8844326,0.0054053045,0.0005656061,0.0006684856,0.0017321456,0.00797725,0.0024961184,0.00025116093,0.0018564336,0.0007460055],"about_ca_topic_score_codex":0.0015991738,"about_ca_topic_score_gemma":0.00026488298,"teacher_disagreement_score":0.14271864,"about_ca_system_score_codex":0.004301562,"about_ca_system_score_gemma":0.007983845,"threshold_uncertainty_score":0.999578},"labels":[],"label_agreement":null},{"id":"W3175217849","doi":"10.1080/10428194.2021.1941936","title":"Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Biopsy; Medicine; Radiology; Follicular lymphoma; Fine-needle aspiration; Lymphoma; Positron emission tomography; Gold standard (test); Pathology","score_opus":0.01065069518265316,"score_gpt":0.25027051749929746,"score_spread":0.2396198223166443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3175217849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574393,0.0008640776,0.000008149705,0.00038415074,0.00009170013,0.001128545,0.00010818085,0.000074782285,0.001596484],"genre_scores_gemma":[0.9982616,0.00020905967,0.00020987433,0.00057597,0.00006752158,0.0001337082,0.00033593277,0.000063333435,0.00014301081],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99690366,0.00019486723,0.0007493207,0.000807749,0.000648606,0.0006958258],"domain_scores_gemma":[0.9975812,0.0007423148,0.00023985707,0.0006672879,0.0003566224,0.00041272628],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020521827,0.0006709452,0.0009922318,0.00037116965,0.00022110916,0.00008865961,0.00017678754,0.00032967082,0.00021909147],"category_scores_gemma":[0.00040155844,0.00043328822,0.00022595229,0.0011751212,0.00027133216,0.00020136884,0.00009517682,0.000081838334,0.000096288575],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012350607,0.0042326157,0.81600755,0.00036678987,0.0012610494,0.003092945,0.0024546045,0.00016759134,0.0020665175,0.0013840771,0.0014246033,0.15519105],"study_design_scores_gemma":[0.027541641,0.0035470629,0.9627655,0.00065393763,0.00035279637,0.0009919541,0.00012070568,0.00042577667,0.002574115,0.00006819766,0.00046747742,0.00049082417],"about_ca_topic_score_codex":0.00092070963,"about_ca_topic_score_gemma":0.000045745386,"teacher_disagreement_score":0.15470022,"about_ca_system_score_codex":0.0056043705,"about_ca_system_score_gemma":0.002541385,"threshold_uncertainty_score":0.9998119},"labels":[],"label_agreement":null},{"id":"W3182533416","doi":"10.1080/10428194.2021.1938027","title":"A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Ibrutinib; Bruton's tyrosine kinase; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Cancer research; Pharmacodynamics; Pharmacology; Internal medicine; Oncology; Lymphoma; Pharmacokinetics; Tyrosine kinase; Chronic lymphocytic leukemia; Biology; Leukemia; Receptor","score_opus":0.00943998338930477,"score_gpt":0.2521259848472878,"score_spread":0.24268600145798305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182533416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961373,0.0009132161,0.000005377185,0.0000480492,0.00012008817,0.0013840978,0.000028971586,0.000037811675,0.0013250472],"genre_scores_gemma":[0.9986378,0.00019509178,0.00016042328,0.00017110465,0.000028445314,0.00006841647,0.00004540842,0.000077559445,0.0006157621],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99580276,0.00032742467,0.0010717761,0.0008577151,0.0012946421,0.00064569403],"domain_scores_gemma":[0.99711394,0.00040914986,0.000504186,0.0010973676,0.00059665495,0.00027870233],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045434976,0.0004962094,0.0010667015,0.00030519522,0.00017557164,0.000045768866,0.00031381205,0.00032331914,0.00003077672],"category_scores_gemma":[0.00031624956,0.00036274243,0.00012668023,0.0011940417,0.000617711,0.0002515074,0.00045078402,0.00021170123,0.0000034714471],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016621528,0.039908417,0.8213907,0.0040103775,0.0008834977,0.0011367133,0.019762453,0.000074342846,0.022436917,0.000977971,0.0008293364,0.071967736],"study_design_scores_gemma":[0.31061935,0.0048785424,0.6559516,0.00078953116,0.0003278971,0.00018984049,0.0031900986,0.0019095683,0.021200445,0.000077393175,0.0004403905,0.00042531372],"about_ca_topic_score_codex":0.0019602252,"about_ca_topic_score_gemma":0.00022223203,"teacher_disagreement_score":0.29399782,"about_ca_system_score_codex":0.013008388,"about_ca_system_score_gemma":0.014065799,"threshold_uncertainty_score":0.99988246},"labels":[],"label_agreement":null},{"id":"W3183715267","doi":"10.1080/10428194.2021.1957865","title":"Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Neutropenia; Adverse effect; Confidence interval; Oncology; Meta-analysis; Anemia; Lymphoma; Observational study; Gastroenterology; Hodgkin lymphoma; Chemotherapy","score_opus":0.04153131334834914,"score_gpt":0.3275803715179592,"score_spread":0.28604905816961007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3183715267","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042190985,0.9870524,0.000012277519,0.000045604582,0.00013457148,0.0077463416,0.00036745227,0.00013867747,0.0002835834],"genre_scores_gemma":[0.006184738,0.98603463,0.00036098255,0.0005890603,0.00006196733,0.004783789,0.00072280597,0.00032180315,0.0009402424],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9862949,0.0035870261,0.00460969,0.0029460555,0.0013029814,0.0012593359],"domain_scores_gemma":[0.98907286,0.004110196,0.0027154745,0.0029199258,0.0004098029,0.0007717612],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002647567,0.0027417026,0.030443206,0.001760924,0.00022382238,0.00018042138,0.00066391315,0.0015786637,0.00023504441],"category_scores_gemma":[0.000701262,0.0018133579,0.0060264594,0.004093588,0.00046664238,0.00024698494,0.00042072812,0.00027686122,0.000034420063],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004128886,0.0014741238,0.00006801417,0.7492909,0.15847443,0.002079849,0.00016735942,0.0000023957168,0.0000033626206,0.00016883953,0.0001603121,0.08769751],"study_design_scores_gemma":[0.019074356,0.0007772535,0.0009817842,0.18554561,0.76889014,0.002966156,0.000085794265,0.00006210177,0.000046010402,0.000019540903,0.019935194,0.001616063],"about_ca_topic_score_codex":0.0019390818,"about_ca_topic_score_gemma":0.00012886121,"teacher_disagreement_score":0.6104157,"about_ca_system_score_codex":0.012557283,"about_ca_system_score_gemma":0.0089216735,"threshold_uncertainty_score":0.9997175},"labels":[],"label_agreement":null},{"id":"W3186223954","doi":"10.1080/10428194.2021.1953006","title":"Gut bacterial gene changes following pegaspargase treatment in pediatric patients with acute lymphoblastic leukemia","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Izaak Walton Killam Health Centre; Dalhousie University","funders":"IWK Health Centre; Nova Scotia Health Research Foundation","keywords":"Asparaginase; Asparagine; Glutamine; Lymphoblastic Leukemia; Asparagine synthetase; Gut microbiome; Gene; Medicine; Microbiome; Biology; Amino acid; Gut flora; Microbiology; Leukemia; Biochemistry; Internal medicine; Bioinformatics","score_opus":0.010383390874948967,"score_gpt":0.24175526932241911,"score_spread":0.23137187844747015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186223954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932586,0.0022367497,0.00004893262,0.00042548313,0.0012426683,0.0012759755,0.00020162931,0.0003278534,0.0009820829],"genre_scores_gemma":[0.9901568,0.0017448424,0.001554414,0.0019439815,0.0016043725,0.00033329445,0.0011541886,0.0002804557,0.0012276308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99295133,0.00038183838,0.0013461623,0.0021239775,0.0014421929,0.0017545089],"domain_scores_gemma":[0.99610317,0.00049176224,0.00053022656,0.0014535646,0.0003007345,0.001120515],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00040490023,0.001414858,0.002153134,0.0006581204,0.00042912996,0.00026786292,0.00038275126,0.00068364956,0.0001457778],"category_scores_gemma":[0.000230917,0.0012710497,0.0004889993,0.0014699922,0.00022693735,0.00048224244,0.00032443207,0.00020606638,0.00009171344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013711819,0.0039465316,0.7911319,0.0017369995,0.004317352,0.023685148,0.012013723,0.00022352776,0.0113069685,0.00023405656,0.0032684172,0.13442357],"study_design_scores_gemma":[0.08655798,0.0022409656,0.8899842,0.00065804337,0.0025493153,0.001287609,0.0005867841,0.00048538524,0.007359309,0.000067626104,0.006359133,0.0018636426],"about_ca_topic_score_codex":0.0029067681,"about_ca_topic_score_gemma":0.0027392292,"teacher_disagreement_score":0.13255993,"about_ca_system_score_codex":0.022042494,"about_ca_system_score_gemma":0.014324752,"threshold_uncertainty_score":0.99986017},"labels":[],"label_agreement":null},{"id":"W3202324403","doi":"10.1080/10428194.2021.1961233","title":"Infections in secondary immunodeficiency patients treated with Privigen<sup>®</sup>or Hizentra<sup>®</sup>: a retrospective US administrative claims study in patients with hematological malignancies","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Pneumocystis jirovecii pneumonia detection and treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"CSL Behring","keywords":"Retrospective cohort study; Medicine; Internal medicine","score_opus":0.009488305154979077,"score_gpt":0.23316239576098807,"score_spread":0.22367409060600899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202324403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994307,0.00024086768,0.0000145209415,0.000052167765,0.000070400085,0.002805186,0.00017378198,0.0002459391,0.002090183],"genre_scores_gemma":[0.9977517,0.000104174134,0.00015539616,0.0002877641,0.00003928408,0.0006506452,0.0003368345,0.00012453813,0.0005496765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993968,0.0004517202,0.001306489,0.0018849164,0.0011040652,0.0012847851],"domain_scores_gemma":[0.99731106,0.00028074358,0.0004092828,0.0009415776,0.00053751725,0.00051981234],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022816105,0.0011821673,0.0018138785,0.00063323794,0.000519161,0.0001941675,0.00023890832,0.0005159786,0.00017366445],"category_scores_gemma":[0.00019448793,0.0008495575,0.00021158521,0.0022604875,0.00047131188,0.0004916033,0.00020177646,0.00048110017,0.000036364047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057316083,0.00849594,0.9712069,0.000119364995,0.0004802669,0.0037936785,0.003686256,0.00037317994,0.000052392803,0.00007510297,0.000028768447,0.0059565525],"study_design_scores_gemma":[0.06586706,0.010572354,0.91518146,0.0005694766,0.00030735476,0.0014339898,0.0031225435,0.0012071672,0.000602796,0.000036141915,0.00019855172,0.0009010764],"about_ca_topic_score_codex":0.0012888524,"about_ca_topic_score_gemma":0.0010660454,"teacher_disagreement_score":0.060135454,"about_ca_system_score_codex":0.011082708,"about_ca_system_score_gemma":0.004641455,"threshold_uncertainty_score":0.99939555},"labels":[],"label_agreement":null},{"id":"W3203935034","doi":"10.1080/10428194.2021.1948026","title":"Anticipation in multiple-case lymphoid cancer families after controlling for ascertainment biases","year":2021,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Anticipation (artificial intelligence); Inheritance (genetic algorithm); Disease; Cancer; Medicine; Oncology; Biology; Genetics; Internal medicine; Gene","score_opus":0.019825228264423077,"score_gpt":0.2570912003199949,"score_spread":0.23726597205557182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203935034","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9773733,0.014351408,0.00057521515,0.0036295257,0.001192322,0.0017725871,0.0008576077,0.00010209015,0.00014596018],"genre_scores_gemma":[0.855419,0.005686419,0.0015384597,0.123377115,0.0040186094,0.004290894,0.003052131,0.00041992002,0.0021974517],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994189,0.00033276883,0.0012316484,0.0021925275,0.0005734909,0.0014805583],"domain_scores_gemma":[0.99725074,0.00048120474,0.0005462065,0.0011664971,0.00030724792,0.00024811778],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00043035301,0.0013089991,0.0013561238,0.00041264587,0.00031049506,0.00025849594,0.00044578765,0.0024049827,0.000045446755],"category_scores_gemma":[0.0004681147,0.0013596874,0.0006307393,0.00031383068,0.0002672862,0.00003614829,0.0003807283,0.00027720284,0.000008617599],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008515739,0.0009040597,0.021830821,0.0059267427,0.004037301,0.045861367,0.002618249,0.0036902474,0.2242668,0.00007058896,0.31296635,0.36931175],"study_design_scores_gemma":[0.042641584,0.000928079,0.0024665825,0.0025186534,0.0011439895,0.006374506,0.0011474362,0.02901195,0.1651636,0.00017534442,0.7437276,0.0047006444],"about_ca_topic_score_codex":0.003458469,"about_ca_topic_score_gemma":0.0018611429,"teacher_disagreement_score":0.43076128,"about_ca_system_score_codex":0.004054334,"about_ca_system_score_gemma":0.0034360136,"threshold_uncertainty_score":0.99996614},"labels":[],"label_agreement":null},{"id":"W3209446816","doi":"10.1080/10428194.2021.1992761","title":"Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Pneumocystis jirovecii pneumonia detection and treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"CSL Behring","keywords":"Medicine; Multivariate analysis; Retrospective cohort study; Internal medicine; Receiver operating characteristic; Psychological intervention; Primary immunodeficiency; Intensive care medicine; Pediatrics; Disease","score_opus":0.010680148477638452,"score_gpt":0.2458394867161154,"score_spread":0.23515933823847696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209446816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958196,0.00026190144,0.000033917408,0.000038955623,0.00019368214,0.00198706,0.00022134754,0.00012737852,0.0013161557],"genre_scores_gemma":[0.9985937,0.00008476726,0.00018064372,0.00014116486,0.000027864107,0.00048744847,0.00014393934,0.00006122551,0.00027927023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965885,0.00022158909,0.00078630494,0.0011741747,0.00049438357,0.00073499285],"domain_scores_gemma":[0.99822915,0.0003901801,0.00029759496,0.00053913187,0.0002826395,0.00026131983],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020977524,0.00064866646,0.0011577056,0.00037058082,0.00038706244,0.000102842314,0.00012279973,0.00034942612,0.00005011469],"category_scores_gemma":[0.0002817039,0.0005138102,0.00020154146,0.001010644,0.00022716199,0.0002632947,0.00011145375,0.00027672356,0.00000858784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014314827,0.0029930582,0.9875521,0.00007040915,0.000250906,0.0006625734,0.002107547,0.00003579252,0.0001526814,0.00016869504,0.000020674312,0.0045540472],"study_design_scores_gemma":[0.038899504,0.004504268,0.9494487,0.00018690909,0.00023714613,0.0007032239,0.0038211448,0.00021084162,0.0010097435,0.0002632354,0.00017930008,0.0005359544],"about_ca_topic_score_codex":0.0012650572,"about_ca_topic_score_gemma":0.0022088073,"teacher_disagreement_score":0.0381034,"about_ca_system_score_codex":0.008153059,"about_ca_system_score_gemma":0.003343885,"threshold_uncertainty_score":0.99973136},"labels":[],"label_agreement":null},{"id":"W3210219109","doi":"10.1080/10428194.2021.1999445","title":"Risk of thyroid disorders in adult and childhood Hodgkin lymphoma survivors 40 years after treatment","year":2021,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Childhood Cancer Survivors' Quality of Life","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Cancer Research UK","keywords":"Medicine; Radiation therapy; Thyroid; Pediatrics; Disease; Thyroid cancer; Chemotherapy; Internal medicine; Proportional hazards model; Oncology","score_opus":0.005786720895113386,"score_gpt":0.23441941803492367,"score_spread":0.22863269713981027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210219109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98619217,0.009632126,0.000024003959,0.00050286297,0.0003913047,0.0008774928,0.00024861927,0.00016718467,0.001964242],"genre_scores_gemma":[0.9806498,0.01576872,0.00090130337,0.0012808861,0.00030757056,0.00019627565,0.00015070409,0.00017670699,0.0005680132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941553,0.00058117294,0.0015086173,0.0016606334,0.00095631403,0.0011379973],"domain_scores_gemma":[0.99655026,0.00062102865,0.0005411247,0.0013418784,0.00021148344,0.0007342411],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059014704,0.0010074205,0.0018711623,0.0005143614,0.00019008484,0.000111104775,0.00025571443,0.0006487009,0.00009786833],"category_scores_gemma":[0.0004263444,0.0009960375,0.0004944842,0.0010341004,0.0006085346,0.0003345527,0.0003159272,0.00017766567,0.00003172803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026332205,0.0016780185,0.59061396,0.00054337207,0.0009493694,0.00081345043,0.014558399,0.000035940608,0.0005771754,0.00031416444,0.00035497273,0.386928],"study_design_scores_gemma":[0.035126757,0.0009144908,0.94936335,0.00068488566,0.0005580479,0.0007424493,0.00330242,0.0004551563,0.0028392714,0.00057768094,0.0044762,0.0009592815],"about_ca_topic_score_codex":0.029564708,"about_ca_topic_score_gemma":0.021397267,"teacher_disagreement_score":0.3859687,"about_ca_system_score_codex":0.0042790314,"about_ca_system_score_gemma":0.0040926603,"threshold_uncertainty_score":0.99954337},"labels":[],"label_agreement":null},{"id":"W4200502803","doi":"10.1080/10428194.2021.2012667","title":"Phase I trials of the lysine-specific demethylase 1 inhibitor, GSK2879552, as mono- and combination-therapy in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes","year":2021,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelodysplastic syndromes; Myeloid leukemia; Refractory (planetary science); Demethylase; Medicine; Internal medicine; Leukemia; Oncology; Cancer research; Biology; Gene; Bone marrow; Biochemistry","score_opus":0.020733444090083104,"score_gpt":0.2678499167161682,"score_spread":0.2471164726260851,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200502803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97004485,0.023533458,0.000108496555,0.0027753664,0.0014055487,0.0012943976,0.0006454805,0.000046149908,0.0001462523],"genre_scores_gemma":[0.8756139,0.10096319,0.0006377446,0.012500404,0.0024169008,0.00036243387,0.002823961,0.00040319146,0.004278232],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99151206,0.0019351353,0.0024217537,0.002067416,0.0010169878,0.001046621],"domain_scores_gemma":[0.9941062,0.001259722,0.0021843314,0.0017151206,0.00042902332,0.0003056314],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0017003639,0.0014552113,0.0023933873,0.000578137,0.0004674658,0.0002703777,0.0008492554,0.0029866956,0.00007900151],"category_scores_gemma":[0.0011417217,0.0011439103,0.0006898936,0.0008708306,0.00075628515,0.000046986497,0.00056485453,0.00084524654,0.000011198338],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062139425,0.0012368714,0.0021511556,0.0009982345,0.003330529,0.0019501265,0.001033741,0.00037673063,0.46397305,0.00019151595,0.12907584,0.38946825],"study_design_scores_gemma":[0.06577127,0.0043855114,0.010206443,0.00094400864,0.0011127695,0.0005618562,0.00021985985,0.000601028,0.32451922,0.0012039475,0.5877862,0.0026879197],"about_ca_topic_score_codex":0.0011553896,"about_ca_topic_score_gemma":0.00014409678,"teacher_disagreement_score":0.45871034,"about_ca_system_score_codex":0.002345619,"about_ca_system_score_gemma":0.005817305,"threshold_uncertainty_score":0.99981976},"labels":[],"label_agreement":null},{"id":"W4210829474","doi":"10.1080/10428194.2022.2030477","title":"Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Vancouver General Hospital; McGill University Health Centre","funders":"Bristol-Myers Squibb","keywords":"Lenalidomide; Pomalidomide; Medicine; Daratumumab; Dexamethasone; Multiple myeloma; Internal medicine; Neutropenia; Oncology; Chemotherapy","score_opus":0.0279549313468648,"score_gpt":0.29230793487169454,"score_spread":0.26435300352482977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210829474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888212,0.0030914901,0.0000117325335,0.0008193678,0.00015896771,0.004154951,0.00276483,0.000086845204,0.000090629655],"genre_scores_gemma":[0.99436253,0.00035739236,0.00033325484,0.00062736555,0.00008790385,0.00047038274,0.0035600946,0.000100772064,0.000100302415],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9927048,0.0014707758,0.0021514532,0.001420283,0.0012227192,0.0010299886],"domain_scores_gemma":[0.9946489,0.0023128493,0.0009215742,0.0010264519,0.00016533316,0.0009248963],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015005997,0.000839101,0.0019670543,0.00037696926,0.0006697026,0.00009472527,0.0002636059,0.00027986075,0.00007924176],"category_scores_gemma":[0.00064623076,0.00058037555,0.00021729682,0.00079771515,0.0006577847,0.00019868264,0.0003168712,0.00029210048,0.0000047657604],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6483105,0.0031502428,0.24767824,0.00007994943,0.0008481949,0.00031140778,0.0017002438,0.00006808348,0.00010318302,0.000016749156,0.0002287462,0.09750451],"study_design_scores_gemma":[0.4422309,0.0041977866,0.5500743,0.000102835686,0.00015021783,0.00002318271,0.00027094633,0.0017670353,0.00023859896,0.000011896002,0.0006099444,0.00032236482],"about_ca_topic_score_codex":0.040500063,"about_ca_topic_score_gemma":0.0019201568,"teacher_disagreement_score":0.30239606,"about_ca_system_score_codex":0.005500226,"about_ca_system_score_gemma":0.004575421,"threshold_uncertainty_score":0.9996648},"labels":[],"label_agreement":null},{"id":"W4213044498","doi":"10.1080/10428194.2022.2042689","title":"Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health","keywords":"Decitabine; Panobinostat; Cancer research; PARP1; Olaparib; Azacitidine; Myeloid leukemia; Cytotoxicity; Pharmacology; PI3K/AKT/mTOR pathway; Poly ADP ribose polymerase; Chemistry; Leukemia; Vorinostat; Apoptosis; Histone deacetylase; Medicine; DNA methylation; In vitro; Immunology; Histone; Polymerase; Biochemistry; DNA","score_opus":0.008695234625414798,"score_gpt":0.2345867560039069,"score_spread":0.2258915213784921,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213044498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99270564,0.001476174,0.00020041861,0.00027113516,0.00022726462,0.0023075275,0.0003301451,0.00024562472,0.0022360638],"genre_scores_gemma":[0.9910232,0.0017008728,0.002298449,0.0011698721,0.00015184356,0.0006416411,0.00037811365,0.00026870455,0.0023672914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99176395,0.0005476576,0.0017489907,0.0020647182,0.0018540729,0.0020205926],"domain_scores_gemma":[0.9955233,0.0007615175,0.0007341804,0.0015917083,0.00033689555,0.001052453],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010985875,0.0013013216,0.0024855093,0.0012629383,0.0006874732,0.00013295568,0.0008743072,0.00057079404,0.00033269645],"category_scores_gemma":[0.0001441768,0.0012059561,0.0002999344,0.001963837,0.0012011365,0.0005085716,0.0013539542,0.0008204812,0.000024088953],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04274539,0.0010100465,0.024527458,0.0015843492,0.0020545593,0.0051586716,0.009617106,0.0017564712,0.83409035,0.0014379945,0.0063798856,0.06963773],"study_design_scores_gemma":[0.13514571,0.010604428,0.21131365,0.00090217363,0.0013274895,0.005403173,0.004583291,0.02643516,0.5918309,0.00092936546,0.008188351,0.00333632],"about_ca_topic_score_codex":0.0053475616,"about_ca_topic_score_gemma":0.000365627,"teacher_disagreement_score":0.24225944,"about_ca_system_score_codex":0.02803489,"about_ca_system_score_gemma":0.014087198,"threshold_uncertainty_score":0.99997383},"labels":[],"label_agreement":null},{"id":"W4220688343","doi":"10.1080/10428194.2022.2043299","title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; National Cancer Institute; Celgene; CLL Global Research Foundation","keywords":"Lenalidomide; Chronic lymphocytic leukemia; Chimeric antigen receptor; CD23; Cancer research; T cell; Antigen; Immunology; Leukemia; Medicine; Immune system; Multiple myeloma; Immunoglobulin E; Antibody","score_opus":0.01615558200279773,"score_gpt":0.26819361320453683,"score_spread":0.2520380312017391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220688343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96072435,0.016786728,0.000026742853,0.0001842326,0.0006958763,0.0020120817,0.000069750095,0.0004481219,0.019052096],"genre_scores_gemma":[0.959233,0.009762021,0.00022306881,0.0025040978,0.0009389372,0.0011179772,0.00021473592,0.0003540877,0.025652062],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9905021,0.000766954,0.0016512385,0.0022564614,0.0022963418,0.0025268923],"domain_scores_gemma":[0.995739,0.000711002,0.00049640913,0.001895641,0.00020712704,0.0009508332],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016713359,0.0013366652,0.0019437582,0.0012803947,0.0010150262,0.0002568287,0.0012000998,0.00059363275,0.0049126637],"category_scores_gemma":[0.00009995303,0.0013267959,0.00069972407,0.0022597092,0.0007399745,0.00048390083,0.0008789208,0.00075323693,0.0002356629],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009147414,0.00036897612,0.0040763593,0.0007071048,0.0005127616,0.003327858,0.0034664664,0.0040722103,0.59372497,0.00039476968,0.0077624,0.3724387],"study_design_scores_gemma":[0.13733348,0.0058457414,0.03205408,0.0005499504,0.00033469245,0.0055772555,0.003575561,0.049472928,0.32476982,0.0009933906,0.43596607,0.0035270164],"about_ca_topic_score_codex":0.009675176,"about_ca_topic_score_gemma":0.00031558538,"teacher_disagreement_score":0.42820367,"about_ca_system_score_codex":0.18236835,"about_ca_system_score_gemma":0.045460492,"threshold_uncertainty_score":0.9999384},"labels":[],"label_agreement":null},{"id":"W4220970057","doi":"10.1080/10428194.2022.2047674","title":"Long-term follow up of relapsed/refractory non-Hodgkin lymphoma patients treated with single-agent selinexor – a retrospective, single center study","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Single Center; Refractory (planetary science); Lymphoma; Internal medicine; Adverse effect; Retrospective cohort study; Oncology; Cohort; Gastroenterology; Surgery","score_opus":0.012991366514394826,"score_gpt":0.23037435745385598,"score_spread":0.21738299093946115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220970057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917512,0.0008321097,0.000016607713,0.00006340607,0.0007842845,0.0033653413,0.00039839145,0.00033026622,0.0024584197],"genre_scores_gemma":[0.99427617,0.0001710184,0.00021248624,0.00062497676,0.00023070669,0.0010087735,0.00090618845,0.0003200009,0.0022496707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918208,0.00044712544,0.0017527589,0.0022495063,0.0022230446,0.0015067395],"domain_scores_gemma":[0.99523354,0.00027176982,0.0011452899,0.001832846,0.0006266078,0.0008899781],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00044464722,0.0015257095,0.0022891087,0.0007996462,0.00091061095,0.00016760713,0.00061946263,0.00039831406,0.00030405624],"category_scores_gemma":[0.00010437549,0.001285029,0.00064530724,0.0014532694,0.00043657064,0.00045398978,0.00070303323,0.00021419836,0.00004550144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007545382,0.022458525,0.8871148,0.0002237525,0.0017543881,0.0019896678,0.0023964134,0.00002058972,0.0016905043,0.000020292307,0.0018629556,0.072922714],"study_design_scores_gemma":[0.122937344,0.018375678,0.8458696,0.00040713078,0.0014591522,0.0011008893,0.0010546525,0.00019979636,0.0048231184,0.000010099725,0.0026186255,0.0011439262],"about_ca_topic_score_codex":0.0021075066,"about_ca_topic_score_gemma":0.00026321659,"teacher_disagreement_score":0.11539196,"about_ca_system_score_codex":0.026842467,"about_ca_system_score_gemma":0.0024822245,"threshold_uncertainty_score":0.9997492},"labels":[],"label_agreement":null},{"id":"W4221042673","doi":"10.1080/10428194.2021.2002321","title":"Real-world treatment patterns and clinical outcomes in patients with AML unfit for first-line intensive chemotherapy <sup>*</sup>","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"AbbVie","keywords":"Medicine; Cytarabine; Internal medicine; Myeloid leukemia; Retrospective cohort study; Oncology; Chemotherapy","score_opus":0.019842773664186884,"score_gpt":0.3008118159603816,"score_spread":0.2809690422961947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221042673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99372005,0.0001407206,0.000065042586,0.0014821102,0.0001671906,0.00338173,0.0004489402,0.00018056859,0.00041364165],"genre_scores_gemma":[0.9880522,0.0014301442,0.0007325653,0.003918371,0.00028202208,0.0010088113,0.00072749396,0.00025224435,0.0035961657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99425846,0.0002676786,0.0013889434,0.0017273759,0.00096848747,0.0013890308],"domain_scores_gemma":[0.99601436,0.0012660186,0.00040499572,0.0011115143,0.00042810218,0.000775008],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066553854,0.0010078113,0.002006698,0.0007757281,0.00062792917,0.00011192125,0.00041356703,0.00034916852,0.00015865249],"category_scores_gemma":[0.00022353418,0.0007959811,0.00041295556,0.0007777841,0.00048816742,0.00024954823,0.0004531146,0.00037796746,0.000012942951],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009016664,0.00092906755,0.8799825,0.00017163718,0.00080999685,0.00032144983,0.0014308034,0.00015333162,0.000005516283,0.0001608463,0.0013874178,0.10563078],"study_design_scores_gemma":[0.099820994,0.0062513603,0.86663795,0.0001668519,0.00036791104,0.00016502381,0.0012668457,0.010749073,0.000092992945,0.00013689637,0.013548167,0.0007959504],"about_ca_topic_score_codex":0.009949648,"about_ca_topic_score_gemma":0.0017275655,"teacher_disagreement_score":0.104834825,"about_ca_system_score_codex":0.01959571,"about_ca_system_score_gemma":0.003498449,"threshold_uncertainty_score":0.99944913},"labels":[],"label_agreement":null},{"id":"W4221096818","doi":"10.1080/10428194.2022.2043304","title":"Momelotinib reduces transfusion requirements in patients with myelofibrosis","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sierra Oncology","keywords":"Myelofibrosis; Medicine; Blood transfusion; Intensive care medicine; Hematologic Neoplasms; Internal medicine; Cancer; Bone marrow","score_opus":0.011677659078381407,"score_gpt":0.22856058992765435,"score_spread":0.21688293084927293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221096818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9670621,0.0010769828,0.0000030692468,0.023578376,0.0005950111,0.0030464078,0.0004066826,0.00023045648,0.0040008724],"genre_scores_gemma":[0.73067254,0.0037801785,0.0009889635,0.24206066,0.0020695026,0.0031599153,0.009720476,0.0008272232,0.0067205196],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99191236,0.00037312307,0.0014587402,0.00242021,0.0022275744,0.0016080054],"domain_scores_gemma":[0.9970912,0.0003601413,0.0006343816,0.0011937367,0.00025293115,0.00046763773],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00032642388,0.0017318543,0.0023504228,0.0010072631,0.0006143797,0.0001968367,0.0004799145,0.0013671679,0.0009649613],"category_scores_gemma":[0.000062671694,0.0014191485,0.000423304,0.0010305205,0.00036593864,0.0003818221,0.0002947982,0.0008969331,0.000065387125],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008458223,0.0022170956,0.36199465,0.0017462798,0.0018608843,0.0059683435,0.002381618,0.00003230581,0.0001842553,0.00006781811,0.44317406,0.17191446],"study_design_scores_gemma":[0.05404688,0.0048483396,0.52793866,0.0020392684,0.0011707023,0.0003347117,0.0002130162,0.00010721676,0.0018842164,0.000057627487,0.40537775,0.0019816041],"about_ca_topic_score_codex":0.0016668394,"about_ca_topic_score_gemma":0.00008321286,"teacher_disagreement_score":0.23638959,"about_ca_system_score_codex":0.015226315,"about_ca_system_score_gemma":0.003578403,"threshold_uncertainty_score":0.99994826},"labels":[],"label_agreement":null},{"id":"W4225252886","doi":"10.1080/10428194.2022.2057484","title":"A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Roche","keywords":"Atezolizumab; Medicine; Internal medicine; Cohort; Myeloid leukemia; Adverse effect; Myeloid; Gastroenterology; Phases of clinical research; Oncology; Clinical trial; Cancer","score_opus":0.018746075209494596,"score_gpt":0.29706529832496653,"score_spread":0.2783192231154719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225252886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910254,0.0016107665,0.00017093147,0.00032418937,0.00018901301,0.0058604213,0.00029304714,0.000096583906,0.00042964623],"genre_scores_gemma":[0.99343187,0.0011522281,0.00048889185,0.00020140539,0.00013419158,0.0027434055,0.00029236774,0.00016896956,0.0013866544],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99436706,0.000355354,0.0015148327,0.001182913,0.0014957055,0.0010841237],"domain_scores_gemma":[0.9960103,0.0010439868,0.0007273065,0.001462261,0.00041716476,0.00033900424],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008367776,0.0008249847,0.001766989,0.00090533955,0.00063343614,0.00005327263,0.0006957029,0.00024985272,0.00008577967],"category_scores_gemma":[0.00008297451,0.00059339224,0.00035264296,0.0018737207,0.00055698765,0.00025027926,0.00031377378,0.00025023636,0.000004218473],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.09489241,0.04878114,0.024436185,0.0010452193,0.0070875217,0.0022921762,0.04091418,0.0019378038,0.02516144,0.0018764647,0.0030171848,0.7485583],"study_design_scores_gemma":[0.6533553,0.10972285,0.08919622,0.00028969548,0.0037003348,0.002575301,0.026065307,0.06674821,0.023259092,0.00033892883,0.023287319,0.0014614721],"about_ca_topic_score_codex":0.0061202752,"about_ca_topic_score_gemma":0.000341402,"teacher_disagreement_score":0.7470968,"about_ca_system_score_codex":0.025475256,"about_ca_system_score_gemma":0.007379149,"threshold_uncertainty_score":0.99965173},"labels":[],"label_agreement":null},{"id":"W4225305158","doi":"10.1080/10428194.2022.2064981","title":"Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Blinatumomab; Medicine; Chemotherapy; Oncology; Internal medicine; Leukemia; Lymphoblastic Leukemia","score_opus":0.009542903617033152,"score_gpt":0.2629823416724143,"score_spread":0.25343943805538116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225305158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911615,0.003195075,0.000011776445,0.0002568739,0.00027767755,0.0040198294,0.0003171634,0.00013902984,0.0006210755],"genre_scores_gemma":[0.99197984,0.0011662623,0.0010978135,0.0013486379,0.00016844811,0.0032503265,0.00026025288,0.00020188236,0.00052655325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99400944,0.00044610535,0.0014156329,0.0017883042,0.001269767,0.0010707639],"domain_scores_gemma":[0.99655616,0.00039839654,0.0007457061,0.0015188355,0.000200752,0.0005801531],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000602701,0.0010429823,0.0019620962,0.0006717588,0.00048585003,0.0001470621,0.00080587226,0.0002661515,0.00036218512],"category_scores_gemma":[0.00006913303,0.0008686416,0.00016051196,0.0013544911,0.00026870501,0.0004502167,0.0008783379,0.00028368138,0.000020487201],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06597168,0.057725012,0.46118817,0.00031089905,0.001328603,0.012158435,0.0096667,0.00019879935,0.00014908529,0.00020239594,0.0025341974,0.38856602],"study_design_scores_gemma":[0.47398984,0.019676104,0.4914822,0.00046092106,0.00071390194,0.0007996419,0.005113047,0.0019805895,0.0007701466,0.000094619776,0.0040151034,0.0009038581],"about_ca_topic_score_codex":0.030736612,"about_ca_topic_score_gemma":0.0020841628,"teacher_disagreement_score":0.40801817,"about_ca_system_score_codex":0.008133803,"about_ca_system_score_gemma":0.003016292,"threshold_uncertainty_score":0.9993764},"labels":[],"label_agreement":null},{"id":"W4229005543","doi":"10.1080/10428194.2022.2060505","title":"Radioimmunotherapy for orbital marginal zone lymphoma: a retrospective review","year":2022,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine","score_opus":0.029441916850048464,"score_gpt":0.30669290550330847,"score_spread":0.27725098865326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4229005543","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011354898,0.98174673,0.00004442344,0.00021041626,0.0013586853,0.009281763,0.0012817617,0.0005807792,0.0043599284],"genre_scores_gemma":[0.0002578679,0.97367775,0.0011620534,0.0024938213,0.0012452801,0.010536963,0.0037023046,0.0007841472,0.006139806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9881962,0.0005922899,0.0033659306,0.0036315494,0.0018308776,0.0023831676],"domain_scores_gemma":[0.9921995,0.0013755006,0.0020827046,0.0028390458,0.00033662273,0.0011666574],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013032256,0.0033372792,0.010240975,0.00096629397,0.0013043345,0.00031606556,0.0010485254,0.0014608973,0.0012293467],"category_scores_gemma":[0.00036997735,0.0028075243,0.0042829076,0.0018969608,0.00063705444,0.00041790056,0.0006326068,0.00039697668,0.00022825568],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00073820556,0.0010959981,0.00009425787,0.046075154,0.0034515553,0.0019916492,0.00016097548,3.12168e-7,0.0000019325785,0.0011105434,0.02925861,0.9160208],"study_design_scores_gemma":[0.028450152,0.0019383891,0.0012331945,0.03702183,0.011114213,0.017110469,0.00008390046,0.000055482575,0.000011863746,0.00010193508,0.90046895,0.0024096107],"about_ca_topic_score_codex":0.001122851,"about_ca_topic_score_gemma":0.000023427572,"teacher_disagreement_score":0.9136112,"about_ca_system_score_codex":0.05380495,"about_ca_system_score_gemma":0.016650455,"threshold_uncertainty_score":0.9999958},"labels":[],"label_agreement":null},{"id":"W4246681679","doi":"10.1080/10428190210192","title":"Results of a Randomized Phase III Trial in Children and Adolescents with Advanced Stage Diffuse Large Cell Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Study","year":2002,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Vincristine; Prednisone; Cyclophosphamide; Internal medicine; Working Formulation; Lymphoma; Diffuse large B-cell lymphoma; Stage (stratigraphy); Methotrexate; Randomized controlled trial; Oncology; Lymphoblastic lymphoma; Chemotherapy; Gastroenterology; Surgery; Non-Hodgkin's lymphoma; Immunology; T cell","score_opus":0.007457312578628314,"score_gpt":0.2532243498802955,"score_spread":0.2457670373016672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246681679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98550266,0.003965742,0.000024176832,0.000054322092,0.0002391441,0.008741999,0.00023872306,0.00015039652,0.0010828251],"genre_scores_gemma":[0.9916195,0.0054262327,0.00036768755,0.00032786836,0.00034050312,0.0011414835,0.00017859576,0.00015644757,0.0004416792],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922825,0.00069474336,0.002510054,0.001969328,0.0011031063,0.0014402671],"domain_scores_gemma":[0.9957203,0.0006599651,0.0013458673,0.0012153228,0.00019510726,0.0008634307],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012962384,0.0013080245,0.0040917303,0.0009616191,0.00031236312,0.000108215885,0.00038240736,0.00063830375,0.000031567288],"category_scores_gemma":[0.00023141001,0.0010072613,0.00048544002,0.0011264357,0.00048932876,0.0004140631,0.00034376624,0.000190234,0.000018431369],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7697125,0.061982654,0.079057515,0.00039161133,0.000816987,0.0020864687,0.0050496114,0.000010064005,0.00016428807,0.000043105643,0.00042007776,0.080265105],"study_design_scores_gemma":[0.8257941,0.010525545,0.15691862,0.00035114377,0.001887669,0.00040543487,0.0008913709,0.0016942973,0.00037024406,0.000009399922,0.00032885754,0.00082332117],"about_ca_topic_score_codex":0.0030062464,"about_ca_topic_score_gemma":0.0002893041,"teacher_disagreement_score":0.079441786,"about_ca_system_score_codex":0.0048327753,"about_ca_system_score_gemma":0.0014800205,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W4280597826","doi":"10.1080/10428194.2022.2076848","title":"Differential use of the hematopoietic cell transplantation-comorbidity index among adult and pediatric transplant physicians","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; AbbVie Canada; Sanofi Genzyme; Genentech; Health Resources and Services Administration; CytoSen Therapeutics; MorphoSys; Kyowa Hakko Kirin; Vertex Pharmaceuticals; Omeros Corporation; Bristol-Myers Squibb; Instituto Nacional de Cancerología; Adaptive Biotechnologies; Incyte; Kiadis Pharma; bluebird bio; Medical College of Wisconsin; StemCyte; CSL Behring; Karyopharm Therapeutics; National Cancer Institute; Gilead Sciences; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Daiichi-Sankyo; Accenture; Merck; GlaxoSmithKline; Be The Match Foundation; Seagen; Astellas Pharma US; Medac; Jazz Pharmaceuticals; National Marrow Donor Program","keywords":"Medicine; Family medicine; Health care; Management; Business; Political science; Law","score_opus":0.010881083615651724,"score_gpt":0.20822707808181493,"score_spread":0.1973459944661632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280597826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99069166,0.00047333058,0.00031864885,0.0040340843,0.0008964655,0.0016941489,0.001168593,0.00016593139,0.00055712776],"genre_scores_gemma":[0.9602583,0.005542669,0.000118300595,0.029374441,0.0011277449,0.00024734825,0.0014423834,0.0002733813,0.0016154541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99389905,0.00046610195,0.0015011485,0.0014223664,0.0016861353,0.0010251958],"domain_scores_gemma":[0.9965463,0.0008900912,0.000920606,0.0011697618,0.0001924057,0.00028080723],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00017255072,0.001236628,0.0017832598,0.0004872292,0.00054397434,0.00014401015,0.00054696307,0.0014267357,0.00022248061],"category_scores_gemma":[0.000028666102,0.0010388141,0.00067186035,0.00070514175,0.00070073653,0.00029854104,0.00012514046,0.0010732051,0.000008630774],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004774759,0.0014379821,0.6232499,0.07730496,0.002120016,0.011688783,0.031137288,0.00022991643,0.0067255385,0.00028688172,0.22829895,0.012745064],"study_design_scores_gemma":[0.028177185,0.00066866726,0.91097385,0.0026752015,0.010217616,0.006575814,0.00060612115,0.0026926652,0.015139832,0.00015963621,0.01929238,0.0028210105],"about_ca_topic_score_codex":0.0026297525,"about_ca_topic_score_gemma":0.00008549074,"teacher_disagreement_score":0.28772402,"about_ca_system_score_codex":0.0016711619,"about_ca_system_score_gemma":0.002172323,"threshold_uncertainty_score":0.99986964},"labels":[],"label_agreement":null},{"id":"W4283259643","doi":"10.1080/10428194.2022.2086251","title":"Optimizing pegaspargase therapy in patients with hypersensitivity reactions","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Eosinophilic Esophagitis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; Izaak Walton Killam Health Centre","funders":"","keywords":"Medicine; Intensive care medicine; Pharmacology","score_opus":0.010771804502194603,"score_gpt":0.2161162079237528,"score_spread":0.20534440342155819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283259643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9621358,0.0017612583,0.000008802352,0.02481427,0.0006924778,0.002116527,0.00031164414,0.0004494527,0.0077097933],"genre_scores_gemma":[0.64028746,0.0015590079,0.0014378851,0.34374005,0.0025631816,0.0006209397,0.0038590454,0.00077386555,0.005158561],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928698,0.0004666583,0.0011702322,0.0021297834,0.0017245953,0.001638918],"domain_scores_gemma":[0.9962338,0.00056955963,0.000681642,0.0017613168,0.0002906935,0.00046295128],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0004253872,0.0015155205,0.002058694,0.0011279495,0.0005926469,0.00017712478,0.0004293102,0.0015596298,0.00037500754],"category_scores_gemma":[0.00012987792,0.0014057665,0.00040526857,0.0011382571,0.00056438823,0.0004515248,0.0003229233,0.0017075709,0.00005620421],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011901318,0.0024743115,0.09927326,0.0022222477,0.0026567534,0.05287132,0.00417312,0.00039691175,0.0005136604,0.00012926625,0.5537143,0.26967353],"study_design_scores_gemma":[0.051416878,0.0028204266,0.25034133,0.0010524021,0.0005827259,0.0032009026,0.00029125414,0.00057554507,0.00031645232,0.000064655775,0.6870447,0.002292736],"about_ca_topic_score_codex":0.0039689923,"about_ca_topic_score_gemma":0.000066782246,"teacher_disagreement_score":0.32184833,"about_ca_system_score_codex":0.01766486,"about_ca_system_score_gemma":0.0049557993,"threshold_uncertainty_score":0.9997594},"labels":[],"label_agreement":null},{"id":"W4285027377","doi":"10.1080/10428194.2022.2095624","title":"PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design","year":2022,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"Janssen Biotech; Chugai Pharmaceutical; H. Lundbeck A/S; Servier; Incyte; AbbVie; Takeda Pharmaceutical Company; Teva Pharmaceutical Industries; Sandoz; MorphoSys; Celgene; Seattle Genetics; Karyopharm Therapeutics; Gilead Sciences; Merck; TG Therapeutics; Amgen","keywords":"Chemoimmunotherapy; Hazard ratio; Medicine; Internal medicine; Clinical trial; Diffuse large B-cell lymphoma; Clinical endpoint; Oncology; Meta-analysis; Progression-free survival; Sample size determination; Surrogate endpoint; Proportional hazards model; Overall survival; Confidence interval; Lymphoma; Nuclear medicine; Rituximab; Statistics","score_opus":0.206374533336237,"score_gpt":0.4167294272308164,"score_spread":0.2103548938945794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285027377","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069160843,0.98120445,0.0002154979,0.00034167067,0.00042171642,0.009104155,0.0011670633,0.0002386095,0.00039073176],"genre_scores_gemma":[0.0054498105,0.977465,0.0014771759,0.00063241983,0.00042992848,0.009994638,0.003216277,0.00027743948,0.0010573233],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98912936,0.0016205,0.0039055084,0.003159716,0.00077858265,0.0014063139],"domain_scores_gemma":[0.9908828,0.004254511,0.0016442001,0.0019795774,0.00016172924,0.0010771566],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0023886207,0.0019964906,0.011149818,0.0016800417,0.00066146615,0.0003287458,0.00060048816,0.0010614011,0.00049847364],"category_scores_gemma":[0.000568691,0.0015532022,0.0073459996,0.0022562663,0.0004552779,0.00021590554,0.00051948807,0.00036723778,0.000046284247],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010749167,0.0021581517,0.00022733172,0.0023853572,0.122129105,0.001517271,0.00010505419,0.000012917673,5.071612e-7,0.0008038025,0.0013740698,0.85853726],"study_design_scores_gemma":[0.10097227,0.002055677,0.0024676395,0.00027214797,0.40343457,0.0021597254,0.000056393983,0.00031459637,0.000004023398,0.00037003573,0.48671302,0.0011799055],"about_ca_topic_score_codex":0.0024211777,"about_ca_topic_score_gemma":0.00015812449,"teacher_disagreement_score":0.8573574,"about_ca_system_score_codex":0.009634995,"about_ca_system_score_gemma":0.010492253,"threshold_uncertainty_score":0.9992778},"labels":[],"label_agreement":null},{"id":"W4285077352","doi":"10.1080/10428194.2022.2095628","title":"Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Kidney Injury Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's & Women's Health Centre of British Columbia","funders":"","keywords":"Medicine; Renal replacement therapy; Hematopoietic stem cell transplantation; Retrospective cohort study; Acute kidney injury; Dialysis; Transplantation; Mortality rate; Survival rate; Internal medicine; Cohort; Surgery; Pediatrics","score_opus":0.013548722463097303,"score_gpt":0.26259608006275537,"score_spread":0.24904735759965807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285077352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463505,0.0009606731,0.0000071775794,0.00024265208,0.00027575565,0.0020313659,0.0005006519,0.00006450205,0.0012821655],"genre_scores_gemma":[0.9961343,0.0011456499,0.000035538622,0.00043805776,0.00014300906,0.00053936907,0.000091497604,0.000067480905,0.0014051358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957069,0.00036401555,0.00090054487,0.00088425836,0.001621888,0.0005223876],"domain_scores_gemma":[0.99799216,0.0002546748,0.00052960234,0.0006909309,0.00027703145,0.00025562246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085005973,0.0003999447,0.00058663817,0.00031787285,0.0007398588,0.000053993866,0.0003263918,0.00013031883,0.000052397136],"category_scores_gemma":[0.00006853698,0.00031567935,0.00013708464,0.0009493322,0.00017655398,0.00019653064,0.00032699612,0.00024644905,0.0000024623862],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010855585,0.0010825323,0.94353807,0.0005242728,0.00032414496,0.00009936367,0.018500969,0.0000503881,0.0023195772,0.00006131586,0.0064517884,0.016191985],"study_design_scores_gemma":[0.050303373,0.0025072906,0.9334441,0.00008723123,0.00043080217,0.00015260534,0.002772439,0.00042574975,0.008430607,0.00005651988,0.0010063234,0.0003829932],"about_ca_topic_score_codex":0.0010144747,"about_ca_topic_score_gemma":0.00003125643,"teacher_disagreement_score":0.039447784,"about_ca_system_score_codex":0.005008271,"about_ca_system_score_gemma":0.0023822354,"threshold_uncertainty_score":0.99992955},"labels":[],"label_agreement":null},{"id":"W4285389858","doi":"10.1080/10428194.2022.2092853","title":"Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Myeloid leukemia; Refractory (planetary science); Pharmacokinetics; Antibody; Oncology; Pharmacology; Internal medicine; Immunology; Cancer; Immunotherapy; Nivolumab","score_opus":0.039697565353864255,"score_gpt":0.3630186783913506,"score_spread":0.32332111303748634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285389858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98412764,0.0006118078,0.000016438224,0.0043880665,0.00027317205,0.009137082,0.00042557283,0.00010190355,0.000918344],"genre_scores_gemma":[0.94762456,0.0027487003,0.00075971667,0.03614579,0.0005151145,0.0011081457,0.0026241483,0.0006819232,0.0077918977],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9899515,0.0012799464,0.0019291501,0.0023442262,0.0029398194,0.0015553775],"domain_scores_gemma":[0.9945693,0.00117444,0.0012198017,0.0018160425,0.00066568423,0.00055472023],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018875317,0.0015596207,0.0027056776,0.0010595632,0.0008455735,0.00040555067,0.0012278676,0.00080857344,0.00032133114],"category_scores_gemma":[0.00021548654,0.0010925352,0.00012296585,0.0017864072,0.00081276917,0.00049857824,0.0016639541,0.0015894147,0.0000057537873],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.32022327,0.015259066,0.031254243,0.003302249,0.00587833,0.009435024,0.016234297,0.000051642095,0.019379199,0.00003463593,0.024217365,0.5547307],"study_design_scores_gemma":[0.6661444,0.099972434,0.113289766,0.0025301368,0.0037430995,0.0019294006,0.002404309,0.005592987,0.0012721354,0.000026793856,0.10018355,0.0029110045],"about_ca_topic_score_codex":0.0027150386,"about_ca_topic_score_gemma":0.00018134022,"teacher_disagreement_score":0.5518197,"about_ca_system_score_codex":0.011049716,"about_ca_system_score_gemma":0.008408324,"threshold_uncertainty_score":0.9997152},"labels":[],"label_agreement":null},{"id":"W4294844962","doi":"10.1080/10428194.2022.2118536","title":"Prognostic factors and outcomes of infant acute lymphoblastic leukemia (ALL), hypodiploid ALL, and mixed-phenotype acute leukemia (MPAL) in Canada: a report from CYP-C","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Children's Hospital; Izaak Walton Killam Health Centre; Dalhousie University; BC Children's Hospital; Centre Hospitalier Universitaire Sainte-Justine; McMaster Children's Hospital; Université Laval; Université de Montréal","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; Phenotype; Internal medicine; Oncology; Leukemia; Acute lymphocytic leukemia; Acute leukemia; Pediatrics; Cancer research; Biology; Gene; Genetics","score_opus":0.011892839809546652,"score_gpt":0.24647278469254,"score_spread":0.23457994488299336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294844962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907241,0.0031823104,0.0000644302,0.00042129567,0.0009100158,0.0023998616,0.0013722295,0.00028185328,0.0006439187],"genre_scores_gemma":[0.9920561,0.0017450678,0.00103066,0.0018770181,0.00020986196,0.0006056331,0.0012605018,0.0004094572,0.0008057373],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98649085,0.00060736603,0.0033156343,0.0033197403,0.0033535028,0.0029129086],"domain_scores_gemma":[0.99091744,0.002990443,0.0014188542,0.002227786,0.00039981617,0.0020456729],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011168038,0.0022327907,0.004100919,0.0012923153,0.0007645978,0.00023906666,0.0011962302,0.0008393078,0.00020881645],"category_scores_gemma":[0.0011646338,0.0020255658,0.00047084,0.0016831697,0.0012168891,0.000739652,0.002824388,0.0009897633,0.0000151627955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0050091115,0.0004175807,0.9147193,0.0007849824,0.0060865576,0.024663461,0.003974435,0.0003827237,0.014672458,0.00034001865,0.00632494,0.022624437],"study_design_scores_gemma":[0.03192818,0.0010905156,0.9231303,0.0004217669,0.003107069,0.009557794,0.002961985,0.015139246,0.0040734955,0.0004306808,0.005975775,0.0021831933],"about_ca_topic_score_codex":0.7157347,"about_ca_topic_score_gemma":0.14158814,"teacher_disagreement_score":0.57414657,"about_ca_system_score_codex":0.080281086,"about_ca_system_score_gemma":0.064139694,"threshold_uncertainty_score":0.9990412},"labels":[],"label_agreement":null},{"id":"W4294908193","doi":"10.1080/10428194.2022.2109157","title":"Development of a distributed international patient data registry for hairy cell leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University; University of Manitoba; Research Institute in Oncology and Hematology","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Cancer Research UK; Hairy Cell Leukemia Foundation","keywords":"Hairy cell leukemia; Excellence; Medicine; Disease registry; Leukemia; Disease; Pathology; Internal medicine; Political science","score_opus":0.03041926185656664,"score_gpt":0.2864874881111542,"score_spread":0.2560682262545876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4294908193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863893,0.001706969,0.0019098752,0.00022008103,0.0010171159,0.0019464912,0.0029605362,0.00025633845,0.0035933095],"genre_scores_gemma":[0.9698875,0.00023111321,0.01651903,0.0007872132,0.00039830297,0.00083963096,0.008960632,0.00020466228,0.0021719304],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924193,0.00017053662,0.001896567,0.0019283784,0.0022041737,0.0013810219],"domain_scores_gemma":[0.9947606,0.00055134227,0.00086271117,0.0026500856,0.00044199728,0.00073327037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011504828,0.0008287155,0.0012505354,0.0005202833,0.000920387,0.00012424961,0.0019652836,0.00039963867,0.00031936326],"category_scores_gemma":[0.0004388668,0.0008428736,0.00033991563,0.00084438926,0.0004965875,0.00039488205,0.003522093,0.00034162044,0.000028524966],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018800905,0.002915106,0.0021496015,0.0046686237,0.002973999,0.0023638431,0.010445852,0.0022267092,0.044122547,0.0018907809,0.18439774,0.7230443],"study_design_scores_gemma":[0.07642787,0.00088708854,0.0032428901,0.0003426123,0.00044152394,0.0030136378,0.0048888093,0.14381139,0.030932529,0.00017950483,0.73444253,0.0013895958],"about_ca_topic_score_codex":0.0012479752,"about_ca_topic_score_gemma":0.000066854736,"teacher_disagreement_score":0.7216547,"about_ca_system_score_codex":0.1141712,"about_ca_system_score_gemma":0.070285715,"threshold_uncertainty_score":0.9994022},"labels":[],"label_agreement":null},{"id":"W4295423248","doi":"10.1080/10428194.2022.2109154","title":"A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"EVERSANA (Canada); Bristol-Myers Squibb (Canada); Dalhousie University; Hamilton Health Sciences; Hôpital de l'Enfant-Jésus; Juravinski Cancer Centre; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; University of British Columbia; McGill University Health Centre; University of Ottawa; Sunnybrook Health Science Centre; Jewish General Hospital; University of Alberta; CancerCare Manitoba; Health Sciences Centre; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelodysplastic syndromes; Medicine; Natural history; International Prognostic Scoring System; Internal medicine; Clinical trial; Myeloid leukemia; Natural history study; Pediatrics; Bone marrow","score_opus":0.009955952144202041,"score_gpt":0.22864631906547972,"score_spread":0.2186903669212777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295423248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944759,0.002395154,0.00005242086,0.00015709383,0.00044650905,0.0006960422,0.00021596337,0.00013488061,0.0014260074],"genre_scores_gemma":[0.99393135,0.0001915379,0.00052253937,0.0004514975,0.000106900196,0.00014391365,0.0001303558,0.00014094151,0.0043809875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941138,0.00057586544,0.0010939839,0.0012416615,0.0019634299,0.0010112537],"domain_scores_gemma":[0.9951224,0.00065073045,0.0011643503,0.0022006042,0.00035608019,0.00050587323],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008205137,0.0007411641,0.001775157,0.0011346593,0.00060117635,0.000052421965,0.0010997306,0.0002800759,0.00025996423],"category_scores_gemma":[0.00036088467,0.00056178164,0.0006485088,0.002648441,0.0016738353,0.00027123652,0.00086314656,0.0006511655,0.0000034080629],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04332791,0.004362213,0.51848346,0.0057837437,0.04003953,0.008518247,0.03600757,0.05129401,0.13575359,0.0052775852,0.020290071,0.13086206],"study_design_scores_gemma":[0.02842996,0.004042549,0.7600879,0.00070665835,0.01117361,0.0067592175,0.0075209024,0.15989588,0.004926873,0.000117172545,0.014613925,0.0017253398],"about_ca_topic_score_codex":0.0069717434,"about_ca_topic_score_gemma":0.0007232298,"teacher_disagreement_score":0.24160443,"about_ca_system_score_codex":0.029567195,"about_ca_system_score_gemma":0.014234636,"threshold_uncertainty_score":0.9996834},"labels":[],"label_agreement":null},{"id":"W4297338547","doi":"10.1080/10428194.2022.2123226","title":"Clinical utility of interim CT scans in patients receiving chemoimmuntherapy for first line treatment of follicular lymphoma","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Princess Margaret Cancer Foundation","keywords":"Chemoimmunotherapy; Medicine; Asymptomatic; Follicular lymphoma; Biopsy; Radiology; Malignancy; Lymphoma; Interim; Internal medicine; Surgery; Oncology; Rituximab","score_opus":0.026550311206926063,"score_gpt":0.2996931429276785,"score_spread":0.27314283172075243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297338547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923527,0.0033236607,0.00003450901,0.00015231967,0.0005541158,0.0023550682,0.00041748703,0.000080853344,0.0007292556],"genre_scores_gemma":[0.99444115,0.002625048,0.00063242385,0.000292395,0.00014002537,0.0010146223,0.00052024965,0.00011856122,0.00021551957],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944507,0.0002852964,0.0023437105,0.0012639653,0.00078337453,0.0008729361],"domain_scores_gemma":[0.99638015,0.00082113314,0.0009144626,0.0012311817,0.0002666302,0.00038642663],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007658095,0.0008185649,0.0023291488,0.00044866392,0.0003560852,0.000032159405,0.00038937276,0.00026206858,0.0001480308],"category_scores_gemma":[0.00018397745,0.0007296614,0.0009568932,0.00077714166,0.00041562124,0.00016776775,0.00028047326,0.00007685848,0.000004011892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004495335,0.007100646,0.5235316,0.00029719184,0.00066165114,0.000107797074,0.0007884352,0.000043619602,0.00012785752,0.00008542443,0.0004063501,0.46235406],"study_design_scores_gemma":[0.095554076,0.0066851596,0.8630911,0.00037424144,0.00053853117,0.00015966283,0.0004342905,0.0040609725,0.0077397004,0.00012509206,0.02066648,0.0005706531],"about_ca_topic_score_codex":0.0033985002,"about_ca_topic_score_gemma":0.00022741071,"teacher_disagreement_score":0.4617834,"about_ca_system_score_codex":0.0092316335,"about_ca_system_score_gemma":0.0028303498,"threshold_uncertainty_score":0.9995155},"labels":[],"label_agreement":null},{"id":"W4297988839","doi":"10.1080/10428194.2022.2126282","title":"Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Antifungal resistance and susceptibility","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surrey Memorial Hospital","funders":"","keywords":"Posaconazole; Medicine; Hematology; Internal medicine; Therapeutic drug monitoring; Gastroenterology; Pharmacology; Antifungal; Pharmacokinetics; Voriconazole","score_opus":0.010899608130516722,"score_gpt":0.2568458399961135,"score_spread":0.24594623186559678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297988839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995253,0.0032105143,0.0000843,0.000008315308,0.00013782202,0.00084522035,0.00023644033,0.000028972703,0.00019540223],"genre_scores_gemma":[0.99904555,0.00051191665,0.00012935698,0.00007293321,0.000012558317,0.00009574002,0.00007406979,0.000033417466,0.000024443349],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99713016,0.000559086,0.0008021667,0.0005742562,0.00048339542,0.00045092852],"domain_scores_gemma":[0.9981388,0.0007449157,0.00041677465,0.0004002006,0.000120291836,0.0001790399],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068550644,0.00034417224,0.0011336787,0.00024400599,0.00022303485,0.0000120299455,0.00013462862,0.00016466233,0.000058340855],"category_scores_gemma":[0.00015185623,0.00031152903,0.00015232533,0.00044292668,0.00041135435,0.00013099644,0.00016635735,0.00014280836,5.4241673e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039684307,0.00033978105,0.95853835,0.00068111054,0.00019258738,0.000057724697,0.0022042633,0.00008612421,0.020625273,0.0004883443,0.00001002295,0.0128079625],"study_design_scores_gemma":[0.019093053,0.00097648957,0.9471898,0.0002816633,0.00022970223,0.000110181325,0.0022283583,0.0016728126,0.02759788,0.00022278125,0.00013913128,0.0002581239],"about_ca_topic_score_codex":0.0016145332,"about_ca_topic_score_gemma":0.000119009615,"teacher_disagreement_score":0.015124622,"about_ca_system_score_codex":0.002716049,"about_ca_system_score_gemma":0.0020156398,"threshold_uncertainty_score":0.99993366},"labels":[],"label_agreement":null},{"id":"W4308365535","doi":"10.1080/10428194.2022.2136968","title":"Expression of TCF3 target genes defines a subclass of diffuse large B-cell lymphoma characterized by up-regulation of MYC target genes and poor clinical outcome following R-CHOP therapy","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine; Leukemia and Lymphoma Society of Canada","keywords":"Diffuse large B-cell lymphoma; CHOP; Gene; Lymphoma; Biology; Cancer research; Transcription factor; Oncology; Internal medicine; Bioinformatics; Genetics; Medicine; Immunology","score_opus":0.018983383939383654,"score_gpt":0.27462303849781894,"score_spread":0.2556396545584353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308365535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717619,0.02489293,0.00011119173,0.00012356302,0.00065531075,0.0014581583,0.00070179673,0.00011270614,0.00018246555],"genre_scores_gemma":[0.9903823,0.005094404,0.001724292,0.000620399,0.00019070214,0.00046515433,0.0006937106,0.00016157085,0.0006674585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930751,0.00061061914,0.0028017017,0.001300896,0.0013026333,0.000909063],"domain_scores_gemma":[0.99566424,0.0008075347,0.0017402836,0.0010212202,0.00024844578,0.00051829545],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00112585,0.00097137387,0.002739509,0.00046899854,0.00046988646,0.00005214959,0.00043361224,0.0004687948,0.00014135826],"category_scores_gemma":[0.00011178127,0.00082817185,0.0009249466,0.00062524097,0.00039713073,0.00040684186,0.0005570438,0.0001193734,0.000004253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006441415,0.008647768,0.5316555,0.0008255956,0.00076936034,0.00011812023,0.0008666618,0.000014508982,0.3859475,0.00018083083,0.0011235367,0.06340924],"study_design_scores_gemma":[0.16427858,0.0028228683,0.41712674,0.00032559552,0.0007394942,0.00028229045,0.0008799909,0.0017040909,0.38252544,0.0001888054,0.028092608,0.0010334824],"about_ca_topic_score_codex":0.0007665242,"about_ca_topic_score_gemma":0.0000073438837,"teacher_disagreement_score":0.15783717,"about_ca_system_score_codex":0.001771585,"about_ca_system_score_gemma":0.0016334296,"threshold_uncertainty_score":0.9994169},"labels":[],"label_agreement":null},{"id":"W4309287965","doi":"10.1080/10428194.2022.2136956","title":"Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Cohort; Internal medicine; Lenalidomide; Oncology; Lymphoma; Refractory (planetary science); Clinical endpoint; Adverse effect; Multiple myeloma; Cancer; Clinical trial; Immunotherapy","score_opus":0.008453224238700503,"score_gpt":0.2541884000132351,"score_spread":0.2457351757745346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309287965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868465,0.0008991163,0.000096529526,0.00020705389,0.00071654393,0.00624734,0.00058298133,0.00041398275,0.002151809],"genre_scores_gemma":[0.98851156,0.00012529545,0.0008296372,0.0016931887,0.0004281008,0.0052137687,0.0011035777,0.00034061607,0.0017542371],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99221927,0.00027200842,0.0014186045,0.0023490114,0.0018960712,0.0018450483],"domain_scores_gemma":[0.9954736,0.0005547212,0.0006845805,0.0017417818,0.00045887905,0.0010864028],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005520104,0.0015223792,0.002022562,0.00068355247,0.0019502204,0.00026708364,0.00067080924,0.00034815184,0.0002489588],"category_scores_gemma":[0.00011187809,0.0012886879,0.0005999869,0.0011236981,0.0003493114,0.00046250963,0.00065819436,0.00016826176,0.00006714742],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039040405,0.060486723,0.27972218,0.0006019686,0.003431686,0.0026650294,0.005527374,0.00016152274,0.00023781699,0.000638051,0.020317659,0.5871696],"study_design_scores_gemma":[0.42460704,0.025184799,0.48443255,0.00017967992,0.0022699973,0.0010346142,0.0026026266,0.0034148446,0.000807045,0.00013462754,0.053541537,0.0017906536],"about_ca_topic_score_codex":0.0019083332,"about_ca_topic_score_gemma":0.00007689207,"teacher_disagreement_score":0.58537894,"about_ca_system_score_codex":0.017193504,"about_ca_system_score_gemma":0.005176039,"threshold_uncertainty_score":0.9997525},"labels":[],"label_agreement":null},{"id":"W4313431583","doi":"10.1080/10428194.2022.2148221","title":"Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development","keywords":"Daratumumab; Medicine; Tapering; Refractory (planetary science); Open label; Multicenter study; Multiple myeloma; Phases of clinical research; Oncology; Internal medicine; Clinical trial; Computer science; Materials science; Lenalidomide","score_opus":0.03396421959788129,"score_gpt":0.2982158978671249,"score_spread":0.26425167826924356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313431583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933383,0.00021398833,0.000006306635,0.00004600783,0.0002545108,0.0049948096,0.000164437,0.00014966595,0.0008319985],"genre_scores_gemma":[0.99634457,0.0002047512,0.00052173744,0.00025085328,0.000072234,0.0005441949,0.00022507878,0.00017031743,0.0016662452],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99404114,0.0005178357,0.0012971307,0.0014325009,0.0013872389,0.001324161],"domain_scores_gemma":[0.9963074,0.0006683979,0.00055062474,0.0015953984,0.00028117563,0.0005970092],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062447187,0.00082483713,0.0013442149,0.000459373,0.0006456805,0.00019899046,0.00085522386,0.00031853045,0.000057656478],"category_scores_gemma":[0.00058814604,0.0005367182,0.00013537731,0.0016842432,0.00037557783,0.0004864995,0.00096165104,0.0003653296,0.000037238173],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054644316,0.015369718,0.6856972,0.0005368809,0.00091979885,0.0021506855,0.0052911914,0.000020684372,0.0018204667,0.0000042413194,0.0008087374,0.2327361],"study_design_scores_gemma":[0.24091116,0.007553521,0.73250747,0.0009203774,0.00028028956,0.00022583338,0.0024218978,0.011889957,0.0011049118,0.0000033600857,0.0015566073,0.0006246278],"about_ca_topic_score_codex":0.0017643409,"about_ca_topic_score_gemma":0.00048312172,"teacher_disagreement_score":0.23211147,"about_ca_system_score_codex":0.004114084,"about_ca_system_score_gemma":0.0019584675,"threshold_uncertainty_score":0.99970895},"labels":[],"label_agreement":null},{"id":"W4313575780","doi":"10.1080/10428194.2022.2156793","title":"The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Bristol-Myers Squibb (Canada); Dalhousie University; Hamilton Health Sciences; McGill University Health Centre; University of Ottawa; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; University of British Columbia; Health Sciences Centre; CancerCare Manitoba; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Genentech; Otsuka Pharmaceutical; Astellas Pharma; Jazz Pharmaceuticals; Astex Pharmaceuticals; Taiho Pharmaceutical; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Janssen Pharmaceuticals; Gilead Sciences; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Myelodysplastic syndromes; Blood transfusion; Anemia; International Prognostic Scoring System; Internal medicine; Quality of life (healthcare); Pediatrics; Bone marrow","score_opus":0.005771964666928705,"score_gpt":0.21999720375555107,"score_spread":0.21422523908862237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313575780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974286,0.0002679224,0.000010986603,0.00022391527,0.0000790512,0.0012102012,0.00016273216,0.00009136424,0.0005252334],"genre_scores_gemma":[0.9981401,0.0007816258,0.000117012634,0.000035170357,0.00006059686,0.000105358784,0.000057692516,0.00009342548,0.00060900586],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99575984,0.0003276152,0.00091322133,0.0009854449,0.0011266785,0.00088718825],"domain_scores_gemma":[0.99644953,0.00088835414,0.0005538945,0.00139521,0.0003439722,0.00036905264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067910284,0.00056422775,0.0011939501,0.0007868298,0.0006356843,0.00009925056,0.0005864437,0.0003501597,0.000015562773],"category_scores_gemma":[0.00039686498,0.00035254197,0.0002697904,0.0038859728,0.0013170874,0.00020340172,0.00033774925,0.00035244809,0.0000022899403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038696588,0.0004946814,0.96557146,0.00061582495,0.0027151885,0.00025541775,0.00717794,0.0037447466,0.005460673,0.00019407514,0.00017647402,0.009723834],"study_design_scores_gemma":[0.01853231,0.0010630247,0.94645226,0.0004874208,0.002579548,0.00008184065,0.0032375932,0.024003739,0.0029897457,0.0000962102,0.000091095746,0.00038523212],"about_ca_topic_score_codex":0.005328476,"about_ca_topic_score_gemma":0.0011309915,"teacher_disagreement_score":0.020258991,"about_ca_system_score_codex":0.0024142212,"about_ca_system_score_gemma":0.0028111623,"threshold_uncertainty_score":0.99989265},"labels":[],"label_agreement":null},{"id":"W4321376636","doi":"10.1080/10428194.2023.2171729","title":"A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER)","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; CancerCare Manitoba; University of Manitoba","funders":"","keywords":"Chronic lymphocytic leukemia; Ibrutinib; Tumor microenvironment; Stromal cell; Cancer research; Fludarabine; Leukemia; Medicine; Bone marrow; Immunology; Internal medicine; Tumor cells; Chemotherapy","score_opus":0.017058968566526552,"score_gpt":0.2730238147016377,"score_spread":0.25596484613511117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321376636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889245,0.0058298106,0.0011501651,0.0008675127,0.0001165657,0.0021423069,0.00016866573,0.00020840963,0.0005920838],"genre_scores_gemma":[0.98210305,0.002684573,0.0066437228,0.0019596529,0.00020435084,0.00059931626,0.00024516368,0.00024178483,0.005318366],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98968065,0.0012171838,0.002104655,0.0025146818,0.0022302687,0.0022525522],"domain_scores_gemma":[0.99274665,0.0026652508,0.0006010889,0.002718912,0.0001044683,0.0011636445],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0053024446,0.001293268,0.002386497,0.0026301586,0.0005015639,0.00021170783,0.0012411948,0.00066029787,0.00010620827],"category_scores_gemma":[0.000542495,0.0011020594,0.0006449955,0.005705143,0.0013279961,0.00033268915,0.0011485058,0.00042051368,0.00018597573],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02627498,0.0006699382,0.0062405984,0.004340334,0.0071093175,0.0073151686,0.048481505,0.03842145,0.78672856,0.0024489255,0.0120272795,0.059941936],"study_design_scores_gemma":[0.11990352,0.0013590626,0.30445284,0.0021441823,0.0070273355,0.002131685,0.006158125,0.38396662,0.07978707,0.0007055067,0.08864197,0.003722078],"about_ca_topic_score_codex":0.0074355784,"about_ca_topic_score_gemma":0.00086768455,"teacher_disagreement_score":0.7069415,"about_ca_system_score_codex":0.20210887,"about_ca_system_score_gemma":0.030489402,"threshold_uncertainty_score":0.9999819},"labels":[],"label_agreement":null},{"id":"W4366603286","doi":"10.1080/10428194.2023.2196593","title":"Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy","year":2023,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genentech; Servier; Astellas Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Pfizer; CareDx; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Constellation Pharmaceuticals; Italfarmaco; Menarini Group; Astellas Pharma US; Gilead Sciences; U.S. Department of Defense","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Myeloproliferative neoplasm; Clinical trial; Janus kinase; Expanded access; Internal medicine; Oncology; Bone marrow; Cytokine","score_opus":0.07429801613504322,"score_gpt":0.3947768205150981,"score_spread":0.3204788043800549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366603286","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0043822373,0.9857004,0.000010702919,0.0000989379,0.00070005393,0.006910394,0.0009315882,0.00027310275,0.0009925355],"genre_scores_gemma":[0.00021552572,0.9868562,0.0015957502,0.0013319356,0.0013728781,0.004525268,0.0014410024,0.00044215773,0.0022192674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9905502,0.00052073237,0.0044938894,0.002179992,0.0009978822,0.0012572865],"domain_scores_gemma":[0.99229276,0.00286446,0.0018294487,0.0016574179,0.00040948286,0.0009464098],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016464419,0.0016585216,0.0092240535,0.0005261546,0.0001702774,0.00009072254,0.0005286557,0.0015377235,0.00012012762],"category_scores_gemma":[0.0013684003,0.0012810609,0.0037372366,0.0010030215,0.0005361746,0.00014326318,0.0004004289,0.00034973875,0.00030429015],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000472957,0.000456357,0.0002899837,0.17733824,0.0019694972,0.00039129687,0.00008152606,1.05700316e-7,2.4249437e-7,0.00029454278,0.009355881,0.80934936],"study_design_scores_gemma":[0.011060884,0.0009835447,0.008070043,0.20461702,0.008270303,0.00068850163,0.00002688489,0.000029022403,0.000007514735,0.000043418633,0.76527584,0.0009270119],"about_ca_topic_score_codex":0.00016908108,"about_ca_topic_score_gemma":0.000010922465,"teacher_disagreement_score":0.8084223,"about_ca_system_score_codex":0.0032015715,"about_ca_system_score_gemma":0.010749343,"threshold_uncertainty_score":0.9997585},"labels":[],"label_agreement":null},{"id":"W4366757045","doi":"10.1080/10428194.2023.2203286","title":"Hereditary alpha-tryptasemia and complete deletion of exon 8 of the c-kit gene in patients with mast cell activation syndrome","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Declaration; Medicine; Informed consent; Conflict of interest; Family medicine; Institutional review board; Alternative medicine; Surgery; Political science; Pathology; Law","score_opus":0.005357887550220224,"score_gpt":0.16998631937248498,"score_spread":0.16462843182226475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366757045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99802977,0.00056246045,0.000018726449,0.00003686049,0.00023034829,0.00043561964,0.00019003506,0.000043084383,0.00045306943],"genre_scores_gemma":[0.9985789,0.0001366399,0.00007235346,0.000081531696,0.000018405368,0.000026184976,0.00045819345,0.00003873614,0.0005890555],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99818563,0.00015561534,0.0005840176,0.00048071524,0.0001550849,0.00043890675],"domain_scores_gemma":[0.99887127,0.00015732636,0.00039035495,0.000430018,0.00010113522,0.00004991206],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00020272269,0.00033392967,0.00055828725,0.0002576135,0.00018308443,0.000013435929,0.00024676137,0.00034120455,0.00006465647],"category_scores_gemma":[0.000022191682,0.00025494868,0.00007972651,0.0005632137,0.00047155988,0.0001515229,0.00020392581,0.00011405065,0.00001842719],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003707559,0.0008480874,0.3442044,0.0016064084,0.00047619813,0.00010832225,0.0029907697,0.00043792932,0.5822008,0.0007317162,0.004531684,0.058156107],"study_design_scores_gemma":[0.01182121,0.00041939292,0.94005954,0.00021513895,0.00007428504,0.000097352386,0.0002645542,0.00020488541,0.043680843,0.000067203306,0.0027891973,0.0003064099],"about_ca_topic_score_codex":0.0016658712,"about_ca_topic_score_gemma":0.00009094089,"teacher_disagreement_score":0.5958551,"about_ca_system_score_codex":0.00064511155,"about_ca_system_score_gemma":0.00039475193,"threshold_uncertainty_score":0.9999903},"labels":[],"label_agreement":null},{"id":"W4366759859","doi":"10.1080/10428194.2023.2199340","title":"Population-level impact of ibrutinib for chronic lymphocytic leukemia in British Columbia, Canada","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; University of British Columbia","funders":"AbbVie; Lundbeck Canada; University of British Columbia; GlaxoSmithKline","keywords":"Ibrutinib; Discontinuation; Medicine; Chronic lymphocytic leukemia; Adverse effect; Internal medicine; Population; Oncology; Leukemia","score_opus":0.020516141504062696,"score_gpt":0.28692706116083677,"score_spread":0.2664109196567741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366759859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928473,0.0018290002,0.00003562327,0.000043368156,0.0005468218,0.0026190646,0.0008859168,0.00036986635,0.0008230309],"genre_scores_gemma":[0.9888599,0.0010900479,0.000375647,0.00031354817,0.000595338,0.0005751354,0.0013657125,0.0003194702,0.0065051913],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99105203,0.00021046268,0.0022519873,0.0018933213,0.0017931424,0.0027990302],"domain_scores_gemma":[0.99471384,0.0014271506,0.00063723844,0.0015363145,0.0005314771,0.0011539572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011757083,0.00091135205,0.0023984856,0.0007263267,0.00051700557,0.00036653294,0.00081603206,0.0009240012,0.00025272288],"category_scores_gemma":[0.0010509201,0.0012219967,0.0007885031,0.0029756129,0.000566154,0.00046027676,0.000494384,0.00029306606,0.000046595404],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0046010776,0.00035402869,0.31181005,0.010515477,0.0030109137,0.008834675,0.0016155723,0.030513657,0.0060977065,0.00036724514,0.1573722,0.46490738],"study_design_scores_gemma":[0.07886876,0.0009043812,0.68320143,0.0014124303,0.00026402847,0.0028823386,0.00038435965,0.22620925,0.00058264093,0.00040152992,0.0036503794,0.0012384738],"about_ca_topic_score_codex":0.9888633,"about_ca_topic_score_gemma":0.9338035,"teacher_disagreement_score":0.4636689,"about_ca_system_score_codex":0.5791635,"about_ca_system_score_gemma":0.3585317,"threshold_uncertainty_score":0.99902296},"labels":[],"label_agreement":null},{"id":"W4375864821","doi":"10.1080/10428194.2023.2203790","title":"Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Etoposide; Oncology; Carmustine; Febrile neutropenia; Melphalan; Cytarabine; Autologous stem-cell transplantation; Follicular lymphoma; Mucositis; Hematopoietic stem cell transplantation; Regimen; Transplantation; Surgery; Neutropenia; Lymphoma; Chemotherapy; Rituximab","score_opus":0.01950455767052423,"score_gpt":0.2957316072068995,"score_spread":0.2762270495363753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375864821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218255,0.00044699077,0.00016831512,0.00027220137,0.00020687938,0.0030449363,0.00009473959,0.00025921786,0.0033241606],"genre_scores_gemma":[0.9957035,0.00038000496,0.00019305841,0.00020846078,0.00018525521,0.00025708188,0.0002325457,0.00012467161,0.0027153825],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9961804,0.0003064699,0.00093334966,0.0009607004,0.0008169953,0.0008020508],"domain_scores_gemma":[0.9970797,0.0012933504,0.00040004618,0.00063229614,0.0003080773,0.0002865846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010338663,0.000541055,0.0010044341,0.00039255916,0.0006680043,0.00019159648,0.00026514975,0.0003119671,0.00007458607],"category_scores_gemma":[0.00010366013,0.00043874752,0.00020837686,0.0008431142,0.00046569863,0.00028377312,0.0001246176,0.00020974274,0.0000147351675],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021373857,0.0038764086,0.17069015,0.006017733,0.0029830402,0.002650024,0.07267953,0.0005896101,0.41224876,0.0020880634,0.0037983598,0.30100447],"study_design_scores_gemma":[0.08848645,0.005069642,0.8089337,0.001238978,0.0014833518,0.0035174775,0.018386783,0.0073241903,0.061613347,0.0005126011,0.0023119806,0.0011215247],"about_ca_topic_score_codex":0.0004082615,"about_ca_topic_score_gemma":0.000040354425,"teacher_disagreement_score":0.6382435,"about_ca_system_score_codex":0.0026720865,"about_ca_system_score_gemma":0.0012913175,"threshold_uncertainty_score":0.9998064},"labels":[],"label_agreement":null},{"id":"W4376254224","doi":"10.1080/10428194.2023.2209232","title":"Return on investment of the lymphoma diagnostic pathway implementation in Alberta, Canada","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Alberta Health; Impact; Alberta Health Services","funders":"","keywords":"Propensity score matching; Return on investment; Medicine; Clinical pathway; Investment (military); Emergency medicine; Health care; Cohort; Medical emergency; Internal medicine; Nursing; Economics","score_opus":0.06703035261450856,"score_gpt":0.32211303332498603,"score_spread":0.25508268071047746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376254224","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985899,0.00069476303,0.000008470827,0.0063119796,0.001106793,0.0011205523,0.00042583002,0.00005706298,0.0043755556],"genre_scores_gemma":[0.9827945,0.00030642294,0.00006387567,0.014934083,0.00020732275,0.00034223637,0.00014090518,0.00007786672,0.0011327721],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934047,0.00047277147,0.0038511828,0.0009792723,0.00036949423,0.00092259893],"domain_scores_gemma":[0.99322754,0.0034748414,0.0019167783,0.0010043316,0.000064153886,0.00031234758],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039738654,0.000490935,0.0011986087,0.0004887873,0.00034672243,0.00008473878,0.000608366,0.00028132554,0.00011941613],"category_scores_gemma":[0.002508851,0.0005014326,0.00018599682,0.000999246,0.00017592456,0.0003301571,0.000215752,0.00009614026,0.00026157396],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00020194564,0.00034051324,0.55617255,0.001418258,0.00039792393,0.00009716357,0.011855519,0.0020805588,0.00009225456,0.23227334,0.16096708,0.034102883],"study_design_scores_gemma":[0.0079062935,0.00014040688,0.8936554,0.00034660366,0.000020249014,0.00003431414,0.002739152,0.0073339664,0.00068146846,0.0095034195,0.0768962,0.000742499],"about_ca_topic_score_codex":0.76494974,"about_ca_topic_score_gemma":0.55791104,"teacher_disagreement_score":0.33748287,"about_ca_system_score_codex":0.016286204,"about_ca_system_score_gemma":0.006371146,"threshold_uncertainty_score":0.99974376},"labels":[],"label_agreement":null},{"id":"W4378953570","doi":"10.1080/10428194.2023.2216819","title":"Exploring new prognostic biomarkers in Mantle Cell Lymphoma: a comparison of the circSCORE and the MCL35 score","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Novo Nordisk Fonden; Greater Copenhagen Health Science Partners; Lundbeckfonden; Kræftens Bekæmpelse","keywords":"Mantle cell lymphoma; Internal medicine; Oncology; Medicine; Lymphoma; Geology","score_opus":0.055044144537478974,"score_gpt":0.2632539157212679,"score_spread":0.20820977118378892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378953570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873681,0.0064501,0.0000052577575,0.0010969425,0.00053486077,0.0018611475,0.000029935583,0.00019575839,0.0024578793],"genre_scores_gemma":[0.99519897,0.0026551073,0.00012733058,0.00048081085,0.00020340928,0.0004848882,0.0000513365,0.00011168334,0.0006864896],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954587,0.0002606597,0.0012220786,0.001079337,0.00089052244,0.0010886947],"domain_scores_gemma":[0.99666363,0.0011079704,0.0004752926,0.0011652687,0.00010598857,0.00048184168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006377799,0.0007924865,0.0014251479,0.0004682898,0.00047353364,0.00013950602,0.0005147144,0.0003275747,0.000019604176],"category_scores_gemma":[0.00028571833,0.00049398595,0.00042279964,0.001898665,0.00096125284,0.0003109043,0.0005890199,0.00013175233,0.000054857264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020067282,0.00082843454,0.71654326,0.00087007,0.00064285385,0.00047484037,0.00723246,0.00007446999,0.0012001179,0.0018791441,0.0051328675,0.26311478],"study_design_scores_gemma":[0.06041758,0.00031602875,0.9129665,0.0012288067,0.0007052843,0.00048985577,0.0031332267,0.005217808,0.010812858,0.00048488262,0.0036554527,0.00057170715],"about_ca_topic_score_codex":0.0056383223,"about_ca_topic_score_gemma":0.00032146744,"teacher_disagreement_score":0.26254308,"about_ca_system_score_codex":0.0030124453,"about_ca_system_score_gemma":0.0028853384,"threshold_uncertainty_score":0.99975115},"labels":[],"label_agreement":null},{"id":"W4381309016","doi":"10.1080/10428194.2023.2226278","title":"Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma","year":2023,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Bendamustine; Medicine; Internal medicine; Lymphoma","score_opus":0.03402183222211579,"score_gpt":0.3065968196357071,"score_spread":0.2725749874135913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381309016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865731,0.0016418347,0.000007696793,0.0047995914,0.00047135682,0.0030888473,0.0004950789,0.0002038702,0.0027186256],"genre_scores_gemma":[0.98242927,0.0010730997,0.00039970753,0.006277863,0.0018580867,0.000280684,0.0005972477,0.0006033841,0.006480684],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99003965,0.0008506148,0.0023982194,0.0021066016,0.002466886,0.002138028],"domain_scores_gemma":[0.99249864,0.0018739456,0.0014283129,0.0031463425,0.00057964213,0.0004731153],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0017047372,0.001837959,0.0031671328,0.0012952356,0.00028603466,0.0001582393,0.0014307331,0.002321807,0.00053917227],"category_scores_gemma":[0.00023380447,0.0013288582,0.0015969665,0.002023738,0.0011474094,0.00020696744,0.000463431,0.0013358848,0.00008254185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019585883,0.0040578065,0.15305841,0.011419602,0.002950002,0.010158555,0.012452279,0.0028215882,0.23261032,0.00003207385,0.30222276,0.24863072],"study_design_scores_gemma":[0.11582452,0.012767391,0.6871687,0.006000251,0.0010209082,0.0016787478,0.0014109453,0.01352725,0.1357335,0.0007169648,0.019604381,0.0045464137],"about_ca_topic_score_codex":0.024004664,"about_ca_topic_score_gemma":0.00013807244,"teacher_disagreement_score":0.5341103,"about_ca_system_score_codex":0.015190648,"about_ca_system_score_gemma":0.009571923,"threshold_uncertainty_score":0.9994365},"labels":[],"label_agreement":null},{"id":"W4385620600","doi":"10.1080/10428194.2023.2234528","title":"Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Rituximab; Gemcitabine; Chimeric antigen receptor; Salvage therapy; Regimen; Clinical trial; Diffuse large B-cell lymphoma; Lymphoma; Chemotherapy regimen; Chemotherapy; Refractory (planetary science); Immunotherapy; Cancer; Biology","score_opus":0.1039930813529429,"score_gpt":0.3912292872957763,"score_spread":0.2872362059428334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385620600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97637874,0.020166183,0.000032147527,0.000078852056,0.00016589848,0.0019191043,0.00016996318,0.00011641265,0.0009727083],"genre_scores_gemma":[0.9783008,0.018818619,0.00040112287,0.00026018632,0.00016753025,0.00018894488,0.00019089773,0.00013395559,0.0015379392],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.988958,0.004674248,0.0027817981,0.0015323568,0.0009720097,0.0010815862],"domain_scores_gemma":[0.9875373,0.009033001,0.0014255359,0.0011959751,0.00027021577,0.00053797016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011959885,0.0009064265,0.008175881,0.0012242864,0.00021103909,0.00007026777,0.00035868897,0.00079004414,0.0002645896],"category_scores_gemma":[0.00042103216,0.00072201295,0.0016750633,0.0034702974,0.0009888879,0.000185249,0.00028533133,0.0002846585,0.000010887978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053640377,0.009666849,0.1667114,0.0035615491,0.15903236,0.00049200293,0.018745223,0.0002347698,0.51570547,0.00036669555,0.0034698662,0.06837341],"study_design_scores_gemma":[0.14724663,0.0024539798,0.74568284,0.00031055819,0.033061173,0.000054584692,0.0023758165,0.0090079615,0.04965974,0.00023921006,0.008605747,0.0013017288],"about_ca_topic_score_codex":0.0011109128,"about_ca_topic_score_gemma":0.00008839298,"teacher_disagreement_score":0.57897145,"about_ca_system_score_codex":0.0010282763,"about_ca_system_score_gemma":0.0016907653,"threshold_uncertainty_score":0.9995231},"labels":[],"label_agreement":null},{"id":"W4385683538","doi":"10.1080/10428194.2023.2242990","title":"High sensitivity c-reactive protein and circulating biomarkers of endothelial dysfunction in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University; Toronto General Hospital; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Nilotinib; Medicine; Ponatinib; Chronic myelogenous leukemia; Myeloid leukemia; Internal medicine; C-reactive protein; Cancer; Oncology; Immunology; Leukemia; Imatinib; Inflammation","score_opus":0.006563382667115001,"score_gpt":0.20799284824514153,"score_spread":0.20142946557802652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385683538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959538,0.00041506506,0.000034616212,0.00008566345,0.00032128106,0.0023444637,0.00015444188,0.00036627467,0.00032438917],"genre_scores_gemma":[0.9976154,0.00014783551,0.0006091655,0.00009503552,0.00033096827,0.00022312833,0.0004878196,0.00021132582,0.0002793468],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99436,0.00033120776,0.0012377215,0.0016325369,0.0011110452,0.0013274357],"domain_scores_gemma":[0.99705523,0.0004970675,0.00074780104,0.0008802489,0.00028981944,0.0005298242],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082159694,0.0010622017,0.0015202841,0.0010197868,0.00036637232,0.00009180702,0.00015663411,0.0006428149,0.00002994715],"category_scores_gemma":[0.00039156046,0.00096352416,0.00020730088,0.0018662196,0.0006614309,0.00064400124,0.00031162068,0.00032248514,0.00002946757],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0076672984,0.0005392931,0.49787232,0.0019414686,0.0011894142,0.0014208427,0.001768279,0.0007387845,0.16763517,0.00019773879,0.00030126455,0.31872815],"study_design_scores_gemma":[0.0555067,0.0013742682,0.874304,0.0025381,0.00037700616,0.00034292953,0.00036867312,0.0068916385,0.05704883,0.00007475717,0.00023196104,0.0009411232],"about_ca_topic_score_codex":0.011611858,"about_ca_topic_score_gemma":0.00070672075,"teacher_disagreement_score":0.3764317,"about_ca_system_score_codex":0.032718617,"about_ca_system_score_gemma":0.0057942835,"threshold_uncertainty_score":0.9998419},"labels":[],"label_agreement":null},{"id":"W4388033587","doi":"10.1080/10428194.2023.2275529","title":"Re: exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Pesticide and Herbicide Environmental Studies","field":"Environmental Science","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; Carleton University","funders":"","keywords":"Glyphosate; Hodgkin lymphoma; Advice (programming); Law; Lymphoma; Actuarial science; Business; Medicine; Political science; Biotechnology; Computer science; Biology; Internal medicine","score_opus":0.010169848182255298,"score_gpt":0.22980972139863137,"score_spread":0.21963987321637607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388033587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99343824,0.0004916325,0.00018097604,0.00026803013,0.00039695817,0.0012171974,0.00017214693,0.0003703822,0.0034644317],"genre_scores_gemma":[0.99287087,0.0011747566,0.001052278,0.0012706224,0.0002105061,0.0004305848,0.00009243399,0.00016739419,0.0027305377],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994886,0.00012554895,0.0008168536,0.0017396538,0.000807082,0.0016248747],"domain_scores_gemma":[0.99724567,0.00069749577,0.00030015717,0.0008182373,0.000020919419,0.0009175414],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000583384,0.0010178104,0.00095844537,0.00022587998,0.0013689037,0.00023105866,0.00061969616,0.00045783367,0.00046402606],"category_scores_gemma":[0.0003068821,0.00093593367,0.00025940067,0.0009201316,0.0007155972,0.00047794677,0.0012535172,0.00011039295,0.0012306611],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014108665,0.0003190287,0.43869,0.00026846788,0.0005388131,0.0003750712,0.018854277,0.0026116234,0.032007527,0.0002918043,0.033336863,0.47129565],"study_design_scores_gemma":[0.0076121576,0.0010099107,0.9349627,0.00010496377,0.0002577652,0.00007912852,0.0042335694,0.002716995,0.00697679,0.0022648207,0.0383481,0.0014331175],"about_ca_topic_score_codex":0.009700337,"about_ca_topic_score_gemma":0.00083909323,"teacher_disagreement_score":0.49627265,"about_ca_system_score_codex":0.0045853877,"about_ca_system_score_gemma":0.00022403074,"threshold_uncertainty_score":0.99993116},"labels":[],"label_agreement":null},{"id":"W4389380274","doi":"10.1080/10428194.2023.2290468","title":"Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC)","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Daratumumab; AL amyloidosis; Refractory (planetary science); Amyloidosis; Medicine; Internal medicine; Oncology; Psychology; Multiple myeloma; Immunoglobulin light chain; Immunology; Bortezomib; Materials science","score_opus":0.01602393768162398,"score_gpt":0.2771956226334811,"score_spread":0.2611716849518571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389380274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840721,0.012306516,0.00009476956,0.00038512045,0.0005275448,0.001868719,0.00037417802,0.00012782833,0.00024323478],"genre_scores_gemma":[0.9750879,0.01883133,0.0006958716,0.0006786789,0.00032275426,0.0030751664,0.0005557142,0.00012383677,0.0006287464],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640673,0.00019025098,0.0009382177,0.0011072542,0.00051242317,0.00084509054],"domain_scores_gemma":[0.9964332,0.000979751,0.00058671035,0.0015920487,0.00018274512,0.00022554767],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00026295867,0.0007607921,0.00083112,0.00011516759,0.000577675,0.000084427484,0.0008709807,0.00047908074,0.00002366456],"category_scores_gemma":[0.00017916458,0.00048402327,0.0006781791,0.00054696226,0.00094386423,0.00003367446,0.00026843057,0.00006984316,0.000015745898],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025704803,0.0020015526,0.07549602,0.00013789695,0.0028306942,0.00004521322,0.0064493,0.00014274725,0.092603,0.0003813899,0.021267904,0.7960738],"study_design_scores_gemma":[0.019058142,0.004483925,0.29604042,0.00018188213,0.0009804247,0.000049770522,0.0041000163,0.0024602904,0.31808248,0.00013856022,0.35336366,0.0010604061],"about_ca_topic_score_codex":0.0035167665,"about_ca_topic_score_gemma":0.00032763163,"teacher_disagreement_score":0.7950134,"about_ca_system_score_codex":0.0011117217,"about_ca_system_score_gemma":0.0010474095,"threshold_uncertainty_score":0.99976116},"labels":[],"label_agreement":null},{"id":"W4389950858","doi":"10.1080/10428194.2023.2295786","title":"The successful management of acute promyelocytic leukemia during pregnancy: a case report","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Discovery Centre; Population Health Research Institute; McMaster University","funders":"Ontario Institute for Cancer Research; Johns Hopkins Children's Center","keywords":"Acute promyelocytic leukemia; Pregnancy; Medicine; Leukemia; Obstetrics; Internal medicine; Biology; Retinoic acid; Genetics","score_opus":0.006557435381448718,"score_gpt":0.23736484786168344,"score_spread":0.23080741248023473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389950858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883745,0.0042970562,0.00013529113,0.00006903231,0.0005115576,0.000863164,0.000049803195,0.00021294752,0.005486671],"genre_scores_gemma":[0.9737173,0.009499544,0.0003831857,0.000052361458,0.00031210642,0.00043777502,0.00025679168,0.00015766121,0.015183325],"study_design_codex":"case_report","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950968,0.00016805933,0.0012508648,0.0014622338,0.0007234431,0.0012985717],"domain_scores_gemma":[0.9968453,0.00011524903,0.0006525829,0.0017704226,0.00025951653,0.00035691538],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054934935,0.0007991506,0.00066567055,0.00019925635,0.0010797697,0.00021312949,0.0009276752,0.000571211,0.000013042753],"category_scores_gemma":[0.000095892276,0.0006552492,0.00037595123,0.0009917422,0.0007365982,0.000049342652,0.0010118613,0.00015585277,0.0000405707],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030640832,0.00035707888,0.007921025,0.00737124,0.0076576313,0.38374865,0.0020397748,0.0009647672,0.24867815,0.004407578,0.009005156,0.32478487],"study_design_scores_gemma":[0.020357864,0.0009924073,0.019042194,0.001945811,0.0017199354,0.21368936,0.0038758914,0.0037483016,0.6781881,0.0014364062,0.051697277,0.0033064699],"about_ca_topic_score_codex":0.000294074,"about_ca_topic_score_gemma":0.000042316085,"teacher_disagreement_score":0.42950994,"about_ca_system_score_codex":0.0019282862,"about_ca_system_score_gemma":0.0023350765,"threshold_uncertainty_score":0.99958986},"labels":[],"label_agreement":null},{"id":"W4390406598","doi":"10.1080/10428194.2023.2290466","title":"Frontline therapy with bendamustine rituximab (BR) and rituximab cyclophosphamide vincristine prednisone (RCVP) confers similar long-term outcomes in patients with treatment naïve Waldenström macroglobulinemia in a real-world setting: a population-based analysis","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia Hospital","funders":"","keywords":"Rituximab; Medicine; Bendamustine; Prednisone; Vincristine; Internal medicine; Waldenstrom macroglobulinemia; Regimen; Cyclophosphamide; Macroglobulinemia; Gastroenterology; Population; Surgery; Chemotherapy; Oncology; Lymphoma; Multiple myeloma","score_opus":0.013781753511820725,"score_gpt":0.2816441447738777,"score_spread":0.267862391262057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390406598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99465156,0.000708371,0.000041568503,0.0004457519,0.00008682634,0.0029937525,0.00033514109,0.00046239092,0.0002746195],"genre_scores_gemma":[0.99171895,0.0010502244,0.0015484829,0.00053105765,0.00011884325,0.00053060375,0.003122454,0.00026528264,0.0011141251],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99177307,0.0003034224,0.0017956845,0.0023369787,0.001724174,0.0020666437],"domain_scores_gemma":[0.9956701,0.0009211044,0.00061643566,0.0014964136,0.00038329815,0.00091265305],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006492143,0.001599948,0.0032277226,0.0025554593,0.0003746064,0.00023424074,0.0004197755,0.000562681,0.00009707792],"category_scores_gemma":[0.00017785905,0.0012149067,0.00035522698,0.0045454297,0.00059180433,0.00035972346,0.00023015536,0.0003488072,0.000026858925],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0123068085,0.0021773512,0.94795835,0.0004034995,0.0015162088,0.002925597,0.0006409369,0.0016766881,0.000042225474,0.000029657185,0.00007085556,0.030251818],"study_design_scores_gemma":[0.23069933,0.0014848319,0.72283787,0.0005664999,0.0008821382,0.000100729376,0.0001371136,0.041916613,0.00028158203,0.00001438244,0.00014284266,0.0009360709],"about_ca_topic_score_codex":0.04477196,"about_ca_topic_score_gemma":0.022395024,"teacher_disagreement_score":0.22512048,"about_ca_system_score_codex":0.05060321,"about_ca_system_score_gemma":0.011237495,"threshold_uncertainty_score":0.99967486},"labels":[],"label_agreement":null},{"id":"W4390535428","doi":"10.1080/10428194.2023.2300719","title":"Real-world data of the use of rivaroxaban in pediatric patients with hematologic malignancies","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Blood Coagulation and Thrombosis Mechanisms","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Rivaroxaban; Medicine; Hematologic malignancy; Hematologic Neoplasms; Intensive care medicine; Internal medicine; Cancer; Atrial fibrillation; Warfarin","score_opus":0.04423736769432415,"score_gpt":0.2669800630131104,"score_spread":0.22274269531878624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390535428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778575,0.00046793834,0.000035540696,0.00011693221,0.0002460634,0.00058634067,0.00011554153,0.00009490655,0.00055096066],"genre_scores_gemma":[0.9975139,0.0004237438,0.0011601256,0.00022124362,0.00006899507,0.000021350781,0.000120948345,0.00005767143,0.00041205817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973628,0.00011578328,0.00078637875,0.00069458503,0.0006341416,0.00040632987],"domain_scores_gemma":[0.9978081,0.00029877006,0.00031928768,0.0012868857,0.00013986434,0.00014708922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025736552,0.00036993177,0.0008047892,0.00045270135,0.00008027741,0.000054935168,0.00042252406,0.00017321545,0.000024165913],"category_scores_gemma":[0.000107268104,0.00023898287,0.000120232966,0.0016245511,0.00031381854,0.0003703567,0.00039621218,0.00010795611,0.000006974072],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049893185,0.00045482942,0.9652783,0.0015951268,0.00021977565,0.00009923196,0.000681899,0.00005193553,0.0014296863,0.012128285,0.001847002,0.01571495],"study_design_scores_gemma":[0.0055313213,0.0002516703,0.9818977,0.00080657017,0.00047234414,0.00006173598,0.00007847777,0.004040399,0.0047006155,0.0002989002,0.0015656484,0.00029459316],"about_ca_topic_score_codex":0.0017206862,"about_ca_topic_score_gemma":0.0005792742,"teacher_disagreement_score":0.016619379,"about_ca_system_score_codex":0.0008955293,"about_ca_system_score_gemma":0.0018136265,"threshold_uncertainty_score":0.97454387},"labels":[],"label_agreement":null},{"id":"W4390976218","doi":"10.1080/10428194.2024.2301738","title":"Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Queen's University; ABB (Canada); University of Alberta; Health Sciences North; Cégep de Rimouski; Moncton Hospital; CancerCare Manitoba; Thunder Bay Regional Health Sciences Centre; Jewish General Hospital; University of Ottawa; University of Manitoba","funders":"AbbVie Canada","keywords":"Venetoclax; Ibrutinib; Medicine; Chronic lymphocytic leukemia; Tumor lysis syndrome; Internal medicine; Rituximab; Lymphoma; Oncology; Observational study; Leukemia; Chemotherapy","score_opus":0.021181746894429886,"score_gpt":0.3121649750153639,"score_spread":0.290983228120934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390976218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9858168,0.009879924,0.000033807144,0.00018928092,0.00029234297,0.002164129,0.000050233728,0.00022356439,0.0013499497],"genre_scores_gemma":[0.9911109,0.0040445365,0.002607719,0.0008169143,0.00031297095,0.0002024344,0.00013621507,0.00022649112,0.00054182217],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9914695,0.00066243624,0.0024810391,0.002046629,0.0016698476,0.0016705205],"domain_scores_gemma":[0.9948788,0.0022794765,0.0005019633,0.0012383694,0.0003349882,0.00076639524],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019186896,0.0009715083,0.001772234,0.0013258044,0.00019133171,0.00031423382,0.0004137412,0.00078239216,0.000026322869],"category_scores_gemma":[0.0007489056,0.0008540585,0.00022678736,0.002114431,0.00089651917,0.001107265,0.0006974654,0.00061245606,0.000029432962],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018956859,0.0005968344,0.36536556,0.01604811,0.0017384092,0.016712457,0.006821437,0.0035712258,0.000067814355,0.0045481035,0.0011750265,0.56439817],"study_design_scores_gemma":[0.11248673,0.0028831991,0.69431597,0.009961909,0.0006092539,0.001668593,0.0011069115,0.1517551,0.00018447748,0.00015894133,0.023553796,0.0013151512],"about_ca_topic_score_codex":0.024034657,"about_ca_topic_score_gemma":0.0011134789,"teacher_disagreement_score":0.563083,"about_ca_system_score_codex":0.25658765,"about_ca_system_score_gemma":0.05529311,"threshold_uncertainty_score":0.999391},"labels":[],"label_agreement":null},{"id":"W4391167737","doi":"10.1080/10428194.2024.2306463","title":"The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre; University of Toronto","funders":"Ministry of Long-Term Care; Ministry of Health, Ontario","keywords":"Diffuse large B-cell lymphoma; Retrospective cohort study; Medicine; Lymphoma; Overall survival; Cohort; Oncology; Internal medicine","score_opus":0.008793164795337854,"score_gpt":0.2719263780576062,"score_spread":0.26313321326226835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391167737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803779,0.004404756,0.00003492216,0.00012726401,0.000742597,0.0025653474,0.00020774758,0.00039747215,0.0111419875],"genre_scores_gemma":[0.9925981,0.002904734,0.00003561861,0.00021123025,0.00039762646,0.000484548,0.00019505165,0.00020839133,0.002964704],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940546,0.00036501265,0.0012021731,0.0016155055,0.0015067259,0.0012559851],"domain_scores_gemma":[0.99625,0.00085929665,0.00040081455,0.001544781,0.00035304867,0.0005921051],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010468968,0.0011435252,0.0015718202,0.00046466754,0.0006942773,0.00044735434,0.00042090568,0.00044437108,0.000087850996],"category_scores_gemma":[0.00018367932,0.00074189215,0.0008851688,0.0010423849,0.0003314706,0.00033884484,0.0002686949,0.00014876413,0.0001368832],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031540592,0.013489907,0.9141366,0.0003700984,0.0034781098,0.0018742846,0.0023951987,0.000045347882,0.0005263359,0.0074069593,0.010487882,0.042635243],"study_design_scores_gemma":[0.049548708,0.0035434163,0.9308901,0.00046508468,0.001040631,0.00036965407,0.000592755,0.0061862227,0.0012639178,0.00046653269,0.004925335,0.00070767076],"about_ca_topic_score_codex":0.005340574,"about_ca_topic_score_gemma":0.00015188204,"teacher_disagreement_score":0.04639465,"about_ca_system_score_codex":0.01969127,"about_ca_system_score_gemma":0.0037870884,"threshold_uncertainty_score":0.9995032},"labels":[],"label_agreement":null},{"id":"W4391692164","doi":"10.1080/10428194.2024.2313626","title":"Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era – forgotten but not gone","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Transplantation; Stem cell; Oncology; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Intensive care medicine; Cancer; Biology","score_opus":0.01426282834381978,"score_gpt":0.249594515214795,"score_spread":0.23533168687097522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391692164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9653366,0.023756612,0.00034457736,0.0010309105,0.0010267514,0.0034742223,0.00027210618,0.00071987795,0.0040382976],"genre_scores_gemma":[0.9811267,0.002716926,0.0013881905,0.0029317122,0.0017269625,0.0014607005,0.00057000713,0.00041177176,0.007667031],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99160117,0.00028775592,0.0018371808,0.0024584518,0.0013260784,0.002489352],"domain_scores_gemma":[0.995188,0.0016116175,0.00039390774,0.0019003008,0.000208804,0.00069735467],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015083952,0.0016371917,0.0017898045,0.0008232322,0.00070386374,0.000616208,0.0009764292,0.0010331344,0.00010381077],"category_scores_gemma":[0.00009258975,0.0012757137,0.0008718945,0.0015864413,0.00056682486,0.0006690803,0.0003928863,0.00067408977,0.0002586357],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0034255981,0.00062690716,0.003599537,0.0074062534,0.0012617543,0.006624705,0.006814446,0.00067448744,0.07834474,0.003622537,0.02415165,0.86344737],"study_design_scores_gemma":[0.13837272,0.005794743,0.093233645,0.007063191,0.0046862466,0.012561281,0.0067831734,0.2005404,0.13073562,0.0010259183,0.39308396,0.006119091],"about_ca_topic_score_codex":0.0032614188,"about_ca_topic_score_gemma":0.00032477133,"teacher_disagreement_score":0.8573283,"about_ca_system_score_codex":0.061545845,"about_ca_system_score_gemma":0.018069977,"threshold_uncertainty_score":0.99963754},"labels":[],"label_agreement":null},{"id":"W4392954109","doi":"10.1080/10428194.2024.2328800","title":"Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"GlaxoSmithKline","keywords":"Ruxolitinib; Myelofibrosis; Anemia; Post-hoc analysis; Medicine; Janus kinase; Internal medicine; Hemoglobin; Randomized controlled trial; Janus kinase 2; Clinical trial; Gastroenterology; Receptor; Bone marrow","score_opus":0.01462902550181141,"score_gpt":0.2639739017926614,"score_spread":0.24934487629084998,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392954109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852715,0.00565842,0.000034798635,0.00246053,0.0005814413,0.0026495743,0.00039832518,0.00020565673,0.002739713],"genre_scores_gemma":[0.9911192,0.0012172803,0.00024209454,0.004470911,0.0004985373,0.0012968072,0.00047508083,0.00013389894,0.0005461816],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99395365,0.0005539847,0.0016025751,0.0015491545,0.0010394392,0.001301178],"domain_scores_gemma":[0.99677855,0.0015877285,0.00020532846,0.00086433254,0.000104896295,0.00045915783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011686056,0.0009957291,0.0013782027,0.00056812016,0.00024941744,0.00036548945,0.00036522964,0.00056375825,0.00022031706],"category_scores_gemma":[0.0002979469,0.00071083504,0.00039136427,0.0013981553,0.0002790781,0.00034998867,0.00017883163,0.00034655028,0.00014024686],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040267143,0.005265865,0.061728626,0.0018046604,0.0009357252,0.00832267,0.016538573,0.00012601732,0.004178064,0.009392359,0.09127273,0.7601676],"study_design_scores_gemma":[0.32531413,0.008071561,0.3401714,0.0037059898,0.00090977695,0.0031315305,0.004126104,0.01745508,0.026210418,0.0016631957,0.26617387,0.0030669163],"about_ca_topic_score_codex":0.0026576198,"about_ca_topic_score_gemma":0.00033333892,"teacher_disagreement_score":0.75710064,"about_ca_system_score_codex":0.0066837603,"about_ca_system_score_gemma":0.0026987689,"threshold_uncertainty_score":0.99953425},"labels":[],"label_agreement":null},{"id":"W4393274863","doi":"10.1080/10428194.2024.2333451","title":"Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m <i>IDH1</i> ) acute myeloid leukemia (AML)","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Venetoclax; IDH1; Isocitrate dehydrogenase; Myeloid leukemia; Internal medicine; Medicine; Refractory (planetary science); Complete remission; Gastroenterology; Myeloid; Leukemia; Oncology; Chemotherapy; Mutant; Chemistry; Biology; Chronic lymphocytic leukemia; Enzyme","score_opus":0.006680696083015651,"score_gpt":0.2386489908476709,"score_spread":0.23196829476465525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393274863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985429,0.004752639,0.00011839304,0.000567844,0.0005106325,0.0027682248,0.0005412842,0.0009855602,0.0043264558],"genre_scores_gemma":[0.987442,0.0022950363,0.0011618559,0.003572907,0.00065362843,0.0005652625,0.0010755017,0.00061909755,0.0026146949],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9890243,0.0003883682,0.0019595874,0.0031297249,0.0023000457,0.0031979862],"domain_scores_gemma":[0.9945553,0.00067899755,0.00037647432,0.0019306361,0.00064955954,0.0018090176],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009976533,0.0019952185,0.0022215645,0.0016703554,0.0005926427,0.0006883132,0.0010182696,0.0013526555,0.00027180885],"category_scores_gemma":[0.00019613926,0.0016732858,0.0006352616,0.0031317666,0.0011117349,0.0013503109,0.0006853493,0.0011313806,0.0006993697],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03137869,0.0015674583,0.07958879,0.0058312826,0.009778474,0.07721402,0.010945499,0.0019787361,0.17376725,0.0041118576,0.027175356,0.5766626],"study_design_scores_gemma":[0.17270166,0.00986186,0.37766725,0.009049429,0.005813433,0.023417166,0.0030590543,0.11885664,0.14918496,0.0019899444,0.116927385,0.011471214],"about_ca_topic_score_codex":0.005333637,"about_ca_topic_score_gemma":0.00065177295,"teacher_disagreement_score":0.5651914,"about_ca_system_score_codex":0.05545568,"about_ca_system_score_gemma":0.030824713,"threshold_uncertainty_score":0.9999438},"labels":[],"label_agreement":null},{"id":"W4394009934","doi":"10.1080/10428194.2024.2336046","title":"Gammopathic dermopathy: characterization of cutaneous MGUS","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Skin Diseases and Diabetes","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Dermatology; Macroglobulinemia; Gammopathy; Monoclonal gammopathy; Monoclonal; Pathology; Multiple myeloma; Immunology; Monoclonal antibody; Antibody","score_opus":0.006898439544060198,"score_gpt":0.2285811013089907,"score_spread":0.2216826617649305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394009934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98667616,0.007985017,0.0001890732,0.00015357474,0.0006451057,0.00048606034,0.000118148535,0.0004400838,0.0033067646],"genre_scores_gemma":[0.99494356,0.0015433328,0.00021237494,0.0008548866,0.00054512353,0.000065981505,0.00032725531,0.00012469637,0.0013828086],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99710727,0.00007586532,0.00075554627,0.00082913466,0.00058358157,0.00064860075],"domain_scores_gemma":[0.998305,0.00024032751,0.00017486815,0.0006186798,0.00016648123,0.0004946503],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00019444861,0.00052077393,0.00078744657,0.00039427564,0.00014962637,0.00015399566,0.0001938043,0.00038671336,0.00017888777],"category_scores_gemma":[0.00015046391,0.00046545645,0.00033385475,0.00066013,0.0002794908,0.00028618192,0.00012667566,0.000107772335,0.00011920344],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009080009,0.0002892839,0.01996323,0.0030375423,0.00044013903,0.0036336216,0.0011191994,0.000011539398,0.21361057,0.0035961657,0.0012550735,0.75213563],"study_design_scores_gemma":[0.017804164,0.0019573178,0.65803665,0.006145276,0.0028920567,0.016773792,0.0006606579,0.053516038,0.15426387,0.0025328577,0.08283013,0.0025872088],"about_ca_topic_score_codex":0.00021906268,"about_ca_topic_score_gemma":0.0000041650815,"teacher_disagreement_score":0.74954844,"about_ca_system_score_codex":0.0019000305,"about_ca_system_score_gemma":0.0030457624,"threshold_uncertainty_score":0.9997797},"labels":[],"label_agreement":null},{"id":"W4394854044","doi":"10.1080/10428194.2024.2340052","title":"Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Frailty in Older Adults","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Western University; McMaster University; Population Health Research Institute","funders":"Janssen Canada; Hamilton Health Sciences","keywords":"Medicine; Multiple myeloma; Frailty Index; Prospective cohort study; Cohort; Geriatric Depression Scale; Internal medicine; Geriatrics; Physical therapy; Cognition; Gerontology; Psychiatry; Depressive symptoms","score_opus":0.005744017384403465,"score_gpt":0.2337024949837621,"score_spread":0.22795847759935864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394854044","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99214715,0.0007293461,0.000074466356,0.000025579264,0.00033086393,0.004566342,0.0001230957,0.0003778699,0.0016252679],"genre_scores_gemma":[0.99498355,0.0003361437,0.00036230197,0.000058170775,0.0001814258,0.00047979073,0.00014446305,0.00015334532,0.0033008193],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99548924,0.0001527695,0.00096622534,0.0015426796,0.0011187937,0.00073028804],"domain_scores_gemma":[0.99761814,0.00032017616,0.00035811876,0.00082091906,0.00041244747,0.0004702072],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039113432,0.00077108445,0.0010088925,0.00063955254,0.00023459447,0.000160881,0.00024266154,0.00028967878,0.000050676626],"category_scores_gemma":[0.00016942088,0.0006318693,0.00013133853,0.0014007217,0.0005126772,0.0006871852,0.00024769348,0.0001945207,0.000016329763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00094163587,0.0006758802,0.9711098,0.0016484058,0.00060910237,0.0002533413,0.003007684,0.000020107616,0.00019500521,0.00005564919,0.0003769319,0.021106437],"study_design_scores_gemma":[0.019057022,0.0018827541,0.9709334,0.0008194795,0.0010746771,0.0001265288,0.0003923734,0.004071045,0.0007957741,0.0000717793,0.00014082971,0.0006343606],"about_ca_topic_score_codex":0.005544961,"about_ca_topic_score_gemma":0.00062360585,"teacher_disagreement_score":0.020472078,"about_ca_system_score_codex":0.004832888,"about_ca_system_score_gemma":0.0017668282,"threshold_uncertainty_score":0.9996133},"labels":[],"label_agreement":null},{"id":"W4394932930","doi":"10.1080/10428194.2024.2338851","title":"Management of relapsed/refractory mantle cell lymphoma","year":2024,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Mantle cell lymphoma; Chimeric antigen receptor; Refractory (planetary science); Medicine; Ibrutinib; Lymphoma; Oncology; Internal medicine; Immunotherapy; Biology; Chronic lymphocytic leukemia; Cancer; Leukemia","score_opus":0.020328474560353502,"score_gpt":0.28568424620108385,"score_spread":0.2653557716407303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394932930","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010657661,0.94913787,0.0000074616114,0.000040579856,0.0015099556,0.0029003473,0.00043405936,0.0005196525,0.0347924],"genre_scores_gemma":[0.009282634,0.97133195,0.00090909365,0.00021754767,0.00063372526,0.0010782123,0.00095789664,0.0006302876,0.0149586275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9901734,0.000295893,0.0031385233,0.0029756634,0.0016145986,0.0018019156],"domain_scores_gemma":[0.99403304,0.00046443805,0.0013811514,0.00274267,0.00021504912,0.0011636768],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00057219807,0.002888885,0.0064451983,0.0013169884,0.00035268546,0.0002644872,0.00093862275,0.0020281882,0.0002067198],"category_scores_gemma":[0.000030589767,0.0022487454,0.0028348763,0.0016351541,0.0006342015,0.00031004983,0.0010562739,0.0003180711,0.0015588632],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00023684818,0.0015479745,0.00004838081,0.07842087,0.0034609917,0.007710719,0.00021704171,7.3247094e-7,0.0000052186533,0.0016240054,0.011461529,0.8952657],"study_design_scores_gemma":[0.01742071,0.00070665387,0.0008581328,0.043757416,0.021926777,0.003530403,0.000261539,0.00007172686,0.00017314243,0.00016803197,0.9092758,0.0018496524],"about_ca_topic_score_codex":0.00065552944,"about_ca_topic_score_gemma":0.00001086208,"teacher_disagreement_score":0.8978143,"about_ca_system_score_codex":0.018941093,"about_ca_system_score_gemma":0.0072762915,"threshold_uncertainty_score":0.9992674},"labels":[],"label_agreement":null},{"id":"W4394993559","doi":"10.1080/10428194.2024.2344052","title":"Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with <i>FLT3-</i> mutant acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Pharmacyclics; Genentech; Swedish Orphan Biovitrum; Daiichi-Sankyo; Syndax Pharmaceuticals; Sierra Oncology; Incyte; National Center for Advancing Translational Sciences; Agios Pharmaceuticals; Astex Pharmaceuticals; PTC Therapeutics; AstraZeneca; Celgene; Leukemia and Lymphoma Society; Astellas Pharma; Instituto Nacional de Cancerología; TG Therapeutics; Pfizer; Amgen","keywords":"Medicine; Myeloid leukemia; Oncology; Chemotherapy; Internal medicine","score_opus":0.017783905045925752,"score_gpt":0.2946410852356914,"score_spread":0.27685718018976563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394993559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870221,0.0007113062,0.0029582677,0.00031214618,0.0006877925,0.0061702537,0.00045421373,0.00053030404,0.0011536321],"genre_scores_gemma":[0.9896959,0.00054462824,0.004382876,0.00091608264,0.0006025002,0.0016830411,0.00065727043,0.00043479333,0.0010829194],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99349403,0.0002569905,0.0012339237,0.0019939907,0.001343869,0.0016771854],"domain_scores_gemma":[0.9956049,0.0010277904,0.0003202072,0.0011685354,0.00084912515,0.0010294768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012418217,0.0011634956,0.001754877,0.0010470053,0.00042427215,0.00026876578,0.0005499379,0.0007630928,0.00008130096],"category_scores_gemma":[0.0002861594,0.0009625874,0.00046912557,0.0020853765,0.0005331201,0.00071530405,0.00028555165,0.00038721942,0.000074454234],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.040760983,0.00079898746,0.017019117,0.006887716,0.004107745,0.00068260287,0.0037706934,0.00035130468,0.16946691,0.002720677,0.01172276,0.7417105],"study_design_scores_gemma":[0.111357026,0.0120835425,0.27980804,0.010231315,0.0028676009,0.0024694225,0.0012910941,0.01642173,0.38378373,0.00066467153,0.17489257,0.004129246],"about_ca_topic_score_codex":0.00075411575,"about_ca_topic_score_gemma":0.00003132811,"teacher_disagreement_score":0.73758125,"about_ca_system_score_codex":0.021303885,"about_ca_system_score_gemma":0.008958526,"threshold_uncertainty_score":0.9992825},"labels":[],"label_agreement":null},{"id":"W4398783795","doi":"10.1080/10428194.2024.2353877","title":"Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Blinatumomab; Refractory (planetary science); Internal medicine; Clinical trial; Lymphoblastic Leukemia; Oncology; Leukemia","score_opus":0.024587027961861088,"score_gpt":0.2825747664574556,"score_spread":0.25798773849559453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398783795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99237055,0.0034931067,0.000035787463,0.00009896062,0.00059713435,0.0014689616,0.00008296545,0.00031046223,0.0015420537],"genre_scores_gemma":[0.9779086,0.0027039454,0.00058128533,0.00037918135,0.00022002967,0.00017417101,0.00009135885,0.00030179886,0.017639598],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934262,0.0005486377,0.0018784979,0.0015059387,0.0014798299,0.0011608937],"domain_scores_gemma":[0.99525166,0.0023677808,0.00044107265,0.0010033028,0.0001966143,0.0007395697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015073597,0.0009420999,0.0026795992,0.0011926156,0.00015748083,0.00016937271,0.0003958165,0.0007867681,0.0004302352],"category_scores_gemma":[0.0006116206,0.00069362257,0.00041609973,0.0013192256,0.0005326596,0.00042051813,0.00027284725,0.00044197438,0.000049063838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.060388055,0.0018406401,0.19997476,0.0044722552,0.0037652575,0.012191083,0.009612683,0.00007267143,0.06768711,0.00029657056,0.019276174,0.6204227],"study_design_scores_gemma":[0.10325694,0.0056889122,0.8225442,0.0017350714,0.0017227012,0.0009674205,0.0005461262,0.003109642,0.00645731,0.00017274225,0.052084576,0.0017143127],"about_ca_topic_score_codex":0.0025798439,"about_ca_topic_score_gemma":0.00021722357,"teacher_disagreement_score":0.6225695,"about_ca_system_score_codex":0.033385873,"about_ca_system_score_gemma":0.009138495,"threshold_uncertainty_score":0.9995515},"labels":[],"label_agreement":null},{"id":"W4399367500","doi":"10.1080/10428194.2024.2346733","title":"Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trial","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Princess Margaret Cancer Centre","funders":"Agence Nationale de la Recherche","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Clinical endpoint; Adverse effect; Internal medicine; Confidence interval; Randomized controlled trial; Population; Anemia; Phases of clinical research; Clinical trial; Gastroenterology; Bone marrow","score_opus":0.006397220163147106,"score_gpt":0.22620042659871015,"score_spread":0.21980320643556303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399367500","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437183,0.0016138214,0.000026962929,0.00005161286,0.000053733493,0.0019544272,0.00023152001,0.00008794012,0.0016081341],"genre_scores_gemma":[0.9971135,0.00073243433,0.0009161156,0.000092932176,0.00006864727,0.00015568158,0.0006428639,0.00008110849,0.00019671598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963251,0.00016345322,0.0011867008,0.0010244672,0.0007367214,0.00056359946],"domain_scores_gemma":[0.99771184,0.00074131624,0.00037172518,0.00059408264,0.0002355299,0.0003455375],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029370293,0.00066893036,0.0020699052,0.0008826162,0.00011234738,0.00007659344,0.00012887351,0.00029671588,0.00005310867],"category_scores_gemma":[0.00007255829,0.00044975654,0.0002662396,0.0019080063,0.00047310995,0.00022764153,0.00008762252,0.00011256306,0.0000025935253],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.107914165,0.0016865461,0.79665774,0.00097552437,0.005723298,0.00022074713,0.0019291207,0.00023603473,0.00015746831,0.0007017792,0.00009524341,0.08370234],"study_design_scores_gemma":[0.1466865,0.00514274,0.83848006,0.0013570035,0.0047041955,0.00003765227,0.000109989465,0.001736252,0.0010043626,0.000006100937,0.00033675504,0.00039838607],"about_ca_topic_score_codex":0.0014880267,"about_ca_topic_score_gemma":0.00020971062,"teacher_disagreement_score":0.08330396,"about_ca_system_score_codex":0.002297065,"about_ca_system_score_gemma":0.0019843215,"threshold_uncertainty_score":0.99979544},"labels":[],"label_agreement":null},{"id":"W4399727620","doi":"10.1080/10428194.2024.2363418","title":"Experience of using venetoclax in relapsed T- cell lymphoma","year":2024,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Venetoclax; Lymphoma; Medicine; Psychology; Oncology; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.023643846805762852,"score_gpt":0.28762061089524205,"score_spread":0.2639767640894792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399727620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673099,0.014998522,0.000029422772,0.0044694273,0.0016663357,0.002421613,0.0002261076,0.0004422476,0.008436448],"genre_scores_gemma":[0.88076586,0.003206406,0.001993872,0.090130836,0.0051771956,0.00067212124,0.00085731345,0.0014287531,0.015767679],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9860014,0.000504793,0.0033329078,0.0036246914,0.0032068877,0.003329354],"domain_scores_gemma":[0.99326,0.0010603684,0.0010517595,0.0032625068,0.00047510926,0.00089024747],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009795227,0.0024442177,0.003982706,0.0025466557,0.0003059592,0.00031838648,0.0015576719,0.004829224,0.00024712173],"category_scores_gemma":[0.00035629285,0.0023764146,0.001145188,0.0028099362,0.0018417839,0.00039522062,0.0013223158,0.0015114185,0.00031867938],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0059275213,0.0009938335,0.001957736,0.03990857,0.002057768,0.12353212,0.015385923,0.0012048926,0.021374697,0.00039853842,0.70946556,0.07779282],"study_design_scores_gemma":[0.1341996,0.0010974124,0.002060598,0.012630659,0.0020859342,0.019359784,0.0017462922,0.1674927,0.029809657,0.000888777,0.6234144,0.0052141515],"about_ca_topic_score_codex":0.021635309,"about_ca_topic_score_gemma":0.000119935044,"teacher_disagreement_score":0.16628781,"about_ca_system_score_codex":0.25320816,"about_ca_system_score_gemma":0.117753856,"threshold_uncertainty_score":0.9988295},"labels":[],"label_agreement":null},{"id":"W4400195209","doi":"10.1080/10428194.2024.2371474","title":"Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant setting","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cytomegalovirus and herpesvirus research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"","keywords":"Alemtuzumab; Medicine; Retrospective cohort study; Cytomegalovirus infection; Cohort; Internal medicine; Cytomegalovirus; Immunology; Cohort study; Oncology; Human cytomegalovirus; Transplantation; Viral disease; Human immunodeficiency virus (HIV); Herpesviridae; Virus","score_opus":0.012586165988133363,"score_gpt":0.2762413753881765,"score_spread":0.26365520940004317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400195209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99147975,0.001599127,0.000059781625,0.00018751402,0.00013585598,0.0031866054,0.000050089955,0.00021008204,0.0030911611],"genre_scores_gemma":[0.994188,0.0038295714,0.00007243512,0.0005163794,0.00021547472,0.0008411621,0.000039952465,0.00010091691,0.00019610298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99484915,0.00047471796,0.0009017234,0.0014139247,0.0012392842,0.0011212032],"domain_scores_gemma":[0.99813575,0.0005728564,0.00015397776,0.0007611584,0.00012392021,0.00025236915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023248058,0.0007167788,0.001182439,0.0008329555,0.00037273244,0.0004022776,0.00032794717,0.00043899904,0.00007611906],"category_scores_gemma":[0.0001014613,0.0004478946,0.00021891322,0.0021471954,0.00037206418,0.00037909404,0.00009970366,0.0007338363,0.00006918713],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002286117,0.0006045589,0.95500416,0.00021486243,0.00031657566,0.006226323,0.008791315,0.000040239527,0.0005148982,0.00018075491,0.00031577636,0.025504448],"study_design_scores_gemma":[0.013846727,0.0020688802,0.9696017,0.00074261153,0.0001656729,0.0027180568,0.0015120932,0.0055211685,0.000532292,0.00016274383,0.0025726575,0.00055539276],"about_ca_topic_score_codex":0.0224273,"about_ca_topic_score_gemma":0.005336377,"teacher_disagreement_score":0.024949055,"about_ca_system_score_codex":0.007611906,"about_ca_system_score_gemma":0.002706943,"threshold_uncertainty_score":0.9997973},"labels":[],"label_agreement":null},{"id":"W4400358109","doi":"10.1080/10428194.2024.2373323","title":"Importance of long-term follow-up of autologous stem cell transplantation for mantle cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Mantle cell lymphoma; Transplantation; Stem cell; Autologous stem-cell transplantation; Term (time); Lymphoma; Medicine; Oncology; Internal medicine; Biology; Cell biology; Astronomy; Physics","score_opus":0.01213021060018144,"score_gpt":0.24807137991661388,"score_spread":0.23594116931643244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400358109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9791878,0.013970055,0.00044837984,0.000090187685,0.0008757653,0.0015582122,0.0004978805,0.0002608459,0.0031109028],"genre_scores_gemma":[0.9910398,0.004008711,0.00082739047,0.00021719834,0.00020844363,0.00036884964,0.00048666802,0.00016891604,0.002674039],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954735,0.00008928356,0.0015284315,0.0012739907,0.00071791356,0.0009168744],"domain_scores_gemma":[0.99724126,0.0006278276,0.0005368031,0.00088839274,0.00025703324,0.0004486771],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035988208,0.00086575956,0.0015424455,0.00048113518,0.00019611273,0.000091205526,0.00033855438,0.0005619298,0.00005771611],"category_scores_gemma":[0.000016995673,0.0007535684,0.00080954627,0.0006105417,0.00034514946,0.0003304668,0.00008779718,0.00007147586,0.00003709899],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00522226,0.0021156985,0.14504592,0.020301966,0.0013152871,0.0034799655,0.004450531,0.000042730866,0.033710387,0.0019496664,0.0036450713,0.7787205],"study_design_scores_gemma":[0.04587828,0.001556137,0.54628134,0.0017299243,0.0026407042,0.001957075,0.0004003157,0.0025194255,0.3939624,0.00020452445,0.001913796,0.0009560666],"about_ca_topic_score_codex":0.0004887653,"about_ca_topic_score_gemma":0.00008321425,"teacher_disagreement_score":0.77776444,"about_ca_system_score_codex":0.0035935184,"about_ca_system_score_gemma":0.0034904324,"threshold_uncertainty_score":0.9994915},"labels":[],"label_agreement":null},{"id":"W4400513282","doi":"10.1080/10428194.2024.2370437","title":"Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trial","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; Juravinski Hospital; Queen's University; Canadian Cancer Society; Kingston Health Sciences Centre; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical trial; Index (typography); Internal medicine; Oncology; Gerontology; World Wide Web; Computer science","score_opus":0.08956660989390927,"score_gpt":0.3489894354522371,"score_spread":0.25942282555832785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400513282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868853,0.0045617493,0.00014469115,0.00024099938,0.002437576,0.0021236057,0.00011757825,0.00025417373,0.0032343445],"genre_scores_gemma":[0.9911473,0.0008545731,0.004217404,0.0007397238,0.0011903597,0.00016341562,0.000101934515,0.00015307714,0.0014322177],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9891392,0.00079028105,0.0054201363,0.0020519164,0.0015522854,0.0010461763],"domain_scores_gemma":[0.9908632,0.00472926,0.0013331118,0.0018510611,0.00040899208,0.0008143567],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004052621,0.0010177277,0.0034151291,0.00094498665,0.0003642229,0.00019604403,0.00078128895,0.0013532386,0.00013314318],"category_scores_gemma":[0.00253548,0.0007726718,0.0015331787,0.003032569,0.0017260228,0.00032756542,0.00080913724,0.0005369066,0.000023302488],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07457813,0.0010019275,0.037518006,0.00073224393,0.0049771755,0.00032402697,0.0018359575,0.000015282012,0.00036331295,0.00037113205,0.003436966,0.87484586],"study_design_scores_gemma":[0.3450084,0.0020737676,0.55334985,0.0014155736,0.0040365895,0.00047237056,0.0006381154,0.010051952,0.0014080838,0.00017497476,0.08045145,0.0009188779],"about_ca_topic_score_codex":0.0006947406,"about_ca_topic_score_gemma":0.00026733687,"teacher_disagreement_score":0.87392694,"about_ca_system_score_codex":0.0029942363,"about_ca_system_score_gemma":0.013984114,"threshold_uncertainty_score":0.9999432},"labels":[],"label_agreement":null},{"id":"W4400690992","doi":"10.1080/10428194.2024.2371472","title":"Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genmab; AbbVie Canada","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Medicine; Oncology; Internal medicine; Cancer research; Materials science","score_opus":0.015303812571067062,"score_gpt":0.27597024301362166,"score_spread":0.2606664304425546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400690992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96398485,0.0055686287,0.000070708265,0.00061489904,0.0005710887,0.0013518605,0.0001474502,0.0008143528,0.026876152],"genre_scores_gemma":[0.9368589,0.0036345166,0.0006329595,0.0013022973,0.00049241004,0.00032247548,0.0001533381,0.0004528916,0.05615019],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9926769,0.00023381088,0.0012764328,0.0020312816,0.0016470453,0.0021345092],"domain_scores_gemma":[0.99590147,0.0010632831,0.00023572988,0.0016926442,0.00020258495,0.0009042782],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010151571,0.0013701506,0.001809948,0.0017163001,0.00037920522,0.00047731283,0.0006429129,0.000723312,0.00069754483],"category_scores_gemma":[0.00008506615,0.0010640884,0.0005274771,0.002201404,0.00065073714,0.00054632744,0.00036350422,0.0004917065,0.00021189149],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013833997,0.014523456,0.207663,0.00420281,0.003025507,0.014278404,0.016570522,0.000039175608,0.15971395,0.01033712,0.009341217,0.5464708],"study_design_scores_gemma":[0.16409889,0.0015512953,0.4965601,0.0020535614,0.00058540876,0.0018706475,0.0024150487,0.008335269,0.011179392,0.00042020148,0.30831638,0.0026137924],"about_ca_topic_score_codex":0.005803711,"about_ca_topic_score_gemma":0.002087014,"teacher_disagreement_score":0.54385704,"about_ca_system_score_codex":0.013305703,"about_ca_system_score_gemma":0.006423783,"threshold_uncertainty_score":0.99990493},"labels":[],"label_agreement":null},{"id":"W4401523698","doi":"10.1080/10428194.2024.2390574","title":"Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Université Laval; Université de Montréal; Hôpital Maisonneuve-Rosemont; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Venetoclax; Ven; Azacitidine; Internal medicine; Myeloid leukemia; Salvage therapy; Neutropenia; Febrile neutropenia; Refractory (planetary science); Acute leukemia; Septic shock; Oncology; Leukemia; Gastroenterology; Sepsis; Chemotherapy","score_opus":0.012312535876723572,"score_gpt":0.27438114018462784,"score_spread":0.26206860430790424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401523698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918915,0.0012734914,0.00012054182,0.00026275977,0.00013301887,0.004321467,0.00027704524,0.0005838483,0.00113631],"genre_scores_gemma":[0.9908751,0.00057037524,0.0018957804,0.0008893003,0.0002151681,0.00063458545,0.00010262566,0.00041434914,0.004402717],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931819,0.00030911434,0.0012514376,0.0022720539,0.001558565,0.001426956],"domain_scores_gemma":[0.99587363,0.00058612146,0.00035983344,0.0015332045,0.0005944124,0.0010528176],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005891985,0.0014546561,0.002461798,0.0010542668,0.00036207176,0.00027695124,0.0005252217,0.00053239684,0.00017081884],"category_scores_gemma":[0.00014151883,0.00091865694,0.000239332,0.0018955205,0.00089503726,0.00057000574,0.0003448317,0.0005302573,0.000056778306],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14101386,0.0016032435,0.67582107,0.0023944962,0.017007984,0.012742976,0.05145684,0.00012966098,0.022234246,0.0002679168,0.0042271595,0.071100585],"study_design_scores_gemma":[0.0881039,0.015563596,0.8493258,0.0035667578,0.002454183,0.002426659,0.012851043,0.009225554,0.0066130836,0.000024603572,0.007914909,0.0019299267],"about_ca_topic_score_codex":0.00654818,"about_ca_topic_score_gemma":0.0010845751,"teacher_disagreement_score":0.17350474,"about_ca_system_score_codex":0.019979887,"about_ca_system_score_gemma":0.0071453196,"threshold_uncertainty_score":0.9998203},"labels":[],"label_agreement":null},{"id":"W4402927660","doi":"10.1080/10428194.2024.2403668","title":"Intensity of survivin expression linked to features of aggressive relapsed/refractory diffuse large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"London Health Sciences Centre; Sunnybrook Hospital; Health Sciences Centre; Sunnybrook Health Science Centre; Queen Elizabeth II Health Sciences Centre; University Health Network; University of Toronto","funders":"Merck Canada","keywords":"Diffuse large B-cell lymphoma; Survivin; Refractory (planetary science); Lymphoma; Cancer research; Medicine; Intensity (physics); Aggressive lymphoma; Oncology; Internal medicine; Rituximab; Biology; Cancer; Physics; Optics","score_opus":0.00902916657617432,"score_gpt":0.24642681576975697,"score_spread":0.23739764919358267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402927660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759298,0.016097086,0.000062382314,0.0002451775,0.001056073,0.0011809672,0.0003597182,0.00033884283,0.0047299634],"genre_scores_gemma":[0.992296,0.002904557,0.0009139113,0.0007994159,0.0003763281,0.00018390737,0.00024385928,0.00019315493,0.0020888976],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9942531,0.00022697763,0.0015006788,0.0016187317,0.0012205697,0.0011799484],"domain_scores_gemma":[0.99527687,0.00083001395,0.0008878278,0.0015026578,0.0005142209,0.0009883937],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055427174,0.0011211177,0.002089614,0.00086143875,0.00027175818,0.00012848801,0.00049071206,0.00088698807,0.00009031904],"category_scores_gemma":[0.0004501106,0.00090059993,0.0007779849,0.0010602274,0.00041389058,0.00037419176,0.00061694434,0.0001885933,0.00010378467],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012785742,0.02187633,0.05680489,0.0077993125,0.0026547213,0.0076617547,0.015502156,0.000033108263,0.2976526,0.0038338988,0.068402596,0.50499284],"study_design_scores_gemma":[0.06881771,0.002314848,0.57548195,0.0070663546,0.0013912267,0.0017284908,0.0016017385,0.000877422,0.30899873,0.00040785654,0.029796934,0.0015167203],"about_ca_topic_score_codex":0.0019294295,"about_ca_topic_score_gemma":0.00009276624,"teacher_disagreement_score":0.51867706,"about_ca_system_score_codex":0.0051875114,"about_ca_system_score_gemma":0.003461948,"threshold_uncertainty_score":0.99934447},"labels":[],"label_agreement":null},{"id":"W4403036158","doi":"10.1080/10428194.2024.2402814","title":"Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; AbbVie Canada; Pharmacyclics; GlaxoSmithKline; Pfizer","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Lymphoma; Internal medicine; Oncology; Leukemia","score_opus":0.013125910070183586,"score_gpt":0.2702881273349522,"score_spread":0.2571622172647686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403036158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97821164,0.0049953563,0.00006530247,0.00016418104,0.0022849233,0.0038549737,0.00009831119,0.0019036189,0.008421709],"genre_scores_gemma":[0.9840444,0.001491505,0.0011556797,0.0005600842,0.0010253063,0.00081377226,0.0006810476,0.0008910697,0.009337181],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9837715,0.000560897,0.0032080063,0.0045619225,0.0034064355,0.0044912416],"domain_scores_gemma":[0.9922887,0.0012878629,0.0006447041,0.003237033,0.0004824722,0.0020591952],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0017012062,0.0029369467,0.0036744017,0.0035236222,0.0008948191,0.0011080651,0.001370527,0.0015261144,0.00023502731],"category_scores_gemma":[0.00039920464,0.0025297012,0.0013245807,0.0054497463,0.0013078535,0.0016931439,0.0009579942,0.0006801815,0.00073275133],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022216825,0.001901468,0.16258186,0.014438845,0.00953045,0.031310067,0.008041684,0.008525841,0.0048351297,0.007609243,0.008011381,0.7209972],"study_design_scores_gemma":[0.2888539,0.0027462393,0.52099717,0.009125885,0.0027898948,0.003998186,0.00082261884,0.144491,0.0048181107,0.000714067,0.014892949,0.0057499562],"about_ca_topic_score_codex":0.037213087,"about_ca_topic_score_gemma":0.0022942196,"teacher_disagreement_score":0.7152473,"about_ca_system_score_codex":0.6244674,"about_ca_system_score_gemma":0.20284642,"threshold_uncertainty_score":0.9999289},"labels":[],"label_agreement":null},{"id":"W4403103653","doi":"10.1080/10428194.2024.2408646","title":"Optimizing multiple Myeloma clinical trials: research direction, addressing limitations, and strategies for improvement","year":2024,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Clinical trial; Medicine; Medical physics; Intensive care medicine; Computer science; Internal medicine","score_opus":0.41103464638971776,"score_gpt":0.51015466070124,"score_spread":0.09912001431152229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403103653","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039771316,0.98573595,0.00021817465,0.00011247212,0.0009332559,0.006821199,0.00043546018,0.00036257564,0.0014037498],"genre_scores_gemma":[0.004268828,0.98150223,0.004596579,0.000107295535,0.0018477521,0.003592128,0.0009878121,0.00036314063,0.0027342474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98875254,0.002096132,0.0035412658,0.0025326863,0.0012971077,0.0017802737],"domain_scores_gemma":[0.98412573,0.011927564,0.00082472793,0.0011286505,0.0006761705,0.0013171651],"candidate_categories":["metaepi_narrow","scholarly_communication","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.009052021,0.0014371123,0.0053796195,0.0014641975,0.0011851321,0.0013892171,0.00041853543,0.0015947709,0.000021416932],"category_scores_gemma":[0.0061419215,0.0010596428,0.0016427138,0.0010794685,0.0009197072,0.00047761257,0.00059768005,0.0008578997,0.0000855517],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007922026,0.00024731897,0.000045004694,0.024964543,0.002416093,0.0003937758,0.0003607814,0.0000011567279,0.000025399992,0.00042129296,0.006193474,0.964139],"study_design_scores_gemma":[0.01756994,0.0017023036,0.00043385368,0.02441633,0.0056620836,0.00089900015,0.0015740402,0.0052147293,0.000034357872,0.0005500107,0.94086313,0.0010802215],"about_ca_topic_score_codex":0.000719095,"about_ca_topic_score_gemma":0.00015318824,"teacher_disagreement_score":0.9630587,"about_ca_system_score_codex":0.0076721744,"about_ca_system_score_gemma":0.016539948,"threshold_uncertainty_score":0.9998379},"labels":[],"label_agreement":null},{"id":"W4403738904","doi":"10.1080/10428194.2024.2416577","title":"Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed/refractory marginal zone lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"BeiGene","keywords":"Ibrutinib; Rituximab; Refractory (planetary science); Medicine; Lymphoma; Internal medicine; Leukemia; Biology","score_opus":0.02549745069079592,"score_gpt":0.28914271282788556,"score_spread":0.26364526213708966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403738904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651709,0.019289358,0.0001581097,0.00032504348,0.0017899595,0.0017646535,0.00024153048,0.0006822999,0.01057815],"genre_scores_gemma":[0.9907939,0.0030173576,0.0015513866,0.00032059406,0.0008530661,0.00026536823,0.00034105766,0.00042426994,0.0024330085],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98853934,0.0006198194,0.002713491,0.0029374317,0.0021982244,0.0029916833],"domain_scores_gemma":[0.99297494,0.0024989673,0.0006416999,0.002016331,0.00032034205,0.0015477],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018217199,0.0018702113,0.0033176842,0.002107615,0.0005644509,0.00040767205,0.0009727722,0.0016096379,0.0003101046],"category_scores_gemma":[0.00046609898,0.0018242572,0.000659675,0.0027279388,0.0021542949,0.00077891693,0.0010541047,0.0008396921,0.00030726637],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.049536016,0.0069884155,0.018706402,0.017824166,0.004775266,0.022764409,0.021744264,0.00040845343,0.015866203,0.010676636,0.022187345,0.8085224],"study_design_scores_gemma":[0.5406765,0.00505073,0.19076471,0.010230438,0.0027944227,0.015987169,0.0080733085,0.09464446,0.020909024,0.0008976913,0.104467474,0.0055040917],"about_ca_topic_score_codex":0.028149603,"about_ca_topic_score_gemma":0.002219849,"teacher_disagreement_score":0.80301833,"about_ca_system_score_codex":0.074667916,"about_ca_system_score_gemma":0.04673162,"threshold_uncertainty_score":0.9996865},"labels":[],"label_agreement":null},{"id":"W4403844943","doi":"10.1080/10428194.2024.2419375","title":"Frailty measures in multiple myeloma: evaluating the impact on outcomes and quality-of-life in clinical trials and real-world practice","year":2024,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Frailty in Older Adults","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Hamilton Health Sciences Foundation; National Institute on Aging; Instituto Nacional de Cancerología; American Society of Hematology","keywords":"Multiple myeloma; Quality of life (healthcare); Clinical Practice; Clinical trial; Medicine; Quality (philosophy); Intensive care medicine; Internal medicine; Family medicine; Nursing","score_opus":0.3352841792584343,"score_gpt":0.5287818209399442,"score_spread":0.1934976416815099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403844943","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.26578677,0.7284009,0.000002309524,0.0003891896,0.00052607775,0.0032790229,0.0001787076,0.000105760126,0.0013312628],"genre_scores_gemma":[0.08430793,0.9124515,0.0003894272,0.0007455313,0.0005326411,0.00040169086,0.00012426788,0.00023112353,0.0008158507],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9799848,0.00809383,0.007279429,0.002062857,0.0015122762,0.0010667688],"domain_scores_gemma":[0.95215833,0.042509448,0.0027641368,0.001596507,0.00023647904,0.0007351224],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.024931693,0.0017068571,0.009982176,0.0012211067,0.00020416084,0.00026076313,0.0005188613,0.0014518145,0.000020061161],"category_scores_gemma":[0.051443033,0.000998906,0.0013879116,0.001457918,0.0008650987,0.00033429798,0.000537976,0.0012364765,0.000031064206],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0019990967,0.00030139842,0.026923394,0.01126764,0.001349559,0.00023136691,0.0009547587,0.0000073403,0.000005871005,0.0002878188,0.00095519517,0.95571655],"study_design_scores_gemma":[0.06402677,0.0025516965,0.64819574,0.070754535,0.009483776,0.0012207356,0.001619109,0.0033470506,0.000009203042,0.0004731525,0.19541134,0.002906866],"about_ca_topic_score_codex":0.025221104,"about_ca_topic_score_gemma":0.0031043235,"teacher_disagreement_score":0.9528097,"about_ca_system_score_codex":0.0063598417,"about_ca_system_score_gemma":0.0110293105,"threshold_uncertainty_score":0.9998445},"labels":[],"label_agreement":null},{"id":"W4404203615","doi":"10.1080/10428194.2024.2422844","title":"Improvement in quality of life in MDS patients who become transfusion independent after treatment","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Royal Victoria Hospital; Royal Victoria Regional Health Centre; Vancouver General Hospital; Princess Margaret Cancer Centre; Dr. Georges-L.-Dumont University Hospital Centre; St. Paul's Hospital; McGill University Health Centre; University of Ottawa; Queen Elizabeth II Health Sciences Centre; CancerCare Manitoba; University Health Network; University of Alberta Hospital; Health Sciences Centre; Alberta Hospital Edmonton; University of British Columbia; Juravinski Cancer Centre; Jewish General Hospital; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Quality of life (healthcare); Intensive care medicine; Medicine; Quality (philosophy); Blood transfusion; Internal medicine; Nursing; Philosophy","score_opus":0.01785048394298953,"score_gpt":0.2723172665011397,"score_spread":0.25446678255815014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404203615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565905,0.001780024,0.000022885031,0.0002959611,0.00016652812,0.0009471768,0.000060409366,0.00007147599,0.0009964699],"genre_scores_gemma":[0.99720854,0.0012089927,0.00007351923,0.0006200016,0.00005341339,0.00033636193,0.00005774833,0.000041367643,0.00040006475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968301,0.00014225641,0.0011933721,0.0008452364,0.0004889539,0.00050009706],"domain_scores_gemma":[0.99879724,0.0002148081,0.00011637909,0.0005132003,0.000066168905,0.00029219582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034578552,0.00042428443,0.00095268525,0.00047258064,0.00005505823,0.00005113175,0.00013747935,0.0003057823,0.00011618967],"category_scores_gemma":[0.00005378595,0.00032844607,0.00023127014,0.0005846547,0.00013567861,0.00015933193,0.000097510274,0.00012447964,0.000019457924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018561558,0.0012592982,0.6912754,0.0007196246,0.00011324707,0.00032414915,0.0013663779,0.000022063101,0.0032659485,0.00068424887,0.0000752984,0.29903814],"study_design_scores_gemma":[0.014612916,0.0014585906,0.9785706,0.00028550418,0.00006112931,0.00004115848,0.00012206059,0.0014953117,0.0009283049,0.00038144618,0.0017336371,0.00030933315],"about_ca_topic_score_codex":0.0048279767,"about_ca_topic_score_gemma":0.0007050598,"teacher_disagreement_score":0.29872882,"about_ca_system_score_codex":0.004249103,"about_ca_system_score_gemma":0.0011364191,"threshold_uncertainty_score":0.99991673},"labels":[],"label_agreement":null},{"id":"W4404419054","doi":"10.1080/10428194.2024.2424373","title":"Deranged cytokine levels are linked to cancer-related cognitive impairment in lymphoma patients receiving R-CHOP chemotherapy","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CHOP; Medicine; Chemotherapy; Oncology; Lymphoma; Internal medicine; Cognitive impairment; Cytokine; Cancer; Cognition; Disease; Psychiatry","score_opus":0.013883912336277275,"score_gpt":0.27780065090409356,"score_spread":0.2639167385678163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404419054","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833002,0.005577439,0.000058967737,0.0019574978,0.0015145367,0.0036956428,0.00039493176,0.0010322827,0.0024684828],"genre_scores_gemma":[0.98778236,0.0026945127,0.00021301123,0.0050375094,0.0005870162,0.0011882544,0.0001532817,0.00034593433,0.00199813],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.992839,0.0002566538,0.0016364979,0.0022069064,0.0012196007,0.0018413544],"domain_scores_gemma":[0.9967547,0.00069216907,0.00039048115,0.0006313111,0.0006065068,0.00092480605],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0006153724,0.0014378488,0.0018300222,0.0013270549,0.00048104767,0.00028749197,0.00034172228,0.0008202168,0.00029165417],"category_scores_gemma":[0.0003492411,0.001373102,0.0004735814,0.002590729,0.0003449532,0.00053588726,0.00035617762,0.0003770642,0.0002551688],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050869146,0.0015260311,0.13441874,0.001439087,0.002790297,0.0016344477,0.01447059,0.00006772393,0.0023015554,0.00005349909,0.0071937786,0.82901734],"study_design_scores_gemma":[0.04957689,0.0012520734,0.919954,0.008547618,0.0007748443,0.0003519188,0.0014651587,0.002953682,0.0024646735,0.00013640431,0.011031452,0.0014912843],"about_ca_topic_score_codex":0.002224508,"about_ca_topic_score_gemma":0.0006242729,"teacher_disagreement_score":0.82752603,"about_ca_system_score_codex":0.025660967,"about_ca_system_score_gemma":0.0038307672,"threshold_uncertainty_score":0.99983716},"labels":[],"label_agreement":null},{"id":"W4404538329","doi":"10.1080/10428194.2024.2430703","title":"Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; National Institutes of Health","keywords":"Persistence (discontinuity); Lymphoma; Toxicity; Term (time); Immune system; Immune checkpoint; Cancer research; Biology; Immunology; Medicine; Immunotherapy; Internal medicine","score_opus":0.011446509951488564,"score_gpt":0.2485690102953221,"score_spread":0.23712250034383353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97318137,0.017751632,0.00003163023,0.00016009818,0.0008237081,0.0013243541,0.00017915637,0.000276663,0.006271396],"genre_scores_gemma":[0.98174685,0.0030493273,0.00019220616,0.00037256235,0.00053243135,0.00021186631,0.00011305642,0.0002665109,0.013515207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9927828,0.00027213254,0.0017997994,0.0017761817,0.0015050808,0.0018640104],"domain_scores_gemma":[0.99678683,0.0003978824,0.00028524804,0.0014692015,0.00026584623,0.0007949871],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011409944,0.0011133612,0.0016990561,0.0011090316,0.0001993049,0.00025644762,0.0006501683,0.0009552575,0.0011271161],"category_scores_gemma":[0.00007911779,0.0010497839,0.00097018405,0.0015857565,0.0006894332,0.00052070303,0.00072590023,0.00039629088,0.00023372011],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003806368,0.0016714913,0.034031574,0.005117304,0.0005156179,0.0078315735,0.0054202736,0.000021757287,0.8127867,0.00008531423,0.0006214479,0.12809058],"study_design_scores_gemma":[0.03808711,0.00096084666,0.20020881,0.0035082302,0.00046390598,0.0032742503,0.0017620509,0.004151286,0.73901314,0.00008968057,0.0067292484,0.0017514225],"about_ca_topic_score_codex":0.001727593,"about_ca_topic_score_gemma":0.00025629182,"teacher_disagreement_score":0.16617724,"about_ca_system_score_codex":0.011293455,"about_ca_system_score_gemma":0.005309911,"threshold_uncertainty_score":0.99978596},"labels":[],"label_agreement":null},{"id":"W4405757822","doi":"10.1080/10428194.2024.2438807","title":"Navigating AML treatment in vascular Ehlers–Danlos syndrome: achieving deeper remission with oral azacitidine—a first case report","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ehlers–Danlos syndrome; Medicine; Azacitidine; Dermatology; Surgery; Genetics; Biology","score_opus":0.015110241712121391,"score_gpt":0.2871527101170982,"score_spread":0.2720424684049768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405757822","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890583,0.0055068457,0.00023636498,0.00076838885,0.0002947384,0.0017932211,0.000039942883,0.00068130536,0.0016208681],"genre_scores_gemma":[0.99122053,0.0012694362,0.0036933243,0.0003581617,0.00038279092,0.00047697587,0.00030293516,0.0003536389,0.0019422069],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.99268466,0.0002665739,0.0014835331,0.0023740362,0.001325015,0.0018661725],"domain_scores_gemma":[0.99607855,0.0006182944,0.00026420492,0.0016177284,0.0002215078,0.0011997238],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011686203,0.0013236102,0.0017016298,0.00057461095,0.0007200031,0.00041871454,0.0003499715,0.00081889547,0.00016622058],"category_scores_gemma":[0.00030406294,0.0010207132,0.0004902316,0.0019419353,0.00053385645,0.00076836237,0.0003519884,0.0007332279,0.00011506138],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000767385,0.00029784808,0.019578122,0.0014685498,0.00084041076,0.78961116,0.0028642467,0.00023651744,0.0019769224,0.00015371879,0.0008297457,0.18137538],"study_design_scores_gemma":[0.025561828,0.0019253688,0.03360083,0.008465171,0.0010771086,0.85185915,0.0028262453,0.036536384,0.0037972427,0.000102888225,0.032341644,0.0019061269],"about_ca_topic_score_codex":0.0126199955,"about_ca_topic_score_gemma":0.00090237363,"teacher_disagreement_score":0.17946926,"about_ca_system_score_codex":0.031502776,"about_ca_system_score_gemma":0.0073937033,"threshold_uncertainty_score":0.99995154},"labels":[],"label_agreement":null},{"id":"W4406669602","doi":"10.1080/10428194.2025.2455485","title":"Are we maintaining minimal residual disease in myeloma?","year":2025,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Minimal residual disease; Multiple myeloma; Medicine; Oncology; Clinical trial; Disease; Intensive care medicine; Residual; Clinical endpoint; Maintenance therapy; Internal medicine; Chemotherapy; Bone marrow; Computer science","score_opus":0.04017158920676689,"score_gpt":0.3358778949116927,"score_spread":0.2957063057049258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406669602","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01150676,0.98079,0.0000068418635,0.00024211605,0.00034458018,0.002904973,0.0005343795,0.0002919961,0.0033783158],"genre_scores_gemma":[0.006681933,0.98134995,0.00038837374,0.0004287042,0.00067836273,0.0011390508,0.0010683278,0.00026596666,0.007999323],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99138314,0.0006601166,0.0019967908,0.0024456738,0.0013025017,0.0022118054],"domain_scores_gemma":[0.9939798,0.001307692,0.0009156527,0.0017346161,0.00017663301,0.001885618],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00061224145,0.0019740318,0.0049823066,0.0019784248,0.00042145114,0.0002631363,0.00074522453,0.001314654,0.00014249954],"category_scores_gemma":[0.0009979781,0.0016702703,0.001142879,0.0016869081,0.0005186825,0.00027761806,0.00082427467,0.0006157721,0.0002072126],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001281007,0.00034243634,0.0044026584,0.033393897,0.0007716722,0.016882427,0.00013593414,0.0000030120623,8.9241274e-7,0.0002405451,0.0035711154,0.9389744],"study_design_scores_gemma":[0.019760866,0.00030741555,0.03980957,0.08992861,0.0028193018,0.0010567833,0.00029920664,0.00042085885,0.000008234164,0.00018748578,0.8437266,0.001675086],"about_ca_topic_score_codex":0.0007834659,"about_ca_topic_score_gemma":0.00017262642,"teacher_disagreement_score":0.9372993,"about_ca_system_score_codex":0.017496234,"about_ca_system_score_gemma":0.020669097,"threshold_uncertainty_score":0.9999818},"labels":[],"label_agreement":null},{"id":"W4407408419","doi":"10.1080/10428194.2025.2461663","title":"Clozapine is associated with an increased risk of Hodgkin and non-Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Hodgkin lymphoma; Clozapine; Lymphoma; Medicine; Oncology; Internal medicine; Psychiatry; Schizophrenia (object-oriented programming)","score_opus":0.00764993146340629,"score_gpt":0.25286658271748363,"score_spread":0.24521665125407735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407408419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919805,0.0037022403,0.000110298926,0.00022339282,0.000111827554,0.0011546682,0.00026725305,0.00022021953,0.0022295788],"genre_scores_gemma":[0.99174696,0.0032187805,0.002352862,0.0008957803,0.00013579855,0.00017844049,0.00030713162,0.00011702999,0.0010472367],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99512655,0.0003691928,0.0009597256,0.0014029043,0.0009894972,0.0011521255],"domain_scores_gemma":[0.9961126,0.0006589928,0.0004899084,0.0012566313,0.00044302273,0.0010388701],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007651426,0.0009373556,0.0016417237,0.0007740502,0.00050312665,0.00015079844,0.00036845106,0.0006341236,0.000090218266],"category_scores_gemma":[0.0004510302,0.00074539933,0.0002671214,0.0013348162,0.00083778787,0.00036167505,0.00027975262,0.00019169827,0.00001884259],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.045628883,0.002056688,0.25945303,0.00068507297,0.004525608,0.0016658448,0.0012186782,0.000012218345,0.0043511894,0.0015696433,0.003020637,0.6758125],"study_design_scores_gemma":[0.08284009,0.0025583447,0.8816473,0.0010623711,0.0014420671,0.00053452485,0.00042490306,0.0071169627,0.01903778,0.0010137303,0.0015970478,0.00072489685],"about_ca_topic_score_codex":0.009525016,"about_ca_topic_score_gemma":0.0008223306,"teacher_disagreement_score":0.67508763,"about_ca_system_score_codex":0.004453872,"about_ca_system_score_gemma":0.0069704256,"threshold_uncertainty_score":0.9994997},"labels":[],"label_agreement":null},{"id":"W4407859877","doi":"10.1080/10428194.2025.2467801","title":"Clinical characteristics and disease outcomes of primary bone lymphoma in the rituximab era: a retrospective study from the Princess Margaret Cancer Center, Toronto, Canada","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Windsor Regional Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Rituximab; Center (category theory); Retrospective cohort study; Disease; Cancer; Gerontology; Lymphoma; Internal medicine","score_opus":0.011134680906223465,"score_gpt":0.27865381948408596,"score_spread":0.26751913857786247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407859877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98384166,0.009093555,0.0000044055755,0.0023870098,0.0006979278,0.001994615,0.0009127354,0.000048418402,0.0010196485],"genre_scores_gemma":[0.98568285,0.0045816004,0.00007317566,0.00832742,0.00023570831,0.0005491444,0.000183145,0.000052127718,0.0003148218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99504256,0.0005146878,0.001530338,0.0012070311,0.0009749166,0.0007304388],"domain_scores_gemma":[0.9963205,0.0011848102,0.0005199824,0.0013169026,0.00020410794,0.0004536934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006851552,0.0007772398,0.0019288608,0.00009267327,0.00038891958,0.00012833066,0.0005181355,0.0002561815,0.000039123002],"category_scores_gemma":[0.00039467437,0.00047556614,0.00028176527,0.00041159923,0.0005034017,0.00021760415,0.0004489923,0.00016047197,0.0000018784675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0014279301,0.0027990877,0.88688517,0.0001363189,0.00084990566,0.00083234865,0.0010194822,5.076039e-7,0.0000064654546,0.00044612115,0.003902506,0.10169417],"study_design_scores_gemma":[0.04073015,0.0002805725,0.9485812,0.0005211346,0.0010987729,0.00006248427,0.0015663384,0.00019831164,0.000018069415,0.00013144886,0.0063984757,0.00041302358],"about_ca_topic_score_codex":0.6514654,"about_ca_topic_score_gemma":0.41783804,"teacher_disagreement_score":0.23362738,"about_ca_system_score_codex":0.01425547,"about_ca_system_score_gemma":0.01196508,"threshold_uncertainty_score":0.9997696},"labels":[],"label_agreement":null},{"id":"W4408305670","doi":"10.1080/10428194.2025.2477725","title":"Time spent in healthcare among older patients with primary central nervous system lymphoma treated with high-dose methotrexate","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services","funders":"","keywords":"Primary central nervous system lymphoma; Methotrexate; Medicine; Central nervous system; Lymphoma; Healthcare system; Primary care; Internal medicine; Health care; Oncology; Family medicine","score_opus":0.004391249264032615,"score_gpt":0.2089634203710185,"score_spread":0.2045721711069859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408305670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908402,0.0016444931,0.000020614905,0.00037721958,0.0002496372,0.0032872795,0.00015738275,0.0005358087,0.0028873829],"genre_scores_gemma":[0.9933848,0.00029666108,0.0008097308,0.0014724997,0.00014028058,0.00065990514,0.0010330514,0.00023888871,0.001964201],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927756,0.0003899788,0.0014442952,0.0021345578,0.0012034515,0.002052097],"domain_scores_gemma":[0.99609715,0.00034275735,0.00057781156,0.0015020993,0.00040294568,0.0010772273],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00033142223,0.0015793517,0.002432188,0.0009704121,0.0004810699,0.00023454083,0.00042169794,0.0007076566,0.000049280017],"category_scores_gemma":[0.000035963134,0.0011754654,0.00032574043,0.00182489,0.0006157899,0.00047787218,0.00026683835,0.00018646725,0.00007134107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052769743,0.0017299314,0.72425073,0.0013137659,0.0010191078,0.0030692848,0.00044443604,0.00010348103,0.00008407027,0.0004904986,0.0008115266,0.2614062],"study_design_scores_gemma":[0.0688728,0.0012902091,0.9192187,0.0039380924,0.0010757089,0.0004979241,0.0003075909,0.0011966825,0.0015458219,0.000018027305,0.0009573668,0.0010810815],"about_ca_topic_score_codex":0.017920893,"about_ca_topic_score_gemma":0.000758872,"teacher_disagreement_score":0.26032513,"about_ca_system_score_codex":0.029462144,"about_ca_system_score_gemma":0.0051247254,"threshold_uncertainty_score":0.9996955},"labels":[],"label_agreement":null},{"id":"W4408914453","doi":"10.1080/10428194.2025.2482890","title":"Analysis of a cancer-care based diagnosis program for lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary; Alberta Health Services","funders":"","keywords":"Lymphoma; Cancer; Medicine; Medical physics; Intensive care medicine; Oncology; Internal medicine","score_opus":0.01046438545395141,"score_gpt":0.30284193546222354,"score_spread":0.29237755000827215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408914453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97384506,0.01663977,0.00020356955,0.00063624897,0.00044348804,0.0032702738,0.0006709553,0.00042585752,0.0038647635],"genre_scores_gemma":[0.982867,0.0021882849,0.0033439533,0.0019351525,0.00016554884,0.007899335,0.0008475226,0.00010768654,0.0006455233],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99488544,0.00012123049,0.0014200966,0.0016280932,0.0007511076,0.0011940071],"domain_scores_gemma":[0.99575275,0.00096677686,0.00056420907,0.0013771419,0.0007544092,0.0005846953],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00028655442,0.00103745,0.0024463397,0.0016631971,0.0004719318,0.00016043335,0.00045466374,0.00069820986,0.00012142037],"category_scores_gemma":[0.00020999815,0.00091560575,0.001583111,0.0033684343,0.00048470596,0.00020057485,0.00019665074,0.000064886925,0.000009125963],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001364913,0.0014173327,0.35491222,0.0012169578,0.0056972657,0.00009444877,0.00042065085,0.0002210135,0.0001995864,0.000840132,0.0028877303,0.63072777],"study_design_scores_gemma":[0.042614937,0.0010530807,0.81275326,0.0011644982,0.020354273,0.000025612422,0.0007516034,0.024126826,0.025084142,0.00011480207,0.07103457,0.0009223676],"about_ca_topic_score_codex":0.0054275566,"about_ca_topic_score_gemma":0.0008480853,"teacher_disagreement_score":0.6298054,"about_ca_system_score_codex":0.010756712,"about_ca_system_score_gemma":0.007311396,"threshold_uncertainty_score":0.99932945},"labels":[],"label_agreement":null},{"id":"W4409274461","doi":"10.1080/10428194.2025.2484367","title":"Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Population Health Research Institute","funders":"Janssen Research and Development; National Cancer Institute; Incyte; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; CSL Behring; Genentech; Pharmacyclics; Daiichi Sankyo Europe; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; ZOLL Medical Corporation","keywords":"Medicine; Hematology; Lymphoma; Internal medicine; Oncology; Clinical Oncology; Heart failure; Intensive care medicine; Cancer","score_opus":0.005310390291872738,"score_gpt":0.23685858464508258,"score_spread":0.23154819435320984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409274461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110746,0.0023764556,0.00033425717,0.00066233345,0.00019821187,0.0036669308,0.00011168706,0.0002265823,0.0013161057],"genre_scores_gemma":[0.9946418,0.000497,0.002229809,0.00051991973,0.0001948204,0.0011000242,0.00013373222,0.00011604475,0.00056684244],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9957924,0.0002980424,0.0007874007,0.0016835071,0.00040982987,0.0010288426],"domain_scores_gemma":[0.9976017,0.00052414346,0.00038272724,0.0007448709,0.0003971674,0.00034940406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038328895,0.0009686351,0.0019275851,0.00061363017,0.0007103076,0.00016206795,0.00017181455,0.00094036857,0.000010262739],"category_scores_gemma":[0.00016243319,0.00081248453,0.0003637358,0.00065959897,0.00069624785,0.000501461,0.0001517564,0.0001241935,0.000005359518],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036422167,0.0024931673,0.32755747,0.0019397096,0.005967683,0.00034619065,0.019043239,0.0002753067,0.014402139,0.0123910615,0.0024078577,0.576754],"study_design_scores_gemma":[0.1501784,0.0046380917,0.7323348,0.0010360287,0.0013291144,0.0010419164,0.016055465,0.000664271,0.071708344,0.0022162795,0.017389106,0.0014082071],"about_ca_topic_score_codex":0.003025529,"about_ca_topic_score_gemma":0.00097128795,"teacher_disagreement_score":0.5753458,"about_ca_system_score_codex":0.022714434,"about_ca_system_score_gemma":0.004691638,"threshold_uncertainty_score":0.9994326},"labels":[],"label_agreement":null},{"id":"W4409684616","doi":"10.1080/10428194.2025.2495112","title":"The paradox of the spleen: is it a nodal or extranodal site of lymphoma?","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"NODAL; Spleen; Lymphoma; Medicine; Pathology; Internal medicine","score_opus":0.012184667552049428,"score_gpt":0.26549384872640247,"score_spread":0.253309181174353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409684616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764958,0.00640062,0.00003397801,0.0035416433,0.0007492476,0.0013502886,0.00017723443,0.00009116638,0.011160008],"genre_scores_gemma":[0.98355556,0.0030182756,0.00030603548,0.0034391147,0.00018465405,0.0002229728,0.000032567958,0.000080993115,0.009159843],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948004,0.0002380147,0.0017024912,0.001060298,0.0011259125,0.0010728929],"domain_scores_gemma":[0.9952235,0.0012140174,0.0007315982,0.002084118,0.00037973202,0.00036699336],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005680625,0.00090870855,0.0015097492,0.00028365495,0.0007904043,0.0001244621,0.00079294853,0.00056809117,0.0001370318],"category_scores_gemma":[0.00028468805,0.0005050969,0.0008996543,0.0014171702,0.0013202071,0.00020422623,0.00052861206,0.00011891644,0.000042549007],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010662076,0.0026164928,0.21862602,0.0019435382,0.0037816302,0.00059803104,0.0055851317,0.00004150155,0.00920983,0.0148630375,0.074196845,0.65787584],"study_design_scores_gemma":[0.042805254,0.00071800494,0.7131546,0.0018353587,0.0018784617,0.0011523683,0.0015438254,0.0022489678,0.081881166,0.00076265325,0.15121965,0.0007996745],"about_ca_topic_score_codex":0.0030326128,"about_ca_topic_score_gemma":0.00037693663,"teacher_disagreement_score":0.6570762,"about_ca_system_score_codex":0.004141754,"about_ca_system_score_gemma":0.007820871,"threshold_uncertainty_score":0.99974006},"labels":[],"label_agreement":null},{"id":"W4411283910","doi":"10.1080/10428194.2025.2514894","title":"Effectiveness of olutasidenib versus ivosidenib in patients with mutated isocitrate dehydrogenase 1 acute myeloid leukemia who are relapsed or refractory to venetoclax: the 2102-HEM-101 trial versus a US electronic health record-based external control arm","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Golder Associates (Canada)","funders":"","keywords":"Venetoclax; Isocitrate dehydrogenase; Refractory (planetary science); Myeloid leukemia; Medicine; Oncology; Leukemia; Internal medicine; Biology; Chronic lymphocytic leukemia; Enzyme","score_opus":0.009896063977063402,"score_gpt":0.2783254034031928,"score_spread":0.2684293394261294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411283910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9887775,0.0013804296,0.0003320598,0.00035735223,0.0007688726,0.007611928,0.00023431866,0.00024475477,0.00029278075],"genre_scores_gemma":[0.99508244,0.00055656285,0.00031644714,0.001564525,0.00023799059,0.001301173,0.00022845562,0.00026517993,0.00044722867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9891824,0.0019153993,0.0021105309,0.0021763858,0.0018176044,0.0027976385],"domain_scores_gemma":[0.99125737,0.0037934682,0.0011812173,0.0019762293,0.00074560224,0.0010461343],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0022887138,0.001514658,0.003100942,0.0012826695,0.0006646662,0.00019257083,0.0011706073,0.0009234815,0.000060140712],"category_scores_gemma":[0.001049495,0.0011376133,0.0005548153,0.0031885954,0.0007959892,0.00043058908,0.00031870967,0.0011228912,0.00003706308],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.94901824,0.00079469266,0.012085149,0.0011856226,0.0023972103,0.0008594691,0.00048463413,0.0026400664,0.0029946102,0.00015355993,0.0010439054,0.02634285],"study_design_scores_gemma":[0.729357,0.024318166,0.21314359,0.0045319544,0.0013643716,0.00009523,0.00037749816,0.008587609,0.01481562,0.000100907,0.001879504,0.0014285374],"about_ca_topic_score_codex":0.009299679,"about_ca_topic_score_gemma":0.0020630073,"teacher_disagreement_score":0.21966122,"about_ca_system_score_codex":0.08069298,"about_ca_system_score_gemma":0.057562027,"threshold_uncertainty_score":0.9997602},"labels":[],"label_agreement":null},{"id":"W4411383594","doi":"10.1080/10428194.2025.2518440","title":"Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo; Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Chimeric antigen receptor; Reimbursement; Medicine; Activity-based costing; Cohort; Health care; Retrospective cohort study; Internal medicine; Immunotherapy; Cancer; Business","score_opus":0.010594177255934879,"score_gpt":0.26298161148964,"score_spread":0.25238743423370513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411383594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98537946,0.0012486117,0.0000057675798,0.0005258366,0.00025257719,0.002936676,0.00013181068,0.0001147857,0.009404476],"genre_scores_gemma":[0.9777242,0.0045120553,0.00032492576,0.002055834,0.00013621892,0.0005133036,0.0005508315,0.00014685057,0.014035779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957792,0.00020602239,0.00082052173,0.0011392678,0.000752461,0.0013025228],"domain_scores_gemma":[0.99753344,0.00042465382,0.00023145282,0.0008533586,0.00040094633,0.00055616844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029667612,0.0007060567,0.0011570383,0.00067639636,0.000304208,0.00007952349,0.0003543729,0.00027457764,0.00017947148],"category_scores_gemma":[0.00004478113,0.0005947957,0.00016077867,0.0018316775,0.00019168055,0.0001586992,0.000092613445,0.00020109364,0.000009061298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007860485,0.00032179186,0.625247,0.0003670323,0.00022851415,0.0000990198,0.0002657637,0.0000073220517,0.005121682,0.000069311085,0.008511086,0.351901],"study_design_scores_gemma":[0.06070096,0.0018639576,0.8242886,0.0007784554,0.00007963658,0.000032548014,0.00052782556,0.0012170905,0.02535935,0.000030975374,0.08426509,0.00085549755],"about_ca_topic_score_codex":0.88760287,"about_ca_topic_score_gemma":0.59286886,"teacher_disagreement_score":0.3510455,"about_ca_system_score_codex":0.036217134,"about_ca_system_score_gemma":0.024667764,"threshold_uncertainty_score":0.99965036},"labels":[],"label_agreement":null},{"id":"W4411429251","doi":"10.1080/10428194.2025.2504719","title":"Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Chemoimmunotherapy; CD20; Rituximab; CHOP; Monoclonal antibody; Vincristine; Cancer research; Lymphoma; Medicine; B cell; Antibody-dependent cell-mediated cytotoxicity; Diffuse large B-cell lymphoma; Antibody; Immunology; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.008323771422152333,"score_gpt":0.27149745491985194,"score_spread":0.2631736834976996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411429251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96999377,0.012283346,0.00012849424,0.0003155423,0.0004374459,0.0017746828,0.000049478032,0.00020082959,0.01481644],"genre_scores_gemma":[0.9874826,0.004625492,0.0010268245,0.0006664795,0.0001744433,0.00015127273,0.00015713794,0.00017126305,0.005544452],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.992766,0.00081961224,0.0018408488,0.0018376623,0.0010581731,0.0016776773],"domain_scores_gemma":[0.9954346,0.0015413818,0.0004770201,0.0014906956,0.00046266054,0.0005936772],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025844881,0.0011468632,0.002182156,0.0011645015,0.0004799308,0.0001818097,0.0006516594,0.00096037175,0.00031708326],"category_scores_gemma":[0.00043555268,0.0010984143,0.0004641565,0.0019005138,0.0011511382,0.00040740444,0.0006082803,0.00047443475,0.000024361074],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040856707,0.0017476416,0.18375774,0.0036090668,0.0003727351,0.00048401728,0.0045617255,0.00002392998,0.6231491,0.00031678035,0.0013417973,0.1765498],"study_design_scores_gemma":[0.082103185,0.0012317924,0.49259093,0.0012308107,0.0004025664,0.00028193346,0.005616783,0.010348707,0.3827328,0.0014206499,0.020331599,0.001708223],"about_ca_topic_score_codex":0.005008964,"about_ca_topic_score_gemma":0.00009136943,"teacher_disagreement_score":0.3088332,"about_ca_system_score_codex":0.0053948592,"about_ca_system_score_gemma":0.0050655515,"threshold_uncertainty_score":0.9991466},"labels":[],"label_agreement":null},{"id":"W4411521899","doi":"10.1080/10428194.2025.2521650","title":"Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Israel Cancer Association","keywords":"Sepsis; Medicine; Intensive care medicine; Intensive care unit; Pediatric intensive care unit; Emergency medicine; Internal medicine","score_opus":0.021549071423951772,"score_gpt":0.2914854479318599,"score_spread":0.2699363765079081,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411521899","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950188,0.0007919088,0.00058963755,0.0006880851,0.00015502804,0.0017307332,0.00021085139,0.00009178636,0.00072318956],"genre_scores_gemma":[0.99591357,0.00016923314,0.00037521464,0.002691787,0.00007424675,0.0002597808,0.00005748483,0.00003614467,0.00042251954],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980079,0.00008653009,0.00046510648,0.0006959753,0.00028728155,0.00045719382],"domain_scores_gemma":[0.9978578,0.00031038694,0.0001704795,0.0006256387,0.00064182794,0.0003938739],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015804413,0.00042569463,0.0008365699,0.00021596471,0.000494639,0.000061667386,0.00020498176,0.00023309042,0.000018494433],"category_scores_gemma":[0.0004141866,0.00025932465,0.00016805984,0.00067034963,0.0002517314,0.00008703715,0.0002121939,0.00010489609,0.0000033494096],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016419918,0.00007019093,0.962236,0.00039250936,0.0006691272,0.000038776463,0.005044344,0.00011347081,0.0015235723,0.0010734132,0.005670781,0.021525832],"study_design_scores_gemma":[0.005275533,0.000914509,0.9471374,0.00052290934,0.0008834712,0.00027438524,0.009466155,0.00006530051,0.02831454,0.000121382895,0.006689467,0.0003349187],"about_ca_topic_score_codex":0.00408993,"about_ca_topic_score_gemma":0.00077755377,"teacher_disagreement_score":0.026790967,"about_ca_system_score_codex":0.0011298028,"about_ca_system_score_gemma":0.0014897403,"threshold_uncertainty_score":0.9999859},"labels":[],"label_agreement":null},{"id":"W4411558199","doi":"10.1080/10428194.2025.2502805","title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: a post hoc analysis of KEYNOTE-204 by prior lines of therapy","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Post-hoc analysis; Refractory (planetary science); Medicine; Post hoc; Oncology; Lymphoma; Internal medicine; Cancer; Materials science; Immunotherapy","score_opus":0.009830960614451054,"score_gpt":0.2684047589855079,"score_spread":0.2585737983710569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411558199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97752464,0.017914912,0.000024103178,0.00034787075,0.0002776483,0.0012538837,0.00032994448,0.00014660304,0.0021804236],"genre_scores_gemma":[0.9850734,0.009773966,0.0005657837,0.0013427845,0.00008603345,0.00028023578,0.00041763677,0.00010733693,0.0023528237],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9938223,0.00031011034,0.0023139475,0.0015156305,0.0009758456,0.0010622088],"domain_scores_gemma":[0.9953439,0.0010963691,0.00095813,0.001620545,0.0005360924,0.00044496672],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005611453,0.0011141468,0.0031936576,0.0022570593,0.00021899666,0.00007486937,0.0005685468,0.00092574814,0.00016969179],"category_scores_gemma":[0.00029816598,0.00087571185,0.0009812602,0.0042038606,0.00063180504,0.000257144,0.00025484036,0.00013170956,0.000012581978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03834166,0.006388776,0.13354374,0.0010295757,0.008692789,0.00086845655,0.0025473007,0.00011307106,0.023231171,0.0009198325,0.0044144257,0.7799092],"study_design_scores_gemma":[0.11111158,0.003677611,0.82090557,0.0012216403,0.004196758,0.00020088333,0.00096421025,0.0038578403,0.034411483,0.00011293625,0.018281726,0.0010577488],"about_ca_topic_score_codex":0.007824774,"about_ca_topic_score_gemma":0.0007098201,"teacher_disagreement_score":0.77885145,"about_ca_system_score_codex":0.00762137,"about_ca_system_score_gemma":0.007467495,"threshold_uncertainty_score":0.9993694},"labels":[],"label_agreement":null},{"id":"W4412366400","doi":"10.1080/10428194.2025.2521656","title":"A charter for improving care for people living with chronic lymphocytic leukemia: six principles for excellence","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation; Alberta Health Services","funders":"AstraZeneca","keywords":"Charter; Chronic lymphocytic leukemia; Excellence; Medicine; Gerontology; Leukemia; Intensive care medicine; Political science; Immunology; Law","score_opus":0.012227065018911371,"score_gpt":0.26680979570576285,"score_spread":0.2545827306868515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412366400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94093,0.011109964,0.030810468,0.0003005827,0.0009886607,0.012517353,0.00040022435,0.00080047676,0.002142252],"genre_scores_gemma":[0.96690255,0.00065720733,0.008960874,0.0011906502,0.0013608561,0.008997086,0.00042062704,0.00044445798,0.011065694],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99130416,0.00012157051,0.0017214867,0.0026434234,0.0010474988,0.0031618688],"domain_scores_gemma":[0.99132276,0.003710507,0.00064072787,0.002049087,0.0013632213,0.0009136748],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001105124,0.0016104754,0.0024368812,0.0009016503,0.0016614966,0.00048553428,0.0010508631,0.0011622874,0.00003746955],"category_scores_gemma":[0.0013240369,0.0014317358,0.00093516486,0.0011504597,0.00071593537,0.0005999094,0.00060613174,0.0002703756,0.000021860405],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034127142,0.0007144665,0.007461681,0.13484113,0.0048335693,0.00041681537,0.023043102,0.00732531,0.031737033,0.020113442,0.018274354,0.71711195],"study_design_scores_gemma":[0.21650063,0.0055241613,0.0083305705,0.007173411,0.0030055316,0.0018261014,0.007231308,0.6089205,0.025087437,0.0004689461,0.1126955,0.003235913],"about_ca_topic_score_codex":0.0040702173,"about_ca_topic_score_gemma":0.0018538034,"teacher_disagreement_score":0.71387607,"about_ca_system_score_codex":0.30503955,"about_ca_system_score_gemma":0.16841638,"threshold_uncertainty_score":0.9996643},"labels":[],"label_agreement":null},{"id":"W4412395052","doi":"10.1080/10428194.2025.2529451","title":"Expanding the phenotypic spectrum of DDX41-related myeloid neoplasms: a case of mature plasmacytoid dendritic cell proliferation associated with acute myeloid leukemia with germline DDX41 mutation","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid; Myeloid leukemia; Phenotype; Germline; Mutation; Immunology; Cancer research; Plasmacytoid dendritic cell; Biology; Medicine; Dendritic cell; Gene; Genetics; Immune system","score_opus":0.006061897744530263,"score_gpt":0.24192004138317377,"score_spread":0.23585814363864352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412395052","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904179,0.001353297,0.00094601343,0.0006544038,0.00027700304,0.002725347,0.00018000753,0.00030471222,0.0031412991],"genre_scores_gemma":[0.9913138,0.00052266405,0.0012501702,0.00059676316,0.00015914968,0.00030863102,0.00055697956,0.00022355859,0.005068242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9931344,0.0005103447,0.0019342792,0.0015108719,0.0013878316,0.0015222848],"domain_scores_gemma":[0.994618,0.0012559213,0.0012726962,0.0014663411,0.0008761691,0.00051089603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001066383,0.0012589522,0.0020002923,0.0011972309,0.0008314184,0.0001970022,0.0006510822,0.0010651615,0.000079732556],"category_scores_gemma":[0.0003889065,0.00089253014,0.00035791076,0.0034578717,0.0013313211,0.0006097998,0.00032075433,0.0008526742,0.00001784748],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10561658,0.0053093866,0.10212845,0.01672134,0.032030776,0.092778586,0.0560729,0.016161509,0.38536444,0.0137859825,0.015718667,0.15831138],"study_design_scores_gemma":[0.130368,0.006236739,0.10519852,0.0070832763,0.008840277,0.060977176,0.011479946,0.08898447,0.575178,0.0017577145,0.000677405,0.003218449],"about_ca_topic_score_codex":0.0023574415,"about_ca_topic_score_gemma":0.0010246251,"teacher_disagreement_score":0.18981358,"about_ca_system_score_codex":0.013116587,"about_ca_system_score_gemma":0.014327372,"threshold_uncertainty_score":0.9993525},"labels":[],"label_agreement":null},{"id":"W4412654447","doi":"10.1080/10428194.2025.2532674","title":"Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"European Union Studies Association; Kite Pharma; Genmab; Genentech Foundation; Daiichi Sankyo Europe; Janssen Biotech; AbbVie Canada; Pharmacyclics; Seattle Genetics; Genentech; MorphoSys; Seagen; Incyte; TG Therapeutics; bluebird bio; Novartis Portugal; BeiGene; Merck KGaA; Regeneron Pharmaceuticals; Astellas Pharma; Takeda Pharmaceuticals U.S.A.; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Adverse effect; Oncology; Confidence interval; Odds ratio; Refractory (planetary science); Lymphoma; Cytokine release syndrome; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.027151610728664,"score_gpt":0.29862573315635244,"score_spread":0.2714741224276884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412654447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949534,0.0026576174,0.00024006332,0.000046705773,0.00052119995,0.0028458738,0.0007227768,0.0001759134,0.0032945327],"genre_scores_gemma":[0.9780204,0.0006231789,0.0013712341,0.00016943067,0.00017788816,0.00035809682,0.0007778961,0.00020642462,0.018295396],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99417025,0.00026076357,0.0017578737,0.0013598277,0.0011181107,0.001333177],"domain_scores_gemma":[0.9951044,0.0011920858,0.0009311276,0.0014885972,0.00072839553,0.00055543485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046536388,0.001084548,0.0026698764,0.0009382521,0.00036599147,0.00007454427,0.0005164542,0.00081366784,0.00048669605],"category_scores_gemma":[0.00010553652,0.0008585396,0.0005844917,0.0012770882,0.00048395016,0.00026801025,0.00021159538,0.00015891464,0.000013811475],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25950179,0.02129625,0.10508328,0.005252095,0.00525222,0.00027308182,0.008254904,0.00007657519,0.10110358,0.00036499064,0.0026349518,0.4909063],"study_design_scores_gemma":[0.3399427,0.020676166,0.3058644,0.0008813177,0.0019024517,0.00003361755,0.0017650548,0.0019615986,0.2863197,0.00007454043,0.0392715,0.0013069682],"about_ca_topic_score_codex":0.0011732552,"about_ca_topic_score_gemma":0.00052214443,"teacher_disagreement_score":0.48959932,"about_ca_system_score_codex":0.0077009825,"about_ca_system_score_gemma":0.00559261,"threshold_uncertainty_score":0.99938655},"labels":[],"label_agreement":null},{"id":"W4413052189","doi":"10.1080/10428194.2025.2531154","title":"The evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma – a narrative literature review","year":2025,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Clinical trial; Randomized controlled trial; Intensive care medicine; Lymphoma; Hodgkin lymphoma; Pediatrics; Internal medicine; Nursing","score_opus":0.015566333508557956,"score_gpt":0.3100154015530648,"score_spread":0.2944490680445068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413052189","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015927578,0.98423827,0.000031341893,0.0001793764,0.00091592007,0.009823101,0.0013718001,0.00021731715,0.0016301008],"genre_scores_gemma":[0.00060711254,0.9764302,0.0005182385,0.00036786502,0.00068859884,0.0074122953,0.0015447498,0.00023175032,0.012199207],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99166584,0.0006290978,0.0029961509,0.0022842037,0.00087896036,0.0015457686],"domain_scores_gemma":[0.9910301,0.0029557818,0.002295593,0.0023200123,0.0007328662,0.00066562457],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00071396923,0.002500589,0.0066271424,0.0008355932,0.0010683966,0.00023410142,0.00076677115,0.001460383,0.000023995935],"category_scores_gemma":[0.0006112396,0.0015607091,0.0031480896,0.0025247796,0.00046374416,0.00031374223,0.00031091063,0.00018535406,0.000027124419],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005565701,0.00056510424,0.00007333395,0.09673084,0.0016518838,0.00021968766,0.0003858994,0.0000016960485,0.0000016694542,0.0018524379,0.0061138603,0.891847],"study_design_scores_gemma":[0.01925296,0.0021680202,0.00047450128,0.10607105,0.012129444,0.0008207685,0.000335668,0.00007213593,0.000025921465,0.00011506074,0.8573527,0.0011817843],"about_ca_topic_score_codex":0.0003738849,"about_ca_topic_score_gemma":0.00008732141,"teacher_disagreement_score":0.89066523,"about_ca_system_score_codex":0.05150756,"about_ca_system_score_gemma":0.03119342,"threshold_uncertainty_score":0.9998359},"labels":[],"label_agreement":null},{"id":"W4413106872","doi":"10.1080/10428194.2025.2542941","title":"Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Romidepsin; Medicine; Discontinuation; Oncology; Lymphoma; Cutaneous T-cell lymphoma; Internal medicine; Vindesine; Chemotherapy; Mycosis fungoides; Histone deacetylase; Vincristine","score_opus":0.015087531009809824,"score_gpt":0.2961551683350083,"score_spread":0.2810676373251985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413106872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97584796,0.007795449,0.0006840869,0.00065296725,0.00045914625,0.0034537506,0.00020252801,0.00039464846,0.010509468],"genre_scores_gemma":[0.9711936,0.0038712309,0.0026799277,0.0013267708,0.00026372436,0.0008871833,0.0003081615,0.00020471522,0.019264657],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941805,0.00019414605,0.0011417518,0.0020330767,0.00074390176,0.0017066268],"domain_scores_gemma":[0.996462,0.0007826474,0.0002916693,0.0011647544,0.00045747022,0.0008414605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027556348,0.0012645156,0.0017338586,0.0007690933,0.0009305591,0.00032816193,0.00038547814,0.0007595401,0.0000783948],"category_scores_gemma":[0.0003064263,0.0011694939,0.0005268889,0.00078090874,0.00076210767,0.000297657,0.00033637485,0.00011944141,0.000049758924],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.016563958,0.0016086175,0.006003344,0.00157326,0.0011867058,0.0021602365,0.0016320114,0.00012646492,0.056463793,0.0022707072,0.0037526507,0.90665823],"study_design_scores_gemma":[0.3341866,0.008753737,0.016444942,0.0018268629,0.003282571,0.03393609,0.004972156,0.07738479,0.24526821,0.005045121,0.26412004,0.004778869],"about_ca_topic_score_codex":0.0016909641,"about_ca_topic_score_gemma":0.00028755766,"teacher_disagreement_score":0.9018794,"about_ca_system_score_codex":0.014735259,"about_ca_system_score_gemma":0.008190863,"threshold_uncertainty_score":0.99907553},"labels":[],"label_agreement":null},{"id":"W4413272991","doi":"10.1080/10428194.2025.2542943","title":"Understanding the clinical approach to “pathologically ambiguous follicular lymphoma” through a Real-World cohort","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"Israel Cancer Research Fund","keywords":"Follicular lymphoma; Cohort; Lymphoma; Follicular phase; Medicine; Oncology; Internal medicine","score_opus":0.06678686074280356,"score_gpt":0.32518067801713424,"score_spread":0.2583938172743307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413272991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81993777,0.0018324743,0.004443166,0.0017599924,0.0009067364,0.0030961742,0.000047733734,0.0006069276,0.16736901],"genre_scores_gemma":[0.9698502,0.0031751378,0.0044362186,0.014914682,0.0005347117,0.0010465794,0.00015776178,0.0001395944,0.00574515],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99200624,0.0005717304,0.0020253921,0.00247706,0.0011996159,0.001719988],"domain_scores_gemma":[0.99524623,0.00089907413,0.0004581221,0.002247464,0.0002588499,0.0008902369],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015850909,0.001325182,0.0022617583,0.0005058091,0.00138729,0.0004442469,0.00086134276,0.0008751534,0.000046381014],"category_scores_gemma":[0.0003887524,0.00091448595,0.0010378896,0.002225152,0.000988965,0.00030941094,0.000754585,0.00024173778,0.0001561357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046253996,0.005839038,0.46993423,0.0007467795,0.0052645663,0.0035942076,0.0032199307,0.00029953677,0.00048447147,0.15251465,0.076087184,0.27739],"study_design_scores_gemma":[0.027100304,0.0007953324,0.90164036,0.00064612523,0.0021042987,0.0011559261,0.0014399457,0.0019576459,0.00067341345,0.004784445,0.05652591,0.0011762817],"about_ca_topic_score_codex":0.004605574,"about_ca_topic_score_gemma":0.00021359355,"teacher_disagreement_score":0.43170616,"about_ca_system_score_codex":0.017910263,"about_ca_system_score_gemma":0.004820495,"threshold_uncertainty_score":0.99994993},"labels":[],"label_agreement":null},{"id":"W4413431624","doi":"10.1080/10428194.2025.2536121","title":"Indolent chronic myeloid leukemia – a historical dinosaur?","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Medicine; Immunology","score_opus":0.010352445609960795,"score_gpt":0.2465565217181639,"score_spread":0.2362040761082031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413431624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94429857,0.017809235,0.00042418358,0.0012288595,0.0019880915,0.0019673265,0.00005349028,0.0010656518,0.031164588],"genre_scores_gemma":[0.9561551,0.0037233562,0.0010153502,0.0034849944,0.0012144706,0.0005835514,0.00026838426,0.0002562325,0.033298563],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9912867,0.0002719406,0.0019655633,0.002641815,0.0014297582,0.0024042164],"domain_scores_gemma":[0.9948148,0.000574478,0.0005607753,0.0024090805,0.00033688667,0.001303984],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00059740705,0.0017920118,0.0024477646,0.0011628867,0.00086337887,0.00025244596,0.00087657623,0.0014316734,0.00032442276],"category_scores_gemma":[0.00035893996,0.001686599,0.0008829645,0.001866406,0.0006367924,0.00052359456,0.00081160036,0.00061409577,0.00044619056],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032617943,0.0010249179,0.032716673,0.0027165022,0.0026160341,0.0034341016,0.0014443372,0.00018816002,0.017686995,0.0064585772,0.103773676,0.82467824],"study_design_scores_gemma":[0.08112467,0.0018093017,0.23851727,0.002729369,0.002359919,0.0037012869,0.000388192,0.010166973,0.020760553,0.0010851644,0.63457865,0.0027786824],"about_ca_topic_score_codex":0.0052707097,"about_ca_topic_score_gemma":0.0002991615,"teacher_disagreement_score":0.82189953,"about_ca_system_score_codex":0.2470424,"about_ca_system_score_gemma":0.030808602,"threshold_uncertainty_score":0.9998647},"labels":[],"label_agreement":null},{"id":"W4414152096","doi":"10.1080/10428194.2025.2537597","title":"XXI International Workshop on CLL 2025","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Linguistic Education and Pedagogy","field":"Arts and Humanities","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Ibrutinib; Venetoclax; Chronic lymphocytic leukemia; Lymphoma; Phases of clinical research; Leukemia","score_opus":0.028118629096691706,"score_gpt":0.2908320198891648,"score_spread":0.2627133907924731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414152096","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.3943069,0.00067561335,0.00008364904,0.002772018,0.008225487,0.00026758993,0.000063394255,0.00027808305,0.5933273],"genre_scores_gemma":[0.82453054,0.00025453742,0.00008911846,0.008679965,0.002012133,0.00007512931,0.000103922364,0.00004158351,0.16421309],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.997626,0.00011847458,0.0006090173,0.00071324245,0.0003896228,0.0005436424],"domain_scores_gemma":[0.998144,0.0006488935,0.0001799526,0.0005573784,0.00025782347,0.0002119934],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003458158,0.00046211627,0.000429259,0.00043879394,0.00066553074,0.00059538544,0.00055793434,0.00023454569,0.0025877757],"category_scores_gemma":[0.00036139903,0.0004285584,0.00018232767,0.00015158305,0.00044292398,0.00019571546,0.00017636782,0.00013779622,0.00050374604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006359817,0.00021549032,0.0007007974,0.000075690914,0.0002529093,0.000047607213,0.014717861,0.000029778985,0.000062813364,0.650976,0.1475374,0.18474768],"study_design_scores_gemma":[0.0036350223,0.00006261542,0.0049689044,0.00024884212,0.000072940595,0.000018443874,0.005747882,0.0009781881,0.0002448042,0.0051712072,0.978378,0.00047313998],"about_ca_topic_score_codex":0.0009764758,"about_ca_topic_score_gemma":0.0003579669,"teacher_disagreement_score":0.8308406,"about_ca_system_score_codex":0.0027157825,"about_ca_system_score_gemma":0.002286935,"threshold_uncertainty_score":0.9998166},"labels":[],"label_agreement":null},{"id":"W4414422124","doi":"10.1080/10428194.2025.2553863","title":"From dimensions through dynamics to outcomes – lymph nodes and skin assessments predict CTCL outcomes","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Retrospective cohort study; Lymph; Predictive value of tests; Lymph node; Cut-off; Cutoff; Clinical trial","score_opus":0.010649052137224705,"score_gpt":0.2962868721994522,"score_spread":0.2856378200622275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414422124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9823794,0.0020656676,0.00041408438,0.002538673,0.0009563544,0.0013116854,0.00049632025,0.0004339283,0.009403903],"genre_scores_gemma":[0.9771934,0.0012278565,0.00597884,0.009478005,0.00016717374,0.00045887055,0.0004826525,0.00013056422,0.004882609],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945826,0.00016183732,0.0012365083,0.001873371,0.0009141812,0.0012315148],"domain_scores_gemma":[0.99610406,0.0010562746,0.00029186418,0.001486875,0.00021681502,0.00084411434],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0002581696,0.0012869948,0.0020779923,0.00048988697,0.00069475506,0.00033855235,0.00041916405,0.00067491265,0.00007248935],"category_scores_gemma":[0.00024800096,0.0010249295,0.00048476094,0.0007713398,0.00038908338,0.0004907742,0.00078228733,0.00013804875,0.000100279765],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048147253,0.0008093887,0.8439731,0.0001727092,0.0019309615,0.00046377984,0.00075594673,0.000022521142,0.0002009009,0.006858091,0.004275128,0.14005598],"study_design_scores_gemma":[0.026520329,0.000277598,0.95209676,0.00069974316,0.001455909,0.00017842275,0.0011178154,0.0031819285,0.001269663,0.0026760073,0.009621092,0.0009047246],"about_ca_topic_score_codex":0.0136203095,"about_ca_topic_score_gemma":0.00033097653,"teacher_disagreement_score":0.13915126,"about_ca_system_score_codex":0.010674001,"about_ca_system_score_gemma":0.0029726701,"threshold_uncertainty_score":0.9999882},"labels":[],"label_agreement":null},{"id":"W4414611697","doi":"10.1080/10428194.2025.2560085","title":"The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review","year":2025,"lang":"en","type":"review","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Incidence (geometry); Confidence interval; Pharmacovigilance; Clinical trial; Clinical endpoint; Cohort; Adverse effect; Cohort study; Malignancy","score_opus":0.012847556902866512,"score_gpt":0.2676493473679365,"score_spread":0.25480179046507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414611697","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006314638,0.9782868,0.0000079029105,0.000013890512,0.00023097402,0.013324419,0.00069519866,0.0001267236,0.0009994595],"genre_scores_gemma":[0.0028683108,0.9870268,0.00040239628,0.00016528534,0.0000711706,0.0044609415,0.0008645285,0.000162627,0.003977941],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9925967,0.0011882186,0.002871868,0.0012215027,0.00091244135,0.0012092929],"domain_scores_gemma":[0.9889817,0.0066638784,0.001871094,0.0016204393,0.00050736853,0.00035549156],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015194746,0.0013387923,0.006569613,0.0006066034,0.000500998,0.00011991886,0.0007419175,0.00070799724,0.000014823363],"category_scores_gemma":[0.0031141865,0.00082417484,0.0014254056,0.0011630529,0.00035094153,0.00016911366,0.00035220155,0.00030279468,0.000016320731],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00027143594,0.00023167659,0.0013609428,0.61046463,0.0010971031,0.00003276054,0.000114445145,7.730095e-8,0.0000017747844,0.000011033546,0.00085674296,0.38555738],"study_design_scores_gemma":[0.023418363,0.0006318298,0.021323288,0.85505694,0.008852867,0.0001059973,0.000113065864,0.00014437735,0.000031990097,0.000050458355,0.08918639,0.0010844169],"about_ca_topic_score_codex":0.00033340263,"about_ca_topic_score_gemma":0.00022213007,"teacher_disagreement_score":0.38447297,"about_ca_system_score_codex":0.0072198603,"about_ca_system_score_gemma":0.006845184,"threshold_uncertainty_score":0.99993634},"labels":[],"label_agreement":null},{"id":"W4414780017","doi":"10.1080/10428194.2025.2561117","title":"Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Carfilzomib; Dexamethasone; Multiple myeloma; Clinical endpoint; Interim analysis; Panobinostat; Clinical trial","score_opus":0.013305664650567555,"score_gpt":0.26235908081363185,"score_spread":0.24905341616306428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414780017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98270607,0.008587664,0.000015049684,0.00008191979,0.0003878083,0.0052895024,0.00022080448,0.0002717166,0.002439474],"genre_scores_gemma":[0.992098,0.0028777353,0.00093723193,0.00016667465,0.00012795877,0.0007144428,0.0004116467,0.00021587429,0.002450442],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919309,0.00082440843,0.0013641878,0.002705934,0.0012402476,0.0019342989],"domain_scores_gemma":[0.9944228,0.0017825828,0.0004717652,0.0016648093,0.0004207644,0.0012372901],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00055485277,0.0017449195,0.0026970722,0.0011254081,0.0010622431,0.000354097,0.00042101223,0.0008150401,0.000039157665],"category_scores_gemma":[0.00075334054,0.0014293445,0.00023713455,0.0014039251,0.0009129966,0.00059839594,0.00049674924,0.0005586532,0.000021953787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.076206535,0.0026530128,0.58523417,0.00048176732,0.002553259,0.0041294917,0.004507605,0.000037064674,0.00032572425,0.000035704186,0.0002465966,0.3235891],"study_design_scores_gemma":[0.24602672,0.011110204,0.73143876,0.0007766054,0.00120779,0.00043248924,0.0020461576,0.0029420902,0.0006362747,0.000026551137,0.0022227475,0.0011335972],"about_ca_topic_score_codex":0.008632018,"about_ca_topic_score_gemma":0.004537893,"teacher_disagreement_score":0.3224555,"about_ca_system_score_codex":0.014165737,"about_ca_system_score_gemma":0.003599119,"threshold_uncertainty_score":0.99952966},"labels":[],"label_agreement":null},{"id":"W4414794257","doi":"10.1080/10428194.2025.2561737","title":"Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma; National Center for Advancing Translational Sciences; Astellas Pharma Canada","keywords":"Discontinuation; Midostaurin; Myeloid leukemia; Sorafenib; Hematopoietic cell; Maintenance therapy; Cohort; Transplantation; Persistence (discontinuity)","score_opus":0.0442771537125276,"score_gpt":0.3291058326767186,"score_spread":0.284828678964191,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414794257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942091,0.000316255,0.000006297463,0.00019894712,0.000060414375,0.0040437914,0.00013923376,0.000042919353,0.0009830595],"genre_scores_gemma":[0.99651545,0.0013888933,0.00026905845,0.00060184055,0.000033853798,0.000219333,0.00049231277,0.000055824163,0.0004234391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995303,0.0005612567,0.0010018772,0.0013840104,0.0008991657,0.0008506862],"domain_scores_gemma":[0.99673986,0.00066460535,0.00034752293,0.0015979167,0.0004086417,0.00024143641],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00090287847,0.00071001693,0.0011529366,0.0009764907,0.00023835404,0.00011867317,0.0007315553,0.000224147,0.000014714205],"category_scores_gemma":[0.0001536705,0.00046406587,0.000094611096,0.0025957543,0.0008217028,0.00037229265,0.00035032956,0.0002752871,0.0000024333501],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0071928576,0.0013641367,0.9605527,0.00013118213,0.0004900918,0.0005293285,0.008554224,0.000046911595,0.000159397,0.00009846913,0.00015053985,0.020730173],"study_design_scores_gemma":[0.036033027,0.005506384,0.92973405,0.0008808827,0.0002506659,0.00007684161,0.020889107,0.005458215,0.00031844556,0.000046703106,0.00038464848,0.00042100364],"about_ca_topic_score_codex":0.07115503,"about_ca_topic_score_gemma":0.007814961,"teacher_disagreement_score":0.06334007,"about_ca_system_score_codex":0.009617014,"about_ca_system_score_gemma":0.00743712,"threshold_uncertainty_score":0.99978113},"labels":[],"label_agreement":null},{"id":"W4415063566","doi":"10.1080/10428194.2025.2562961","title":"Expert consensus opinion on the management of hairy cell leukemia in elderly patients","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Hairy cell leukemia; Cladribine; Expert opinion; Leukemia; MEDLINE","score_opus":0.01441489767900824,"score_gpt":0.2759394004783551,"score_spread":0.26152450279934686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415063566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9382877,0.0032225086,0.000038948,0.00048952294,0.0007369879,0.0021229018,0.000033930482,0.00015275062,0.054914773],"genre_scores_gemma":[0.98938537,0.0033735193,0.0006159234,0.0022053411,0.00015292746,0.00035630795,0.000093770024,0.000119805154,0.0036970165],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993731,0.00033161053,0.0015789539,0.0014630429,0.0014520875,0.0014432872],"domain_scores_gemma":[0.99595416,0.0010126679,0.0004022727,0.0018958651,0.00031226673,0.00042276867],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087582256,0.00093406276,0.0012769786,0.0008325595,0.00035901007,0.000109118075,0.0008318886,0.00067351665,0.00009769661],"category_scores_gemma":[0.00015977904,0.00072971714,0.00039200048,0.0016167164,0.00084225746,0.00014308767,0.0006380145,0.00037471444,0.000099795834],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01652272,0.00297541,0.01615022,0.008319484,0.0024082924,0.0025984147,0.005330706,0.0010175471,0.003780856,0.03477458,0.085932404,0.82018936],"study_design_scores_gemma":[0.36945453,0.0043327655,0.30236757,0.0147211235,0.0007140792,0.00063854695,0.008018212,0.066402294,0.06672487,0.0029537969,0.1600505,0.0036216984],"about_ca_topic_score_codex":0.00549185,"about_ca_topic_score_gemma":0.00008081937,"teacher_disagreement_score":0.81656766,"about_ca_system_score_codex":0.085625194,"about_ca_system_score_gemma":0.019178595,"threshold_uncertainty_score":0.9995154},"labels":[],"label_agreement":null},{"id":"W4415791945","doi":"10.1080/10428194.2025.2579735","title":"Reporting and enrollment disparities in hematologic malignancy trials between 2000–2023","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Foundation; Princess Margaret Cancer Centre; Women's College Hospital; University of Toronto","funders":"Leukemia and Lymphoma Society","keywords":"Hematologic malignancy; Clinical trial; Ethnic group; Race (biology); Multiple myeloma; Odds; Odds ratio; Diversity (politics)","score_opus":0.23835864244616492,"score_gpt":0.4826570369256505,"score_spread":0.24429839447948556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415791945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724838,0.008626087,0.00010634345,0.0026867294,0.00033081527,0.0011864,0.0000326562,0.0001659651,0.014381212],"genre_scores_gemma":[0.9802948,0.0050758375,0.0010877944,0.0019348363,0.0002673859,0.000245325,0.000055516583,0.000059509992,0.010978951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99095565,0.0006054786,0.0046719178,0.00145733,0.0011056794,0.0012039453],"domain_scores_gemma":[0.98300123,0.013714942,0.0013604067,0.0010616981,0.00029742013,0.00056429487],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.012969006,0.0006231887,0.0028274416,0.00066708296,0.00035984564,0.00021933757,0.00037570973,0.001357919,0.00006815071],"category_scores_gemma":[0.034080792,0.00052806287,0.00034927356,0.00096945406,0.0008217069,0.00020850672,0.00070690596,0.00073840976,0.000026621865],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001045652,0.00022976976,0.8368689,0.003067733,0.00047262153,0.0019084438,0.0005765517,0.000007665939,0.001218457,0.02417413,0.002146345,0.12828378],"study_design_scores_gemma":[0.020581884,0.00041431232,0.9004475,0.0044444855,0.00042417803,0.00051737286,0.00082097127,0.00067620963,0.005477983,0.060742207,0.004714904,0.0007379916],"about_ca_topic_score_codex":0.0036230618,"about_ca_topic_score_gemma":0.00035843422,"teacher_disagreement_score":0.12754579,"about_ca_system_score_codex":0.005429296,"about_ca_system_score_gemma":0.008383926,"threshold_uncertainty_score":0.99993855},"labels":[],"label_agreement":null},{"id":"W4415949216","doi":"10.1080/10428194.2025.2577861","title":"Real-world experience and outcomes of decitabine/cedazuridine or azacitidine for the treatment of myelodysplastic syndrome/chronic myelomonocytic leukemia","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Azacitidine; Myelodysplastic syndromes; Chronic myelomonocytic leukemia; Leukemia; Disease; Clinical trial","score_opus":0.02106423577910986,"score_gpt":0.31566702946963227,"score_spread":0.2946027936905224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415949216","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884,0.0048989193,0.0006619535,0.0005087894,0.00042602155,0.0029935562,0.00017217637,0.00016219092,0.0013364371],"genre_scores_gemma":[0.97019494,0.014321893,0.0016601273,0.00028829588,0.00018744616,0.0010432727,0.00008406103,0.00014416395,0.01207582],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943143,0.00015480437,0.0018528698,0.0014238642,0.00085028127,0.0014038723],"domain_scores_gemma":[0.9924792,0.004196575,0.00060675055,0.001693126,0.00047472055,0.0005495954],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054706994,0.0011455448,0.0025603191,0.001042582,0.00055361533,0.00009862096,0.00069412525,0.00048743785,0.000100629346],"category_scores_gemma":[0.000604668,0.0007458936,0.0005492789,0.0017697223,0.0017565701,0.0003075201,0.00035231348,0.00018280603,0.000009415808],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02544689,0.0017883643,0.12793107,0.00857731,0.008144763,0.0016976057,0.0076370286,0.0007239107,0.042535823,0.016520098,0.0055300123,0.7534671],"study_design_scores_gemma":[0.083276466,0.008077459,0.73661375,0.002125312,0.0035243058,0.0020785185,0.002889903,0.052757267,0.07327435,0.00071294984,0.033021756,0.0016479746],"about_ca_topic_score_codex":0.0050196894,"about_ca_topic_score_gemma":0.0006369041,"teacher_disagreement_score":0.75181913,"about_ca_system_score_codex":0.02350501,"about_ca_system_score_gemma":0.014637511,"threshold_uncertainty_score":0.9994992},"labels":[],"label_agreement":null},{"id":"W4415949455","doi":"10.1080/10428194.2025.2579721","title":"Clinical outcomes with venetoclax-based therapy in patients with relapsed/refractory B-cell lymphomas","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Lymphoma; Radiation therapy; Disease; MEDLINE; Clinical trial","score_opus":0.00894682280453036,"score_gpt":0.25578112319509644,"score_spread":0.24683430039056609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415949455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871813,0.0017004274,0.00003499539,0.0002638444,0.00035228074,0.001962101,0.000041916344,0.00027512902,0.008188024],"genre_scores_gemma":[0.99004185,0.0007369112,0.0013050633,0.0054047923,0.00009921071,0.00043425837,0.00024237,0.00015487138,0.0015806999],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943248,0.00028086157,0.0014076983,0.0017510095,0.0010031521,0.0012324679],"domain_scores_gemma":[0.9961243,0.00086760474,0.000486723,0.001548082,0.00032442666,0.0006488236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045568324,0.0012268192,0.001967147,0.00071491214,0.00033347172,0.0001557029,0.000412174,0.00075781666,0.000070321395],"category_scores_gemma":[0.00008666534,0.00083562784,0.00043244602,0.0011133527,0.0006426797,0.00032503923,0.00013223992,0.00023741699,0.000057219753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0076138917,0.0030716744,0.85140085,0.0001609771,0.0005588811,0.00042264682,0.00012991774,0.000085883315,0.000012806704,0.00022670496,0.0010868738,0.13522887],"study_design_scores_gemma":[0.14967187,0.0038427028,0.82955533,0.00072154746,0.00041110188,0.000034192624,0.000100232355,0.00034596218,0.000726482,0.000053321095,0.013750205,0.0007870785],"about_ca_topic_score_codex":0.001727846,"about_ca_topic_score_gemma":0.0002046672,"teacher_disagreement_score":0.14205797,"about_ca_system_score_codex":0.011868971,"about_ca_system_score_gemma":0.011025172,"threshold_uncertainty_score":0.99940944},"labels":[],"label_agreement":null},{"id":"W4416167189","doi":"10.1080/10428194.2025.2582732","title":"Real-world outcomes in adult histiocytosis: the uncharted territory of orphan diseases","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Histiocytic Disorders and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Cohort; Incidence (geometry); Concomitant; Langerhans cell histiocytosis; Histiocytosis; Disease; Presentation (obstetrics)","score_opus":0.006449946712818376,"score_gpt":0.2540275627804528,"score_spread":0.24757761606763443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416167189","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97888416,0.0015864039,0.0000159659,0.0006885126,0.00039666542,0.0007652621,0.00009281447,0.0001317631,0.017438443],"genre_scores_gemma":[0.9860937,0.0008153678,0.00012005482,0.0013612962,0.00006978052,0.00021817298,0.00010634234,0.000048492962,0.011166785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99726486,0.00012146913,0.00088331744,0.0006783793,0.0004697275,0.00058224564],"domain_scores_gemma":[0.9981747,0.0003389445,0.00024189068,0.0008476211,0.0001531922,0.00024362313],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015107644,0.0005277732,0.001055731,0.00055426004,0.00024456484,0.000046924717,0.00029783873,0.000217446,0.000057204157],"category_scores_gemma":[0.0001752352,0.00037467352,0.00028942365,0.00080779084,0.0005081613,0.00013962618,0.00013681989,0.000101757745,0.000022413653],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014968379,0.0014760465,0.8406851,0.00072059495,0.0009844045,0.00044882562,0.0011117249,0.000026971877,0.00057637034,0.009423235,0.009065848,0.13398401],"study_design_scores_gemma":[0.023342917,0.00021173796,0.9595415,0.0008596054,0.00084688707,0.000043808275,0.0007482071,0.001687658,0.0010995959,0.0008652157,0.010358488,0.0003943819],"about_ca_topic_score_codex":0.0129378885,"about_ca_topic_score_gemma":0.0020134088,"teacher_disagreement_score":0.13358963,"about_ca_system_score_codex":0.005441143,"about_ca_system_score_gemma":0.0033409568,"threshold_uncertainty_score":0.99987054},"labels":[],"label_agreement":null},{"id":"W4416176438","doi":"10.1080/10428194.2025.2584685","title":"Allogeneic hematopoietic stem cell transplantation in adult with acute lymphoblastic leukemia: evolving indications and modalities in shifting landscape","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Chimeric antigen receptor; Blinatumomab; Minimal residual disease; Hematopoietic stem cell transplantation; Transplantation; Immunotherapy; Savior sibling; Lymphoblastic Leukemia","score_opus":0.006378976277003266,"score_gpt":0.23520483413680687,"score_spread":0.2288258578598036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416176438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867211,0.0025668754,0.0012667509,0.0004201193,0.00013588565,0.0014050021,0.00006728453,0.00023603694,0.0071809427],"genre_scores_gemma":[0.99213886,0.003061883,0.0012013839,0.001081878,0.00009719109,0.00050084444,0.00015215503,0.00015033377,0.0016154423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99387014,0.00029744607,0.0015125672,0.0016970718,0.0010041695,0.0016186271],"domain_scores_gemma":[0.99674267,0.0011484307,0.00036091838,0.00088761357,0.00028956722,0.0005707946],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006587244,0.001036975,0.0014853036,0.0019124316,0.00043187378,0.0002801015,0.0004919414,0.0008511364,0.00003861947],"category_scores_gemma":[0.000112402275,0.00094421103,0.00016253862,0.0022680762,0.0006548096,0.0006521573,0.0002859267,0.0004504331,0.000025664855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011750958,0.0012925029,0.8015648,0.01321124,0.0016684358,0.01327145,0.03635658,0.002860733,0.015619661,0.012085874,0.0017873598,0.08853038],"study_design_scores_gemma":[0.0837213,0.0009263755,0.7891671,0.0063138944,0.0014851298,0.0065680468,0.011556391,0.0857288,0.0108741,0.0012055789,0.00026525342,0.0021880348],"about_ca_topic_score_codex":0.003006057,"about_ca_topic_score_gemma":0.0014683065,"teacher_disagreement_score":0.08634234,"about_ca_system_score_codex":0.014843777,"about_ca_system_score_gemma":0.01203772,"threshold_uncertainty_score":0.99930084},"labels":[],"label_agreement":null},{"id":"W4417167552","doi":"10.1080/10428194.2025.2598362","title":"Autologous stem cell transplantation for the treatment of MGRS (monoclonal gammopathy of renal significance): experience from the University of Calgary","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Transplantation; Autologous stem-cell transplantation; Incidence (geometry); Complication; Multiple myeloma; Disease","score_opus":0.008110316246793741,"score_gpt":0.22195686639460535,"score_spread":0.21384655014781162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417167552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886509,0.0068870243,0.0030331896,0.0000689248,0.00012954726,0.0006336878,0.00034093138,0.000012519521,0.00024323548],"genre_scores_gemma":[0.99070364,0.0078788465,0.00056101184,0.00009965818,0.000037330614,0.000057499397,0.00014217061,0.000017597155,0.000502225],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859947,0.00011232573,0.00040178385,0.00046192185,0.00016600746,0.00025850802],"domain_scores_gemma":[0.99847776,0.0005187375,0.0003287626,0.0005195443,0.00009505785,0.00006013665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000095883384,0.00028862737,0.00042491386,0.000045602246,0.00019686154,0.000010584788,0.0003816723,0.00022200482,0.000009053204],"category_scores_gemma":[0.000010581861,0.00020149519,0.00028328339,0.0001549354,0.00053475524,0.000011284878,0.00005062742,0.000023325863,7.786731e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0063688895,0.0009333851,0.10278257,0.00035659678,0.0015355514,0.0000475036,0.011385187,0.0009130725,0.4054448,0.0007647314,0.0015418903,0.46792582],"study_design_scores_gemma":[0.0075942036,0.0007258657,0.23796351,0.00007928237,0.0005928169,0.000011666032,0.0025334053,0.0009001991,0.7407094,0.00005201775,0.008615992,0.00022160492],"about_ca_topic_score_codex":0.0032345362,"about_ca_topic_score_gemma":0.00029728707,"teacher_disagreement_score":0.4677042,"about_ca_system_score_codex":0.00057896326,"about_ca_system_score_gemma":0.0011037331,"threshold_uncertainty_score":0.8216736},"labels":[],"label_agreement":null},{"id":"W4417304678","doi":"10.1080/10428194.2025.2594059","title":"Treatment patterns and overall survival among patients with myelodysplastic syndromes treated in the US community oncology setting: a real-world retrospective observational study","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Observational study; Retrospective cohort study; Myelodysplastic syndromes; Overall survival; Survival analysis; Proportional hazards model; Hematopoietic stem cell transplantation","score_opus":0.02971087010040666,"score_gpt":0.3065243523480963,"score_spread":0.2768134822476896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417304678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913861,0.000072620605,0.000009216273,0.00036421578,0.0001204921,0.0028767285,0.000117355004,0.0001338306,0.004919433],"genre_scores_gemma":[0.99646556,0.00022405018,0.00009207859,0.00060483196,0.000081120095,0.0005665237,0.0003671626,0.00007669315,0.0015219876],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947584,0.0014748959,0.0008848804,0.0010023902,0.00090435875,0.0009750475],"domain_scores_gemma":[0.996003,0.0019652147,0.0003069483,0.0010653137,0.0003409055,0.00031863412],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009129021,0.0008246112,0.0013764586,0.00072178815,0.0008115277,0.00018532111,0.00045916077,0.00035614244,0.000028086266],"category_scores_gemma":[0.0002511778,0.000559193,0.00013155222,0.0012744168,0.0006158099,0.00031285593,0.00034817253,0.0005526612,0.000006091052],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026676725,0.0018415841,0.9794064,0.00014114173,0.00070454215,0.0008190216,0.0039464165,0.000023975728,0.000025507077,0.0003441286,0.00020613678,0.009873442],"study_design_scores_gemma":[0.046139754,0.004076409,0.94308066,0.00031635235,0.0005425043,0.00014957853,0.002882055,0.0017009124,0.00004037407,0.000118299366,0.0004962007,0.0004569097],"about_ca_topic_score_codex":0.08330913,"about_ca_topic_score_gemma":0.029686999,"teacher_disagreement_score":0.05362213,"about_ca_system_score_codex":0.025781559,"about_ca_system_score_gemma":0.0038679477,"threshold_uncertainty_score":0.99968594},"labels":[],"label_agreement":null},{"id":"W7117532524","doi":"10.1080/10428194.2025.2598663","title":"Time to diagnosis and treatment in lymphoma and implications for health-related outcomes: a systematic review","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hatch (Canada)","funders":"","keywords":"Checklist; Presentation (obstetrics); Lymphoma; Confidence interval; Interval (graph theory); MEDLINE; Consistency (knowledge bases); Medical diagnosis","score_opus":0.014372511580656168,"score_gpt":0.2987673864370383,"score_spread":0.28439487485638215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117532524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8532812,0.11396512,0.000019300745,0.019844595,0.00011780552,0.011316495,0.0002412082,0.00023322858,0.0009810608],"genre_scores_gemma":[0.87372756,0.070342116,0.0011878499,0.026193488,0.00006477716,0.021444136,0.00033785668,0.0001680823,0.0065341145],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99538904,0.0002102245,0.0017940146,0.0013800919,0.00027799554,0.000948655],"domain_scores_gemma":[0.9963604,0.0012654449,0.0004004437,0.0010315499,0.000147805,0.0007943087],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00057988265,0.0009240095,0.003015356,0.00062765187,0.0004343302,0.00013347549,0.00020038137,0.00035018552,0.000025180847],"category_scores_gemma":[0.00046045834,0.00071993645,0.00034089733,0.0009167153,0.00021443151,0.00018076188,0.00018785271,0.000045267512,0.000059432554],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009588468,0.003626706,0.22361633,0.15657082,0.0037736036,0.00030554386,0.002783223,0.0000104533465,0.00013348476,0.0055716555,0.021927824,0.5807215],"study_design_scores_gemma":[0.042311113,0.0018245957,0.8652553,0.07034526,0.003114467,0.0010492988,0.0002766921,0.00077021326,0.0001962635,0.00055456825,0.013239159,0.0010630661],"about_ca_topic_score_codex":0.0018406139,"about_ca_topic_score_gemma":0.00026143386,"teacher_disagreement_score":0.641639,"about_ca_system_score_codex":0.011796023,"about_ca_system_score_gemma":0.002740228,"threshold_uncertainty_score":0.9995252},"labels":[],"label_agreement":null}]}